FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Brugge, WR DeWitt, J Klapman, JB Ashfaq, R Shidham, V Chhieng, D Kwon, R Baloch, Z Zarka, M Staerkel, G AF Brugge, William R. DeWitt, John Klapman, Jason B. Ashfaq, Raheela Shidham, Vinod Chhieng, David Kwon, Richard Baloch, Zubair Zarka, Matthew Staerkel, Gregg TI Techniques for cytologic sampling of pancreatic and bile duct lesions: The Papanicolaou Society of Cytopathology Guidelines SO CYTOJOURNAL LA English DT Article DE Bile duct; cytology; fine-needle aspiration; pancreas; techniques ID FINE-NEEDLE-ASPIRATION; MALIGNANT BILIARY OBSTRUCTION; BRUSH CYTOLOGY; STRICTURE DILATION; DIAGNOSTIC-ACCURACY; 25-GAUGE NEEDLES; CANCER-DETECTION; ERCP; BIOPSY; 22-GAUGE AB The Papanicolaou Society of Cytopathology has developed a set of guidelines for pancreatobiliary cytology, including indications for endoscopic ultrasound guided fine-needle aspiration biopsy, techniques of the endoscopic retrograde cholangiopancreatography, terminology and nomenclature of pancreatobiliary disease, ancillary testing, and postbiopsy management. All documents are based on the expertise of the authors, a review of literature, discussions of the draft document at several national and international meetings over an 18 month period and synthesis of online comments of the draft document on the Papanicolaou Society of Cytopathology website [www.papsociety.org]. This document presents the results of these discussions regarding the use of sampling techniques in the cytological diagnosis of biliary and pancreatic lesions. This document summarizes the current state of the art for techniques in acquiring cytology specimens from the biliary tree as well as solid and cystic lesions of the pancreas. C1 [Brugge, William R.] Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA. [DeWitt, John] Indiana Univ, Med Ctr, Dept Med, Indianapolis, IN USA. [Klapman, Jason B.] Univ S Florida, H Lee Moffitt Canc Ctr, Gastrointestinal Oncol Dept, Tampa, FL 33682 USA. [Kwon, Richard] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA. [Shidham, Vinod] Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA. [Chhieng, David] Yale Univ, Med Ctr, Dept Pathol, New Haven, CT USA. [Baloch, Zubair] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA. [Zarka, Matthew] Mayo Clin, Dept Pathol, Scottsdale, AZ USA. [Staerkel, Gregg] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ashfaq, Raheela] Caris Diagnost, Dallas, TX USA. RP Brugge, WR (reprint author), Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA. EM wbrugge@partners.org; jodewitt@iupui.edu; jason.klapman@moffitt.org; raheela@sbcglobal.net; vshidham@med.wayne.edu; david.chhieng@yale.edu; rskwon@umich.edu; baloch@mail.med.upenn.edu; Zarka.Matthew@mayo.edu; gstaerke@mdanderson.org NR 36 TC 4 Z9 4 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0974-5963 EI 1742-6413 J9 CYTOJOURNAL JI CytoJournal PD JUN 2 PY 2014 VL 11 AR 2 DI 10.4103/1742-6413.133311 PG 6 WC Pathology SC Pathology GA AO3QV UT WOS:000341249800002 PM 25191516 ER PT J AU Kurtycz, DFI Field, A Tabatabai, L Michaels, C Young, N Schmidt, CM Farrell, J Gopal, D Simeone, D Merchant, NB Pitman, MB AF Kurtycz, Daniel F. I. Field, Andrew Tabatabai, Laura Michaels, Claire Young, Nancy Schmidt, C. Max Farrell, James Gopal, Deepak Simeone, Diane Merchant, Nipun B. Pitman, Martha Bishop TI Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology Guidelines SO CYTOJOURNAL LA English DT Article DE Cytology; guidelines; management; pancreas; Papanicolaou Society of Cytopathology; treatment ID INTERNATIONAL CONSENSUS GUIDELINES; EUS-GUIDED FNA; ENDOSCOPIC ULTRASOUND; NEUROENDOCRINE TUMORS; PATHOLOGICAL CLASSIFICATION; LYMPHOEPITHELIAL CYSTS; MUCINOUS CYSTS; PANCREAS; DIAGNOSIS; MANAGEMENT AB The Papanicolaou Society of Cytopathology (PSC) has developed a set of guidelines for pancreatobiliary cytology including indications for endoscopic ultrasound (EUS) guided fine-needle aspiration (FNA) biopsy, techniques of EUS-FNA, terminology and nomenclature for pancreatobiliary cytology, ancillary testing and post-procedure management. All documents are based on the expertise of the authors, a review of the literature and discussions of the draft document at several national and international meetings over an 18 month period and synthesis of online comments of the draft document on the PSC web site (www.papsociety.org). This document selectively presents the results of these discussions and focuses on the follow-up and treatment options for patients after procedures performed for obtaining cytology samples for the evaluation of biliary strictures and solid and cystic masses in the pancreas. These recommendations follow the six-tiered terminology and nomenclature scheme proposed by committee III. C1 [Kurtycz, Daniel F. I.] Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA. [Field, Andrew] St Vincents Hosp, Dept Surg, Sydney, NSW 2010, Australia. [Tabatabai, Laura] UCSF, San Francisco, CA 94143 USA. [Michaels, Claire] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Young, Nancy] Albert Einstein Coll Med, Philadelphia, PA USA. [Schmidt, C. Max] Indiana Univ, Bloomington, IN 47405 USA. [Farrell, James] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Gopal, Deepak] Univ Wisconsin, Div Gastroenterol, Madison, WI 53706 USA. [Simeone, Diane] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Merchant, Nipun B.] Vanderbilt Univ, Div Surg Oncol, Nashville, TN USA. [Pitman, Martha Bishop] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Kurtycz, DFI (reprint author), Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA. EM dkurtycz@wisc.edu; afield@stvincents.com.au; laura.tabatabai@ucsf.edu; Claire.michael@case.edu; YoungNan@einstein.edu; maxschmi@iupui.edu; jfarrell@mednet.ucla.edu; dvg@medicine.wisc.edu; simeone@umich.edu; nipun.merchant@vanderbilt.edu; mpitman@mgh.harvard.edu NR 57 TC 1 Z9 1 U1 0 U2 2 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0974-5963 EI 1742-6413 J9 CYTOJOURNAL JI CytoJournal PD JUN 2 PY 2014 VL 11 AR 5 DI 10.4103/1742-6413.133356 PG 9 WC Pathology SC Pathology GA AO3QV UT WOS:000341249800005 PM 25191519 ER PT J AU Layfield, LJ Ehya, H Filie, AC Hruban, RH Jhala, N Joseph, L Vielh, P Pitman, MB AF Layfield, Lester J. Ehya, Hormoz Filie, Armando C. Hruban, Ralph H. Jhala, Nirag Joseph, Loren Vielh, Philippe Pitman, Martha B. TI Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines SO CYTOJOURNAL LA English DT Article DE Ancillary studies; biliary tract; endoscopic ultrasound; fine-needle aspiration; molecular diagnosis; pancreas ID FINE-NEEDLE-ASPIRATION; IN-SITU HYBRIDIZATION; CYST FLUID ANALYSIS; DIGITAL IMAGE-ANALYSIS; ACINAR CELL-CARCINOMA; TUMOR-SUPPRESSOR GENE; K-RAS MUTATIONS; PAPILLARY MUCINOUS NEOPLASMS; ENDOBILIARY BRUSH CYTOLOGY; BILE-DUCT STRICTURES AB The Papanicolaou Society of Cytopathology has developed a set of guidelines for pancreatobiliary cytology including indications for endoscopic ultrasound guided fine needle aspiration, terminology and nomenclature of pancreatobiliary disease, ancillary testing and post-biopsy management. All documents are based on the expertise of the authors, a review of the literature, discussion of the draft document at several national and international meetings and synthesis of selected online comments of the draft document. This document presents the results of these discussions regarding the use of ancillary testing in the cytologic diagnosis of biliary and pancreatic lesions. Currently, fluorescence in-situ hybridization (FISH) appears to be the most clinically relevant ancillary technique for cytology of bile duct strictures. The addition of FISH analysis to routine cytologic evaluation appears to yield the highest sensitivity without loss in specificity. Loss of immunohistochemical staining for the protein product of the SMAD4 gene and positive staining for mesothelin support a diagnosis of ductal adenocarcinoma. Immunohistochemical markers for endocrine and exocrine differentiation are sufficient for a diagnosis of endocrine and acinar tumors. Nuclear staining for beta-catenin supports a diagnosis of solid-pseudopapillary neoplasm. Cyst fluid analysis for amylase and carcinoembryonic antigen aids in the pre-operative classification of pancreatic cysts. A number of gene mutations (KRAS, GNAS, von Hippel-Lindau, RNF43 and CTNNB1) may be of aid in the diagnosis of cystic neoplasms. Other ancillary techniques do not appear to improve diagnostic sensitivity sufficiently to justify their increased costs. C1 [Layfield, Lester J.] Univ Missouri, Dept Pathol, Dept Pathol & Anat Sci, Columbia, MO 65201 USA. [Ehya, Hormoz] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA. [Joseph, Loren] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. [Pitman, Martha B.] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA. [Filie, Armando C.] NCI, Pathol Lab, Bethesda, MD 20892 USA. [Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD USA. [Jhala, Nirag] Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Vielh, Philippe] Inst Gustave Roussy, Dept Pathol, Villejuif, France. RP Layfield, LJ (reprint author), Univ Missouri, Dept Pathol, Dept Pathol & Anat Sci, Columbia, MO 65201 USA. EM layfieldl@health.missouri.edu; hormoz.eya@fccc.edu; afilie@mail.nih.gov; rhruban@jhmi.edu; Nirag.Jhala@uphs.upenn.edu; ljlj@midway.uchicago.edu; vielh@igr.fr; mpitman@mgh.harvard.edu NR 117 TC 8 Z9 8 U1 0 U2 6 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0974-5963 EI 1742-6413 J9 CYTOJOURNAL JI CytoJournal PD JUN 2 PY 2014 VL 11 AR 4 DI 10.4103/1742-6413.133352 PG 12 WC Pathology SC Pathology GA AO3QV UT WOS:000341249800004 PM 25191518 ER PT J AU Pitman, MB Centeno, BA Ali, SZ Genevay, M Stelow, E Mino-Kenudson, M Fernandez-del Castillo, C Schmidt, CM Brugge, WR Layfield, LJ AF Pitman, Martha B. Centeno, Barbara A. Ali, Syed Z. Genevay, Muriel Stelow, Ed Mino-Kenudson, Mari Fernandez-del Castillo, Carlos Schmidt, C. Max Brugge, William R. Layfield, Lester J. TI Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology Guidelines SO CYTOJOURNAL LA English DT Article DE Guidelines; nomenclature; pancreas; Papanicolaou Society of Cytopathology; terminology ID FINE-NEEDLE-ASPIRATION; PAPILLARY MUCINOUS NEOPLASMS; ACINAR-CELL CARCINOMA; CYST FLUID ANALYSIS; DUCT BRUSHING CYTOLOGY; INTERNATIONAL CONSENSUS GUIDELINES; ATYPICAL EPITHELIAL-CELLS; INTRAEPITHELIAL NEOPLASIA; DIFFERENTIAL-DIAGNOSIS; NEUROENDOCRINE TUMORS AB The Papanicolaou Society of Cytopathology has developed a set of guidelines for pancreatobiliary cytology including indications for endoscopic ultrasound (EUS) guided fine-needle aspiration (FNA) biopsy, techniques of EUS-FNA, terminology and nomenclature of pancreatobiliary disease, ancillary testing and post-biopsy treatment and management. All documents are based on the expertise of the authors, a review of the literature, discussion of the draft document at several national and international meetings over an 18 month period and synthesis of online comments of the draft document on the Papanicolaou Society of Cytopathology web site [www.papsociety.org]. This document selectively presents the results of these discussions and focuses on a proposed standardized terminology scheme for pancreatobiliary specimens that correlate cytological diagnosis with biological behavior and increasingly conservative patient management of surveillance only. The proposed terminology scheme recommends a six-tiered system: Non-diagnostic, negative, atypical, neoplastic [benign or other], suspicious and positive. Unique to this scheme is the "neoplastic" category separated into "benign" (serous cystadenoma) or "other" (premalignant mucinous cysts, neuroendocrine tumors and solid-pseudopapillary neoplasms (SPNs)). The positive or malignant category is reserved for high-grade, aggressive malignancies including ductal adenocarcinoma, acinar cell carcinoma, poorly differentiated neuroendocrine carcinomas, pancreatoblastoma, lymphoma and metastases. Interpretation categories do not have to be used. Some pathology laboratory information systems require an interpretation category, which places the cytological diagnosis into a general category. This proposed scheme provides terminology that standardizes the category of the various diseases of the pancreas, some of which are difficult to diagnose specifically by cytology. In addition, this terminology scheme attempts to provide maximum flexibility for patient management, which has become increasingly conservative for some neoplasms. C1 [Pitman, Martha B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02138 USA. [Centeno, Barbara A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Ali, Syed Z.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Genevay, Muriel] Hosp Pathol Clin, Geneva, Switzerland. [Stelow, Ed] Univ Virginia, Med Ctr, Charlottesville, VA USA. [Fernandez-del Castillo, Carlos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA. [Schmidt, C. Max] Indiana Univ, Med Ctr, Dept Surg, Indianapolis, IN 46202 USA. [Brugge, William R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Gastroenterol, Boston, MA USA. [Layfield, Lester J.] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO USA. RP Pitman, MB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02138 USA. EM mpitman@partners.org; barbara.centeno@moffitt.org; sali@jhmi.edu; Muriel.Genevay@dianapath.ch; es7yj@cms.mail.virginia.edu; mminokenudson@partners.org; cfernandez@partners.org; maxschmi@iupui.edu; wbrugge@partners.org; layfieldl@health.missouri.edu NR 86 TC 4 Z9 4 U1 0 U2 1 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0974-5963 EI 1742-6413 J9 CYTOJOURNAL JI CytoJournal PD JUN 2 PY 2014 VL 11 AR 3 DI 10.4103/1742-6413.133343 PG 13 WC Pathology SC Pathology GA AO3QV UT WOS:000341249800003 PM 25191517 ER PT J AU Kana, RK Uddin, LQ Kenet, T Chugani, D Muller, RA AF Kana, Rajesh K. Uddin, Lucina Q. Kenet, Tal Chugani, Diane Mueller, Ralph-Axel TI Brain connectivity in autism SO FRONTIERS IN HUMAN NEUROSCIENCE LA English DT Editorial Material DE brain connectivity; multimodal imaging methods; diffusion tensor imaging; functional connectivity; autism spectrum disorders; white matter ID HIGH-FUNCTIONING AUTISM; UNDERCONNECTIVITY; DISORDER; MOTION; MRI C1 [Kana, Rajesh K.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Uddin, Lucina Q.] Univ Miami, Coral Gables, FL 33124 USA. [Kenet, Tal] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Chugani, Diane] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA. [Chugani, Diane] Wayne State Univ, Dept Neurol, Detroit, MI USA. [Mueller, Ralph-Axel] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA. RP Kana, RK (reprint author), Univ Alabama Birmingham, Birmingham, AL 35294 USA. OI Uddin, Lucina/0000-0003-2278-8962 NR 28 TC 18 Z9 19 U1 5 U2 24 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5161 J9 FRONT HUM NEUROSCI JI Front. Hum. Neurosci. PD JUN 2 PY 2014 VL 8 AR 349 DI 10.3389/fnhum.2014.00349 PG 4 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA AM0XE UT WOS:000339570200001 PM 24917800 ER PT J AU Colen, RR Vangel, M Wang, JX Gutman, DA Hwang, SN Wintermark, M Jain, R Jilwan-Nicolas, M Chen, JY Raghavan, P Holder, CA Rubin, D Huang, E Kirby, J Freymann, J Jaffe, CC Flanders, A Zinn, PO AF Colen, Rivka R. Vangel, Mark Wang, Jixin Gutman, David A. Hwang, Scott N. Wintermark, Max Jain, Rajan Jilwan-Nicolas, Manal Chen, James Y. Raghavan, Prashant Holder, Chad A. Rubin, Daniel Huang, Eric Kirby, Justin Freymann, John Jaffe, Carl C. Flanders, Adam Zinn, Pascal O. CA TCGA Glioma Phenotype Res Grp TI Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project SO BMC MEDICAL GENOMICS LA English DT Article DE Radiogenomics; MRI segmentation; Glioblastoma; Imaging genomics; Invasion; Biomarker ID FACTOR-KAPPA-B; CANCER-CELL METABOLISM; GLIOBLASTOMA-MULTIFORME; GENE-EXPRESSION; MICROARRAY ANALYSIS; IDENTIFICATION; HETEROGENEITY; MITOCHONDRIA; GENERATION; PROFILE AB Background: Invasion of tumor cells into adjacent brain parenchyma is a major cause of treatment failure in glioblastoma. Furthermore, invasive tumors are shown to have a different genomic composition and metabolic abnormalities that allow for a more aggressive GBM phenotype and resistance to therapy. We thus seek to identify those genomic abnormalities associated with a highly aggressive and invasive GBM imaging-phenotype. Methods: We retrospectively identified 104 treatment-naive glioblastoma patients from The Cancer Genome Atlas (TCGA) whom had gene expression profiles and corresponding MR imaging available in The Cancer Imaging Archive (TCIA). The standardized VASARI feature-set criteria were used for the qualitative visual assessments of invasion. Patients were assigned to classes based on the presence (Class A) or absence (Class B) of statistically significant invasion parameters to create an invasive imaging signature; imaging genomic analysis was subsequently performed using GenePattern Comparative Marker Selection module (Broad Institute). Results: Our results show that patients with a combination of deep white matter tracts and ependymal invasion (Class A) on imaging had a significant decrease in overall survival as compared to patients with absence of such invasive imaging features (Class B) (8.7 versus 18.6 months, p < 0.001). Mitochondrial dysfunction was the top canonical pathway associated with Class A gene expression signature. The MYC oncogene was predicted to be the top activation regulator in Class A. Conclusion: We demonstrate that MRI biomarker signatures can identify distinct GBM phenotypes associated with highly significant survival differences and specific molecular pathways. This study identifies mitochondrial dysfunction as the top canonical pathway in a very aggressive GBM phenotype. Thus, imaging-genomic analyses may prove invaluable in detecting novel targetable genomic pathways. C1 [Colen, Rivka R.; Wang, Jixin] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA. [Vangel, Mark] Massachussets Gen Hosp, Boston, MA USA. [Gutman, David A.; Hwang, Scott N.; Holder, Chad A.] Emory Univ, Dept Radiol, Atlanta, GA 30322 USA. [Wintermark, Max; Jilwan-Nicolas, Manal; Raghavan, Prashant] Univ Virginia, Charlottesville, VA USA. [Jain, Rajan] NYU, Dept Radiol, Med Ctr, New York, NY 10016 USA. [Chen, James Y.] Univ Calif San Diego, San Diego, CA 92103 USA. [Chen, James Y.] Univ Calif San Diego, San Diego Med Ctr, Dept Radiol, San Diego, CA 92103 USA. [Rubin, Daniel] Stanford Univ, Stanford, CA 94305 USA. [Huang, Eric; Kirby, Justin; Freymann, John] Leidos Biomed Res Inc, Clin Monitoring Res Program, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA. [Jaffe, Carl C.] NCI, NIH, Rockville, MD USA. [Flanders, Adam] Thomas Jefferson Univ Hosp, Dept Radiol, Philadelphia, PA 19107 USA. [Zinn, Pascal O.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA. RP Colen, RR (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, 1400 Pressler St,Unit 1482,Rm FCT 16-5037, Houston, TX 77030 USA. EM rcolen@mdanderson.org; zinn@bcm.edu OI Hwang, Scott/0000-0002-6496-2087; Wintermark, Max/0000-0002-6726-3951 FU John S. Dunn Research Foundation Center for Radiological Sciences; MDACC; National Cancer Institute, National Institutes of Health [HHSN261200800001E] FX This work was supported in part by the John S. Dunn Research Foundation Center for Radiological Sciences (RRC). This work was supported in part by MDACC startup funding (RRC). This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government (JK and JF). NR 45 TC 16 Z9 16 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1755-8794 J9 BMC MED GENOMICS JI BMC Med. Genomics PD JUN 2 PY 2014 VL 7 AR 30 DI 10.1186/1755-8794-7-30 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA AK5KX UT WOS:000338464600001 PM 24889866 ER PT J AU Weber, GF Chousterman, BG Hilgendorf, I Robbins, CS Theurl, I Gerhardt, LMS Iwamoto, Y Quach, TD Ali, M Chen, JW Rothstein, TL Nahrendorf, M Weissleder, R Swirski, FK AF Weber, Georg F. Chousterman, Benjamin G. Hilgendorf, Ingo Robbins, Clinton S. Theurl, Igor Gerhardt, Louisa M. S. Iwamoto, Yoshiko Quach, Tam D. Ali, Muhammad Chen, John W. Rothstein, Thomas L. Nahrendorf, Matthias Weissleder, Ralph Swirski, Filip K. TI Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID COLONY-STIMULATING FACTOR; INFLUENZA-VIRUS INFECTION; ANTIBODY-PRODUCING CELLS; IMMUNOGLOBULIN-M; DEFICIENT MICE; BONE-MARROW; T-CELLS; DIFFERENTIATION; EXPRESSION; BLIMP-1 AB Pneumonia is a major cause of mortality worldwide and a serious problem in critical care medicine, but the immunophysiological processes that confer either protection or morbidity are not completely understood. We show that in response to lung infection, B1a B cells migrate from the pleural space to the lung parenchyma to secrete polyreactive emergency immunoglobulin M ( IgM). The process requires innate response activator (IRA) B cells, a transitional B1a-derived inflammatory subset which controls IgM production via autocrine granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling. The strategic location of these cells, coupled with the capacity to produce GM-CSF-dependent IgM, ensures effective early frontline defense against bacteria invading the lungs. The study describes a previously unrecognized GM-CSF-IgM axis and positions IRA B cells as orchestrators of protective IgM immunity. C1 [Weber, Georg F.; Chousterman, Benjamin G.; Hilgendorf, Ingo; Robbins, Clinton S.; Theurl, Igor; Gerhardt, Louisa M. S.; Iwamoto, Yoshiko; Ali, Muhammad; Chen, John W.; Nahrendorf, Matthias; Weissleder, Ralph; Swirski, Filip K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Weber, Georg F.] Tech Univ Dresden, Med Fak Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, D-01307 Dresden, Germany. [Quach, Tam D.; Rothstein, Thomas L.] Feinstein Inst Med Res, Ctr Oncol & Cell Biol, Manhasset, NY 11030 USA. [Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. RP Swirski, FK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. EM georg.weber@uniklinikum-dresden.de; fswirski@mgh.harvard.edu FU National Institutes of Health [R01HL095612, R56AI104695, AI029690]; German Research Foundation; Societe Francaise d'Anesthesie-Reanimation; Institut Servier; Fondation Groupe Pasteur Mutualite; Fulbright Scholarship (Monahan Foundation); MGH Executive Committee on Research (ECOR) Postdoctoral Award; Max Kade Foundation; Boehringer Ingelheim Fonds; Fulbright Scholarship (Fulbright Scholarship) FX This work was supported by National Institutes of Health grant R01HL095612 and R56AI104695 (to F.K. Swirski) and AI029690 (to T.L. Rothstein). G.F. Weber and I. Hilgendorf were supported by the German Research Foundation. B.G. Chousterman was supported by Societe Francaise d'Anesthesie-Reanimation, Institut Servier, Fondation Groupe Pasteur Mutualite, and a Fulbright Scholarship (Monahan Foundation and Harvard French Scholarship Fund). C.S. Robbins was supported by the MGH Executive Committee on Research (ECOR) Postdoctoral Award. I. Theurl was supported by the Max Kade Foundation. L.M.S. Gerhardt was supported by the Boehringer Ingelheim Fonds. NR 55 TC 33 Z9 33 U1 2 U2 5 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1007 EI 1540-9538 J9 J EXP MED JI J. Exp. Med. PD JUN 2 PY 2014 VL 211 IS 6 BP 1243 EP 1256 DI 10.1084/jem.20131471 PG 14 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA AJ0RV UT WOS:000337364500018 PM 24821911 ER PT J AU Tompkins, RG AF Tompkins, R. G. TI GENOMIC RESPONSES IN MOUSE MODELS POORLY MIMIC HUMAN INFLAMMATORY DISEASES SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Tompkins, R. G.] Harvard Univ, Sch Med, Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 5 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA SP0136 BP 37 EP 37 DI 10.1136/annrheumdis-2014-eular.1698 PG 1 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919800137 ER PT J AU Stone, JH AF Stone, J. H. TI IGG4-RELATED DISEASE SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Stone, J. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA SP0205 BP 53 EP 53 DI 10.1136/annrheumdis-2014-eular.6350 PG 1 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919800205 ER PT J AU Owczarczyk, K Holweg, C Ortmann, W Behrens, T Brunetta, P Specks, U Phippard, D Ding, L Lim, N Tchao, N Ikle, D Stone, J AF Owczarczyk, K. Holweg, C. Ortmann, W. Behrens, T. Brunetta, P. Specks, U. Phippard, D. Ding, L. Lim, N. Tchao, N. Ikle, D. Stone, J. CA Rave-Itn Res Grp TI THE ROLE OF BASELINE FCRL5 MRNA EXPRESSION IN PREDICTING RESPONSE TO RITUXIMAB (RTX) THERAPY IN PATIENTS WITH GRANULOMATOUS POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA) SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Owczarczyk, K.] Royal Free Hosp, London NW3 2QG, England. [Holweg, C.; Ortmann, W.; Behrens, T.; Brunetta, P.] Genentech Inc, San Francisco, CA USA. [Specks, U.] Mayo Clin Fdn, Rochester, MN USA. [Ding, L.] NIAID, Bethesda, MD 20892 USA. [Ikle, D.] Rho, Chapel Hill, NC USA. [Stone, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA OP0232 BP 150 EP 150 DI 10.1136/annrheumdis-2014-eular.4265 PG 1 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919800452 ER PT J AU Castelino, FV George, LM Bain, G Goulet, L Lafyatis, R Tager, AM AF Castelino, F. V. George, L. M. Bain, G. Goulet, L. Lafyatis, R. Tager, A. M. TI AUTOTAXIN IS OVER-EXPRESSED IN SYSTEMIC SCLEROSIS (SSC) SKIN, MEDIATES BLEOMYCIN-INDUCED DERMAL FIBROSIS VIA IL-6, AND IS A TARGET FOR SSC THERAPY SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Castelino, F. V.] Massachusetts Gen Hosp, Rheumatol, Boston, MA 02114 USA. [George, L. M.; Tager, A. M.] Massachusetts Gen Hosp, Pulmonary & Crit Care, Boston, MA 02114 USA. [Bain, G.; Goulet, L.] PharmAkea Therapeut, San Diego, CA USA. [Lafyatis, R.] Boston Univ, Rheumatol, Boston, MA 02215 USA. NR 1 TC 1 Z9 1 U1 3 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA OP0241 BP 153 EP 153 DI 10.1136/annrheumdis-2014-eular.2979 PG 1 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919800461 ER PT J AU Ng, B AF Ng, B. TI FACTORS ASSOCIATED WITH METHOTREXATE TREATMENT DURATION, INCLUDING SUBCUTANEOUS USE, IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONS FROM THE VETERANS AFFAIRS DATABASE SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Ng, B.] VA Puget Sound Healthcare Syst, Div Rheumatol, Seattle, WA USA. [Ng, B.] Univ Washington, Seattle, WA 98195 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA THU0115 BP 217 EP 218 DI 10.1136/annrheumdis-2014-eular.3021 PG 2 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919801132 ER PT J AU Zeron, PB Retamozo, S Gheitasi, H Bove, A Kostov, B Siso-Almirall, A Ramos-Casals, M Stone, JH AF Brito Zeron, P. Retamozo, S. Gheitasi, H. Bove, A. Kostov, B. Siso-Almirall, A. Ramos-Casals, M. Stone, J. H. CA GEAS-SEMI Study Grp TI IGG4-RELATED DISEASE OR PRIMARY SJOGREN SYNDROME? ORGAN-SPECIFIC INVOLVEMENT AND IMMUNOLOGICAL PROFILE ARE CLUES IN DIFFERENTIATING TWO DISEASES WITH A COMMON CLINICAL PRESENTATION SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Brito Zeron, P.; Retamozo, S.; Gheitasi, H.; Bove, A.; Ramos-Casals, M.] Hosp Clin Barcelona, IDIBAPS, Lab Autoimmune Dis Josep Font, Dept Autoimmune Dis,ICMiD, Barcelona, Spain. [Kostov, B.; Siso-Almirall, A.] CAPSE, Primary Care Res Grp, IDIBAPS, Ctr Assistencia Primaria ABS Les Corts, Barcelona, Spain. [Stone, J. H.] Harvard Univ, Sch Med, Boston, MA USA. [Stone, J. H.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA THU0396 BP 318 EP 319 DI 10.1136/annrheumdis-2014-eular.5099 PG 2 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919801412 ER PT J AU Nagaraja, V Spiegel, BM Hays, RD Khanna, P Chang, L Melmed, GY Bolus, R Khanna, D AF Nagaraja, V. Spiegel, B. M. Hays, R. D. Khanna, P. Chang, L. Melmed, G. Y. Bolus, R. Khanna, D. TI DEVELOPMENT AND VALIDATION OF PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS (R)) GASTROINTESTINAL (GI) SYMPTOM SCALES IN SYSTEMIC SCLEROSIS SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Nagaraja, V.; Khanna, P.; Khanna, D.] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Spiegel, B. M.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. [Hays, R. D.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. [Chang, L.; Bolus, R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Melmed, G. Y.] Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA FRI0223 BP 463 EP 463 DI 10.1136/annrheumdis-2014-eular.2423 PG 1 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919802328 ER PT J AU Singh, JA AF Singh, J. A. TI THE IMPACT OF GOUT ON PATIENT'S LIVES AND DIFFERENCES BY RACE AND GENDER: A PATIENT PERSPECTIVE SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, J. A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA SAT0520 BP 779 EP 780 DI 10.1136/annrheumdis-2014-eular.1147 PG 2 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919804247 ER PT J AU Singh, JA AF Singh, J. A. TI FACILITATORS AND BARRIERS TO ADHERENCE TO URATE-LOWERING THERAPY IN AFRICAN-AMERICANS WITH GOUT: A QUALITATIVE STUDY SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, J. A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA SAT0519 BP 779 EP 779 DI 10.1136/annrheumdis-2014-eular.1148 PG 1 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919804246 ER PT J AU Singh, JA Bharat, A Edwards, L AF Singh, J. A. Bharat, A. Edwards, L. TI AN INTERNET SURVEY OF COMMON TREATMENTS USED BY PATIENTS WITH GOUT SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, J. A.; Bharat, A.] Univ Alabama Birmingham, Birmingham, AL USA. [Edwards, L.] Univ Florida, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA AB0833 BP 1078 EP 1078 DI 10.1136/annrheumdis-2014-eular.4846 PG 1 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919806113 ER PT J AU Bessette, L Liote, F Moragues, C Moericke, R Zhang, Z Ferreira, A Lecomte, P Kessabi, S Tian, H Li, L Singh, J AF Bessette, L. Liote, F. Moragues, C. Moericke, R. Zhang, Z. Ferreira, A. Lecomte, P. Kessabi, S. Tian, H. Li, L. Singh, J. TI BURDEN OF REFRACTORY GOUTY ARTHRITIS AMONG DIFFICULT-TO-TREAT PATIENTS OVER ONE YEAR: POST- HOC ANALYSIS FROM MOTION OBSERVATIONAL STUDY SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Bessette, L.] CHUL, Quebec City, PQ, Canada. [Liote, F.] Hosp Lariboisiere, Paris, France. [Moragues, C.] Hosp Platon, Barcelona, Spain. [Moericke, R.] Inst Pravent Med, Magdeburg, Germany. [Moericke, R.] Klin Forsch GbR, Magdeburg, Germany. [Zhang, Z.] Haerbin Med Univ, Affiliated Hosp 1, Haerbin City, Peoples R China. [Ferreira, A.; Lecomte, P.; Kessabi, S.] Novartis Pharmaceut AG, Basel, Switzerland. [Tian, H.] Novartis Pharmaceut, E Hanover, NJ USA. [Li, L.] Novartis Pharmaceut, Shanghai, Peoples R China. [Singh, J.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA AB1069 BP 1154 EP 1155 DI 10.1136/annrheumdis-2014-eular.4348 PG 2 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919806349 ER PT J AU Bessette, L Liote, F Moragues, C Moericke, R Zhang, Z Lecomte, P Ferreira, A Kessabi, S Tian, H Li, L Singh, J AF Bessette, L. Liote, F. Moragues, C. Moericke, R. Zhang, Z. Lecomte, P. Ferreira, A. Kessabi, S. Tian, H. Li, L. Singh, J. TI DISEASE BURDEN OF REFRACTORY GOUTY ARTHRITIS: A ONE YEAR MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 15th Annual European Congress of Rheumatology (EULAR) CY JUN 11-14, 2014 CL Paris, FRANCE C1 [Bessette, L.] CHUL, Quebec City, PQ, Canada. [Liote, F.] Hop Lariboisiere, F-75475 Paris, France. [Moragues, C.] Hosp Platon, Barcelona, Spain. [Moericke, R.] Inst Pravent Med, Magdeburg, Germany. [Moericke, R.] Klin Forsch GbR, Magdeburg, Germany. [Zhang, Z.] Haerbin Med Univ, Affiliated Hosp 1, Haerbin City, Peoples R China. [Lecomte, P.; Ferreira, A.; Kessabi, S.] Novartis Pharmaceut AG, Basel, Switzerland. [Tian, H.] Novartis Pharmaceut, E Hanover, NJ USA. [Li, L.] Novartis Pharmaceut, Shanghai, Peoples R China. [Singh, J.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2014 VL 73 SU 2 MA AB1068 BP 1154 EP 1154 DI 10.1136/annrheumdis-2014-eular.4215 PG 1 WC Rheumatology SC Rheumatology GA AX4RT UT WOS:000346919806348 ER PT J AU Guanci, MM AF Guanci, Mary McKenna TI We recently had a 50-year-old patient with a large middle cerebral artery (MCA) ischemic stroke who deteriorated within hours of admission. When his right pupil became large and nonreactive, the neurosurgeon was called who did a craniectomy. He ordered mild hypothermia (34 degrees C target) for 72 hours. What are the challenges and nursing interventions related to instituting mild hypothermia in this patient population? SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT LA English DT Letter ID THERAPEUTIC HYPOTHERMIA C1 Massachusetts Gen Hosp, Neurosci ICU, Boston, MA 02114 USA. RP Guanci, MM (reprint author), Massachusetts Gen Hosp, Neurosci ICU, Boston, MA 02114 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-7658 EI 2153-7933 J9 THER HYPOTHERMIA TEM JI Ther. Hypothermia Temp. Manag. PD JUN 1 PY 2014 VL 4 IS 2 BP 102 EP 102 PG 1 WC Critical Care Medicine SC General & Internal Medicine GA CF3UL UT WOS:000352474100013 ER PT J AU Cole, C AF Cole, Clare TI Successful Pregnancy and Delivery with Maple Syrup Urine Disease SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING LA English DT Meeting Abstract DE maple syrup urine disease; pregnancy; postpartum C1 [Cole, Clare] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-2175 EI 1552-6909 J9 JOGNN-J OBST GYN NEO JI JOGNN PD JUN PY 2014 VL 43 SU 1 SI SI BP S95 EP S96 DI 10.1111/1552-6909.12336 PG 2 WC Nursing; Obstetrics & Gynecology SC Nursing; Obstetrics & Gynecology GA CB9NR UT WOS:000349959000133 ER PT J AU Mifflin, J AF Mifflin, Jeffrey TI CARLETON WATKINS: The Stanford Albums SO JOURNAL OF THE WEST LA English DT Book Review C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 2 PU ABC-CLIO PI SANTA BARBARA PA 130 CREMONA DR, SANTA BARBARA, CA 93117 USA SN 0022-5169 EI 1930-0115 J9 J WEST JI J. West PD SUM PY 2014 VL 53 IS 3 BP 89 EP 89 PG 1 WC History SC History GA CC1DQ UT WOS:000350081800014 ER PT J AU Mifflin, J AF Mifflin, Jeffrey TI IRON MUSE: Photographing the Transcontinental Railroad SO JOURNAL OF THE WEST LA English DT Book Review C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ABC-CLIO PI SANTA BARBARA PA 130 CREMONA DR, SANTA BARBARA, CA 93117 USA SN 0022-5169 EI 1930-0115 J9 J WEST JI J. West PD SUM PY 2014 VL 53 IS 3 BP 95 EP 95 PG 1 WC History SC History GA CC1DQ UT WOS:000350081800029 ER PT J AU Baker, JM Boyce, FM AF Baker, Jessica M. Boyce, Frederick M. TI High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Cellular Biology; Issue 88; Luciferases; Gene Transfer Techniques; Transfection; High-Throughput Screening Assays; Transfections; Robotics ID ALPHA-SYNUCLEIN GENE; FAMILIAL PARKINSONS-DISEASE; MAMMALIAN-CELLS; ALLELIC VARIATION; DUPLICATION; LOCUS; TRANSCRIPTION; NACP-REP1; SYSTEM; GENOME AB We present a rapid and inexpensive high-throughput screening protocol to identify transcriptional regulators of alpha-synuclein, a gene associated with Parkinson's disease. 293T cells are transiently transfected with plasmids from an arrayed ORF expression library, together with luciferase reporter plasmids, in a one-gene-per-well microplate format. Firefly luciferase activity is assayed after 48 hr to determine the effects of each library gene upon alpha-synuclein transcription, normalized to expression from an internal control construct (a hCMV promoter directing Renilla luciferase). This protocol is facilitated by a bench-top robot enclosed in a biosafety cabinet, which performs aseptic liquid handling in 96-well format. Our automated transfection protocol is readily adaptable to high-throughput lentiviral library production or other functional screening protocols requiring triple-transfections of large numbers of unique library plasmids in conjunction with a common set of helper plasmids. We also present an inexpensive and validated alternative to commercially-available, dual luciferase reagents which employs PTC124, EDTA, and pyrophosphate to suppress firefly luciferase activity prior to measurement of Renilla luciferase. Using these methods, we screened 7,670 human genes and identified 68 regulators of alpha-synuclein. This protocol is easily modifiable to target other genes of interest. C1 [Baker, Jessica M.; Boyce, Frederick M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Boyce, FM (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. EM fmboyce@rics.bwh.harvard.edu NR 23 TC 1 Z9 1 U1 2 U2 7 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD JUN PY 2014 IS 88 AR e50282 DI 10.3791/50282 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CB0BQ UT WOS:000349290100003 ER PT J AU Jones, CN Hoang, AN Dimisko, L Hamza, B Martel, J Irimia, D AF Jones, Caroline N. Hoang, Anh N. Dimisko, Laurie Hamza, Bashar Martel, Joseph Irimia, Daniel TI Microfluidic Platform for Measuring Neutrophil Chemotaxis from Unprocessed Whole Blood SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Bioengineering; Issue 88; chemotaxis; neutrophil; whole blood assay; microfluidic device; chemoattractant; migration; inflammation ID INFLAMMATION AB Neutrophils play an essential role in protection against infections and their numbers in the blood are frequently measured in the clinic. Higher neutrophil counts in the blood are usually an indicator of ongoing infections, while low neutrophil counts are a warning sign for higher risks for infections. To accomplish their functions, neutrophils also have to be able to move effectively from the blood where they spend most of their life, into tissues, where infections occur. Consequently, any defects in the ability of neutrophils to migrate can increase the risks for infections, even when neutrophils are present in appropriate numbers in the blood. However, measuring neutrophil migration ability in the clinic is a challenging task, which is time consuming, requires large volume of blood, and expert knowledge. To address these limitations, we designed a robust microfluidic assays for neutrophil migration, which requires a single droplet of unprocessed blood, circumvents the need for neutrophil separation, and is easy to quantify on a simple microscope. In this assay, neutrophils migrate directly from the blood droplet, through small channels, towards the source of chemoattractant. To prevent the granular flow of red blood cells through the same channels, we implemented mechanical filters with right angle turns that selectively block the advance of red blood cells. We validated the assay by comparing neutrophil migration from blood droplets collected from finger prick and venous blood. We also compared these whole blood (WB) sources with neutrophil migration from samples of purified neutrophils and found consistent speed and directionality between the three sources. This microfluidic platform will enable the study of human neutrophil migration in the clinic and the research setting to help advance our understanding of neutrophil functions in health and disease. C1 [Jones, Caroline N.; Hoang, Anh N.; Dimisko, Laurie; Hamza, Bashar; Martel, Joseph; Irimia, Daniel] Massachusetts Gen Hosp, Dept Surg, BioMEMS Resource Ctr, Boston, MA 02114 USA. [Jones, Caroline N.; Hoang, Anh N.; Irimia, Daniel] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Jones, Caroline N.; Hoang, Anh N.; Irimia, Daniel] Shriners Burns Hosp, Boston, MA USA. [Martel, Joseph] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. RP Irimia, D (reprint author), Massachusetts Gen Hosp, Dept Surg, BioMEMS Resource Ctr, Boston, MA 02114 USA. EM DIRIMIA@partners.org FU National Institutes of Health [GM092804, DE019938]; Shriners Burns Hospital FX Support from the National Institutes of Health (grants GM092804, DE019938) and Shriners Burns Hospital. NR 17 TC 1 Z9 1 U1 1 U2 3 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD JUN PY 2014 IS 88 AR e51215 DI 10.3791/51215 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CB0BQ UT WOS:000349290100015 ER PT J AU Parsania, S Shabani, M Moazzami, K Razavinasab, M Larizadeh, MH Nazeri, M Asadi-Shekaari, M Kermani, M AF Parsania, Shahrnaz Shabani, Mohammad Moazzami, Kasra Razavinasab, Moazamehosdadat Larizadeh, Mohammad Hassan Nazeri, Masoud Asadi-Shekaari, Majid Kermani, Moein TI Gender difference in motor impairments induced by chronic administration of vinblastine SO IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES LA English DT Article DE Anticancer; Learning and memory; Motor function; Vinblastine ID SEXUAL-DIMORPHISM; FEMALE RATS; PERIPHERAL NEUROPATHY; CISPLATIN; EXPOSURE; MEMORY; PERFORMANCE; VINFLUNINE; COLCHICINE; LEUKEMIA AB Objective(s): Neurotoxicity of anticancer drugs complicates treatment of cancer patients. Vinblastine (VBL) is reported to induce motor and cognitive impairments in patients receiving chronic low-dose regimen. Materials and Methods: The effects of VBL treatment on motor, learning and memory functions of male and female Wistar rats were studied by behavioral related tests. Animals were given chronic intraperitoneal injections of VBL (0.2 mg/kg/week for 5 weeks) from postnatal day 23 to 52. Motor function was evaluated using grasping test and balancing was evaluated by the rotarod. Spatial learning and memory and anxiety-like behavior were determined using Morris water maze (MWM) task and open field test, respectively. Results: Administration of VBL caused severe damage to motor and balance function of male rats in comparison to female rats treated with VBL and rats treated with saline. Memory and locomotion were affected in both male and female rats compared with saline treated rats, while a sex difference was also observed in these parameters; male rats showed more impairment compared with female ones. Both male and female rats showed cognitive impairments in MWM task and no sex differences were observed in these functions. Conclusion: Results revealed that VBL is a potent neurotoxic agent and despite the profound effect of VBL on motor and cognitive functions, it seems that male rats are more susceptible to motor deficits induced by VBL. C1 [Parsania, Shahrnaz; Razavinasab, Moazamehosdadat] Kerman Univ Med Sci, Neuropharmacol Inst, Physiol Res Ctr, Kerman, Iran. [Shabani, Mohammad; Asadi-Shekaari, Majid] Kerman Univ Med Sci, Neuropharmacol Inst, Kerman Neurosci Res Ctr, Kerman, Iran. [Moazzami, Kasra] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02129 USA. [Larizadeh, Mohammad Hassan] Kerman Univ Med Sci, Dept Radiat Oncol, Kerman, Iran. [Nazeri, Masoud; Kermani, Moein] Kerman Univ Med Sci, Student Res Committee, Kerman, Iran. RP Shabani, M (reprint author), Kerman Univ Med Sci, Neuropharmacol Inst, Kerman Neurosci Res Ctr, Kerman, Iran. EM shabanimoh@yahoo.com RI Asadi-Shekaari, Majid/H-1791-2015 OI Asadi-Shekaari, Majid/0000-0003-4367-2280 NR 40 TC 2 Z9 2 U1 0 U2 1 PU MASHHAD UNIV MED SCIENCES PI MASHHAD PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN SN 2008-3866 EI 2008-3874 J9 IRAN J BASIC MED SCI JI Iran. J. Basic Med. Sci. PD JUN PY 2014 VL 17 IS 6 BP 433 EP 440 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA AU1BJ UT WOS:000345355700007 PM 25140205 ER PT J AU Hess, DR Altobelli, NP AF Hess, Dean R. Altobelli, Neila P. TI Tracheostomy Tubes SO RESPIRATORY CARE LA English DT Article DE airway management; decannulation; fenestrated tracheostomy tube; inner cannula; speaking valve; tracheostomy button; tracheostomy team; tracheostomy tube ID VENTILATOR-DEPENDENT PATIENTS; MECHANICAL VENTILATION; SPEAKING VALVE; NEUROMUSCULAR DISEASE; SPEECH PRODUCTION; WARD MORTALITY; MATERIAL WEAR; DECANNULATION; CARE; TEAM AB Tracheostomy tubes are used to administer positive-pressure ventilation, to provide a patent airway, and to provide access to the lower respiratory tract for airway clearance. They are available in a variety of sizes and styles from several manufacturers. The dimensions of tracheostomy tubes are given by their inner diameter, outer diameter, length, and curvature. Differences in dimensions between tubes with the same inner diameter from different manufacturers are not commonly appreciated but may have important clinical implications. Tracheostomy tubes can be cuffed or uncuffed and may be fenestrated. Some tracheostomy tubes are designed with an inner cannula. It is important for clinicians caring for patients with a tracheostomy tube to appreciate the nuances of various tracheostomy tube designs and to select a tube that appropriately fits the patient. The optimal frequency of changing a chronic tracheostomy tube is controversial. Specialized teams may be useful in managing patients with a tracheostomy. Speech can be facilitated with a speaking valve in patients with a tracheostomy tube who are breathing spontaneously. In mechanically ventilated patients with a tracheostomy, a talking tracheostomy tube, a deflated cuff technique with a speaking valve, or a deflated cuff technique without a speaking valve can be used to facilitate speech. C1 [Hess, Dean R.; Altobelli, Neila P.] Massachusetts Gen Hosp, Resp Care Dept, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. RP Hess, DR (reprint author), Massachusetts Gen Hosp, Ellison 401, Boston, MA 02114 USA. EM dhess@partners.org NR 54 TC 3 Z9 5 U1 1 U2 8 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD JUN PY 2014 VL 59 IS 6 BP 956 EP 971 DI 10.4187/respcare.02920 PG 16 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CA8VT UT WOS:000349199700018 PM 24891201 ER PT J AU Pardee, AB AF Pardee, Arthur B. TI Francois Jacob memorial SO RESEARCH IN MICROBIOLOGY LA English DT Biographical-Item C1 Dana Farber Inst, Dept Adult Oncol, Boston, MA 02115 USA. RP Pardee, AB (reprint author), Dana Farber Inst, Dept Adult Oncol, Boston, MA 02115 USA. EM arthur_pardee@dfci.harvard.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0923-2508 EI 1769-7123 J9 RES MICROBIOL JI Res. Microbiol. PD JUN PY 2014 VL 165 IS 5 BP 394 EP 395 DI 10.1016/j.resmic.2014.05.037 PG 2 WC Microbiology SC Microbiology GA AY5PS UT WOS:000347625000030 ER PT J AU Kong, CY Kroep, S Curtius, K Hazelton, WD Jeon, J Meza, R Heberle, CR Miller, MC Choi, SE Lansdorp-Vogelaar, I van Ballegooijen, M Feuer, EJ Inadomi, JM Hur, C Luebeck, EG AF Kong, Chung Yin Kroep, Sonja Curtius, Kit Hazelton, William D. Jeon, Jihyoun Meza, Rafael Heberle, Curtis R. Miller, Melecia C. Choi, Sung Eun Lansdorp-Vogelaar, Iris van Ballegooijen, Marjolein Feuer, Eric J. Inadomi, John M. Hur, Chin Luebeck, E. Georg TI Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; SERVICES TASK-FORCE; BARRETTS-ESOPHAGUS; COLORECTAL-CANCER; COST-EFFECTIVENESS; GASTRIC CARDIA; MEDICARE POPULATION; NATURAL-HISTORY; BREAST-CANCER AB Background: The incidence of esophageal adenocarcinoma (EAC) has increased five-fold in the United States since 1975. The aim of our study was to estimate future U. S. EAC incidence and mortality and to shed light on the potential drivers in the disease process that are conduits for the dramatic increase in EAC incidence. Methods: A consortium of three research groups calibrated independent mathematical models to clinical and epidemiologic data including EAC incidence from the Surveillance, Epidemiology, and End Results (SEER 9) registry from 1975 to 2010. We then used a comparative modeling approach to project EAC incidence and mortality to year 2030. Results: Importantly, all three models identified birth cohort trends affecting cancer progression as a major driver of the observed increases in EAC incidence and mortality. All models predict that incidence and mortality rates will continue to increase until 2030 but with a plateauing trend for recent male cohorts. The predicted ranges of incidence and mortality rates (cases per 100,000 person years) in 2030 are 8.4 to 10.1 and 5.4 to 7.4, respectively, for males, and 1.3 to 1.8 and 0.9 to 1.2 for females. Estimates of cumulative cause-specific EAC deaths between both sexes for years 2011 to 2030 range between 142,300 and 186,298, almost double the number of deaths in the past 20 years. Conclusions: Through comparative modeling, the projected increases in EAC cases and deaths represent a critical public health concern that warrants attention from cancer control planners to prepare potential interventions. Impact: Quantifying this burden of disease will aid health policy makers to plan appropriate cancer control measures. (C) 2014 AACR. C1 [Kong, Chung Yin; Heberle, Curtis R.; Miller, Melecia C.; Choi, Sung Eun; Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Heberle, Curtis R.; Miller, Melecia C.; Choi, Sung Eun; Hur, Chin] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Kong, Chung Yin; Hur, Chin] Harvard Univ, Sch Med, Boston, MA USA. [Curtius, Kit] Univ Washington, Sch Med, Dept Appl Math, Seattle, WA USA. [Inadomi, John M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA. [Jeon, Jihyoun] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98104 USA. [Hazelton, William D.; Luebeck, E. Georg] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA. [Meza, Rafael] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Feuer, Eric J.] NCI, Surveillance Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Kroep, Sonja; Lansdorp-Vogelaar, Iris; van Ballegooijen, Marjolein] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. RP Kong, CY (reprint author), Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. EM joey@mgh-ita.org OI Heberle, Curtis/0000-0003-1445-5420; Hur, Chin/0000-0002-2819-7576 FU NIH [U01CA152926, K25CA133141] FX This work was supported by the NIH (grant No. U01CA152926 to the CISNET Esophagus group and grant No. K25CA133141 to Dr. C.Y. Kong). NR 37 TC 13 Z9 15 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUN PY 2014 VL 23 IS 6 BP 997 EP 1006 DI 10.1158/1055-9965.EPI-13-1233 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AT9UD UT WOS:000345270800011 PM 24692500 ER PT J AU Wu, L Goldstein, AM Yu, K Yang, XR Rabe, KG Arslan, AA Canzian, F Wolpin, BM Stolzenberg-Solomon, R Amundadottir, LT Petersen, GM AF Wu, Lang Goldstein, Alisa M. Yu, Kai Yang, Xiaohong Rose Rabe, Kari G. Arslan, Alan A. Canzian, Federico Wolpin, Brian M. Stolzenberg-Solomon, Rachael Amundadottir, Laufey T. Petersen, Gloria M. TI Variants Associated with Susceptibility to Pancreatic Cancer and Melanoma Do Not Reciprocally Affect Risk SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID GENOME-WIDE ASSOCIATION; LOCI AB Background: Melanoma cases may exist in pancreatic cancer kindreds, whereas there is increased risk of pancreatic cancer in familial melanoma. The two cancers may share genetic susceptibility variants in common. Methods: Three dbGaP (datasets in Genotypes and Phenotypes)-deposited GWAS (genome-wide association study) datasets (MD Anderson melanoma, PanScan 1, and PanScan 2 for pancreatic cancer) were used. Thirty-seven melanoma susceptibility variants in 22 genomic regions from published GWAS, plus melanoma-related genes and pathways were examined for pancreatic cancer risk in the PanScan datasets. Conversely, nine known pancreatic cancer susceptibility variants were examined for melanoma risk in the MD Anderson dataset. Results: In the PanScan data, initial associations were found with melanoma susceptibility variants in NCOA6 [rs4911442; OR, 1.32; 95% confidence interval (CI), 1.03-1.70; P = 0.03], YWHAZP5 (rs17119461; OR, 2.62; 95% CI, 1.08-6.35; P = 0.03), and YWHAZP5(rs17119490; OR, 2.62; 95% CI, 1.08-6.34; P = 0.03), TYRP1 (P = 0.04), and IFNA13 (P = 0.04). In the melanoma dataset, two pancreatic cancer susceptibility variants were associated: NR5A2 (rs12029406; OR, 1.39; 95% CI, 1.01-1.92; P = 0.04) and CLPTM1L-TERT (rs401681; OR, 1.16; 95% CI, 1.01-1.34; P = 0.04). None of these associations remained significant after correcting for multiple comparisons. Conclusion: Reported variants of melanoma genes and pathways do not play a role in pancreatic cancer predisposition. Reciprocally, pancreatic cancer susceptibility variants are not associated with melanoma risk. Impact: Known melanoma-related genes and pathways, as well as GWAS-derived susceptibility variants of melanoma and pancreatic cancer, do not explain the shared genetic etiology of these two cancers. (C) 2014 AACR. C1 [Wu, Lang; Rabe, Kari G.; Petersen, Gloria M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA. [Goldstein, Alisa M.; Yu, Kai; Yang, Xiaohong Rose; Stolzenberg-Solomon, Rachael; Amundadottir, Laufey T.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Arslan, Alan A.] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA. [Arslan, Alan A.] NYU, Sch Med, Dept Environm Med, New York, NY USA. [Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Canzian, Federico] German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany. RP Petersen, GM (reprint author), Mayo Clin, Coll Med, Dept Hlth Sci Res, 200 First St Southwest, Rochester, MN 55905 USA. EM Petersen.Gloria@mayo.edu RI Amundadottir, Laufey/L-7656-2016 OI Amundadottir, Laufey/0000-0003-1859-8971 FU Mayo Clinic SPORE in Pancreatic Cancer [P50CA102701]; Intramural Research Program of the NIH, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG); NIH/NCRR CTSA [TL1 RR024152]; [R01CA97075] FX This study was supported in part by Mayo Clinic SPORE in Pancreatic Cancer (P50CA102701), R01CA97075, and the Intramural Research Program of the NIH, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG). L. Wu is a trainee in the program funded by NIH/NCRR CTSA grant number TL1 RR024152. NR 8 TC 10 Z9 11 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUN PY 2014 VL 23 IS 6 BP 1121 EP 1124 DI 10.1158/1055-9965.EPI-13-0627 PG 4 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA AT9UD UT WOS:000345270800025 PM 24642353 ER PT J AU Choi, JE Mostoslavsky, R AF Choi, Jee-Eun Mostoslavsky, Raul TI Sirtuins, metabolism, and DNA repair SO CURRENT OPINION IN GENETICS & DEVELOPMENT LA English DT Article ID FATTY-ACID OXIDATION; HISTONE DEACETYLASE SIRT6; TUMOR-SUPPRESSOR; CELL-CYCLE; GLUTAMINE-METABOLISM; CALORIE RESTRICTION; GENOMIC INSTABILITY; MAMMALIAN SIRTUINS; LIPID-METABOLISM; SKELETAL-MUSCLE AB Cells evolve to actively coordinate nutrient availability with cellular activity in order to maintain metabolic homeostasis. In addition, active pathways to repair DNA damage are crucial to avoid deleterious genomic instability. In recent years, it has become increasingly clear that availability of intermediate metabolites may play an important role in DNA repair, suggesting that these two seemingly distant cellular activities may be highly coordinated. The sirtuin family of proteins now described as deacylases (they can also remove acyl groups other than acetyl moieties), it appears to have evolved to control both metabolism and DNA repair. In this review, we discuss recent advances that lay the foundation to understanding the role of sirtuins in these two biological processes, and the potential crosstalk to coordinate them. C1 [Choi, Jee-Eun] Harvard Univ, Biol & Biomed Sci Grad Program, Sch Med, Boston, MA 02115 USA. [Choi, Jee-Eun; Mostoslavsky, Raul] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. RP Mostoslavsky, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. EM rmostoslavsky@mgh.harvard.edu FU NIH [GM093072-01, DK088190-01A1, CA175727-01A1]; National Pancreatic Foundation FX Work in the Mostoslavsky lab is supported in part by NIH grants GM093072-01, DK088190-01A1, CA175727-01A1 and the National Pancreatic Foundation. RM is the Kristine and Bob Higgins MGH Research Scholar, a Howard Goodman Awardee and the Andrew Warshaw Institute for Pancreatic Cancer Research Fellow. NR 86 TC 31 Z9 32 U1 0 U2 10 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0959-437X EI 1879-0380 J9 CURR OPIN GENET DEV JI Curr. Opin. Genet. Dev. PD JUN PY 2014 VL 26 BP 24 EP 32 DI 10.1016/j.gde.2014.05.005 PG 9 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA AT6PH UT WOS:000345060800005 PM 25005742 ER PT J AU Drapeau, E Dorr, NP Elder, GA Buxbaum, JD AF Drapeau, Elodie Dorr, Nate P. Elder, Gregory A. Buxbaum, Joseph D. TI Absence of strong strain effects in behavioral analyses of Shank3-deficient mice SO DISEASE MODELS & MECHANISMS LA English DT Article DE Shank3; Phelan-McDermid syndrome; Autism spectrum disorders; 22q13; Mouse strain; Genetic modifier; Behavior ID AUTISM SPECTRUM DISORDERS; 22Q13 DELETION SYNDROME; COPY NUMBER VARIATION; INBRED MOUSE STRAINS; POSTSYNAPTIC DENSITY PROTEINS; KNOCKOUT MICE; MUTANT MICE; SYNAPTIC FUNCTION; LABORATORY MICE; SHANK FAMILY AB Haploinsufficiency of SHANK3, caused by chromosomal abnormalities or mutations that disrupt one copy of the gene, leads to a neurodevelopmental syndrome called Phelan-McDermid syndrome, symptoms of which can include absent or delayed speech, intellectual disability, neurological changes and autism spectrum disorders. The SHANK3 protein forms a key structural part of the post-synaptic density. We previously generated and characterized mice with a targeted disruption of Shank3 in which exons coding for the ankyrin-repeat domain were deleted and expression of full-length Shank3 was disrupted. We documented specific deficits in synaptic function and plasticity, along with reduced reciprocal social interactions, in Shank3 heterozygous mice. Changes in phenotype owing to a mutation at a single locus are quite frequently modulated by other loci, most dramatically when the entire genetic background is changed. In mice, each strain of laboratory mouse represents a distinct genetic background and alterations in phenotype owing to gene knockout or transgenesis are frequently different across strains, which can lead to the identification of important modifier loci. We have investigated the effect of genetic background on phenotypes of Shank3 heterozygous, knockout and wild-type mice, using C57BL/6, 129SVE and FVB/Ntac strain backgrounds. We focused on observable behaviors with the goal of carrying out subsequent analyses to identify modifier loci. Surprisingly, there were very modest strain effects over a large battery of analyses. These results indicate that behavioral phenotypes associated with Shank3 haploinsufficiency are largely strain-independent. C1 [Drapeau, Elodie; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA. [Drapeau, Elodie; Dorr, Nate P.; Elder, Gregory A.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Elder, Gregory A.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Elder, Gregory A.] James J Peters VA Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Syst Biol Ctr New York, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA. RP Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA. EM joseph.buxbaum@mssm.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU National Institutes of Health [R01MH093725]; Beatrice and Samuel A. Seaver Foundation; Simons Foundation Autism Research Initiative FX This work was supported by the National Institutes of Health [grant number: R01MH093725], the Beatrice and Samuel A. Seaver Foundation, and the Simons Foundation Autism Research Initiative. NR 75 TC 8 Z9 8 U1 1 U2 7 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 1754-8403 EI 1754-8411 J9 DIS MODEL MECH JI Dis. Model. Mech. PD JUN PY 2014 VL 7 IS 6 BP 667 EP 681 DI 10.1242/dmm.013821 PG 15 WC Cell Biology; Pathology SC Cell Biology; Pathology GA AT5SQ UT WOS:000345002600008 PM 24652766 ER PT J AU Gonzalez-Quesada, CJ Giugliano, RP AF Gonzalez-Quesada, Carlos J. Giugliano, Robert P. TI Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice (vol 14, pg 111, 2014) SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS LA English DT Correction C1 [Gonzalez-Quesada, Carlos J.] Brigham & Womens Hosp, Dept Med, Phyllis Jen Ctr Primary Care, Boston, MA 02115 USA. [Giugliano, Robert P.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA. RP Giugliano, RP (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA. EM rgiugliano@partners.org NR 1 TC 0 Z9 0 U1 0 U2 0 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1175-3277 EI 1179-187X J9 AM J CARDIOVASC DRUG JI Am. J. Cardiovasc. Drugs PD JUN PY 2014 VL 14 IS 3 BP 237 EP 237 DI 10.1007/s40256-014-0075-2 PG 1 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA AT0BA UT WOS:000344600600008 ER PT J AU Wu, Y Johnson, KB Roccaro, G Lopez, J Zheng, H Muiru, A Ufere, N Rajbhandari, R Kattan, O Chung, RT AF Wu, Ying Johnson, Kara B. Roccaro, Giorgio Lopez, Joanna Zheng, Hui Muiru, Anthony Ufere, Nneka Rajbhandari, Ruma Kattan, Omar Chung, Raymond T. TI Poor Adherence to AASLD Guidelines for Chronic Hepatitis B Management and Treatment in a Large Academic Medical Center SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID PERSISTENTLY NORMAL ALT; VIRUS INFECTION; POPULATION; CIRRHOSIS; UPDATE; LEVEL; HBV AB OBJECTIVES: Adherence to the American Association for the Study of Liver Disease (AASLD) guidelines for the management of chronic hepatitis B (CHB) has not been systematically assessed. We sought to comprehensively evaluate adherence to five key areas of these guidelines. We also evaluated physician and patient factors underlying nonadherence, and predictors of nonadherence such as physician type, patient demographic factors, and phase of CHB infection. METHODS: Nine hundred and sixty-two adult patients were retrospectively identified. Each patient chart was reviewed in detail. The primary outcome was adherence to five areas of the AASLD guidelines: (i) timely alanine aminotransferase (ALT)/hepatitis B virus DNA level checks needed to monitor inactive carrier and immune-tolerant phases; (ii) liver biopsy to guide decisions on initiating treatment; (iii) treatment initiation when indicated; (iv) hepatocellular carcinoma (HCC) screening; (v) testing for hepatitis A virus (HAV) immunity, HIV, and hepatitis C virus (HCV) co-infections. RESULTS: Sixty percent did not undergo clinically indicated liver biopsies, largely owing to physician nonadherence. Eighty-nine percent of these missed biopsies were needed to further assess possible e-antigen-negative CHB. A high treatment initiation rate was found for the treatment eligible, but 121 patients had unclear treatment eligibility as they warranted, but did not undergo, liver biopsy. Forty-five percent did not have timely HCC screening, although gastroenterology physicians had the highest odds of adherence, and 29 % did not have timely CHB lab assessment; patients seen by gastroenterologists had twice the odds compared with primary care physicians of undergoing timely lab monitoring. Thirty-five, 24, and 54 % were not tested for HAV, HCV, and HIV co-infections. CONCLUSIONS: Our findings show remarkably poor adherence to AASLD guidelines, particularly in the areas of liver biopsy, timely HCC and ALT monitoring, and testing for co-infection. These findings call for greater efforts to meet physician knowledge gaps, incorporation of decision support tools, and improved communication among providers. C1 [Wu, Ying; Johnson, Kara B.; Rajbhandari, Ruma; Chung, Raymond T.] Massachusetts Gen Hosp, Ctr Liver, Boston, MA 02114 USA. [Wu, Ying; Johnson, Kara B.; Rajbhandari, Ruma; Chung, Raymond T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Wu, Ying; Johnson, Kara B.; Roccaro, Giorgio; Lopez, Joanna; Zheng, Hui; Muiru, Anthony; Ufere, Nneka; Rajbhandari, Ruma; Kattan, Omar; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Wu, Ying; Johnson, Kara B.; Roccaro, Giorgio; Lopez, Joanna; Muiru, Anthony; Ufere, Nneka; Rajbhandari, Ruma; Kattan, Omar; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RP Chung, RT (reprint author), Massachusetts Gen Hosp, Ctr Liver, 55 Fruit St, Boston, MA 02114 USA. EM RTChung@partners.org OI Rajbhandari, Ruma/0000-0001-8281-550X FU Bristol Myers Squibb Virology Fellowship; NIH [DK007191, DK078772] FX Financial assistance was provided by Bristol Myers Squibb Virology Fellowship; and NIH DK007191 (Ying Wu, Kara B. Johnson) DK078772 (Raymond T. Chung). NR 25 TC 17 Z9 18 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUN PY 2014 VL 109 IS 6 BP 867 EP 875 DI 10.1038/ajg.2014.72 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS7UA UT WOS:000344458900012 PM 24732869 ER PT J AU Huang, SA AF Huang, Stephen A. TI A Baby Boy with Hypothyroidism and Hemangioendothelioma Comment SO CLINICAL CHEMISTRY LA English DT Editorial Material C1 [Huang, Stephen A.] Boston Childrens Hosp, Div Endocrinol, Thyroid Program, Boston, MA 02115 USA. [Huang, Stephen A.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Thyroid Sect, Boston, MA 02115 USA. [Huang, Stephen A.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Huang, SA (reprint author), Boston Childrens Hosp, 300 Long Wood Ave, Boston, MA 02115 USA. EM stephen.huang@childrens.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD JUN PY 2014 VL 60 IS 6 BP 821 EP 821 DI 10.1373/clinchem.2013.214304 PG 1 WC Medical Laboratory Technology SC Medical Laboratory Technology GA AT2QG UT WOS:000344778600006 PM 24872367 ER PT J AU Hershenberg, R Gros, DF Brawman-Mintzer, O AF Hershenberg, Rachel Gros, Daniel F. Brawman-Mintzer, Olga TI Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder SO CNS DRUGS LA English DT Review ID FUMARATE QUETIAPINE XR; SEROTONIN REUPTAKE INHIBITORS; OBSESSIVE-COMPULSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; POSTTRAUMATIC-STRESS-DISORDER; MAJOR DEPRESSIVE DISORDER; OPEN-LABEL TRIAL; DOUBLE-BLIND; PANIC DISORDER; PRIMARY-CARE AB Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines, pregabalin, which gained European Commission approval. Although short- and long-term efficacy have been established for these agents in controlled trials, response rates of 60-70 % are insufficient, remission rates are relatively modest, and relapse rates considerable. Moreover, questions increasingly arise regarding tolerability and side-effect profiles. As an alternative, antipsychotics have long been of interest for the treatment of anxiety disorders, but investigation had been tempered by their potential for irreversible side effects. With the improved side-effect profiles of atypical antipsychotics, these agents are increasingly being investigated across Axis I disorders. Atypical antipsychotics such as quetiapine, aripiprazole, olanzapine, and risperidone have been shown to be helpful in addressing a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and have since been used in the treatment of a range of mood and anxiety disorders. In this article, we review the efficacy and tolerability of atypical antipsychotics as adjunctive therapy and/or monotherapy for individuals with GAD, a currently off-label indication. The most evidence has accumulated for quetiapine. Findings suggest that approximately 50 % of participants tolerate the side effects, most commonly sedation and fatigue. Among this subset, those who continue treatment demonstrate significant reductions in anxiety when used as adjunctive therapy or monotherapy. The appropriateness of the use of antipsychotics in the treatment of GAD is discussed. C1 [Hershenberg, Rachel] Philadelphia VA Med Ctr, Educ & Clin Ctr, VISN Mental Illness Res 4, Philadelphia, PA 19104 USA. [Hershenberg, Rachel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gros, Daniel F.; Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Gros, Daniel F.; Brawman-Mintzer, Olga] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Brawman-Mintzer, O (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. EM rhersh@mail.med.upenn.edu; mintzero@musc.edu FU Forest Laboratories FX This material is the result of work supported with resources and the use of facilities of the VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA, and the Ralph H. Johnson Veterans Affairs Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. There were no conflicts of interest in the preparation of this manuscript for Drs. Rachel Hershenberg or Daniel F. Gros. Dr. Olga Brawman-Mintzer received grant support from Forest Laboratories. NR 97 TC 8 Z9 8 U1 6 U2 16 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1172-7047 EI 1179-1934 J9 CNS DRUGS JI CNS Drugs PD JUN PY 2014 VL 28 IS 6 BP 519 EP 533 DI 10.1007/s40263-014-0162-6 PG 15 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AT0FT UT WOS:000344613300004 PM 24794100 ER PT J AU Fisher, LB Overholser, JC AF Fisher, Lauren B. Overholser, James C. TI The Measurement of Positive Attitudes: The Glass is Half Full SO JOURNAL OF RATIONAL-EMOTIVE AND COGNITIVE-BEHAVIOR THERAPY LA English DT Article DE Positive cognitions; Positive thoughts; Depression; Assessment; Coping ID BECK DEPRESSION INVENTORY; SUICIDE IDEATION; PSYCHIATRIC OUTPATIENTS; COGNITIVE VULNERABILITY; HOPELESSNESS SCALE; PSYCHOMETRIC PROPERTIES; EVENTUAL SUICIDE; FUTURE THINKING; LIFE; DISORDERS AB Positive thoughts play a significant role in the experience and recovery from depression. The Coping Attitudes Scale (CAS) is a rationally derived measure of positive cognitions. The CAS contains statements reflective of coping attitudes along five domains: life perspective, personal accomplishment, positive future, self-worth, and coping with problems. The current study examined the CAS in psychiatric outpatients and college students. Measures of depression, hopelessness, suicidal ideation and positive attitudes were administered to 82 adult psychiatric outpatients and 156 college students. Depression and hopelessness were strongly, negatively, partially correlated with each of the CAS factors, after controlling for age. Relationships among individual CAS factors and suicidal ideation demonstrated weak to moderate partial associations, after controlling for age. Depression was significantly associated with the coping with problems subscale (R-2 = .530). Hopelessness was significantly related to the positive future subscale (R-2 = .696). Further, the CAS demonstrated a significant relationship with depression and hopelessness, even after accounting for the Automatic Thoughts Questionnaire-Revised, Positive subscale. The CAS may be an improved measure of positive attitudes that could be useful in establishing a patient's baseline of positive thinking, determining targets for therapy, and in monitoring progress in treatment. C1 [Fisher, Lauren B.] Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Overholser, James C.] Case Western Reserve Univ, Dept Psychol Sci, Cleveland, OH 44106 USA. RP Fisher, LB (reprint author), Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, One Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM lbfisher@partners.org NR 60 TC 1 Z9 1 U1 3 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-9085 EI 1573-6563 J9 J RATION-EMOT COGN-B JI J. Ration.-Emot. Cogn.-Behav. Ther. PD JUN PY 2014 VL 32 IS 2 BP 121 EP 138 DI 10.1007/s10942-013-0173-0 PG 18 WC Psychology, Clinical SC Psychology GA AT0IP UT WOS:000344620400001 ER PT J AU Aslakson, RA Schuster, ALR Miller, J Weiss, M Volandes, AE Bridges, JFP AF Aslakson, Rebecca A. Schuster, Anne L. R. Miller, Judith Weiss, Matthew Volandes, Angelo E. Bridges, John F. P. TI An Environmental Scan of Advance Care Planning Decision Aids for Patients Undergoing Major Surgery: A Study Protocol SO PATIENT-PATIENT CENTERED OUTCOMES RESEARCH LA English DT Article ID CONJOINT-ANALYSIS; CONTROLLED-TRIAL; PALLIATIVE CARE; VIDEO IMAGES; LIFE; END; INTERVENTIONS; DIRECTIVES; HEALTH; OUTCOMES AB Background Patients who undergo major surgery are at risk for perioperative morbidity and mortality. It would be appropriate to initiate advance care planning with patients prior to surgery, but surgeons may experience difficulty initiating such conversations. Rather than focus on changing clinician behavior, advance care planning decision aids can be an innovative vehicle to motivate advance care planning among surgical patients and their families. Objective The purpose of this paper is to describe a study protocol for conducting an environmental scan concerning advance care planning decision aids that may be relevant to patients undergoing high-risk surgery. Methods/design This study will gather information from written or verbal data sources that incorporate professional and lay perspectives: a systematic review, a grey literature review, key informant interviews, and patient and family engagement. It is envisioned that this study will generate three outcomes: a synthesis of current evidence, a summary of gaps in knowledge, and a taxonomy of existing advance care planning decision aids. Discussion This environmental scan will demonstrate principles of patient-centered outcomes research, and it will exemplify a pioneering approach for reviewing complex interventions. Anticipated limitations are that information will be gathered from a small sample of patients and families, and that potentially relevant information could also be missing from the environmental scan due to the inclusion/exclusion criteria. Outcomes from the environmental scan will inform future patient-centered research to develop and evaluate a new decision aid. C1 [Aslakson, Rebecca A.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA. [Schuster, Anne L. R.; Bridges, John F. P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Weiss, Matthew] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA. [Volandes, Angelo E.] Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA. RP Aslakson, RA (reprint author), Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, 600 North Wolfe St,Meyer 297A, Baltimore, MD 21287 USA. EM raslaks1@jhmi.edu FU Patient-Centered Outcomes Research Institute (PCORI) Communication and Dissemination Research Award [CD-12-11-4362] FX This work was (partially) supported through a Patient-Centered Outcomes Research Institute (PCORI) Communication and Dissemination Research Award (CD-12-11-4362). NR 47 TC 4 Z9 4 U1 4 U2 12 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1178-1653 EI 1178-1661 J9 PATIENT JI Patient PD JUN PY 2014 VL 7 IS 2 BP 207 EP 217 DI 10.1007/s40271-014-0046-3 PG 11 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AS6IH UT WOS:000344366900009 PM 24469597 ER PT J AU Garrett-Bakelman, FE Li, S Chung, S Hricik, T Rapaport, F Mayden, C Bar, H Liu, L Patel, J Sheridan, C Ishii, J Zumbo, P Gandara, J Becker, M Brown, A Lewis, ID To, LB D'Andrea, RJ Dohner, K Bullinger, L Dohner, H Sanders, M Valk, PJ Delwel, R Lowenberg, B Michor, F Guzman, M Park, C Carroll, M Levine, R Mason, CE Melnick, A AF Garrett-Bakelman, F. E. Li, S. Chung, S. Hricik, T. Rapaport, F. Mayden, C. Bar, H. Liu, L. Patel, J. Sheridan, C. Ishii, J. Zumbo, P. Gandara, J. Becker, M. Brown, A. Lewis, I. D. To, L. Bik D'Andrea, R. J. Doehner, K. Bullinger, L. Doehner, H. Sanders, M. Valk, P. J. Delwel, R. Lowenberg, B. Michor, F. Guzman, M. Park, C. Carroll, M. Levine, R. Mason, C. E. Melnick, A. TI DNA METHYLATION PATTERNS AT DISEASE RELAPSE IN ACUTE MYELOID LEUKEMIA TARGET CONVERGENT ELEMENTS AND PATHWAYS DESPITE INTER-PATIENT HETEROGENEITY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Garrett-Bakelman, F. E.; Melnick, A.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Li, S.; Mayden, C.; Zumbo, P.; Gandara, J.; Mason, C. E.] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY USA. [Li, S.; Mason, C. E.] Weill Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY USA. [Chung, S.; Hricik, T.; Rapaport, F.; Patel, J.; Park, C.; Levine, R.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Bar, H.] Cornell Univ, Dept Stat Sci, Ithaca, NY USA. [Liu, L.] Harvard Univ, Sch Med, Boston, MA USA. [Sheridan, C.; Ishii, J.] Weill Cornell Med Coll, Epigen Core, New York, NY USA. [Zumbo, P.] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY USA. [Becker, M.] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY 14627 USA. [Brown, A.; D'Andrea, R. J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia. [Brown, A.; D'Andrea, R. J.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia. [Brown, A.; Lewis, I. D.; To, L. Bik; D'Andrea, R. J.] SA Pathol, Directorate Haematol, Adelaide, SA, Australia. [Brown, A.; Lewis, I. D.; To, L. Bik; D'Andrea, R. J.] Univ Adelaide, Adelaide, SA, Australia. [Doehner, K.; Bullinger, L.; Doehner, H.] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany. [Sanders, M.; Valk, P. J.; Delwel, R.; Lowenberg, B.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands. [Michor, F.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Guzman, M.] Weill Cornell Med Coll, New York, NY USA. [Carroll, M.] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA. [Levine, R.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P137 BP 16 EP 16 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900039 ER PT J AU Brown, JR Harb, WA Hill, BT Gabrilove, J Sharman, JP Schreeder, MT Barr, PM Foran, JM Miller, TP Burger, JA Kelly, KR Mahadevan, D Ma, S Barnett, E Marine, J Nava-Parada, P Azaryan, A Mei, J Kipps, TJ AF Brown, J. R. Harb, W. A. Hill, B. T. Gabrilove, J. Sharman, J. P. Schreeder, M. T. Barr, P. M. Foran, J. M. Miller, T. P. Burger, J. A. Kelly, K. R. Mahadevan, D. Ma, S. Barnett, E. Marine, J. Nava-Parada, P. Azaryan, A. Mei, J. Kipps, T. J. TI PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Brown, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Harb, W. A.] Horizon Oncol Ctr, Lafayette, IN 47905 USA. [Hill, B. T.] Cleveland Clin, Taussig Canc Inst, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA. [Gabrilove, J.] Mt Sinai Sch Med, New York, NY USA. [Sharman, J. P.] Willamette Valley Canc Inst, Eugene, OR USA. [Sharman, J. P.] Res Ctr US Oncol Res, Eugene, OR USA. [Schreeder, M. T.] Clearview Canc Inst, Huntsville, AL 35805 USA. [Barr, P. M.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA. [Foran, J. M.] Mayo Clin, Jacksonville, FL USA. [Miller, T. P.] Univ Arizona, Ctr Canc, Tucson, AZ USA. [Burger, J. A.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kelly, K. R.] Univ Texas Hlth Sci Ctr San Antonio, CTRC Inst Drug Dev, San Antonio, TX 78229 USA. [Mahadevan, D.] Univ Tennessee, Ctr Hlth Sci, ACORN Res LLC, West Clin, Memphis, TN 38163 USA. [Ma, S.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Barnett, E.; Marine, J.; Nava-Parada, P.; Mei, J.] Celgene Corp, Summit, NJ USA. [Azaryan, A.] Celgene Corp, Berkeley Hts, NJ USA. [Kipps, T. J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P235 BP 54 EP 55 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900136 ER PT J AU Michele, C Cagnetta, A Tai, YT Chauhan, D Nencioni, A Patrone, F Gobbi, M Munshi, N Anderson, KC AF Michele, C. Cagnetta, A. Tai, Y. T. Chauhan, D. Nencioni, A. Patrone, F. Gobbi, M. Munshi, N. Anderson, K. C. TI IDENTIFICATION OF NOVEL ALTERNATIVE SPLICE VARIANTS OF SIRTUINS IN MULTIPLE MYELOMA: A BIOLOGICALLY RELEVANT INDICATOR OF POOR OUTCOME SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Michele, C.; Cagnetta, A.; Nencioni, A.; Patrone, F.; Gobbi, M.] IRCCS AOU San Martino IST, Genoa, Italy. [Michele, C.; Cagnetta, A.; Tai, Y. T.; Chauhan, D.; Munshi, N.; Anderson, K. C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P327 BP 94 EP 94 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900228 ER PT J AU Fulciniti, M Samur, MK Bandi, R Bashin, M Shah, P Gkotzamanidou, M Cagnetta, A Magrangeas, F Minvielle, S Li, C Anderson, K Avet-Ioiseau, H Munshi, N AF Fulciniti, M. Samur, M. Kemal Bandi, R. Bashin, M. Shah, P. Gkotzamanidou, M. Cagnetta, A. Magrangeas, F. Minvielle, S. Li, C. Anderson, K. Avet-Ioiseau, H. Munshi, N. TI TRANSCRIPTIONAL REGULATION OF ALTERNATE SPLICING BY DP1 AND THEIR FUNCTIONAL IMPACT IN MULTIPLE MYELOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Fulciniti, M.; Samur, M. Kemal; Bandi, R.; Bashin, M.; Shah, P.; Gkotzamanidou, M.; Cagnetta, A.; Li, C.; Anderson, K.; Munshi, N.] Dana Farber Canc Inst, Boston, MA USA. [Magrangeas, F.; Minvielle, S.] Ctr Canc Res, Nantes, France. [Avet-Ioiseau, H.] Unite Genom Myelome, Toulouse, France. RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P339 BP 99 EP 100 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900240 ER PT J AU Gkotzamanidou, M Shammas, M Dimopoulos, AM Anderson, KC Munshi, NC Souliotis, VL AF Gkotzamanidou, M. Shammas, M. Dimopoulos, A. M. Anderson, K. C. Munshi, N. C. Souliotis, V. L. TI MODIFYING DNA REPAIR PATHWAYS IN CHEMOTHERAPY BY GENOTOXIC DRUGS - TOWARDS PERSONALIZED MYELOMA THERAPY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Gkotzamanidou, M.; Shammas, M.; Anderson, K. C.; Munshi, N. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Dimopoulos, A. M.] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece. [Souliotis, V. L.] Natl Hellen Res Fdn, Athens, Greece. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P344 BP 101 EP 101 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900245 ER PT J AU Plesner, T Arkenau, HT Lokhorst, HM Gimsing, P Krejcik, J Lemech, C Minnema, MC Lassen, U Ahmadi, T Yeh, H Guckert, M Brun, NC Lisby, S Basse, L Palumbo, A Richardson, PG AF Plesner, T. Arkenau, H. T. Lokhorst, H. M. Gimsing, P. Krejcik, J. Lemech, C. Minnema, M. C. Lassen, U. Ahmadi, T. Yeh, H. Guckert, M. Brun, N. C. Lisby, S. Basse, L. Palumbo, A. Richardson, P. G. TI SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Plesner, T.; Krejcik, J.] Vejle Hosp, Vejle, Denmark. [Arkenau, H. T.; Lemech, C.] Sarah Cannon Res Ctr, London, England. [Lokhorst, H. M.; Minnema, M. C.] UMC Utrecht, Utrecht, Netherlands. [Gimsing, P.; Lassen, U.] Univ Copenhagen, Copenhagen, Denmark. [Ahmadi, T.; Yeh, H.; Guckert, M.] Janssen Res & Dev, Raritan, NJ USA. [Brun, N. C.; Lisby, S.; Basse, L.] Genmab AS, Copenhagen, Denmark. [Palumbo, A.] Univ Turin, Turin, Italy. [Richardson, P. G.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P350 BP 104 EP 104 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900251 ER PT J AU Richardson, P Hofmeister, C Raje, N Siegel, D Lonial, S Laubach, J Efebera, Y Vesole, DH Nooka, AK Rosenblatt, J Zaki, MH Hua, Y Li, Y Shah, S Wang, J Anderson, KC AF Richardson, P. Hofmeister, C. Raje, N. Siegel, D. Lonial, S. Laubach, J. Efebera, Y. Vesole, D. H. Nooka, A. K. Rosenblatt, J. Zaki, M. H. Hua, Y. Li, Y. Shah, S. Wang, J. Anderson, K. C. TI POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN LENALIDOMIDE-REFRACTORY AND PROTEASOME INHIBITOR-EXPOSED MYELOMA: THE MM-005 TRIAL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Richardson, P.; Laubach, J.; Anderson, K. C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Hofmeister, C.] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA. [Raje, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Siegel, D.; Vesole, D. H.] Hackensack UMC, John Theurer Canc Ctr, Hackensack, NJ USA. [Lonial, S.; Nooka, A. K.] Winship Canc Inst, Atlanta, GA USA. [Efebera, Y.] Ohio State Univ, Columbus, OH 43210 USA. [Rosenblatt, J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Zaki, M. H.; Hua, Y.; Li, Y.; Shah, S.; Wang, J.] Celgene Corp, Summit, NJ USA. RI Efebera, Yvonne/E-3012-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P351 BP 104 EP 104 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900252 ER PT J AU Lokhorst, H Laubach, J Nahi, H Plesner, T Gimsing, P Hansson, M Minnema, M Lassen, U Krejcik, J Ahmadi, T Khan, I Uhlar, C Lisby, S Basse, L Brun, N Richardson, P AF Lokhorst, H. Laubach, J. Nahi, H. Plesner, T. Gimsing, P. Hansson, M. Minnema, M. Lassen, U. Krejcik, J. Ahmadi, T. Khan, I. Uhlar, C. Lisby, S. Basse, L. Brun, N. Richardson, P. TI DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Lokhorst, H.; Minnema, M.] UMC Utrecht, Utrecht, Netherlands. [Laubach, J.; Richardson, P.] Harvard Univ, Sch Med, Boston, MA USA. [Laubach, J.; Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nahi, H.] Karolinska Inst Internal Med, Stockholm, Sweden. [Plesner, T.; Krejcik, J.] Vejle Hosp, Vejle, Denmark. [Gimsing, P.; Lassen, U.] Univ Copenhagen Hosp, DK-2100 Copenhagen, Denmark. [Hansson, M.] Lund Univ, Stockholm, Sweden. [Ahmadi, T.; Khan, I.; Uhlar, C.] Janssen R&D, Raritan, NJ USA. [Lisby, S.; Basse, L.; Brun, N.] Genmab AS, Copenhagen, Denmark. NR 1 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P356 BP 106 EP 107 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900257 ER PT J AU Richardson, PG Rosenbaum, CA Hofmeister, CC Htut, M Vesole, DH Berdeja, JG Liedtke, M Chari, A Smith, SD Lebovic, D Berg, D Liao, E Tejura, B Hui, AM Baz, R AF Richardson, P. G. Rosenbaum, C. A. Hofmeister, C. C. Htut, M. Vesole, D. H. Berdeja, J. G. Liedtke, M. Chari, A. Smith, S. D. Lebovic, D. Berg, D. Liao, E. Tejura, B. Hui, A. M. Baz, R. TI ORAL INVESTIGATIONAL PROTEASOME INHIBITOR IXAZOMIB CITRATE (MLN9708) PLUS LENALIDOMIDE-DEXAMETHASONE IN ELDERLY PATIENTS (PTS) WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Richardson, P. G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rosenbaum, C. A.] Univ Chicago, Chicago, IL 60637 USA. [Hofmeister, C. C.] Ohio State Univ, Columbus, OH 43210 USA. [Htut, M.] City Hope Natl Med, Hematol & Stem Cell Transplant, Duarte, CA USA. [Vesole, D. H.] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA. [Berdeja, J. G.] Sarah Cannon Res Inst, Nashville, TN USA. [Liedtke, M.] Stanford Canc Inst, Stanford, CA USA. [Chari, A.] Mt Sinai Sch Med, New York, NY USA. [Smith, S. D.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Lebovic, D.] Univ Michigan, Ann Arbor, MI 48109 USA. [Berg, D.; Liao, E.; Tejura, B.; Hui, A. M.] Takeda Pharmaceut Int Co, Cambridge, MA USA. [Baz, R.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P355 BP 106 EP 106 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900256 ER PT J AU Raje, N Vogl, D Bensinger, W Voorhees, P Hari, P Berdeja, J Jagannath, S Jones, S Wheeler, C Supko, J Orlowski, R Richardson, P Lonial, S AF Raje, N. Vogl, D. Bensinger, W. Voorhees, P. Hari, P. Berdeja, J. Jagannath, S. Jones, S. Wheeler, C. Supko, J. Orlowski, R. Richardson, P. Lonial, S. TI RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Raje, N.; Supko, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Vogl, D.] Univ Penn, Philadelphia, PA 19104 USA. [Bensinger, W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Voorhees, P.] Univ N Carolina, Chapel Hill, NC USA. [Hari, P.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Berdeja, J.] Sarah Cannon Res Inst, Nashville, TN USA. [Jagannath, S.] Mt Sinai Hosp, New York, NY 10029 USA. [Jones, S.; Wheeler, C.] Acetylon Pharmaceut Inc, Boston, MA USA. [Orlowski, R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lonial, S.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P358 BP 107 EP 108 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900259 ER PT J AU Laubach, JP Raje, N Armand, P Schlossman, RL Rosenblatt, J Matous, JV Hedlund, J Martin, M Reynolds, C Shain, KH Zackon, I Stampleman, L Boswell, EN Chuma, S Liguori, R Handisides, DR Kroll, S Anderson, KC Richardson, PG Ghobrial, IM AF Laubach, J. P. Raje, N. Armand, P. Schlossman, R. L. Rosenblatt, J. Matous, J. V. Hedlund, J. Martin, M. Reynolds, C. Shain, K. H. Zackon, I. Stampleman, L. Boswell, E. N. Chuma, S. Liguori, R. Handisides, D. R. Kroll, S. Anderson, K. C. Richardson, P. G. Ghobrial, I. M. TI PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Laubach, J. P.; Armand, P.; Schlossman, R. L.; Boswell, E. N.; Chuma, S.; Liguori, R.; Anderson, K. C.; Richardson, P. G.; Ghobrial, I. M.] Harvard Univ, Dana Farber Canc Inst, Sch Med, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Cambridge, MA 02138 USA. [Raje, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rosenblatt, J.] Beth Israel Deaconess, Boston, MA USA. [Matous, J. V.] Colorado Blood Canc Inst, Denver, CO USA. [Hedlund, J.] Maine Ctr Canc Med, Scarborough, ME USA. [Hedlund, J.; Martin, M.; Reynolds, C.; Zackon, I.; Stampleman, L.; Liguori, R.; Ghobrial, I. M.] Blood Canc Res Partnership, Boston, MA USA. [Martin, M.] West Clin, Memphis, TN USA. [Reynolds, C.] Ocala Oncol Ctr, Ocala, FL USA. [Shain, K. H.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Zackon, I.] New York Oncol, Hematol, Albany, NY USA. [Stampleman, L.] Pacific Canc Care, Salina, CA USA. [Handisides, D. R.; Kroll, S.] Threshold Pharmaceut Inc, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P360 BP 108 EP 109 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900261 ER PT J AU Rampal, R Al-Shahrour, F Abdel-Wahab, O Patel, J Brunel, JP Mermel, C Bass, A Pretz, J Ahn, J Hricik, T Kilpivaara, O Wadleigh, M Busque, L Gililand, DG Golub, T Ebert, B Levine, R AF Rampal, R. Al-Shahrour, F. Abdel-Wahab, O. Patel, J. Brunel, J. P. Mermel, C. Bass, A. Pretz, J. Ahn, J. Hricik, T. Kilpivaara, O. Wadleigh, M. Busque, L. Gililand, D. G. Golub, T. Ebert, B. Levine, R. TI INTEGRATED GENOMIC ANALYSIS ILLUSTRATES THE CENTRAL ROLE OF JAK-STAT PATHWAY ACTIVATION IN MYELOPROLIFERATIVE NEOPLASM PATHOGENESIS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Rampal, R.; Abdel-Wahab, O.; Patel, J.; Ahn, J.; Hricik, T.; Levine, R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Al-Shahrour, F.; Brunel, J. P.; Bass, A.; Pretz, J.; Wadleigh, M.; Ebert, B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mermel, C.; Golub, T.] Broad Inst Harvard Univ & MIT, Boston, MA USA. [Kilpivaara, O.] Univ Helsinki, Helsinki, Finland. [Busque, L.] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada. [Gililand, D. G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P390 BP 121 EP 121 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900291 ER PT J AU Kuruvilla, J Cerchietti, L Wagner-Johnston, N Stone, R Jacobsen, E Mau-Sorensen, M Brown, P Baz, R Shal, B Flynn, J Flinn, I Kukreti, V Tiedemann, R Goy, A Landesman, Y Klebanov, B Shacham, E Saint-Martin, JR Marshall, T McCartney, J McCauley, D Carlson, R Rebello, S Rashal, T Mirza, MR Shacham, S Kauffman, M Gutierrez, M AF Kuruvilla, J. Cerchietti, L. Wagner-Johnston, N. Stone, R. Jacobsen, E. Mau-Sorensen, M. Brown, P. Baz, R. Shal, B. Flynn, J. Flinn, I. Kukreti, V. Tiedemann, R. Goy, A. Landesman, Y. Klebanov, B. Shacham, E. Saint-Martin, J. R. Marshall, T. McCartney, J. McCauley, D. Carlson, R. Rebello, S. Rashal, T. Mirza, M. R. Shacham, S. Kauffman, M. Gutierrez, M. TI THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) ACTIVITY IN DOUBLE HIT DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) IN PRECLINICAL MODELS & CLINICAL ACTIVITY IN PATIENTS WITH DLBCL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Kuruvilla, J.; Kukreti, V.; Tiedemann, R.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Cerchietti, L.] Cornell Univ, Wiel Cornell Med Coll, New York, NY 10021 USA. [Wagner-Johnston, N.] Washington Univ, Sch Med, St Louis, MO USA. [Stone, R.; Jacobsen, E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mau-Sorensen, M.] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark. [Brown, P.] Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark. [Baz, R.; Shal, B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Flynn, J.] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA. [Flinn, I.] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA. [Goy, A.; Gutierrez, M.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Landesman, Y.; Klebanov, B.; Shacham, E.; Saint-Martin, J. R.; Marshall, T.; McCartney, J.; McCauley, D.; Carlson, R.; Rashal, T.; Mirza, M. R.; Shacham, S.; Kauffman, M.] Karyopharm Therapeut, Natick, MA USA. [Rebello, S.] Ozmosis Res, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 5 U2 5 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P466 BP 152 EP 152 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900366 ER PT J AU Staber, P Zhang, P Ye, M Welner, R Levantini, E Di Ruscio, A Ebralidze, A Bach, C Zhang, H Zhang, J Huang, G Tenen, D AF Staber, P. Zhang, P. Ye, M. Welner, R. Levantini, E. Di Ruscio, A. Ebralidze, A. Bach, C. Zhang, H. Zhang, J. Huang, G. Tenen, D. TI THE RUNX-PU.1 PATHWAY PRESERVES NORMAL AND AML/ETO9A LEUKEMIC STEM CELLS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Staber, P.] Med Univ Vienna, Div Hematol, Vienna, Austria. [Zhang, P.; Ye, M.; Welner, R.; Levantini, E.; Di Ruscio, A.; Ebralidze, A.; Bach, C.; Zhang, H.; Zhang, J.] BIDMC, Boston, MA USA. [Huang, G.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Tenen, D.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P516 BP 172 EP 172 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830900415 ER PT J AU San-Miguel, J Hungria, VT Yoon, SS Beksac, M Dimopoulos, MA Elghandour, A Jedrzejczak, WW Guenther, A Nakorn, TN Siritanaratkul, N Schlossman, RL Hou, J Moreau, P Lonial, S Lee, JH Einsele, H Salwender, H Sopala, M Bengoudifa, BR Corrado, C Binlich, F Richardson, P AF San-Miguel, J. Hungria, V. T. Yoon, S. S. Beksac, M. Dimopoulos, M. A. Elghandour, A. Jedrzejczak, W. W. Guenther, A. Nakorn, T. Na Siritanaratkul, N. Schlossman, R. L. Hou, J. Moreau, P. Lonial, S. Lee, J. H. Einsele, H. Salwender, H. Sopala, M. Bengoudifa, B. R. Corrado, C. Binlich, F. Richardson, P. TI RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (PANORAMA 1) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [San-Miguel, J.] Univ Navarra, E-31080 Pamplona, Spain. [Hungria, V. T.] Irmandade da Santa Casa de Misericordia Sao Paulo, Sao Paulo, Brazil. [Yoon, S. S.] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea. [Beksac, M.] Ankara Univ, Sch Med, TR-06100 Ankara, Turkey. [Dimopoulos, M. A.] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece. [Elghandour, A.] Univ Alexandria, Alexandria, Egypt. [Jedrzejczak, W. W.] Med Univ Warsaw, Warsaw, Poland. [Guenther, A.] Univ Hosp Schleswig Holstein, Div Stem Cell Transplantat & Immunotherapy, Dept Med 2, Kiel, Germany. [Guenther, A.] Univ Kiel, Kiel, Germany. [Nakorn, T. Na] Chulalongkorn Univ, Bangkok, Thailand. [Nakorn, T. Na] King Chulalongkorn Mem Hosp, Bangkok, Thailand. [Siritanaratkul, N.] Siriraj Hosp, Bangkok, Thailand. [Schlossman, R. L.; Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hou, J.] Chang Zheng Hosp, Shanghai, Peoples R China. [Moreau, P.] Univ Hosp Nantes, Nantes, France. [Lonial, S.] Winship Canc Inst, Atlanta, GA USA. [Lee, J. H.] Gachon Univ, Dept Internal Med, Gil Hosp, Inchon, South Korea. [Einsele, H.] Univ Wurzburg, Med Klin & Poliklin 2, D-97070 Wurzburg, Germany. [Salwender, H.] Asklepios Klin Altona, Hamburg, Germany. [Sopala, M.; Bengoudifa, B. R.; Corrado, C.] Novartis Pharma AG, Basel, Switzerland. [Binlich, F.] Novartis Pharma SAS, Rueil Malmaison, France. RI richard, chrystelle/K-8595-2015; OI Elghandour, ASHRAF/0000-0002-8841-048X NR 0 TC 0 Z9 0 U1 1 U2 10 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S641 BP 219 EP 220 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901090 ER PT J AU Facon, T Dimopoulos, MA Dispenzieri, A Catalano, JV Belch, A Hulin, C Cavo, M Pinto, A Weisel, KC Ludwig, H Bahlis, N Banos, A Tiab, M Delforge, M Cavenagh, J Geraldes, C Lee, JJ Chen, C Oriol, A De La Rubia, J Qiu, L White, D Binder, D Anderson, KC Moreau, P Attal, M Knight, R Chen, G Van Oostendorp, J Jacques, CJ Ervin-Haynes, A Benboubker, L AF Facon, T. Dimopoulos, M. A. Dispenzieri, A. Catalano, J. V. Belch, A. Hulin, C. Cavo, M. Pinto, A. Weisel, K. C. Ludwig, H. Bahlis, N. Banos, A. Tiab, M. Delforge, M. Cavenagh, J. Geraldes, C. Lee, J. J. Chen, C. Oriol, A. De La Rubia, J. Qiu, L. White, D. Binder, D. Anderson, K. C. Moreau, P. Attal, M. Knight, R. Chen, G. Van Oostendorp, J. Jacques, C. J. Ervin-Haynes, A. Benboubker, L. TI LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE (RD) VS. MELPHALAN-PREDNISONE-THALIDOMIDE (MPT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS): THE FIRST TRIAL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Facon, T.] CHRU Lille, Serv Malad Sang, Hop Claude Huriez, F-59037 Lille, France. [Dimopoulos, M. A.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Dispenzieri, A.] Mayo Clin, Ctr Canc, Rochester, MN USA. [Catalano, J. V.] Monash Univ, Frankston Hosp, Frankston, Australia. [Belch, A.] Univ Alberta, Edmonton, AB, Canada. [Belch, A.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. [Hulin, C.] Univ Hosp, Nancy, France. [Cavo, M.] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy. [Pinto, A.] IRCCS, Hematol Oncol Unit, Ist G Pascale, Naples, Italy. [Weisel, K. C.] Univ Tubingen, Tubingen, Germany. [Ludwig, H.] Wilhelminen Hosp, Dept Internal Med 1, Ctr Oncol & Hematol, Vienna, Austria. [Bahlis, N.] Univ Calgary, Calgary, AB, Canada. [Banos, A.] Ctr Hosp Cote Basque, Bayonne, France. [Tiab, M.] Ctr Hosp, Dept Med Interne Oudairies, La Roche Sur Yon, France. [Delforge, M.] Univ Hosp Leuven, Leuven, Belgium. [Cavenagh, J.] St Bartholomews Hosp, Dept Haematol, London, England. [Geraldes, C.] Coimbra Univ Hosp, Clin Hematol Dept, Coimbra, Portugal. [Lee, J. J.] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Jeollanamdo, South Korea. [Chen, C.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Oriol, A.] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain. [De La Rubia, J.] Hosp Univ La Fe, Valencia, Spain. [Qiu, L.] CAMS, State Key Lab Expt Hematol, Inst Hematol, Tianjin, Peoples R China. [Qiu, L.] CAMS, Blood Dis Hosp, Tianjin, Peoples R China. [Qiu, L.] PUMC, Tianjin, Peoples R China. [White, D.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. [Binder, D.] Kantonsspital Winterthur, Winterthur, Switzerland. [Anderson, K. C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Moreau, P.] CHU Nantes, Serv Hematol, F-44035 Nantes 01, France. [Attal, M.] Univ Hop Purpan, Ctr Hosp Reg, Toulouse, France. [Knight, R.; Chen, G.; Van Oostendorp, J.; Jacques, C. J.; Ervin-Haynes, A.] Celgene Corp, Summit, NJ USA. [Benboubker, L.] Univ Hosp Tours, Tours, France. RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015 OI FACON, THIERRY/0000-0001-7705-8460; NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S643 BP 220 EP 221 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901092 ER PT J AU Stewart, AK Jacobus, S Fonseca, R Weiss, M Callander, NS Chanan-Khan, AA Rajkumar, SV AF Stewart, A. K. Jacobus, S. Fonseca, R. Weiss, M. Callander, N. S. Chanan-Khan, A. A. Rajkumar, S. V. TI E1A06: A PHASE III TRIAL COMPARING MELPHALAN, PREDNISONE, AND THALIDOMIDE (MPT) VERSUS MELPHALAN, PREDNISONE, AND LENALIDOMIDE (MPR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA MM) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Stewart, A. K.; Fonseca, R.] Mayo Clin, Scottsdale, AZ USA. [Jacobus, S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weiss, M.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. [Callander, N. S.] Univ Wisconsin, Madison, WI 53706 USA. [Chanan-Khan, A. A.] Mayo Clin, Jacksonville, FL 32224 USA. [Rajkumar, S. V.] Mayo Clin, Rochester, MN USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S642 BP 220 EP 220 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901091 ER PT J AU Groschel, S Sanders, MA Hoogenboezem, R de Wit, E Britta, BA Erpelinck, C van der Velden, VH Havermans, M Avellino, R van Lom, K Rombouts, EJ van Duin, M Dohner, K Beverloo, HB Bradner, JE Dohner, H Lowenberg, B Valk, PJ Bindels, EM de Laat, W Delwel, R AF Groschel, S. Sanders, M. A. Hoogenboezem, R. de Wit, E. Britta, B. A. Erpelinck, C. van der Velden, V. H. Havermans, M. Avellino, R. van Lom, K. Rombouts, E. J. van Duin, M. Doehner, K. Beverloo, H. B. Bradner, J. E. Doehner, H. Lowenberg, B. Valk, P. J. Bindels, E. M. de laat, W. Delwel, R. TI A SINGLE ONCOGENIC ENHANCER-REARRANGEMENT CAUSES CONCOMITANT EVI1 AND GATA2 DEREGULATION IN LEUKEMIA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Groschel, S.; Sanders, M. A.; Hoogenboezem, R.; Erpelinck, C.; Havermans, M.; Avellino, R.; van Lom, K.; Rombouts, E. J.; van Duin, M.; Lowenberg, B.; Valk, P. J.; Bindels, E. M.; Delwel, R.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands. [de Wit, E.; Britta, B. A.; de laat, W.] Hubrecht Inst KNAW, Utrecht, Netherlands. [de Wit, E.; Britta, B. A.; de laat, W.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [van der Velden, V. H.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands. [Doehner, K.; Doehner, H.] Uniklin Ulm, Ulm, Germany. [Beverloo, H. B.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands. [Bradner, J. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S691 BP 243 EP 243 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901140 ER PT J AU Hillmen, P Brown, JR O'Brien, S Barrientos, J Kay, NE Reddy, NM Coutre, S Tam, C Mulligan, S Jaeger, U Devereux, S Barr, PM Furman, R Kipps, T Cymbalista, F Pocock, C Thornton, P Caligaris-Cappio, F Robak, T Delgado, J Schuster, SJ Montillo, M Schuh, A DeVos, S Gill, D Bloor, A Dearden, C Moreno, C Jones, JJ Chu, AD Fardis, M McGreivy, J Clow, F James, D Byrd, JC AF Hillmen, P. Brown, J. R. O'Brien, S. Barrientos, J. Kay, N. E. Reddy, N. M. Coutre, S. Tam, C. Mulligan, S. Jaeger, U. Devereux, S. Barr, P. M. Furman, R. Kipps, T. Cymbalista, F. Pocock, C. Thornton, P. Caligaris-Cappio, F. Robak, T. Delgado, J. Schuster, S. J. Montillo, M. Schuh, A. DeVos, S. Gill, D. Bloor, A. Dearden, C. Moreno, C. Jones, J. J. Chu, A. D. Fardis, M. McGreivy, J. Clow, F. James, D. Byrd, J. C. TI RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE((TM)) TRIAL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Hillmen, P.] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England. [Brown, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [O'Brien, S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Barrientos, J.] Hofstra North Shore LIJ Sch Med, Hempstead, NY USA. [Kay, N. E.] Mayo Clin, Rochester, MN USA. [Reddy, N. M.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Coutre, S.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Tam, C.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Tam, C.] St Vincents Hosp, Melbourne, Vic, Australia. [Mulligan, S.] Royal N Shore Hosp, Sydney, NSW, Australia. [Jaeger, U.] Med Univ Vienna, Vienna, Austria. [Devereux, S.] NHS Fdn Trust Denmark Hill, Kings Coll Hosp, London, England. [Barr, P. M.] Univ Rochester, Ctr Canc, Rochester, NY 14627 USA. [Furman, R.] New York Presbyterian Hosp, Cornell Med Ctr, New York, NY USA. [Kipps, T.] Moores UCSD Canc Ctr, San Diego, CA USA. [Cymbalista, F.] Hop Avicenne, Paris, France. [Pocock, C.] East Kent Hosp Univ NHS Fdn Trust, Kent & Canterbury Hosp, Canterbury, Kent, England. [Thornton, P.] Beaumont Hosp, Dublin 9, Ireland. [Caligaris-Cappio, F.] Univ Vita Salute San Raffaele, Milan, Italy. [Robak, T.] Med Univ Lodz, Lodz, Poland. [Robak, T.] Copernicus Mem Hosp, Lodz, Poland. [Delgado, J.] Hosp Clin Barcelona, Barcelona, Spain. [Schuster, S. J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Montillo, M.] Osped Niguarda Ca Granda, Milan, Italy. [Schuh, A.] Oxford Biomed Res Ctr, Oxford, England. [DeVos, S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gill, D.] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia. [Bloor, A.] Christie NHS Fdn Trust Hematol & Transplant Unit, Manchester, Lancs, England. [Dearden, C.] Royal Marsden Hosp, Sutton, Surrey, England. [Dearden, C.] Inst Canc Res, Sutton, Surrey, England. [Moreno, C.] Hosp Santa Creu St Pau, Barcelona, Spain. [Jones, J. J.; Byrd, J. C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Chu, A. D.; Fardis, M.; McGreivy, J.; Clow, F.; James, D.] Pharmacyclics Inc, Sunnyvale, CA USA. RI Delgado, Julio/D-4891-2013 OI Delgado, Julio/0000-0002-5157-4376 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S693 BP 244 EP 244 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901142 ER PT J AU Gkotzamanidou, M Shammas, M Samur, MK Souliotis, VL Fulciniti, M Minvielle, S Magrangeas, F Avet-Loiseau, H Anderson, KC Munshi, NC AF Gkotzamanidou, M. Shammas, M. Samur, M. Kemal Souliotis, V. L. Fulciniti, M. Minvielle, S. Magrangeas, F. Avet-Loiseau, H. Anderson, K. C. Munshi, N. C. TI HDAC8 INHIBITS MYELOMA CELLULAR GROWTH THROUGH REGULATION OF HOMOLOGOUS RECOMBINATION AND CYTOSKELETON INTEGRITY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Gkotzamanidou, M.; Shammas, M.; Fulciniti, M.; Anderson, K. C.; Munshi, N. C.] Harvard Univ, Sch Med, Boston, MA USA. [Samur, M. Kemal] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Souliotis, V. L.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Athens, Greece. [Minvielle, S.; Magrangeas, F.; Avet-Loiseau, H.] Univ Nantes, Ctr Canc Res Nantes Angers, Nantes, France. RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015 NR 0 TC 0 Z9 0 U1 0 U2 3 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S697 BP 246 EP 246 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901146 ER PT J AU Cottini, F Hideshima, T Xu, C Ponzoni, M Richardson, P Cappio, FC Anderson, K Tonon, G AF Cottini, F. Hideshima, T. Xu, C. Ponzoni, M. Richardson, P. Cappio, F. Caligaris Anderson, K. Tonon, G. TI INHIBITION OF THE STK4 KINASE RESTORES THE HIPPO CO-FACTOR YAP1 AND INDUCES DNA-DAMAGE MEDIATED APOPTOSIS IN MULTIPLE MYELOMA CELLS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Cottini, F.; Hideshima, T.; Xu, C.; Richardson, P.; Anderson, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ponzoni, M.] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy. [Cappio, F. Caligaris; Tonon, G.] Ist Sci San Raffaele, Div Mol Oncol, I-20132 Milan, Italy. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S699 BP 247 EP 247 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901148 ER PT J AU Roccaro, A Sacco, A Moschetta, M Mishima, Y Maiso, P Lonardi, S Zboralski, D Krushinski, A Rossi, G Ghobrial, I AF Roccaro, A. Sacco, A. Moschetta, M. Mishima, Y. Maiso, P. Lonardi, S. Zboralski, D. Krushinski, A. Rossi, G. Ghobrial, I. TI IN VIVO TARGETING OF STROMAL-DERIVED FACTOR-1 AS A STRATEGY TO PREVENT MYELOMA CELL BONE TO BONE DISSEMINATION SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Roccaro, A.; Sacco, A.; Moschetta, M.; Mishima, Y.; Maiso, P.; Ghobrial, I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lonardi, S.; Rossi, G.] Spedali Civili Brescia, Brescia, Italy. [Zboralski, D.; Krushinski, A.] NOXXON Pharma AG, Berlin, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S700 BP 247 EP 248 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901149 ER PT J AU Roberts, AW Ma, S Kipps, T Barrientos, JC Davids, MS Anderson, MA Tam, C Mason-Bright, T Rudersdorf, NK Yang, J Munasinghe, W Zhu, M Cerri, E Enschede, SH Humerickhouse, RA Seymour, JF AF Roberts, A. W. Ma, S. Kipps, T. Barrientos, J. C. Davids, M. S. Anderson, M. A. Tam, C. Mason-Bright, T. Rudersdorf, N. K. Yang, J. Munasinghe, W. Zhu, M. Cerri, E. Enschede, S. H. Humerickhouse, R. A. Seymour, J. F. TI ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Roberts, A. W.; Anderson, M. A.] Royal Melbourne Hosp, Melbourne, Vic, Australia. [Roberts, A. W.; Anderson, M. A.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia. [Ma, S.] Northwestern Univ, Chicago, IL 60611 USA. [Kipps, T.] Univ Calif San Diego, San Diego, CA 92103 USA. [Barrientos, J. C.] Hofstra North Shore LIJ Sch Med, New Hide Pk, NY USA. [Davids, M. S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tam, C.; Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Mason-Bright, T.; Rudersdorf, N. K.; Yang, J.; Munasinghe, W.; Zhu, M.; Cerri, E.; Enschede, S. H.; Humerickhouse, R. A.] AbbVie, N Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S703 BP 249 EP 249 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901152 ER PT J AU Seymour, JF Davids, MS Pagel, JM Kahl, BS Wierda, WG Puvvada, S Gerecitano, JF Kipps, TJ Anderson, MA Huang, DC Rudersdorf, NK Gressick, LA Montalvo, NP Yang, J Zhu, M Dunbar, M Cerri, E Enschede, SH Humerickhouse, RA Roberts, AW AF Seymour, J. F. Davids, M. S. Pagel, J. M. Kahl, B. S. Wierda, W. G. Puvvada, S. Gerecitano, J. F. Kipps, T. J. Anderson, M. A. Huang, D. C. Rudersdorf, N. K. Gressick, L. A. Montalvo, N. P. Yang, J. Zhu, M. Dunbar, M. Cerri, E. Enschede, S. H. Humerickhouse, R. A. Roberts, A. W. TI ABT-199 (GDC-0199) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA: HIGH RESPONSE RATES AMONG PATIENTS WITH HIGH RISK DISEASE FEATURES INCLUDING UNMUTATED IGHV SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Davids, M. S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pagel, J. M.] Univ Washington, Seattle, WA 98195 USA. [Kahl, B. S.] Univ Wisconsin, Madison, WI 53706 USA. [Wierda, W. G.] Univ Texas Houston, Houston, TX USA. [Puvvada, S.] Univ Arizona, Tucson, AZ USA. [Gerecitano, J. F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Kipps, T. J.] Univ Calif San Diego, San Diego, CA 92103 USA. [Anderson, M. A.; Roberts, A. W.] Royal Melbourne Hosp, Melbourne, Vic, Australia. [Anderson, M. A.; Huang, D. C.; Roberts, A. W.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia. [Rudersdorf, N. K.; Gressick, L. A.; Montalvo, N. P.; Yang, J.; Zhu, M.; Dunbar, M.; Cerri, E.; Enschede, S. H.; Humerickhouse, R. A.] AbbVie, N Chicago, IL USA. NR 0 TC 2 Z9 2 U1 1 U2 6 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S702 BP 249 EP 249 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901151 ER PT J AU DeBoer, R Mulkey, F Koval, G Wetzler, M Marcucci, G Stone, RM Larson, RA Geyer, S Mullighan, C Stock, W AF DeBoer, R. Mulkey, F. Koval, G. Wetzler, M. Marcucci, G. Stone, R. M. Larson, R. A. Geyer, S. Mullighan, C. Stock, W. TI CLINICAL IMPACT OF ABL1 KINASE AND IKZF1 MUTATIONS IN ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): MOLECULAR ANALYSIS OF CALGB 10001 AND 9665 (ALLIANCE) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [DeBoer, R.; Larson, R. A.; Stock, W.] Univ Chicago, Chicago, IL 60637 USA. [Mulkey, F.] Duke Univ, Alliance Stat & Data Ctr, Durham, NC 27706 USA. [Koval, G.] Indiana Univ, Gary, IN USA. [Wetzler, M.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Marcucci, G.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Geyer, S.] Ohio State Univ, Med Ctr, Alliance Stat & Data Ctr, Columbus, OH 43210 USA. [Mullighan, C.] St Jude Childrens Res Hosp, Memphis, TN USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S723 BP 258 EP 258 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901172 ER PT J AU Walter, D Lier, A Geiselhart, A Huntscha, S Brocks, D Bayindir, I Kaschutnig, P Mudder, K Holland-Letz, T Schmezer, P Lane, S Essers, MAG Williams, DA Williams, DA Trumpp, A Milsom, MD AF Walter, D. Lier, A. Geiselhart, A. Huntscha, S. Brocks, D. Bayindir, I. Kaschutnig, P. Muedder, K. Holland-Letz, T. Schmezer, P. Lane, S. Essers, M. A. G. Williams, D. A. Williams, D. A. Trumpp, A. Milsom, M. D. TI STRESS-INDUCED EXIT FROM QUIESCENCE INDUCES DE NOVO DNA DAMAGE IN HEMATOPOIETIC STEM CELLS AND RESULTS IN BONE MARROW FAILURE IN THE ABSENCE OF A FUNCTIONAL FANCONI ANEMIA SIGNALLING PATHWAY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Walter, D.; Lier, A.; Huntscha, S.; Muedder, K.; Essers, M. A. G.; Trumpp, A.; Milsom, M. D.] Heidelberg Inst Stem Cell Technol & Expt Med HIST, Heidelberg, Germany. [Geiselhart, A.; Brocks, D.; Bayindir, I.; Kaschutnig, P.; Holland-Letz, T.; Schmezer, P.; Essers, M. A. G.; Trumpp, A.; Milsom, M. D.] German Canc Res Ctr, Heidelberg, Germany. [Lane, S.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia. [Williams, D. A.; Williams, D. A.] Boston Childrens Hosp, Boston, MA USA. [Williams, D. A.] Harvard Univ, Sch Med, Boston, MA USA. [Williams, D. A.] Dana Faber Canc Inst, Boston, MA USA. [Williams, D. A.] Harvard Stem Cell Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S729 BP 261 EP 261 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901178 ER PT J AU le Coutre, PD Kim, DW Pinilla-Ibarz, J Paquette, R Chuah, C Nicolini, FE Apperley, JF Khoury, HJ Talpaz, M DiPersio, JF DeAngelo, D Abruzzese, E Rea, D Baccarani, M Muller, M Gambacorti-Passerini, C Lustgarten, S Haluska, FG Guilhot, F Deininger, MW Hochhaus, A Hughes, TP Shah, NP Kantarjian, HM Cortes, JE AF le Coutre, P. D. Kim, D. W. Pinilla-Ibarz, J. Paquette, R. Chuah, C. Nicolini, F. E. Apperley, J. F. Khoury, H. J. Talpaz, M. DiPersio, J. F. DeAngelo, D. Abruzzese, E. Rea, D. Baccarani, M. Muller, M. Gambacorti-Passerini, C. Lustgarten, S. Haluska, F. G. Guilhot, F. Deininger, M. W. Hochhaus, A. Hughes, T. P. Shah, N. P. Kantarjian, H. M. Cortes, J. E. TI PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME- POSITIVE (PH plus ) LEUKEMIAS RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION: LONGER-TERM FOLLOW-UP OF THE PACE TRIAL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [le Coutre, P. D.] Charite, D-13353 Berlin, Germany. [Kim, D. W.] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea. [Pinilla-Ibarz, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Paquette, R.] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Chuah, C.] Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore. [Nicolini, F. E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Apperley, J. F.] Univ London Imperial Coll Sci Technol & Med, London, England. [Khoury, H. J.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, J. F.] Washington Univ, Sch Med, St Louis, MO USA. [DeAngelo, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, E.] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy. [Rea, D.] Hop St Louis, Paris, France. [Baccarani, M.] Orsola Malpighi Univ Hosp, Bologna, Italy. [Muller, M.] Univ Med Mannheim, Med Klin 3, Mannheim, Germany. [Gambacorti-Passerini, C.] Azienda Osped San Gerardo Univ Milano Bicocca, Unita Ric Clin Ematol, Monza, Italy. [Lustgarten, S.; Haluska, F. G.] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA. [Guilhot, F.] CHU Poitiers Univ Hosp, Poitiers, France. [Deininger, M. W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hochhaus, A.] Univ Klinikum Jena, Jena, Germany. [Hughes, T. P.] SA Pathol, Adelaide, SA, Australia. [Shah, N. P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kantarjian, H. M.; Cortes, J. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P893 BP 334 EP 334 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901340 ER PT J AU Nicolini, FE Cortes, JE Kim, DW Pinilla-Ibarz, J le Coutre, PD Paquette, R Chuah, C Apperley, JF Khoury, HJ Talpaz, M DiPersio, JF DeAngelo, DJ Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Lustgarten, S Rivera, VM Haluska, FG Guilhot, F Deininger, MW Hughes, TP Shah, NP Kantarjian, HM Hochhaus, A AF Nicolini, F. E. Cortes, J. E. Kim, D. W. Pinilla-Ibarz, J. le Coutre, P. D. Paquette, R. Chuah, C. Apperley, J. F. Khoury, H. J. Talpaz, M. DiPersio, J. F. DeAngelo, D. J. Abruzzese, E. Rea, D. Baccarani, M. Muller, M. C. Gambacorti-Passerini, C. Lustgarten, S. Rivera, V. M. Haluska, F. G. Guilhot, F. Deininger, M. W. Hughes, T. P. Shah, N. P. Kantarjian, H. M. Hochhaus, A. TI CLINICAL IMPACT OF DOSE MODIFICATION AND DOSE INTENSITY ON RESPONSE TO PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Nicolini, F. E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Cortes, J. E.; Kantarjian, H. M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kim, D. W.] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea. [Pinilla-Ibarz, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [le Coutre, P. D.] Charite, D-13353 Berlin, Germany. [Paquette, R.] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Chuah, C.] Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore. [Apperley, J. F.] Univ London Imperial Coll Sci Technol & Med, London, England. [Khoury, H. J.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, J. F.] Washington Univ, Sch Med, St Louis, MO USA. [DeAngelo, D. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, E.] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy. [Rea, D.] Hop St Louis, Serv Malad Sang, Paris, France. [Rea, D.] Hop St Louis, CIC Clin Invest Ctr, Paris, France. [Baccarani, M.] S Orsola Malpighi Univ Hosp, Bologna, Italy. [Muller, M. C.] Univ Med, Med Klin 3, Mannheim, Germany. [Gambacorti-Passerini, C.] Azienda Osped San Gerardo Univ Milano Bicocca, Unita Ric Clin Ematol, Monza, Italy. [Lustgarten, S.; Rivera, V. M.; Haluska, F. G.] ARIAD Pharmaceut Inc, Cambridge, MA USA. [Guilhot, F.] Univ Hosp, CHU Poitiers, Poitiers, France. [Deininger, M. W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hughes, T. P.] Inst Med & Vet Sci, Adelaide, SA 5000, Australia. [Shah, N. P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hochhaus, A.] Univ Klinikum Jena, Jena, Germany. NR 0 TC 0 Z9 0 U1 0 U2 3 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P894 BP 334 EP 334 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901341 ER PT J AU Cagnetta, A Cea, M Fulciniti, M Yu-Tzu, T Chauhan, D Gobbi, M Treon, S Anderson, KC AF Cagnetta, A. Cea, M. Fulciniti, M. Yu-Tzu, T. Chauhan, D. Gobbi, M. Treon, S. Anderson, K. C. TI INHIBITION OF NAMPT AUGMENTS IBRUTINIB INDUCED KILLING IN MYD88 L265P EXPRESSING WALDENSTROM'S MACROGLOBULINEMIA CELLS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Cagnetta, A.; Cea, M.; Fulciniti, M.; Yu-Tzu, T.; Chauhan, D.; Treon, S.; Anderson, K. C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cea, M.; Gobbi, M.] IRCCS AOU San Martino IST, Genoa, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P951 BP 358 EP 358 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901398 ER PT J AU Mellqvist, UH Paba-Prada, C Palumbo, A Plesner, T Sonneveld, P Voorhees, P Byrne, C Harmenberg, J Nordstrom, E Richardson, PG AF Mellqvist, U. H. Paba-Prada, C. Palumbo, A. Plesner, T. Sonneveld, P. Voorhees, P. Byrne, C. Harmenberg, J. Nordstrom, E. Richardson, P. G. TI AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Mellqvist, U. H.] Boras Hosp, Boras, Sweden. [Paba-Prada, C.; Richardson, P. G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Palumbo, A.] Turin Hosp, Turin, Italy. [Plesner, T.] Vejle Hosp, Vejle, Denmark. [Sonneveld, P.] Erasmus, Rotterdam, Netherlands. [Voorhees, P.] Univ N Carolina, Chapel Hill, NC USA. [Byrne, C.] Oncopeptides AB, Miami, FL USA. [Harmenberg, J.; Nordstrom, E.] Oncopeptides AB, Stockholm, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P988 BP 375 EP 376 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830901435 ER PT J AU Casper, C Chaturvedi, S Munshi, N Wong, R Qi, M Schaffer, M Bandekar, R Huang, Y Hall, B Vermeulen, J Reddy, M Van Rhee, F AF Casper, C. Chaturvedi, S. Munshi, N. Wong, R. Qi, M. Schaffer, M. Bandekar, R. Huang, Y. Hall, B. Vermeulen, J. Reddy, M. Van Rhee, F. TI INFLAMMATORY AND ANEMIA-RELATED MARKERS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SILTUXIMAB (ANTI-IL-6 MONOCLONAL ANTIBODY) IN MULTICENTRIC CASTLEMAN'S DISEASE PATIENTS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Casper, C.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Chaturvedi, S.; Qi, M.; Schaffer, M.; Bandekar, R.; Huang, Y.; Hall, B.; Reddy, M.] Janssen Res & Dev, Spring House, PA USA. [Munshi, N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Wong, R.] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China. [Vermeulen, J.] Janssen Res & Dev, Leiden, Netherlands. [Van Rhee, F.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA P1211 BP 465 EP 465 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830902196 ER PT J AU Roccaro, A Sacco, A Jimenez, C Maiso, P Moschetta, M Mishima, Y Alajawai, Y Kuhne, M Cardarelli, P Cohen, L San Miguel, J Garcia-Sanz, R Ghobrial, I AF Roccaro, A. Sacco, A. Jimenez, C. Maiso, P. Moschetta, M. Mishima, Y. Alajawai, Y. Kuhne, M. Cardarelli, P. Cohen, L. San Miguel, J. Garcia-Sanz, R. Ghobrial, I. TI A NOVEL ACTIVATING SOMATIC MUTATION OF CXCR4 PLAYS A CRUCIAL ROLE IN MODULATING WALDENSTROM MACROGLOBULINEMIA BIOLOGY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Roccaro, A.; Sacco, A.; Maiso, P.; Moschetta, M.; Mishima, Y.; Alajawai, Y.; Ghobrial, I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jimenez, C.; Garcia-Sanz, R.] Univ Salamanca, E-37008 Salamanca, Spain. [Kuhne, M.; Cardarelli, P.] Bristol Myers Squibb, Redwood City, CA USA. [Cohen, L.] Bristol Myers Squibb, Lawrenceville, NJ USA. [San Miguel, J.] Univ Navarra, E-31080 Pamplona, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S1301 BP 502 EP 503 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830902286 ER PT J AU Placke, T Faber, K Nonami, A Putwain, S Salih, H Heidel, F Kramer, A Root, D Barbie, D Armstrong, S Hahn, W Huntly, B Sykes, S Milsom, M Scholl, C Frohling, S AF Placke, T. Faber, K. Nonami, A. Putwain, S. Salih, H. Heidel, F. Kraemer, A. Root, D. Barbie, D. Armstrong, S. Hahn, W. Huntly, B. Sykes, S. Milsom, M. Scholl, C. Froehling, S. TI REQUIREMENT FOR CDK6 IN MLL-REARRANGED ACUTE MYELOID LEUKEMIA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Placke, T.; Froehling, S.] Natl Ctr Tumor Dis, Heidelberg, Germany. [Faber, K.; Scholl, C.] Univ Ulm, D-89069 Ulm, Germany. [Nonami, A.; Barbie, D.; Hahn, W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Putwain, S.; Huntly, B.] Cambridge Inst Med Res, Cambridge, England. [Salih, H.] Univ Tubingen, Tubingen, Germany. [Heidel, F.] Univ Magdeburg, D-39106 Magdeburg, Germany. [Kraemer, A.; Milsom, M.] German Canc Res Ctr, Heidelberg, Germany. [Root, D.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Armstrong, S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Sykes, S.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S1323 BP 513 EP 513 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830902308 ER PT J AU Wedeh, G Cerny-Reiterer, S Hadzijusufovic, E Herrmann, H Blatt, K Eisenwort, G Hoermann, G Sperr, WR Muellauer, L Vakoc, CR Bradner, JE Horny, H Zuber, J Arock, M Valent, P AF Wedeh, G. Cerny-Reiterer, S. Hadzijusufovic, E. Herrmann, H. Blatt, K. Eisenwort, G. Hoermann, G. Sperr, W. R. Muellauer, L. Vakoc, C. R. Bradner, J. E. Horny, H. P. Zuber, J. Arock, M. Valent, P. TI THE EPIGENETIC READER BRD4 SERVES AS A NOVEL MARKER AND TARGET IN AGGRESSIVE SYSTEMIC MASTOCYTOSIS AND MAST CELL LEUKEMIA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Wedeh, G.; Arock, M.] Ecole Normale Super, LBPA, Cachan, France. [Wedeh, G.; Cerny-Reiterer, S.; Hadzijusufovic, E.; Blatt, K.; Sperr, W. R.; Valent, P.] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria. [Cerny-Reiterer, S.; Hadzijusufovic, E.; Herrmann, H.; Eisenwort, G.; Sperr, W. R.; Valent, P.] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol LB CO, Vienna, Austria. [Hadzijusufovic, E.] Univ Vet Med, Clin Unit Internal Med, Clin Small Anim, Dept Clin Compan Anim & Horses, Vienna, Austria. [Hoermann, G.] Med Univ Vienna, Dept Lab Med, Vienna, Austria. [Muellauer, L.] Med Univ Vienna, Dept Clin Pathol, Vienna, Austria. [Vakoc, C. R.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA. [Bradner, J. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Horny, H. P.] Univ Munich, Inst Pathol, D-80539 Munich, Germany. [Zuber, J.] Res Inst Mol Pathol IMP, Vienna, Austria. RI Hadzijusufovic, Emir/B-8109-2016; Hoermann, Gregor/B-8832-2016 OI Hadzijusufovic, Emir/0000-0001-7409-4204; Hoermann, Gregor/0000-0002-7374-4380 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S1327 BP 514 EP 515 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830902312 ER PT J AU Davids, MS Seymour, JF Gerecitano, JF Kahl, BS Pagel, JM Wierda, WG Anderson, M Rudersdorf, NK Gressick, LA Montalvo, NP Yang, J Zhu, M Dunbar, M Cerri, E Enschede, SH Humerickhouse, RA Roberts, AW AF Davids, M. S. Seymour, J. F. Gerecitano, J. F. Kahl, B. S. Pagel, J. M. Wierda, W. G. Anderson, M. A. Rudersdorf, N. K. Gressick, L. A. Montalvo, N. P. Yang, J. Zhu, M. Dunbar, M. Cerri, E. Enschede, S. H. Humerickhouse, R. A. Roberts, A. W. TI PHASE I STUDY OF ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: RESPONSES OBSERVED IN DIFFUSE LARGE B-CELL (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT HIGHER COHORT DOSES SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Davids, M. S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Gerecitano, J. F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Kahl, B. S.] Univ Wisconsin, Madison, WI 53706 USA. [Pagel, J. M.] Univ Washington, Seattle, WA 98195 USA. [Wierda, W. G.] Univ Texas Houston, Houston, TX USA. [Anderson, M. A.; Roberts, A. W.] Royal Melbourne Hosp, Melbourne, Vic, Australia. [Anderson, M. A.; Roberts, A. W.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia. [Rudersdorf, N. K.; Gressick, L. A.; Montalvo, N. P.; Yang, J.; Zhu, M.; Dunbar, M.; Cerri, E.; Enschede, S. H.; Humerickhouse, R. A.] AbbVie, N Chicago, IL USA. NR 0 TC 4 Z9 5 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S1348 BP 525 EP 525 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830902332 ER PT J AU Garzon, R Flinn, I Berdeja, J DeAngelo, D Wadleigh, M Yee, K Schuh, A Mau-Sorensen, M Brown, P Lancet, J Shah, B Gutierrez, M Gabrail, N Wagner-Johnston, N Blum, W Carlson, R Klebanov, B McCauley, D Shacham, E McCartney, J Marshall, T Saint-Martin, JR Rebello, S Rashal, T Kauffman, M Shacham, S Mirza, M Stone, R AF Garzon, R. Flinn, I. Berdeja, J. DeAngelo, D. Wadleigh, M. Yee, K. Schuh, A. Mau-Sorensen, M. Brown, P. Lancet, J. Shah, B. Gutierrez, M. Gabrail, N. Wagner-Johnston, N. Blum, W. Carlson, R. Klebanov, B. McCauley, D. Shacham, E. McCartney, J. Marshall, T. Saint-Martin, J. R. Rebello, S. Rashal, T. Kauffman, M. Shacham, S. Mirza, M. Stone, R. TI A PHASE 1 DOSE ESCALATION STUDY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY ACUTE MYELOID LEUKEMIA (AML) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Garzon, R.; Blum, W.] Ohio State Univ, Columbus, OH 43210 USA. [Flinn, I.; Berdeja, J.] Sarah Cannon Res Inst, Nashville, TN USA. [DeAngelo, D.; Wadleigh, M.; Stone, R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Yee, K.; Schuh, A.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Mau-Sorensen, M.] Rigshosp Univ Hosp, Dept Oncol, Copenhagen, Denmark. [Brown, P.] Rigshosp Univ Hosp, Dept Hematol, Copenhagen, Denmark. [Lancet, J.; Shah, B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Gutierrez, M.] Hackensack Univ Med Ctr, Hackensack, NJ USA. [Gabrail, N.] Gabrail Canc Ctr, Canton, OH USA. [Wagner-Johnston, N.] Washington Univ, Sch Med, St Louis, MO USA. [Carlson, R.; Klebanov, B.; McCauley, D.; Shacham, E.; McCartney, J.; Marshall, T.; Saint-Martin, J. R.; Rashal, T.; Kauffman, M.; Shacham, S.; Mirza, M.] Karyopharm Therapeut, Natick, MA USA. [Rebello, S.] Ozmosis Res, Toronto, ON, Canada. RI Garzon, Ramiro/E-3104-2011 NR 0 TC 1 Z9 1 U1 1 U2 7 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA S1353 BP 527 EP 528 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830902337 ER PT J AU Dombret, H Seymour, JF Butrym, A Wierzbowska, A Selleslag, D Jang, JH Kumar, R Cavenagh, J Schuh, A Candoni, A Recher, C Sandhu, I Bernal, T Al-Ali, HK Martinelli, G Stone, RM Minden, MD McIntyre, H Songer, S Lucy, L Beach, C Dohner, H AF Dombret, H. Seymour, J. F. Butrym, A. Wierzbowska, A. Selleslag, D. Jang, J. H. Kumar, R. Cavenagh, J. Schuh, A. Candoni, A. Recher, C. Sandhu, I. Bernal, T. Al-Ali, H. K. Martinelli, G. Stone, R. M. Minden, M. D. McIntyre, H. Songer, S. Lucy, L. Beach, C. Doehner, H. TI RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Dombret, H.] Hop St Louis, Paris 10, France. [Seymour, J. F.] Peter MacCallum Canc Ctr, East Melbourne, Australia. [Butrym, A.] Wroclaw Med Univ, Wroclaw, Poland. [Wierzbowska, A.] Med Univ Lodz, Lodz, Poland. [Selleslag, D.] Algemeen Ziekenhuis St Jan, Brugge, Belgium. [Jang, J. H.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. [Kumar, R.] Canc Care Manitoba, Winnipeg, MB, Canada. [Cavenagh, J.] Barts Hlth NHS Trust, London, England. [Schuh, A.; Minden, M. D.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Candoni, A.] Azienda Osped Univ S Maria della Misericordia Udi, Udine, Italy. [Recher, C.] Ctr Hosp Univ Toulouse, Toulouse 09, France. [Sandhu, I.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada. [Bernal, T.] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain. [Al-Ali, H. K.] Univ Klinikum Leipzig, Leipzig, Germany. [Martinelli, G.] Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Bologna, Italy. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [McIntyre, H.; Songer, S.; Lucy, L.; Beach, C.] Celgene Corp, Summit, NJ USA. [Doehner, H.] Univ Ulm Klinikum, Ulm, Germany. RI Wierzbowska, Agnieszka/S-9449-2016 NR 0 TC 4 Z9 4 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA LB2433 BP 788 EP 789 PG 2 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830904042 ER PT J AU Agresta, S Stein, EM Tallman, MS Levine, RL Yua, H Yen, K Fan, B Flinn, IW Fathi, AT Stone, RM DeAngelo, DJ DeBotton, S Pollyea, DA AF Agresta, S. Stein, E. M. Tallman, M. S. Levine, R. L. Yua, H. Yen, K. Fan, B. Flinn, I. W. Fathi, A. T. Stone, R. M. DeAngelo, D. J. DeBotton, S. Pollyea, D. A. TI A PHASE I STUDY OF AG-221, A FIRST IN CLASS, POTENT INHIBITOR OF THE IDH2-MUTANT PROTEIN, IN PATIENTS WITH IDH2 MUTANT POSITIVE ADVANCED HEMATOLOGIC MALIGNANCIES SO HAEMATOLOGICA LA English DT Meeting Abstract CT 19th Congress of the European-Hematology-Association CY JUN 12-15, 2014 CL Milan, ITALY SP European Hematol Assoc C1 [Agresta, S.; Yua, H.; Yen, K.; Fan, B.] Agios, Clin Dev, Cambridge, MA USA. [Stein, E. M.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA. [Tallman, M. S.; Levine, R. L.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA. [Flinn, I. W.] Sarah Cannon, Sarah Cannon Res Inst, Nashville, TN USA. [Fathi, A. T.] Massachusetts Gen, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Stone, R. M.; DeAngelo, D. J.] Harvard, Sch Med, Harvard Univ, Boston, MA USA. [DeBotton, S.] Inst Gustave Roussy, Villejuif, France. [Pollyea, D. A.] Univ Colorado, Ctr Canc, Aurora, CO USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 SU 1 MA LB2434 BP 789 EP 789 PG 1 WC Hematology SC Hematology GA AQ5FD UT WOS:000342830904043 ER PT J AU Basu, PP Shah, NJ Siriki, R Rahaman, M AF Basu, P. Patrick Shah, Niraj J. Siriki, Ravi Rahaman, Md TI Telaprevir with Adjusted Dose of Ribavirin in Naive CHC-G1: Efficacy and Treatment in CHC in Hemodialysis Population. TARGET C Trial- A Placebo Randomized Control Clinical Trial. SO LIVER TRANSPLANTATION LA English DT Meeting Abstract CT Joint International Congress of ILTS, ELITA and LICAGE CY JUN 04-07, 2014 CL London, ENGLAND SP ILTS, ELITA, LICAGE C1 [Basu, P. Patrick] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JUN PY 2014 VL 20 SU 1 MA P-298 BP S244 EP S244 PG 1 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA AM6FU UT WOS:000339959602150 ER PT J AU Basu, PP Shah, NJ Aloysius, M AF Basu, P. Patrick Shah, Niraj J. Aloysius, Mark TI Role of Intravenous N-Acetyl Cysteine (NAC) With Steroid in Acute Alcoholic Hepatitis (AAH) With High Morbidity Score: A Randomized Open Label Prospective Clinical Pilot Trial SO LIVER TRANSPLANTATION LA English DT Meeting Abstract CT Joint International Congress of ILTS, ELITA and LICAGE CY JUN 04-07, 2014 CL London, ENGLAND SP ILTS, ELITA, LICAGE C1 [Basu, P. Patrick] Columbia Sch Phys & Surg, New York, NY USA. [Basu, P. Patrick; Aloysius, Mark] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JUN PY 2014 VL 20 SU 1 MA P-54 BP S168 EP S168 PG 1 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA AM6FU UT WOS:000339959601203 ER PT J AU Basu, PP Shah, NJ Aloysius, M AF Basu, P. Patrick Shah, Niraj J. Aloysius, Mark TI Role of Mycophenolate Mofetil (MMF) in Steroid Non Responsive Severe Acute Alcoholic Hepatitis: A Randomized Open Label Placebo Control Prospective Clinical Pilot Trial SO LIVER TRANSPLANTATION LA English DT Meeting Abstract CT Joint International Congress of ILTS, ELITA and LICAGE CY JUN 04-07, 2014 CL London, ENGLAND SP ILTS, ELITA, LICAGE C1 [Basu, P. Patrick] Columbia Sch Phys & Surg, New York, NY USA. [Aloysius, Mark] Kings Cty Hosp, Med Ctr, New York, NY USA. [Shah, Niraj J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JUN PY 2014 VL 20 SU 1 MA O-122 BP S142 EP S142 PG 1 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA AM6FU UT WOS:000339959601122 ER PT J AU Basu, PP Shah, NJ Aloysius, M Siriki, R Rahaman, M AF Basu, P. Patrick Shah, Niraj J. Aloysius, Mark Siriki, Ravi Rahaman, Md TI Romiplostim's Effect to Optimize SVR with Telaprevir, Ribavirin, And Peg Interferon-alfa 2a in Thrombocytopenic Cirrhotics with Chronic Hepatitis C. A Placebo Controlled Prospective Clinical Trial: RESTRAINT C Trial. SO LIVER TRANSPLANTATION LA English DT Meeting Abstract CT Joint International Congress of ILTS, ELITA and LICAGE CY JUN 04-07, 2014 CL London, ENGLAND SP ILTS, ELITA, LICAGE C1 [Basu, P. Patrick] Columbia Univ Coll Phys & Surg, New York, NY USA. [Basu, P. Patrick; Aloysius, Mark; Siriki, Ravi; Rahaman, Md] NSLIJHS, Hofstra North Shore LIJ Sch Med, New York, NY USA. [Shah, Niraj J.] Mt Sinai Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JUN PY 2014 VL 20 SU 1 MA O-69 BP S124 EP S124 PG 1 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA AM6FU UT WOS:000339959601069 ER PT J AU Curry, MP Terrault, N O'Leary, J Forns, X Brown, R Chung, RT Gane, E Fenkel, JM Gordon, F Kuo, A Schiano, T Schiff, E Befeler, A McHutchison, JG Symonds, WT Denning, J McNair, L Arterburn, S Moonka, D Everson, G Afdhal, N AF Curry, Michael P. Terrault, Norah O'Leary, Jacqueline Forns, Xavier Brown, Robert, Jr. Chung, Raymond T. Gane, Edward Fenkel, Jonathan M. Gordon, Fredric Kuo, Alexander Schiano, Thomas Schiff, Eugene Befeler, Alex McHutchison, John G. Symonds, William T. Denning, Jill McNair, Lindsay Arterburn, Sarah Moonka, Dilip Everson, Gregory Afdhal, Nezam TI Sofosbuvir Plus Ribavirin before Transplantation Prevented HCV Infection Post-Transplant in Patients with HCV Cirrhosis and HCC: Results of an Open-Label Trial SO LIVER TRANSPLANTATION LA English DT Meeting Abstract CT Joint International Congress of ILTS, ELITA and LICAGE CY JUN 04-07, 2014 CL London, ENGLAND SP ILTS, ELITA, LICAGE C1 [Curry, Michael P.; Afdhal, Nezam] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA. [O'Leary, Jacqueline] Baylor Univ, Med Ctr, Dallas, TX USA. [Forns, Xavier] Hosp Clin Barcelona, Liver Unit, IDIBAPS, CIBEREHD, Barcelona, Spain. [Brown, Robert, Jr.] Columbia Univ, New York, NY 10027 USA. [Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gane, Edward] Auckland City Hosp, Auckland, New Zealand. [Fenkel, Jonathan M.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Gordon, Fredric] Lahey Clin Fdn, Burlington, MA USA. [Kuo, Alexander] Univ Calif San Diego, San Diego, CA 92103 USA. [Schiano, Thomas] Mt Sinai Sch Med, New York, NY USA. [Schiff, Eugene] Univ Miami, Miami, FL USA. [Befeler, Alex] St Louis Univ, St Louis, MO 63103 USA. [McHutchison, John G.; Symonds, William T.; Denning, Jill; McNair, Lindsay; Arterburn, Sarah] Gilead Sci Inc, Foster City, CA 94404 USA. [Moonka, Dilip] Henry Ford Hlth Syst, Detroit, MI USA. [Everson, Gregory] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JUN PY 2014 VL 20 SU 1 MA O-137 BP S150 EP S150 PG 1 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA AM6FU UT WOS:000339959601146 ER PT J AU Liu, QL Rehman, H Krishnasamy, Y Schnellmann, R Lemasters, J Zhong, Z AF Liu, Qinlong Rehman, Hasibur Krishnasamy, Yasodha Schnellmann, Rick Lemasters, John Zhong, Zhi TI AMP-Activated Protein Kinase (AMPK) Deficiency Increases Mitochondrial Dysfunction after Liver Transplantation in Mice SO LIVER TRANSPLANTATION LA English DT Meeting Abstract CT Joint International Congress of ILTS, ELITA and LICAGE CY JUN 04-07, 2014 CL London, ENGLAND SP ILTS, ELITA, LICAGE C1 [Liu, Qinlong; Rehman, Hasibur; Krishnasamy, Yasodha; Schnellmann, Rick; Lemasters, John; Zhong, Zhi] Med Univ S Carolina, Charleston, SC USA. [Schnellmann, Rick] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JUN PY 2014 VL 20 SU 1 MA P-518 BP S312 EP S312 PG 1 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA AM6FU UT WOS:000339959602387 ER PT J AU Op den Dries, S Westerkamp, AC Karimian, N Gouw, ASH Markmann, JF Lisman, T Yeh, H Uygun, K Martins, P Porte, RJ AF Op den Dries, Sanna Westerkamp, Andrie C. Karimian, Negin Gouw, Annette S. H. Markmann, James F. Lisman, Ton Yeh, Heidi Uygun, Korkut Martins, Paulo Porte, Robert J. TI Injury of Peribiliary Glands and Vascular Plexus before Liver Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures SO LIVER TRANSPLANTATION LA English DT Meeting Abstract CT Joint International Congress of ILTS, ELITA and LICAGE CY JUN 04-07, 2014 CL London, ENGLAND SP ILTS, ELITA, LICAGE C1 [Op den Dries, Sanna; Westerkamp, Andrie C.; Karimian, Negin; Lisman, Ton; Porte, Robert J.] Univ Med Ctr Groningen UMCG, Dept Surg, Sect Hepatopancreatobiliary Surg & Liver Transpla, Groningen, Netherlands. [Gouw, Annette S. H.] Univ Med Ctr Groningen UMCG, Dept Pathol, Groningen, Netherlands. [Op den Dries, Sanna; Markmann, James F.; Yeh, Heidi; Uygun, Korkut; Martins, Paulo] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD JUN PY 2014 VL 20 SU 1 MA O-112 BP S138 EP S139 PG 2 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA AM6FU UT WOS:000339959601112 ER PT J AU Mateos, MV Bringhen, S Richardson, PG Lahuerta, JJ Larocca, A Oriol, A Boccadoro, M Garcia-Sanz, R Di Raimondo, F Esseltine, DL van de Velde, H Desai, A Londhe, A San Miguel, JF Palumbo, A AF Mateos, Maria-Victoria Bringhen, Sara Richardson, Paul G. Jose Lahuerta, Juan Larocca, Alessandra Oriol, Albert Boccadoro, Mario Garcia-Sanz, Ramon Di Raimondo, Francesco Esseltine, Dixie-Lee van de Velde, Helgi Desai, Avinash Londhe, Anil San Miguel, Jesus F. Palumbo, Antonio TI Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy SO HAEMATOLOGICA LA English DT Article ID DIAGNOSED MULTIPLE-MYELOMA; PERIPHERAL NEUROPATHY; INITIAL TREATMENT; TRIAL; MAINTENANCE; INDUCTION; PHASE-3; REVERSIBILITY; THALIDOMIDE; RISK AB Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules. In VISTA, the regimen comprised four 6-week twice-weekly cycles, plus five 6-week once-weekly cycles. In the GIMEMA MM-03-05 study, the bortezomib-melphalan-prednisone regimen was either per VISTA ('GIMEMA twice-weekly'), or comprised nine 5-week once-weekly cycles ('GIMEMA once-weekly'). In the GEM2005MAS65 study, the regimen comprised one 6-week twice-weekly cycle, plus five 5-week once-weekly cycles. We evaluated the cumulative bortezomib dose administered during bortezomib-melphalan-prednisone, as well as efficacy and tolerability, using patient-level study data. Over all bortezomib-melphalan-prednisone cycles (nine in VISTA/GIMEMA; six in GEM2005MAS65), the median cumulative bortezomib dose administered was 38.5, 42.1, 40.3, and 32.9 mg/m(2) in VISTA, GIMEMA twice-weekly, GIMEMA once-weekly, and GEM2005MAS65, respectively, and the respective proportions of planned bortezomib dose actually delivered were 57.0%, 62.3%, 86.1%, and 90.4%. Response rates following bortezomib-melphalan-prednisone were 74-87% and appeared generally similar between studies. Three-year survival rates were 67.9-75.7% across studies. Grade 3/4 peripheral neuropathy rates were 13% in VISTA and 14% in GIMEMA twice-weekly, but were lower at 2% in GIMEMA once-weekly and 7% in GEM2005MAS65. Discontinuations and bortezomib dose reductions due to peripheral neuropathy were reduced in GIMEMA once-weekly versus VISTA and GIMEMA twice-weekly. Exclusive or predominant use of once-weekly bortezomib dosing in GIMEMA once-weekly and GEM2005MAS65 resulted in high efficacy, comparable with that demonstrated in VISTA, and similar cumulative bortezomib dose with reduced toxicity. Trials are registered with ClinicalTrials.gov: VISTA (Identifier: 00111319), GIMEMA MM-03-05 (Identifier: 01063179), and GEM2005MAS65 (Identifier: 00443235). C1 [Mateos, Maria-Victoria; Garcia-Sanz, Ramon] IBMCC USAL CSIC, CIC, Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain. [Bringhen, Sara; Larocca, Alessandra; Boccadoro, Mario; Palumbo, Antonio] Univ Turin, Myeloma Unit, Div Hematol, Azienda Osped Univ AOU S Giovanni Battista, Turin, Italy. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jose Lahuerta, Juan] Hosp Univ 12 Octubre, Madrid, Spain. [Oriol, Albert] Hosp Badalona Germans Trias & Pujol, Badalona, Spain. [Di Raimondo, Francesco] Univ Catania, Osped Ferrarotto, Catania, Italy. [Esseltine, Dixie-Lee] Takeda Pharmaceut Int Co, Cambridge, MA USA. [van de Velde, Helgi] Janssen Res & Dev, Beerse, Belgium. [Desai, Avinash] Janssen Global Serv, Raritan, NJ USA. [Londhe, Anil] Janssen Res & Dev, Horsham, PA USA. [San Miguel, Jesus F.] Univ Navarra Clin, Ctr Invest Med Aplicada, Pamplona, Spain. RP Mateos, MV (reprint author), IBMCC USAL CSIC, CIC, Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain. EM mvmateos@usal.es RI Garcia-Sanz, Ramon/B-7986-2017; OI Garcia-Sanz, Ramon/0000-0003-4120-2787; SAN MIGUEL, JESUS/0000-0002-9183-4857 FU Millennium: The Takeda Oncology Company; Janssen Global Services FX The authors would like to acknowledge the writing assistance of Steve Hill of FireKite during the development of this publication, which was funded by Millennium: The Takeda Oncology Company, and Janssen Global Services. NR 23 TC 9 Z9 9 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN 1 PY 2014 VL 99 IS 6 BP 1114 EP 1122 DI 10.3324/haematol.2013.099341 PG 9 WC Hematology SC Hematology GA AQ5FN UT WOS:000342832100029 PM 24763402 ER PT J AU Halban, PA Polonsky, KS Bowden, DW Hawkins, MA Ling, C Mather, KJ Powers, AC Rhodes, CJ Sussel, L Weir, GC AF Halban, Philippe A. Polonsky, Kenneth S. Bowden, Donald W. Hawkins, Meredith A. Ling, Charlotte Mather, Kieren J. Powers, Alvin C. Rhodes, Christopher J. Sussel, Lori Weir, Gordon C. TI beta-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID STIMULATED INSULIN-SECRETION; HUMAN PANCREATIC-ISLETS; GASTRIC-BYPASS-SURGERY; DNA METHYLATION; EPIGENETIC REGULATION; HISTONE MODIFICATIONS; ACTIVATING MUTATIONS; SUSCEPTIBILITY LOCI; GLYCEMIC CONTROL; CONTROLLED-TRIAL AB OBJECTIVE: This article examines the foundation of beta-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS: A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS: The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of beta-cell failure, natural history of beta-cell failure, and impact of therapeutic interventions. CONCLUSIONS: beta-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased beta-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of beta-cell failure; 2) identify and characterize genetic loci for T2D; 3) target beta-cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of beta-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to beta-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and beta-cells. C1 [Halban, Philippe A.] Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland. [Polonsky, Kenneth S.] Univ Chicago, Endocrinol Sect, Dept Med, Chicago, IL 60637 USA. [Bowden, Donald W.] Wake Forest Univ, Ctr Genom & Personalized Med Res, Winston Salem, NC 27106 USA. [Bowden, Donald W.] Wake Forest Univ, Ctr Diabet Res, Winston Salem, NC 27106 USA. [Hawkins, Meredith A.] Albert Einstein Coll Med, Dept Med Endocrinol, Bronx, NY 10461 USA. [Hawkins, Meredith A.] Albert Einstein Coll Med, Global Diabet Inst, Bronx, NY 10461 USA. [Ling, Charlotte] Lund Univ, Dept Clin Sci, Lund, Sweden. [Mather, Kieren J.] Indiana Univ, Dept Endocrinol, Indianapolis, IN 46202 USA. [Powers, Alvin C.] Vanderbilt Univ, Sch Med, Div Diabet, Nashville, TN 37232 USA. Vanderbilt Univ, Sch Med, Div Diabet Endocrinol & Metab, Nashville, TN 37232 USA. [Rhodes, Christopher J.] Univ Chicago, Dept Med, Kovler Diabet Ctr, Chicago, IL 60637 USA. [Sussel, Lori] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10027 USA. [Weir, Gordon C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Halban, PA (reprint author), Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland. EM philippe.halban@unige.ch FU Novo Nordisk; Sanofi; Merck Co.; Eli Lilly Co. FX Duality of Interest. K.J.M. received study support from Novo Nordisk, Sanofi, and Merck & Co. C.J.R. received compensation for consulting work at Sanofi, Merck & Co., and enGene and also received compensation from Merck & Co. for a speaker role. G.C.W. received a consulting fee from Merck & Co., Novo Nordisk, and Eli Lilly & Co. No other potential conflicts of interest relevant to this article were reported.; This article is based on a conference jointly sponsored by the Endocrine Society and the American Diabetes Association and supported by an educational grant from Novo Nordisk, Sanofi, and Lilly USA. NR 86 TC 19 Z9 19 U1 2 U2 11 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2014 VL 99 IS 6 BP 1983 EP 1992 DI 10.1210/jc.2014-1425 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8PI UT WOS:000342340500037 PM 24712577 ER PT J AU Tritos, NA Johannsson, G Korbonits, M Miller, KK Feldt-Rasmussen, U Yuen, KCJ King, D Mattsson, AF Jonsson, PJ Koltowska-Haggstrom, M Klibanski, A Biller, BMK AF Tritos, Nicholas A. Johannsson, Gudmundur Korbonits, Marta Miller, Karen K. Feldt-Rasmussen, Ulla Yuen, Kevin C. J. King, Donna Mattsson, Anders F. Jonsson, Peter J. Koltowska-Haggstrom, Maria Klibanski, Anne Biller, Beverly M. K. TI Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID QUALITY-OF-LIFE; CARDIOVASCULAR RISK-FACTORS; ONSET GH DEFICIENCY; HYPOPITUITARY PATIENTS; DIABETES-MELLITUS; ENDOCRINE-SOCIETY; PITUITARY DISEASE; TREATED PATIENTS; QOL-AGHDA; THERAPY AB Context: GH deficiency (GHD) may occur in adults with cured acromegaly (acroGHD). Objective: Our objective was to examine the effectiveness and safety of GH replacement in acroGHD. Design: This study was a retrospective analysis of data from KIMS (Pfizer International Metabolic Database). Setting: Data were extracted from a pharmaco-epidemiological survey of >16 000 GHD adults from 31 countries. Patients: The effectiveness population included 115 adults with acroGHD and 142 age-, gender-, and body mass index-matched GHD adults with nonfunctioning pituitary adenoma (NFPA) followed up to 5 years on GH. The safety population included 164 adults with acroGHD and 2469 with NFPA, all GH-replaced. Both acroGHD and NFPA were compared with several cohorts from the general population (including the World Health Organization Global Burden of Disease). Outcome Measures: Outcome measures included quality of life (QoL-AGHDA), lipids, serious adverse events, and additional safety endpoints. Results: Median GH dose was 0.3 mg/d in acroGHD and NFPA at 5 years. There were comparable improvements in QoL-AGHDA and total and low-density lipoprotein cholesterol in acroGHD and NFPA. High-density lipoprotein cholesterol increased only in acroGHD. Cardiovascular mortality was increased in acroGHD vs NFPA(standardized mortality ratio = 3.03, P = .02). All-cause mortality was similar in acroGHD (ratio between observed/expected cases [95% confidence interval] = 1.32 [0.70-2.25]) and lower in NFPA [observed/expected = 0.58 [0.48-0.70]) in comparison with the general population. There was no difference in incidence of all cancers, benign or malignant brain tumors, or diabetes mellitus between acroGHD and NFPA. Conclusions: GH replacement has comparable effects on quality of life and lipids in acroGHD and NFPA. Further investigation is needed to examine whether the increased cardiovascular mortality may be attributed to the history of previous GH excess in acroGHD. C1 [Tritos, Nicholas A.; Miller, Karen K.; Klibanski, Anne; Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Tritos, Nicholas A.; Miller, Karen K.; Klibanski, Anne; Biller, Beverly M. K.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Johannsson, Gudmundur] Sahlgrens Univ Hosp, Dept Endocrinol, SE-41345 Gothenburg, Sweden. [Korbonits, Marta] Queen Mary Univ London, Dept Endocrinol Barts, London EC1M 6BQ, England. [Korbonits, Marta] Queen Mary Univ London, London Sch Med, London EC1M 6BQ, England. [Feldt-Rasmussen, Ulla] Univ Copenhagen, Natl Univ Hosp, Rigshosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark. [Yuen, Kevin C. J.] Oregon Hlth & Sci Univ, Div Endocrinol Diabet & Clin Nutr, Portland, OR 97239 USA. [King, Donna] Pfizer Inc, New York, NY 10017 USA. [Jonsson, Peter J.; Koltowska-Haggstrom, Maria] Pfizer Endocrine Care, SE-19091 Soilentuna, Sweden. RP Tritos, NA (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Zero Emerson Pl,Suite 112, Boston, MA 02114 USA. EM ntritos@partners.org OI Johannsson, Gudmundur/0000-0003-3484-8440; Korbonits, Marta/0000-0002-4101-9432 FU Pfizer; Ipsen; Novo-Nordisk; Novartis; Syntaxin; Eli Lilly; Versartis; Rhythm Pharmaceuticals FX N.A.T. has received research support from Pfizer and Ipsen and consulting honoraria from Pfizer and Corcept; G.J. has received research grants from Novo-Nordisk and Pfizer, occasional speaker honoraria from Pfizer, Novo-Nordisk, Merck Serono, and Otsuka and has served on the advisory board for Pfizer and acted as consultant for Viropharma and Astra Zeneca; M.K. has received research support from Pfizer, Novartis, and Syntaxin and occasional consulting and speaker honoraria from Pfizer, Chiasma, Sanofi, and Syntaxin; U.F.-R. has received research grants from Novo-Nordisk and Novartis, occasional consulting and speaker honoraria from Pfizer, Novo-Nordisk, IPSEN, and Novartis and serves on the advisory board for Pfizer; K.C.J.Y. has received research grants from Pfizer, Novo Nordisk, Eli Lilly, and Versartis and served on the advisory boards for Pfizer, Novo Nordisk, and Corcept Therapeutics; D.K., A.F.M., and P.J.J. are full-time employees of Pfizer; M.K.-H. was employed by Pfizer Health AB during the study; K.K.M. has received research grants for investigator-initiated studies from Pfizer and Ipsen; A.K. has received research grant support from Ipsen, Novartis, and Rhythm Pharmaceuticals; and B.M.K.B. has served as a consultant to Pfizer, Novartis, and Novo Nordisk and as the principal investigator of research grants from Novo Nordisk and Novartis to Massachusetts General Hospital. NR 54 TC 9 Z9 9 U1 0 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2014 VL 99 IS 6 BP 2018 EP 2029 DI 10.1210/jc.2014-1013 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8PI UT WOS:000342340500042 PM 24694339 ER PT J AU Shores, MM Biggs, ML Arnold, AM Smith, NL Longstreth, WT Kizer, JR Hirsch, CH Cappola, AR Matsumoto, AM AF Shores, Molly M. Biggs, Mary L. Arnold, Alice M. Smith, Nicholas L. Longstreth, W. T., Jr. Kizer, Jorge R. Hirsch, Calvin H. Cappola, Anne R. Matsumoto, Alvin M. TI Testosterone, Dihydrotestosterone, and Incident Cardiovascular Disease and Mortality in the Cardiovascular Health Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID LOW SERUM TESTOSTERONE; CORONARY-ARTERY DISEASE; ENDOGENOUS SEX-HORMONES; POPULATION-BASED COHORT; OLDER MEN; PLASMA TESTOSTERONE; ELDERLY-MEN; ANDROGEN DEFICIENCY; PREDICT MORTALITY; MASS-SPECTROMETRY AB Context: Low testosterone (T) is associated with prevalent cardiovascular disease (CVD) and mortality. DHT, a more potent androgen, may also be associated with CVD and mortality, but few studies have examined this. Objective: The study objective was to examine whether T and DHT are risk factors for incident CVD and mortality. Design: In a longitudinal cohort study, we evaluated whether total T, calculated free T (cFT), DHT, and calculated free DHT were associated with incident CVD and mortality in men in the Cardiovascular Health Study (mean age 76, range 66-97 years) who were free of CVD at the time of blood collection. Main Outcome: The main outcomes were incident CVD and all-cause mortality. Results: Among 1032 men followed for a median of 9 years, 436 incident CVD events and 777 deaths occurred. In models adjusted for cardiovascular risk factors, total T and cFT were not associated with incident CVD or all-cause mortality, whereas DHT and calculated free DHT had curvilinear associations with incident CVD (P < .002 and P = .04, respectively) and all-cause mortality (P < .001 for both). Conclusions: In a cohort of elderly men, DHT and calculated free DHT were associated with incident CVD and all-cause mortality. Further studies are needed to confirm these results and to clarify the underlying physiologic mechanisms. C1 [Shores, Molly M.; Smith, Nicholas L.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Smith, Nicholas L.] VA Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Shores, Molly M.] Univ Washington, Dept Psychiat & Behav Sci, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Biggs, Mary L.; Arnold, Alice M.] Univ Washington, Dept Biostat, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Smith, Nicholas L.; Longstreth, W. T., Jr.] Univ Washington, Dept Epidemiol, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Matsumoto, Alvin M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA. [Hirsch, Calvin H.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA. [Cappola, Anne R.] Univ Penn, Dept Internal Med, Div Endocrinol, Philadelphia, PA 19104 USA. RP Shores, MM (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way,S-116A, Seattle, WA 98108 USA. EM molly.shores@va.gov FU VA Research Service; VA Epidemiology Research and Information Center; VA Geriatric Research, Education and Clinical Center; NIH [1R01HL091952]; National Heart, Lung, and Blood Institute [HHSN268201200036C, N01-HC-85239, N01 HC-55222, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC85086, HL080295]; National Institute on Aging [AG-023629] FX This work was supported by the VA Research Service, the VA Epidemiology Research and Information Center, and the VA Geriatric Research, Education and Clinical Center; by NIH 1R01HL091952 and contracts HHSN268201200036C, N01-HC-85239, N01 HC-55222, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC85086, and Grant HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by AG-023629 from the National Institute on Aging. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org. NR 43 TC 22 Z9 22 U1 0 U2 4 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2014 VL 99 IS 6 BP 2061 EP 2068 DI 10.1210/jc.2013-3576 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8PI UT WOS:000342340500047 PM 24628549 ER PT J AU Ghosh, P Vaidya, A Sahoo, R Goldfine, A Herring, N Bry, L Chorev, M Halperin, JA AF Ghosh, Pamela Vaidya, Anand Sahoo, Rupam Goldfine, Allison Herring, Neil Bry, Lynn Chorev, Michael Halperin, Jose A. TI Glycation of the Complement Regulatory Protein CD59 Is a Novel Biomarker for Glucose Handling in Humans SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MANNOSE-BINDING LECTIN; VASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE; DIABETIC-NEPHROPATHY; ENDOTHELIAL-CELLS; TOLERANCE; ACTIVATION; NEUROPATHY; ASSOCIATION; PREVALENCE AB Context: Human CD59, an inhibitor of the membrane attack complex of complement, is inactivated by glycation. Glycation inactivation of CD59 enhances complement-mediated injury in target organs of diabetes complications. Objective: We hypothesized that circulating soluble glycated CD59 (GCD59) represents a novel biomarker of blood glucose handling and aimed to conduct human study protocols to test this hypothesis. Design, Setting, Participants, and Outcome Measures: Using a newly developed ELISA, we measured circulating soluble GCD59 in samples from 3 separate human studies evaluating acute and chronic glucose handling and glucose responses to insulin therapy. Study 1 (normal vs diabetic subjects) evaluated the cross-sectional association between GCD59 and glycated hemoglobin (HbA1c) in 400 subjects with and without type 2 diabetes. Study 2 (oral glucose tolerance test [OGTT] in nondiabetics) evaluated whether fasting GCD59 independently predicted the 2-hour glucose response to an OGTT in 109 subjects without a diagnosis of diabetes. Study 3 (intensified insulin treatment) evaluated the effect of intensification of glycemic control with insulin on GCD59 in 21 poorly controlled individuals with diabetes. Results: In study 1 (normal vs diabetic subjects), GCD59 was independently and positively associated with HbA1c in individuals with and without diabetes (beta = 1.1, P < .0001 and beta = 1.1, P < .001, respectively). In study 2 (OGTT in nondiabetics), a single GCD59 measurement independently predicted the results of the 2-hour OGTT (beta = 19.8, P < .05) after multivariate modeling. In study 3 (intensified insulin treatment), intensification of glucose control with insulin resulted in a concomitant and parallel reduction of average weekly glucose and GCD59 within 2 weeks. Conclusions: We observed robust relationships between a single measurement of blood levels of GCD59 and both acute (2-hour OGTT) and chronic (HbA1c) measures of glucose handling. Lowering of GCD59 levels closely reflected lowering of average weekly glucose within 2 weeks. The role of GCD59 in the diagnosis, management, and vascular risk stratification in diabetes warrants further investigation. C1 [Ghosh, Pamela; Sahoo, Rupam; Chorev, Michael; Halperin, Jose A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA. [Vaidya, Anand] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Vaidya, Anand] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Herring, Neil; Bry, Lynn] Partners Hlthcare Syst, Crimson Biospecimen Core, Boston, MA 02115 USA. [Goldfine, Allison] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Halperin, JA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. EM jose_halperin@hms.harvard.edu RI SAHOO, RUPAM/B-3935-2016 FU National Institutes of Health [DK62294, DK089206]; National Heart, Lung, and Blood Institute of the National Institutes of Health [K23HL111771] FX This work was supported by National Institutes of Health Grants DK62294 (to J.A.H.), DK089206 (to J.A.H.), and by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K23HL111771 (to A.V.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 37 TC 3 Z9 3 U1 1 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2014 VL 99 IS 6 BP E999 EP E1006 DI 10.1210/jc.2013-4232 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP8PI UT WOS:000342340500008 PM 24628556 ER PT J AU Boyer, N Gupta, R Schevchuck, A Hindnavis, V Maliske, S Sheldon, M Drachman, D Yeghiazarians, Y AF Boyer, Nathan Gupta, Rajesh Schevchuck, Alex Hindnavis, Vindhya Maliske, Seth Sheldon, Mark Drachman, Douglas Yeghiazarians, Yerem TI Coronary Artery Aneurysms in Acute Coronary Syndrome: Case Series, Review, and Proposed Management Strategy SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Review DE aneurysm; coronary disease; catheterization; revascularization; infarction ID POLYTETRAFLUOROETHYLENE-COVERED STENT; ACUTE MYOCARDIAL-INFARCTION; PACLITAXEL-ELUTING STENT; ST-SEGMENT ELEVATION; HEART-ASSOCIATION; KAWASAKI-DISEASE; IMPLANTATION; ECTASIA; COMMITTEE; GRAFT AB Coronary artery aneurysm (CAA) is an uncommon clinical finding, with an incidence varying from 1.5%-4.9% in adults, and is usually considered a variant of coronary artery disease (CAD). CAA identified in the context of acute coronary syndrome (ACS) represents a unique management challenge, particularly if the morphology of the CAA is suspected to have provoked the acute clinical syndrome. CAA is associated with thrombus formation due to abnormal laminar flow, as well as abnormal platelet and endothelial-derived pathophysiologic factors within the CAA. Once formed, mural thrombus may potentiate the deposition of additional thrombus within aneurysmal segments. Percutaneous revascularization of CAA has been associated with complications including distal embolization of thrombus, no-reflow phenomenon, stent malapposition, dissection, and rupture. Presently, there are no formal guidelines to direct the management of CAA in patients presenting with ACS; controversies exist whether conservative, surgical, or catheter-based management should be pursued. In this manuscript, we present an extensive review of the existing literature and associated clinical guidelines, and propose a management algorithm for patients with this complex clinical scenario. Armed with this perspective, therapeutic decisions may be tailored to synthesize patient factors and preferences, individualized clinical assessment, and existing American Heart Association/American College of Cardiology guidelines for management of ACS. C1 [Boyer, Nathan; Hindnavis, Vindhya; Yeghiazarians, Yerem] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Gupta, Rajesh; Drachman, Douglas] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiovasc, Boston, MA USA. [Maliske, Seth] Univ Iowa, Sch Med, Hosp & Clin, Iowa City, IA 52242 USA. Univ New Mexico, Dept Internal Med, Div Cardiol, Albuquerque, NM 87131 USA. RP Boyer, N (reprint author), 505 Parnassus Ave,Box 0103, San Francisco, CA 94143 USA. EM nathan.boyer@ucsf.edu NR 41 TC 6 Z9 7 U1 1 U2 8 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 EI 1557-2501 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD JUN PY 2014 VL 26 IS 6 BP 283 EP 290 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AP8VP UT WOS:000342357700019 PM 24907086 ER PT J AU Hawryluk, EB Tsao, H AF Hawryluk, Elena B. Tsao, Hensin TI Melanoma: Clinical Features and Genomic Insights SO COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY LA English DT Article ID PRIMARY CUTANEOUS MELANOMA; BRAF INHIBITOR RESISTANCE; V600E MUTANT MELANOMA; UVEAL MELANOMA; MALIGNANT-MELANOMA; METASTATIC MELANOMA; MELANOCYTIC NEVI; MEK INHIBITION; MC1R VARIANTS; ULTRAVIOLET-RADIATION AB Recent efforts in genomic research have enabled the characterization of molecular mechanisms underlying many types of cancers, ushering novel approaches for diagnosis and therapeutics. Melanoma is a molecularly heterogeneous disease, as many genetic alterations have been identified and the clinical features can vary. Although discoveries of frequent mutations including BRAF have already made clinically significant impact on patient care, there is a growing body of literature suggesting a role for additional mutations, driver and passenger types, in disease pathophysiology. Although some mutations have been strongly associated with clinical phenotypes of melanomas (such as physical distribution or morphologic subtype), the function or implications of many of the recently identified mutations remains less clear. The phenotypic and clinical impact of genomic mutations in melanoma remains a promising opportunity for progress in the care of melanoma patients. C1 [Hawryluk, Elena B.] Harvard Univ, Boston Childrens Hosp, Sch Med, Dermatol Program, Boston, MA 02115 USA. [Hawryluk, Elena B.; Tsao, Hensin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA. RP Tsao, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA. EM htsao@partners.org FU Dermatology Foundation; [K24 CA149202] FX The authors gratefully acknowledge Dr. Matthew Hawryluk for his critical review and comments on this work. Funding for this effort is supported in part by K24 CA149202, the generous donors to the Massachusetts General Hospital Millennium Melanoma fund (both to H.T.), and the Dermatology Foundation Fellowship in Pediatric Dermatology (E.B.H.). NR 113 TC 0 Z9 0 U1 0 U2 2 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1943-0264 J9 CSH PERSPECT BIOL JI Cold Spring Harbor Perspect. Biol. PD JUN PY 2014 VL 6 IS 6 AR a015388 DI 10.1101/cshperspect.a015388 PG 17 WC Cell Biology SC Cell Biology GA AO8AY UT WOS:000341575800009 ER PT J AU Duebgen, M Martinez-Quintanilla, J Tamura, K Hingtgen, S Redjal, N Wakimoto, H Shah, K AF Duebgen, Matthias Martinez-Quintanilla, Jordi Tamura, Kaoru Hingtgen, Shawn Redjal, Navid Wakimoto, Hiroaki Shah, Khalid TI Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID MESENCHYMAL PROGENITOR CELLS; HIGH-GRADE GLIOMA; MALIGNANT GLIOMA; CLINICAL-EXPERIENCE; CELLULAR VEHICLES; CANCER-THERAPY; GLIOBLASTOMA; VECTORS; VIROTHERAPY; EFFICACY AB Background The current treatment regimen for malignant glioblastoma multiforme (GBM) is tumor resection followed by chemotherapy and radiation therapy. Despite the proven safety of oncolytic herpes simplex virus (oHSV) in clinical trials for GBMs, its efficacy is suboptimal mainly because of insufficient viral spread after tumor resection. Methods Human mesenchymal stem cells (MSC) were loaded with oHSV (MSC-oHSV), and their fate was explored by real-time imaging in vitro and in vivo. Using novel diagnostic and armed oHSV mutants and real-time multimodality imaging, the efficacy of MSC-oHSV and its proapoptotic variant, oHSV-TRAIL encapsulated in biocompatible synthetic extracellular matrix (sECM), was tested in different mouse GBM models, which more accurately reflect the current clinical settings of malignant, resistant, and resected tumors. All statistical tests were two-sided. Results MSC-oHSVs effectively produce oHSV progeny, which results in killing of GBMs in vitro and in vivo mediated by a dynamic process of oHSV infection and tumor destruction. sECM-encapsulated MSC-oHSVs result in statistically significant increased anti-GBM efficacy compared with direct injection of purified oHSV in a preclinical model of GBM resection, resulting in prolonged median survival in mice (P < .001 with Gehan-Breslow-Wilcoxin test). To supersede resistant tumors, MSC loaded with oHSV-TRAIL effectively induce apoptosis-mediated killing and prolonged median survival in mice bearing oHSV- and TRAIL-resistant GBM in vitro (P < .001 with chi(2) contingency test). Conclusions Human MSC loaded with different oHSV variants provide a platform to translate oncolytic virus therapies to clinics in a broad spectrum of GBMs after resection and could also have direct implications in different cancer types. C1 [Duebgen, Matthias; Martinez-Quintanilla, Jordi; Hingtgen, Shawn; Redjal, Navid; Wakimoto, Hiroaki; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA USA. [Duebgen, Matthias; Martinez-Quintanilla, Jordi; Tamura, Kaoru; Hingtgen, Shawn; Redjal, Navid; Wakimoto, Hiroaki; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. [Redjal, Navid; Wakimoto, Hiroaki] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA. [Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Shah, K (reprint author), Massachusetts Gen Hosp, Mol Neurotherapy & Imaging Lab, MGH East 149,13th St, Charlestown, MA 02129 USA. EM kshah@mgh.harvard.edu FU American Cancer Society; James McDonald Foundation FX This work was supported by American Cancer Society (to KS) and James McDonald Foundation (to KS). NR 39 TC 11 Z9 11 U1 2 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2014 VL 106 IS 6 AR dju090 DI 10.1093/jnci/dju090 PG 9 WC Oncology SC Oncology GA AO8WT UT WOS:000341636800005 PM 24838834 ER PT J AU Pilarski, R Burt, R Kohlman, W Pho, L Shannon, KM Swisher, E AF Pilarski, Robert Burt, Randall Kohlman, Wendy Pho, Lana Shannon, Kristen M. Swisher, Elizabeth TI RE: Cowden Syndrome and PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria Response SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Letter C1 [Pilarski, Robert] Ohio State Univ, Div Human Genet, Dept Internal Med, Columbus, OH 43240 USA. [Pilarski, Robert] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43240 USA. [Burt, Randall; Kohlman, Wendy; Pho, Lana] Huntsman Canc Inst, Salt Lake City, UT USA. [Burt, Randall; Kohlman, Wendy] Univ Utah, Sch Med, Salt Lake City, UT USA. [Pho, Lana] Univ Utah, Dept Dermatol, Salt Lake City, UT USA. [Shannon, Kristen M.] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Risk Assessment, Boston, MA USA. [Swisher, Elizabeth] Univ Washington, Med Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA. RP Pilarski, R (reprint author), Ohio State Univ, James Comprehens Canc Ctr, 2001 Polaris Pkwy, Columbus, OH 43240 USA. EM robert.pilarski@osumc.edu RI Pilarski, Robert/E-3871-2011 NR 2 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2014 VL 106 IS 6 AR dju131 DI 10.1093/jnci/dju131 PG 1 WC Oncology SC Oncology GA AO8WT UT WOS:000341636800020 PM 24899680 ER PT J AU Stout, NK Lee, SJ Schechter, CB Kerlikowske, K Alagoz, O Berry, D Buist, DSM Cevik, M Chisholm, G de Koning, HJ Huang, H Hubbard, RA Miglioretti, DL Munsell, MF Trentham-Dietz, A van Ravesteyn, NT Tosteson, ANA Mandelblatt, JS AF Stout, Natasha K. Lee, Sandra J. Schechter, Clyde B. Kerlikowske, Karla Alagoz, Oguzhan Berry, Donald Buist, Diana S. M. Cevik, Mucahit Chisholm, Gary de Koning, Harry J. Huang, Hui Hubbard, Rebecca A. Miglioretti, Diana L. Munsell, Mark F. Trentham-Dietz, Amy van Ravesteyn, Nicolien T. Tosteson, Anna N. A. Mandelblatt, Jeanne S. TI Benefits, Harms, and Costs for Breast Cancer Screening After US Implementation of Digital Mammography SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID SERVICES TASK-FORCE; FILM MAMMOGRAPHY; UNITED-STATES; RISK-FACTORS; DENSITY; WOMEN; AGE; CARE; RECOMMENDATION; POPULATION AB Background Compared with film, digital mammography has superior sensitivity but lower specificity for women aged 40 to 49 years and women with dense breasts. Digital has replaced film in virtually all US facilities, but overall population health and cost from use of this technology are unclear. Methods Using five independent models, we compared digital screening strategies starting at age 40 or 50 years applied annually, biennially, or based on density with biennial film screening from ages 50 to 74 years and with no screening. Common data elements included cancer incidence and test performance, both modified by breast density. Lifetime outcomes included mortality, quality-adjusted life-years, and screening and treatment costs. Results For every 1000 women screened biennially from age 50 to 74 years, switching to digital from film yielded a median within-model improvement of 2 life-years, 0.27 additional deaths averted, 220 additional false-positive results, and $0.35 million more in costs. For an individual woman, this translates to a health gain of 0.73 days. Extending biennial digital screening to women ages 40 to 49 years was cost-effective, although results were sensitive to quality-of-life decrements related to screening and false positives. Targeting annual screening by density yielded similar outcomes to targeting by age. Annual screening approaches could increase costs to $5.26 million per 1000 women, in part because of higher numbers of screens and false positives, and were not efficient or cost-effective. Conclusions The transition to digital breast cancer screening in the United States increased total costs for small added health benefits. The value of digital mammography screening among women aged 40 to 49 years depends on women's preferences regarding false positives. C1 [Stout, Natasha K.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA. [Stout, Natasha K.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Lee, Sandra J.; Huang, Hui] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Schechter, Clyde B.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA. [Schechter, Clyde B.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Gen Internal Med Sect, Dept Vet Affairs, San Francisco, CA 94143 USA. [Alagoz, Oguzhan; Cevik, Mucahit] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI USA. [Alagoz, Oguzhan; Trentham-Dietz, Amy] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Alagoz, Oguzhan; Trentham-Dietz, Amy] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Berry, Donald; Chisholm, Gary; Munsell, Mark F.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA. [Buist, Diana S. M.; Hubbard, Rebecca A.] Grp Hlth Res Inst, Seattle, WA USA. [de Koning, Harry J.; van Ravesteyn, Nicolien T.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. [Miglioretti, Diana L.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Tosteson, Anna N. A.] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Mandelblatt, Jeanne S.] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA. [Mandelblatt, Jeanne S.] Lombardi Comprehens Canc Ctr, Canc Prevent & Control Program, Washington, DC USA. RP Stout, NK (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,6th Fl, Boston, MA 02215 USA. EM natasha_stout@hms.harvard.edu FU National Cancer Institute at the National Institutes of Health [UC2CA148577]; National Cancer Institute as part of the Cancer Intervention and Surveillance Modeling Network [U01CA152958]; National Cancer Institute, National Cancer Institute at the National Institutes of Health [U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040, HHSN261201100031C, P01CA154292] FX This work was supported by grant number UC2CA148577 from the National Cancer Institute at the National Institutes of Health. The models used in this analysis were also supported by grant number U01CA152958 from the National Cancer Institute as part of the Cancer Intervention and Surveillance Modeling Network. This work was also supported by the National Cancer Institute-funded BCSC grant numbers U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040, HHSN261201100031C, and P01CA154292 from the National Cancer Institute at the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. NR 40 TC 18 Z9 18 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2014 VL 106 IS 6 AR dju092 DI 10.1093/jnci/dju092 PG 8 WC Oncology SC Oncology GA AO8WT UT WOS:000341636800007 PM 24872543 ER PT J AU Clark, CR Baril, NC Achille, E Foster, S Johnson, N Taylor-Clark, K Gagne, JJ Olukoya, O Huisingh, CE Ommerborn, MJ Viswanath, K AF Clark, Cheryl R. Baril, Nashira C. Achille, Erline Foster, Shauntell Johnson, Natacha Taylor-Clark, Kalahn Gagne, Joshua J. Olukoya, Oluwakemi Huisingh, Carrie E. Ommerborn, Mark J. Viswanath, K. TI Trust Yet Verify: Physicians as Trusted Sources of Health Information on HPV for Black Women in Socioeconomically Marginalized Populations SO PROGRESS IN COMMUNITY HEALTH PARTNERSHIPS-RESEARCH EDUCATION AND ACTION LA English DT Article DE Human papilloma virus; human papilloma virus vaccines; African Americans; health knowledge; attitudes; practice; health communication ID HUMAN-PAPILLOMAVIRUS VACCINE; CERVICAL-CANCER; AFRICAN-AMERICAN; UNITED-STATES; CARE-SYSTEM; DISPARITIES; DISTRUST; PARENTS; EXPERIENCES; INFECTION AB Background: Human papilloma virus (HPV) infection is highest among Black women and women of low socioeconomic position (SEP). These groups face inequities in access to health information on HPV. Objectives: Our study sought to understand key information channels for delivering health information regarding HPV and the HPV vaccine to Black women of low SEP in Boston, Massachusetts. We anticipated that, owing to a legacy of experiences of discrimination, Black women of low SEP would prefer information from trusted and accessible sources, including friends, family, and community agencies, rather than clinical providers. Methods: We conducted a qualitative analysis using focus groups. We conducted five focus groups among 25 women in Boston, Massachusetts. Results: Contrary to what we anticipated, we found that women in all of the focus groups preferred to receive information from a physician or health center. Participants preferred to receive print materials they could triangulate with other sources. Notably, study participants had high access to care. Conclusions: Our study suggests that physicians are trusted and preferred sources of information on HPV for Black women of low SEP in Boston. Our data underscore an important avenue for intervention: to improve dissemination of HPV-related information through physicians, including outreach in community settings. C1 [Clark, Cheryl R.] Brigham & Womens Faulkner Hosp Program, Div Gen Med & Primary Care, Boston, MA 02130 USA. [Clark, Cheryl R.; Johnson, Natacha; Huisingh, Carrie E.; Ommerborn, Mark J.] Brigham & Womens Hosp, Ctr Community Hlth & Hlth Equ, Boston, MA 02115 USA. [Clark, Cheryl R.; Baril, Nashira C.; Achille, Erline; Foster, Shauntell] Boston REACH Coalit, Boston, MA USA. [Baril, Nashira C.; Achille, Erline] Boston Publ Hlth Commiss, Ctr Hlth Equ & Social Justice, Boston, MA USA. [Taylor-Clark, Kalahn] Natl Partnership Women & Families, Washington, DC USA. [Taylor-Clark, Kalahn] Brookings Inst, Washington, DC 20036 USA. [Gagne, Joshua J.] Dana Farber Canc Inst, Survey & Data Management Core, Boston, MA USA. [Olukoya, Oluwakemi] Boston Publ Hlth Commiss, Boston, MA USA. [Viswanath, K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Viswanath, K.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Cambridge, MA 02138 USA. RP Clark, CR (reprint author), Brigham & Womens Faulkner Hosp Program, Div Gen Med & Primary Care, Boston, MA 02130 USA. FU NCI NIH HHS [3U01CA114644] NR 26 TC 0 Z9 0 U1 2 U2 8 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1557-0541 EI 1557-055X J9 PROG COMM HLTH PARTN JI Prog. Community Health Partnersh. PD SUM PY 2014 VL 8 IS 2 BP 169 EP 179 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AO7UO UT WOS:000341558300003 PM 25152098 ER PT J AU Donnelly, JP Baddley, JW Wang, HE AF Donnelly, John P. Baddley, John W. Wang, Henry E. TI Reply to "Acute Sinusitis and Pharyngitis as Inappropriate Indications for Antibiotic Use" SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Letter ID RESPIRATORY-TRACT INFECTIONS C1 [Donnelly, John P.; Wang, Henry E.] Univ Alabama Birmingham, Dept Emergency Med, Birmingham, AL USA. [Baddley, John W.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. EM jbaddley@uab.edu OI Donnelly, John/0000-0002-0646-9470 FU None [HS013852] NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JUN PY 2014 VL 58 IS 6 BP 3573 EP 3573 DI 10.1128/AAC.02779-14 PG 1 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AK9VP UT WOS:000338776900082 PM 24829388 ER PT J AU Kadayifci, A Parlar, S Aydinli, M Dag, MS Demir, U Savas, MC AF Kadayifci, A. Parlar, S. Aydinli, M. Dag, M. S. Demir, U. Savas, M. C. TI Unsedated transnasal versus conventional oral endoscopy in endoscopy naive patients SO ACTA GASTRO-ENTEROLOGICA BELGICA LA English DT Article DE transnasal endoscopy; ultrathin endoscope; unsedated oral endoscopy; tolerability ID UPPER GASTROINTESTINAL ENDOSCOPY; RANDOMIZED-TRIAL; TRANSORAL ESOPHAGOGASTRODUODENOSCOPY; PERORAL ENDOSCOPY; EGD; SEDATION; DIAMETER; SAFETY; PERFORMANCE; TOLERANCE AB Background and study aims : Unsedated transnasal upper endoscopy (TNE) has been suggested as a more comfortable and safer method than unsedated transoral endoscopy (TOE). However, the numbers of comparative trials are limited. The current study aimed to assess the tolerability, safety, and efficacy of TNE in endoscopy naive patients. Patients and methods : The current study was designed as a randomized, prospective, parallel arm trial including all eligible patients referred for upper endoscopy. Patients were randomized with a 1:1 ratio to undergo either unsedated TOE using a standard endoscope or unsedated TNE using an ultrathin endoscope. Post-procedure, all patients were asked to complete a questionnaire to assess pain, discomfort, distress and tolerability using a 10 cm visual analog scale (VAS). Patients' expectations and future preferences were also determined by multiple choice questions. Endoscope insertion rate, procedure duration, and side-effects were recorded for each patient. Results : Each group included 200 patients. With the exception of nasal pain, mean VAS scores were significantly lower in TNE patients when compared to TOE patients (p = 0.0001). 85% and 54.5% of patients in TNE and TOE groups, respectively, found the procedure better than expected (p = 0001). A repeat procedure was significantly more acceptable for TNE than TOE (82.4% and 60.5%, respectively). Endoscope insertion failed in 3.5% of TNE patients. Mild epistaxis was observed in 4% of TNE patients. Conclusion : Unsedated TNE was tolerated better in endoscopy naive patients than unsedated TOE in a large parallel arm trial. C1 [Kadayifci, A.; Aydinli, M.; Dag, M. S.; Demir, U.; Savas, M. C.] Gaziantep Univ, Fac Med, Div Gastroenterol, Gaziantep, Turkey. [Parlar, S.] Gaziantep Univ, Fac Hlth Sci, Dept Internal Med Nursing, Gaziantep, Turkey. RP Kadayifci, A (reprint author), Massachusetts Gen Hosp, 3-H GI Associates,Zero Emerson Pl,Blossom St, Boston, MA 02114 USA. EM akadayifci@mgh.harvard.edu NR 23 TC 1 Z9 1 U1 0 U2 0 PU UNIV CATHOLIQUE LOUVAIN-UCL PI BRUSSELS PA CLIN UNIV SAINT LUC, AVE HIPPOCRATE 10, BRUSSELS, B-1200, BELGIUM SN 0001-5644 EI 1477-4607 J9 ACTA GASTRO-ENT BELG JI Acta Gastro-Enterol. Belg. PD JUN PY 2014 VL 77 IS 2 BP 224 EP 228 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AO3MP UT WOS:000341234800003 PM 25090820 ER PT J AU Li, G Millard, SP Peskind, ER Zhang, J Yu, CE Leverenz, JB Mayer, C Shofer, JS Raskind, MA Quinn, JF Galasko, DR Montine, TJ AF Li, Ge Millard, Steven P. Peskind, Elaine R. Zhang, Jing Yu, Chang-En Leverenz, James B. Mayer, Cynthia Shofer, Jane S. Raskind, Murray A. Quinn, Joseph F. Galasko, Douglas R. Montine, Thomas J. TI Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span SO JAMA NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; OLDER-ADULTS; FOLLOW-UP; IN-VIVO; DECLINE; BRAIN; DEMENTIA; MODELS; MATTER; RATIO AB IMPORTANCE Age-related cognitive decline among older individuals with normal cognition is a complex trait that potentially derives from processes of aging, inherited vulnerabilities, environmental factors, and common latent diseases that can progress to cause dementia, such as Alzheimer disease and vascular brain injury. OBJECTIVE To use cerebrospinal fluid (CSF) biomarkers to gain insight into this complex trait. DESIGN, SETTING, AND PARTICIPANTS Secondary analyses of an academic multicenter cross-sectional (n = 315) and longitudinal (n = 158) study of 5 neuropsychological tests (Immediate Recall, Delayed Recall, Trail Making Test Parts A and B, and Category Fluency) in cognitively normal individuals aged 21 to 100 years. MAIN OUTCOMES AND MEASURES To investigate the association of these cognitive function test results with age, sex, educational level, inheritance of the epsilon 4 allele of the apolipoprotein E gene, and CSF concentrations of beta-amyloid 42 (A beta 42) and tau (biomarkers of Alzheimer disease) as well as F-2-isoprostanes (measures of free radical injury). RESULTS Age and educational level were broadly predictive of cross-sectional cognitive performance; of the genetic and CSF measures, only greater CSF F-2-isoprostane concentration was significantly associated with poorer executive function (adjusted R-2 <= 0.31). Longitudinal measures of cognitive abilities, except Category Fluency, also were associated broadly with age; of the genetic and CSF measures, only lower baseline CSF A beta 42 concentration was associated with longitudinal measures of immediate and delayed recall (marginal R-2 <= 0.31). CONCLUSIONS AND RELEVANCE Our results suggest that age and educational level accounted for a substantial minority of variance in cross-sectional or longitudinal cognitive test performance in this large group of cognitively normal adults. Latent Alzheimer disease and other diseases that produce free radical injury, such as vascular brain injury, accounted for a small amount of variation in cognitive test performance across the adult human life span. Additional genetic and environmental factors likely contribute substantially to age-related cognitive decline. C1 [Li, Ge; Peskind, Elaine R.; Leverenz, James B.; Shofer, Jane S.; Raskind, Murray A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Millard, Steven P.; Peskind, Elaine R.; Mayer, Cynthia; Raskind, Murray A.] VA Puget Sound Hlth Care Syst, Vet Affairs VA Northwest Network Mental Illness R, Seattle, WA USA. [Zhang, Jing; Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Yu, Chang-En] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Yu, Chang-En] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] VA Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. [Galasko, Douglas R.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA. RP Montine, TJ (reprint author), Univ Washington, Sch Med, Dept Pathol, POB 357470, Seattle, WA 98195 USA. EM tmontine@uw.edu FU National Institutes of Health [AG023185, AG031892, AG05131, AG05136, AG08017, AG033693, U01-NS082137]; Department of Veterans Affairs; Oregon Clinical and Translational Research Institute [UL1TR000128]; Jane and Lee Seidman Fund; Nancy and Buster Alvord Endowment FX This work was supported by National Institutes of Health grants AG023185, AG031892, AG05131, AG05136, AG08017, AG033693, and U01-NS082137; the Department of Veterans Affairs; the Oregon Clinical and Translational Research Institute grant UL1TR000128; the Jane and Lee Seidman Fund; and the Nancy and Buster Alvord Endowment. NR 46 TC 12 Z9 12 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD JUN PY 2014 VL 71 IS 6 BP 742 EP 751 DI 10.1001/jamaneurol.2014.445 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA AN3IF UT WOS:000340479800012 PM 24756381 ER PT J AU Lu, LX Della-Torre, E Stone, JH Clark, SW AF Lu, Lucy X. Della-Torre, Emanuel Stone, John H. Clark, Stephen W. TI IgG4-Related Hypertrophic Pachymeningitis Clinical Features, Diagnostic Criteria, and Treatment SO JAMA NEUROLOGY LA English DT Review ID CEREBROSPINAL-FLUID ANALYSIS; IGG4 PRODUCTION; DISEASE; IL-10; CELLS AB IMPORTANCE IgG4-related hypertrophic pachymeningitis (IgG4-RHP) is an increasingly recognized manifestation of IgG4-related disease, a fibroinflammatory condition that can affect virtually any organ. It is estimated that IgG4-RHP may account for a high proportion of cases of hypertrophic pachymeningitis once considered idiopathic. OBJECTIVE To summarize the current knowledge on IgG4-RHP including its pathological, clinical, and radiological presentations. Particular emphasis is placed on diagnostic and therapeutic implications. EVIDENCE REVIEW This review is based on 21 reports published in the English medical literature since 2009. PubMed was searched with the following terms: IgG4, pachymeningitis, IgG4-related pachymeningitis, IgG4-related disease, IgG4-related, and IgG4 meningitis. Only cases with biopsy-proven IgG4-RHP were considered and included in this review. FINDINGS Little is known with certainty regarding the pathogenesis of IgG4-RHP. The presence of oligoclonally restricted IgG4-positive plasma cells within inflammatory meningeal niches strongly suggests a specific response against a still unknown antigen. Clinical presentation of IgG4-RHP is not distinguishable from other forms of hypertrophic pachymeningitis and reflects mechanical compression of vascular or nerve structures, leading to functional deficits. Signs of systemic IgG4-related disease may concomitantly be present. Diagnostic process should rely primarily on magnetic resonance imaging, cerebrospinal fluid analysis, and meningeal biopsy. In particular, hallmark histopathological features of IgG4-RHP are a lymphoplasmacytic infiltration of IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis. High-dose glucocorticoids are still the treatment of choice for IgG4-RHP because immunosuppressive agents have shown variable efficacy in reducing the meningeal hypertrophy. Rituximab is a promising therapeutic approach but experience with B-cell depletion strategies remains limited. CONCLUSIONS AND RELEVANCE IgG4-related disease accounts for an increasing proportion of cases of idiopathic hypertrophic pachymeningitis. Clinicians should become familiar with this alternative differential diagnosis because a prompt, specific therapeutic approach may avoid long-term neurological complications. C1 [Lu, Lucy X.; Clark, Stephen W.] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA. [Della-Torre, Emanuel] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Unit Med & Clin Immunol, Milan, Italy. [Stone, John H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA. [Clark, Stephen W.] Vanderbilt Univ, Dept Neurol, Sch Med, Nashville, TN 37232 USA. RP Clark, SW (reprint author), Vanderbilt Univ, Dept Neurol, 1161 21st Ave, Nashville, TN 37232 USA. EM stephen.w.clark@vanderbilt.edu OI Della Torre, Emanuel/0000-0002-9192-4270 NR 17 TC 30 Z9 39 U1 0 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD JUN PY 2014 VL 71 IS 6 BP 785 EP 793 DI 10.1001/jamaneurol.2014.243 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA AN3IF UT WOS:000340479800019 PM 24733677 ER PT J AU De Freitas, J Falls, BA Haque, OS Bursztajn, HJ AF De Freitas, Julian Falls, Brian A. Haque, Omar S. Bursztajn, Harold J. TI Recognizing Misleading Pharmaceutical Marketing Online SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID HEALTH INFORMATION; DRUG COMPANIES; INTERNET AB In light of decision-making psychology, this article details how drug marketing operates across established and novel web domains and identifies some common misleading trends and influences on prescribing and patient-initiated medication requests. The Internet has allowed pharmaceutical marketing to become more salient than ever before. Although the Internet's growth has improved the dissemination of pharmaceutical information, it has also led to the increased influence of misleading pharmaceutical marketing. Such mismarketing is of concern, especially in psychiatry, since psychotropics generate considerable revenue for drug companies. In a climate of resource-limited drug regulation and time-strapped physicians, we recommend improving both independent monitoring and consumer awareness of Internet-enabled, potentially misleading, pharmaceutical marketing influences. C1 [De Freitas, Julian] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England. [Falls, Brian A.] Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Haque, Omar S.] Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Bursztajn, Harold J.] Harvard Univ, Sch Med, Dept Psychiat, Program Psychiat & Law,Beth Israel Deaconess Med, Cambridge, MA 02138 USA. [Bursztajn, Harold J.] Massachusetts Mental Hlth Ctr, Cambridge, MA USA. RP Bursztajn, HJ (reprint author), 96 Larchwood Dr, Cambridge, MA 02138 USA. EM harold_bursztajn@hms.harvard.edu NR 31 TC 0 Z9 0 U1 2 U2 5 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 EI 1943-3662 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PD JUN 1 PY 2014 VL 42 IS 2 BP 219 EP 225 PG 7 WC Law; Psychiatry SC Government & Law; Psychiatry GA AN8LW UT WOS:000340856700012 ER PT J AU Possis, E Bui, T Gavian, M Leskela, J Linardatos, E Loughlin, J Strom, T AF Possis, Elizabeth Bui, Thao Gavian, Margaret Leskela, Jennie Linardatos, Effie Loughlin, Jennifer Strom, Thad TI Driving Difficulties Among Military Veterans: Clinical Needs and Current Intervention Status SO MILITARY MEDICINE LA English DT Review ID POSTTRAUMATIC-STRESS-DISORDER; VEHICLE ACCIDENT SURVIVORS; MENTAL-HEALTH PROBLEMS; RISK-TAKING BEHAVIORS; SENSATION-SEEKING; RESIDENTIAL-TREATMENT; VIETNAM VETERANS; ERA VETERANS; US VETERANS; GULF-WAR AB Military personnel deployed to Iraq and Afghanistan often develop mental health difficulties, which may manifest as problematic driving behavior. Veterans may be more likely to engage in risky driving and to subsequently be involved in motor vehicle accidents and fatalities. This article reviews literature on driving difficulties among military veterans and evaluates available research on the potential pathways that underlie risky driving behavior. Current interventions for problematic driving behaviors are considered, and the necessity of modifying these interventions to address the unique difficulties encountered by military veterans is highlighted. The review concludes with a discussion of clinical implications of these findings and identification of possible avenues for future research and intervention. C1 [Possis, Elizabeth; Leskela, Jennie; Strom, Thad] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN 55417 USA. [Bui, Thao] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Gavian, Margaret] North Mem Med Ctr, Psychiat Partial Hosp Program, Robbinsdale, MN 55422 USA. [Linardatos, Effie] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03756 USA. [Loughlin, Jennifer] Barrow Neurol Inst, Phoenix, AZ 85013 USA. RP Possis, E (reprint author), Minneapolis Vet Affairs Hlth Care Syst, One Vet Dr 116A, Minneapolis, MN 55417 USA. NR 58 TC 5 Z9 5 U1 1 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD JUN PY 2014 VL 179 IS 6 BP 633 EP 639 DI 10.7205/MlLMED-D-13-00327 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AN7UM UT WOS:000340806500008 PM 24902130 ER PT J AU Chan, K Hernandez, L Yang, HD Goetz, MB AF Chan, Kee Hernandez, Leilani Yang, Heidi Goetz, Matthew Bidwell TI Comparative Cost Analysis of Clinical Reminder for HIV Testing at the Veterans Affairs Healthcare System SO VALUE IN HEALTH LA English DT Article DE AIDS; cost analysis; Veterans Affairs Healthcare System ID STRATEGIES; SETTINGS; STATEMENT; RECEIPT; TRIAL AB Objective: To estimate the cost and health outcomes associated with a new HIV testing strategy that utilizes routine-based clinical reminders. Methods: We conducted an economic analysis of 1) traditional pretest/post-test counseling; 2) counseling and a new clinical reminders system; and 3) only clinical reminder in the veterans' health care system. A payer perspective decision model was conducted to calculate the 1-year budget impact of three HIV testing strategies. Parameter values were obtained from the literature, including patients' probability of accepting test, and costs associated with HIV testing procedures. Deidentified patient data, including total population screened and number of new HIV cases, were collected from one clinic in Los Angeles, California, from August 2004 to December 2011. Annual total costs and costs per new case were calculated on the basis of parameter values and patient data Sensitivity analyses were conducted to evaluate the robustness of the critical variable on costs. Results: The total cost of the clinical reminder system with pretest counseling was $81,726 over 1 year compared with $109,208 for traditional HIV testing. Under a clinical reminder system with no pretest counseling, the number of HIV tests performed and the number of new diagnoses increased for that year. In addition, cost per new diagnoses was the lowest. Conclusions: The clinical reminder system can reduce the cost per cases identified and promote better performance of HIV testing compared with traditional HIV testing. The fundamental decision model can be used for hospital facilities outside the Veteran Affairs adopting a similar program for improving the HIV testing rate. C1 [Chan, Kee; Hernandez, Leilani; Yang, Heidi] Boston Univ, Sargent Coll, Coll Hlth & Rehabil Sci, Dept Hlth Sci, Boston, MA 02215 USA. [Chan, Kee] Ctr Hlth Qual & Econ Res, Bedford, MA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Infect Dis Sect, Los Angeles, CA 90095 USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA. RP Chan, K (reprint author), Boston Univ, Sargent Coll, Coll Hlth & Rehabil Sci, 635 Commonwealth Ave, Boston, MA 02215 USA. EM keechan@bu.edu OI Goetz, Matthew/0000-0003-4542-992X NR 14 TC 1 Z9 1 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD JUN PY 2014 VL 17 IS 4 BP 334 EP 339 DI 10.1016/j.jval.2014.03.001 PG 6 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA AO1ON UT WOS:000341082900005 PM 24968992 ER PT J AU Spring, BQ Palanisami, A Hasan, T AF Spring, Bryan Q. Palanisami, Akilan Hasan, Tayyaba TI Microscale receiver operating characteristic analysis of micrometastasis recognition using activatable fluorescent probes indicates leukocyte imaging as a critical factor to enhance accuracy SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE cancer micrometastases; molecular imaging; activatable probes; leukocytes; immunoconjugates; image analysis ID GROWTH-FACTOR RECEPTOR; EPITHELIAL OVARIAN-CANCER; VIVO; CELLS; MICROENDOSCOPY; PHOTOIMMUNOTHERAPY; MICROENVIRONMENT; ENDOMICROSCOPY; CARCINOMATOSIS; METASTASES AB Molecular-targeted probes are emerging with applications for optical biopsy of cancer. An underexplored potential clinical use of these probes is to monitor residual cancer micrometastases that escape cytoreductive surgery and chemotherapy. Here, we show that leukocytes, or white blood cells, residing in nontumor tissues-as well as those infiltrating micrometastatic lesions-uptake cancer cell-targeted, activatable immunoconjugates nonspecifically, which limits the accuracy and resolution of micrometastasis recognition using these probes. Receiver operating characteristic analysis of freshly excised tissues from a mouse model of peritoneal carcinomatosis suggests that dual-color imaging, adding an immunostain for leukocytes, offers promise for enabling accurate recognition of single cancer cells. Our results indicate that leukocyte identification improves micrometastasis recognition sensitivity and specificity from 92 to 93%-for multicellular metastases >20 to 30 m in size-to 98 to 99.9% for resolving metastases as small as a single cell. (C) 2014 Society of Photo-Optical Instrumentation Engineers (SPIE) C1 [Spring, Bryan Q.; Palanisami, Akilan; Hasan, Tayyaba] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Spring, Bryan Q.; Palanisami, Akilan; Hasan, Tayyaba] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA 02214 USA. [Hasan, Tayyaba] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Hasan, Tayyaba] Harvard Univ, Cambridge, MA 02139 USA. [Hasan, Tayyaba] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hasan, T (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM thasan@mgh.harvard.edu FU U. S. National Institutes of Health [R01-AR40352, RC1-CA146337, R01-CA160998, P01-CA084203, F32-CA144210] FX This work was supported by U. S. National Institutes of Health grants R01-AR40352, RC1-CA146337, R01-CA160998, and P01-CA084203 to T. H. and F32-CA144210 to B. Q. S. NR 39 TC 1 Z9 1 U1 1 U2 5 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD JUN PY 2014 VL 19 IS 6 AR 066006 DI 10.1117/1.JBO.19.6.066006 PG 5 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA AN2RL UT WOS:000340432900013 PM 24919449 ER PT J AU Chang, G Meadows, ME Smallwood, JA Antin, JH Orav, EJ AF Chang, Grace Meadows, Mary-Ellen Smallwood, Jennifer A. Antin, Joseph H. Orav, E. John TI Cognitive and Other Predictors of Change in Quality of Life One Year After Treatment for Chronic Myelogenous Leukemia or Myelodysplastic Syndrome SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID BONE-MARROW-TRANSPLANTATION; CANCER-PATIENTS; CELL TRANSPLANTATION; MENTAL-HEALTH; SURVIVORS; ASSOCIATION; DIAGNOSIS; SYSTEM; MEMORY; SF-36 AB The role of cognitive function in quality of life is important among the growing numbers of survivors after cancer treatment. The authors conducted a prospective cohort study of 106 adults evaluated 5.6 months (median) after diagnosis and 77 of 83 (93%) survivors 12 months later with neuropsychological assessments yielding information about simple reaction time to stimuli and other aspects of cognitive function and with two quality of life measures. The two most consistent predictors of change in quality of life were baseline quality of life ratings and simple reaction time. This novel finding about simple reaction time warrants further confirmation. C1 [Chang, Grace; Meadows, Mary-Ellen; Antin, Joseph H.; Orav, E. John] Harvard Med Sch, Boston, MA 02115 USA. [Chang, Grace; Meadows, Mary-Ellen; Smallwood, Jennifer A.; Antin, Joseph H.; Orav, E. John] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chang, Grace] VA Boston Healthcare Syst, Brockton, MA USA. [Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Chang, G (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM grace.chang2@va.gov FU American Cancer Society [RSG-01-246-01]; National Institute on Alcohol Abuse and Alcoholism [K24AA00289] FX This study was funded by grants from the American Cancer Society (RSG-01-246-01, GC) and the National Institute on Alcohol Abuse and Alcoholism (K24AA00289, GC). Study sponsors had no involvement in study design; data acquisition, analysis, or interpretation; writing or submission of the manuscript. NR 41 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2014 VL 26 IS 3 BP 249 EP 257 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AN3ML UT WOS:000340492100043 PM 24817387 ER PT J AU Mendez, MF Shapira, JS AF Mendez, Mario F. Shapira, Jill S. TI Kissing or "Osculation" in Frontotemporal Dementia SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID KLUVER-BUCY-SYNDROME; TEMPORAL-LOBE EPILEPSY AB The authors investigated the neuropsychiatry of kissing in frontotemporal dementia. Among 15 patients, two had compulsive social kissing, bitemporal involvement, and Kluver-Bucy symptoms, and four pursued kissing with sexually disinhibited behavior. Future research should clarify the neuropsychiatric significance of kissing behavior. C1 [Mendez, Mario F.; Shapira, Jill S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90089 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehavioral Sci, Los Angeles, CA USA. [Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90089 USA. EM mmendez@ucla.edu FU NIA [R01AG034499-03] FX Supported by NIA grant # R01AG034499-03. NR 12 TC 0 Z9 0 U1 0 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2014 VL 26 IS 3 BP 258 EP 261 PG 4 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AN3ML UT WOS:000340492100044 PM 24922478 ER PT J AU Byrd, JK Smith, KJ de Almeida, JR Albergotti, WG Davis, KS Kim, SW Johnson, JT Ferris, RL Duvvuri, U AF Byrd, J. Kenneth Smith, Kenneth J. de Almeida, John R. Albergotti, W. Greer Davis, Kara S. Kim, Seungwon W. Johnson, Jonas T. Ferris, Robert L. Duvvuri, Umamaheswar TI Transoral Robotic Surgery and the Unknown Primary: A Cost-Effectiveness Analysis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE transoral robotic surgery; TORS; occult primary; cost-effectiveness analysis ID SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASES; PRIMARY TUMORS; RADICAL PROSTATECTOMY; EXTRACAPSULAR SPREAD; NECK; HEAD; TECHNOLOGY; MANAGEMENT; PARADIGM AB Objective. To evaluate the cost-effectiveness of transoral robotic surgery (TORS) for the diagnosis and treatment of cervical unknown primary squamous cell carcinoma (CUP). Study Design. Case series with chart review. Setting. Tertiary academic hospital. Subjects and Methods. A retrospective chart review was performed on patients with new occult primary squamous cell carcinoma of the head and neck with nondiagnostic imaging and/or endoscopy who were treated with TORS at a tertiary hospital between 2009 and 2012. Direct costs were obtained from the hospital's billing system, and national data were used for inpatient hospital costs and physician fees. The proportion of tumors found in 3 strategies was used as effectiveness to calculate the incremental cost-effectiveness ratio. Results. In total, 206 head and neck robotic cases were performed at our institution between December 2009 and December 2012. Three surgeons performed TORS on 22 patients for occult primary squamous cell carcinoma. The primary tumor was located in 19 of 22 patients (86.4%). The incremental cost-effectiveness ratio for sequential and simultaneous examination under anesthesia with tonsillectomy (EUA) and TORS base of tongue resection was $8619 and $5774 per additional primary identified, respectively. Conclusion. Sequential EUA followed by TORS is associated with an incremental cost-effectiveness ratio of $8619 compared with traditional EUA alone. Bilateral base of tongue resection should be considered in the workup of these patients, particularly if the palatine tonsils have already been removed. C1 [Byrd, J. Kenneth; Albergotti, W. Greer; Davis, Kara S.; Kim, Seungwon W.; Johnson, Jonas T.; Ferris, Robert L.; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Smith, Kenneth J.] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA. [de Almeida, John R.] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada. [Duvvuri, Umamaheswar] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Byrd, JK (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA. EM byrdjk@upmc.edu FU Department of Veterans Affairs FX This work was supported in part by funds from the Department of Veterans Affairs; this work does not reflect the views of the U.S. government or the Department of Veterans Affairs. NR 22 TC 17 Z9 17 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JUN PY 2014 VL 150 IS 6 BP 976 EP 982 DI 10.1177/0194599814525746 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AN2YC UT WOS:000340451000014 PM 24618502 ER PT J AU Priesol, AJ Valko, Y Merfeld, DM Lewis, RF AF Priesol, Adrian J. Valko, Yulia Merfeld, Daniel M. Lewis, Richard F. TI Motion Perception in Patients with Idiopathic Bilateral Vestibular Hypofunction SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE motion; orientation; perception; psychophysics; vestibular ID CANAL FUNCTION AB We measured vestibular perceptual thresholds in patients with idiopathic bilateral vestibulopathy to assess the distribution of peripheral vestibular damage in this disorder. Thresholds were measured with standard psychometric techniques in 4 patients and compared with thresholds in normal subjects and patients with completely absent peripheral vestibular function. Motion paradigms included yaw rotation (testing the lateral canals), interaural translation (testing the utricles), superior-inferior translation (testing the saccules), and roll tilt (testing the vertical semicircular canals and the otolith organs). We found that perceptual thresholds were abnormally elevated in the patients with idiopathic bilateral vestibulopathy for yaw rotation at all frequencies and for interaural translation at only the lower frequencies. Thresholds were normal for the other 2 motion paradigms. The results demonstrate that the distribution of vestibular dysfunction in this disorder is not uniform but, rather, can affect lateral canal and utricular thresholds while relatively sparing vertical canal and saccular function. C1 [Priesol, Adrian J.; Merfeld, Daniel M.; Lewis, Richard F.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. [Priesol, Adrian J.; Valko, Yulia; Merfeld, Daniel M.; Lewis, Richard F.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA. [Lewis, Richard F.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02114 USA. RP Lewis, RF (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA. EM richard_lewis@meei.harvard.edu FU NIH [NIH/NIDCD R01-DC04158] FX Funding source: NIH (NIH/NIDCD R01-DC04158). NR 9 TC 11 Z9 11 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JUN PY 2014 VL 150 IS 6 BP 1040 EP 1042 DI 10.1177/0194599814526557 PG 3 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AN2YC UT WOS:000340451000023 PM 24647642 ER PT J AU Fritsch, EF Rajasagi, M Ott, PA Brusic, V Hacohen, N Wu, CJ AF Fritsch, Edward F. Rajasagi, Mohini Ott, Patrick A. Brusic, Vladimir Hacohen, Nir Wu, Catherine J. TI HLA-Binding Properties of Tumor Neoepitopes in Humans SO CANCER IMMUNOLOGY RESEARCH LA English DT Article ID CYTOLYTIC T-LYMPHOCYTES; MINOR HISTOCOMPATIBILITY ANTIGEN; ACTIVE-SPECIFIC IMMUNOTHERAPY; COLONY-STIMULATING FACTOR; RENAL-CELL CARCINOMA; POINT MUTATION; HUMAN-MELANOMA; METASTATIC MELANOMA; LUNG-CARCINOMA; HIGH-FREQUENCY AB Cancer genome sequencing has enabled the rapid identification of the complete repertoire of coding sequence mutations within a patient's tumor and facilitated their use as personalized immunogens. Although a variety of techniques are available to assist in the selection of mutation-defined epitopes to be included within the tumor vaccine, the ability of the peptide to bind to patient MHC is a key gateway to peptide presentation. With advances in the accuracy of predictive algorithms for MHC class I binding, choosing epitopes on the basis of predicted affinity provides a rapid and unbiased approach to epitope prioritization. We show herein the retrospective application of a prediction algorithm to a large set of bona fide T cell-defined mutated human tumor antigens that induced immune responses, most of which were associated with tumor regression or long-term disease stability. The results support the application of this approach for epitope selection and reveal informative features of these naturally occurring epitopes to aid in epitope prioritization for use in tumor vaccines. (C) 2014 AACR. C1 [Fritsch, Edward F.; Rajasagi, Mohini; Brusic, Vladimir; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Fritsch, Edward F.; Rajasagi, Mohini; Ott, Patrick A.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hacohen, Nir] Massachusetts Gen Hosp, Dept Med, Div Allergy Immunol & Rheumatol, Boston, MA 02114 USA. [Ott, Patrick A.; Brusic, Vladimir; Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Fritsch, Edward F.; Hacohen, Nir] Broad Inst MIT & Harvard, Cambridge, MA USA. RP Wu, CJ (reprint author), Dana Farber Canc Inst, Dana 540B,450 Brookline Ave, Boston, MA 02115 USA. EM cwu@partners.org FU Blavatnik Family Foundation; NIH [NHLBI:5 R01 HL103532-03, NCI:1R01CA155010-02] FX The work on neoepitope-based vaccines was financially supported by the Blavatnik Family Foundation and the NIH (NHLBI:5 R01 HL103532-03; NCI:1R01CA155010-02). NR 54 TC 41 Z9 41 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2326-6066 EI 2326-6074 J9 CANCER IMMUNOL RES JI Cancer Immunol. Res. PD JUN PY 2014 VL 2 IS 6 BP 522 EP 529 DI 10.1158/2326-6066.CIR-13-0227 PG 8 WC Oncology; Immunology SC Oncology; Immunology GA AM7HC UT WOS:000340035300004 PM 24894089 ER PT J AU Morgenroth, DC Medverd, JR Seyedali, M Czerniecki, JM AF Morgenroth, David C. Medverd, Jonathan R. Seyedali, Mahyo Czerniecki, Joseph M. TI The relationship between knee joint loading rate during walking and degenerative changes on magnetic resonance imaging SO CLINICAL BIOMECHANICS LA English DT Article DE Osteoarthritis; Knee; Gait ID TRANS-TIBIAL AMPUTATION; ADDUCTION MOMENT; TIBIOFEMORAL OSTEOARTHRITIS; DISEASE SEVERITY; IN-VITRO; CARTILAGE; GAIT; BONE; IMPACT; STRENGTH AB Background: While animal study and cadaveric study have demonstrated an association between knee joint loading rate and joint degeneration, the relationship between knee joint loading rate during walking and osteoarthritis has not yet been sufficiently studied in humans. Methods: Twenty-eight participants (14 transfemoral amputees and 14 age and body mass matched controls) underwent knee MRI with subsequent assessment using the semiquantitative Whole-Organ Magnetic Resonance Image Score. Each subject also underwent gait analysis in order to determine knee adduction moment loading rate, peak, and impulse and an exploratory measure, knee adduction moment rate * magnitude. Findings; Significant correlations were found between medial tibiofemoral joint degeneration and knee adduction moment peak (slope = 0.42 [SE 0.20]; P = .037), loading rate (slope = 12.3 [SE 3.2]; P = .0004), and rate * magnitude (slope = 437 [SE 100]; P < .0001). These relationships continued to be significant after adjusting for body mass or subject type. The relationship between medial knee semiquantitative MRI score and knee adduction moment loading rate and rate * magnitude continued to be significant even after adjusting for peak moment (P < .0001), however, the relationship between medial knee semiquantitative MRI score and peak moment was no longer significant after adjusting for either loading rate or rate * magnitude (P > .2 in both cases). Interpretation; This study suggests an independent relationship between knee adduction moment loading rate and medial tibiofemoral joint degeneration. Our results support the hypothesis that rate of loading, represented by the knee adduction moment loading rate, is strongly associated with medial tibiofemoral joint degeneration independent of knee adduction moment peak and impulse. Published by Elsevier Ltd. C1 [Morgenroth, David C.; Seyedali, Mahyo; Czerniecki, Joseph M.] VAPSHCS, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence, Seattle, WA USA. [Medverd, Jonathan R.] VAPSHCS, Dept Vet Affairs, Dept Radiol, Seattle, WA USA. [Morgenroth, David C.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Medverd, Jonathan R.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. RP Morgenroth, DC (reprint author), VA Puget Sound Hlth Care Syst, RCS 117,1660 S Columbian Way, Seattle, WA 98108 USA. EM dmorgen@uw.edu FU U.S. Department of Veterans Affairs, Office of Research and Development (RRD Center) [A4843C]; National Institutes of Health (NIH) [K12 HD001097] FX This material is based on work supported in part by the U.S. Department of Veterans Affairs, Office of Research and Development (RR&D Center Grant A4843C). Additionally, David Morgenroth's work on this project was supported by the National Institutes of Health (NIH grant K12 HD001097). None of the authors have any conflicts of interest related to this work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 43 TC 6 Z9 6 U1 0 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 EI 1879-1271 J9 CLIN BIOMECH JI Clin. Biomech. PD JUN PY 2014 VL 29 IS 6 BP 664 EP 670 DI 10.1016/j.clinbiomech.2014.04.008 PG 7 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA AN1KH UT WOS:000340340700010 PM 24820134 ER PT J AU Wawer, MJ Jaramillo, DE Dancik, V Fass, DM Haggarty, SJ Shamji, AF Wagner, BK Schreiber, SL Clemons, PA AF Wawer, Mathias J. Jaramillo, David E. Dancik, Vlado Fass, Daniel M. Haggarty, Stephen J. Shamji, Alykhan F. Wagner, Bridget K. Schreiber, Stuart L. Clemons, Paul A. TI Automated Structure-Activity Relationship Mining: Connecting Chemical Structure to Biological Profiles SO JOURNAL OF BIOMOLECULAR SCREENING LA English DT Article DE structure-activity relationships; small-molecule profiling; high-content screening; frequent-itemset mining; association-rule mining ID HISTONE DEACETYLASE INHIBITORS; DIVERSITY-ORIENTED SYNTHESIS; SMALL MOLECULES; DRUG DISCOVERY; STRATEGY; CANCER; DIFFERENTIATION; IDENTIFICATION; MECHANISM; RESOURCE AB Understanding the structure-activity relationships (SARs) of small molecules is important for developing probes and novel therapeutic agents in chemical biology and drug discovery. Increasingly, multiplexed small-molecule profiling assays allow simultaneous measurement of many biological response parameters for the same compound (e. g., expression levels for many genes or binding constants against many proteins). Although such methods promise to capture SARs with high granularity, few computational methods are available to support SAR analyses of high-dimensional compound activity profiles. Many of these methods are not generally applicable or reduce the activity space to scalar summary statistics before establishing SARs. In this article, we present a versatile computational method that automatically extracts interpretable SAR rules from high-dimensional profiling data. The rules connect chemical structural features of compounds to patterns in their biological activity profiles. We applied our method to data from novel cell-based gene-expression and imaging assays collected on more than 30,000 small molecules. Based on the rules identified for this data set, we prioritized groups of compounds for further study, including a novel set of putative histone deacetylase inhibitors. C1 [Wawer, Mathias J.; Jaramillo, David E.; Dancik, Vlado; Fass, Daniel M.; Haggarty, Stephen J.; Shamji, Alykhan F.; Wagner, Bridget K.; Schreiber, Stuart L.; Clemons, Paul A.] Broad Inst, Ctr Sci Therapeut, Cambridge, MA 02142 USA. [Fass, Daniel M.; Haggarty, Stephen J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Chem Neurobiol Lab,Ctr Human Genet Res,Dept Neuro, Boston, MA USA. [Fass, Daniel M.; Haggarty, Stephen J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Chem Neurobiol Lab,Ctr Human Genet Res,Dept Psych, Boston, MA USA. RP Clemons, PA (reprint author), Broad Inst, Ctr Sci Therapeut, 7 Cambridge Ctr, Cambridge, MA 02142 USA. EM pclemons@broadinstitute.org OI Haggarty, Stephen J./0000-0002-7872-168X FU National Institute of General Medical Sciences as part of the Center of Excellence for Chemical Methodology and Library Development [P50-GM069721]; National Institutes of Health (NIH) RoadMap Molecular Libraries Initiative [U54-HG005032] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Cheminformatics and data-mining work was supported by the National Institute of General Medical Sciences (P50-GM069721, awarded to S. L. S.), as part of the Center of Excellence for Chemical Methodology and Library Development. Profiling measurements were supported as part of the National Institutes of Health (NIH) RoadMap Molecular Libraries Initiative (U54-HG005032, awarded to S. L. S.). Associated data can be accessed at http://www.broadinstitute.org/scientific-community/science/programs/csof t/thera peutics-platform/mlpcn/accessing-mlpcn-data. D.M.F. and S.J.H. NR 33 TC 8 Z9 8 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0571 EI 1552-454X J9 J BIOMOL SCREEN JI J. Biomol. Screen PD JUN PY 2014 VL 19 IS 5 SI SI BP 738 EP 748 DI 10.1177/1087057114530783 PG 11 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Chemistry, Analytical SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry GA AM9OG UT WOS:000340210300013 PM 24710340 ER PT J AU Vempati, UD Chung, C Mader, C Koleti, A Datar, N Vidovic, D Wrobel, D Erickson, S Muhlich, JL Berriz, G Benes, CH Subramanian, A Pillai, A Shamu, CE Schurer, SC AF Vempati, Uma D. Chung, Caty Mader, Chris Koleti, Amar Datar, Nakul Vidovic, Dusica Wrobel, David Erickson, Sean Muhlich, Jeremy L. Berriz, Gabriel Benes, Cyril H. Subramanian, Aravind Pillai, Ajay Shamu, Caroline E. Schuerer, Stephan C. TI Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS) SO JOURNAL OF BIOMOLECULAR SCREENING LA English DT Article DE database and data management; data standards; metadata; cell-based assays; enzyme assays or enzyme kinetics; gene expression ID MINIMUM INFORMATION; ONTOLOGY; INHIBITOR; PROJECT AB The National Institutes of Health Library of Integrated Network-based Cellular Signatures (LINCS) program is generating extensive multidimensional data sets, including biochemical, genome-wide transcriptional, and phenotypic cellular response signatures to a variety of small-molecule and genetic perturbations with the goal of creating a sustainable, widely applicable, and readily accessible systems biology knowledge resource. Integration and analysis of diverse LINCS data sets depend on the availability of sufficient metadata to describe the assays and screening results and on their syntactic, structural, and semantic consistency. Here we report metadata specifications for the most important molecular and cellular components and recommend them for adoption beyond the LINCS project. We focus on the minimum required information to model LINCS assays and results based on a number of use cases, and we recommend controlled terminologies and ontologies to annotate assays with syntactic consistency and semantic integrity. We also report specifications for a simple annotation format (SAF) to describe assays and screening results based on our metadata specifications with explicit controlled vocabularies. SAF specifically serves to programmatically access and exchange LINCS data as a prerequisite for a distributed information management infrastructure. We applied the metadata specifications to annotate large numbers of LINCS cell lines, proteins, and small molecules. The resources generated and presented here are freely available. C1 [Vempati, Uma D.; Chung, Caty; Mader, Chris; Koleti, Amar; Datar, Nakul; Vidovic, Dusica; Schuerer, Stephan C.] Univ Miami, Ctr Computat Sci, Miami, FL 33154 USA. [Wrobel, David; Erickson, Sean; Shamu, Caroline E.] Harvard Univ, Sch Med, ICCB Longwood Screening Facil, Boston, MA USA. [Muhlich, Jeremy L.; Berriz, Gabriel; Shamu, Caroline E.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA. [Benes, Cyril H.] Massachusetts Gen Hosp, Ctr Mol Therapeut, Boston, MA 02114 USA. [Subramanian, Aravind] Broad Inst, Cambridge, MA USA. [Pillai, Ajay] NHGRI, NIH, Rockville, MD USA. [Schuerer, Stephan C.] Univ Miami, Dept Mol & Cellular Pharmacol, Miami, FL 33154 USA. RP Schurer, SC (reprint author), Univ Miami, Dept Mol & Cellular Pharmacol, Ctr Computat Sci, 610D Clin Res Bldg,LC-213, Miami, FL 33154 USA. EM sschurer@med.miami.edu OI Pillai, Ajay/0000-0002-9789-7189 FU LINCS project [1U01HL111561, 3U01HL111561-01S1, 3U01HL111561-02S1, U54HG006097, U54 HG006093] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the LINCS project grants 1U01HL111561, 3U01HL111561-01S1, and 3U01HL111561-02S1, U54HG006097, U54 HG006093. NR 26 TC 22 Z9 22 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0571 EI 1552-454X J9 J BIOMOL SCREEN JI J. Biomol. Screen PD JUN PY 2014 VL 19 IS 5 SI SI BP 803 EP 816 DI 10.1177/1087057114522514 PG 14 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Chemistry, Analytical SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry GA AM9OG UT WOS:000340210300019 PM 24518066 ER PT J AU Ceppi, F Langlois-Pelletier, C Gagne, V Rousseau, J Ciolino, C De Lorenzo, S Kevin, KM Cijov, D Sallan, SE Silverman, LB Neuberg, D Kutok, JL Sinnett, D Laverdiere, C Krajinovic, M AF Ceppi, Francesco Langlois-Pelletier, Chloe Gagne, Vincent Rousseau, Julie Ciolino, Claire De Lorenzo, Samanta Kevin, Kojok M. Cijov, Diana Sallan, Stephen E. Silverman, Lewis B. Neuberg, Donna Kutok, Jeffery L. Sinnett, Daniel Laverdiere, Caroline Krajinovic, Maja TI Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia SO PHARMACOGENOMICS LA English DT Article DE childhood leukemia; peripheral neurotoxicity; pharmacogenetics; polymorphisms; treatment outcome; vincristine ID MULTIDRUG-RESISTANCE; MDR1 GENE; SEQUENCE DIVERSITY; CYP3A5 EXPRESSION; PHARMACOKINETICS; C3435T; CELLS; IDENTIFICATION; DISPOSITION; ASSOCIATION AB Background: Vincristine (VCR) is a standard component in the treatment of childhood acute lymphoblastic leukemia (ALL). VCR cytotoxicity is primarily due to its ability to disrupt the formation of microtubules of the mitotic spindle. Patients & methods: A total of 17 polymorphisms in regulatory and coding regions of genes controlling VCR targets (TUBB1, MAP4, ACTG1 and CAPG) or potentially influencing VCR levels (ABCB1 and CYP3A5) were investigated for an association with peripheral neuropathy and outcome in childhood ALL patients. Results: High-grade neurotoxicity was more frequent in carriers of the A allele of synonymous (Ala310) G to A (rs1135989) variation in the ACTG1 gene. Substitution (rs4728709) in the promoter of the ABCB1 gene had a protective effect against lower grade neurotoxicity and C to A variation (rs3770102) located 17 nucleotides upstream from the transcription start site had a protective effect against high-grade neurotoxicity. Patients with the ABCB1 3435TT genotype had lower event-free survival; the association with event-free survival was not supported by the analysis in the replication patient set. Conclusion: The polymorphisms in the ACTG1, CAPG and ABCB1 genes may modulate VCR-related neurotoxicity, whereas the risk of relapse seems not to be affected by the genes of the VCR pathway. C1 [Ceppi, Francesco; Langlois-Pelletier, Chloe; Gagne, Vincent; Rousseau, Julie; Ciolino, Claire; De Lorenzo, Samanta; Kevin, Kojok M.; Cijov, Diana; Sinnett, Daniel; Laverdiere, Caroline; Krajinovic, Maja] CHU St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada. [Sallan, Stephen E.; Silverman, Lewis B.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. [Sallan, Stephen E.; Silverman, Lewis B.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA. [Kutok, Jeffery L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Sinnett, Daniel; Laverdiere, Caroline; Krajinovic, Maja] Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada. [Krajinovic, Maja] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada. RP Krajinovic, M (reprint author), CHU St Justine, Res Ctr, 3175 Chemin Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada. EM maja.krajinovic@umontreal.ca FU Canadian Institutes of Health Research; Leukemia Lymphoma Society of Canada; Charles Bruneau Foundation; Centre d'excellence en Oncologie pediatrique et en soins palliatifs; National Cancer Institute/NIH [5 P01CA06848] FX Canadian Institutes of Health Research, Leukemia Lymphoma Society of Canada, Charles Bruneau Foundation, and Centre d'excellence en Oncologie pediatrique et en soins palliatifs supported this study. Dana-Farber Cancer Institute ALL treatment protocols are supported by the National Cancer Institute/NIH grant 5 P01CA06848. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 52 TC 7 Z9 8 U1 0 U2 6 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1462-2416 EI 1744-8042 J9 PHARMACOGENOMICS JI Pharmacogenomics PD JUN PY 2014 VL 15 IS 8 BP 1105 EP 1116 DI 10.2217/PGS.14.68 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AM9YJ UT WOS:000340236900009 PM 25084203 ER PT J AU Galland-Girodet, S Maire, JP De-Mones, E Benech, J Bouhoreira, K Protat, B Demeaux, H Darrouzet, V Huchet, A AF Galland-Girodet, Sigolene Maire, Jean-Philippe De-Mones, Erwan Benech, Julie Bouhoreira, Kheireddine Protat, Benoit Demeaux, Helene Darrouzet, Vincent Huchet, Aymeri TI The role of radiation therapy in the management of head and neck paragangliomas: Impact of quality of life versus treatment response SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE Head and neck paragangliomas; Quality of life; Radiation therapy; Tumor response ID GLOMUS-JUGULARE TUMORS; INTENSITY-MODULATED RADIOTHERAPY; LOCAL-CONTROL; EUROPEAN-ORGANIZATION; CANCER PATIENTS; TEMPORAL BONE; VAGALE TUMORS; EORTC QLQ-C30; SURGERY; TOXICITY AB Purpose: To assess the impact of radiotherapy in paragangliomas (PGLs) with regard to overall survival, local control, volumetric response and particularly quality of life (QoL). Materials and methods: From 1985 to 2010, 130 cases of head and neck (H&N) PGLs were managed at Bordeaux University Hospital. With a median follow-up of 7.6 years, we retrospectively present a cohort of 30 consecutive patients treated with radiation therapy for H&N PGLs. QoL was evaluated for 20 patients by the EORTC QLQ-C30 and H&N35 questionnaires through a cross-sectional study. Results: The 5-year overall survival and local control were 95% and 96% respectively. QoL is altered following management of PGLs. The H&N35 score is lower after combined modality therapy (surgery +/- embolization and radiation therapy) for speech and hearing (p = 0.004), trismus (p = 0.003) and total score (p = 0.01) than after radiotherapy alone. Tumor shrinkage was significant at 2 and 3 years after radiotherapy (p = 0.018; p = 0.043). Conclusion: Ultimate QoL should be a major goal of any treatment strategy for this benign disease. Definitive radiotherapy should be considered as a reasonable alternative to multimodality treatment as it provides comparable disease control with an apparent improvement in QoL. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Galland-Girodet, Sigolene; Maire, Jean-Philippe; Darrouzet, Vincent] Univ Bordeaux, Bordeaux, France. [Galland-Girodet, Sigolene; Maire, Jean-Philippe; Benech, Julie; Bouhoreira, Kheireddine; Protat, Benoit; Demeaux, Helene; Huchet, Aymeri] CHU Bordeaux, Dept Radiat Oncol, Bordeaux, France. [De-Mones, Erwan; Darrouzet, Vincent] CHU Bordeaux, Dept Otorhinolaryngol & Skull Base Surg, Bordeaux, France. [Galland-Girodet, Sigolene] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. RP Galland-Girodet, S (reprint author), Polyclin Bordeaux Nord Aquitaine, Serv Radiotherapie Oncol Med, 15 Rue Claude Boucher, F-33000 Bordeaux, France. EM dr.sgalland@bordeauxnord.com NR 39 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD JUN PY 2014 VL 111 IS 3 BP 463 EP 467 DI 10.1016/j.radonc.2014.06.002 PG 5 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA AN0VO UT WOS:000340302300023 PM 24996453 ER PT J AU Cattaneo, Z Bona, S Bauer, C Silvanto, J Herbert, AM Vecchi, T Merabet, LB AF Cattaneo, Zaira Bona, Silvia Bauer, Corinna Silvanto, Juha Herbert, Andrew M. Vecchi, Tomaso Merabet, Lotfi B. TI Symmetry Detection in Visual Impairment: Behavioral Evidence and Neural Correlates SO SYMMETRY-BASEL LA English DT Review DE symmetry detection; blind; visual impairment; haptic; plasticity ID LATERAL OCCIPITAL COMPLEX; MIRROR SYMMETRY; ELECTROPHYSIOLOGICAL INDEXES; BILATERAL SYMMETRY; HAPTIC DISCRIMINATION; UNFAMILIAR DISPLAYS; PROCESSING SYMMETRY; AMBLYOPIC VISION; WORKING-MEMORY; HUMAN BRAIN AB Bilateral symmetry is an extremely salient feature for the human visual system. An interesting issue is whether the perceptual salience of symmetry is rooted in normal visual development. In this review, we discuss empirical work on visual and tactile symmetry detection in normally sighted and visually impaired individuals. On the one hand, available evidence suggests that efficient visual symmetry detection may need normal binocular vision development. On the other hand, converging evidence suggests that symmetry can develop as a principle of haptic perceptual organization in individuals lacking visual experience. Certain features of visual symmetry detection, however, such as the higher salience of the patterns containing a vertical axis of symmetry, do not systematically apply to the haptic modality. The neural correlates (revealed with neuroimaging) associated with visual and haptic symmetry detection are also discussed. C1 [Cattaneo, Zaira] Univ Milano Bicocca, Dept Psychol, I-20126 Milan, Italy. [Cattaneo, Zaira; Vecchi, Tomaso] Natl Neurol Inst C Mondino, Brain Connect Ctr, I-27100 Pavia, Italy. [Bona, Silvia; Silvanto, Juha] Aalto Univ, Sch Sci, OV Lounasmaa Lab, Brain Res Unit, Espoo 02150, Finland. [Bauer, Corinna; Merabet, Lotfi B.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Lab Visual Neuroplast, Boston, MA 02115 USA. [Silvanto, Juha] Univ Westminster, Fac Sci & Technol, Dept Psychol, London W1W 6UW, England. [Herbert, Andrew M.] Rochester Inst Technol, Dept Psychol, Rochester, NY 14623 USA. [Vecchi, Tomaso] Univ Pavia, Dept Brain & Behav Sci, I-27100 Pavia, Italy. RP Cattaneo, Z (reprint author), Univ Milano Bicocca, Dept Psychol, I-20126 Milan, Italy. EM zaira.cattaneo@unimib.it; silvia.bona@aalto.fi; Corinna_Bauer@meei.harvard.edu; J.Silvanto@westminster.ac.uk; amhgss@rit.edu; vecchi@unipv.it; Lotfi_Merabet@meei.harvard.edu FU NIH/NEI [EY019924]; MIUR FIRB [RBFR12F0BD] FX This work was supported by an NIH/NEI RO1 Grant EY019924 (L.B.M.) and by a MIUR FIRB Grant RBFR12F0BD (Z.C.). NR 74 TC 3 Z9 3 U1 1 U2 6 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2073-8994 J9 SYMMETRY-BASEL JI Symmetry-Basel PD JUN PY 2014 VL 6 IS 2 BP 427 EP 443 DI 10.3390/sym6020427 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AM9KH UT WOS:000340200000016 ER PT J AU Raffetto, JD Mannello, F AF Raffetto, J. D. Mannello, F. TI Pathophysiology of chronic venous disease SO INTERNATIONAL ANGIOLOGY LA English DT Review DE Genetics; Inflammation; Varicose veins; Venous ulcer; Microcirculation; Extracellular matrix ID VARICOSE-VEIN FORMATION; SMOOTH-MUSCLE-CELLS; CHRONIC LEG ULCERS; MATRIX-METALLOPROTEINASE ACTIVITY; COLLAGEN TYPE-III; EXTRACELLULAR-MATRIX; ELEVATED EXPRESSION; GENE POLYMORPHISMS; CYTOKINE LEVELS; INSUFFICIENCY AB Chronic venous disease (CVD) is a debilitating condition with a prevalence between 60-70%. The disease pathophysiology is complex and involves genetic susceptibility and environmental factors, with individuals developing visible telengiectasias, reticular veins, and varicose veins. Patient with significant lower extremity symptoms have pain, dermal irritation, swelling, skin changes, and are at risk of developing debilitating venous ulceration. The signature of CVD is an increase in venous pressure referred to as venous hypertension. The various symptoms presenting in CVD and the clinical signs that are observed indicate that there is inflammation, secondary to venous hypertension, and it leads to a number of inflammatory pathways that become activated. The endothelium and glycocalyx via specialized receptors are critical at sensing changes in shear stress, and expression of adhesion molecules allows the activation of leukocytes leading to endothelial attachment, diapedisis, and transmigration into the venous wall/valves resulting in venous wall injury and inflammatory cells in the interstitial tissues. There is a complex of cytokines, chemokines, growth factors, proteases and proteinases, produced by activated leukocytes, that are expressed and unbalanced resulting in an environment of persistent inflammation with the clinical changes that are commonly seen, consisting of varicose veins to more advanced presentations of skin changes and venous ulceration. The structural integrity of protein and the extracellular matrix is altered, enhancing the progressive events of CVD. Work focusing on metabolic changes, miRNA regulation, inflammatory modulation and the glycocalyx will further our knowledge in the pathophysiology of CVD, and provide answers critical to treatment and prevention. C1 [Raffetto, J. D.] VA Boston Healthcare Syst, Div Vasc Surg, West Roxbury, MA USA. [Raffetto, J. D.] Brigham & Womens Hosp, Div Vasc & Endovasc Surg, Boston, MA 02115 USA. [Raffetto, J. D.] Harvard Univ, Sch Med, Boston, MA USA. [Mannello, F.] Univ Carlo Bo, Sect Clin Biochem & Cell Biol, Dept Biomol Sci, Urbino, Italy. RP Raffetto, JD (reprint author), VA Boston HCS, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM joseph.raffetto@med.va.gov NR 59 TC 11 Z9 11 U1 0 U2 6 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0392-9590 EI 1827-1839 J9 INT ANGIOL JI Int. Angiol. PD JUN PY 2014 VL 33 IS 3 BP 212 EP 221 PG 10 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AM4XN UT WOS:000339859600002 PM 24755829 ER PT J AU Mannello, F Ligi, D Raffetto, JD AF Mannello, F. Ligi, D. Raffetto, J. D. TI Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease SO INTERNATIONAL ANGIOLOGY LA English DT Article DE Glycosaminoglycans; Glycocalyx; Inflammation; Macrophages; Lymphocytes; Interleukins; Cytokines Chemokines ID HUMAN ENDOTHELIAL-CELLS; VARICOSE-VEINS; GLYCOCALYX; PATHOGENESIS; ISCHEMIA/REPERFUSION; HYPERPOLARIZATION; INSUFFICIENCY; INFILTRATION; HYPERTENSION; MECHANISMS AB Inflammation represents an important epiphenomenon in the etiopathogenesis of chronic venous disease, a worldwide debilitating condition affecting millions of subjects. The pathophysiology of chronic venous disease (CVD) is based on the hemodynamic abnormalities in conjunction to alterations in cellular and extracellular matrix biocompounds. The endothelial dysfunction results from early perturbation in the endothelium linked to glycocalyx injury and promoted by inflammatory cells and mediators (such as matrix metalloproteinases and interleukins), which lead to progressive dilation of the vein resulting in chronic venous insufficiency. Activated leukocytes during the inflammatory process release enzymes, free radicals, chemokines and inflammatory cytokines in the vessel microenvironment, which are responsible for the changes of the venous wall and venous valve, reflux and venous hypertension, and the development/progression of tissue destruction and skin changes. Sulodexide, a highly purified mixture of glycosaminoglycans composed by 80% fast moving heparin and 20% of dermatan sulphate, exhibits anti-thrombotic and profibrinolytic properties, restoring also the essential endothelial glycocalyx. Glycosaminoglycan sulodexide has been also characterized to reduce the release of inflammatory cytokines/chemokines and to inhibit the matrix metalloproteinases-related proteolytic cascades, counteracting endothelial dysfunctions. The pleiotropic effects of sulodexide set the basis for a very promising agent in treating the spectrum of CVD. C1 [Mannello, F.; Ligi, D.] Univ Carlo Bo, Sect Clin Biochem & Cell Biol, Dept Biomol Sci, Urbino, Italy. [Raffetto, J. D.] VA Boston Healthcare Syst, Div Vasc Surg, West Roxbury, MA USA. [Raffetto, J. D.] Brigham & Womens Hosp, Div Vasc & Endovasc Surg, Boston, MA 02115 USA. [Raffetto, J. D.] Harvard Univ, Sch Med, Boston, MA USA. RP Mannello, F (reprint author), Univ Carlo Bo, Sect Clin Biochem & Cell Biol, Dept Biomol Sci, Urbino, Italy. EM ferdinando.mannello@uniurb.it NR 53 TC 12 Z9 12 U1 0 U2 0 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0392-9590 EI 1827-1839 J9 INT ANGIOL JI Int. Angiol. PD JUN PY 2014 VL 33 IS 3 BP 236 EP 242 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AM4XN UT WOS:000339859600005 PM 24936532 ER PT J AU Petryshen, T AF Petryshen, T. TI Roles of genetics-based animal models in drug development in bipolar disorder SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 29th CINP World Congress of Neuropsychopharmacology CY JUN 22-26, 2014 CL Vancouver, CANADA SP CINP C1 [Petryshen, T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUN PY 2014 VL 17 SI 1 MA S-03-002 BP 5 EP 5 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AM3RB UT WOS:000339769200017 ER PT J AU Fava, M Lophaven, S Olsen, C AF Fava, M. Lophaven, S. Olsen, C. TI Effects of vortioxetine on cognitive symptoms of major depressive disorder (MDD) SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 29th CINP World Congress of Neuropsychopharmacology CY JUN 22-26, 2014 CL Vancouver, CANADA SP CINP C1 [Fava, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lophaven, S.; Olsen, C.] H Lundbeck & Co AS, Valby, Denmark. NR 0 TC 1 Z9 1 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUN PY 2014 VL 17 SI 1 MA P-04-026 BP 61 EP 61 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AM3RB UT WOS:000339769200243 ER PT J AU English, B Johnstone, J Johe, K Gertsik, L Sherman, M Fava, M Ereshefsky, L AF English, B. Johnstone, J. Johe, K. Gertsik, L. Sherman, M. Fava, M. Ereshefsky, L. TI Effects of NSI-189, a neurogenic compound, on quantitative electroencephalography (qEEG) in patients with major depressive disorder (MDD) during a phase 1b randomized, double-blind, placebo controlled, multiple ascending dose study SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 29th CINP World Congress of Neuropsychopharmacology CY JUN 22-26, 2014 CL Vancouver, CANADA SP CINP C1 [English, B.; Sherman, M.; Ereshefsky, L.] PAREXEL Int, Glendale, MA USA. [Johnstone, J.] Q Metrx, Glendale, MA USA. [Johe, K.] Neuralstem Inc, Rockville, MD USA. [Gertsik, L.] Calif Clin Trials, Glendale, MA USA. [Fava, M.] Massachusetts Gen Hosp, Dept Psychiat, MGH Clin Trials Network, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUN PY 2014 VL 17 SI 1 MA P-32-003 BP 119 EP 119 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA AM3RB UT WOS:000339769200466 ER PT J AU Soltis, K Acierno, R Gros, DF Yoder, M Tuerk, PW AF Soltis, Kathryn Acierno, Ron Gros, Daniel F. Yoder, Matthew Tuerk, Peter W. TI Post-Traumatic Stress Disorder: Ethical and Legal Relevance to the Criminal Justice System SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article ID NATIONAL COMORBIDITY SURVEY; INTERNATIONAL CONSENSUS GROUP; COGNITIVE-PROCESSING THERAPY; MENTAL-HEALTH-SERVICES; PROLONGED EXPOSURE; PSYCHIATRIC-DISORDERS; MILITARY PERSONNEL; RISK-FACTORS; US VETERANS; GULF-WAR C1 [Soltis, Kathryn] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Acierno, Ron; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC USA. [Acierno, Ron] Med Univ S Carolina, Coll Nursing, Charleston, SC USA. [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Primary Care Integrat Program, Charleston, SC USA. [Gros, Daniel F.; Yoder, Matthew; Tuerk, Peter W.] MUSC, Dept Psychiat & Behav Sci, Charleston, SC USA. [Yoder, Matthew] Ralph H Johnson Vet Affairs Med Ctr, Posttraumat Stress Clin, Charleston, SC USA. [Tuerk, Peter W.] APA Accredited MUSC VA Psychol Internship Program, Charleston, SC USA. RP Soltis, K (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. NR 81 TC 2 Z9 2 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1073-1105 EI 1748-720X J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SUM PY 2014 VL 42 IS 2 SI SI BP 147 EP 154 DI 10.1111/jlme.12130 PG 8 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA AM2XI UT WOS:000339714400006 PM 25040378 ER PT J AU Hamner, MB AF Hamner, Mark B. TI The Role of PTSD in Adjudicating Violent Crimes SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; DOMESTIC VIOLENCE; ABUSE; PREVALENCE; VICTIMS C1 [Hamner, Mark B.] Med Univ S Carolina, Charleston, SC 29425 USA. [Hamner, Mark B.] Ralph H Johnson VA Med Ctr, PTSD Clin, Charleston, SC USA. [Hamner, Mark B.] Amer Psychiat Assoc, Washington, DC 20005 USA. RP Hamner, MB (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. NR 19 TC 2 Z9 2 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1073-1105 EI 1748-720X J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SUM PY 2014 VL 42 IS 2 SI SI BP 155 EP 160 DI 10.1111/jlme.12131 PG 6 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA AM2XI UT WOS:000339714400007 PM 25040379 ER PT J AU Wangelin, BC Tuerk, PW AF Wangelin, Bethany C. Tuerk, Peter W. TI PTSD in Active Combat Soldiers: To Treat or Not to Treat SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE THERAPY; OPERATION IRAQI FREEDOM; NATIONAL-GUARD SOLDIERS; HEALTH TREATMENT-SEEKING; MENTAL-HEALTH; PSYCHOLOGICAL SYMPTOMS; MARITAL SATISFACTION; TREATMENT SERVICES; VIETNAM VETERANS C1 [Wangelin, Bethany C.; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC 29401 USA. [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Tuerk, Peter W.] APA Accredited MUSC VA Psychol Internship Program, Charleston, SC USA. RP Wangelin, BC (reprint author), Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC 29401 USA. NR 81 TC 2 Z9 2 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1073-1105 EI 1748-720X J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SUM PY 2014 VL 42 IS 2 SI SI BP 161 EP 170 DI 10.1111/jlme.12132 PG 10 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA AM2XI UT WOS:000339714400008 PM 25040380 ER PT J AU Hwong, AR Qaragholi, N Carpenter, D Joffe, S Campbell, EG Lehmann, LS AF Hwong, Alison R. Qaragholi, Noor Carpenter, Daniel Joffe, Steven Campbell, Eric G. Lehmann, Lisa Soleymani TI A Systematic Review of State and Manufacturer Physician Payment Disclosure Websites: Implications for Implementation of the Sunshine Act SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article ID CONFLICTS-OF-INTEREST; INDUSTRY; TRANSPARENCY; LAWS C1 [Hwong, Alison R.; Campbell, Eric G.; Lehmann, Lisa Soleymani] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Hwong, Alison R.] Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA. [Hwong, Alison R.] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA. [Qaragholi, Noor] Univ Virginia, Charlottesville, VA USA. [Carpenter, Daniel] Harvard Univ, Radcliffe Inst, Cambridge, MA 02138 USA. [Joffe, Steven] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Campbell, Eric G.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Lehmann, Lisa Soleymani] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Hwong, AR (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. OI Joffe, Steven/0000-0002-0667-7384 FU NIH [1UL1RR025758-01]; Safra Center for Ethics, Harvard University; Brigham and Women's Hospital Department of Medicine FX Supported by NIH 1UL1RR025758-01 (LSL, SJ), the Safra Center for Ethics, Harvard University (LSL, DC) and Brigham and Women's Hospital Department of Medicine (LSL). NR 22 TC 4 Z9 4 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1073-1105 EI 1748-720X J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SUM PY 2014 VL 42 IS 2 SI SI BP 208 EP 219 DI 10.1111/jlme.12136 PG 12 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA AM2XI UT WOS:000339714400012 PM 25040384 ER PT J AU Healy, DY Leopold, DA Gray, ST Holbrook, EH AF Healy, David Y., Jr. Leopold, Donald A. Gray, Stacey T. Holbrook, Eric H. TI The Perforation Technique: A Modification to the Frontal Sinus Osteoplastic Flap SO LARYNGOSCOPE LA English DT Editorial Material DE Frontal sinus; external approaches; bossing ID FAT OBLITERATION; OPERATIONS; SURGERY C1 [Healy, David Y., Jr.; Gray, Stacey T.; Holbrook, Eric H.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Healy, David Y., Jr.; Gray, Stacey T.; Holbrook, Eric H.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Leopold, Donald A.] Univ Vermont, Dept Otolaryngol Head & Neck Surg, Burlington, VT USA. RP Healy, DY (reprint author), Naval Med Ctr Portsmouth, Dept Otolaryngol Head & Neck Surg, 620 John Paul Jones Circle, Portsmouth, VA 23708 USA. EM dyhealy@hotmail.com NR 6 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD JUN PY 2014 VL 124 IS 6 BP 1314 EP 1317 DI 10.1002/lary.24460 PG 4 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA AL9SF UT WOS:000339480400018 PM 24122789 ER PT J AU Carter, MS Lookabaugh, S Lee, DJ AF Carter, Margaret S. Lookabaugh, Sarah Lee, Daniel J. TI Endoscopic-Assisted Repair of Superior Canal Dehiscence Syndrome SO LARYNGOSCOPE LA English DT Editorial Material DE superior canal dehiscence syndrome; SCD; SCDS; endoscopy; middle fossa craniotomy ID SURGICAL-MANAGEMENT; SKULL BASE; BONE; SURGERY C1 [Carter, Margaret S.; Lookabaugh, Sarah; Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Carter, Margaret S.; Lookabaugh, Sarah; Lee, Daniel J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Lee, DJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM daniel_lee@meei.harvard.edu NR 17 TC 8 Z9 8 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD JUN PY 2014 VL 124 IS 6 BP 1464 EP 1468 DI 10.1002/lary.24523 PG 5 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA AL9SF UT WOS:000339480400043 PM 24403248 ER PT J AU Phelan, E Schneider, R Lorenz, K Dralle, H Kamani, D Potenza, A Sritharan, N Shin, J Randolph, GW AF Phelan, Eimear Schneider, Rick Lorenz, Kerstin Dralle, Henning Kamani, Dipti Potenza, Andre Sritharan, Niranjan Shin, Jenifer Randolph, Gregory W. TI Continuous Vagal IONM Prevents Recurrent Laryngeal Nerve Paralysis by Revealing Initial EMG Changes of Impending Neuropraxic Injury: A Prospective, Multicenter Study SO LARYNGOSCOPE LA English DT Article DE Continuous vagal monitoring; CIONM; vagal electrodes; recurrent laryngeal nerve paralysis; recurrent laryngeal nerve injury; vocal cord paralysis; adverse EMG changes; neuromonitoring; IONM; thyroid surgery; combined events; amplitude and latency changes ID THYROID-SURGERY; PARATHYROID SURGERY; ENDOCRINE SURGEONS; ANCHOR ELECTRODE; STIMULATION; PALSY; IDENTIFICATION; COMPLICATIONS; ASSOCIATION; STATEMENT AB Objectives/Hypothesis: Existing intraoperative neuromonitoring (IONM) formats stimulate the recurrent laryngeal nerve (RLN) intermittently, exposing it to risk for injury in between stimulations. We report electrophysiologic parameters of continuous vagal monitoring, utilizing a novel real-time IONM format, and relate these parameters to intraoperative surgical maneuvers that delineate nascent adverse but reversible electrophysiologic parameters to prevent nerve injury. These results are correlated with postoperative vocal cord functional outcome. Study Design: Prospective multicenter tertiary study. Method: Evoked vagal nerve waveform amplitude and latency changes during 102 thyroidectomies were recorded. Adverse electrophysiologic response was categorized into 1-concordant amplitude reduction and latency increase events (combined events) and 2-loss of signal (LOS). Surgical maneuvers were modified when adverse electrophysiologic findings were noted. All patients underwent preoperative and postoperative laryngoscopy; intraoperative electrophysiologic findings were correlated with postoperative laryngeal function. Results: Continuous vagal monitoring did not result in stimulation-evoked nerve injury or intraoperative adverse cardiac, pulmonary, or gastrointestinal effects. Both intraoperative combined events and LOS were associated with development of vocal cord paralysis (VCP) (P=0.001 and P >0.001 respectively). Combined events had a positive predictive value (PPV) of 33%, negative predictive value (NPV) of 97%, and were reversible in 73%. LOS had a PPV of 83%, NPV of 98%, and was reversible in only 17%. Milder combined events and isolated amplitude or latency changes were not associated with VCP. Conclusions: Continuous vagal monitoring is safe and provides real-time RLN evaluation during surgical maneuvers. Combined events and LOS, both easily identifiable intraoperatively, are related to the development of VCP. A combined event represents a largely reversible electrophysiologic change when the associated surgical maneuver is aborted. If allowed to continue, it can advance to LOS (which typically is significantly less reversible) and to postoperative VCP. Continuous vagal monitoring has utility in identifying real-time adverse concordant amplitude and latency changes (combined events), which can prompt modification of the associated surgical maneuver and may prevent RLN paralysis during thyroidectomy. C1 [Phelan, Eimear; Kamani, Dipti; Potenza, Andre; Sritharan, Niranjan; Shin, Jenifer; Randolph, Gregory W.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Thyroid & Parathyroid Surg, Boston, MA 02114 USA. [Randolph, Gregory W.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Div Surg Oncol, Boston, MA 02115 USA. [Schneider, Rick; Dralle, Henning] Univ Halle Wittenberg, Div Gen Visceral & Vasc Surg, D-06108 Halle, Germany. RP Randolph, GW (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Thyroid & Parathyroid Surg, 243 Charles St, Boston, MA 02114 USA. EM Gregory_Randolph@meei.harvard.edu RI Shin, Jennifer/A-3169-2016 NR 43 TC 33 Z9 33 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD JUN PY 2014 VL 124 IS 6 BP 1498 EP 1505 DI 10.1002/lary.24550 PG 8 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA AL9SF UT WOS:000339480400049 PM 24307596 ER PT J AU Fritsch, EF Hacohen, N Wu, CJ AF Fritsch, Edward F. Hacohen, Nir Wu, Catherine J. TI Personal neoantigen cancer vaccines The momentum builds SO ONCOIMMUNOLOGY LA English DT Editorial Material DE neoantigen; vaccine; personalized; central tolerance; T cells ID T-CELLS; PATIENT AB Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient's tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation. C1 [Fritsch, Edward F.; Hacohen, Nir; Wu, Catherine J.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA. [Fritsch, Edward F.; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Hacohen, Nir] Massachusetts Gen Hosp, Dept Med, Div Allergy Immunol & Rheumatol, Boston, MA 02114 USA. [Wu, Catherine J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA. RP Wu, CJ (reprint author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA. EM cwu@partners.org NR 11 TC 16 Z9 16 U1 3 U2 9 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2162-4011 EI 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PD JUN PY 2014 VL 3 IS 6 AR e29311 DI 10.4161/onci.29311 PG 3 WC Oncology; Immunology SC Oncology; Immunology GA AM6EX UT WOS:000339957200021 PM 25101225 ER PT J AU Miller, DM Flaherty, KT Tsao, H AF Miller, David M. Flaherty, Keith T. Tsao, Hensin TI Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma SO SEMINARS IN CUTANEOUS MEDICINE AND SURGERY LA English DT Article ID T-LYMPHOCYTE ANTIGEN-4; STAGE-III MELANOMA; METASTATIC MELANOMA; ADJUVANT THERAPY; RAF INHIBITORS; PHASE-II; PEGYLATED INTERFERON-ALPHA-2B; RECOMBINANT INTERLEUKIN-2; TUMOR MICROENVIRONMENT; CANCER-IMMUNOTHERAPY AB Key molecular and immunological insights over the past decade have radically changed the face of therapy in melanoma. Whereas 5 years ago, treatment for advanced melanoma was restricted to the alkylating agent da-carbazine and the immunostimulants interleukin-2 and interferon-alpha-2b, today the therapeutic menu includes precise therapies that target key determinants in oncogenic pathways and immune checkpoints. In this chapter, we will review the current status and future directions of targeted therapies for melanoma directed at mitogen-activated pathways and immune checkpoints. (C) 2014 Frontline Medical Communications C1 [Miller, David M.] Columbia Univ, Dept Dermatol, Med Ctr, New York, NY 10027 USA. [Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA 02114 USA. [Tsao, Hensin] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Tsao, Hensin] Massachusetts Gen Hosp, MGH Canc Ctr, Dept Dermatol, Boston, MA 02114 USA. RP Tsao, H (reprint author), Massachusetts Gen Hosp, Edwards 211,55 Fruit St, Boston, MA 02114 USA. EM htsao@partners.org NR 90 TC 6 Z9 6 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1085-5629 EI 1558-0768 J9 SEMIN CUTAN MED SURG JI Semin. Cutan. Med. Surg. PD JUN PY 2014 VL 33 IS 2 BP 60 EP 67 PG 8 WC Dermatology; Surgery SC Dermatology; Surgery GA AM2VG UT WOS:000339708300002 PM 25085663 ER PT J AU Steensma, DP Montori, VM Shampo, MA Kyle, RA AF Steensma, David P. Montori, Victor M. Shampo, Marc A. Kyle, Robert A. TI Daniel Alcides Carrion - Peruvian Hero and Medical Martyr SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material C1 [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Steensma, David P.] Harvard Univ, Sch Med, Boston, MA USA. [Montori, Victor M.; Shampo, Marc A.; Kyle, Robert A.] Mayo Clin, Rochester, MN USA. RP Steensma, DP (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. OI Montori, Victor/0000-0003-0595-2898 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JUN PY 2014 VL 89 IS 6 BP E55 EP E56 DI 10.1016/j.mayocp.2013.08.025 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA AL0VZ UT WOS:000338846400002 PM 24943706 ER PT J AU Kraft, S Granter, SR AF Kraft, Stefan Granter, Scott R. TI Molecular Pathology of Skin Neoplasms of the Head and Neck SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID MERKEL-CELL-CARCINOMA; MUIR-TORRE-SYNDROME; TUMOR-SUPPRESSOR GENE; BROOKE-SPIEGLER-SYNDROME; CUTANEOUS MALIGNANT-MELANOMA; IN-SITU HYBRIDIZATION; NF-KAPPA-B; COMPARATIVE GENOMIC HYBRIDIZATION; NONPOLYPOSIS COLORECTAL-CANCER; DNA MISMATCH REPAIR AB Context.-Skin neoplasms include the most common malignancies affecting humans. Many show an ultraviolet (UV)-induced pathogenesis and often affect the head and neck region. Objective.-To review literature on cutaneous neoplasms that show a predilection for the head and neck region and that are associated with molecular alterations. Data Sources.-Literature review. Conclusions.-Common nonmelanoma skin cancers, such as basal and squamous cell carcinomas, show a UV-induced pathogenesis. Basal cell carcinomas are characterized by molecular alterations of the Hedgehog pathway, affecting patched and smoothened genes. While squamous cell carcinomas show UV-induced mutations in several genes, driver mutations are only beginning to be identified. In addition, certain adnexal neoplasms also predominantly affect the head and neck region and show interesting, recently discovered molecular abnormalities, or are associated with hereditary conditions whose molecular genetic pathogenesis is well understood. Furthermore, recent advances have led to an increased understanding of the molecular pathogenesis of melanoma. Certain melanoma subtypes, such as lentigo maligna melanoma and desmoplastic melanoma, which are more often seen on the chronically sun-damaged skin of the head and neck, show differences in their molecular signature when compared to the other more common subtypes, such as superficial spreading melanoma, which are more prone to occur at sites with acute intermittent sun damage. In summary, molecular alterations in cutaneous neoplasms of the head and neck are often related to UV exposure. Their molecular footprint often reflects the histologic tumor type, and familiarity with these changes will be increasingly necessary for diagnostic and therapeutic considerations. C1 [Kraft, Stefan] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kraft, Stefan; Granter, Scott R.] Harvard Univ, Sch Med, Boston, MA USA. [Granter, Scott R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Kraft, S (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pathol, Martinistr 52, D-20246 Hamburg, Germany. EM stefkraft@hotmail.com NR 513 TC 10 Z9 10 U1 1 U2 7 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD JUN PY 2014 VL 138 IS 6 BP 759 EP 787 DI 10.5858/arpa.2013-0157-RA PG 29 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA AM1FP UT WOS:000339592100009 PM 24878016 ER PT J AU Menendez, ME Bot, AGJ Neuhaus, V Ring, D Johnson, AH AF Menendez, Mariano E. Bot, Arjan G. J. Neuhaus, Valentin Ring, David Johnson, A. Holly TI Factors Influencing Discharge Disposition After Ankle Arthrodesis SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE ankle arthrodesis; ankle fusion; discharge; hospital stay; risk factors ID CARE RESOURCE UTILIZATION; UNITED-STATES; RISK-FACTORS; PERIOPERATIVE-OUTCOMES; SURGERY EPIDEMIOLOGY; METABOLIC SYNDROME; PATIENT OUTCOMES; HIP-ARTHROPLASTY; ELDERLY-PATIENTS; SPINE FUSION AB Background: Although functional and morbidity outcomes following ankle arthrodesis have been widely studied, patterns of health care resource utilization remain unclear. The purpose of this study was to identify preoperative and postoperative risk factors for nonroutine discharge following ankle arthrodesis. A secondary study aim was to determine risk factors associated with prolonged hospital stay. Methods: Using the National Health Discharge Survey (NHDS) database for the years 2001 through 2007, an estimated 40 941 patients having undergone ankle arthrodesis were identified and separated into those who were discharged to home (routine discharge) and those who were discharged to rehabilitation facilities (nonroutine discharge). Factors influencing discharge disposition and hospital length of stay were determined using multivariable binary logistic regression analysis. Results: Risk factors for nonroutine discharge were increasing age, male sex, diabetes mellitus, atrial fibrillation, more than 1 general or surgery-related complication, additional days of care, and the 2005 to 2007 time period. Risk factors associated with prolonged hospital stay were advanced age, female sex, diabetes mellitus, more than 1 general or surgery-related complication, and the 2001 to 2004 time period. Conclusion: Early identification of these factors might prove useful for better allocation of resources and implementation of effective strategies aimed at preventing longer hospitalizations and nonroutine discharges in selected patients at risk. Level of Evidence: Level II, prognostic study. C1 [Menendez, Mariano E.; Bot, Arjan G. J.; Neuhaus, Valentin] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. [Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Johnson, A. Holly] Harvard Univ, Sch Med, Boston, MA USA. RP Menendez, ME (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, 55 Fruit St,Ste 2100, Boston, MA 02114 USA. EM marianofurrer@gmail.com OI Neuhaus, Valentin/0000-0003-4012-5628 NR 50 TC 3 Z9 3 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1071-1007 EI 1944-7876 J9 FOOT ANKLE INT JI Foot Ankle Int. PD JUN PY 2014 VL 35 IS 6 BP 578 EP 583 DI 10.1177/1071100714528499 PG 6 WC Orthopedics SC Orthopedics GA AL7QN UT WOS:000339329800007 PM 24677223 ER PT J AU Klinge, SA McClure, P Fellars, T DiGiovanni, CW AF Klinge, Stephen A. McClure, Philip Fellars, Todd DiGiovanni, Christopher W. TI Modification of the Weil/Maceira Metatarsal Osteotomy for Coronal Plane Malalignment During Crossover Toe Correction: Case Series SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE metatarsophalangeal joint; crossover toe deformity; instability; metatarsal osteotomy ID METATARSOPHALANGEAL JOINT INSTABILITY; BREVIS TENDON TRANSFER; 2ND TOE; DEFORMITY; EXTENSOR; FLEXOR; PLATE; TIP AB Background: Metatarsophalangeal joint (MPJ) instability, which often involves the second ray, may result in dorsal translation and coronal drift of the proximal phalanx, with subsequent crossover of the first and second toe. After traditionally described soft tissue and osteotomy procedures are used to treat this deformity, coronal plane malalignment may persist, but few additional surgical options have been described to address this problem. Methods: We present a retrospective series of 5 patients who underwent a supplemental technique to augment coronal plane MPJ realignment. All patients underwent preplanned concomitant procedures. Crossover angulation of the second MPJ, amount of coronal translation required, and overall first-second ray alignment were compared pre- and postoperatively. Results: Depending on the severity of refractory deformity after soft tissue release and decompressive metatarsal osteotomy, 1.5 to 4.5 mm of coronal plane metatarsal head translation was required to achieve 3 to 20 degrees of overall valgus correction at the MPJ and complete correction of the crossover toe deformity. All patients were satisfied and had good function at last follow-up, a mean of 10.2 months, although 3 patients exhibited some level of second MPJ stiffness. One patient ended up with a component of residual floating toe deformity that was considered more of an incomplete correction of dorsal MPJ subluxation rather than any technical complication of this translational osteotomy modification designed to primarily correct coronal plane malalignment. A second patient had asymptomatic angular malalignment through partial (coronal plane) malrotation of the metatarsal osteotomy before it had healed. Conclusions: We have found this technique modification to be a very effective and simple means of treating recalcitrant lesser MPJ coronal plane malalignment when traditional soft tissue and bony techniques fail to fully restore anatomic MPJ position. Level of Evidence: Level IV, retrospective case series. C1 [Klinge, Stephen A.; McClure, Philip; Fellars, Todd] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA. [DiGiovanni, Christopher W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP DiGiovanni, CW (reprint author), Harvard Univ, Sch Med, Dept Orthopaed Surg, Yawkey Ctr Outpatient Care 55 Fruit St,Yaw 3F, Boston, MA 02114 USA. EM CWDiGiovanni@MGH.Harvard.edu NR 16 TC 1 Z9 1 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1071-1007 EI 1944-7876 J9 FOOT ANKLE INT JI Foot Ankle Int. PD JUN PY 2014 VL 35 IS 6 BP 584 EP 591 DI 10.1177/1071100714527745 PG 8 WC Orthopedics SC Orthopedics GA AL7QN UT WOS:000339329800008 PM 24651712 ER PT J AU Thase, ME AF Thase, Michael E. TI Combining Cognitive Therapy and Pharmacotherapy for Depressive Disorders: A Review of Recent Developments SO INTERNATIONAL JOURNAL OF COGNITIVE THERAPY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; BEHAVIORAL-ANALYSIS SYSTEM; MAJOR DEPRESSION; RECURRENT DEPRESSION; BIPOLAR DISORDER; CHRONIC FORMS; PSYCHOTHERAPY; MEDICATION; PREVENTION; NEFAZODONE AB Cognitive Behavior Therapy (CBT) and pharmacotherapy, including antidepressants for depressive disorders and mood stabilizers for bipolar disorders, are effective and widely disseminated treatments that often are considered the first line of therapy for these common, yet potentially disabling conditions. Given the imperfect and often unpredictable effects of these treatments, as well as the obvious differences in the aspects of depressive syndromes that they target, there has been a longstanding and widespread belief that these strategies will have additive effects. After 30-plus years of research-and slow progress-it now seems reasonably clear that CBT and pharmacotherapy have a partially additive benefit for patients with depressive disorders; this effect is proposed to be largely explained by improving outcomes for patients who are less responsive to one or both of the monotherapies. This article summarizes the research literature, including newer studies that examining differential impact on neural circuits and the metabolic activity of relevant brain regions. C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Thase, ME (reprint author), 3535 Market St,Suite 670, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 38 TC 1 Z9 1 U1 2 U2 23 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 1937-1209 EI 1937-1217 J9 INT J COGN THER JI Int. J. Cogn. Ther. PD JUN PY 2014 VL 7 IS 2 BP 108 EP 121 PG 14 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AM1NI UT WOS:000339612800002 ER PT J AU Crnej, A Omoto, M Dohlman, TH Graney, JM Dohlman, CH Drnovsek-Olup, B Dana, R AF Crnej, Alja Omoto, Masahiro Dohlman, Thomas H. Graney, John M. Dohlman, Claes H. Drnovsek-Olup, Brigita Dana, Reza TI A Novel Murine Model for Keratoprosthesis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE keratoprosthesis; murine model ID BOSTON TYPE-1 KERATOPROSTHESIS; I KERATOPROSTHESIS; GLAUCOMA; SURGERY; EYES; ENDOPHTHALMITIS; MULTICENTER; OUTCOMES; RISK AB PURPOSE. To establish a murine model for keratoprosthesis. METHODS. A miniature keratoprosthesis (m-KPro) device was created consisting of a poly[methyl methacrylate] front part and a titanium back plate, designed after the Boston KPro, which is in widespread clinical use. BALB/c mice were used and a 2 mm in diameter donor cornea was punched out. After 2-mm trepanation of the syngeneic recipient cornea, extracapsular crystalline lens extraction was performed. The m-KPro was assembled onto the cornea button in a similar manner to human KPro implantation. The cornea-device complex was secured to the recipient bed with eight interrupted 11-0 sutures. All mice (n = 10) were followed up for 8 weeks postoperatively. RESULTS. All m-KPros were successfully implanted and retained in all 10 animals. There were no critical complications such as endophthalmitis, corneal melting, device extrusions, leakage, extensive inflammation, or weight loss in the animals. We observed mild to moderate donor and host corneal neovascularization in all cases throughout the follow-up period. CONCLUSIONS. We have established a novel murine model of KPro implantation that we anticipate will serve as a good experimental system for evaluating host responses after KPro surgery. C1 [Crnej, Alja; Omoto, Masahiro; Dohlman, Thomas H.; Dohlman, Claes H.; Dana, Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA. [Crnej, Alja; Omoto, Masahiro; Dohlman, Thomas H.; Dohlman, Claes H.; Dana, Reza] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Graney, John M.] JG Machine Co Inc, Wilmington, MA USA. [Drnovsek-Olup, Brigita] Univ Eye Hosp, Univ Med Ctr, Ljubljana, Slovenia. RP Dana, R (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM reza_dana@meei.harvard.edu FU Boston-KPro research fund; National Institutes of Health [EY12963] FX Supported by the Boston-KPro research fund and the National Institutes of Health (EY12963). The authors alone are responsible for the content and writing of the paper. NR 25 TC 3 Z9 3 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2014 VL 55 IS 6 BP 3681 EP 3685 DI 10.1167/iovs.14-14058 PG 5 WC Ophthalmology SC Ophthalmology GA AL9TX UT WOS:000339485800038 PM 24833747 ER PT J AU Kondo, K Ishikado, A Morino, K Nishio, Y Ugi, S Kajiwara, S Kurihara, M Iwakawa, H Nakao, K Uesaki, S Shigeta, Y Imanaka, H Yoshizaki, T Sekine, O Makino, T Maegawa, H King, GL Kashiwagi, A AF Kondo, Keiko Ishikado, Atsushi Morino, Katsutaro Nishio, Yoshihiko Ugi, Satoshi Kajiwara, Sadae Kurihara, Mika Iwakawa, Hiromi Nakao, Keiko Uesaki, Syoko Shigeta, Yasutami Imanaka, Hiromichi Yoshizaki, Takeshi Sekine, Osamu Makino, Taketoshi Maegawa, Hiroshi King, George L. Kashiwagi, Atsunori TI A high-fiber, low-fat diet improves periodontal disease markers in high-risk subjects: a pilot study SO NUTRITION RESEARCH LA English DT Article DE Dietary fiber; Periodontal diseases; Obesity; Glucose tolerance test; Prediabetic state; Intervention study ID C-REACTIVE PROTEIN; ADIPONECTIN CONCENTRATION; DIABETES-MELLITUS; NATIONAL-HEALTH; GLYCEMIC INDEX; OLDER-ADULTS; WEIGHT-LOSS; OBESITY; JAPANESE; ATHEROSCLEROSIS AB Periodontal disease is related to aging, smoking habits, diabetes mellitus, and systemic inflammation. However, there remains limited evidence about causality from intervention studies. An effective diet for prevention of periodontal disease has not been well established. The current study was an intervention study examining the effects of a high-fiber, low-fat diet on periodontal disease markers in high-risk subjects. Forty-seven volunteers were interviewed for recruitment into the study. Twenty-one volunteers with a body mass index of at least 25.0 kg/m(2) or with impaired glucose tolerance were enrolled in the study. After a 2- to 3-week run-in period, subjects were provided with a test meal consisting of high fiber and low fat (30 kcal/kg of ideal body weight) 3 times a day for 8 weeks and followed by a regular diet for 24 weeks. Four hundred twenty-five teeth from 17 subjects were analyzed. Periodontal disease markers assessed as probing depth (2.28 vs 2.21 vs 2.13 mm; P < .0001), clinical attachment loss (6.11 vs 6.06 vs 5.98 mm; P < .0001), and bleeding on probing (16.2 vs 13.2 vs 14.6%; P = .005) showed significant reductions after the test-meal period, and these improvements persisted until the follow-up period. Body weight (P < .0001), HbA1c (P < .0001), and high-sensitivity C-reactive protein (P = .038) levels showed improvement after the test-meal period; they returned to baseline levels after the follow-up period. In conclusion, treatment with a high-fiber, low-fat diet for 8 weeks effectively improved periodontal disease markers as well as metabolic profiles, at least in part, by effects other than the reduction of total energy intake. (C) 2014 Elsevier Inc. All rights reserved. C1 [Kondo, Keiko; Ishikado, Atsushi; Morino, Katsutaro; Ugi, Satoshi; Nakao, Keiko; Yoshizaki, Takeshi; Sekine, Osamu; Maegawa, Hiroshi; Kashiwagi, Atsunori] Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Otsu, Shiga 5202192, Japan. [Ishikado, Atsushi; Uesaki, Syoko; Shigeta, Yasutami; Imanaka, Hiromichi; Makino, Taketoshi] Sunstar Inc, R&D Dept, Takatsuki, Osaka 5691195, Japan. [Nishio, Yoshihiko] Kagoshima Univ, Dept Grad Sch Med & Dent Sci, Div Endocrinol Diabet & Metab, Kagoshima 8908544, Japan. [Kajiwara, Sadae] Sunstar Fdn Oral Hlth Promot, Takatsuki, Osaka 5691195, Japan. [Kurihara, Mika; Iwakawa, Hiromi] Shiga Univ Med Sci, Div Clin Nutr, Otsu, Shiga 5202192, Japan. [King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Vasc Cell Biol,Res Div, Boston, MA 02215 USA. RP Ishikado, A (reprint author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Seta Tsuldnowa Cho, Otsu, Shiga 5202192, Japan. EM kon@belle.shiga-med.ac.jp; ishikado@belle.shiga-med.ac.jp; morino@belle.shiga-med.ac.jp; ynishio@m3.kufm.kagoshima-u.ac.jp; sugi@belle.shiga-med.ac.jp; sadae.kajiwara@jp.sunstar.com; kuri@belle.shiga-med.ac.jp; iwakawa@belle.shiga-med.ac.jp; kein@belle.shiga-med.ac.jp; syoko.uesaki@jp.sunstar.com; yasutami.shigeta@jp.sunstar.com; hiromichi.imanaka@jp.sunstar.com; yosizaki@belle.shiga-med.ac.jp; sekine@belle.shiga-med.ac.jp; taketoshi.makino@jp.sunstar.com; maegawa@belle.shiga-med.ac.jp; george.king@joslin.harvard.edu; kasiwagi@belle.shiga-med.ac.jp FU Department of Medicine, Shiga University of Medical Science; Sunstar; Astellas Pharma; Boehringer-Mannheim; Dainippon Sumitomo Pharma; Mitsubishi Tanabe Pharma Corporation; MSD; Pfizer; Sanofi; Takeda Pharmaceutical Company; Teijin Pharma FX We thank Mayumi Yamanaka and Shinya Koshinuma for their expert technical assistance and the volunteers for their participation. This study was funded by the Department of Medicine, Shiga University of Medical Science, and also partially supported by Sunstar. The Department of Medicine, Shiga University of Medical Science, received research promotion grants (Shougaku Kifukin) from Astellas Pharma, Boehringer-Mannheim, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma Corporation, MSD, Pfizer, Sanofi, Takeda Pharmaceutical Company, and Teijin Pharma. The research topics of these donation grants are not restricted. NR 38 TC 7 Z9 7 U1 1 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0271-5317 J9 NUTR RES JI Nutr. Res. PD JUN PY 2014 VL 34 IS 6 BP 491 EP 498 DI 10.1016/j.nutres.2014.06.001 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AM1XF UT WOS:000339641900004 PM 25026916 ER PT J AU Doran, KM Curry, LA Vashi, AA Platis, S Rowe, M Gang, M Vaca, FE AF Doran, Kelly M. Curry, Leslie A. Vashi, Anita A. Platis, Stephanie Rowe, Michael Gang, Maureen Vaca, Federico E. TI "Rewarding and Challenging at the Same Time": Emergency Medicine Residents' Experiences Caring for Patients Who Are Homeless SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID SAFETY-NET EMERGENCY; STUDENTS ATTITUDES; CARE; PEOPLE; URBAN; POPULATION; DEPARTMENTS; INTERVENTION; PHYSICIANS; LEARNERS AB Objectives: The objectives were to examine how emergency medicine (EM) residents learn to care for patients in the emergency department (ED) who are homeless and how providing care for patients who are homeless influences residents' education and professional development as emergency physicians. Methods: We conducted in-depth, one-on-one interviews with EM residents from two programs. A random sample of residents stratified by training year was selected from each site. Interviews were digitally recorded and professionally transcribed. A team of researchers with diverse content-relevant expertise reviewed transcripts independently and applied codes to text segments using a grounded theory approach. The team met regularly to reconcile differences in code interpretations. Data collection and analysis occurred iteratively, and interviews continued until theoretical saturation was achieved. Results: Three recurring themes emerged from 23 resident interviews. First, residents learn unique aspects of EM by caring for patients who are homeless. This learning encompasses both specific knowledge and skills (e. g., disease processes infrequently seen in other populations) and professional development as an emergency physician (e. g., the core value of service in EM). Second, residents learn how to care for patients who are homeless through experience and informal teaching rather than through a formal curriculum. Residents noted little formal curricular time dedicated to homelessness and instead learned during clinical shifts through personal experience and by observing more senior physicians. One unique method of learning was through stories of "misses," in which patients who were homeless had bad outcomes. Third, caring for patients who are homeless affects residents emotionally in complex, multifaceted ways. Emotions were dominated by feelings of frustration. This frustration was often related to feelings of futility in truly helping homeless patients, particularly for patients who were frequent visitors to the ED and who had concomitant alcohol dependence. Conclusions: Caring for ED patients who are homeless is an important part of EM residency training. Our findings suggest the need for increased formal curricular time dedicated to the unique medical and social challenges inherent in treating patients who are homeless, as well as enhanced support and resources to improve the ability of residents to care for this vulnerable population. Future research is needed to determine if such interventions improve EM resident education and, ultimately, result in improved care for ED patients who are homeless. (C) 2014 by the Society for Academic Emergency Medicine C1 [Doran, Kelly M.; Vashi, Anita A.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA. [Doran, Kelly M.; Vashi, Anita A.] US Dept Vet Affairs, New Haven, CT USA. [Doran, Kelly M.; Vashi, Anita A.; Vaca, Federico E.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA. [Curry, Leslie A.; Platis, Stephanie] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Curry, Leslie A.] Yale Univ, Sch Med, Robert Wood Johnson Fdn RWJF Clin Scholars Progra, New Haven, CT USA. [Rowe, Michael] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Doran, Kelly M.; Gang, Maureen] NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA. RP Doran, KM (reprint author), NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA. EM kelly.doran@nyumc.org FU RWJF; U.S. Department of Veterans Affairs through the RWJF Clinical Scholars Program FX Financial support for this study was received from the RWJF and the U.S. Department of Veterans Affairs through the RWJF Clinical Scholars Program. The funder had no role in the study conduct or presentation of the results. NR 44 TC 1 Z9 1 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD JUN PY 2014 VL 21 IS 6 BP 673 EP 679 DI 10.1111/acem.12388 PG 7 WC Emergency Medicine SC Emergency Medicine GA AL5GR UT WOS:000339162200009 PM 25039552 ER PT J AU Li, PY Tsai, TY Li, JS Zhang, Y Kwon, YM Rubash, HE Li, GA AF Li, Pingyue Tsai, Tsung-Yuan Li, Jing-Sheng Zhang, Yu Kwon, Young-Min Rubash, Harry E. Li, Guoan TI Morphological measurement of the knee : race and sex effects SO ACTA ORTHOPAEDICA BELGICA LA English DT Article ID ANTHROPOMETRIC MEASUREMENTS; TIBIAL COMPONENT; PROXIMAL TIBIA; ARTHROPLASTY; POPULATION; DESIGN; PROSTHESES; MORPHOMETRY; REPLACEMENT; ANATOMY AB Three-dimensional knee models of 148 Chinese (61 males, 87 female) and of 127 Caucasian (79 male, 48 female) were constructed. The anteroposterior (fAP, tAP) and mediolateral (fML, tML) dimensions of cross-section of the femur and tibia after simulated TKA bony resection were measured. Females have smaller femoral aspect ratios (fML/fAP) than males (Chinese : 1.22 +/- 0.05 vs 1.29 +/- 0.04; Caucasians : 1.18 +/- 0.05 vs 1.25 +/- 0.05) (P < 0.05). The tibial aspect ratios (tML/tAP) of the Chinese males (1.56 +/- 0.07) and the Caucasian females (1.54 +/- 0.07) are smaller than that of the Caucasian males (1.61 +/- 0.08) (P < 0.05). In regression analysis, for the same fAP or tAP dimension, females have narrower femoral condyles or tibia platforms than males; the Caucasian males have narrower femoral condyle or wider tibial platform than the Chinese males. For the same fAP dimension, males have lager tibial platforms than females; the Chinese males have larger tibial platforms than the Caucasian males. Racial and sex differences of the resected femur and tibia surfaces were found between a Chinese population and a Caucasian population. The relationship between the femur and tibia also showed racial and sex differences. These results may provide guidelines for future development of sex-specific as well as race-specific total knee replacement surgeries. C1 [Li, Pingyue; Zhang, Yu] Guangzhou Gen Hosp Guangzhou Mil Command, Dept Orthopaed Surg, Guangzhou, Guangdong, Peoples R China. [Tsai, Tsung-Yuan; Li, Jing-Sheng; Kwon, Young-Min; Rubash, Harry E.; Li, Guoan] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Tsai, Tsung-Yuan; Li, Jing-Sheng; Kwon, Young-Min; Rubash, Harry E.; Li, Guoan] Harvard Univ, Sch Med, Boston, MA USA. RP Li, GA (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA. EM Li.Guoan@mgh.harvard.edu OI Tsai, Tsung-Yuan/0000-0003-1522-2987 NR 30 TC 3 Z9 4 U1 0 U2 1 PU ACTA MEDICA BELGICA PI BRUSSELS PA AVENUE WINSTON CHURCHILL, WINSTON CHURCHILL-LAAN, 11 BOX 30, B-1180 BRUSSELS, BELGIUM SN 0001-6462 J9 ACTA ORTHOP BELG JI Acta Orthop. Belg. PD JUN PY 2014 VL 80 IS 2 BP 260 EP 268 PG 9 WC Orthopedics SC Orthopedics GA AL8UL UT WOS:000339415100017 PM 25090801 ER PT J AU Myaskovsky, L Pleis, J Dew, M Switzer, G Shapiro, R AF Myaskovsky, L. Pleis, J. Dew, M. Switzer, G. Shapiro, R. TI Race, Experience of Discrimination, and Other Non-Medical Factors Predict Differences in Acceptance for Kidney Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Myaskovsky, L.; Pleis, J.; Switzer, G.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Myaskovsky, L.; Pleis, J.; Dew, M.; Switzer, G.; Shapiro, R.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B1197 BP 827 EP 827 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303588 ER PT J AU Myaskovsky, L Pleis, J Ramkumar, M Langone, A Saha, S Thomas, C AF Myaskovsky, L. Pleis, J. Ramkumar, M. Langone, A. Saha, S. Thomas, C. TI Fewer Race Disparities in the National VA Kidney Transplant Program. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Myaskovsky, L.; Pleis, J.; Ramkumar, M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Myaskovsky, L.; Pleis, J.; Ramkumar, M.] Univ Pittsburgh, Pittsburgh, PA USA. [Langone, A.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA. [Saha, S.] Portland VA Med Ctr, Portland, OR 97239 USA. [Thomas, C.] Iowa City VA Healthcare Syst, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B1196 BP 827 EP 827 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303587 ER PT J AU Blumenthal, KG Youngster, I Shenoy, ES Banerji, A Nelson, SB AF Blumenthal, Kimberly G. Youngster, Ilan Shenoy, Erica S. Banerji, Aleena Nelson, Sandra B. TI Tolerability of Cefazolin after Immune-Mediated Hypersensitivity Reactions to Nafcillin in the Outpatient Setting SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID PARENTERAL ANTIMICROBIAL THERAPY; STAPHYLOCOCCUS-AUREUS BACTEREMIA; PENICILLIN-ALLERGIC PATIENTS; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; ACUTE INTERSTITIAL NEPHRITIS; BETA-LACTAM ANTIBIOTICS; ADVERSE DRUG-REACTIONS; NONIMMEDIATE REACTIONS; METHICILLIN-RESISTANT AB The objective of the present study was to assess the safety and tolerability of cefazolin therapy among patients with methicillin-sensitive Gram-positive bacterial infections who develop non-IgE-mediated hypersensitivity reactions (HSRs) to nafcillin. In this retrospective cohort analysis of the Outpatient Parenteral Antimicrobial Therapy program at the Massachusetts General Hospital from 2007 through 2013, we identified patients switched from nafcillin to cefazolin after an immune-mediated HSR. We reviewed patient demographics, details about the original HSR, and outcomes after the switch to cefazolin therapy. HSRs were classified by reaction type and likely mechanism. There were 467 patients treated with nafcillin, of which 60 (12.8%) were switched to cefazolin during their prescribed course. Of the 60 patients who transitioned to cefazolin, 17 (28.3%) were switched because of non-IgE-mediated HSRs. HSRs included maculopapular rash (n = 10), immune-mediated nephritis (n = 3), isolated eosinophilia (n = 2), immune-mediated hepatitis (n = 1), and a serum sickness-like reaction (n = 1). All but one patient (94.1%) who switched to cefazolin tolerated the drug with resolution of the HSR and completed their therapy with cefazolin. No patient experienced worsening of their rash or progressive organ dysfunction. With appropriate monitoring, therapy with cefazolin after non-IgE-mediated HSRs to nafcillin appears to be safe. C1 [Blumenthal, Kimberly G.; Banerji, Aleena] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Blumenthal, Kimberly G.; Shenoy, Erica S.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. [Blumenthal, Kimberly G.; Shenoy, Erica S.; Banerji, Aleena; Nelson, Sandra B.] Harvard Univ, Sch Med, Boston, MA USA. [Youngster, Ilan] Boston Childrens Hosp, Dept Pediat, Div Infect Dis, Boston, MA USA. [Youngster, Ilan; Shenoy, Erica S.; Nelson, Sandra B.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA. [Shenoy, Erica S.] Massachusetts Gen Hosp, Infect Control Unit, Boston, MA 02114 USA. RP Blumenthal, KG (reprint author), Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. EM kblumenthal1@partners.org RI Youngster, Ilan/J-5047-2014 OI Youngster, Ilan/0000-0001-5233-1213 FU NIAID NIH HHS [K01 AI110524] NR 67 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JUN PY 2014 VL 58 IS 6 BP 3137 EP 3143 DI 10.1128/AAC.02504-13 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA AK9VP UT WOS:000338776900018 PM 24637693 ER PT J AU Somarouthu, BS Shinagare, AB Rosenthal, MH Tirumani, H Hornick, JL Ramaiya, NH Tirumani, SH AF Somarouthu, B. S. Shinagare, A. B. Rosenthal, M. H. Tirumani, H. Hornick, J. L. Ramaiya, N. H. Tirumani, S. H. TI Multimodality imaging features, metastatic pattern and clinical outcome in adult extraskeletal Ewing sarcoma: experience in 26 patients SO BRITISH JOURNAL OF RADIOLOGY LA English DT Article ID PRIMITIVE NEUROECTODERMAL TUMORS; FAMILY; DISEASE; PET/CT AB Objective: To describe the multimodality imaging features, metastatic pattern and clinical outcome in adult extraskeletal Ewing sarcoma (EES). Methods: In this institutional reviewboard-approved, health insurance portability and accountability act-compliant retrospective study, we included 26 patients (17 females and 9 males; mean age, 36 years; range, 18-85 years) with pathologically confirmed EES seen at our institute between 1999 and 2011, who had imaging of primary tumour. Imaging of primary tumour in all 26 patients and follow-up imaging in 23 was reviewed by two radiologists in consensus. Clinical data were extracted from electronic medical records. Results: The most common primary sites were the torso (n = 13), extremities (n = 10) and head and neck (HN) region (n = 3). The mean tumour size was 9 cm (range, 3-22 cm); tumours of the torso were larger than those of other areas (p > 0.05). Compared with the skeletal muscle, tumours were isodense on CT (21/21), hypointense (n = 5) to isointense (n = 14) on T-1 weighted image, hyperintense on T-2 weighted image (19/19) and were fluorine-18 fludeoxyglucose (F-18-FDG)-avid [10/10; mean maximum standardized uptake value of 7 (range, 3-11)]. Necrosis (15/26), haemorrhage (5/26) and adjacent organ invasion (14/26) were present without calcification. Median follow-up was 16 months. 5 patients had local recurrence (torso, 3; extremity, 1; and HN, 1). Metastases developed in 11 patients (torso, 7; extremities, 3; and HN, 1;p > 0.05); 8 at presentation, most commonly to lung (9/11), peritoneum (4/11), muscles (4/11) and lymph nodes (4/11). Nine patients (torso, 7; extremity, 1; and HN, 1) died (10 months median survival) (p > 0.05). Conclusion: Adult EESs are large tumours, which frequently invade adjacent organs and metastasize to the lung. EESs of the torso are larger, have more frequent metastases and poorer outcomes. Advances in knowledge: Adult EESs of the torso have poor outcomes compared with other EESs. C1 [Somarouthu, B. S.; Shinagare, A. B.; Rosenthal, M. H.; Tirumani, H.; Ramaiya, N. H.; Tirumani, S. H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA. [Shinagare, A. B.; Rosenthal, M. H.; Ramaiya, N. H.; Tirumani, S. H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Hornick, J. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 44 Binney St, Boston, MA 02115 USA. EM sreeharsha_tirumani@DFCI.harvard.edu RI Rosenthal, Michael/D-4080-2015 NR 21 TC 5 Z9 5 U1 0 U2 0 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0007-1285 EI 1748-880X J9 BRIT J RADIOL JI Br. J. Radiol. PD JUN PY 2014 VL 87 IS 1038 AR 20140123 DI 10.1259/bjr.20140123 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AL6QC UT WOS:000339256600019 PM 24734938 ER PT J AU Uher, R Payne, JL Pavlova, B Perlis, RH AF Uher, Rudolf Payne, Jennifer L. Pavlova, Barbara Perlis, Roy H. TI MAJOR DEPRESSIVE DISORDER IN DSM-5: IMPLICATIONS FOR CLINICAL PRACTICE AND RESEARCH OF CHANGES FROM DSM-IV SO DEPRESSION AND ANXIETY LA English DT Review DE major depressive disorder; persistent depressive disorder; classification; psychopathology; assessment; diagnosis ID PREMENSTRUAL DYSPHORIC DISORDER; BEREAVEMENT-RELATED DEPRESSION; POSTTRAUMATIC-STRESS-DISORDER; TEST-RETEST RELIABILITY; BIPOLAR DISORDER; ANTIDEPRESSANT TREATMENT; HOPELESSNESS DEPRESSION; CHILDHOOD MALTREATMENT; PSYCHIATRIC-DISORDERS; PERINATAL DEPRESSION AB The changes in diagnostic criteria for major depressive disorder (MDD) from the fourth to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) may appear small but have important consequences for how the diagnosis is used. In DSM-5, MDD is part of the new "Depressive disorders" section, which is separate from "Bipolar disorders", marking a division in what had been known as "Mood disorders". A small wording change has expanded the core mood criterion to include hopelessness, potentially broadening the diagnosis. The replacement of an operationalized bereavement exclusion with a call for clinical judgment in distinguishing normal reactions to significant loss from a disorder in need of clinical attention makes the diagnosis less objective and complicates investigations of the relationship between adversity and depression. A new persistent depressive disorder category is intended to encompass both dysthymia and chronic depression, but its relationship to MDD is ambiguous with conflicting statements on whether the two diagnoses should be concurrent if both sets of criteria are fulfilled. Clarification is also needed on whether MDD can be concurrent with the new broad "other specified bipolar and related disorders". New specifiers of MDD "with anxious distress" and "with mixed features" allow characterization of additional symptoms. The specifier "with perinatal onset" expands on the DSM-IV "postnatal onset" to include onset during pregnancy. We review the changes in MDD definition, provide guidance on their implementation and discuss their implications for clinical practice and research. Depression and Anxiety 31: 459-471, 2014. (C) 2013 Wiley Periodicals, Inc. C1 [Uher, Rudolf; Pavlova, Barbara] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada. [Uher, Rudolf] Kings Coll London, Inst Psychiat, London WC2R 2LS, England. [Payne, Jennifer L.] Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD USA. [Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA. [Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Uher, R (reprint author), Mood Disorders Program, Abbie J Lane Bldg,3rd Floor,5909 Vet Mem Lane, Halifax, NS B3H 2E2, Canada. EM uher@dal.ca OI Uher, Rudolf/0000-0002-2998-0546 FU Corcept; Canada Research Chairs program FX Contract grant sponsor: Corcept. Dr. Uher is supported by the Canada Research Chairs program (http://www.chairs-chaires.gc.ca/) NR 78 TC 32 Z9 34 U1 6 U2 51 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JUN PY 2014 VL 31 IS 6 BP 459 EP 471 DI 10.1002/da.22217 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AL3XZ UT WOS:000339066600001 PM 24272961 ER PT J AU Stein, DJ McLaughlin, KA Koenen, KC Atwoli, L Friedman, MJ Hill, ED Maercker, A Petukhova, M Shahly, V van Ommeren, M Alonso, J Borges, G de Girolamo, G de Jonge, P Demyttenaere, K Florescu, S Karam, EG Kawakami, N Matschinger, H Okoliyski, M Posada-Villa, J Scott, KM Viana, MC Kessler, RC AF Stein, Dan J. McLaughlin, Katie A. Koenen, Karestan C. Atwoli, Lukoye Friedman, Matthew J. Hill, Eric D. Maercker, Andreas Petukhova, Maria Shahly, Victoria van Ommeren, Mark Alonso, Jordi Borges, Guilherme de Girolamo, Giovanni de Jonge, Peter Demyttenaere, Koen Florescu, Silvia Karam, Elie G. Kawakami, Norito Matschinger, Herbert Okoliyski, Michail Posada-Villa, Jose Scott, Kate M. Viana, Maria Carmen Kessler, Ronald C. TI DSM-5 AND ICD-11 DEFINITIONS OF POSTTRAUMATIC STRESS DISORDER: INVESTIGATING "NARROW" AND "BROAD" APPROACHES SO DEPRESSION AND ANXIETY LA English DT Article DE Posttraumatic stress disorder; World Mental Health Surveys; epidemiology; nosology; DSM-IV; DSM-5; ICD-10; ICD-11 ID CLINICAL-SIGNIFICANCE CRITERION; CONFIRMATORY FACTOR-ANALYSIS; MENTAL-HEALTH; FRIEDMAN 2013; PTSD; SYMPTOMS; IMPACT; CLASSIFICATION; COMORBIDITY; PROPOSALS AB Background: The development of the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and ICD-11 has led to reconsideration of diagnostic criteria for posttraumatic stress disorder (PTSD). The World Mental Health (WMH) Surveys allow investigation of the implications of the changing criteria compared to DSM-IV and ICD-10. Methods: WMH Surveys in 13 countries asked respondents to enumerate all their lifetime traumatic events (TEs) and randomly selected one TE per respondent for PTSD assessment. DSM-IV and ICD-10 PTSD were assessed for the 23,936 respondents who reported lifetime TEs in these surveys with the fully structured Composite International Diagnostic Interview (CIDI). DSM-5 and proposed ICD-11 criteria were approximated. Associations of the different criteria sets with indicators of clinical severity (distress-impairment, suicidality, comorbid fear-distress disorders, PTSD symptom duration) were examined to investigate the implications of using the different systems. Results: A total of 5.6% of respondents met criteria for "broadly defined" PTSD (i.e., full criteria in at least one diagnostic system), with prevalence ranging from 3.0% with DSM-5 to 4.4% with ICD-10. Only one-third of broadly defined cases met criteria in all four systems and another one third in only one system (narrowly defined cases). Between-system differences in indicators of clinical severity suggest that ICD-10 criteria are least strict and DSM-IV criteria most strict. The more striking result, though, is that significantly elevated indicators of clinical significance were found even for narrowly defined cases for each of the four diagnostic systems. Conclusions: These results argue for a broad definition of PTSD defined by any one of the different systems to capture all clinically significant cases of PTSD in future studies. Depression and Anxiety 31: 494-505, 2014. (C) 2014 Wiley Periodicals, Inc. C1 [Stein, Dan J.] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa. [McLaughlin, Katie A.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Koenen, Karestan C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Atwoli, Lukoye] Moi Univ, Dept Psychiat, Eldoret, Kenya. [Friedman, Matthew J.] US Dept Vet Affairs, Natl Ctr PTSD, VA Med Ctr, White River Jct, VT USA. [Hill, Eric D.; Petukhova, Maria; Kessler, Ronald C.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Maercker, Andreas; Shahly, Victoria] Univ Zurich, Dept Psychol, Div Psychopathol, CH-8006 Zurich, Switzerland. [van Ommeren, Mark] WHO, Dept Mental Hlth & Subst Abuse, CH-1211 Geneva, Switzerland. [Alonso, Jordi] Hosp Mar, IMIM, Hlth Serv Res Unit, Barcelona, Spain. [Alonso, Jordi] CIBER Epidemol & Salud Publ CIBERESP, Barcelona, Spain. [Borges, Guilherme] Natl Inst Psychiat Mexico, Dept Epidemiol Res, Div Epidemiol & Psychosocial Res, Mexico City, DF, Mexico. [Borges, Guilherme] Metropolitan Autonomous Univ, Mexico City, DF, Mexico. [de Girolamo, Giovanni] IRCCS Ctr S Giovanni Dio Fatebenefratelli, Brescia, Italy. [de Jonge, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat PdJ, NL-9713 AV Groningen, Netherlands. [Demyttenaere, Koen] Univ Hosp Gasthuisberg, Dept Psychiat, Leuven, Belgium. [Florescu, Silvia] Natl Sch Publ Hlth Management & Profess Dev, Hlth Serv Res & Evaluat Ctr, Bucharest, Romania. [Karam, Elie G.] Balamand Univ, St George Hosp Univ Med Ctr, Fac Med, IDRAAC,MIND, Beirut, Lebanon. [Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Dept Mental Hlth, Tokyo, Japan. [Matschinger, Herbert] Univ Leipzig, Inst Social Med Occupat Hlth & Publ Hlth, Publ Hlth Res Unit HM, D-04109 Leipzig, Germany. [Okoliyski, Michail] Minist Hlth, Natl Ctr Publ Hlth & Anal, Dept Mental Hlth, Sofia, Bulgaria. [Posada-Villa, Jose] Pontificia Univ Javeriana, Inst Colombiano Sistema Nervioso, Bogota, Colombia. [Scott, Kate M.] Univ Otago, Dept Psychol Med, Dunedin, New Zealand. [Viana, Maria Carmen] Univ Fed Espirito Santo, Dept Social Med, Vitoria, Brazil. RP Stein, DJ (reprint author), Univ Cape Town, Groote Schuur Hosp, Dept Psychiat, J2,Anzio Rd, ZA-7925 Cape Town, South Africa. EM dan.stein@uct.ac.za RI Stein, Dan/A-1752-2008; Alonso, Jordi/A-5514-2010; OI Stein, Dan/0000-0001-7218-7810; Alonso, Jordi/0000-0001-8627-9636; Borges, Guilherme/0000-0002-3269-0507; Atwoli, Lukoye/0000-0001-7710-9723; McLaughlin, Katie/0000-0002-1362-2410 FU United States National Institute of Mental Health [R01MH070884]; John D. and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public Health Service [R13-MH066849, R01-MH069864, R01-MH092526, R01-DA016558]; Fogarty International Center [FIRCA R03-TW006481]; Pan American Health Organization; Eli Lilly & Company Foundation; Ortho-McNeil Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Shire Pharmaceuticals; State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]; European Commission [QLG5-1999-01042, SANCO 2004123]; Piedmont Region; Fondo de Investigacion Sanitaria; Instituto de Salud Carlos III [FIS 00/0028, CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]; Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Departament de Salut, Generalitat de Catalunya; Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; National Institute of Health/Fogarty International Center [R03 TW006481-01]; Astra Zeneca; Hikma Pharm; Janssen Cilag; MSD; Novartis; Sanofi Aventis; Servier; National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]; National Council on Science and Technology [CONACyT-G30544-H]; Health & Social Care Research & Development Division; Champalimaud Foundation; Gulbenkian Foundation; Foundation for Science and Technology (FCT); Ministry of Health; Ministry of Public Health; National Institute of Mental Health (NIMH) [U01-MH60220] FX Contract grant sponsor: United States National Institute of Mental Health; Contract grant number: R01MH070884; Contract grant sponsor: John D. and Catherine T. MacArthur Foundation; Contract grant sponsor: The Pfizer Foundation; Contract grant sponsor: The US Public Health Service; Contract grant numbers: R13-MH066849, R01-MH069864, R01-MH092526, and R01-DA016558; Contract grant sponsor: Fogarty International Center; Contract grant number: FIRCA R03-TW006481; Contract grant sponsor: The Pan American Health Organization; Contract grant sponsor: the Eli Lilly & Company Foundation; Contract grant sponsor: Ortho-McNeil Pharmaceutical, Inc.; Contract grant sponsor: GlaxoSmithKline; Contract grant sponsor: Bristol-Myers Squibb; Contract grant sponsor: Shire Pharmaceuticals; Contract grant sponsor: State of Sao Paulo Research Foundation (FAPESP) Thematic Project; Contract grant number: 03/00204-3; Contract grant sponsor: European Commission; Contract grant numbers: QLG5-1999-01042 and SANCO 2004123; Contract grant sponsor: The Piedmont Region; Contract grant sponsor: Fondo de Investigacion Sanitaria; Contract grant sponsor: Instituto de Salud Carlos III; Contract grant number: FIS 00/0028; Contract grant sponsor: Ministerio de Ciencia y Tecnologia, Spain; Contract grant number: SAF 2000-158-CE; Contract grant sponsor: Departament de Salut, Generalitat de Catalunya; Contract grant sponsor: Instituto de Salud Carlos III; Contract grant numbers: CIBER CB06/02/0046 and RETICS RD06/0011 REM-TAP; Contract grant sponsor: Japan Ministry of Health, Labour and Welfare; Contract grant numbers: H13-SHOGAI-023, H14-TOKUBETSU-026, and H16-KOKORO-013; Contract grant sponsor: National Institute of Health/Fogarty International Center; Contract grant number: R03 TW006481-01; Contract grant sponsor: Astra Zeneca; Contract grant sponsor: Hikma Pharm; Contract grant sponsor: Janssen Cilag; Contract grant sponsor: MSD; Contract grant sponsor: Novartis; Contract grant sponsor: Sanofi Aventis; Contract grant sponsor: Servier; Contract grant sponsor: The National Institute of Psychiatry Ramon de la Fuente; Contract grant number: INPRFMDIES 4280; Contract grant sponsor: National Council on Science and Technology; Contract grant number: CONACyT-G30544-H; Contract grant sponsor: Health & Social Care Research & Development Division; Contract grant sponsor: Champalimaud Foundation; Contract grant sponsor: Gulbenkian Foundation; Contract grant sponsor: Foundation for Science and Technology (FCT); Contract grant sponsor: Ministry of Health; Contract grant sponsor: Ministry of Public Health (former Ministry of Health); Contract grant sponsor: National Institute of Mental Health (NIMH); Contract grant number: U01-MH60220. NR 40 TC 30 Z9 30 U1 5 U2 37 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JUN PY 2014 VL 31 IS 6 BP 494 EP 505 DI 10.1002/da.22279 PG 12 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AL3XZ UT WOS:000339066600005 PM 24894802 ER PT J AU West, AM Bittner, EA Ortiz, VE AF West, Amy M. Bittner, Edward A. Ortiz, Vilma E. TI The effects of preoperative, video-assisted anesthesia education in Spanish on Spanish-speaking patients' anxiety, knowledge, and satisfaction: a pilot study SO JOURNAL OF CLINICAL ANESTHESIA LA English DT Article DE General anesthesia; Limited English proficiency (LEP); Patient anxiety, preoperative; Preoperative interview; Spanish-speaking patients; Video instruction ID RANDOMIZED CONTROLLED-TRIAL; INFORMATION; INTERVIEW AB We studied the effect of an instructional video in Spanish on self-reported anxiety, knowledge about general anesthesia procedures, and satisfaction with the preoperative anesthesia process in patients requiring a Spanish interpreter. This prospective, randomized, nonblinded pilot study took place at Massachusetts General Hospital (MGH), a university-affiliated tertiary-care hospital. Twenty adult, ASA physical status 1, 2, and 3 patients, scheduled for elective surgery (gynecological, orthopedic, and intrabdominal surgery) during general anesthesia were studied. Anxiety, knowledge, and patient satisfaction were assessed using a visual analog scale (VAS). There was a significant reduction in anxiety score in patients who viewed the video compared with those who did not (median reduction 2 vs 0; P = 0.020). There was an increase in satisfaction score in the video group (median increase 2 vs 0; P = 0.046). There was no difference in reported knowledge-improvement scores between the two groups (3.5 vs 4; P = 0.908). In Spanish-speaking patients, the addition of an instructional video in Spanish to a preanesthesia interview decreased anxiety and increased patient satisfaction. (C) 2014 Elsevier Inc. All rights reserved. C1 [West, Amy M.; Bittner, Edward A.; Ortiz, Vilma E.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Bittner, Edward A.; Ortiz, Vilma E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP West, AM (reprint author), 154 Harvard St,Apt 7, Brookline, MA 02446 USA. EM amy_west@hms.harvard.edu FU Student National Medical Association, Washington, DC [20011]; summer internship at the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA FX Supported by a David E. Satcher, MD, PhD fellowship, Student National Medical Association, Washington, DC 20011; and a summer internship at the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA. NR 13 TC 2 Z9 2 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0952-8180 EI 1873-4529 J9 J CLIN ANESTH JI J. Clin. Anesth. PD JUN PY 2014 VL 26 IS 4 BP 325 EP 329 DI 10.1016/j.jclinane.2013.12.008 PG 5 WC Anesthesiology SC Anesthesiology GA AL7IL UT WOS:000339307300014 PM 24882604 ER PT J AU Brown, MC AF Brown, M. Christian TI Single-unit labeling of medial olivocochlear neurons: the cochlear frequency map for efferent axons SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE cochlear amplifier; outer hair cell; masking; acoustic protection; descending system ID AUDITORY-NERVE FIBERS; GUINEA-PIG COCHLEA; BASILAR-MEMBRANE MOTION; EMISSION FINE-STRUCTURE; 2-TONE SUPPRESSION; TONOTOPIC ORGANIZATION; RESPONSE PROPERTIES; STIMULUS VARIABLES; STIMULATION; CAT AB Medial olivocochlear (MOC) neurons are efferent neurons that project axons from the brain to the cochlea. Their action on outer hair cells reduces the gain of the "cochlear amplifier," which shifts the dynamic range of hearing and reduces the effects of noise masking. The MOC effects in one ear can be elicited by sound in that ipsilateral ear or by sound in the contralateral ear. To study how MOC neurons project onto the cochlea to mediate these effects, single-unit labeling in guinea pigs was used to study the mapping of MOC neurons for neurons responsive to ipsilateral sound vs. those responsive to contralateral sound. MOC neurons were sharply tuned to sound frequency with a well-defined characteristic frequency (CF). However, their labeled termination spans in the organ of Corti ranged from narrow to broad, innervating between 14 and 69 outer hair cells per axon in a "patchy" pattern. For units responsive to ipsilateral sound, the midpoint of innervation was mapped according to CF in a relationship generally similar to, but with more variability than, that of auditory-nerve fibers. Thus, based on CF mappings, most of the MOC terminations miss outer hair cells involved in the cochlear amplifier for their CF, which are located more basally. Compared with ipsilaterally responsive neurons, contralaterally responsive neurons had an apical offset in termination and a larger span of innervation (an average of 10.41% cochlear distance), suggesting that when contralateral sound activates the MOC reflex, the actions are different than those for ipsilateral sound. C1 [Brown, M. Christian] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA. [Brown, M. Christian] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Brown, MC (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM Chris_Brown@meei.harvard.edu FU National Institute of Child Health and Human Development [DC-01089] FX This work was supported by National Institute of Child Health and Human Development Grant DC-01089. NR 69 TC 8 Z9 8 U1 2 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JUN PY 2014 VL 111 IS 11 BP 2177 EP 2186 DI 10.1152/jn.00045.2014 PG 10 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA AL5JX UT WOS:000339171000003 PM 24598524 ER PT J AU Karmali, F Lim, K Merfeld, DM AF Karmali, Faisal Lim, Koeun Merfeld, Daniel M. TI Visual and vestibular perceptual thresholds each demonstrate better precision at specific frequencies and also exhibit optimal integration SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE vision; semicircular canals; otoliths; roll tilt; psychophysics; human ID QUALITATIVELY DIFFERENT MECHANISMS; SELF-MOTION PERCEPTION; WHOLE-BODY; VESTIBULOOCULAR REFLEX; CUE INTEGRATION; INERTIAL CUES; VERTICAL AXIS; TILT; DIRECTION; ROLL AB Prior studies show that visual motion perception is more precise than vestibular motion perception, but it is unclear whether this is universal or the result of specific experimental conditions. We compared visual and vestibular motion precision over a broad range of temporal frequencies by measuring thresholds for vestibular (subject motion in the dark), visual (visual scene motion) or visual-vestibular (subject motion in the light) stimuli. Specifically, thresholds were measured for motion frequencies spanning a two-decade physiological range (0.05-5 Hz) using single-cycle sinusoidal acceleration roll tilt trajectories (i.e., distinguishing left-side down from right-side down). We found that, while visual and vestibular thresholds were broadly similar between 0.05 and 5.0 Hz, each cue is significantly more precise than the other at certain frequencies. Specifically, we found that 1) visual and vestibular thresholds were indistinguishable at 0.05 Hz and 2 Hz (i.e., similarly precise); 2) visual thresholds were lower (i.e., vision more precise) than vestibular thresholds between 0.1 Hz and 1 Hz; and 3) visual thresholds were higher (i.e., vision less precise) than vestibular thresholds above 2 Hz. This shows that vestibular perception can be more precise than visual perception at physiologically relevant frequencies. We also found that sensory integration of visual and vestibular information is consistent with static Bayesian optimal integration of visual-vestibular cues. In contrast with most prior work that degraded or altered sensory cues, we demonstrated static optimal integration using natural cues. C1 [Karmali, Faisal; Lim, Koeun; Merfeld, Daniel M.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA. [Karmali, Faisal; Merfeld, Daniel M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Karmali, F (reprint author), Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, 243 Charles St, Boston, MA 02114 USA. EM faisal_karmali@yahoo.com OI Karmali, Faisal/0000-0002-1140-4954 FU National Institute of Deafness and Other Communications Disorders [R01-DC04158] FX This research was supported by National Institute of Deafness and Other Communications Disorders Grant R01-DC04158. NR 64 TC 7 Z9 7 U1 6 U2 13 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JUN PY 2014 VL 111 IS 12 BP 2393 EP 2403 DI 10.1152/jn.00332.2013 PG 11 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA AL5KE UT WOS:000339171700001 PM 24371292 ER PT J AU Enzinger, AC Zhang, BH Weeks, JC Prigerson, HG AF Enzinger, Andrea C. Zhang, Baohui Weeks, Jane C. Prigerson, Holly G. TI Clinical Trial Participation as Part of End-of-Life Cancer Care: Associations With Medical Care and Quality of Life Near Death SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Palliative care; end-of-life care; clinical trials; cancer ID PHASE-1 ONCOLOGY TRIALS; CELL LUNG-CANCER; PALLIATIVE CARE; THERAPEUTIC MISCONCEPTION; INVESTIGATIONAL THERAPY; INITIAL VALIDATION; INFORMED-CONSENT; BENEFIT; PREFERENCES; DISCUSSIONS AB Context. Clinical trials are a common therapeutic option for patients with advanced incurable cancer. Objectives. To examine the associations between trial participation and end-of-life (EOL) outcomes, including aggressive care and quality of life (QOL). Methods. Coping with Cancer, a multicenter prospective cohort study of patients with metastatic cancer, progressed after at least first-line chemotherapy. Baseline chart review documented clinical trial participation. Baseline interviews assessed psychosocial characteristics and EOL preferences. Caregiver interview and chart review assessed medical care and QOL near death. The primary outcome was aggressive EOL care (ventilation, resuscitation, or intensive care unit admission in last week of life). Propensity score weighting balanced patient characteristics that differed by trial participation, including care preferences and EOL discussion. Propensity scoreeweighted regression models estimated the effect of trial participation on outcomes. Results. Of 352 patients followed to death, 37 were enrolled in a clinical trial at baseline. In propensity scoreeweighted analyses, trial participation was significantly associated with aggressive EOL care (21.6% vs. 12.0%, adjusted odds ratio [AOR] 2.04, 95% confidence interval [CI] 1.00e4.15), late hospice enrollment (51.4% vs. 42.2%, AOR 1.96, 95% CI 1.10e3.50), hospital death (48.6% vs. 25.7%, AOR 2.74, 95% CI 1.37e5.47), intensive care unit death (16.2% vs. 6.3%, AOR 3.53, 95% CI 1.29e9.65), and inferior QOL near death (least squares mean 5.93 vs. 7.69, P < 0.001). Controlling for EOL care, trial enrollment was no longer associated with QOL near death (P 0.342). Conclusion. Clinical trial participation is associated with aggressive EOL care. Aggressive EOL care appears to explain the association between trial participation and QOL near death. (C) 2014 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Enzinger, Andrea C.; Zhang, Baohui; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02215 USA. [Enzinger, Andrea C.; Weeks, Jane C.; Prigerson, Holly G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Enzinger, Andrea C.; Zhang, Baohui; Weeks, Jane C.; Prigerson, Holly G.] Dana Farber Canc Inst, McGraw Patterson Ctr Populat Sci, Boston, MA 02215 USA. [Enzinger, Andrea C.; Weeks, Jane C.; Prigerson, Holly G.] Harvard Univ, Sch Med, Boston, MA USA. RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM holly_prigerson@dfci.harvard.edu FU National Institute of Mental Health [MH 63892]; National Cancer Institute [CA 156732]; Fetzer Foundation; National Institutes of Health [IH T32 CA009172-38] FX This research was supported by grant MH 63892 from the National Institute of Mental Health, grants CA 106370 and CA 156732 from the National Cancer Institute (H. G. P.), the Fetzer Foundation (H. G. P.), and National Institutes of Health grant IH T32 CA009172-38 (A. C. E.). The funding organizations neither had a role in the design or conduct of the study nor did they play any role in the collection, management, analysis, or interpretation of the data or the preparation, review, or approval of the manuscript. Dr. H. G. P. and Dr. A. C. E. had full access to all the data in the study and take full responsibility for the integrity of the data and accuracy of the data analysis. None of the authors have a relationship with any entity having financial interest in this topic. NR 52 TC 8 Z9 8 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JUN PY 2014 VL 47 IS 6 BP 1078 EP 1090 DI 10.1016/j.jpainsymman.2013.07.004 PG 13 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AL0YO UT WOS:000338853200016 PM 24099894 ER PT J AU Kirchhoff, AC Hart, G Campbell, EG AF Kirchhoff, Anne C. Hart, Gary Campbell, Eric G. TI Rural and Urban Primary Care Physician Professional Beliefs and Quality Improvement Behaviors SO JOURNAL OF RURAL HEALTH LA English DT Article DE primary care physicians; professionalism; quality; rural; urban ID PATIENT; COMMUNITY; HOSPITALS; AMERICA; ACCESS; ACT AB Purpose: We evaluated whether primary care physicians (PCPs) from urban and rural practices differ on attitudes and behaviors related to quality improvement (QI) activities, patient relationships, and professionalism/self-regulation. Methods: Data from a national survey that assessed physician attitudes and behaviors based on the Physician Charter on Medical Professionalism were used. Of the 1,891 survey respondents, N = 840 were PCPs (n = 274 family medicine (response rate = 67.5%); n = 257 general internal medicine (60.8%); and n = 309 pediatricians (72.7%)). Using Rural-Urban Commuting Area (RUCA) codes, PCPs were classified as urban and rural according to their practice ZIP code. Findings: A total of n = 691 physicians were urban and n = 127 rural. Attitudes regarding participating in QI did not differ by practice location; however, rural PCPs were more likely to have reviewed an other physician's records for QI than urban PCPs (65.6% vs 48.0%, P < .001). Rural physicians were more likely to agree that physicians should talk with their patients about the cost of care than urban PCPs (40.5% vs 29.2%, P = .02). While all PCPs endorsed attitudes regarding the importance of professional behaviors (eg, reporting impaired/incompetent colleagues, disclosing medical errors) at generally similar levels, their behaviors differed. More rural physicians had a personal knowledge of an impaired/incompetent physician than urban physicians (20.7% vs 12.7%, P = .02). Conclusions: PCPs from rural and urban areas share similar attitudes regarding the importance of participating in QI and fulfilling professional responsibilities. However, certain behaviors (eg, knowledge of impaired colleagues) do differ. These results should be confirmed in larger studies of rural PCPs. C1 [Kirchhoff, Anne C.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA. [Hart, Gary] Huntsman Canc Inst, Salt Lake City, UT USA. [Hart, Gary] Univ N Dakota, Sch Med & Hlth Sci, Ctr Rural Hlth, Grand Forks, ND 58201 USA. [Campbell, Eric G.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Campbell, Eric G.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Kirchhoff, AC (reprint author), 2000 Circle Hope, Salt Lake City, UT 84103 USA. EM anne.kirchhoff@hci.utah.edu FU Institute on Medicine as a Profession at Columbia University FX This study was supported by a grant from the Institute on Medicine as a Profession at Columbia University. NR 28 TC 1 Z9 1 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD SUM PY 2014 VL 30 IS 3 BP 235 EP 243 DI 10.1111/jrh.12067 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AL3TT UT WOS:000339052900002 PM 24528129 ER PT J AU Britton, WB Lepp, NE Niles, HF Rocha, T Fisher, NE Gold, JS AF Britton, Willoughby B. Lepp, Nathaniel E. Niles, Halsey F. Rocha, Tomas Fisher, Nathan E. Gold, Jonathan S. TI A randomized controlled pilot trial of classroom-based mindfulness meditation compared to an active control condition in sixth-grade children SO JOURNAL OF SCHOOL PSYCHOLOGY LA English DT Article DE Children; Pre-adolescent; Mindfulness meditation; Contemplative education; School; Social and emotional learning ID MENTAL-HEALTH-SERVICES; TRAIT ANXIETY INVENTORY; NONSUICIDAL SELF-INJURY; VISUAL ANALOG SCALES; SUICIDAL IDEATION; STRESS REDUCTION; PSYCHIATRIC-DISORDERS; EXECUTIVE FUNCTION; COGNITIVE THERAPY; EARLY ADOLESCENCE AB The current study is a pilot trial to examine the effects of a nonelective, classroom-based, teacher-implemented, mindfulness meditation intervention on standard clinical measures of mental health and affect in middle school children. A total of 101 healthy sixth-grade students (55 boys, 46 girls) were randomized to either an Asian history course with daily mindfulness meditation practice (intervention group) or an African history course with a matched experiential activity (active control group). Self-reported measures included the Youth Self Report (YSR), a modified Spielberger State-Trait Anxiety Inventory, and the Cognitive and Affective Mindfulness Measure Revised. Both groups decreased significantly on clinical syndrome subscales and affect but did not differ in the extent of their improvements. Meditators were significantly less likely to develop suicidal ideation or thoughts of self-harm than controls. These results suggest that mindfulness training may yield both unique and non-specific benefits that are shared by other novel activities. (C) 2014 Society for the Study of School Psychology. Published by Elsevier Ltd. All rights reserved. C1 [Britton, Willoughby B.; Lepp, Nathaniel E.; Niles, Halsey F.; Rocha, Tomas; Fisher, Nathan E.; Gold, Jonathan S.] Brown Univ Contemplat Studies Initiat, Providence, RI USA. [Niles, Halsey F.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. [Rocha, Tomas] Mind & Life Inst, Boulder, CO USA. [Gold, Jonathan S.] Moses Brown Sch, Providence, RI USA. [Britton, Willoughby B.; Fisher, Nathan E.] Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02906 USA. RP Britton, WB (reprint author), Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, 185 Brown St, Providence, RI 02906 USA. EM Willoughby_Britton@Brown.edu FU NCCIH NIH HHS [K23-AT006328-01A1, T32-AT001287, T32 AT001287, K23 AT006328]; NIMH NIH HHS [MH067553-05, T32 MH067553] NR 163 TC 21 Z9 21 U1 18 U2 107 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4405 EI 1873-3506 J9 J SCHOOL PSYCHOL JI J. Sch. Psychol. PD JUN PY 2014 VL 52 IS 3 BP 263 EP 278 DI 10.1016/j.jsp.2014.03.002 PG 16 WC Psychology, Educational SC Psychology GA AL5AC UT WOS:000339144900002 PM 24930819 ER PT J AU Aerts, HJWL Velazquez, ER Leijenaar, RTH Parmar, C Grossmann, P Cavalho, S Bussink, J Monshouwer, R Haibe-Kains, B Rietveld, D Hoebers, F Rietbergen, MM Leemans, CR Dekker, A Quackenbush, J Gillies, RJ Lambin, P AF Aerts, Hugo J. W. L. Velazquez, Emmanuel Rios Leijenaar, Ralph T. H. Parmar, Chintan Grossmann, Patrick Cavalho, Sara Bussink, Johan Monshouwer, Rene Haibe-Kains, Benjamin Rietveld, Derek Hoebers, Frank Rietbergen, Michelle M. Leemans, C. Rene Dekker, Andre Quackenbush, John Gillies, Robert J. Lambin, Philippe TI Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach SO NATURE COMMUNICATIONS LA English DT Article ID CELL LUNG-CANCER; HETEROGENEITY; VARIABILITY; EVOLUTION; SURVIVAL; RECIST; STAGE AB uman cancers exhibit strong phenotypic differences that can be visualized noninvasively by medical imaging. Radiomics refers to the comprehensive quantification of tumour phenotypes by applying a large number of quantitative image features. Here we present a radiomic analysis of 440 features quantifying tumour image intensity, shape and texture, which are extracted from computed tomography data of 1,019 patients with lung or head-and-neck cancer. We find that a large number of radiomic features have prognostic power in independent data sets of lung and head-and-neck cancer patients, many of which were not identified as significant before. Radiogenomics analysis reveals that a prognostic radiomic signature, capturing intratumour heterogeneity, is associated with underlying gene-expression patterns. These data suggest that radiomics identifies a general prognostic phenotype existing in both lung and head-and-neck cancer. This may have a clinical impact as imaging is routinely used in clinical practice, providing an unprecedented opportunity to improve decision-support in cancer treatment at low cost. C1 [Aerts, Hugo J. W. L.; Velazquez, Emmanuel Rios; Leijenaar, Ralph T. H.; Parmar, Chintan; Cavalho, Sara; Hoebers, Frank; Dekker, Andre; Lambin, Philippe] Maastricht Univ, Res Inst GROW, Dept Radiat Oncol MAASTRO, NL-6229 ET Maastricht, Netherlands. [Aerts, Hugo J. W. L.; Velazquez, Emmanuel Rios; Parmar, Chintan; Grossmann, Patrick] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Radiat Oncol, Boston, MA 02215 USA. [Aerts, Hugo J. W. L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Radiol, Boston, MA 02215 USA. [Aerts, Hugo J. W. L.; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Bussink, Johan; Monshouwer, Rene] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands. [Haibe-Kains, Benjamin] Univ Toronto, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON M5G 1L7, Canada. [Haibe-Kains, Benjamin] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada. [Rietveld, Derek] Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, NL-1081 HZ Amsterdam, Netherlands. [Rietbergen, Michelle M.; Leemans, C. Rene] Vrije Univ Amsterdam, Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-1081 HZ Amsterdam, Netherlands. [Gillies, Robert J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA. RP Aerts, HJWL (reprint author), Maastricht Univ, Res Inst GROW, Dept Radiat Oncol MAASTRO, NL-6229 ET Maastricht, Netherlands. EM Hugo_Aerts@dfci.harvard.edu RI Bussink, Jan/N-3584-2014; Monshouwer, R./L-4527-2015; Aerts, Hugo/P-6350-2015; Haibe-Kains, Benjamin/D-3702-2011; OI Aerts, Hugo/0000-0002-2122-2003; Haibe-Kains, Benjamin/0000-0002-7684-0079; , Patrick/0000-0003-4918-6902; Dekker, Andre/0000-0002-0422-7996; Gillies, Robert/0000-0002-8888-7747 FU National Institute of Health (Radiomics of NSCLC) [NIH-USA U01 CA 143062-01]; CTMM (AIRFORCE project) [030-103]; EU 6th program (METOXIA, EURECA, ARTFORCE); EU 7th program (METOXIA, EURECA, ARTFORCE); euroCAT (IVA); Dutch Cancer Society [KWF UM 2011-5020, KWF UM 2009-4454]; Innovative Medicines Initiative Joint Undertaking; 7th framework program abd EFPIA companies' kind contribution [115151] FX We acknowledge financial support from the National Institute of Health (NIH-USA U01 CA 143062-01, Radiomics of NSCLC), the CTMM framework (AIRFORCE project, grant 030-103), EU 6th and 7th framework program (METOXIA, EURECA, ARTFORCE), euroCAT (IVA Interreg-www.eurocat.info), and the Dutch Cancer Society (KWF UM 2011-5020, KWF UM 2009-4454). We also acknowledge financial support from the Innovative Medicines Initiative Joint Undertaking (www.imi.europa.eu), based on resources from the 7th framework program abd EFPIA companies' kind contribution (Grant agreement No. 115151). NR 28 TC 187 Z9 194 U1 25 U2 95 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2014 VL 5 AR 4006 DI 10.1038/ncomms5006 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AL0SE UT WOS:000338836200003 PM 24892406 ER PT J AU Kang, S Singh, J Melo, MV Gulur, P AF Kang, Stanley Singh, Jagmeet Melo, Marcos Vidal Gulur, Padma TI Spinal Cord Stimulation for Intercostal Neuralgia in a Patient With Implantable Cardiac Defibrillator and Biventricular Pacing SO NEUROMODULATION LA English DT Letter DE ICD; implantable cardiac defibrillator; SCS; spinal cord stimulator ID CARDIOVERTER-DEFIBRILLATOR; REFRACTORY ANGINA; PACEMAKER C1 [Kang, Stanley; Singh, Jagmeet; Melo, Marcos Vidal; Gulur, Padma] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Singh, Jagmeet; Melo, Marcos Vidal; Gulur, Padma] Harvard Univ, Sch Med, Boston, MA USA. RP Gulur, P (reprint author), 15 Parkman St,WACC 330, Boston, MA USA. EM pgulur@partners.org NR 10 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1094-7159 EI 1525-1403 J9 NEUROMODULATION JI Neuromodulation PD JUN PY 2014 VL 17 IS 4 BP 386 EP 388 DI 10.1111/ner.12082 PG 3 WC Medicine, Research & Experimental; Clinical Neurology SC Research & Experimental Medicine; Neurosciences & Neurology GA AL6KQ UT WOS:000339241700026 PM 23837496 ER PT J AU Wang, YY Li, WD Patel, SS Cong, J Zhang, N Sabbatino, F Liu, XY Qi, Y Huang, PG Lee, H Taghian, A Li, JJ DeLeo, AB Ferrone, S Epperly, MW Ferrone, CR Ly, A Brachtel, EF Wang, XH AF Wang, Yangyang Li, Wende Patel, Shalin S. Cong, Juan Zhang, Nan Sabbatino, Francesco Liu, Xiaoyan Qi, Yuan Huang, Peigen Lee, Hang Taghian, Alphonse Li, Jian-Jian DeLeo, Albert B. Ferrone, Soldano Epperly, Michael W. Ferrone, Cristina R. Ly, Amy Brachtel, Elena F. Wang, Xinhui TI Blocking the formation of radiation-induced breast cancer stem cells SO ONCOTARGET LA English DT Article DE Breast Cancer; Radiation; Cancer Stem Cells; NF-kappaB Stemness genes ID TRACE-ELEMENTS; ALDEHYDE DEHYDROGENASE; INITIATING CELLS; DISULFIRAM; COPPER; IDENTIFICATION; EXPRESSION; TISSUE; SERUM; TUMORIGENESIS AB The goal of adjuvant (post-surgery) radiation therapy (RT) for breast cancer (BC) is to eliminate residual cancer cells, leading to better local tumor control and thus improving patient survival. However, radioresistance increases the risk of tumor recurrence and negatively affects survival. Recent evidence shows that breast cancer stem cells (BCSCs) are radiation-resistant and that relatively differentiated BC cells can be reprogrammed into induced BCSCs (iBCSCs) via radiation-induced re-expression of the stemness genes. Here we show that in irradiation (IR)-treated mice bearing syngeneic mammary tumors, IR-induced stemness correlated with increased spontaneous lung metastasis (51.7%). However, IR-induced stemness was blocked by targeting the NF-kappa B- stemness gene pathway with disulfiram (DSF) and Copper (Cu2+). DSF is an inhibitor of aldehyde dehydrogenase (ALDH) and an FDA-approved drug for treating alcoholism. DSF binds to Cu2+ to form DSF-Cu complexes (DSF/Cu), which act as a potent apoptosis inducer and an effective proteasome inhibitor, which, in turn, inhibits NF-kappa B activation. Treatment of mice with RT and DSF significantly inhibited mammary primary tumor growth (79.4%) and spontaneous lung metastasis (89.6%) compared to vehicle treated mice. This anti-tumor efficacy was associated with decreased stem cell properties (or stemness) in tumors. We expect that these results will spark clinical investigation of RT and DSF as a novel combinatorial treatment for breast cancer. C1 [Wang, Yangyang; Cong, Juan; Zhang, Nan; Sabbatino, Francesco; Liu, Xiaoyan; Qi, Yuan; Ferrone, Soldano; Wang, Xinhui] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. [Li, Wende; Huang, Peigen; Taghian, Alphonse] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Patel, Shalin S.; Ferrone, Soldano] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. [Lee, Hang] Massachusetts Gen Hosp, Dept Biostat Ctr, Boston, MA 02114 USA. [Li, Jian-Jian] Univ Calif Davis, Dept Radiat Oncol, Sacramento, CA 95817 USA. [DeLeo, Albert B.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Epperly, Michael W.] Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA USA. [Ferrone, Cristina R.] Massachusetts Gen Hosp, Dept Surg, Div Gen & Gastrointestinal Surg, Boston, MA 02114 USA. [Ly, Amy; Brachtel, Elena F.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Wang, Yangyang; Li, Wende; Patel, Shalin S.; Cong, Juan; Zhang, Nan; Sabbatino, Francesco; Huang, Peigen; Lee, Hang; Taghian, Alphonse; Ferrone, Soldano; Ferrone, Cristina R.; Ly, Amy; Brachtel, Elena F.; Wang, Xinhui] Harvard Univ, Sch Med, Boston, MA USA. RP Wang, XH (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. EM xwang30@mgh.harvard.edu RI Sabbatino, Francesco/F-4992-2014 OI Sabbatino, Francesco/0000-0001-6431-8278 FU NIH [RO3 CA141086, R01-1CA138188, 2P50CA121973-06, 7R01CA110249-06]; Susan G. Komen Postdoctoral Fellowship [KG111486] FX This study was supported by NIH grant RO3 CA141086 (X.W.), Susan G. Komen Postdoctoral Fellowship KG111486 (Y.W.) and NIH grants R01-1CA138188 (S. F.), 2P50CA121973-06 (S. F.) and 7R01CA110249-06 (S. F.). NR 47 TC 19 Z9 22 U1 0 U2 4 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JUN PY 2014 VL 5 IS 11 BP 3743 EP 3755 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA AL3UG UT WOS:000339054500027 PM 25003837 ER PT J AU Borre, PV Gunda, V McFadden, DG Sadow, PM Varmeh, S Bernasconi, M Parangi, S AF Borre, Pierre Vanden Gunda, Viswanath McFadden, David G. Sadow, Peter M. Varmeh, Shohreh Bernasconi, Maria Parangi, Sareh TI Combined BRAF(V600E-) and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer SO ONCOTARGET LA English DT Article DE Thyroid; BRAF; SRC ID FOCAL ADHESION KINASE; BRAF INHIBITION; BREAST-CANCER; RAF INHIBITORS; METASTATIC MELANOMA; FEEDBACK INHIBITION; TARGETING SRC; CELL-LINES; WILD-TYPE; PHASE-II AB Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective treatments. Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models of thyroid cancer, however, neither drug induces notable apoptosis. Here we report that the SRC-inhibitor dasatinib further sensitizes BRAF(V600E)-positive thyroid cancer cells to the BRAF(V600E)-inhibitor PLX4720. Combined treatment with PLX4720 and dasatinib synergistically inhibited proliferation and reduced migration in PTC and ATC cells. Whereas PLX4720 did not induce robust apoptosis in thyroid cancer cells, combined treatment with dasatinib induced apoptosis in 4 of 6 lines. In an immunocompetent orthotopic mouse model of ATC, combined PLX4720 and dasatinib treatment significantly reduced tumor volume relative to PLX4720 treatment alone. Immune cell infiltration was increased by PLX4720 treatment and this effect was maintained in mice treated with both PLX4720 and dasatinib. Further, combined treatment significantly increased caspase 3 cleavage in vivo relative to control or either treatment alone. In conclusion, combined PLX4720 and dasatinib treatment induces apoptosis, increases immune cell infiltration and reduces tumor volume in a preclinical model of ATC, suggesting that the combination of these FDA-approved drugs may have potential for the treatment of patients with ATC or refractory PTC. C1 [Borre, Pierre Vanden; Gunda, Viswanath; Sadow, Peter M.; Varmeh, Shohreh; Bernasconi, Maria; Parangi, Sareh] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. [McFadden, David G.] Massachusetts Gen Hosp, Dept Med, Thyroid Unit, Boston, MA 02114 USA. RP Parangi, S (reprint author), Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. EM sparangi@partners.org FU National Institute of Health [R01CA149738, F32CA177282]; American College of Surgeons; American Thyroid Association FX Supported by National Institute of Health Grants R01CA149738 (to SP) and F32CA177282 (to PVB). Sareh Parangi is additionally funded through the American College of Surgeons and the American Thyroid Association. NR 63 TC 4 Z9 4 U1 0 U2 6 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JUN PY 2014 VL 5 IS 12 BP 3996 EP 4010 PG 15 WC Oncology; Cell Biology SC Oncology; Cell Biology GA AL3UM UT WOS:000339055200004 ER PT J AU Kushwaha, D Ramakrishnan, V Ng, K Steed, T Nguyen, T Futalan, D Akers, JC Sarkaria, J Jiang, T Chowdhury, D Carter, BS Chen, CC AF Kushwaha, Deepa Ramakrishnan, Valya Ng, Kimberly Steed, Tyler Thien Nguyen Futalan, Diahnn Akers, Johnny C. Sarkaria, Jann Jiang, Tao Chowdhury, Dipanjan Carter, Bob S. Chen, Clark C. TI A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas SO ONCOTARGET LA English DT Article DE microRNA; Glioblastoma; MGMT; Temozolomide; miRNA cooperativity ID PROMOTER METHYLATION; METHYLTRANSFERASE MGMT; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ADJUVANT TEMOZOLOMIDE; PROTEIN EXPRESSION; TARGET PREDICTION; MICRORNA TARGETS; PHASE-3 TRIAL; DNA; RADIOTHERAPY AB MGMT expression is a critical determinant for therapeutic resistance to DNA alkylating agents. We previously demonstrated that MGMT expression is post-transcriptionally regulated by miR-181d and other miRNAs. Here, we performed a genome-wide screen to identify MGMT regulating miRNAs. Candidate miRNAs were further tested for inverse correlation with MGMT expression in clinical specimens. We identified 15 candidate miRNAs and characterized the top candidate, miR-603. Transfection of miR-603 suppressed MGMT mRNA/protein expression in vitro and in vivo; this effect was reversed by transfection with antimiR-603. miR-603 affinity-precipitated with MGMT mRNA and suppressed luciferase activity in an MGMT-3'UTR-luciferase assay, suggesting direct interaction between miR-603 and MGMT 3'UTR. miR-603 transfection enhanced the temozolomide (TMZ) sensitivity of MGMT-expressing glioblastoma cell lines. Importantly, miR-603 mediated MGMT suppression and TMZ resistance were reversed by expression of an MGMT cDNA. In a collection of 74 clinical glioblastoma specimens, both miR-603 and miR-181d levels inversely correlated with MGMT expression. Moreover, a combined index of the two miRNAs better reflected MGMT expression than each individually. These results suggest that MGMT is co-regulated by independent miRNAs. Characterization of these miRNAs should contribute toward strategies for enhancing the efficacy of DNA alkylating agents. C1 [Kushwaha, Deepa; Ng, Kimberly; Chowdhury, Dipanjan] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Ramakrishnan, Valya; Steed, Tyler; Thien Nguyen; Futalan, Diahnn; Akers, Johnny C.; Carter, Bob S.; Chen, Clark C.] Univ Calif San Diego, Div Neurosurg, Moores Canc Ctr, Ctr Theoret & Appl Neurooncol, San Diego, CA 92103 USA. [Sarkaria, Jann] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA. [Jiang, Tao] Tiantan Med Ctr, Dept Neurosurg, Beijing, Peoples R China. RP Chen, CC (reprint author), Univ Calif San Diego, Div Neurosurg, Moores Canc Ctr, Ctr Theoret & Appl Neurooncol, San Diego, CA 92103 USA. EM clarkchen@ucsd.edu RI Jiang, Tao/N-8142-2014; RAMAKRISHNAN, VALYA/L-6415-2016 FU NIAID NIH HHS [R01 AI101897]; NIGMS NIH HHS [T32 GM007198] NR 51 TC 26 Z9 26 U1 2 U2 4 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JUN PY 2014 VL 5 IS 12 BP 4026 EP 4039 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA AL3UM UT WOS:000339055200006 PM 24994119 ER PT J AU Shahbazi, J Scarlett, CJ Norris, MD Liu, B Haber, M Tee, AE Carrier, A Biankin, AV London, WB Marshall, GM Lock, RB Liu, T AF Shahbazi, Jeyran Scarlett, Christopher J. Norris, Murray D. Liu, Bing Haber, Michelle Tee, Andrew E. Carrier, Alice Biankin, Andrew V. London, Wendy B. Marshall, Glenn M. Lock, Richard B. Liu, Tao TI Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1 SO ONCOTARGET LA English DT Article DE N-Myc; HDAC2; p53; TP53INP1 ID BET BROMODOMAIN INHIBITION; C-MYC; NEUROBLASTOMA; EXPRESSION; APOPTOSIS; TARGET; LEUKEMIA; CANCER; DIFFERENTIATION; CELLS AB Myc oncoproteins and histone deacetylases (HDACs) exert oncogenic effects by modulating gene transcription. Paradoxically, N-Myc induces p53 gene expression. Tumor protein 53-induced nuclear protein 1 (TP53INP1) phosphorylates p53 protein at serine 46, leading to enhanced p53 activity, transcriptional activation of p53 target genes and programmed cell death. Here we aimed to identify the mechanism through which N-Myc overexpressing p53 wild-type neuroblastoma cells acquired resistance to apoptosis. TP53INP1 was found to be one of the genes most significantly repressed by HDAC2 and N-Myc according to Affymetrix microarray gene expression datasets. HDAC2 and N-Myc reduced TP53INP1 gene expression by direct binding to the TP53INP1 gene promoter, leading to transcriptional repression of TP53INP1, p53 protein de-phosphorylation at serine 46, neuroblastoma cell proliferation and survival. Moreover, low levels of TP53INP1 expression in human neuroblastoma tissues correlated with high levels of N-Myc expression and poor patient outcome, and the BET bromodomain inhibitors JQ1 and I-BET151 reduced N-Myc expression and reactivated TP53INP1 expression in neuroblastoma cells. These findings identify TP53INP1 repression as an important co-factor for N-Myc oncogenesis, and provide further evidence for the potential application of BET bromodomain inhibitors in the therapy of N-Myc-induced neuroblastoma. C1 [Shahbazi, Jeyran; Norris, Murray D.; Liu, Bing; Haber, Michelle; Tee, Andrew E.; Marshall, Glenn M.; Lock, Richard B.; Liu, Tao] Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia. [Shahbazi, Jeyran] Univ New S Wales, UNSW Sci, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia. [Scarlett, Christopher J.] Univ Newcastle, Sch Environm & Life Sci, Ourimbah, Australia. [Scarlett, Christopher J.; Biankin, Andrew V.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia. [Carrier, Alice] Univ Aix Marseille, CRCM Stress Cellulaire, INSERM, U1068, F-13009 Marseille, France. [Biankin, Andrew V.] Univ Glasgow, Wolfson Wohl Canc Res Ctr, Glasgow, Lanark, Scotland. [Biankin, Andrew V.] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland. [London, Wendy B.] Dana Farber Canc Inst, Childrens Oncol Grp Stat, Boston, MA 02115 USA. [London, Wendy B.] Dana Farber Canc Inst, Ctr Data, Boston, MA 02115 USA. [London, Wendy B.] Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA. [Marshall, Glenn M.] Sydney Childrens Hosp, Kids Canc Ctr, Sydney, NSW, Australia. [Liu, Tao] Univ New S Wales, UNSW Med, Sch Womens & Childrens Hlth, Sydney, NSW, Australia. RP Liu, T (reprint author), Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia. EM tliu@ccia.unsw.edu.au RI Liu, Tao/A-3922-2015; Lock, Richard/G-4253-2013; OI Biankin, Andrew/0000-0002-0362-5597 FU National Health and Medical Research Council; Cancer Council NSW; Cancer Institute NSW; Cancer Australia; Cure Cancer Australia Foundation; ARC Future Fellowship FX The authors were supported by National Health and Medical Research Council, Cancer Council NSW, Cancer Institute NSW, Cancer Australia and Cure Cancer Australia Foundation grants. T. Liu is a recipient of an ARC Future Fellowship. Children's Cancer Institute Australia is affiliated with University of New South Wales and Sydney Children's Hospitals Network. NR 41 TC 15 Z9 15 U1 1 U2 9 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JUN PY 2014 VL 5 IS 12 BP 4257 EP 4268 PG 12 WC Oncology; Cell Biology SC Oncology; Cell Biology GA AL3UM UT WOS:000339055200024 PM 24952595 ER PT J AU Podlaha, O De, S Gonen, M Michor, F AF Podlaha, Ondrej De, Subhajyoti Gonen, Mithat Michor, Franziska TI Histone Modifications Are Associated with Transcript Isoform Diversity in Normal and Cancer Cells SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID HUMAN GENOME; CHROMATIN STATE; DNA METHYLATION; PROSTATE-CANCER; PWWP DOMAIN; RNA-SEQ; LANDSCAPE; ARCHITECTURE; RECOGNITION; RECRUITMENT AB Mechanisms that generate transcript diversity are of fundamental importance in eukaryotes. Although a large fraction of human protein-coding genes and lincRNAs produce more than one mRNA isoform each, the regulation of this phenomenon is still incompletely understood. Much progress has been made in deciphering the role of sequence-specific features as well as DNA-and RNA-binding proteins in alternative splicing. Recently, however, several experimental studies of individual genes have revealed a direct involvement of epigenetic factors in alternative splicing and transcription initiation. While histone modifications are generally correlated with overall gene expression levels, it remains unclear how histone modification enrichment affects relative isoform abundance. Therefore, we sought to investigate the associations between histone modifications and transcript diversity levels measured by the rates of transcription start-site switching and alternative splicing on a genome-wide scale across protein-coding genes and lincRNAs. We found that the relationship between enrichment levels of epigenetic marks and transcription start-site switching is similar for protein-coding genes and lincRNAs. Furthermore, we found associations between splicing rates and enrichment levels of H2az, H3K4me1, H3K4me2, H3K4me3, H3K9ac, H3K9me3, H3K27ac, H3K27me3, H3K36me3, H3K79me2, and H4K20me, marks traditionally associated with enhancers, transcription initiation, transcriptional repression, and others. These patterns were observed in both normal and cancer cell lines. Additionally, we developed a novel computational method that identified 840 epigenetically regulated candidate genes and predicted transcription start-site switching and alternative exon splicing with up to 92% accuracy based on epigenetic patterning alone. Our results suggest that the epigenetic regulation of transcript isoform diversity may be a relatively common genome-wide phenomenon representing an avenue of deregulation in tumor development. C1 [Podlaha, Ondrej; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Podlaha, Ondrej; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [De, Subhajyoti] Univ Colorado, Dept Med, Sch Med, Aurora, CO USA. [De, Subhajyoti] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [De, Subhajyoti] Univ Colorado, Mol Oncol Program, Ctr Canc, Aurora, CO USA. [Gonen, Mithat] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. RP Podlaha, O (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. EM michor@jimmy.harvard.edu FU NIH [NIH U54CA143798] FX NIH grant: NIH U54CA143798: Evolutionary Dynamics of Brain, Lung, and Hematopoietic Tumors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 5 Z9 5 U1 1 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD JUN PY 2014 VL 10 IS 6 AR e1003611 DI 10.1371/journal.pcbi.1003611 PG 13 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA AL0WP UT WOS:000338848100005 PM 24901363 ER PT J AU Juraeva, D Haenisch, B Zapatka, M Frank, J Witt, SH Muhleisen, T Treutlein, J Strohmaier, J Meier, S Degenhardt, F Giegling, I Ripke, S Leber, M Lange, C Schulze, T Mossner, R Nenadic, I Sauer, H Rujescu, D Maier, W Borglum, A Ophoff, R Cichon, S Nothen, M Rietschel, M Mattheisen, M Brors, B AF Juraeva, Dilafruz Haenisch, Britta Zapatka, Marc Frank, Josef Witt, Stephanie H. Muehleisen, ThomasW. Treutlein, Jens Strohmaier, Jana Meier, Sandra Degenhardt, Franziska Giegling, Ina Ripke, Stephan Leber, Markus Lange, Christoph Schulze, ThomasG. Moessner, Rainald Nenadic, Igor Sauer, Heinrich Rujescu, Dan Maier, Wolfgang Borglum, Anders Ophoff, Roel Cichon, Sven Noethen, MarkusM. Rietschel, Marcella Mattheisen, Manuel Brors, Benedikt CA GRP Investigators iPSYCH-GEMS SCZ Working Grp TI Integrated Pathway-Based Approach Identifies Association between Genomic Regions at CTCF and CACNB2 and Schizophrenia SO PLOS GENETICS LA English DT Article ID WIDE ASSOCIATION; ENRICHMENT ANALYSIS; GENE-EXPRESSION; COMMON VARIANTS; ANNOTATION; TRANSPORT; DISEASES; HAPMAP; GAMMA; MOTIF AB In the present study, an integrated hierarchical approach was applied to: (1) identify pathways associated with susceptibility to schizophrenia; (2) detect genes that may be potentially affected in these pathways since they contain an associated polymorphism; and (3) annotate the functional consequences of such single-nucleotide polymorphisms (SNPs) in the affected genes or their regulatory regions. The Global Test was applied to detect schizophrenia-associated pathways using discovery and replication datasets comprising 5,040 and 5,082 individuals of European ancestry, respectively. Information concerning functional gene-sets was retrieved from the Kyoto Encyclopedia of Genes and Genomes, Gene Ontology, and the Molecular Signatures Database. Fourteen of the gene-sets or pathways identified in the discovery dataset were confirmed in the replication dataset. These include functional processes involved in transcriptional regulation and gene expression, synapse organization, cell adhesion, and apoptosis. For two genes, i.e. CTCF and CACNB2, evidence for association with schizophrenia was available (at the gene-level) in both the discovery study and published data from the Psychiatric Genomics Consortium schizophrenia study. Furthermore, these genes mapped to four of the 14 presently identified pathways. Several of the SNPs assigned to CTCF and CACNB2 have potential functional consequences, and a gene in close proximity to CACNB2, i.e. ARL5B, was identified as a potential gene of interest. Application of the present hierarchical approach thus allowed: (1) identification of novel biological gene-sets or pathways with potential involvement in the etiology of schizophrenia, as well as replication of these findings in an independent cohort; (2) detection of genes of interest for future follow-up studies; and (3) the highlighting of novel genes in previously reported candidate regions for schizophrenia. C1 [Juraeva, Dilafruz; Brors, Benedikt] German Canc Res Ctr, Div Theoret Bioinformat, Heidelberg, Germany. [Haenisch, Britta; Lange, Christoph] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany. [Haenisch, Britta; Muehleisen, ThomasW.; Degenhardt, Franziska; Cichon, Sven; Noethen, MarkusM.] Univ Bonn, Inst Human Genet, Bonn, Germany. [Haenisch, Britta] Fed Inst Drugs & Med Devices BfArM, Bonn, Germany. [Haenisch, Britta] Univ Bonn, Dept Psychiat, Bonn, Germany. [Zapatka, Marc] German Canc Res Ctr, Div Mol Genet, Heidelberg, Germany. [Frank, Josef; Witt, Stephanie H.; Treutlein, Jens; Strohmaier, Jana; Meier, Sandra; Rietschel, Marcella] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Genet Epidemiol Psychiat, Mannheim, Germany. [Muehleisen, ThomasW.; Degenhardt, Franziska; Cichon, Sven; Noethen, MarkusM.; Mattheisen, Manuel] Univ Bonn, Dept Genom, Life & Brain Ctr, Bonn, Germany. [Muehleisen, ThomasW.; Cichon, Sven] Res Ctr Juelich, Inst Neurosci & Med INM 1, Julich, Germany. [Meier, Sandra] Aarhus Univ, Dept Econ & Business, NCRR, Aarhus, Denmark. [Giegling, Ina; Rujescu, Dan] Univ Munich, Dept Psychiat, Div Mol & Clin Neurobiol, D-80539 Munich, Germany. [Giegling, Ina; Rujescu, Dan] Univ Halle Wittenberg, Dept Psychiat, D-06108 Halle, Germany. [Ripke, Stephan] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Ripke, Stephan] Broad Inst MIT & Harvard, Cambridge, MA USA. [Leber, Markus] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany. [Lange, Christoph; Mattheisen, Manuel] Univ Bonn, Dept Genom Math, Bonn, Germany. [Lange, Christoph; Mattheisen, Manuel] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Schulze, ThomasG.] Univ Gottingen, Univ Med Ctr, Dept Psychiat & Psychotherapy, D-37073 Gottingen, Germany. [Moessner, Rainald; Maier, Wolfgang] Univ Bonn, Dept Psychiat, Bonn, Germany. [Nenadic, Igor; Sauer, Heinrich] Jena Univ Hosp, Dept Psychiat & Psychotherapy, Jena, Germany. [Borglum, Anders; Mattheisen, Manuel] Aarhus Univ, Dept Biomed, Aarhus C, Denmark. [Borglum, Anders; Mattheisen, Manuel] iSEQ, Ctr Integrated Sequencing, Aarhus, Denmark. [Borglum, Anders; Mattheisen, Manuel] iPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, Aarhus, Denmark. [Borglum, Anders; Mattheisen, Manuel] iPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, Copenhagen, Denmark. [Borglum, Anders] Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark. [Ophoff, Roel] UCLA Ctr Neurobehav Genet, Los Angeles, CA USA. [Ophoff, Roel] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Psychiat, Utrecht, Netherlands. [Cichon, Sven] Univ Basel Hosp, Dept Med Genet, CH-4031 Basel, Switzerland. RP Juraeva, D (reprint author), German Canc Res Ctr, Div Theoret Bioinformat, Heidelberg, Germany. EM d.juraeva@dkfz-heidelberg.de RI Myin-Germeys, Inez /L-5106-2014; Brors, Benedikt/E-5620-2013; Mortensen, Preben/D-2358-2015; Mattheisen, Manuel/B-4949-2012; OI Brors, Benedikt/0000-0001-5940-3101; Mortensen, Preben/0000-0002-5230-9865; Mattheisen, Manuel/0000-0002-8442-493X; Myin-Germeys, Inez/0000-0002-3731-4930; Grove, Jakob/0000-0003-2284-5744; Bruggeman, Richard/0000-0002-3238-8471; Nothen, Markus/0000-0002-8770-2464 FU BMBF through the Integrated Genome Research Network (IG) MooDS under National Genome Research Network plus (NGFNplus) [01GS08144, 01GS08147, 01GS08149]; European Community's Seventh Framework Programme (FP7) [279227]; European Union Seventh Framework Programme (FP7) [242257]; DFG; Junior Scientist Grant (Rotationsstelle) of IZKF, Jena University Hospital FX This study was supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Genome Research Network (IG) MooDS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia; grant 01GS08144 to MMN and SC, grant 01GS08147 to MR, grant 01GS08149 to BB), under the auspices of the National Genome Research Network plus (NGFNplus). The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 279227 (CRESTAR). Further funding came from the European Union Seventh Framework Programme (FP7/2007-2011) under grant agreement no. 242257 (ADAMS). The Heinz Nixdorf Recall cohort was established with the support of the Heinz Nixdorf Foundation (Dr G Schmidt, Chairman). MMN is a member of the DFG-funded Excellence Cluster ImmunoSensation. IN was supported by a Junior Scientist Grant (Rotationsstelle) of IZKF, Jena University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 63 TC 10 Z9 10 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7390 EI 1553-7404 J9 PLOS GENET JI PLoS Genet. PD JUN PY 2014 VL 10 IS 6 AR e1004345 DI 10.1371/journal.pgen.1004345 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA AL0WL UT WOS:000338847700004 PM 24901509 ER PT J AU Kemp, JP Medina-Gomez, C Estrada, K St Pourcain, B Heppe, DHM Warrington, NM Oei, L Ring, SM Kruithof, CJ Timpson, NJ Wolber, LE Reppe, S Gautvik, K Grundberg, E Ge, B van der Eerden, B van de Peppel, J Hibbs, MA Ackert-Bicknell, CL Choi, K Koller, DL Econs, MJ Williams, FMK Foroud, T Zillikens, MC Ohlsson, C Hofman, A Uitterlinden, AG Smith, GD Jaddoe, VWV Tobias, JH Rivadeneira, F Evans, DM AF Kemp, John P. Medina-Gomez, Carolina Estrada, Karol St Pourcain, Beate Heppe, Denise H. M. Warrington, Nicole M. Oei, Ling Ring, Susan M. Kruithof, Claudia J. Timpson, Nicholas J. Wolber, Lisa E. Reppe, Sjur Gautvik, Kaare Grundberg, Elin Ge, Bing van der Eerden, Bram van de Peppel, Jeroen Hibbs, Matthew A. Ackert-Bicknell, Cheryl L. Choi, Kwangbom Koller, Daniel L. Econs, Michael J. Williams, Frances M. K. Foroud, Tatiana Zillikens, M. Carola Ohlsson, Claes Hofman, Albert Uitterlinden, Andre G. Smith, George Davey Jaddoe, Vincent W. V. Tobias, Jonathan H. Rivadeneira, Fernando Evans, David M. TI Phenotypic Dissection of Bone Mineral Density Reveals Skeletal Site Specificity and Facilitates the Identification of Novel Loci in the Genetic Regulation of Bone Mass Attainment SO PLOS GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; PREMENOPAUSAL WOMEN; METAANALYSIS; FRACTURES; SNPS; TOOL; MAP; ANNOTATION; DISEASES; PROJECT AB Heritability of bone mineral density (BMD) varies across skeletal sites, reflecting different relative contributions of genetic and environmental influences. To quantify the degree to which common genetic variants tag and environmental factors influence BMD, at different sites, we estimated the genetic (r(g)) and residual (r(e)) correlations between BMD measured at the upper limbs (UL-BMD), lower limbs (LL-BMD) and skull (SK-BMD), using total-body DXA scans of,4,890 participants recruited by the Avon Longitudinal Study of Parents and their Children (ALSPAC). Point estimates of r(g) indicated that appendicular sites have a greater proportion of shared genetic architecture (LL-/UL-BMD r(g) = 0.78) between them, than with the skull (UL-/SK-BMD r(g) = 0.58 and LL-/SK-BMD r(g) = 0.43). Likewise, the residual correlation between BMD at appendicular sites (r(e) = 0.55) was higher than the residual correlation between SK-BMD and BMD at appendicular sites (r(e) = 0.20-0.24). To explore the basis for the observed differences in r(g) and r(e), genome-wide association meta-analyses were performed (n similar to 9,395), combining data from ALSPAC and the Generation R Study identifying 15 independent signals from 13 loci associated at genome-wide significant level across different skeletal regions. Results suggested that previously identified BMD-associated variants may exert site-specific effects (i.e. differ in the strength of their association and magnitude of effect across different skeletal sites). In particular, variants at CPED1 exerted a larger influence on SK-BMD and UL-BMD when compared to LL-BMD (P = 2.01x10(-37)), whilst variants at WNT16 influenced UL-BMD to a greater degree when compared to SK- and LL-BMD (P = 2.31x10(-14)). In addition, we report a novel association between RIN3 (previously associated with Paget's disease) and LL-BMD (rs754388: beta = 0.13, SE = 0.02, P = 1.4x10(-10)). Our results suggest that BMD at different skeletal sites is under a mixture of shared and specific genetic and environmental influences. Allowing for these differences by performing genome-wide association at different skeletal sites may help uncover new genetic influences on BMD. C1 [Kemp, John P.; St Pourcain, Beate; Ring, Susan M.; Timpson, Nicholas J.; Smith, George Davey; Evans, David M.] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England. [Kemp, John P.; Warrington, Nicole M.; Evans, David M.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia. [Medina-Gomez, Carolina; Oei, Ling; van der Eerden, Bram; van de Peppel, Jeroen; Zillikens, M. Carola; Uitterlinden, Andre G.; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands. [Medina-Gomez, Carolina; Heppe, Denise H. M.; Kruithof, Claudia J.; Hofman, Albert; Uitterlinden, Andre G.; Jaddoe, Vincent W. V.; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Generat Study Grp R, Rotterdam, Netherlands. [Medina-Gomez, Carolina; Heppe, Denise H. M.; Oei, Ling; Kruithof, Claudia J.; Hofman, Albert; Uitterlinden, Andre G.; Jaddoe, Vincent W. V.; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Estrada, Karol] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [St Pourcain, Beate] Univ Bristol, Sch Oral & Dent Sci, Bristol, Avon, England. [St Pourcain, Beate] Univ Bristol, Sch Expt Psychol, Bristol, Avon, England. [Heppe, Denise H. M.; Jaddoe, Vincent W. V.] Erasmus Univ, Med Ctr, Dept Paediat, Rotterdam, Netherlands. [Wolber, Lisa E.; Williams, Frances M. K.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England. [Reppe, Sjur; Gautvik, Kaare] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway. [Gautvik, Kaare] Oslo Deacon Hosp, Dept Med Biochem, Oslo, Norway. [Grundberg, Elin] McGill Univ, Dept Human Genet, Montreal, PQ, Canada. [Grundberg, Elin; Ge, Bing] McGill Univ, Montreal, PQ, Canada. [Grundberg, Elin; Ge, Bing] Genome Quebec Innovat Ctr, Montreal, PQ, Canada. [Hibbs, Matthew A.] Trinity Univ, Dept Comp Sci, San Antonio, TX USA. [Hibbs, Matthew A.; Ackert-Bicknell, Cheryl L.; Choi, Kwangbom] Jackson Lab, Bar Harbor, ME 04609 USA. [Koller, Daniel L.; Econs, Michael J.; Foroud, Tatiana] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA. [Econs, Michael J.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden. [Tobias, Jonathan H.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England. RP Kemp, JP (reprint author), Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England. EM j.p.kemp@bristol.ac.uk RI Warrington, Nicole/P-4868-2014; Rivadeneira, Fernando/O-5385-2015; Fox, Laura /C-6249-2016; Oei, Ling/E-8163-2013; Davey Smith, George/A-7407-2013; OI Evans, David/0000-0003-0663-4621; Timpson, Nicholas/0000-0002-7141-9189; Warrington, Nicole/0000-0003-4195-775X; Rivadeneira, Fernando/0000-0001-9435-9441; Medina-Gomez, Carolina/0000-0001-7999-5538; Kemp, John/0000-0002-9105-2249; Oei, Ling/0000-0003-3523-458X; Davey Smith, George/0000-0002-1407-8314; Williams, Frances/0000-0002-2998-2744; St Pourcain, Beate/0000-0002-4680-3517 FU Medical Research Council [MC_UU_12013/4]; Australian Research Council [FT130101709]; Wellcome Trust [WT083431MA, 092731]; UK Medical Research Council; University of Bristol; 23andMe; European Commission [HEALTH-F2-2008-201865-GEFOS]; German Bundesministerium fuer Forschung und Technology [01 AK 803 A-H, 01 IG 07015 G]; Erasmus Medical Center, Rotterdam; Erasmus University Rotterdam; Netherlands Organization for Health Research and Development (ZonMw); Netherlands Organisation for Scientific Research (NWO); Ministry of Health, Welfare and Sport; Netherlands Organization for Health Research and Development (VWVJ) [ZonMw 907.00303, ZonMw 916.10159, ZonMw VIDI 016.136.367]; European Commission; Genetic Laboratory of the Department of Internal Medicine, Erasmus MC Rotterdam; NIH [R01 AG041517, M01 RR-00750, R01 AR43351-11, U01HL072515-06, F32 AR059469, R01 AR/AG 41398, R01 AR 050066]; National Heart, Lung, and Blood Institute's Framingham Heart Study [N01 HC 25195]; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center FX ALSPAC: This work was supported by the Medical Research Council MC_UU_12013/4. DME is funded by an Australian Research Council Future Fellowship (FT130101709). JPK is funded by a Wellcome Trust 4-year PhD studentship in molecular, genetic, and life course epidemiology (WT083431MA). The UK Medical Research Council and the Wellcome Trust (Grant ref: 092731) and the University of Bristol provide core support for ALSPAC. 23andMe funded the generation of the ALSPAC GWA data. Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust. Generation R Study: The musculoskeletal research of the Generation R Study is partly supported by the European Commission grant HEALTH-F2-2008-201865-GEFOS. The grid resources used by this study were funded by the German Bundesministerium fuer Forschung und Technologyunder grants #01 AK 803 A-H and #01 IG 07015 G. The general design of Generation R Study is made possible by financial support from the Erasmus Medical Center, Rotterdam, the Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Netherlands Organisation for Scientific Research (NWO), and the Ministry of Health, Welfare and Sport. VWVJ and FR received additional grants from the Netherlands Organization for Health Research and Development (VWVJ: ZonMw 907.00303, ZonMw 916.10159 and FR: ZonMw VIDI 016.136.367). CMG is supported by the European Commission's EACEA within the framework of the Erasmus Mundus Partnerships programme Erasmus-Columbus (ERACOL) and by the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC Rotterdam. Miscellaneous: Participants in the premenopausal BMD meta-analysis study were funded by NIH grants R01 AG041517, M01 RR-00750, R01 AR43351-11, U01HL072515-06, F32 AR059469, R01 AR/AG 41398, and R01 AR 050066. Genotyping was provided by CIDR (NIH HHSN268200782096C) and the Azar Foundation. The Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health and Boston University School of Medicine were supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (N01 HC 25195) and its contract with Affymetrix, Inc. for genotyping services (N02 HL 64278). Analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. A portion of this research was conducted using the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Please note that in all cases, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 35 Z9 35 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD JUN PY 2014 VL 10 IS 6 AR e1004423 DI 10.1371/journal.pgen.1004423 PG 18 WC Genetics & Heredity SC Genetics & Heredity GA AL0WL UT WOS:000338847700039 PM 24945404 ER PT J AU Yu, HH Cheng, L Cho, KS AF Yu, Honghua Cheng, Lin Cho, Kin-Sang TI The potential of stem cell-based therapy for retinal repair SO NEURAL REGENERATION RESEARCH LA English DT Article ID MACULAR DEGENERATION; PROGENITOR CELLS; SUBRETINAL SPACE; CLINICAL-TRIALS; GANGLION-CELLS; DIFFERENTIATION; TRANSPLANTATION; INTEGRATION; LINES; DEATH AB Like injured neurons in the brain or spinal cord, neurons in the retina are incapable to regenerate following injury and ultimately would lead to irreversible neuronal loss and vision impairment. Over decades, extensive effort has been made to develop strategies to protect retinal neurons from death; however, the outcome is limited (Pettmann and Henderson, 1998; Bahr, 2000; Lagali and Picketts, 2011). Replacing the degenerated retinal neurons by newly generated and functional neurons would be an ideal scenario. The rapid development of stem cell biology has recently demonstrated that stem cells could be a potential source of cells for cell replacement therapy because these cells have the self-renewal capacity and could be differentiated into many cell types. This review will discuss the therapeutic potential of stem cell-based therapy to retinal degenerative diseases. C1 [Yu, Honghua] Gen Hosp Guangzhou Mil Command PLA, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China. [Cheng, Lin] Cent S Univ, Dept Clin Pharmacol, Xiangya Hosp, Changsha, Hunan, Peoples R China. [Cheng, Lin] Cent S Univ, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China. [Cheng, Lin] Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China. [Yu, Honghua; Cheng, Lin; Cho, Kin-Sang] Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, Boston, MA 02114 USA. RP Cho, KS (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA. EM Kinsang_Cho@meei.harvard.edu OI Cheng, Lin/0000-0002-4960-8186 NR 76 TC 0 Z9 0 U1 0 U2 5 PU SHENYANG EDITORIAL DEPT NEURAL REGENERATION RES PI SHENYANG PA PO BOX 1234, SHENYANG, LIAONING 110004, PEOPLES R CHINA SN 1673-5374 J9 NEURAL REGEN RES JI Neural Regen. Res. PD JUN PY 2014 VL 9 IS 11 BP 1100 EP 1103 DI 10.4103/1673-5374.135311 PG 4 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA AL0FX UT WOS:000338803900003 PM 25206766 ER PT J AU Glick, AR Khan, IA Sher, L AF Glick, Amy R. Khan, Imran A. Sher, Leo TI Treatment of Antipsychotic-Induced Sialorrhea SO PSYCHIATRIC ANNALS LA English DT Editorial Material ID CLOZAPINE-INDUCED SIALORRHEA; STRATEGIES C1 [Glick, Amy R.; Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Khan, Imran A.; Sher, Leo] James J Peters VA Med Ctr, New York, NY USA. RP Glick, AR (reprint author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl, New York, NY 10029 USA. EM amy.glick@mountsinai.org NR 10 TC 0 Z9 0 U1 0 U2 3 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 EI 1938-2456 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD JUN PY 2014 VL 44 IS 6 BP 267 EP 269 DI 10.3928/00485713-20140609-02 PG 3 WC Psychiatry SC Psychiatry GA AL0PB UT WOS:000338827700002 ER PT J AU Vacanti, JP Kulig, KM AF Vacanti, Joseph P. Kulig, Katherine M. TI Liver cell therapy and tissue engineering for transplantation SO SEMINARS IN PEDIATRIC SURGERY LA English DT Article DE Hepatocytes; Liver transplantation alternatives; Organ engineering; Stem cells; Tissue engineering; Xenotransplantation; Regenerative medicine ID EMBRYONIC STEM-CELLS; HEPATOCYTE-LIKE CELLS; IN-VITRO DIFFERENTIATION; BIOARTIFICIAL LIVER; ASSIST DEVICE; CONTROLLED-TRIAL; CORD BLOOD; HEPATIC DIFFERENTIATION; PROGENITOR CELLS; SUPPORT-SYSTEM AB Liver transplantation remains the only definitive treatment for liver failure and is available to only a tiny fraction of patients with end-stage liver diseases. Major limitations for the procedure include donor organ shortage, high cost, high level of required expertise, and long-term consequences of immune suppression. Alternative cell-based liver therapies could potentially greatly expand the number of patients provided with effective treatment Investigative research into augmenting or replacing liver function extends into three general strategies. Bioartificial livers (BALs) are extracorporeal devices that utilize cartridges of primary hepatocytes or cell lines to process patient plasma. Injection of liver cell suspensions aims to foster organ regeneration or provide a missing metabolic function arising from a genetic defect. Tissue engineering recreates the organ in vitro for subsequent implantation to augment or replace patient liver function. Translational models and clinical trials have highlighted both the immense challenges involved and some striking examples of success. (C) 2014 Published by Elsevier Inc. C1 [Vacanti, Joseph P.; Kulig, Katherine M.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Vacanti, Joseph P.; Kulig, Katherine M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Vacanti, Joseph P.; Kulig, Katherine M.] MassGen Hosp Children, Dept Pediat Surg, Boston, MA USA. [Vacanti, Joseph P.] Harvard Univ, Sch Med, Boston, MA USA. RP Vacanti, JP (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,WRN 1151, Boston, MA 02114 USA. EM jvacanti@partners.org NR 63 TC 9 Z9 9 U1 3 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1055-8586 EI 1532-9453 J9 SEMIN PEDIATR SURG JI Semin. Pediatr. Surg. PD JUN PY 2014 VL 23 IS 3 BP 150 EP 155 DI 10.1053/j.sempedsurg.2014.05.001 PG 6 WC Pediatrics; Surgery SC Pediatrics; Surgery GA AL1SL UT WOS:000338906300008 PM 24994529 ER PT J AU Sharkey, KM Crawford, SL Kim, S Joffe, H AF Sharkey, Katherine M. Crawford, Sybil L. Kim, Semmie Joffe, Hadine TI Objective sleep interruption and reproductive hormone dynamics in the menstrual cycle SO SLEEP MEDICINE LA English DT Article DE Menstrual cycle; Progesterone; Estradiol; Estrone; Sleep; Premenopausal; Polysomnography ID PREMENSTRUAL DYSPHORIC DISORDER; POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; BODY TEMPERATURES; MASS-SPECTROMETRY; HYPOGONADAL WOMEN; HEALTHY WOMEN; PROGESTERONE; ESTRADIOL; THERAPY AB Objectives: Women report greater sleep disturbance during the premenstrual phase of the menstrual cycle and during menses. However, the putative hormonal basis of perceived menstrual cycle-related sleep disturbance has not been investigated directly. We examined associations, of objective measures of sleep fragmentation with reproductive hormone levels in healthy, premenopausal women. Methods: Twenty-seven women with monthly menses had hormone levels measured at two time points during a single menstrual cycle: the follicular phase and the peri-ovulatory to mid-luteal phase. A single night of home polysomnography (PSG) was recorded on the day of the peri-ovulatory/mid-luteal-phase blood draw. Serum progesterone, estradiol, and estrone levels concurrent with PSG and rate of change in progesterone (PROGslope) from the follicular blood draw to PSG were correlated with log-transformed wake after sleep onset (InWASO%) and number of wakes/hour of sleep (InWake-Index) using linear regression. Results: Sleep was more fragmented in association with a steeper PROGslope (InWASO% p = 0.016; InWake-Index p = 0.08) and higher concurrent estrone level (InWASO% p = 0.03; InWake-Index p = 0.01), but the effect of estrone on WASO was lost after accounting for PROGslope. WASO% and Wake-Index were not associated with concomitant progesterone or estradiol levels. Conclusions: A steeper rate of rise in progesterone levels from the follicular phase through the mid-luteal phase was associated with significantly greater WASO, establishing a link between reproductive hormone dynamics and sleep fragmentation in the luteal phase of the menstrual cycle. (C) 2014 Elsevier B.V. All rights reserved. C1 [Sharkey, Katherine M.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Med, Providence, RI 02903 USA. [Sharkey, Katherine M.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02903 USA. [Crawford, Sybil L.] Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, Worcester, MA 01655 USA. [Kim, Semmie; Joffe, Hadine] Harvard Univ, Sch Med, Brigham & Womens Hosp, Womens Hormones & Aging Res Program,Dept Psychiat, Boston, MA 02115 USA. [Joffe, Hadine] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. RP Joffe, H (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Womens Hormones & Aging Res Program,Dept Psychiat, 75 Francis St, Boston, MA 02115 USA. EM hjoffe@partners.org FU NIH (United States); Cephalon/Teva; [5 R01 MH082922]; [K23 MH086689] FX The authors thank Susan Regan, Ph.D, for her valuable contributions to this study. This work was supported by 5 R01 MH082922 (HJ) and K23 MH086689 (KMS). KMS, SK, and SC have no conflicts to report. HJ receives research funding from NIH (United States) and Cephalon/Teva, and serves as a consultant for Noven and as an unpaid consultant to Sunovion. NR 38 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 EI 1878-5506 J9 SLEEP MED JI Sleep Med. PD JUN PY 2014 VL 15 IS 6 BP 688 EP 693 DI 10.1016/j.sleep.2014.02.003 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA AK7PW UT WOS:000338621200017 PM 24841109 ER PT J AU Varghese, M Ho, L Wang, J Zhao, W Levine, S Ono, K Mannino, S Pasinetti, GM AF Varghese, Merina Ho, Lap Wang, Jun Zhao, Wei Levine, Samara Ono, Kenjiro Mannino, Salvatore Pasinetti, Giulio Maria TI Green coffee as a novel agent for Alzheimer's disease prevention by attenuating diabetes SO TRANSLATIONAL NEUROSCIENCE LA English DT Article DE Coffee; Alzheimer's disease; Diabetes; Diabetes type 2; Brain; Energy metabolism ID INDUCED INSULIN-RESISTANCE; AMYLOID-BETA LEVELS; COGNITIVE IMPAIRMENT; DECAFFEINATED COFFEE; CHLOROGENIC ACID; MOUSE MODEL; CAFFEINE; MICE; RISK; CONSUMPTION AB Diabetes type 2, caused mainly by insulin resistance, is growing in incidence worldwide. In addition to being a major public health concern, type 2 diabetes is also a risk factor for dementia, including Alzheimer's disease type dementia. Coffee consumption is reported to have protective effects in both diabetes and Alzheimer's disease. We review here the reported beneficial effects of coffee in both disease conditions and the previously identified active ingredients of coffee. Furthermore, we revisit our recent findings of improved glucose utilization in the periphery and in the brain in a mouse model of high-fat diet induced type 2 diabetes after treatment with a decaffeinated green coffee preparation. Overall, consumption of coffee appears to improve diabetes and reduce the risk of dementia, although future studies are required to further identify the active components and the type of coffee that is most effective in addressing these conditions. C1 [Varghese, Merina; Ho, Lap; Wang, Jun; Zhao, Wei; Levine, Samara; Pasinetti, Giulio Maria] Mt Sinai Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Ho, Lap; Wang, Jun; Zhao, Wei; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. [Ono, Kenjiro] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol & Aging, Kanazawa, Ishikawa 9209640, Japan. [Mannino, Salvatore] Osped Alzano, Geriatr Output Unit, Bergamo, Italy. RP Varghese, M (reprint author), Mt Sinai Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 NR 44 TC 2 Z9 2 U1 4 U2 20 PU DE GRUYTER OPEN LTD PI WARSAW PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND SN 2081-3856 EI 2081-6936 J9 TRANSL NEUROSCI JI Transl. Neurosci. PD JUN PY 2014 VL 5 IS 2 BP 111 EP 116 DI 10.2478/s13380-014-0213-y PG 6 WC Neurosciences SC Neurosciences & Neurology GA AK8AV UT WOS:000338650400001 ER PT J AU Lin, JJ Mahindra, A Santo, L Amin, S Sohani, AR Raje, N AF Lin, J. J. Mahindra, A. Santo, L. Amin, S. Sohani, A. R. Raje, N. TI MicroRNA expression patterns in medullary and extramedullary plasmacytoma SO BLOOD CANCER JOURNAL LA English DT Letter ID MULTIPLE-MYELOMA; BONE; PROLIFERATION; ANGIOGENESIS C1 [Lin, J. J.; Mahindra, A.; Santo, L.; Amin, S.; Sohani, A. R.; Raje, N.] Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA 02114 USA. RP Lin, JJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA 02114 USA. EM nraje@partners.org OI Amin, Samir/0000-0002-3207-9505 NR 15 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2044-5385 J9 BLOOD CANCER J JI Blood Cancer J. PD JUN PY 2014 VL 4 AR e223 DI 10.1038/bcj.2014.41 PG 3 WC Oncology SC Oncology GA AL0VP UT WOS:000338845400007 PM 24972152 ER PT J AU Bah, N Maillet, L Ryan, J Dubreil, S Gautier, F Letai, A Juin, P Barille-Nion, S AF Bah, N. Maillet, L. Ryan, J. Dubreil, S. Gautier, F. Letai, A. Juin, P. Barille-Nion, S. TI Bcl-xL controls a switch between cell death modes during mitotic arrest SO CELL DEATH & DISEASE LA English DT Article ID PACLITAXEL-INDUCED APOPTOSIS; BREAST-CANCER; PHOSPHORYLATION SITE; CHECKPOINT; IDENTIFICATION; CHEMOTHERAPY; INHIBITOR; SENSITIVITY; DEPENDENCY; BCL-X(L) AB Antimitotic agents such as microtubule inhibitors (paclitaxel) are widely used in cancer therapy while new agents blocking mitosis onset are currently in development. All these agents impose a prolonged mitotic arrest in cancer cells that relies on sustained activation of the spindle assembly checkpoint and may lead to subsequent cell death by incompletely understood molecular events. We have investigated the role played by anti-apoptotic Bcl-2 family members in the fate of mitotically arrested mammary tumor cells treated with paclitaxel, or depleted in Cdc20, the activator of the anaphase promoting complex. Under these conditions, a weak and delayed mitotic cell death occurs that is caspase-and Bax/Bak-independent. Moreover, BH3 profiling assays indicate that viable cells during mitotic arrest are primed to die by apoptosis and that Bcl-xL is required to maintain mitochondrial integrity. Consistently, Bcl-xL depletion, or treatment with its inhibitor ABT-737 (but not with the specific Bcl-2 inhibitor ABT-199), during mitotic arrest converts cell response to antimitotics to efficient caspase and Bax-dependent apoptosis. Apoptotic priming under conditions of mitotic arrest relies, at least in part, on the phosphorylation on serine 62 of Bcl-xL, which modulates its interaction with Bax and its sensitivity to ABT-737. The phospho-mimetic S62D-Bcl-xL mutant is indeed less efficient than the corresponding phospho-deficient S62A-Bcl-xL mutant in sequestrating Bax and in protecting cancer cells from mitotic cell death or yeast cells from Bax-induced growth inhibition. Our results provide a rationale for combining Bcl-xL targeting to antimitotic agents to improve clinical efficacy of antimitotic strategy in cancer therapy. C1 [Bah, N.; Maillet, L.; Dubreil, S.; Gautier, F.; Juin, P.; Barille-Nion, S.] Univ Nantes, Inst Rech Sante, Team Cell Survival & Tumor Escape Breast Canc 8, INSERM,UMR 892,CNRS 6299, F-44007 Nantes, France. [Ryan, J.; Letai, A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Gautier, F.; Juin, P.] Ctr Lutte Canc Rene Gauducheau, ICO, F-44805 St Herblain, France. [Gautier, F.] Univ Nantes, Inst Rech Sante, Plateforme IMPACT Biogenouest, F-44007 Nantes 1, France. RP Barille-Nion, S (reprint author), Univ Nantes, Inst Rech Sante, Team Cell Survival & Tumor Escape Breast Canc 8, INSERM,UMR 892,CNRS 6299, 8 Quai Moncousu,BP 70721, F-44007 Nantes, France. EM sophie.barille@inserm.fr RI Barille-Nion, sophie/K-8057-2015; Gautier, Fabien/K-9119-2015; JUIN, Philippe/H-3636-2014; MAILLET, Laurent/K-7959-2015 OI JUIN, Philippe/0000-0002-4997-3888; MAILLET, Laurent/0000-0002-8169-060X FU la Ligue contre le Cancer de Loire-Atlantique; la Ligue Regionale contre le Cancer Grand-Ouest; French Society of Cancer FX We thank Philippe Hulin for his technical support in Cellular and Tissular Imaging Core Facility of Nantes University (MicroPICell). We also thank the Cytometry Facilty Cytocell from Nantes for expert technical assistance. We thank Claude Prigent and Francois Paris for fruitful discussions. We thank Sophie de Carne for providing us the MCF-7-YFP and MCF-7-YFP-Bcl-xL cell lines. N Bah was supported by la Ligue contre le Cancer de Loire-Atlantique. We thank la Ligue Regionale contre le Cancer Grand-Ouest and the French Society of Cancer for their financial support. NR 34 TC 17 Z9 18 U1 3 U2 15 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-4889 J9 CELL DEATH DIS JI Cell Death Dis. PD JUN PY 2014 VL 5 AR e1291 DI 10.1038/cddis.2014.251 PG 12 WC Cell Biology SC Cell Biology GA AK9WE UT WOS:000338778500019 PM 24922075 ER PT J AU Udell, JA Braunwald, E Antman, EM Murphy, SA Montalescot, G Wiviott, SD AF Udell, Jacob A. Braunwald, Eugene Antman, Elliot M. Murphy, Sabina A. Montalescot, Gilles Wiviott, Stephen D. TI Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention A TRITON-TIMI 38 Subgroup Analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE antiplatelet therapy; myocardial infarction; periprocedural myocardial injury; prasugrel; primary percutaneous coronary intervention ID UNIVERSAL DEFINITION; CLASSIFICATION-SYSTEM; REPERFUSION THERAPY; AMERICAN-COLLEGE; HEART; PRETREATMENT; TICAGRELOR; CARDIOLOGY; SOCIETY; INJURY AB Objectives This study sought to evaluate the efficacy of prasugrel versus clopidogrel in ST-segment elevation myocardial infarction (STEMI) by the timing of percutaneous coronary intervention (PCI). Background Treatment strategies and outcomes for patients with STEMI may differ when treated with primary compared with secondary PCI. Methods STEMI patients in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) were randomized to prasugrel or clopidogrel on presentation if primary PCI was intended or later during secondary PCI. Primary PCI was defined as within 12 h of symptom onset. The primary endpoint was cardiovascular death, myocardial infarction (MI), or stroke. Because periprocedural MI is difficult to assess in the setting of STEMI, we performed analyses excluding these events. Results Reductions in the primary endpoint with prasugrel versus clopidogrel (hazard ratio [HR]: 0.79; 95% confidence interval [CI]: 0.65 to 0.97; p = 0.022) were consistent between primary and secondary PCI patients at 15 months (HR: 0.89; 95% CI: 0.69 to 1.13 vs. HR: 0.65; 95% CI: 0.46 to 0.93; p interaction = 0.15). However, a tendency toward a difference in treatment effect at 30 days (HR: 0.68; 95% CI: 0.54 to 0.87; p = 0.002) was observed between primary and secondary PCI patients (HR: 0.81; 95% CI: 0.60 to 1.09 vs. HR: 0.51; 95% CI: 0.34 to 0.76; p interaction = 0.06). When periprocedural MI was excluded, the efficacy of prasugrel remained consistent among primary and secondary PCI patients at 30 days (HR: 0.53; 95% CI: 0.34 to 0.81 vs. HR: 0.44; 95% CI: 0.22 to 0.88; p interaction = 0.68) and 15 months (HR: 0.76; 95% CI: 0.56 to 1.03 vs. HR: 0.75; 95% CI: 0.46 to 1.21; p interaction = 0.96). Conclusions The efficacy of prasugrel versus clopidogrel was consistent irrespective of the timing of PCI, particularly in preventing nonprocedural events. (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38; NCT00097591) (C) 2014 by the American College of Cardiology Foundation C1 [Udell, Jacob A.] Univ Toronto, Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada. [Udell, Jacob A.] Univ Toronto, Womens Coll Hosp, Dept Med, Cardiovasc Div, Toronto, ON, Canada. [Braunwald, Eugene; Antman, Elliot M.; Murphy, Sabina A.; Wiviott, Stephen D.] Harvard Univ, Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div,Dept Med,Med Sch, Boston, MA 02115 USA. [Montalescot, Gilles] Univ Paris 06, INSERM, Hop La Pitie Salpetriere, AP HP,ACT Study Grp,Inst Cardiol,UMRS 1166, Paris, France. RP Wiviott, SD (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM swiviott@partners.org FU Eli Lilly and Company; Daiichi Sankyo Company Ltd.; Canadian Institutes of Health Research (Ottawa, Ontario, Canada); Canadian Foundation for Women's Health (Ottawa, Ontario, Canada); Eli Lilly; Daiichi Sankyo; Abbott Vascular; Accumetrics; AstraZeneca; Biotronik; Bristol-Myers Squibb; Federation Francaise de Cardiologie; Fondation de France; INSERM; Institut de France; Medtronic; Menarini; Nanospheres; Pfizer; Roche; Sanofi-Aventis; Stentys; Societe Francaise de Cardiologie; Medicines Company; Bayer; Boehringer-Ingelheim; Duke Institute; Europa; GlaxoSmithKline; Iroko; Lead Up; Novartis; Springer; TIMI Study Group; WebMD; Wolters; Arena; Bristol-Myers-Squibb; Eisai; Merck; Aegerion; Angelmed; Boston Clinical Research Institute; ICON Clinical; Janssen; Xoma FX TRITON-TIMI 38 received funding from Eli Lilly and Company and Daiichi Sankyo Company Ltd. No additional funding for this analysis was provided. Dr. Udell was supported in part by a Postdoctoral Research Fellowship from the Canadian Institutes of Health Research (Ottawa, Ontario, Canada) and the Canadian Foundation for Women's Health (Ottawa, Ontario, Canada). The TIMI Study Group has received significant research grant support from Eli Lilly and Daiichi Sankyo. Dr. Braunwald has received significant research grant support from Eli Lilly and Daiichi Sankyo; and lecture honoraria from Daiichi Sankyo. Dr. Antman has received significant research grant support from Eli Lilly and Daiichi Sankyo. Ms. Murphy has received research funding from Eli Lilly. Dr. Montalescot and his research units have received significant research grant support from Abbott Vascular, Accumetrics, AstraZeneca, Biotronik, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Federation Francaise de Cardiologie, Fondation de France, INSERM, Institut de France, Medtronic, Menarini, Nanospheres, Pfizer, Roche, Sanofi-Aventis, Stentys, Societe Francaise de Cardiologie, and The Medicines Company; and consulting fees from AstraZeneca, Accumetrics, Bayer, Biotronik, Bristol-Myers Squibb, Boehringer-Ingelheim, Duke Institute, Eli Lilly, Europa, GlaxoSmithKline, Iroko, Lead Up, Medtronic, Menarini, Novartis, Pfizer, Roche, Sanofi-Aventis, Springer, The Medicines Company, TIMI Study Group, WebMD, and Wolters. S. A. Murphy has received research funding from Eli Lilly. Dr Wiviott has received significant research grants from Arena, AstraZeneca, Bristol-Myers-Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Merck, and Sanofi-Aventis; and consulting fees from Aegerion, Angelmed, Arena, AstraZeneca, Boston Clinical Research Institute, Bristol-Myers-Squibb, Daiichi Sankyo, Eisai, Eli Lilly, ICON Clinical, Janssen, and Xoma. Dr. Udell has reported that he has no relationships relevant to the contents of this paper to disclose. NR 25 TC 17 Z9 17 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JUN PY 2014 VL 7 IS 6 BP 604 EP 612 DI 10.1016/j.jcin.2014.01.160 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AL2HI UT WOS:000338946200013 PM 24947719 ER PT J AU Hu, SN Jia, HB Vergallo, R Abtahian, F Tian, JW Soeda, T Rosenfield, K Jang, IK AF Hu, Sining Jia, Haibo Vergallo, Rocco Abtahian, Farhad Tian, Jinwei Soeda, Tsunenari Rosenfield, Kenneth Jang, Ik-Kyung TI Plaque Erosion In Vivo Diagnosis and Treatment Guided by Optical Coherence Tomography SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material DE acute coronary syndrome; optical coherence tomography; plaque erosion ID SUDDEN CORONARY DEATH C1 [Hu, Sining; Jia, Haibo; Tian, Jinwei] Harbin Med Univ, Key Lab Myocardial Ischemia, Chinese Minist Educ, Dept Cardiol,Affiliated Hosp 2, Harbin, Peoples R China. [Hu, Sining; Jia, Haibo; Vergallo, Rocco; Abtahian, Farhad; Tian, Jinwei; Soeda, Tsunenari; Rosenfield, Kenneth; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div, Boston, MA USA. RP Jang, IK (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St GRB 800, Boston, MA 02114 USA. EM ijang@partners.org NR 4 TC 2 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JUN PY 2014 VL 7 IS 6 BP E63 EP E64 DI 10.1016/j.jcin.2013.10.024 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AL2HI UT WOS:000338946200007 PM 24947729 ER PT J AU Hall, JA Tabata, M Rodgers, JT Puigserver, P AF Hall, Jessica A. Tabata, Mitsuhisa Rodgers, Joseph T. Puigserver, Pere TI USP7 Attenuates Hepatic Gluconeogenesis Through Modulation of FoxO1 Gene Promoter Occupancy SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID FORKHEAD TRANSCRIPTION FACTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; UBIQUITIN-SPECIFIC PROTEASE; BINDING PROTEIN-1 PROMOTER; INSULIN-RESPONSE SEQUENCE; DNA-BINDING; FACTOR FKHR; SUBCELLULAR-LOCALIZATION; NUCLEAR EXCLUSION; COACTIVATOR PGC-1 AB Hepatic forkhead protein FoxO1 is a key component of systemic glucose homeostasis via its ability to regulate the transcription of rate-limiting enzymes in gluconeogenesis. Important in the regulation of FoxO1 transcriptional activity are the modifying/demodifying enzymes that lead to posttranslational modification. Here, we demonstrate the functional interaction and regulation of FoxO1 by herpesvirus-associated ubiquitin-specific protease 7 (USP7; also known as herpesvirus-associated ubiquitin-specific protease, HAUSP), a deubiquitinating enzyme. We show that USP7-mediated mono-deubiquitination of FoxO1 results in suppression of FoxO1 transcriptional activity through decreased FoxO1 occupancy on the promoters of gluconeogenic genes. Knockdown of USP7 in primary hepatocytes leads to increased expression of FoxO1-target gluconeogenic genes and elevated glucose production. Consistent with this, USP7 gain-of-function suppresses the fasting/cAMP-induced activation of gluconeogenic genes in hepatocyte cells and in mouse liver, resulting in decreased hepatic glucose production. Notably, we show that the effects of USP7 on hepatic glucose metabolism depend on FoxO1. Together, these results place FoxO1 under the intimate regulation of deubiquitination and glucose metabolic control with important implication in diseases such as diabetes. C1 [Hall, Jessica A.; Tabata, Mitsuhisa; Rodgers, Joseph T.; Puigserver, Pere] Harvard Univ, Sch Med, Dana Farber Canc Inst & Cell Biol, Dept Canc Biol, Boston, MA 02115 USA. RP Puigserver, P (reprint author), Dana Farber Canc Inst, 450 Brookline Ave CLSB-11144, Boston, MA 02215 USA. EM Pere_Puigserver@dfci.harvard.edu FU American Heart Association; American Diabetes Association; National Institute of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01 069966] FX This work was supported by an American Heart Association predoctoral fellowship (J.A.H.) and postdoctoral fellowship (M. T.). P. P. received support from American Diabetes Association and National Institute of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 069966). NR 66 TC 8 Z9 8 U1 0 U2 7 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JUN PY 2014 VL 28 IS 6 BP 912 EP 924 DI 10.1210/me.2013-1420 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AK8SL UT WOS:000338698200011 PM 24694308 ER PT J AU Huang, P Schulz, TJ Beauvais, A Tseng, YH Gussoni, E AF Huang, Ping Schulz, Tim J. Beauvais, Ariane Tseng, Yu-Hua Gussoni, Emanuela TI Intramuscular adipogenesis is inhibited by myo-endothelial progenitors with functioning Bmpr1a signalling SO NATURE COMMUNICATIONS LA English DT Article ID MUSCLE SATELLITE CELLS; BONE MORPHOGENETIC PROTEIN; ADULT SKELETAL-MUSCLE; STEM-CELLS; FIBRO/ADIPOGENIC PROGENITORS; MYOGENIC DIFFERENTIATION; LINEAGE ANALYSIS; SELF-RENEWAL; GENE MYF-5; REGENERATION AB Developing human muscle contains inter-myofibre progenitors expressing Bmp-receptor 1a (Bmpr1a) and Myf5 that respond to stimulation with Bmp4. Here we ablate Bmpr1a in Myf5- and MyoD-expressing cells in vivo. Mutant mice reveal increased intramuscular fat and reduced myofibre size in selected muscles, or following muscle injury. Myo-endothelial progenitors are the most affected cell type: clonal studies demonstrate that ablation of Bmpr1a in myo-endothelial cells results in decreased myogenic activity, while adipogenic differentiation is significantly increased. Downstream phospho-Smad 1, 5, 8 signalling is also severely decreased in mutant myo-endothelial cells. Lineage tracing of endothelial cells using VE-cadherin(Cre) driver failed to reveal a significant contribution of these cells to developing or injured skeletal muscle. Thus, myo-endothelial progenitors with functioning Bmpr1a signalling demonstrate myogenic potential, but their main function in vivo is to inhibit intramuscular adipogenesis, both through a cell-autonomous and a cell-cell interaction mechanism. C1 [Huang, Ping; Beauvais, Ariane; Gussoni, Emanuela] Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA. [Schulz, Tim J.; Tseng, Yu-Hua] Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02115 USA. RP Gussoni, E (reprint author), Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA. EM gussoni@enders.tch.harvard.edu RI Schulz, Tim/F-4842-2013 OI Schulz, Tim/0000-0002-8413-3972 FU NICHD; Scientist Development Grant from AHA [0730285N]; NIH/NINDS [2R01 NS047727] FX We thank the Dana Farber Hematologic Neoplasia Flow Cytometry Core for their outstanding services. We also thank Dr. Paul B. Yu for helpful discussions and for the pSmad 2 and pSmad 1,3 antibodies. The Pax7 antibody (DSHB, University of Iowa) was developed under the auspices of the NICHD. P.H. was supported by a Scientist Development Grant from AHA (0730285N). This work was supported by NIH/NINDS 2R01 NS047727 grant to E.G. NR 68 TC 9 Z9 9 U1 0 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2014 VL 5 AR 4063 DI 10.1038/ncomms5063 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AL0SV UT WOS:000338838000007 PM 24898859 ER PT J AU Lim, EJ Ober, TJ Edd, JF Desai, SP Neal, D Bong, KW Doyle, PS McKinley, GH Toner, M AF Lim, Eugene J. Ober, Thomas J. Edd, Jon F. Desai, Salil P. Neal, Douglas Bong, Ki Wan Doyle, Patrick S. McKinley, Gareth H. Toner, Mehmet TI Inertio-elastic focusing of bioparticles in microchannels at high throughput SO NATURE COMMUNICATIONS LA English DT Article ID PARTICLE IMAGE VELOCIMETRY; OLDROYD-B FLUIDS; POISEUILLE FLOW; SEPARATION; TURBULENCE; SPHERE; INSTABILITY; TECHNOLOGY; MIGRATION; BREAKUP AB Controlled manipulation of particles from very large volumes of fluid at high throughput is critical for many biomedical, environmental and industrial applications. One promising approach is to use microfluidic technologies that rely on fluid inertia or elasticity to drive lateral migration of particles to stable equilibrium positions in a microchannel. Here, we report on a hydrodynamic approach that enables deterministic focusing of beads, mammalian cells and anisotropic hydrogel particles in a microchannel at extremely high flow rates. We show that on addition of micromolar concentrations of hyaluronic acid, the resulting fluid viscoelasticity can be used to control the focal position of particles at Reynolds numbers up to Re approximate to 10,000 with corresponding flow rates and particle velocities up to 50 ml min(-1) and 130 ms(-1). This study explores a previously unattained regime of inertio-elastic fluid flow and demonstrates bioparticle focusing at flow rates that are the highest yet achieved. C1 [Lim, Eugene J.; Edd, Jon F.; Desai, Salil P.; Bong, Ki Wan; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Charlestown, MA 02129 USA. [Lim, Eugene J.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Ober, Thomas J.; McKinley, Gareth H.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. [Neal, Douglas] LaVision Inc, Ypsilanti, MI 48197 USA. [Bong, Ki Wan] Korea Univ, Dept Chem & Biol Engn, Seoul 136713, South Korea. [Doyle, Patrick S.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. RP McKinley, GH (reprint author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA. EM gareth@mit.edu; mehmet_toner@hms.harvard.edu FU National Institutes of Biomedical Imaging and Bioengineering (P41 BioMicroElectroMechanical Systems Resource Center) [P41 EB002503]; NSF; Institute for Collaborative Biotechnologies from the U.S. Army Research Office [W911NF-09-0001] FX We thank Bashar Hamza for his cell culture work, Bavand Keshavarz for rheological measurements of test fluids and Patrick Nash for assembling the fluidic circuit. We also thank Octavio Hurtado and A.J. Aranyosi for the coordination of the research lab and guidance. This work was supported in part by the National Institutes of Biomedical Imaging and Bioengineering (P41 BioMicroElectroMechanical Systems Resource Center, P41 EB002503). T.J.O. acknowledges the NSF Graduate Research Fellowship for funding. P.S.D. and K.W.B. were supported by the Institute for Collaborative Biotechnologies through grant W911NF-09-0001 from the U.S. Army Research Office. The content of the information does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred. NR 59 TC 35 Z9 35 U1 8 U2 83 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2014 VL 5 AR 4120 DI 10.1038/ncomms5120 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AL0SY UT WOS:000338838300015 PM 24939508 ER PT J AU Zhou, XZ Menche, J Barabasi, AL Sharma, A AF Zhou, XueZhong Menche, Joerg Barabasi, Albert-Laszlo Sharma, Amitabh TI Human symptoms-disease network SO NATURE COMMUNICATIONS LA English DT Article ID ELECTRONIC HEALTH RECORDS; INFLAMMATORY-BOWEL-DISEASE; PARKINSONS-DISEASE; PHENOTYPE ONTOLOGY; ALZHEIMERS-DISEASE; GENES; INFORMATION; MODEL; INTERACTOME; DISCOVERY AB In the post-genomic era, the elucidation of the relationship between the molecular origins of diseases and their resulting phenotypes is a crucial task for medical research. Here, we use a large-scale biomedical literature database to construct a symptom-based human disease network and investigate the connection between clinical manifestations of diseases and their underlying molecular interactions. We find that the symptom-based similarity of two diseases correlates strongly with the number of shared genetic associations and the extent to which their associated proteins interact. Moreover, the diversity of the clinical manifestations of a disease can be related to the connectivity patterns of the underlying protein interaction network. The comprehensive, high-quality map of disease-symptom relations can further be used as a resource helping to address important questions in the field of systems medicine, for example, the identification of unexpected associations between diseases, disease etiology research or drug design. C1 [Zhou, XueZhong] Beijing Jiaotong Univ, Sch Comp & Informat Technol, Beijing 100044, Peoples R China. [Zhou, XueZhong] Beijing Jiaotong Univ, Beijing Key Lab Traff Data Anal & Min, Beijing 100044, Peoples R China. [Zhou, XueZhong; Menche, Joerg; Barabasi, Albert-Laszlo; Sharma, Amitabh] Northeastern Univ, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA. [Zhou, XueZhong; Menche, Joerg; Barabasi, Albert-Laszlo; Sharma, Amitabh] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02215 USA. [Menche, Joerg; Barabasi, Albert-Laszlo] Budapest Univ Technol & Econ, Dept Theoret Phys, H-1111 Budapest, Hungary. [Barabasi, Albert-Laszlo] Cent European Univ, Ctr Network Sci, H-1051 Budapest, Hungary. [Barabasi, Albert-Laszlo; Sharma, Amitabh] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. RP Zhou, XZ (reprint author), Beijing Jiaotong Univ, Sch Comp & Informat Technol, Beijing 100044, Peoples R China. EM xzzhou@bjtu.edu.cn; amitabh.sharma@channing.harvard.edu RI Menche, Jorg/G-3994-2015 OI Menche, Jorg/0000-0002-1583-6404 FU National Science Foundation of China [61105055, 81230086]; National Basic Research Program of China [2014CB542903]; National Key Technology RD Program [2013BAI02B01, 2013BAI13B04]; National S&T Major Special Project [2012ZX09503-001-003]; Beijing Municipal S&T Program of China [Z131110002813118]; MapGen grant [1U01HL108630-01]; EC-FP7 Program, Synergy-COPD [270086]; U.S. National Institutes of Health [HL066289, HL105339] FX We thank Baoyan Liu, Chaoming Song, Dashun Wang and Andrew Michaelson for useful discussions and suggestions, and especially Lili Xu, Guangli Song, Haixun Qi, Minghui Lv, Yiwei Wang, Xiaofeng Zhou and Hongwei Chu for the manual validation of the selected PubMed records. X.Z. was supported by the National Science Foundation of China (61105055, 81230086), National Basic Research Program of China (2014CB542903), National Key Technology R&D Program (2013BAI02B01, 2013BAI13B04), National S&T Major Special Project (2012ZX09503-001-003) and Beijing Municipal S&T Program of China (Z131110002813118). This work was supported by MapGen grant (1U01HL108630-01) and by the EC-FP7 Program, Synergy-COPD, GA no 270086. Additional support was provided by HL066289 and HL105339 grants from the U.S. National Institutes of Health. NR 69 TC 49 Z9 51 U1 3 U2 34 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2014 VL 5 AR 4212 DI 10.1038/ncomms5212 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AL0TI UT WOS:000338839300001 PM 24967666 ER PT J AU Tewari, KS Sill, MW Long, HJ Penson, RT Huang, H Ramondetta, LM Landrum, LM Oaknin, A Reid, TJ Leitao, MM Michael, HE Monk, BJ AF Tewari, Krishnansu S. Sill, Michael W. Long, Harry J., III Penson, Richard T. Huang, Helen Ramondetta, Lois M. Landrum, Lisa M. Oaknin, Ana Reid, Thomas J. Leitao, Mario M. Michael, Helen E. Monk, Bradley J. TI Improved Survival With Bevacizumab in Advanced Cervical Cancer SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Tewari, Krishnansu S.] Univ Calif Irvine, Med Ctr, Orange, CA 92697 USA. [Sill, Michael W.; Huang, Helen] SUNY Buffalo, Roswell Pk Canc Inst, Buffalo, NY 14260 USA. [Long, Harry J., III] Mayo Clin, Rochester, MN USA. [Penson, Richard T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ramondetta, Lois M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Landrum, Lisa M.] Univ Oklahoma, Oklahoma City, OK USA. [Oaknin, Ana] Vall dHebron Univ Hosp, Barcelona, Spain. [Reid, Thomas J.] Univ Cincinnati, Coll Med, Womens Canc Ctr Kettering, Kettering, OH USA. [Leitao, Mario M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Michael, Helen E.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Monk, Bradley J.] Univ Arizona, Ctr Canc, Phoenix, AZ USA. [Monk, Bradley J.] Creighton Univ, St Josephs Hosp & Med Ctr, Phoenix, AZ USA. RP Tewari, KS (reprint author), Univ Calif Irvine, Med Ctr, Orange, CA 92697 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD JUN PY 2014 VL 69 IS 6 BP 331 EP 332 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AK9WS UT WOS:000338779900013 ER PT J AU Scott, JC Pietrzak, RH Southwick, SM Jordan, J Silliker, N Brandt, CA Haskell, SG AF Scott, J. Cobb Pietrzak, Robert H. Southwick, Steven M. Jordan, Jessica Silliker, Norman Brandt, Cynthia A. Haskell, Sally G. TI Military Sexual Trauma Interacts With Combat Exposure to Increase Risk for Posttraumatic Stress Symptomatology in Female Iraq and Afghanistan Veterans SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID MALE VIETNAM VETERANS; MENTAL-HEALTH; GENDER-DIFFERENCES; NATIONAL SAMPLE; WOMEN VETERANS; CHILD-ABUSE; LIFE EVENTS; GULF-WAR; DISORDER; SYMPTOMS AB Objective: Sexual trauma during military service is increasingly recognized as a substantial public health problem and is associated with detrimental effects on veteran mental health. In this study, we examined associations between childhood trauma, military sexual trauma (MST), combat exposure, and military-related posttraumatic stress symptomatology (PTSS) in the Women Veterans Cohort Study (WVCS), a community-based sample of veterans who served in the recent conflicts in Iraq and Afghanistan. Method: From July 2008 to December 2011, 365 female veterans completed a survey that assessed combat exposure, military sexual trauma, military-related PTSS (assessed using the PTSD [posttraumatic stress disorder] Checklist-Military Version), and demographic, life history, and other psychopathology variables. Results: High rates of childhood trauma (59.7%) and MST (sexual assault = 14.7%; sexual harassment = 34.8%) were observed in this sample. A hierarchical regression revealed that active duty status, childhood trauma, combat exposure, and MST were independently associated with increased severity of military-related PTSS (Ps < .05). Moreover, a significant interaction emerged between MST and combat exposure in predicting military-related PTSS (P = .030), suggesting that the relationship between combat exposure and PTSS was altered by MST status. Specifically, under conditions of high combat exposure, female veterans with MST had significantly higher PTSS compared to female veterans without MST. Conclusions: Taken together, results suggest that exposure to multiple traumas during military service may have synergistic effects on posttraumatic stress symptoms in female veterans. Moreover, our findings highlight the importance of prevention efforts to protect female veterans from the detrimental effects of MST, particularly those who are exposed to high levels of combat. (C) Copyright 2014 Physicians Postgraduate Press, Inc. C1 [Scott, J. Cobb; Pietrzak, Robert H.; Southwick, Steven M.; Jordan, Jessica] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Scott, J. Cobb; Pietrzak, Robert H.; Southwick, Steven M.; Jordan, Jessica] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Scott, J. Cobb] Philadelphia VA Med Ctr, Vet Integrated Serv Network VISN, Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA 19104 USA. [Silliker, Norman; Brandt, Cynthia A.; Haskell, Sally G.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Brandt, Cynthia A.] Dept Emergency Med, New Haven, CT USA. [Brandt, Cynthia A.] Yale Ctr Med Informat, New Haven, CT USA. [Haskell, Sally G.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Scott, JC (reprint author), Philadelphia VA Med Ctr, MIRECC 116,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM scott1@mail.med.upenn.edu FU Veterans Administration (VA) Health Services Research and Development Service (HSRD) [DHI07-065]; Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder; VA Clinical Science & Research Developmental Award [IK2 CX000772] FX Funding for this study was provided by Veterans Administration (VA) Health Services Research and Development Service (HSR&D) grant #DHI07-065 to Drs Haskell and Brandt. Preparation of this report was also supported in part by the Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder and a VA Clinical Science & Research Developmental Award (IK2 CX000772) to Dr Scott. NR 64 TC 12 Z9 12 U1 3 U2 29 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUN PY 2014 VL 75 IS 6 BP 637 EP 643 DI 10.4088/JCP.13m08808 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AK5IO UT WOS:000338458200015 ER PT J AU van der Kolk, BA Stone, L West, J Rhodes, A Emerson, D Suvak, M Spinazzola, J AF van der Kolk, Bessel A. Stone, Laura West, Jennifer Rhodes, Alison Emerson, David Suvak, Michael Spinazzola, Joseph TI Yoga as an Adjunctive Treatment for Posttraumatic Stress Disorder: A Randomized Controlled Trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ADVERSE CHILDHOOD EXPERIENCES; LOW-BACK-PAIN; BRAIN GABA LEVELS; MINDFULNESS MEDITATION; PSYCHOMETRIC PROPERTIES; CLINICAL-IMPLICATIONS; EXPOSURE THERAPY; EXTREME STRESS; ANXIETY; PTSD AB Background: More than a third of the approximately 10 million women with histories of interpersonal violence in the United States develop posttraumatic stress disorder (PTSD). Currently available treatments for this population have a high rate of incomplete response, in part because problems in affect and impulse regulation are major obstacles to resolving PTSD. This study explored the efficacy of yoga to increase affect tolerance and to decrease PTSD symptomatology. Method: Sixty-four women with chronic, treatment-resistant PTSD were randomly assigned to either trauma-informed yoga or supportive women's health education, each as a weekly 1-hour class for 10 weeks. Assessments were conducted at pretreatment, midtreatment, and posttreatment and included measures of DSM-IV PTSD, affect regulation, and depression. The study ran from 2008 through 2011. Results: The primary outcome measure was the Clinician-Administered PTSD Scale (CAPS). At the end of the study, 16 of 31 participants (52%) in the yoga group no longer met criteria for PTSD compared to 6 of 29 (21%) in the control group (n = 60, chi(2)(1) = 6.17, P = .013). Both groups exhibited significant decreases on the CAPS, with the decrease falling in the large effect size range for the yoga group (d = 1.07) and the medium to large effect size decrease for the control group (d = 0.66). Both the yoga (b = -9.21, t = -2.34, P = .02, d = -0.37) and control (b = -22.12, t = -3.39, P = .001, d = -0.54) groups exhibited significant decreases from pretreatment to the midtreatment assessment. However, a significant group x quadratic trend interaction (d = -0.34) showed that the pattern of change in Davidson Trauma Scale significantly differed across groups. The yoga group exhibited a significant medium effect size linear (d = -0.52) trend. In contrast, the control group exhibited only a significant medium effect size quadratic trend (d = 0.46) but did not exhibit a significant linear trend (d = -0.29). Thus, both groups exhibited significant decreases in PTSD symptoms during the first half of treatment, but these improvements were maintained in the yoga group, while the control group relapsed after its initial improvement. Discussion: Yoga significantly reduced PTSD symptomatology, with effect sizes comparable to well-researched psychotherapeutic and psychopharmacologic approaches. Yoga may improve the functioning of traumatized individuals by helping them to tolerate physical and sensory experiences associated with fear and helplessness and to increase emotional awareness and affect tolerance. (C) Copyright 2014 Physicians Postgraduate Press, Inc. C1 [van der Kolk, Bessel A.; Stone, Laura; West, Jennifer; Rhodes, Alison; Emerson, David; Spinazzola, Joseph] Justice Resource Inst, Ctr Trauma, Brookline, MA 02446 USA. [van der Kolk, Bessel A.; Spinazzola, Joseph] Natl Child Traumat Stress Network, Brookline, MA USA. [van der Kolk, Bessel A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Suvak, Michael] Suffolk Univ, Natl Ctr PTSD, Boston, MA 02114 USA. [Suvak, Michael] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA. RP van der Kolk, BA (reprint author), Justice Resource Inst, Ctr Trauma, 1269 Beacon St, Brookline, MA 02446 USA. EM bessel1@mac.com FU US National Center for Complementary and Alternative Medicine (NCCAM) [1R21AT003905-01A2] FX This study was supported by grant 1R21AT003905-01A2 from the US National Center for Complementary and Alternative Medicine (NCCAM). NR 67 TC 22 Z9 22 U1 16 U2 81 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUN PY 2014 VL 75 IS 6 BP E559 EP E565 DI 10.4088/JCP.13m08561 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AK5IO UT WOS:000338458200003 PM 25004196 ER PT J AU Kagan, VE Kapralov, AA St Croix, CM Watkins, SC Kisin, ER Kotchey, GP Balasubramanian, K Vlasova, II Yu, J Kim, K Seo, W MallampaIli, RK Star, A Shvedova, AA AF Kagan, Valerian E. Kapralov, Alexandr A. St Croix, Claudette M. Watkins, Simon C. Kisin, Elena R. Kotchey, Gregg P. Balasubramanian, Krishnakumar Vlasova, Irina I. Yu, Jaesok Kim, Kang Seo, Wanji MallampaIli, Rama K. Star, Alexander Shvedova, Anna A. TI Lung Macrophages "Digest" Carbon Nanotubes Using a Superoxide/Peroxynitrite Oxidative Pathway SO ACS NANO LA English DT Article DE single-walled carbon nanotubes; peroxynitrite; biodegradation; lung ID DARK-FIELD MICROSCOPY; IN-VIVO; NITRIC-OXIDE; PULMONARY INFLAMMATION; REACTIVE OXYGEN; PEROXYNITRITE; CELLS; NANOPARTICLES; NANOMATERIALS; NEUTROPHILS AB In contrast to short-lived neutrophils, macrophages display persistent presence in the lung of animals after pulmonary exposure to carbon nanotubes. While effective in the clearance of bacterial pathogens and injured host cells, the ability of macrophages to "digest" carbonaceous nanoparticles has not been documented. Here, we used chemical, biochemical, and cell and animal models and demonstrated oxidative biodegradation of oxidatively functionalized single-walled carbon nanotubes via superoxide/NO* -> peroxynitrite-driven oxidative pathways of activated macrophages facilitating clearance of nanoparticles from the lung. C1 [Kagan, Valerian E.; Kapralov, Alexandr A.; Balasubramanian, Krishnakumar; Vlasova, Irina I.] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA. [MallampaIli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Pittsburgh, PA USA. [Kagan, Valerian E.; Kapralov, Alexandr A.; St Croix, Claudette M.; Balasubramanian, Krishnakumar; Vlasova, Irina I.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA. [Watkins, Simon C.] Univ Pittsburgh, Dept Physiol & Cell Biol, Pittsburgh, PA USA. [Kotchey, Gregg P.; Seo, Wanji; Star, Alexander] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA. [Yu, Jaesok; Kim, Kang; MallampaIli, Rama K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [MallampaIli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. [Shvedova, Anna A.] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV USA. [Vlasova, Irina I.] Res Inst Physicochem Med, Moscow 119495, Russia. RP Kagan, VE (reprint author), Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA. EM kagan@pitt.edu OI Kapralov, Oleksandr/0000-0002-3006-916X FU National Institute for Occupational Safety and Health (NIOSH) [OH008282]; National Institutes of Health, NIEHS [R01ES019304, U19AI068021, PO1HL114453]; RFBR [12-04-01293]; EPA STAR Graduate Fellowship [FP-91713801] FX This work was supported by the National Institute for Occupational Safety and Health (NIOSH), OH008282, and National Institutes of Health, NIEHS R01ES019304, U19AI068021, PO1HL114453, and RFBR 12-04-01293. G.P.K. acknowledges an EPA STAR Graduate Fellowship, FP-91713801. NR 50 TC 46 Z9 46 U1 0 U2 26 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1936-0851 EI 1936-086X J9 ACS NANO JI ACS Nano PD JUN PY 2014 VL 8 IS 6 BP 5610 EP 5621 DI 10.1021/nn406484b PG 12 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA AK0FV UT WOS:000338089200025 PM 24871084 ER PT J AU Shore, S Carey, EP Turakhia, MP Jackevicius, CA Cunningham, F Pilote, L Bradley, SM Maddox, TM Grunwald, GK Baron, AE Rumsfeld, JS Varosy, PD Schneider, PM Marzec, LN Ho, PM AF Shore, Supriya Carey, Evan P. Turakhia, Mintu P. Jackevicius, Cynthia A. Cunningham, Fran Pilote, Louise Bradley, Steven M. Maddox, Thomas M. Grunwald, Gary K. Baron, Anna E. Rumsfeld, John S. Varosy, Paul D. Schneider, Preston M. Marzec, Lucas N. Ho, P. Michael TI Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration SO AMERICAN HEART JOURNAL LA English DT Article ID ATRIAL-FIBRILLATION; ANTITHROMBOTIC TREATMENT; MEDICATION ADHERENCE; CLINICAL-PRACTICE; WARFARIN; ANTICOAGULATION; ETEXILATE; CARE; UNDERTREATMENT; CHALLENGES AB Background Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We aimed to describe adherence to dabigatran in the first year after initiation and assess the association between non-adherence to dabigatran and clinical outcomes in a large integrated healthcare system. Methods We studied a national cohort of 5,376 patients with NVAF, initiated on dabigatran between October-2010 and September-2012 at all Veterans Affairs hospitals. Adherence to dabigatran was calculated as proportion of days covered (PDC) and association between PDC and outcomes was assessed using standard regression techniques. Results Mean age of the study cohort was 71.3 +/- 9.7 years; 98.3% were men and mean CHADS(2) score was 2.4 +/- 1.2 (mean CHA(2)DS(2)VASc score 3.2 +/- 1.4). Median PDC was 94% (IQR 76%-100%; mean PDC 84% +/- 22%) over a median follow-up of 244 days (IQR 140-351). A total of 1,494 (27.8%) patients had a PDC <80% and were classified as non-adherent. After multivariable adjustment, lower adherence was associated with increased risk for combined all-cause mortality and stroke (HR 1.13, 95% CI 1.07-1.19 per 10% decrease in PDC). Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction. Conclusions In the year after initiation, adherence to dabigatran for a majority of patients is very good. However, 28% of patients in our cohort had poor adherence. Furthermore, lower adherence to dabigatran was associated with increased adverse outcomes. Concerted efforts are needed to optimize adherence to NOACs. C1 [Shore, Supriya; Carey, Evan P.; Bradley, Steven M.; Maddox, Thomas M.; Grunwald, Gary K.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA. [Shore, Supriya; Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Univ Colorado, Sch Med, Aurora, CO USA. [Shore, Supriya; Carey, Evan P.; Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Colorado Cardiovasc Outcomes Res Consortium, Denver, CO USA. [Carey, Evan P.; Grunwald, Gary K.; Baron, Anna E.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA. [Turakhia, Mintu P.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Turakhia, Mintu P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Jackevicius, Cynthia A.] Vet Affairs Greater Angeles Hlth Care Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA USA. [Cunningham, Fran] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. [Cunningham, Fran] Ctr Medicat Safety, Hines, IL USA. [Pilote, Louise] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. RP Ho, PM (reprint author), VA Eastern Colorado Hlth Care Syst, Cardiol Sect, 111B,1055 Clermont St, Denver, CO 80220 USA. EM michael.ho@va.gov FU NHLBI NIH HHS [T32 HL007822] NR 28 TC 47 Z9 47 U1 1 U2 11 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD JUN PY 2014 VL 167 IS 6 BP 810 EP 817 DI 10.1016/j.ahj.2014.03.023 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AK3US UT WOS:000338350800009 PM 24890529 ER PT J AU Meijers, WC Januzzi, JL deFilippi, C Adourian, AS Shah, SJ van Veldhuisen, DJ de Boer, RA AF Meijers, Wouter C. Januzzi, James L. deFilippi, Christopher Adourian, Aram S. Shah, Sanjiv J. van Veldhuisen, Dirk J. de Boer, Rudolf A. TI Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials SO AMERICAN HEART JOURNAL LA English DT Article ID NATRIURETIC PEPTIDE ASSAY; SYSTOLIC DYSFUNCTION; PROGNOSTIC VALUE; HF-ACTION; DYSPNEA; HOSPITALIZATION; MORTALITY; FIBROSIS; DISEASE; MARKER AB Background Rehospitalization is a major cause for heart failure (HF)-related morbidity and is associated with considerable loss of quality of life and costs. The rate of unplanned rehospitalization in patients with HF is unacceptably high; current risk stratification to identify patients at risk for rehospitalization is inadequate. We evaluated whether measurement of galectin-3 would be helpful in identifying patients at such risk. Methods We analyzed pooled data from patients (n = 902) enrolled in 3 cohorts (COACH, n = 592; PRIDE, n = 181; and UMD H-23258, n = 129) originally admitted because of HF. Mean patient age was between 61.6 and 72.9 years across the cohorts, with a wide range of left ventricular ejection fraction. Galectin-3 levels were measured during index admission. We used fixed and random-effects models, as well as continuous and categorical reclassification statistics to assess the association of baseline galectin-3 levels with risk of postdischarge rehospitalization at different time points and the composite end point all-cause mortality and rehospitalization. Results Compared with patients with galectin-3 concentrations less than 17.8 ng/mL, those with results exceeding this value were significantly more likely to be rehospitalized for HF at 30, 60, 90, and 120 days after discharge, with odds ratios (ORs) of 2.80 (95% CI 1.41-5.57), 2.61 (95% CI 1.46-4.65), 3.01 (95% CI 1.79-5.05), and 2.79 (95% CI 1.75-4.45), respectively. After adjustment for age, gender, New York Heart Association class, renal function (estimated glomerular filtration rate), left ventricular ejection fraction, and B-type natriuretic peptide, galectin-3 remained an independent predictor of HF rehospitalization. The addition of galectin-3 to risk models significantly reclassified patient risk of postdischarge rehospitalization and fatal event at each time point (continuous net reclassification improvement at 30 days of +42.6% [95% CI + 19.9%-65.4%], P < .001). Conclusions Among patients hospitalized for HF, plasma galectin-3 concentration is useful for the prediction of near-term rehospitalization. C1 [Meijers, Wouter C.; van Veldhuisen, Dirk J.; de Boer, Rudolf A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [deFilippi, Christopher] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Adourian, Aram S.] BG Med, Waltham, MA USA. [Shah, Sanjiv J.] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA. RP de Boer, RA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, POB 30-001, Groningen, Netherlands. EM r.a.de.boer@umcg.nl FU BG Medicine; Critical Diagnostics; Roche; Singulex; Abbott; AstraZeneca; Novartis; Pfizer; Baxter; Radiometer; Healtcare Diagnostics Laboratory; Siemens FX J.L.J. and R.A.d.B. have received grant support from BG Medicine. J.L.J. and C.d.F. have received grants from Critical Diagnostics, Roche, and Singulex. C.d.F. has received consultancies from Radiometer, Healtcare Diagnostics Laboratory, and Siemens. R.A.d.B. received research grants and or speaker's fees from Abbott, BG Medicine, AstraZeneca, Novartis, Pfizer, Baxter, and Novartis. The University Medical Center Groningen, where W.C.M., D.J.v.V., and R.A.d.B. are employed, has received research grants from BG Medicine. A.S.A. is employed by BG Medicine and has ownership interest. NR 44 TC 39 Z9 39 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD JUN PY 2014 VL 167 IS 6 BP 853 EP U117 DI 10.1016/j.ahj.2014.02.011 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AK3US UT WOS:000338350800015 PM 24890535 ER PT J AU Sacks, GD Diggs, BS Hadjizacharia, P Green, D Salim, A Malinoski, DJ AF Sacks, Greg D. Diggs, Brian S. Hadjizacharia, Pantelis Green, Donald Salim, Ali Malinoski, Darren J. TI Reducing the rate of catheter-associated bloodstream infections in a surgical intensive care unit using the Institute for Healthcare Improvement central line bundle SO AMERICAN JOURNAL OF SURGERY LA English DT Article DE Catheter-associated line infections; Infection control; Central venous catheters; Quality improvement; Healthcare cost; Checklist ID PRACTICE GUIDELINES; PREVENTION; QUALITY AB BACKGROUND: Central line-associated bloodstream infections (CLABSIs) are a significant source of morbidity and mortality. This study sought to determine whether implementation of the Institute for Healthcare Improvement (IHI) Central Line Bundle would reduce the incidence of CLABSIs. METHODS: The IHI Central Line Bundle was implemented in a surgical intensive care unit. Patient demographics and the rate of CLABSIs per 1,000 catheter days were compared between the pre- and postintervention groups. Contemporaneous infection rates in an adjacent ICU were measured. RESULTS: Baseline demographics were similar between the pre- and postintervention groups. The rate of CLABSIs per catheter days decreased from 19/3,784 to 3/1,870 after implementation of the IHI Bundle (1.60 vs 5.02 CLABSIs per 1,000 catheter days; rate ratio .32 [.08 to .99, P < .05]). There was no significant change in CLABSIs in the control ICU. CONCLUSIONS: Implementation of the IHI Central Line Bundle reduced the incidence of CLABSIs in our SICU by 68%, preventing 12 CLABSIs, 2.5 deaths, and saving $198,600 annually. (C) 2014 Elsevier Inc. All rights reserved. C1 [Sacks, Greg D.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Diggs, Brian S.; Malinoski, Darren J.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. [Hadjizacharia, Pantelis; Green, Donald] Univ Arizona, Dept Surg, Tucson, AZ USA. [Salim, Ali] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Malinoski, Darren J.] Portland VA Med Ctr, Sect Surg Crit Care, Portland, OR USA. RP Malinoski, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. EM darren.malinoski@va.gov NR 24 TC 14 Z9 15 U1 0 U2 8 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 EI 1879-1883 J9 AM J SURG JI Am. J. Surg. PD JUN PY 2014 VL 207 IS 6 BP 817 EP 823 DI 10.1016/j.amjsurg.2013.08.041 PG 7 WC Surgery SC Surgery GA AK5BY UT WOS:000338440100003 PM 24576582 ER PT J AU Kim, J Lee, K Stott, R Zhao, G SooHoo, J Xiong, W Lian, M Fitzgerald, L Shi, S Deng, S Yeh, H Markmann, J AF Kim, J. Lee, K. Stott, R. Zhao, G. SooHoo, J. Xiong, W. Lian, M. Fitzgerald, L. Shi, S. Deng, S. Yeh, H. Markmann, J. TI TGF-b-Producing Regulatory B Cells Induce Regulatory T Cells and Promote Transplantation Tolerance. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Kim, J.; Lee, K.; Stott, R.; Zhao, G.; SooHoo, J.; Xiong, W.; Lian, M.; Fitzgerald, L.; Shi, S.; Deng, S.; Yeh, H.; Markmann, J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Zhao, G.; Xiong, W.; Deng, S.] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 658 BP 20 EP 20 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300059 ER PT J AU Kim, J Lee, K Stott, R SooHoo, J Yeh, H Markmann, J AF Kim, J. Lee, K. Stott, R. SooHoo, J. Yeh, H. Markmann, J. TI NKT Cells May Play a Role in B Cell-Dependent Transplant Tolerance. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 1414 BP 28 EP 28 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300087 ER PT J AU Oura, T Hotta, K Cosimi, B Benichou, G Kawai, T AF Oura, T. Hotta, K. Cosimi, B. Benichou, G. Kawai, T. TI Suppression of CD8(+) Memory T Cell Proliferation and Expansion of T Regulatory Cells By Bone Marrow Derived Autologous Mesenchymal Stem Cells in Nonhuman Primates SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Oura, T.; Hotta, K.; Cosimi, B.; Benichou, G.; Kawai, T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplant Ctr, Boston, MA USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 2274 BP 43 EP 43 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300146 ER PT J AU Boneschansker, L Bruneau, S Nakayama, H Yan, J Wong, E Irimia, D Klagsbrun, M Briscoe, D AF Boneschansker, L. Bruneau, S. Nakayama, H. Yan, J. Wong, E. Irimia, D. Klagsbrun, M. Briscoe, D. TI Netrin-1 Is a Novel Molecule That Elicits Chemoattraction of Activated CD4+T-Lymphocytes Via Interactions With Neogenin. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Boneschansker, L.; Bruneau, S.; Nakayama, H.; Klagsbrun, M.; Briscoe, D.] Boston Childrens Hosp, Boston, MA USA. [Yan, J.; Wong, E.; Irimia, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 2899 BP 47 EP 47 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300160 ER PT J AU Tonsho, M Boskovic, S Lee, S Aoyama, A Smith, N Colvin, R Kawai, T Madsen, J Benichou, G Allan, J AF Tonsho, M. Boskovic, S. Lee, S. Aoyama, A. Smith, N. Colvin, R. Kawai, T. Madsen, J. Benichou, G. Allan, J. TI Successful Tolerance Induction of Lung Allografts in Non-Human Primates SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 2946 BP 48 EP 48 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300164 ER PT J AU Farkash, E Nicole, B Nickeleit, V Papadimitriou, J Roberts, I Emerson, L McDaid, J Colvin, R AF Farkash, E. Nicole, B. Nickeleit, V. Papadimitriou, J. Roberts, I. Emerson, L. McDaid, J. Colvin, R. TI T Antigen Dependent Oncogenic Pathways Are Active in Post-Transplant Tumors Driven By BK Polyoma Virus. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Farkash, E.] Univ Michigan, Ann Arbor, MI 48109 USA. [Farkash, E.; Nicole, B.; McDaid, J.; Colvin, R.] Mass Gen Hosp, Boston, MA USA. [Nickeleit, V.] Univ N Carolina, Chapel Hill, NC USA. [Papadimitriou, J.] Univ Maryland, Baltimore, MD 21201 USA. [Roberts, I.] Oxford Univ Hosp, Oxford, England. [Emerson, L.] Univ Utah, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 732 BP 86 EP 87 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300268 ER PT J AU Saidi, R Hertl, M Cosimi, A AF Saidi, R. Hertl, M. Cosimi, A. TI Outcomes of Full-Right-Full Left Split Liver Transplantation in Adults in US: A Propensity-Score Matched Ananlysis SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Saidi, R.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Hertl, M.; Cosimi, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 614 BP 157 EP 157 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300474 ER PT J AU op den Dries, S Westerkamp, A Karimian, N Gouw, A Bruinsma, B Markmann, J Lisman, T Yeh, H Uygun, K Martins, P Porte, R AF op den Dries, S. Westerkamp, A. Karimian, N. Gouw, A. Bruinsma, B. Markmann, J. Lisman, T. Yeh, H. Uygun, K. Martins, P. Porte, R. TI Injury to Peribiliary Glands and Vascular Plexus Before Liver Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [op den Dries, S.; Westerkamp, A.; Karimian, N.; Lisman, T.; Porte, R.] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Sect Hepatobiliary Surg & Liver Transplantat, Groningen, Netherlands. [op den Dries, S.; Markmann, J.; Yeh, H.; Martins, P.] Harvard Univ, Sch Med, Dept Surg, Div Transplantat,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Gouw, A.] Univ Groningen, Dept Pathol, Univ Med Ctr Groningen, Groningen, Netherlands. [Bruinsma, B.; Uygun, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med Surg Serv, Boston, MA USA. [Bruinsma, B.; Uygun, K.] Shriners Burns Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 2117 BP 175 EP 175 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300536 ER PT J AU Axelrod, D Smith, K Chaidarun, S Markmann, J Lei, J Freeman, R Gardner, T AF Axelrod, D. Smith, K. Chaidarun, S. Markmann, J. Lei, J. Freeman, R. Gardner, T. TI Total Pancreatectomy With Auto Islet Transplantation Using Offsite Recovery of Islets. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Axelrod, D.; Smith, K.; Freeman, R.] Dartmouth Hitchcock, Surg, Lebanon, NH USA. [Chaidarun, S.; Gardner, T.] Dartmouth Hitchcock, Med, Lebanon, NH USA. [Markmann, J.; Lei, J.] Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 597 BP 210 EP 210 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033300625 ER PT J AU De Wolf, S Morris, H Robins, H Kawai, T Shen, Y Sykes, M AF De Wolf, S. Morris, H. Robins, H. Kawai, T. Shen, Y. Sykes, M. TI Role of Deletion of Donor-Reactive T Cells in Long-Term Human Allograft Tolerance Achieved Via Combined Kidney and Bone Marrow Transplantation (CKBMT). SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [De Wolf, S.; Morris, H.; Shen, Y.; Sykes, M.] Columbia Univ, Med Ctr, New York, NY USA. [Robins, H.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Kawai, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 591 BP 221 EP 222 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301004 ER PT J AU Yamada, Y Ohura, T Hotta, K Tonsho, M Dehnadi, A Bernard-Stoecklin, S Smith, R Colvin, R Benichou, G Cosimi, B Kawai, T AF Yamada, Y. Ohura, T. Hotta, K. Tonsho, M. Dehnadi, A. Bernard-Stoecklin, S. Smith, R. Colvin, R. Benichou, G. Cosimi, B. Kawai, T. TI Novel ELISPOT-Based Assay to Detect Insidious Anti-Donor B Cell Response in Non-Human Primate Recipients Tolerant of MHC Mismatched Kidney Allografts. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Yamada, Y.; Ohura, T.; Hotta, K.; Tonsho, M.; Dehnadi, A.; Bernard-Stoecklin, S.; Smith, R.; Colvin, R.; Benichou, G.; Cosimi, B.; Kawai, T.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 592 BP 222 EP 222 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301005 ER PT J AU Hor, K Diefenbach, E Anderson, P Nankivell, B Chapman, J Alexander, S Rosales, I Colvin, R Murphy, B Webster, A O'Connell, P AF Hor, K. Diefenbach, E. Anderson, P. Nankivell, B. Chapman, J. Alexander, S. Rosales, I. Colvin, R. Murphy, B. Webster, A. O'Connell, P. TI Proteomic Analysis Identified Urine Proteins Predictive of Chronic Allograft Injury. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Hor, K.; Diefenbach, E.; Anderson, P.; Nankivell, B.; Chapman, J.; Alexander, S.; Webster, A.; O'Connell, P.] Westmead Millennium Inst, Sydney, NSW, Australia. [Rosales, I.; Colvin, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Murphy, B.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 1334 BP 224 EP 224 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301014 ER PT J AU Gao, B Moore, C Porcheray, F Rong, C Abidoglu, C DeVito, J Paine, R Girouard, T Saidman, S Schoenfeld, D Levin, B Wong, W Fu, Y Zom, E AF Gao, B. Moore, C. Porcheray, F. Rong, C. Abidoglu, C. DeVito, J. Paine, R. Girouard, T. Saidman, S. Schoenfeld, D. Levin, B. Wong, W. Fu, Y. Zom, E. TI Pre-Transplant IgG Reactivity to Apoptotic Cells Correlates With Late Kidney Allograft Loss. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Gao, B.; Moore, C.; Porcheray, F.; Rong, C.; Abidoglu, C.; DeVito, J.; Paine, R.; Girouard, T.; Saidman, S.; Schoenfeld, D.; Zom, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Gao, B.; Fu, Y.] Jilin Univ, Hosp 1, Changchun 130023, Peoples R China. [Rong, C.] Changchun Univ Chinese Med, Affiliated Hosp, Changchun, Peoples R China. [Levin, B.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Wong, W.] Columbia Univ, New York Presbyterian Hosp, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 1435 BP 225 EP 225 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301017 ER PT J AU Gao, B Rong, C Porcheray, F Moore, C Girouard, T Saidman, S Wong, W Zorn, E AF Gao, B. Rong, C. Porcheray, F. Moore, C. Girouard, T. Saidman, S. Wong, W. Zorn, E. TI Polyreactive Antibodies Crossreactive to HLA and Self-Antigens Contribute to Overall Serum Reactivity. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Gao, B.; Rong, C.; Porcheray, F.; Moore, C.; Girouard, T.; Saidman, S.; Zorn, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Gao, B.] Jilin Univ, Hosp 1, Changchun 130023, Peoples R China. [Rong, C.] Changchun Univ Chinese Med, Affiliated Hosp, Changchun, Peoples R China. [Wong, W.] Columbia Univ Med Ctr, New York Presbyterian Hosp, Div Nephrol, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA 1437 BP 226 EP 226 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301019 ER PT J AU Chen, G Ko, D Wang, C Yuan, X Qin, J Han, M Lai, X He, X Chen, L AF Chen, G. Ko, D. Wang, C. Yuan, X. Qin, J. Han, M. Lai, X. He, X. Chen, L. TI Impact of Machine Perfusion On Outcomes of Kidney Transplantation From Donation After Cardiac Death: A Prospective Randomized Controlled Trial. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Chen, G.; Wang, C.; Yuan, X.; Qin, J.; Han, M.; Lai, X.; He, X.; Chen, L.] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510275, Guangdong, Peoples R China. [Ko, D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA 02115 USA. [Ko, D.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Div Transplantat, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2675 BP 267 EP 267 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301168 ER PT J AU Boneschansker, L Yan, J Wong, E Irimia, D Briscoe, D AF Boneschansker, L. Yan, J. Wong, E. Irimia, D. Briscoe, D. TI Analyzing Chemorepulsion: A Critical Leukocyte Migration Pattern With Potential to Protect the Graft Microenvironment SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Boneschansker, L.; Briscoe, D.] Boston Childrens Hosp, Transplant Res Program, Boston, MA USA. [Yan, J.; Wong, E.; Irimia, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA A96 BP 292 EP 292 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301263 ER PT J AU Bruinsma, B Ozer, S Geerts, S Chen, Y Golberg, A Weeder, P Rodriguez, D Uygun, K Yarmush, M Uygun, B AF Bruinsma, B. Ozer, S. Geerts, S. Chen, Y. Golberg, A. Weeder, P. Rodriguez, D. Uygun, K. Yarmush, M. Uygun, B. TI Tissue Engineered Human Liver Grafts SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Bruinsma, B.; Ozer, S.; Geerts, S.; Chen, Y.; Golberg, A.; Weeder, P.; Rodriguez, D.; Uygun, K.; Yarmush, M.; Uygun, B.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA A557 BP 301 EP 301 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301297 ER PT J AU Galan, Y Marina, J Trowell, A Tocco, G Benichou, G AF Galan, Y. Marina, J. Trowell, A. Tocco, G. Benichou, G. TI Effects of Lymphangiogenesis Blockade On Cell Trafficking, Alloimmunity and Rejection After Skin or Heart Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Galan, Y.; Marina, J.; Trowell, A.; Tocco, G.; Benichou, G.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B758 BP 306 EP 307 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301316 ER PT J AU Gans, J Ndishabandi, D Shinoda, K Madsen, J Colvin, R Alessandrini, A AF Gans, J. Ndishabandi, D. Shinoda, K. Madsen, J. Colvin, R. Alessandrini, A. TI Allogeneic Murine Plasmacytold Dendritic Cells Induce Regulatory T Cells In Vitro Which Can Prolong Cardiac Allograft Survival In Vivo SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Gans, J.; Ndishabandi, D.; Shinoda, K.; Madsen, J.; Colvin, R.; Alessandrini, A.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. [Gans, J.] Sarnoff Cardiovasc Res Fdn, Great Falls, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B761 BP 307 EP 307 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301319 ER PT J AU Marino, J Tocco, G Mordecai, S Benichou, G AF Marino, J. Tocco, G. Mordecai, S. Benichou, G. TI Trafficking of Infra-Graft Donor T Cells After Skin Transplantation in Mice. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Marino, J.; Tocco, G.; Benichou, G.] Massachusetts Gen Hosp, Dept Surg, Transplantat Res Ctr, Boston, MA 02114 USA. [Marino, J.; Tocco, G.; Mordecai, S.; Benichou, G.] Harvard Univ, Sch Med, Boston, MA USA. [Mordecai, S.] Massachusetts Gen Hosp, Dept Pathol, Flow & Imaging Cytometry Core, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B759 BP 307 EP 307 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301317 ER PT J AU Madariaga, M Michel, S La Muraglia, G Harrington, E Connolly, J Selkirk, W Farkash, E Allan, J Chen, Y Sachs, D Wang, Z Madsen, J Huang, C AF Madariaga, M. Michel, S. La Muraglia, G., II Harrington, E., Jr. Connolly, J. Selkirk, W. Farkash, E. Allan, J. Chen, Y. Sachs, D. Wang, Z. Madsen, J. Huang, C. TI Depletion of T Regulatory Cells By Novel Bivalent IL2 Fusion Toxin in Miniature Swine SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Madariaga, M.; Michel, S.; La Muraglia, G., II; Harrington, E., Jr.; Connolly, J.; Selkirk, W.; Farkash, E.; Allan, J.; Sachs, D.; Wang, Z.; Madsen, J.; Huang, C.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. [Madariaga, M.; Michel, S.; La Muraglia, G., II; Harrington, E., Jr.; Connolly, J.; Selkirk, W.; Farkash, E.; Allan, J.; Chen, Y.; Sachs, D.; Wang, Z.; Madsen, J.; Huang, C.] Harvard Univ, Sch Med, Boston, MA USA. [Chen, Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B1143 BP 314 EP 314 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301345 ER PT J AU Schuetz, C Lei, J Machaidze, Z Saidman, S Yeh, H Kim, J Shi, S Zhang, X Wei, L Soohoo, J Wang, T Markmann, J AF Schuetz, C. Lei, J. Machaidze, Z. Saidman, S. Yeh, H. Kim, J. Shi, S. Zhang, X. Wei, L. Soohoo, J. Wang, T. Markmann, J. TI Challenges in Pre-Clinical Transplantation of Encapsulated Xenogenic Islets SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Schuetz, C.; Lei, J.; Machaidze, Z.; Yeh, H.; Kim, J.; Shi, S.; Zhang, X.; Wei, L.; Soohoo, J.; Markmann, J.] Massachusetts Gen Hosp, Transplant Surg Div, Boston, MA 02114 USA. [Saidman, S.] Massachusetts Gen Hosp, Histocompatibil Lab, Boston, MA 02114 USA. [Shi, S.; Wang, T.] Vanderbilt Univ, Sch Engn, Nashville, TN 37235 USA. RI Schuetz, Christian/K-5234-2013 OI Schuetz, Christian/0000-0002-6828-4543 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA C1559 BP 332 EP 332 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301414 ER PT J AU Karimian, N op den Dries, S Westerkamp, A Gouw, A Markmann, J Lisman, T Yeh, H Uygun, K Martins, P Porte, R AF Karimian, N. op den Dries, S. Westerkamp, A. Gouw, A. Markmann, J. Lisman, T. Yeh, H. Uygun, K. Martins, P. Porte, R. TI Injury of Peribiliary Glands and Vascular Plexus Before Liver Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Karimian, N.; op den Dries, S.; Westerkamp, A.; Lisman, T.; Porte, R.] Univ Med Ctr Groningen, Dept Surg, Sect Hepatopancreatobiliary Surg & Liver Transpla, Groningen, Netherlands. [Gouw, A.] Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands. [op den Dries, S.; Markmann, J.; Yeh, H.; Uygun, K.; Martins, P.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA C1651 BP 342 EP 342 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301453 ER PT J AU Schuetz, C Patti, M Cagliero, E Crisalli, K Yeh, H Lillemoe, K Markmann, J AF Schuetz, C. Patti, M. Cagliero, E. Crisalli, K. Yeh, H. Lillemoe, K. Markmann, J. TI Recurrent Hypoglycemia Following Total Pancreatectomy and Islet Autotransplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Schuetz, C.; Crisalli, K.; Yeh, H.; Markmann, J.] Massachusetts Gen Hosp, Transplant Surg Div, Boston, MA 02114 USA. [Lillemoe, K.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Cagliero, E.] Massachusetts Gen Hosp, Diabet Ctr, Boston, MA 02114 USA. [Patti, M.] Joslin Diabet Ctr, Boston, MA 02215 USA. RI Schuetz, Christian/K-5234-2013 OI Schuetz, Christian/0000-0002-6828-4543 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA C1708 BP 358 EP 358 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301510 ER PT J AU Michel, S La Muraglia, G Madariaga, M Allan, J Titus, J Selig, M Farkash, E Anderson, L Madsen, J AF Michel, S. La Muraglia, G., II Madariaga, M. Allan, J. Titus, J. Selig, M. Farkash, E. Anderson, L. Madsen, J. TI Superior Donor Heart Preservation Using Hypothermic Oxygenated Perfusion. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Michel, S.; La Muraglia, G., II; Madariaga, M.; Allan, J.; Titus, J.; Madsen, J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA. [Selig, M.; Farkash, E.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Anderson, L.] Paragonix Technol, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA C2053 BP 370 EP 370 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301555 ER PT J AU Bruinsma, B Sridharan, G Weeder, P Izamis, M Martins, P Yeh, H Uygun, K AF Bruinsma, B. Sridharan, G. Weeder, P. Izamis, M. Martins, P. Yeh, H. Uygun, K. TI Indicators of Liver Viability in the Ex Vivo Perfused Human Liver. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Bruinsma, B.; Sridharan, G.; Weeder, P.; Izamis, M.; Uygun, K.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. [Martins, P.] Massachusetts Gen Hosp, Transplant Unit, Boston, MA 02114 USA. [Yeh, H.] UMass Mem, Transplant Surg, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA C2065 BP 373 EP 374 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301567 ER PT J AU Farris, A Farkash, E Della Pelle, P Collins, A Smith, R Colvin, R AF Farris, A. Farkash, E. Della Pelle, P. Collins, A. Smith, R. Colvin, R. TI Activated NK Cells in Glomeruli Are Characteristic of Chronic Antibody Mediated Rejection SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Farris, A.] Emory Univ, Atlanta, GA 30322 USA. [Farkash, E.] Univ Michigan, Ann Arbor, MI 48109 USA. [Della Pelle, P.; Collins, A.; Smith, R.; Colvin, R.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2310 BP 381 EP 382 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301596 ER PT J AU Marino, J Trowell, A Singh, P Benichou, G AF Marino, J. Trowell, A. Singh, P. Benichou, G. TI B Cell Depletion Prevents the Development of Memory T Cell Direct Alloreactivity After Allotransplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Marino, J.; Trowell, A.; Singh, P.; Benichou, G.] Harvard Univ, Sch Med, Dept Surg, Transplantat Res Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2324 BP 386 EP 386 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301610 ER PT J AU Marino, J Galan, Y Trowell, A Benichou, G AF Marino, J. Galan, Y. Trowell, A. Benichou, G. TI B Cell Depletion Promotes the Development of Donor Hematopoietic Chimerism SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Marino, J.; Galan, Y.; Trowell, A.; Benichou, G.] Harvard Univ, Sch Med, Dept Surg, Transplantat Res Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2329 BP 387 EP 387 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301615 ER PT J AU Navarro-Alvarez, N Zhu, A Arellano, R Randolph, M Duggan, M Am, J Sachs, D Vagefi, P AF Navarro-Alvarez, N. Zhu, A. Arellano, R. Randolph, M. Duggan, M. Am, J. Sachs, D. Vagefi, P. TI Post-Natal B-Cell Tolerance Following In-Utero Intraportal Injection of Xenogeneic Cells SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Navarro-Alvarez, N.; Zhu, A.; Arellano, R.; Randolph, M.; Duggan, M.; Am, J.; Sachs, D.; Vagefi, P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2333 BP 388 EP 388 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301619 ER PT J AU McDaid, J Markmann, J Kim, J AF McDaid, J. Markmann, J. Kim, J. TI Bespoke Immunosuppression: Targeting Alloreactive T-Cells Using c-FLIP siRNA Prolongs Allograft Survival SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [McDaid, J.] Queens Univ Belfast, Belfast, Antrim, North Ireland. [Markmann, J.; Kim, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2757 BP 392 EP 392 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301634 ER PT J AU Kim, J Stott, R Soohoo, J Lee, K Zhao, G Yeh, H Deng, S Markmann, J AF Kim, J. Stott, R. Soohoo, J. Lee, K. Zhao, G. Yeh, H. Deng, S. Markmann, J. TI Elevated Levels of Interferon-gamma Production By Memory T Cells Do Not Promote Transplant Tolerance Resistance in Aged Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Kim, J.; Stott, R.; Soohoo, J.; Lee, K.; Zhao, G.; Yeh, H.; Deng, S.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kim, J.; Stott, R.; Soohoo, J.; Lee, K.; Zhao, G.; Yeh, H.; Deng, S.; Markmann, J.] Harvard Univ, Sch Med, Boston, MA USA. [Zhao, G.; Deng, S.] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China. [Zhao, G.; Deng, S.] Sichuan Acad Med Sci, Chengdu, Sichuan, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2768 BP 395 EP 395 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301645 ER PT J AU Cameron, A Wesson, R Singer, A Wang, Y Hu, X Okabayashi, T Sachs, D Arn, S Abdullah, K Delone, P Ruben, D Montgomery, R Williams, M Sun, Z AF Cameron, A. Wesson, R. Singer, A. Wang, Y. Hu, X. Okabayashi, T. Sachs, D. Arn, S. Abdullah, K. Delone, P. Ruben, D. Montgomery, R. Williams, M. Sun, Z. TI Endogenous Stem Cell Mobilization Via CXCR4 Antagonism Allows for Drug Free Kidney Transplantation in a Large Animal Preclinical Model. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Cameron, A.; Wesson, R.; Singer, A.; Wang, Y.; Hu, X.; Okabayashi, T.; Ruben, D.; Montgomery, R.; Williams, M.; Sun, Z.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Abdullah, K.; Delone, P.] Genzyme Sanofi, Cambridge, MA USA. [Sachs, D.; Arn, S.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2780 BP 397 EP 398 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301657 ER PT J AU Kato, Y Griesemer, A Duran-Struuck, R Wu, A Woodland, D Weiner, J Ohmura, Y Martinez, M Alonso, P Baker, S Karolewski, B Lefkowitch, J Kawai, T Kato, T Sykes, M AF Kato, Y. Griesemer, A. Duran-Struuck, R. Wu, A. Woodland, D. Weiner, J. Ohmura, Y. Martinez, M. Alonso, P. Baker, S. Karolewski, B. Lefkowitch, J. Kawai, T. Kato, T. Sykes, M. TI The First Tolerance Induction Model for Combined Liver and Donor Bone Marrow Transplantation in Cynomolgus Monkey SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Kato, Y.; Griesemer, A.; Woodland, D.; Weiner, J.; Ohmura, Y.; Kato, T.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Kato, Y.; Griesemer, A.; Duran-Struuck, R.; Wu, A.; Woodland, D.; Weiner, J.; Ohmura, Y.; Alonso, P.; Sykes, M.] Columbia Univ, Columbia Ctr Translat Immunol, New York, NY USA. [Martinez, M.; Lefkowitch, J.] Columbia Univ, New York, NY USA. [Duran-Struuck, R.; Baker, S.; Karolewski, B.] Columbia Univ, Inst Comparat Med, New York, NY USA. [Kawai, T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2782 BP 398 EP 398 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301659 ER PT J AU Madariaga, M Michel, S La Muraglia, G Villani, V Sejikima, M Leonard, D Powell, H Farkash, E Colvin, R Allan, J Cetrulo, C Huang, C Sachs, D Yamada, K Madsen, J AF Madariaga, M. Michel, S. La Muraglia, G., II Villani, V. Sejikima, M. Leonard, D. Powell, H. Farkash, E. Colvin, R. Allan, J. Cetrulo, C., Jr. Huang, C. Sachs, D. Yamada, K. Madsen, J. TI Assessing the Renal Elements Responsible for Kidney-Induced Cardiac Allograft Tolerance in Miniature Swine SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2781 BP 398 EP 398 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301658 ER PT J AU Tonsho, M Benichou, G Boskovic, S Nadazdin, O Smith, N Allan, J Colvin, R Sachs, D Cosimi, A Kawai, T Madsen, J AF Tonsho, M. Benichou, G. Boskovic, S. Nadazdin, O. Smith, N. Allan, J. Colvin, R. Sachs, D. Cosimi, A. Kawai, T. Madsen, J. TI Delayed Induction of Mixed Chimerism Permits Kidney-Induced Cardiac Allograft Tolerance to Be Applied to Recipients of Cadaveric Heart Allografts SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Tonsho, M.; Benichou, G.; Boskovic, S.; Nadazdin, O.; Smith, N.; Allan, J.; Colvin, R.; Cosimi, A.; Kawai, T.; Madsen, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tonsho, M.; Benichou, G.; Boskovic, S.; Nadazdin, O.; Smith, N.; Allan, J.; Colvin, R.; Sachs, D.; Cosimi, A.; Kawai, T.; Madsen, J.] Harvard Univ, Sch Med, Boston, MA USA. [Allan, J.; Sachs, D.; Madsen, J.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2783 BP 398 EP 398 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301660 ER PT J AU Shinoda, K Akiyoshi, T Chase, C Farkash, E Russell, P Madsen, J Colvin, R Alessandrini, A AF Shinoda, K. Akiyoshi, T. Chase, C. Farkash, E. Russell, P. Madsen, J. Colvin, R. Alessandrini, A. TI Depletion of Foxp3(+) T Cells Abrogates Tolerance of Organ Allografts in Murine Mixed Chimeras Without Inducing Recipient Reactivity to Donor Hematopoietic Cells SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Shinoda, K.; Akiyoshi, T.; Chase, C.; Farkash, E.; Russell, P.; Madsen, J.; Colvin, R.; Alessandrini, A.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. [Shinoda, K.; Chase, C.; Farkash, E.; Russell, P.; Madsen, J.; Colvin, R.; Alessandrini, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2785 BP 399 EP 399 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301662 ER PT J AU La Muraglia, G Madariaga, M Michel, S Mordecai, K Preffer, F Hanekamp, I Madsen, J AF La Muraglia, G., II Madariaga, M. Michel, S. Mordecai, K. Preffer, F. Hanekamp, I. Madsen, J. TI A Novel Approach to the Quantification and Characterization of Cell Mediated Cytotoxicity Using the Amnis ImageStream(x) SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [La Muraglia, G., II; Madariaga, M.; Michel, S.; Hanekamp, I.; Madsen, J.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. [Michel, S.] Univ Munich, Munich, Germany. [Mordecai, K.; Preffer, F.; Madsen, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [La Muraglia, G., II; Madariaga, M.; Michel, S.; Hanekamp, I.; Madsen, J.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2794 BP 401 EP 401 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301671 ER PT J AU Hotta, K Aoyama, A Oura, T Tonsho, M Yamada, Y Allan, J Madsen, J Cosimi, B Kawai, T AF Hotta, K. Aoyama, A. Oura, T. Tonsho, M. Yamada, Y. Allan, J. Madsen, J. Cosimi, B. Kawai, T. TI Donor Specific Regulatory T-Cell Expansion Is Associated With the Maintenance of Allograft Tolerance Induced By Transient Mixed Chimerism SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Hotta, K.; Aoyama, A.; Oura, T.; Tonsho, M.; Yamada, Y.; Allan, J.; Madsen, J.; Cosimi, B.; Kawai, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2806 BP 404 EP 405 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301683 ER PT J AU Madariaga, M Michel, S La Muraglia, G Sihag, S Leonard, D Powell, H Farkash, E Colvin, R Cetrulo, C Huang, C Sachs, D Madsen, J Allan, J AF Madariaga, M. Michel, S. La Muraglia, G., II Sihag, S. Leonard, D. Powell, H. Farkash, E. Colvin, R. Cetrulo, C., Jr. Huang, C. Sachs, D. Madsen, J. Allan, J. TI Recipient-Matching of Passenger Leukocytes Prolongs Survival of Donor Lung Allografts in Miniature Swine SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2809 BP 405 EP 405 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301686 ER PT J AU Villani, V Scalea, J Gillon, B Sekijima, M Tasaki, M Cormack, T Sachs, D Yamada, K AF Villani, V. Scalea, J. Gillon, B. Sekijima, M. Tasaki, M. Cormack, T. Sachs, D. Yamada, K. TI Adoptive Transfer of Renal Allograft Tolerance in a Large Animal Model SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Villani, V.; Scalea, J.; Gillon, B.; Sekijima, M.; Tasaki, M.; Cormack, T.; Sachs, D.; Yamada, K.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2807 BP 405 EP 405 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301684 ER PT J AU Yeh, H Machaidze, Z Wamala, I Navarro-Alvarez, N Shi, S Zhu, A Hertl, M Elias, N Farkash, E Fraser, J Vagefi, P Smith, R Robson, S Van Cott, E Sachs, D Markmann, J AF Yeh, H. Machaidze, Z. Wamala, I. Navarro-Alvarez, N. Shi, S. Zhu, A. Hertl, M. Elias, N. Farkash, E. Fraser, J. Vagefi, P. Smith, R. Robson, S. Van Cott, E. Sachs, D. Markmann, J. TI Increased Transfusion-Free Survival Following Auxiliary Liver Xenotransplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Yeh, H.; Machaidze, Z.; Wamala, I.; Navarro-Alvarez, N.; Shi, S.; Zhu, A.; Hertl, M.; Elias, N.; Farkash, E.; Fraser, J.; Vagefi, P.; Smith, R.; Van Cott, E.; Sachs, D.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Robson, S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2845 BP 415 EP 415 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301722 ER PT J AU Alvarez, NN Machaidze, Z Hertl, M Vagefi, P Elias, N Buhler, L Sachs, D Markmann, J Yeh, H AF Alvarez, N. Navarro Machaidze, Z. Hertl, M. Vagefi, P. Elias, N. Buhler, L. Sachs, D. Markmann, J. Yeh, H. TI Auxiliary Liver Xenotransplantation Improves Liver Regeneration and Survival in 90% Hepatectomy Model of Liver Failure in Baboons. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Alvarez, N. Navarro; Machaidze, Z.; Hertl, M.; Vagefi, P.; Elias, N.; Sachs, D.; Markmann, J.; Yeh, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Buhler, L.] Univ Geneva, Sch Med, CH-1211 Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2849 BP 416 EP 416 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301726 ER PT J AU Tena, A Leonard, D Tasaki, M Mallard, C Germana, S Farkash, E Mastroianni, M Sachs, D Hawley, R AF Tena, A. Leonard, D. Tasaki, M. Mallard, C. Germana, S. Farkash, E. Mastroianni, M. Sachs, D. Hawley, R. TI Initial Evidence for Functional Immune Modulation in Primate Recipients of Porcine Skin Grafts Following Conditioning With Human CD47 Transgenic Pig Hematopoietic Stem Cells. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Tena, A.; Leonard, D.; Tasaki, M.; Mallard, C.; Germana, S.; Farkash, E.; Mastroianni, M.; Sachs, D.; Hawley, R.] Massachusetts Gen Hosp, Transplant Biol Res Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2854 BP 417 EP 417 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033301731 ER PT J AU Elias, N Ko, D Farrell, M Shao, S Crisalli, K Tolkoff-Rubin, N Cosimi, B AF Elias, N. Ko, D. Farrell, M. Shao, S. Crisalli, K. Tolkoff-Rubin, N. Cosimi, B. TI Dactinomycin Based Immunosuppression Maintains Long Term Renal Graft Survival. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Elias, N.; Ko, D.; Farrell, M.; Shao, S.; Crisalli, K.; Tolkoff-Rubin, N.; Cosimi, B.] Massachusetts Gen Hosp, Transplant Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA A217 BP 462 EP 462 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033302096 ER PT J AU Farkash, E Brousades, N Farrell, M Della Pelle, T Colvin, R AF Farkash, E. Brousades, N. Farrell, M. Della Pelle, T. Colvin, R. TI BK Polyoma Virus Drives a Subset of Kidney and Bladder Cancers in Solid Organ Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Farkash, E.; Brousades, N.; Farrell, M.; Della Pelle, T.; Colvin, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Farkash, E.] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B1017 BP 555 EP 555 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033302423 ER PT J AU Chandran, S Arroyo, D Vagefi, P Wojciechowski, D AF Chandran, S. Arroyo, D. Vagefi, P. Wojciechowski, D. TI Adjuvant Ciprofloxacin Therapy for Refractory BK Polyomavirus Infection in Kidney Transplant Recipients. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Chandran, S.; Wojciechowski, D.] UCSF, San Francisco, CA USA. [Arroyo, D.] Univ Gregorio Maranon, Gen Hosp, Madrid, Spain. [Vagefi, P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B1037 BP 560 EP 560 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033302443 ER PT J AU Cardarelli, F Kandula, P Greka, A Mundel, P Weins, A Riella, L AF Cardarelli, F. Kandula, P. Greka, A. Mundel, P. Weins, A. Riella, L. TI Analysis of Glomerular B7-1 Staining in Renal Allograft Biopsies. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA C1787 BP 577 EP 577 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033302506 ER PT J AU Adler, J Yeh, H Markmann, J AF Adler, J. Yeh, H. Markmann, J. TI Risk Factors Associated With Renal Allograft Thrombosis and Obstacles to Re-Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Adler, J.; Yeh, H.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2531 BP 644 EP 644 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033302745 ER PT J AU Satomi, M Bracamonte-Baran, W Jankowska-Gan, E Shea, S Benichou, G Burlingham, W AF Satomi, M. Bracamonte-Baran, W. Jankowska-Gan, E. Shea, S. Benichou, G. Burlingham, W. TI Can Bi-Directional Regulation Play a Beneficial Role in Skin Allograft Survival? SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Satomi, M.] Osaka City Univ, Dept Surg, Osaka 558, Japan. [Satomi, M.; Bracamonte-Baran, W.; Jankowska-Gan, E.; Burlingham, W.] Univ Wisconsin, Dept Surg, Madison, WI USA. [Shea, S.; Benichou, G.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA A2973 BP 660 EP 660 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303002 ER PT J AU Faustman, D Mera, T AF Faustman, D. Mera, T. TI Removal of Donor HLA Class I Proteins with Papain: Translation for Possible Whole Organ Practices SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 Massachusetts Gen Hosp, Immunobiol Labs, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA C3039 BP 678 EP 678 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303067 ER PT J AU Weeder, P op den Dries, S Yeh, H Markmann, J Uygun, K Porte, R Martins, P AF Weeder, P. op den Dries, S. Yeh, H. Markmann, J. Uygun, K. Porte, R. Martins, P. TI Identification of Donor Factors Associated With Pretransplant Injury of The Donor Bile Duct and The Occurence of Non-Anastomotic Biliary Strictures After Liver Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Weeder, P.; op den Dries, S.; Porte, R.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Weeder, P.; Yeh, H.; Markmann, J.] Massachusetts Gen Hosp, Transplant Div, Boston, MA 02114 USA. [Weeder, P.; Uygun, K.] Harvard Univ, Sch Med, Ctr Engn Med, Boston, MA USA. [Martins, P.] Umass Mem Med Ctr, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B1074 BP 722 EP 722 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303227 ER PT J AU Adler, J Dong, N Nguyen, L Schoenfeld, D Markmann, J Yeh, H AF Adler, J. Dong, N. Nguyen, L. Schoenfeld, D. Markmann, J. Yeh, H. TI Longer Liver Transplant Waiting Lists Associated With Sicker Patients in Donor Service Areas SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Adler, J.; Dong, N.; Markmann, J.; Yeh, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nguyen, L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Schoenfeld, D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B1089 BP 726 EP 727 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303242 ER PT J AU Schaenman, J Morris, M Kotton, C Danziger-Isakov, L Kumar, D AF Schaenman, J. Morris, M. Kotton, C. Danziger-Isakov, L. Kumar, D. TI Medical Center Support for Transplant Infectious Diseases Programs SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Schaenman, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA. [Morris, M.] Univ Miami, Miller Sch Med, Div Infect Dis, Dept Med, Miami, FL 33136 USA. [Kotton, C.] Mass Gen Hosp, Div Infect Dis, Dept Med, Boston, MA USA. [Danziger-Isakov, L.] Cincinnati Childrens, Dept Pediat, Cincinnati, OH USA. [Kumar, D.] Univ Hlth Network, Multi Organ Transplant Program, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2395 BP 771 EP 772 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303403 ER PT J AU Donnelly, J Wang, H Locke, J Mannon, R Baddley, J AF Donnelly, J. Wang, H. Locke, J. Mannon, R. Baddley, J. TI Healthcare Facility-Associated Clostridium difficile Infection in Solid Organ Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Donnelly, J.; Wang, H.] Univ Alabama Birmingham, Dept Emergency Med, Birmingham, AL USA. [Locke, J.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Mannon, R.; Baddley, J.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Baddley, J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA D2397 BP 772 EP 772 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303405 ER PT J AU Yeh, H Markmann, J Hunsicker, L AF Yeh, H. Markmann, J. Hunsicker, L. TI Higher Income Associated With Lower Risk of Liver Disease But Higher Likelihood of Listing for Liver Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Yeh, H.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hunsicker, L.] Univ Iowa, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B827 BP 816 EP 816 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303548 ER PT J AU Adler, J Pratt, J Werger, N Marquez, A McLaughlin, E Markmann, J Yeh, H AF Adler, J. Pratt, J. Werger, N. Marquez, A. McLaughlin, E. Markmann, J. Yeh, H. TI Psychosocial and Economic Differences Between Donors and Recipients. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Adler, J.; Pratt, J.; Werger, N.; Marquez, A.; McLaughlin, E.; Markmann, J.; Yeh, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B842 BP 820 EP 820 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303563 ER PT J AU Adler, J Nguyen, L Markmann, J Yeh, H AF Adler, J. Nguyen, L. Markmann, J. Yeh, H. TI Socioeconomic Disparities Among Deceased Donors and Renal Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Adler, J.; Markmann, J.; Yeh, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nguyen, L.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B1226 BP 835 EP 836 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033303617 ER PT J AU Asselbergs, F Lord, G Snyder, M Birdwell, K Schadt, E Oetting, W Petersdorf, E MacArthur, D Shaked, A Keating, B AF Asselbergs, F. Lord, G. Snyder, M. Birdwell, K. Schadt, E. Oetting, W. Petersdorf, E. MacArthur, D. Shaked, A. Keating, B. TI The International Genomics & Translational Research in Transplantation Network (iGeneTrain). SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Asselbergs, F.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [Lord, G.] Guys & St Thomas Hosp, London SE1 9RT, England. [Lord, G.] Kings Coll London, London WC2R 2LS, England. [Snyder, M.] Stanford Univ, Stanford, CA 94305 USA. [Birdwell, K.] Vanderbilt Univ, Nashville, TN 37235 USA. [Schadt, E.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Oetting, W.] Univ Minnesota, Sch Pharm, Minneapolis, MN 55455 USA. [Petersdorf, E.] Univ Washington, Dept Hematol & Oncol, Seattle, WA 98195 USA. [MacArthur, D.] Harvard Univ, Sch Med, Broad Inst, Cambridge, MA 02138 USA. [MacArthur, D.] Massachusetts Gen Hosp, Cambridge, MA USA. [Shaked, A.; Keating, B.] Univ Penn, Transplant Inst, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA A521 BP 891 EP 891 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033304071 ER PT J AU Gao, B Rong, C Moore, C Porcheray, F Wong, W Kawai, T Sykes, M Cosimi, B Sachs, D Zorn, E AF Gao, B. Rong, C. Moore, C. Porcheray, F. Wong, W. Kawai, T. Sykes, M. Cosimi, B. Sachs, D. Zorn, E. TI Dynamics of B Cell Recovery in Tolerant Recipients of Combined Kidney Bone Marrow Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT World Transplant Congress CY JUL 26-31, 2014 CL San Francisco, CA C1 [Gao, B.; Rong, C.; Moore, C.; Porcheray, F.; Wong, W.; Kawai, T.; Cosimi, B.; Sachs, D.; Zorn, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Gao, B.] Jilin Univ, Hosp 1, Changchun 130023, Peoples R China. [Rong, C.] Changchun Univ Chinese Med, Affiliated Hosp, Changchun, Peoples R China. [Sykes, M.] Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 SU 3 MA B787 BP 896 EP 896 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ9LU UT WOS:000338033304089 ER PT J AU Saxena, R Bjonnes, A Prescott, J Dib, P Natt, P Lane, J Lerner, M Cooper, JA Ye, YQ Li, KW Maubaret, CG Codd, V Brackett, D Mirabello, L Kraft, P Dinney, CP Stowell, D Peyton, M Ralhan, S Wander, GS Mehra, NK Salpea, KD Gu, J Wu, XF Mangino, M Hunter, DJ De Vivo, I Humphries, SE Samani, NJ Spector, TD Savage, SA Sanghera, DK AF Saxena, Richa Bjonnes, Andrew Prescott, Jennifer Dib, Patrick Natt, Praveen Lane, Jacqueline Lerner, Megan Cooper, Jackie A. Ye, Yuanqing Li, Ka Wah Maubaret, Cecilia G. Codd, Veryan Brackett, Daniel Mirabello, Lisa Kraft, Peter Dinney, Colin P. Stowell, Donald Peyton, Marvin Ralhan, Sarju Wander, Gurpreet S. Mehra, Narinder K. Salpea, Klelia D. Gu, Jian Wu, Xifeng Mangino, Massimo Hunter, David J. De Vivo, Immaculata Humphries, Steve E. Samani, Nilesh J. Spector, Tim D. Savage, Sharon A. Sanghera, Dharambir K. TI Genome-Wide Association Study Identifies Variants in Casein Kinase II (CSNK2A2) to be Associated With Leukocyte Telomere Length in a Punjabi Sikh Diabetic Cohort SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE cardiovascular diseases; diabetes mellitus, type 2; genome-wide association study; telomere length ID CORONARY-HEART-DISEASE; ASIAN INDIAN SIKHS; WHITE BLOOD-CELLS; GENETIC-VARIATION; GENOTYPE IMPUTATION; ATHEROSCLEROSIS; LOCUS; RISK; SHORTER; PROTEIN AB Background-Telomere length is a heritable trait, and short telomere length has been associated with multiple chronic diseases. We investigated the relationship of relative leukocyte telomere length with cardiometabolic risk and performed the first genome-wide association study and meta-analysis to identify variants influencing relative telomere length in a population of Sikhs from South Asia. Methods and Results-Our results revealed a significant independent association of shorter relative telomere length with type 2 diabetes mellitus and heart disease. Our discovery genome-wide association study (n=1616) was followed by stage 1 replication of 25 top signals (P<10(-6)) in an additional Sikhs (n=2397). On combined discovery and stage 1 metaanalysis (n=4013), we identified a novel relative telomere length locus at chromosome 16q21 represented by an intronic variant (rs74019828) in the CSNK2A2 gene (beta=-0.38; P=4.5x10(-8)). We further tested 3 top variants by genotyping in UK cardiovascular disease (UKCVD) (whites n=2952) for stage 2. Next, we performed in silico replication of 139 top signals (P<10(-5)) in UK Twin, Nurses Heart Study, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, and MD Anderson Cancer Controls (n=10033) and joint meta-analysis (n=16998). The observed signal in CSNK2A2 was confined to South Asians and could not be replicated in whites because of significant difference in allele frequencies (P<0.001). CSNK2A2 phosphorylates telomeric repeat binding factor 1 and plays an important role for regulation of telomere length homoeostasis. Conclusions-By identification of a novel signal in telomere pathway genes, our study provides new molecular insight into the underlying mechanism that may regulate telomere length and its association with human aging and cardiometabolic pathophysiology. C1 [Saxena, Richa; Bjonnes, Andrew; Lane, Jacqueline] Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Prescott, Jennifer; Hunter, David J.; De Vivo, Immaculata] Brigham & Womens Hosp, Channing Div Network Med, Dept Med, Boston, MA 02115 USA. [Prescott, Jennifer; Hunter, David J.; De Vivo, Immaculata] Harvard Univ, Sch Med, Boston, MA USA. [Saxena, Richa; Bjonnes, Andrew; Lane, Jacqueline; Hunter, David J.] Massachusetts Inst Technol & Harvard, Broad Ins, Cambridge, MA USA. [Dib, Patrick; Natt, Praveen; Sanghera, Dharambir K.] Univ Oklahoma, Dept Pediat, Coll Med, Hlth Sci Ctr, Oklahoma City, OK 73104 USA. [Lerner, Megan; Brackett, Daniel; Stowell, Donald; Peyton, Marvin] Univ Oklahoma, Dept Surg, Hlth Sci Ctr, Oklahoma City, OK 73104 USA. [Prescott, Jennifer; Kraft, Peter; Hunter, David J.; De Vivo, Immaculata] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Dept Epidemiol, Boston, MA 02115 USA. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Cooper, Jackie A.; Li, Ka Wah; Maubaret, Cecilia G.; Salpea, Klelia D.; Humphries, Steve E.] UCL, BHF Labs, Inst Cardiovasc Sci, London, England. [Ye, Yuanqing; Gu, Jian; Wu, Xifeng] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA. [Codd, Veryan; Mangino, Massimo; Samani, Nilesh J.; Spector, Tim D.] Glenfield Hosp, Natl Inst Hlth Res, Leicester Cardiovasc Biomed Res Unit, Leicester, Leics, England. [Mirabello, Lisa; Savage, Sharon A.] NCI, Div Canc Epidemiol & Genet, NIH, US Dept HHS, Bethesda, MD 20892 USA. [Dinney, Colin P.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA. [Ralhan, Sarju; Wander, Gurpreet S.] Hero DMC Heart Inst, Ludhiana, Punjab, India. [Mehra, Narinder K.] All India Inst Med Sci & Res, New Delhi, India. RP Sanghera, DK (reprint author), Univ Oklahoma, Dept Pediat, Coll Med, Hlth Sci Ctr, 940 Stanton L Young Blvd,Rm 317 BMSB, Oklahoma City, OK 73104 USA. EM Dharambir-sanghera@ouhsc.edu RI Savage, Sharon/B-9747-2015; mangino, massimo/F-5134-2011; OI Savage, Sharon/0000-0001-6006-0740; mangino, massimo/0000-0002-2167-7470; Humphries, Stephen E/0000-0002-8221-6547 FU National Institutes of Health - National Institute of Diabetes and Digestive and Kidney Diseases [R01DK082766]; National Genome Research Institute [NOT-HG-11-009]; Vice President for Research Bridge grant from University of Oklahoma Health Sciences Center, Oklahoma City, OK FX This work was partly supported by National Institutes of Health grants-R01DK082766 funded by the National Institute of Diabetes and Digestive and Kidney Diseases and NOT-HG-11-009 funded by National Genome Research Institute and Vice President for Research Bridge grant from University of Oklahoma Health Sciences Center, Oklahoma City, OK. The genotyping and analysis for UKCVD was supported by the British Heart Foundation (PG08/008). Study-specific funding sources for the replication studies are provided in the Material in the Data Supplement. NR 53 TC 7 Z9 7 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD JUN PY 2014 VL 7 IS 3 BP 287 EP 295 DI 10.1161/CIRCGENETICS.113.000412 PG 9 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA AK1VY UT WOS:000338207300009 PM 24795349 ER PT J AU Guan, WH Steffen, BT Lemaitre, RN Wu, JHY Tanaka, T Manichaikul, A Foy, M Rich, SS Wang, L Nettleton, JA Tang, WH Gu, X Bandinelli, S King, IB McKnight, B Psaty, BM Siscovick, D Djousse, L Chen, YDI Ferrucci, L Fornage, M Mozafarrian, D Tsai, MY Steffen, LM AF Guan, Weihua Steffen, Brian T. Lemaitre, Rozenn N. Wu, Jason H. Y. Tanaka, Toshiko Manichaikul, Ani Foy, Millennia Rich, Stephen S. Wang, Lu Nettleton, Jennifer A. Tang, Weihong Gu, Xiangjun Bandinelli, Stafania King, Irena B. McKnight, Barbara Psaty, Bruce M. Siscovick, David Djousse, Luc Chen, Yii-Der Ida Ferrucci, Luigi Fornage, Myriam Mozafarrian, Dariush Tsai, Michael Y. Steffen, Lyn M. TI Genome-Wide Association Study of Plasma N6 Polyunsaturated Fatty Acids Within the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE epidemiology; genome-wide association study; N6 fatty acids; polyunsaturated fatty acids ID ACUTE MYOCARDIAL-INFARCTION; FADS GENETIC-VARIANTS; ARACHIDONIC-ACID; ADIPOSE-TISSUE; DISEASE; POPULATION; ATHEROSCLEROSIS; DIETARY; DESIGN; GENOTYPES AB Background-Omega6 (n6) polyunsaturated fatty acids (PUFAs) and their metabolites are involved in cell signaling, inflammation, clot formation, and other crucial biological processes. Genetic components, such as variants of fatty acid desaturase (FADS) genes, determine the composition of n6 PUFAs. Methods and Results-To elucidate undiscovered biological pathways that may influence n6 PUFA composition, we conducted genome-wide association studies and meta-analyses of associations of common genetic variants with 6 plasma n6 PUFAs in 8631 white adults (55% women) across 5 prospective studies. Plasma phospholipid or total plasma fatty acids were analyzed by similar gas chromatography techniques. The n6 fatty acids linoleic acid (LA), gamma-linolenic acid (GLA), dihomo-GLA, arachidonic acid, and adrenic acid were expressed as percentage of total fatty acids. We performed linear regression with robust SEs to test for single-nucleotide polymorphism-fatty acid associations, with pooling using inverse-variance-weighted meta-analysis. Novel regions were identified on chromosome 10 associated with LA (rs10740118; P=8.1x10(-9); near NRBF2), on chromosome 16 with LA, GLA, dihomo-GLA, and arachidonic acid (rs16966952; P=1.2x10(-15), 5.0x10(-11), 7.6x10(-65), and 2.4x10(-10), respectively; NTAN1), and on chromosome 6 with adrenic acid after adjustment for arachidonic acid (rs3134950; P=2.1x10(-10); AGPAT1). We confirmed previous findings of the FADS cluster on chromosome 11 with LA and arachidonic acid, and further observed novel genome-wide significant association of this cluster with GLA, dihomo-GLA, and adrenic acid (P=2.3x10(-72), 2.6x10(-151), and 6.3x10(-140), respectively). Conclusions-Our findings suggest that along with the FADS gene cluster, additional genes may influence n6 PUFA composition. C1 [Guan, Weihua] Univ Minnesota, Div Biostat, Sch Publ Hlth, Minneapolis, MN 55454 USA. [Steffen, Brian T.; Tsai, Michael Y.] Univ Minnesota, Sch Publ Med, Minneapolis, MN 55454 USA. [Tang, Weihong; Steffen, Lyn M.] Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, Minneapolis, MN 55454 USA. [Lemaitre, Rozenn N.; McKnight, Barbara; Psaty, Bruce M.; Siscovick, David] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Lemaitre, Rozenn N.; McKnight, Barbara; Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Wu, Jason H. Y.; Wang, Lu; Mozafarrian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Epidemiol & Nutr, Boston, MA 02115 USA. [Mozafarrian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Wu, Jason H. Y.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia. [Tanaka, Toshiko; Ferrucci, Luigi] NIA, Clin Res Branch, NIH, Baltimore, MD 21224 USA. [Manichaikul, Ani; Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA. [Manichaikul, Ani] Univ Virginia, Div Biostat & Epidemiol, Charlottesville, VA USA. [Foy, Millennia; Gu, Xiangjun; Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX 77030 USA. [Nettleton, Jennifer A.] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA. [Bandinelli, Stafania] ASF, Geriatr Rehabil Unit, Florence, Italy. [King, Irena B.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Djousse, Luc] Harvard Univ, Sch Med, Div Aging, Brigham & Womens Hosp,Dept Med, Cambridge, MA 02138 USA. [Djousse, Luc] Boston VA Healthcare Syst, Boston, MA USA. [Chen, Yii-Der Ida] Cedars Sinai Med Ctr, Med Genet Res Inst, Los Angeles, CA 90048 USA. [Mozafarrian, Dariush] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc Med, Sch Med, Boston, MA 02115 USA. RP Steffen, LM (reprint author), Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, 1300 South Second St,Suite 300, Minneapolis, MN 55454 USA. EM steffen@umn.edu RI Djousse, Luc/F-5033-2017 OI Djousse, Luc/0000-0002-9902-3047 FU National Heart, Lung, and Blood Institute (NHLBI) [HL105756]; NHLBI [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C]; National Human Genome Research Institute (NHGRI) [U01HG004402]; National Institutes of Health (NIH) [HSN268200625226C]; NIH Roadmap for Medical Research [UL1RR025005]; National Institute of Neurological Disorders and Stroke; National Institute on Aging (NIA) [AG023629]; National Center for Advancing Translational Sciences, CTSI [UL1TR000124]; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center [DK063491]; NHGRI [U01-HG-004729, U01-HG-004446, U01-HG-004424]; Italian Ministry of Health [ICS110.1/RF97.71]; US NIA [263 MD 9164, 263 MD 821336]; Intramural research program of the NIA, NIH, Baltimore, MD; K01 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIKDD) [5K01DK082729-02]; NHLBI. [HL105756, N01HC85086, HL080295, HL087652, HL085710, N01-HC-95095, N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-45134, N01-HC-05187, N01-HC-45205, N01-HC-45204, R01-HL-084099, N01-HC-95159, N01-HC-95160]; The NHLBI [HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641, R01HL59367, R01HL086694]; The NHLBI. [N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, RR-024156, N02HL64278, HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083] FX Infrastructure for the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium is supported, in part, by the National Heart, Lung, and Blood Institute (NHLBI) grant HL105756. The Atherosclerosis Risk in Communities (ARIC) Study is performed as a collaborative study supported by NHLBI contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute (NHGRI) contract U01HG004402; and National Institutes of Health (NIH) contract HSN268200625226C. Infrastructure was partly supported by grant number UL1RR025005, a component of the NIH Roadmap for Medical Research. The Cardiovascular Health Study (CHS) was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and grants HL080295, HL087652, and HL105756 from the NHLBI, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by AG023629 from the National Institute on Aging (NIA). The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The fatty acid measurements were supported by grant HL085710 from NHLBI. The Coronary Artery Risk Development in Young Adults (CARDIA) study is funded by contracts N01-HC-95095, N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-45134, N01-HC-05187, N01-HC-45205, and N01-HC-45204 from the NHLBI to the CARDIA investigators. Genotyping of the CARDIA participants was supported by grants U01-HG-004729, U01-HG-004446, and U01-HG-004424 from the NHGRI and R01-HL-084099 from the NHLBI to Dr Foy. The Invecchiare in Chianti (InCHIANTI) study baseline (1998-2000) was supported as a targeted project (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the US NIA Contracts 263 MD 9164 and 263 MD 821336 and was supported, in part, by the Intramural research program of the NIA, NIH, Baltimore, MD. The Multi-Ethnic Study of Atherosclerosis (MESA) and MESA SNP Health Association Resource (SHARe) were supported by contracts N01-HC-95159 through N01-HC-95169 and RR-024156 from the NHLBI. Funding for MESA SHARe genotyping was provided by NHLBI Contract N02HL64278. Dr Nettleton was supported by a K01 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIKDD) (5K01DK082729-02). NR 49 TC 9 Z9 9 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD JUN PY 2014 VL 7 IS 3 BP 321 EP 331 DI 10.1161/CIRCGENETICS.113.000208 PG 11 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA AK1VY UT WOS:000338207300013 PM 24823311 ER PT J AU Bis, JC White, CC Franceschini, N Brody, J Zhang, XL Muzny, D Santibanez, J Gibbs, R Liu, XM Lin, HH Boerwinkle, E Psaty, BM North, KE Cupples, LA O'Donnell, CJ AF Bis, Joshua C. White, Charles C. Franceschini, Nora Brody, Jennifer Zhang, Xiaoling Muzny, Donna Santibanez, Jireh Gibbs, Richard Liu, Xiaoming Lin, Honghuang Boerwinkle, Eric Psaty, Bruce M. North, Kari E. Cupples, L. Adrienne O'Donnell, Christopher J. CA CHARGE Subclinical Atherosclerosis TI Sequencing of 2 Subclinical Atherosclerosis Candidate Regions in 3669 Individuals Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE atherosclerosis; carotid artery, common; epidemiology; genetics; plaque, atherosclerotic; sequence analysis, DNA ID INTIMA-MEDIA THICKNESS; KERNEL ASSOCIATION TEST; WIDE ASSOCIATION; TASK-FORCE; METAANALYSIS; VARIANTS; RISK; LOCI; DESIGN; FRAMINGHAM AB Background-Atherosclerosis, the precursor to coronary heart disease and stroke, is characterized by an accumulation of fatty cells in the arterial intimal-medial layers. Common carotid intima media thickness (cIMT) and plaque are subclinical atherosclerosis measures that predict cardiovascular disease events. Previously, genome-wide association studies demonstrated evidence for association with cIMT (SLC17A4) and plaque (PIK3CG). Methods and Results-We sequenced 120 kb around SLC17A4 (6p22.2) and 251 kb around PIK3CG (7q22.3) among 3669 European ancestry participants from the Atherosclerosis Risk in Communities (ARIC) study, Cardiovascular Health Study (CHS), and Framingham Heart Study (FHS) in Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. Primary analyses focused on 438 common variants (minor allele frequency >= 1%), which were independently meta-analyzed. A 3' untranslated region CCDC71L variant (rs2286149), upstream from PIK3CG, was the most significant finding in cIMT (P=0.00033) and plaque (P=0.0004) analyses. A SLC17A4 intronic variant was also associated with cIMT (P=0.008). Both were in low linkage disequilibrium with the genome-wide association study single nucleotide polymorphisms. Gene-based tests including T1 count and sequence kernel association test for rare variants (minor allele frequency <1%) did not yield statistically significant associations. However, we observed nominal associations for rare variants in CCDC71L and SLC17A3 with cIMT and of the entire 7q22 region with plaque (P=0.05). Conclusions-Common and rare variants in PIK3CG and SLC17A4 regions demonstrated modest association with subclinical atherosclerosis traits. Although not conclusive, these findings may help to understand the genetic architecture of regions previously implicated by genome-wide association studies and identify variants within these regions for further investigation in larger samples. C1 [Bis, Joshua C.; Brody, Jennifer; Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA. [Bis, Joshua C.; Brody, Jennifer; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA 98101 USA. [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA. [White, Charles C.; Zhang, Xiaoling; Lin, Honghuang; Cupples, L. Adrienne; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA. [White, Charles C.; Cupples, L. Adrienne] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02215 USA. [Franceschini, Nora; North, Kari E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [North, Kari E.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA. [Muzny, Donna; Santibanez, Jireh; Gibbs, Richard; Boerwinkle, Eric] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA. [Liu, Xiaoming; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Lin, Honghuang] Boston Univ, Dept Med, Sch Med, Boston, MA 02215 USA. [Psaty, Bruce M.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA. [Liu, Xiaoming; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA. [O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA. RP Bis, JC (reprint author), Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. EM joshbis@uw.edu OI Lin, Honghuang/0000-0003-3043-3942 FU National Institutes of Health through the American Recovery and Reinvestment Act [5RC2HL102419]; National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100 008C, HHSN268201100009C, HHSN2682011000010C, HHSN268 2011000011C, HHSN2682011000012C]; Boston University [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278]; National Institute on Aging (NIA) [AG023629]; National Center for Advancing Translational Sciences, CTSI [UL1TR000124]; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) [DK063491]; the NHLBI [N01-HC-25195, HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC85085, N01HC45133]; NHLBI [HL080295, HL087652, HL105756, HL103612, HL120393]; [R01HL087641]; [R01HL59367]; [R01HL086694] FX Funding support for Building on GWAS for NHLBI-Diseases: The US CHARGE Consortium was provided by the National Institutes of Health through the American Recovery and Reinvestment Act of 2009 (5RC2HL102419). Data for Building on GWAS for NHLBI-Diseases: The US CHARGE Consortium were provided by Eric Boerwinkle on behalf of the Atherosclerosis Risk in Communities (ARIC) study; L. Adrienne Cupples, principal investigator for the Framingham Heart Study (FHS); and Bruce Psaty, principal investigator for the Cardiovascular Health Study. Sequencing was performed at the Baylor Genome Center (U54 HG003273). The ARIC study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100 008C, HHSN268201100009C, HHSN2682011000010C, HHSN268 2011000011C, and HHSN2682011000012C), R01HL087641, R01HL59367, and R01HL086694. The authors thank the staff and participants of the ARIC study for their important contributions. The FHS is conducted and supported by the NHLBI in collaboration with Boston University (contract no. N01-HC-25195), and its contract with Affymetrix, Inc, for genome-wide genotyping services (contract no. N02-HL-6-4278), for quality control by FHS investigators using genotypes in the SNP Health Association Resource (SHARe) project. A portion of this research was conducted using the Linux Cluster for Genetic Analysis (LinGA) computing resources at Boston University Medical Campus. This Cardiovascular Health Study research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC85085, N01HC45133; and NHLBI grants HL080295, HL087652, HL105756, HL103612, and HL120393 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org/. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 31 TC 3 Z9 3 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD JUN PY 2014 VL 7 IS 3 BP 359 EP 364 DI 10.1161/CIRCGENETICS.113.000116 PG 6 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA AK1VY UT WOS:000338207300018 PM 24951662 ER PT J AU Magnani, JW Brody, JA Prins, BP Arking, DE Lin, HH Yin, XY Liu, CT Morrison, AC Zhang, F Spector, TD Alonso, A Bis, JC Heckbert, SR Lumley, T Sitlani, CM Cupples, A Lubitz, SA Soliman, EZ Pulit, SL Newton-Cheh, C O'Donnell, CJ Ellinor, PT Benjamin, EJ Muzny, DM Gibbs, RA Santibanez, J Taylor, HA Rotter, JI Lange, LA Psaty, BM Jackson, R Rich, SS Boerwinkle, E Jamshidi, Y Sotoodehnia, N AF Magnani, Jared W. Brody, Jennifer A. Prins, Bram P. Arking, Dan E. Lin, Honghuang Yin, Xiaoyan Liu, Ching-Ti Morrison, Alanna C. Zhang, Feng Spector, Tim D. Alonso, Alvaro Bis, Joshua C. Heckbert, Susan R. Lumley, Thomas Sitlani, Colleen M. Cupples, Adrienne Lubitz, Steven A. Soliman, Elsayed Z. Pulit, Sara L. Newton-Cheh, Christopher O'Donnell, Christopher J. Ellinor, Patrick T. Benjamin, Emelia J. Muzny, Donna M. Gibbs, Richard A. Santibanez, Jireh Taylor, Herman A. Rotter, Jerome I. Lange, Leslie A. Psaty, Bruce M. Jackson, Rebecca Rich, Stephen S. Boerwinkle, Eric Jamshidi, Yalda Sotoodehnia, Nona CA CHARGE Consortium NHLBIs Exome Sequencing UK10K TI Sequencing of SCN5A Identifies Rare and Common Variants Associated With Cardiac Conduction: Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE electrocardiography; genomics ID SICK SINUS SYNDROME; LONG QT SYNDROME; SODIUM-CHANNEL; QRS DURATION; PR INTERVAL; DILATED CARDIOMYOPATHY; WIDE ASSOCIATION; CODING VARIANTS; MUTATIONS; DISEASE AB Background-The cardiac sodium channel SCN5A regulates atrioventricular and ventricular conduction. Genetic variants in this gene are associated with PR and QRS intervals. We sought to characterize further the contribution of rare and common coding variation in SCN5A to cardiac conduction. Methods and Results-In Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study, we performed targeted exonic sequencing of SCN5A (n=3699, European ancestry individuals) and identified 4 common (minor allele frequency >1%) and 157 rare variants. Common and rare SCN5A coding variants were examined for association with PR and QRS intervals through meta-analysis of European ancestry participants from CHARGE, National Heart, Lung, and Blood Institute's Exome Sequencing Project (n=607), and the UK10K (n=1275) and by examining Exome Sequencing Project African ancestry participants (n=972). Rare coding SCN5A variants in aggregate were associated with PR interval in European and African ancestry participants (P=1.3x10(-3)). Three common variants were associated with PR and QRS interval duration among European ancestry participants and one among African ancestry participants. These included 2 well-known missense variants: rs1805124 (H558R) was associated with PR and QRS shortening in European ancestry participants (P=6.25x10(-4) and P=5.2x10(-3), respectively) and rs7626962 (S1102Y) was associated with PR shortening in those of African ancestry (P=2.82x10(-3)). Among European ancestry participants, 2 novel synonymous variants, rs1805126 and rs6599230, were associated with cardiac conduction. Our top signal, rs1805126 was associated with PR and QRS lengthening (P=3.35x10(-7) and P=2.69x10(-4), respectively) and rs6599230 was associated with PR shortening (P=2.67x10(-5)). Conclusions-By sequencing SCN5A, we identified novel common and rare coding variants associated with cardiac conduction. C1 [Magnani, Jared W.; Lin, Honghuang; Yin, Xiaoyan; Liu, Ching-Ti; Cupples, Adrienne; Newton-Cheh, Christopher; O'Donnell, Christopher J.; Benjamin, Emelia J.] NHLBI, Framingham, MA USA. [Magnani, Jared W.; Lin, Honghuang; Yin, Xiaoyan; Liu, Ching-Ti; Cupples, Adrienne; Newton-Cheh, Christopher; O'Donnell, Christopher J.; Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Boston, MA 02118 USA. [Magnani, Jared W.; Benjamin, Emelia J.] Boston Univ, Sch Med, Sect Cardiovasc Med, Boston, MA 02118 USA. [Lin, Honghuang] Boston Univ, Sch Med, Sect Computat Biomed, Boston, MA 02118 USA. [Brody, Jennifer A.; Bis, Joshua C.; Heckbert, Susan R.; Sitlani, Colleen M.; Psaty, Bruce M.; Sotoodehnia, Nona] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Heckbert, Susan R.; Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Sotoodehnia, Nona] Univ Washington, Div Cardiol, Seattle, WA 98195 USA. [Prins, Bram P.; Zhang, Feng; Jamshidi, Yalda] St Georges Univ London, Human Genet Res Ctr, London, England. [Arking, Dan E.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Yin, Xiaoyan; Liu, Ching-Ti; Cupples, Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Morrison, Alanna C.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Zhang, Feng; Spector, Tim D.] Kings Coll London, Dept Twin Res, St Thomas Hosp, London WC2R 2LS, England. [Zhang, Feng; Spector, Tim D.] Kings Coll London, Genet Epidemiol Unit, St Thomas Hosp, London WC2R 2LS, England. [Alonso, Alvaro] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Lumley, Thomas] Univ Auckland, Dept Stat, Auckland 1, New Zealand. [Lubitz, Steven A.; Pulit, Sara L.; Newton-Cheh, Christopher; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA. [Lubitz, Steven A.; Newton-Cheh, Christopher; O'Donnell, Christopher J.; Ellinor, Patrick T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol,Dept Med, Boston, MA USA. [Soliman, Elsayed Z.] Wake Forest Univ, Bowman Gray Sch Med, Epidemiol Cardiol Res Ctr, Winston Salem, NC USA. [Pulit, Sara L.; Newton-Cheh, Christopher] Broad Inst, Cambridge, MA USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA. [Muzny, Donna M.; Gibbs, Richard A.; Santibanez, Jireh; Boerwinkle, Eric] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA. [Taylor, Herman A.] Univ Mississippi, Med Ctr, Jackson, MI USA. [Rotter, Jerome I.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA. [Lange, Leslie A.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Jackson, Rebecca] Ohio State Univ, Dept Med, Wexner Med Ctr, Columbus, OH 43210 USA. [Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA. RP Magnani, JW (reprint author), Boston Univ, Sch Med, Sect Cardiovasc Med, 88 E Newton St, Boston, MA 02118 USA. EM jmagnani@bu.edu; nsotoo@uw.edu RI Alonso, Alvaro/A-4917-2010; OI Alonso, Alvaro/0000-0002-2225-8323; Jamshidi, Yalda/0000-0003-0151-6482; Lin, Honghuang/0000-0003-3043-3942; Benjamin, Emelia/0000-0003-4076-2336 FU National Institutes of Health (NIH) through the American Recovery and Reinvestment Act [5RC2HL102419]; NHLBI [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN26820110 0009C, HHSN2682011000010C, HHSN2682011000011C, HHSN2682011000012C]; Boston University [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278]; Boston University School of Medicine Department of Medicine Career Investment Award; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine; Boston Medical Center; National Institute on Aging [AG023629]; Wellcome Trust [WT091310]; ENGAGE project [HEALTH-F4-2007-201413]; Department of Health via the National Institute for Health Research (NIHR); British Heart Foundation [PG/12/38/29615]; the NHLBI [N01-HC-25195, HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079]; NHLBI. [N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295, HL087652, HL105756]; [6R01-NS 17950NIH]; [1RO1HL092577]; [1R01 HL102214l]; [1RC1HL101056]; [5R21DA027021]; [1RO1HL104156]; [K23HL11472]; [1K24HL105780]; [1R03AG045075] FX Funding support for building on Genome-wide association studies (GWAS) for National Heart, Lung, and Blood Institute (NHLBI) diseases: the US Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) Consortium Targeted Sequencing Study was provided by the National Institutes of Health (NIH) through the American Recovery and Reinvestment Act of 2009 (5RC2HL102419). Data for building on GWAS for NHLBI diseases: the US CHARGE Consortium was provided by Dr Boerwinkle on behalf of the Atherosclerosis Risk in Communities (ARIC) Study, Dr Cupples, principal investigator for the Framingham Heart Study, and Dr Psaty, principal investigator for the Cardiovascular Health Study. The ARIC Study is performed as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN26820110 0009C, HHSN2682011000010C, HHSN2682011000011C, and HHSN2682011000012C). The Framingham Heart Study is conducted and supported by the NHLBI in collaboration with Boston University (contract No. N01-HC-25195) and its contract with Affymetrix, Inc, for genome-wide genotyping services (contract No. N02-HL-6-4278), for quality control by Framingham Heart Study investigators using genotypes in the SNP Health Association Resource (SHARe) project. This project was supported by 6R01-NS 17950NIH, 1RO1HL092577, 1R01 HL102214l, 1RC1HL101056, 5R21DA027021, 1RO1HL104156, K23HL11472, 1K24HL105780, and 1R03AG045075. Dr Magnani is further supported by a Boston University School of Medicine Department of Medicine Career Investment Award. A portion of this research was conducted using the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Cardiovascular Health Study (CHS): This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and NHLBI grants HL080295, HL087652, and HL105756 with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided through AG023629 from the National Institute on Aging. A full list of CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. UK10K: The UK10K project was funded by the Wellcome Trust award WT091310. Twins UK (TUK): TUK was funded by the Wellcome Trust and ENGAGE project grant agreement HEALTH-F4-2007-201413. The study also receives support from the Department of Health via the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London. Dr Spector is an NIHR senior Investigator and ERC Senior Researcher. Funding for the project was also provided by the British Heart Foundation grant PG/12/38/29615 (Dr Jamshidi). NR 46 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD JUN PY 2014 VL 7 IS 3 BP 365 EP 373 DI 10.1161/CIRCGENETICS.113.000098 PG 9 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA AK1VY UT WOS:000338207300019 PM 24951663 ER PT J AU Cornes, BK Brody, JA Nikpoor, N Morrison, AC Dang, HCP Ahn, BS Wang, S Dauriz, M Barzilay, JI Dupuis, J Florez, JC Coresh, J Gibbs, RA Kao, WHL Liu, CT McKnight, B Muzny, D Pankow, JS Reid, JG White, CC Johnson, AD Wong, TY Psaty, BM Boerwinkle, E Rotter, JI Siscovick, DS Sladek, R Meigs, JB AF Cornes, Belinda K. Brody, Jennifer A. Nikpoor, Naghmeh Morrison, Alanna C. Huan Chu Pham Dang Ahn, Byung Soo Wang, Shuai Dauriz, Marco Barzilay, Joshua I. Dupuis, Josee Florez, Jose C. Coresh, Josef Gibbs, Richard A. Kao, W. H. Linda Liu, Ching-Ti McKnight, Barbara Muzny, Donna Pankow, James S. Reid, Jeffrey G. White, Charles C. Johnson, Andrew D. Wong, Tien Y. Psaty, Bruce M. Boerwinkle, Eric Rotter, Jerome I. Siscovick, David S. Sladek, Robert Meigs, James B. TI Association of Levels of Fasting Glucose and Insulin With Rare Variants at the Chromosome 11p11.2-MADD Locus Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE genetic epidemiology; glucose; human genetics; insulin; molecular genetics ID HUMAN GENE-EXPRESSION; TRANSCRIPTION FACTOR; CARDIOVASCULAR HEALTH; WIDE ASSOCIATION; GLYCEMIC TRAITS; BETA-CELL; DNA; POPULATION; RISK; PATHOPHYSIOLOGY AB Background-Common variation at the 11p11.2 locus, encompassing MADD, ACP2, NR1H3, MYBPC3, and SPI1, has been associated in genome-wide association studies with fasting glucose and insulin (FI). In the Cohorts for Heart and Aging Research in Genomic Epidemiology Targeted Sequencing Study, we sequenced 5 gene regions at 11p11.2 to identify rare, potentially functional variants influencing fasting glucose or FI levels. Methods and Results-Sequencing (mean depth, 38x) across 16.1 kb in 3566 individuals without diabetes mellitus identified 653 variants, 79.9% of which were rare (minor allele frequency <1%) and novel. We analyzed rare variants in 5 gene regions with FI or fasting glucose using the sequence kernel association test. At NR1H3, 53 rare variants were jointly associated with FI (P=2.73x10(-3)); of these, 7 were predicted to have regulatory function and showed association with FI (P=1.28x10(-3)). Conditioning on 2 previously associated variants at MADD (rs7944584, rs10838687) did not attenuate this association, suggesting that there are >2 independent signals at 11p11.2. One predicted regulatory variant, chr11: 47227430 (hg18; minor allele frequency=0.00068), contributed 20.6% to the overall sequence kernel association test score at NR1H3, lies in intron 2 of NR1H3, and is a predicted binding site for forkhead box A1 (FOXA1), a transcription factor associated with insulin regulation. In human HepG2 hepatoma cells, the rare chr11: 47227430 A allele disrupted FOXA1 binding and reduced FOXA1-dependent transcriptional activity. Conclusions-Sequencing at 11p11.2-NR1H3 identified rare variation associated with FI. One variant, chr11: 47227430, seems to be functional, with the rare A allele reducing transcription factor FOXA1 binding and FOXA1-dependent transcriptional activity. C1 [Cornes, Belinda K.; Dauriz, Marco; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Diabet Unit, Boston, MA 02114 USA. [Cornes, Belinda K.; Dauriz, Marco; Florez, Jose C.; Meigs, James B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Brody, Jennifer A.; McKnight, Barbara; Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [McKnight, Barbara] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [McKnight, Barbara] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Nikpoor, Naghmeh; Huan Chu Pham Dang; Ahn, Byung Soo; Sladek, Robert] McGill Univ, Fac Med, Dept Human Genet, Montreal, PQ, Canada. [Nikpoor, Naghmeh; Huan Chu Pham Dang; Ahn, Byung Soo; Sladek, Robert] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA. [Gibbs, Richard A.; Muzny, Donna; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Human Genome Sequencing Ctr, Baylor Coll Med, Houston, TX 77030 USA. [Wang, Shuai; Dupuis, Josee; Liu, Ching-Ti; White, Charles C.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. [Dauriz, Marco] Univ Verona, Div Endocrinol Diabet & Metab, Dept Med, Sch Med, I-37100 Verona, Italy. [Dauriz, Marco] Hosp Trust Verona, Verona, Italy. [Barzilay, Joshua I.] Kaiser Permanente Georgia, Div Endocrinol, Atlanta, GA USA. [Barzilay, Joshua I.] Emory Univ, Sch Med, Atlanta, GA USA. [Dupuis, Josee; Johnson, Andrew D.] NHLBI, Framingham Heart Study, Cardiovasc Epidemiol & Human Genom Ctr, Framingham, MA USA. [Florez, Jose C.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA. [Coresh, Josef] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA. [Coresh, Josef; Kao, W. H. Linda; Reid, Jeffrey G.] Johns Hopkins Univ, Dept Epidemiol, Johns Hopkins Univ Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Wong, Tien Y.] Duke NUS Grad Med Sch, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore. [Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Yong Loo Lin Sch Med, Singapore 117548, Singapore. [Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Rotter, Jerome I.] Harbor UCLA Med Ctr Torrance, Inst Translat Genom & Populat Sci, Los Angeles Biomed Reasearch Inst, Torrance, CA USA. [Rotter, Jerome I.] Harbor UCLA Med Ctr Torrance, Dept Pediat, Torrance, CA USA. RP Meigs, JB (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM jmeigs@partners.org RI Johnson, Andrew/G-6520-2013; Dauriz, Marco/S-5843-2016; OI Dauriz, Marco/0000-0002-5542-5941; Sladek, Robert/0000-0002-2730-1204; Pankow, James/0000-0001-7076-483X FU National Institutes of Health (NIH) through the American Recovery and Reinvestment Act (ARRA) [5RC2HL102419]; Baylor Genome Center [U54 HG003273]; National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN2682011 00009C, HHSN2682011000010C, HHSN2682011000011C, HHSN2682011000012C]; Boston University [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278]; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine; Boston Medical Center; American Diabetes Association Mentored Post Doctoral Fellowship Award; National Institute on Aging (NIA) [AG023629]; the NHLBI [N01-HC-25195, HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080]; NHLBI. [N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295, HL087652, HL105756]; [R01DK078616]; [K24 DK080140] FX Funding support for Building on GWAS for NHLBI-diseases: the US CHARGE Consortium was provided by the National Institutes of Health (NIH) through the American Recovery and Reinvestment Act of 2009 (ARRA; 5RC2HL102419). Data for Building on GWAS for NHLBI-diseases: the US CHARGE Consortium was provided by Dr Boerwinkle on behalf of the ARIC study, L. Adrienne Cupples, principal investigator for the FHS, and Dr Psaty, principal investigator for the CHS. Support was also received from the Baylor Genome Center (U54 HG003273). The ARIC study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN2682011 00009C, HHSN2682011000010C, HHSN2682011000011C, and HHSN2682011000012C). The FHS is conducted and supported by the NHLBI in collaboration with Boston University (contract No. N01-HC-25195), and its contract with Affymetrix, Inc, for genome-wide genotyping services (contract No. N02-HL-6-4278) and for quality control by FHS investigators using genotypes in the SNP Health Association Resource (SHARe) project. A portion of this research was conducted using the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. This research is also supported by R01DK078616, K24 DK080140 and an American Diabetes Association Mentored Post Doctoral Fellowship Award (Dr Meigs). This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants HL080295, HL087652, HL105756 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through AG023629 from the National Institute on Aging (NIA). A full list of CHS investigators and institutions can be found at https://chs-nhlbi.org/pi. NR 46 TC 4 Z9 4 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD JUN PY 2014 VL 7 IS 3 BP 374 EP 382 DI 10.1161/CIRCGENETICS.113.000169 PG 9 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA AK1VY UT WOS:000338207300020 PM 24951664 ER PT J AU Nattel, S Guasch, E Savelieva, I Cosio, FG Valverde, I Halperin, JL Conroy, JM Al-Khatib, SM Hess, PL Kirchhof, P De Bono, J Lip, GYH Banerjee, A Ruskin, J Blendea, D Camm, AJ AF Nattel, Stanley Guasch, Eduard Savelieva, Irina Cosio, Francisco G. Valverde, Irene Halperin, Jonathan L. Conroy, Jennifer M. Al-Khatib, Sana M. Hess, Paul L. Kirchhof, Paulus De Bono, Joseph Lip, Gregory Y. H. Banerjee, Amitava Ruskin, Jeremy Blendea, Dan Camm, A. John TI Early management of atrial fibrillation to prevent cardiovascular complications SO EUROPEAN HEART JOURNAL LA English DT Review DE Atrial fibrillation; Post-operative AF; Atrial remodelling; Integrated care pathways; Anticoagulation; Rhythm control; Natural history ID ACUTE MYOCARDIAL-INFARCTION; COMPREHENSIVE RISK REDUCTION; HEART RHYTHM ASSOCIATION; FOLLOW-UP; EUROPEAN-SOCIETY; POTASSIUM CURRENT; CARDIAC-SURGERY; MOLECULAR-MECHANISMS; CONSENSUS CONFERENCE; UPSTREAM THERAPIES AB Atrial fibrillation (AF) is generally considered a progressive disease, typically evolving from paroxysmal through persistent to 'permanent' forms, a process attributed to electrical and structural remodelling related to both the underlying disease and AF itself. Medical treatment has yet to demonstrate clinical efficacy in preventing progression. Large clinical trials performed to date have failed to show benefit of rhythm control compared with rate control, but these trials primarily included patients at late stages in the disease process. One possible explanation is that intervention at only an early stage of progression may improve prognosis. Evolving observations about the progressive nature of AF, along with the occurrences of major complications such as strokes upon AF presentation, led to the notion that earlier and more active approaches to AF detection, rhythm-reversion, and maintenance of sinus rhythm may be a useful strategy in AF management. Approaches to early and sustained rhythm control include measures that prevent development of the AF substrate, earlier catheter ablation, and novel antiarrhythmic drugs. Improved classifications of AF mechanism, pathogenesis, and remodelling may be helpful to enable patient-specific pathophysiological diagnosis and therapy. Potential novel therapeutic options under development include microRNA-modulation, heatshock protein inducers, agents that influence Ca2+ handling, vagal stimulators, and more aggressive mechanism-based ablation strategies. In this review, of research into the basis and management of AF in acute and early settings, it is proposed that progression from paroxysmal to persistent AF can be interrupted, with potentially favourable prognostic impact. C1 [Nattel, Stanley; Guasch, Eduard] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Savelieva, Irina; Camm, A. John] St Georges Univ London, Div Clin Sci, London SW17 0RE, England. [Cosio, Francisco G.; Valverde, Irene] Hosp Univ Getafe, Dept Cardiol, Madrid, Spain. [Halperin, Jonathan L.; Conroy, Jennifer M.] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA. [Al-Khatib, Sana M.; Hess, Paul L.] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27710 USA. [Lip, Gregory Y. H.; Banerjee, Amitava] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England. [De Bono, Joseph] Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England. [Kirchhof, Paulus] Univ Birmingham, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. [Kirchhof, Paulus] Sandwell & West Birmingham NHS Trust, Birmingham, W Midlands, England. [Kirchhof, Paulus] Hosp Univ Munster, Dept Cardiol & Angiol, Munster, Germany. [Kirchhof, Paulus] German Atrial Fibrillat Competence NETwork AFNET, Munster, Germany. [Ruskin, Jeremy; Blendea, Dan] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Camm, AJ (reprint author), St Georges Univ London, Div Clin Sci, Cranmer Terrace, London SW17 0RE, England. EM jcamm@sgul.ac.uk RI Banerjee, Amitava/D-4381-2014; OI Banerjee, Amitava/0000-0001-8741-3411; Guasch, Eduard/0000-0003-4238-5319; Kirchhof, Paulus/0000-0002-1881-0197 FU Astellas Pharma, USA; Atricure/Boston Biomedical Associates; AstraZeneca; Bayer AG HealthCare; Boehringer Ingelheim, Pharmaceuticals, Inc.; Bristol Meyers-Squibb; Daiichi-Sankyo; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Johnson& Johnson, Pfizer, Inc.; Sanofi and Biotronik, Inc.; 3M Medica; MEDA Pharma; Medtronic; Merck; MSD; Otsuka Pharma; Pfizer/BMS; Sanofi; Servier; Siemens; TAKEDA; 3M Medica/MEDA Pharma; Cardiovascular Therapeutics; OMRON; St Jude Medical; German Federal Ministry for Education and Research; Fondation Leducq; German Research Foundation; European Union; BMS; Boston Scientific FX S.N.: Consultant/advisor to Xention, listed as inventor on the following patents awarded or pending belonging to the Montreal Heart Institute: Preventing atrial fibrillation with the use of statin drugs; TRPC3 channels are critical for regulating fibroblast proliferation in the heart; MiR21 as a target in prevention of atrial fibrillation. E. G. I. V., J.M.C., P. L. H., A. B., and D. B. have no conflict of interest to declare. I. S.: Advisor/speaker/investigator for Sanofi, Bristol-Myers Squibb (BMS), Takeda, Daiichi, Boehringer Ingelheim, Servier, Astrazeneca, Astellas, Mitsubishi Pharma and Merck. F. G. C. Fellowship program support by Medtronic and Sorin. Speaker's honoraria from Sanofi, St Jude. J.L.H.: Consulting fees from Astellas Pharma, USA, Atricure/Boston Biomedical Associates, AstraZeneca, Bayer AG HealthCare, Boehringer Ingelheim, Pharmaceuticals, Inc., Bristol Meyers-Squibb, Daiichi-Sankyo, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Johnson& Johnson, Pfizer, Inc., Sanofi and Biotronik, Inc. S. M. Al-K. has no conflicts of interest to declare and did not receive any honoraria for her participation in the meetings that led to development of this manuscript. P. K.: Consulting fees and honoraria from 3M Medica, MEDA Pharma, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Daicchi-Sankyo, MEDA Pharma, Medtronic, Merck, MSD, Otsuka Pharma, Pfizer/BMS, Sanofi, Servier, Siemens, and TAKEDA. Research Grants from 3M Medica/MEDA Pharma, Cardiovascular Therapeutics, Medtronic, OMRON, Sanofi, St Jude Medical, German Federal Ministry for Education and Research, Fondation Leducq, German Research Foundation and the European Union. Travel support received from the European Society of Cardiology, the European Heart Rhythm Association and from the German Atrial Fibrillation Competence NETwork. J.d.B.: Research funding from BMS and travel funding from St Jude Medical, Boston Scientific and Medtronic. G.Y.H.L.: Consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola and Boehringer Ingelheim. Speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi. J.R.: Consultant-Atricure Inc., Arrhythmia Education Inc., Astellas/Cardiome, BiosenseWebster, Inc., Bristol-Myers Squibb, CardioInsight, InfoBionic (equity), Medtronic, Inc., Pfizer, Portola (equity), Sanofi Aventis, and Third Rock Ventures; Fellowship Support-Biosense Webster, Inc., Boston Scientific Corp., Medtronic, Inc., and St Jude Medical. A.J.C.: Consultant/advisor to St Jude, Medtronic, Boston Scientific, Sanofi, Cardiome, Pfizer, BMS, Bayer, Boehringer Ingelheim. NR 100 TC 44 Z9 45 U1 1 U2 18 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD JUN PY 2014 VL 35 IS 22 BP 1448 EP U32 DI 10.1093/eurheartj/ehu028 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AJ8SE UT WOS:000337976800012 PM 24536084 ER PT J AU Gupta, DK Shah, AM Giugliano, RP Ruff, CT Antman, EM Grip, LT Deenadayalu, N Hoffman, E Patel, I Shi, M Mercuri, M Mitrovic, V Braunwald, E Solomon, SD AF Gupta, Deepak K. Shah, Amil M. Giugliano, Robert P. Ruff, Christian T. Antman, Elliott M. Grip, Laura T. Deenadayalu, Naveen Hoffman, Elaine Patel, Indravadan Shi, Minggao Mercuri, Michele Mitrovic, Veselin Braunwald, Eugene Solomon, Scott D. CA ENGAGE AF-TIMI 48 Echocardiograp TI Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48 SO EUROPEAN HEART JOURNAL LA English DT Article DE Atrial fibrillation; ENGAGE AF-TIMI 48; Left atrium; Echocardiography; Stroke ID CATHETER-BASED TECHNIQUES; MAZE III OPERATION; EURO HEART SURVEY; RISK STRATIFICATION; MECHANICAL FUNCTION; PREDICTING STROKE; CONTROLLED-TRIALS; FOLLOW-UP; THERAPY; ECHOCARDIOGRAPHY AB Aims The complex relationship between left atrial (LA) structure and function, electrical burden of atrial fibrillation (AF) and stroke risk is not well understood. We aimed to describe LA structure and function in AF. Methods and results Left atrial structure and function was assessed in 971 subjects enrolled in the echocardiographic substudy of ENGAGE AF-TIMI 48. Left atrial size, emptying fraction (LAEF), and contractile function were compared across AF types (paroxysmal, persistent, or permanent) and CHADS(2) scores as an estimate of stroke risk. The majority of AF patients (55%) had both LA enlargement and reduced LAEF, with an inverse relationship between LA size and LAEF (R = -0.57, P < 0.001). With an increasing electrical burden of AF and higher CHADS(2) scores, LA size increased and LAEF declined. Moreover, 19% of AF subjects had impaired LAEF despite normal LA size, and LA contractile dysfunction was present even among the subset of AF subjects in sinus rhythm at the time of echocardiography. Conclusions In a contemporary AF population, LA structure and function were increasingly abnormal with a greater electrical burden of AF and higher stroke risk estimated by the CHADS(2) score. Moreover, LA dysfunction was present despite normal LA size and sinus rhythm, suggesting that the assessment of LA function may add important incremental information in the evaluation of AF patients. C1 [Gupta, Deepak K.; Shah, Amil M.; Solomon, Scott D.] Harvard Univ, Brigham andWomens Hosp, Cardiovasc Div, Dept Med,Sch Med, Boston, MA 02115 USA. [Giugliano, Robert P.; Ruff, Christian T.; Antman, Elliott M.; Grip, Laura T.; Deenadayalu, Naveen; Hoffman, Elaine; Braunwald, Eugene] Harvard Univ, Brigham andWomens Hosp, Cardiovasc Div, Dept Med,Sch Med,TIMI Study Grp, Boston, MA 02115 USA. [Patel, Indravadan; Shi, Minggao; Mercuri, Michele] Daiichi Sankyo Pharma Dev, Edison, NJ USA. [Mitrovic, Veselin] Kerckhoff Clin Nauheim, Bad Nauheim, Germany. RP Gupta, DK (reprint author), Harvard Univ, Brigham andWomens Hosp, Cardiovasc Div, Dept Med,Sch Med, 75 Francis St, Boston, MA 02115 USA. EM ssolomon@rics.bwh.harvard.edu FU Daiichi Sankyo Pharma Development (Edison, NJ, USA); NIH [T32 HL094301-02] FX The ENGAGE AF-TIMI 48 study was funded by Daiichi Sankyo Pharma Development (Edison, NJ, USA). Support was provided by the NIH training grant (T32 HL094301-02). NR 42 TC 34 Z9 40 U1 1 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD JUN PY 2014 VL 35 IS 22 BP 1457 EP 1465 DI 10.1093/eurheartj/eht500 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AJ8SE UT WOS:000337976800013 PM 24302269 ER PT J AU Troughton, RW Frampton, CM Brunner-La Rocca, HP Pfisterer, M Eurlings, LWM Erntell, H Persson, H O'Connor, CM Moertl, D Karlstrom, P Dahlstrom, U Gaggin, HK Januzzi, JL Berger, R Richards, AM Pinto, YM Nicholls, MG AF Troughton, Richard W. Frampton, Christopher M. Brunner-La Rocca, Hans-Peter Pfisterer, Matthias Eurlings, Luc W. M. Erntell, Hans Persson, Hans O'Connor, Christopher M. Moertl, Deddo Karlstrom, Patric Dahlstrom, Ulf Gaggin, Hanna K. Januzzi, James L. Berger, Rudolf Richards, A. Mark Pinto, Yigal M. Nicholls, M. Gary TI Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis SO EUROPEAN HEART JOURNAL LA English DT Article DE Natriuretic peptides; B-type Natriuretic peptide; Heart failure AB Aims Natriuretic peptide-guided (NP-guided) treatment of heart failure has been tested against standard clinically guided care in multiple studies, but findings have been limited by study size. We sought to perform an individual patient data meta-analysis to evaluate the effect of NP-guided treatment of heart failure on all-cause mortality. Methods and results ligible randomized clinical trials were identified from searches of Medline and EMBASE databases and the Cochrane Clinical Trials Register. The primary pre-specified outcome, all-cause mortality was tested using a Cox proportional hazards regression model that included study of origin, age (< 75 or >= 75 years), and left ventricular ejection fraction (LVEF, <= 45 or > 45%) as covariates. Secondary endpoints included heart failure or cardiovascular hospitalization. Of 11 eligible studies, 9 provided individual patient data and 2 aggregate data. For the primary endpoint individual data from 2000 patients were included, 994 randomized to clinically guided care and 1006 to NP-guided care. All-cause mortality was significantly reduced by NP-guided treatment [hazard ratio = 0.62 (0.45-0.86); P = 0.004] with no heterogeneity between studies or interaction with LVEF. The survival benefit from NP-guided therapy was seen in younger (< 75 years) patients [0.62 (0.45-0.85); P = 0.004] but not older (>= 75 years) patients [0.98 (0.75-1.27); P = 0.96]. Hospitalization due to heart failure [0.80 (0.67-0.94); P = 0.009] or cardiovascular disease [0.82 (0.67-0.99); P = 0.048] was significantly lower in NP-guided patients with no heterogeneity between studies and no interaction with age or LVEF. Conclusion Natriuretic peptide-guided treatment of heart failure reduces all-cause mortality in patients aged < 75 years and overall reduces heart failure and cardiovascular hospitalization. C1 [Troughton, Richard W.; Frampton, Christopher M.; Nicholls, M. Gary] Univ Otago, Christchurch Hosp, Dept Med, Christchurch 8140, New Zealand. [Richards, A. Mark] Natl Univ Heart Ctr Singapore, Singapore, Singapore. [Pfisterer, Matthias] Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland. [Brunner-La Rocca, Hans-Peter; Eurlings, Luc W. M.] Maastricht Univ Med Ctr, Dept Cardiol, Maastricht, Netherlands. [Erntell, Hans; Persson, Hans] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Berger, Rudolf] Med Univ Vienna, Dept Cardiol, Vienna, Austria. [Moertl, Deddo] LKH, Dept Cardiol, St Polten, Austria. [Karlstrom, Patric] Cty Hosp Ryhov, Dept Med, Div Cardiol, Jonkoping, Sweden. [Dahlstrom, Ulf] Linkoping Univ, Cty Council Ostergotland, Dept Cardiol, Dept Med & Hlth Sci, Linkoping, Sweden. [Gaggin, Hanna K.; Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Pinto, Yigal M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. RP Troughton, RW (reprint author), Univ Otago, Christchurch Hosp, Dept Med, POB 4345, Christchurch 8140, New Zealand. EM richard.troughton@cdhb.health.nz FU Christchurch Heart Institute at the University of Otago, Christchurch FX None specific to the meta-analysis. Funding related to the original studies included in the meta-analysis is outlined in the attached appendix. Funding to pay the Open Access publication charges for this article was provided by the Christchurch Heart Institute at the University of Otago, Christchurch. NR 0 TC 62 Z9 65 U1 2 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD JUN PY 2014 VL 35 IS 23 BP 1559 EP 1567 DI 10.1093/eurheartj/ehu090 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AK0OF UT WOS:000338112700016 PM 24603309 ER PT J AU Kang, JH Loomis, SJ Yaspan, BL Bailey, JC Weinreb, RN Lee, RK Lichter, PR Budenz, DL Liu, Y Realini, T Gaasterland, D Gaasterland, T Friedman, DS McCarty, CA Moroi, SE Olson, L Schuman, JS Singh, K Vollrath, D Wollstein, G Zack, DJ Brilliant, M Sit, AJ Christen, WG Fingert, J Forman, JP Buys, ES Kraft, P Zhang, K Allingham, RR Pericak-Vance, MA Richards, JE Hauser, MA Haines, JL Wiggs, JL Pasquale, LR AF Kang, J. H. Loomis, S. J. Yaspan, B. L. Bailey, J. C. Weinreb, R. N. Lee, R. K. Lichter, P. R. Budenz, D. L. Liu, Y. Realini, T. Gaasterland, D. Gaasterland, T. Friedman, D. S. McCarty, C. A. Moroi, S. E. Olson, L. Schuman, J. S. Singh, K. Vollrath, D. Wollstein, G. Zack, D. J. Brilliant, M. Sit, A. J. Christen, W. G. Fingert, J. Forman, J. P. Buys, E. S. Kraft, P. Zhang, K. Allingham, R. R. Pericak-Vance, M. A. Richards, J. E. Hauser, M. A. Haines, J. L. Wiggs, J. L. Pasquale, L. R. TI Vascular tone pathway polymorphisms in relation to primary open-angle glaucoma SO EYE LA English DT Article ID NITRIC-OXIDE SYNTHASE; OPTIC-NERVE HEAD; RETINAL BLOOD-FLOW; OCULAR PERFUSION-PRESSURE; CENTRAL CORNEAL THICKNESS; HIGH-TENSION GLAUCOMA; VISUAL-FIELD DEFECTS; ENDOTHELIAL DYSFUNCTION; INTRAOCULAR-PRESSURE; HEALTHY-SUBJECTS AB Aims Vascular perfusion may be impaired in primary open-angle glaucoma (POAG); thus, we evaluated a panel of markers in vascular tone-regulating genes in relation to POAG. Methods We used Illumina 660W-Quad array genotype data and pooled P-values from 3108 POAG cases and 3430 controls from the combined National Eye Institute Glaucoma Human Genetics Collaboration consortium and Glaucoma Genes and Environment studies. Using information from previous literature and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, we compiled single-nucleotide polymorphisms (SNPs) in 186 vascular tone-regulating genes. We used the 'Pathway Analysis by Randomization Incorporating Structure' analysis software, which performed 1000 permutations to compare the overall pathway and selected genes with comparable randomly generated pathways and genes in their association with POAG. Results The vascular tone pathway was not associated with POAG overall or POAG subtypes, defined by the type of visual field loss (early paracentral loss (n = 224 cases) or only peripheral loss (n 993 cases)) (permuted P>0.20). In gene-based analyses, eight were associated with POAG overall at permuted P<0.001: PRKAA1, CAV1, ITPR3, EDNRB, GNB2, DNM2, HFE, and MYL9. Notably, six of these eight (the first six listed) code for factors involved in the endothelial nitric oxide synthase activity, and three of these six (CAV1, ITPR3, and EDNRB) were also associated with early paracentral loss at P<0.001, whereas none of the six genes reached P<0.001 for peripheral loss only. Discussion Although the assembled vascular tone SNP set was not associated with POAG, genes that code for local factors involved in setting vascular tone were associated with POAG. C1 [Kang, J. H.; Christen, W. G.; Forman, J. P.; Pasquale, L. R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA. [Loomis, S. J.; Wiggs, J. L.; Pasquale, L. R.] Dept Ophthalmol, Boston, MA USA. [Yaspan, B. L.] Genentech Inc, San Francisco, CA 94080 USA. [Bailey, J. C.; Olson, L.; Haines, J. L.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA. [Weinreb, R. N.; Zhang, K.] Univ Calif San Diego, Dept Ophthalmol, San Diego, CA 92103 USA. [Weinreb, R. N.; Zhang, K.] Univ Calif San Diego, Hamilton Glaucoma Ctr, San Diego, CA 92103 USA. [Lee, R. K.; Pericak-Vance, M. A.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst & Human Genom, Miami, FL 33136 USA. [Lichter, P. R.; Moroi, S. E.; Richards, J. E.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA. [Budenz, D. L.] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC USA. [Liu, Y.; Allingham, R. R.; Hauser, M. A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA. [Liu, Y.; Hauser, M. A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Realini, T.] West Virginia Univ Eye Inst, Dept Ophthalmol, Morgantown, WV USA. [Gaasterland, T.] Univ Calif San Diego, Scripps Genome Ctr, San Diego, CA 92103 USA. [Friedman, D. S.; Zack, D. J.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Baltimore, MD 21205 USA. [McCarty, C. A.] Essentia Inst Rural Hlth, Duluth, MN USA. [Schuman, J. S.; Wollstein, G.] Univ Pittsburgh, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA 15260 USA. [Singh, K.] Stanford Univ, Dept Ophthalmol, Palo Alto, CA 94304 USA. [Vollrath, D.] Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA. [Brilliant, M.] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA. [Sit, A. J.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA. [Fingert, J.] Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA. [Fingert, J.] Univ Iowa, Coll Med, Dept Anat Cell Biol, Iowa City, IA USA. [Buys, E. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA. [Kraft, P.] Harvard Univ, Dept Biostat & Epidemiol, Sch Med, Boston, MA 02115 USA. RP Kang, JH (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, 181 Longwood Ave, Boston, MA 02115 USA. EM nhjhk@channing.harvard.edu OI Sit, Arthur/0000-0002-3904-2625; Zack, Don/0000-0002-7966-1973 FU Allergan (Irvine, CA, USA); The Harvard Glaucoma Center of Excellence, a Harvard Department of Ophthalmology; Research to Prevent Blindness Inc. (New York, NY, USA); The Arthur Ashley Foundation; The Glaucoma Research Foundation (San Francisco, CA, USA); American Health Assistance Foundation (Clarksburg, MD, USA); Glaucoma Foundation (New York, NY, USA); NIH [R01EY022746]; National Institutes of Health [P01 CA87969, CA49449, UM1 CA167552, HL35464, HHSN268200782096C]; National Human Genome Research Institute (Bethesda, MD, USA) [HG004728, HG004424, HG004446]; National Eye Institute [HG005259-01]; The National Eye Institute (Bethesda, MD) through ARRA [3R01EY015872-05S1, 3R01EY019126-02S1]; National Institutes of Health (Bethesda, MD) [EY015543, EY006827, HL073389, EY13315, EY09611, EY015473, EY009149, HG004608, EY008208, EY012118, EY015682, EY011671, EY09580, EY013178, EY010886, EY009847, EY011008, EY144428, EY144448, EY18660, UL1TR000427, U01HG006389, P30 EY014104, R01 EY022305, R21 EY022766] FX A Horizon Grant to MEEI from Allergan (Irvine, CA, USA) supported the collection of some glaucoma feature data. The Harvard Glaucoma Center of Excellence, a Harvard Department of Ophthalmology Scholar Award, and Margolis fund (Boston, MA) support LRP and JLW. LRP, JER, and JLW are also supported by Research to Prevent Blindness Inc. (New York, NY, USA). The Arthur Ashley Foundation also supports Dr Pasquale. The Glaucoma Research Foundation (San Francisco, CA, USA), American Health Assistance Foundation (Clarksburg, MD, USA), and the Glaucoma Foundation (New York, NY, USA) support YL. EB is supported by NIH Grant R01EY022746. The following National Institutes of Health grants support the maintenance of the NHS and Health Professionals Follow-up, allowing these health professionals to contribute to this analysis: P01 CA87969, CA49449, UM1 CA167552, and HL35464. The following grants from the National Human Genome Research Institute (Bethesda, MD, USA) supported GLAUGEN: HG004728 (LRP), HG004424 (Broad Institute to support genotyping), and HG004446 (C Laurie, U Washington, to support genotype data cleaning and analysis). Genotyping services for the NEIGHBOR study were provided by the Center for Inherited Disease Research (CIDR) and were supported by the National Eye Institute through Grant HG005259-01 (JLW). In addition, CIDR is funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. The National Eye Institute (Bethesda, MD) through ARRA Grants 3R01EY015872-05S1 (JLW) and 3R01EY019126-02S1 (MAH) supported the collection and processing of samples for the NEIGHBOR data set. Funding for the collection of cases and controls was provided by National Institutes of Health (Bethesda, MD) Grants: EY015543 (RRA), EY006827 (DG), HL073389 (E Hauser); EY13315 (MAH); EY09611 (S Hankinson), EY015473 (LRP), EY009149 (PRL), HG004608 (CAM), EY008208 (P Medeiros), EY012118 (MAP-V), EY015682 (TR), EY011671 (JER), EY09580 (JER), EY013178 (JSS), EY010886 (JLW), EY009847 (JLW), EY011008 (L Zangwill), EY144428 (KZ), EY144448 (KZ), EY18660 (KZ), UL1TR000427 (MHB) and U01HG006389 (CAM), P30 EY014104, R01 EY022305, and R21 EY022766. NR 73 TC 6 Z9 6 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-222X EI 1476-5454 J9 EYE JI Eye PD JUN PY 2014 VL 28 IS 6 BP 662 EP 671 DI 10.1038/eye.2014.42 PG 10 WC Ophthalmology SC Ophthalmology GA AK3QQ UT WOS:000338340200004 PM 24603425 ER PT J AU Qazi, Y Aggarwal, S Hamrah, P AF Qazi, Yureeda Aggarwal, Shruti Hamrah, Pedram TI Image-guided evaluation and monitoring of treatment response in patients with dry eye disease SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY LA English DT Review DE IVCM; OCT; Dry eye disease; Meibomian gland dysfunction; Confocal microscopy ID MEIBOMIAN GLAND DYSFUNCTION; OPTICAL COHERENCE TOMOGRAPHY; VIVO CONFOCAL MICROSCOPY; QUALITY-OF-LIFE; ANTERIOR-CHAMBER PARAMETERS; MENISCUS HEIGHT MEASUREMENT; PRIMARY SJOGRENS-SYNDROME; AQUEOUS TEAR DEFICIENCY; CONTACT-LENS WEARERS; HIGH-SCHOOL-STUDENTS AB Background Dry eye disease (DED) is one of the most common ocular disorders worldwide. The pathophysiological mechanisms involved in the development of DED are not well-understood, and thus treating DED has been a significant challenge for ophthalmologists. Most of the currently available diagnostic tests demonstrate low correlation to patient symptoms and have low reproducibility. Methods Recently, sophisticated in vivo imaging modalities have become available for patient care, namely, in vivo confocal microscopy (IVCM) and optical coherence tomography (OCT). These emerging modalities are powerful and non-invasive, allowing real-time visualization of cellular and anatomical structures of the cornea and ocular surface. Here we discuss how, by providing both qualitative and quantitative assessment, these techniques can be used to demonstrate early subclinical disease, grade layer-by-layer severity, and allow monitoring of disease severity by cellular alterations. Imaging-guided stratification of patients may also be possible in conjunction with clinical examination methods. Conclusions Visualization of subclinical changes and stratification of patients in vivo allows objective image-guided evaluation of tailored treatment response based on cellular morphological alterations specific to each patient. This image-guided approach to DED may ultimately improve patient outcomes and make it possible to study the efficacy of novel therapies in clinical trials. C1 [Qazi, Yureeda; Aggarwal, Shruti; Hamrah, Pedram] Massachusetts Eye & Ear Infirm, Cornea & Refract Surg Serv, Cornea Serv, Ocular Surface Imaging Ctr, Boston, MA 02114 USA. [Qazi, Yureeda; Aggarwal, Shruti; Hamrah, Pedram] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. RP Hamrah, P (reprint author), Massachusetts Eye & Ear Infirm, Cornea & Refract Surg Serv, Cornea Serv, Ocular Surface Imaging Ctr, 243 Charles St, Boston, MA 02114 USA. EM pedram_hamrah@meei.harvard.edu FU National Institute of Health [NIH K08-EY020575]; Research to Prevent Blindness Career Development Award; Falk Medical Research Foundation FX We would like to thank our sponsors for their generous support through grants from the National Institute of Health (NIH K08-EY020575 to PH), Research to Prevent Blindness Career Development Award (PH) and Falk Medical Research Foundation (PH). NR 231 TC 6 Z9 6 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0721-832X EI 1435-702X J9 GRAEF ARCH CLIN EXP JI Graefes Arch. Clin. Exp. Ophthalmol. PD JUN PY 2014 VL 252 IS 6 BP 857 EP 872 DI 10.1007/s00417-014-2618-2 PG 16 WC Ophthalmology SC Ophthalmology GA AK5UN UT WOS:000338492000001 PM 24696045 ER PT J AU Dupree, JM Patel, K Singer, SJ West, M Wang, R Zinner, MJ Weissman, JS AF Dupree, James M. Patel, Kavita Singer, Sara J. West, Mallory Wang, Rui Zinner, Michael J. Weissman, Joel S. TI Attention To Surgeons And Surgical Care Is Largely Missing From Early Medicare Accountable Care Organizations SO HEALTH AFFAIRS LA English DT Article ID HEALTH-CARE AB The Affordable Care Act supports the growth of accountable care organizations (ACOs) as a potentially powerful model for health care delivery and payment. The model focuses on primary care. However, surgeons and other specialists have a large role to play in caring for ACOs' patients. No studies have yet investigated the role of surgical care in the ACO model. Using case studies and a survey, we examined the early experience of fifty-nine Medicare-approved ACOs in providing surgical care. We found that ACOs have so far devoted little attention to surgical care. Instead, they have emphasized coordinating care for patients with chronic conditions and reducing unnecessary hospital readmissions and ED visits. In the years to come, ACOs will likely focus more on surgical care. Some ACOs have the ability to affect surgical practice patterns through referral pressures, but local market conditions may limit ACOs' abilities to alter surgeons' behavior. Policy makers, ACO administrators, and surgeons need to be aware of these trends because they have the potential to affect the surgical care provided to ACO patients as well as the success of ACOs themselves. C1 [Dupree, James M.] Amer Coll Surg, Chicago, IL USA. [Patel, Kavita] Brookings Inst, Engelberg Ctr Hlth Care Reform, Washington, DC 20036 USA. [Singer, Sara J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Singer, Sara J.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [West, Mallory] Brookings Inst, Washington, DC 20036 USA. [Wang, Rui; Zinner, Michael J.; Weissman, Joel S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Weissman, Joel S.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. RP Dupree, JM (reprint author), Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. EM jim.dupree@gmail.com FU American College of Surgeons FX This study was funded by a grant from the American College of Surgeons. Findings from this research were presented at the 2013 AcademyHealth Annual Research Meeting in Baltimore, Maryland, June 24, 2013. Kathy Corso provided valuable research assistance for this project. NR 14 TC 27 Z9 27 U1 2 U2 5 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JUN PY 2014 VL 33 IS 6 BP 972 EP 979 DI 10.1377/hlthaff.2013.1300 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AK1PL UT WOS:000338187200008 PM 24889946 ER PT J AU Hebert, PL Liu, CF Wong, ES Hernandez, SE Batten, A Lo, S Lemon, JM Conrad, DA Grembowski, D Nelson, K Fihn, SD AF Hebert, Paul L. Liu, Chuan-Fen Wong, Edwin S. Hernandez, Susan E. Batten, Adam Lo, Sophie Lemon, Jaclyn M. Conrad, Douglas A. Grembowski, David Nelson, Karin Fihn, Stephan D. TI Patient-Centered Medical Home Initiative Produced Modest Economic Results For Veterans Health Administration, 2010-12 SO HEALTH AFFAIRS LA English DT Article ID PRIMARY-CARE; COST SAVINGS; GROWTH; ACCESS AB In 2010 the Veterans Health Administration (VHA) began a nationwide initiative called Patient Aligned Care Teams (PACT) that reorganized care at all VHA primary care clinics in accordance with the patient-centered medical home model. We analyzed data for fiscal years 2003-12 to assess how trends in health care use and costs changed after the implementation of PACT. We found that PACT was associated with modest increases in primary care visits and with modest decreases in both hospitalizations for ambulatory care-sensitive conditions and outpatient visits with mental health specialists. We estimated that these changes avoided $596 million in costs, compared to the investment in PACT of $774 million, for a potential net loss of $178 million in the study period. Although PACT has not generated a positive return, it is still maturing, and trends in costs and use are favorable. Adopting patient-centered care does not appear to have been a major financial risk for the VHA. C1 [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Vet Affairs VA Hlth Serv Res & Dev Ctr Vet Ctr, Value Driven Hlth, Seattle, WA 98108 USA. [Hebert, Paul L.; Liu, Chuan-Fen; Hernandez, Susan E.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA. [Liu, Chuan-Fen; Wong, Edwin S.; Batten, Adam; Nelson, Karin] Value Driven Hlth, VA Hlth Serv Res & Dev Ctr Vet Ctr, Seattle, WA USA. [Lo, Sophie] Vet Hlth Adm Off Analyt & Business Intelligence, Bedford, MA USA. [Lemon, Jaclyn M.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Conrad, Douglas A.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Grembowski, David] Univ Washington, Seattle, WA 98195 USA. [Nelson, Karin; Fihn, Stephan D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, VHA Off Analyt & Business Intelligence, Seattle, WA USA. RP Hebert, PL (reprint author), VA Puget Sound Hlth Care Syst, Vet Affairs VA Hlth Serv Res & Dev Ctr Vet Ctr, Value Driven Hlth, Seattle, WA 98108 USA. EM paul.hebert2@va.gov FU Veterans Health Administration (VHA) Patient Centered Medical Home Demonstration Laboratory Coordination Center [XVA-61-041]; VHA Health Services Research and Development Career Development Award [CDA 13-024] FX This research was presented at the Society of General Internal Medicine Annual Meeting, Denver, Colorado, April 23, 2013; and the AcademyHealth Annual Research Meeting, Baltimore, Maryland, June 23, 2013. This work was funded by the Veterans Health Administration (VHA) Patient Centered Medical Home Demonstration Laboratory Coordination Center (Grant No. XVA-61-041). Edwin Wong is supported by a VHA Health Services Research and Development Career Development Award (Grant No. CDA 13-024). The views expressed herein are those of the authors and do not necessary represent the views of the Department of Veterans Affairs or other affiliated institutions. NR 21 TC 13 Z9 13 U1 1 U2 3 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JUN PY 2014 VL 33 IS 6 BP 980 EP 987 DI 10.1377/hlthaff.2013.0893 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AK1PL UT WOS:000338187200009 PM 24889947 ER PT J AU Guy, GP Yabroff, KR Ekwueme, DU Smith, AW Dowling, EC Rechis, R Nutt, S Richardson, LC AF Guy, Gery P., Jr. Yabroff, K. Robin Ekwueme, Donatus U. Smith, Ashley Wilder Dowling, Emily C. Rechis, Ruth Nutt, Stephanie Richardson, Lisa C. TI Estimating The Health And Economic Burden Of Cancer Among Those Diagnosed As Adolescents And Young Adults SO HEALTH AFFAIRS LA English DT Article ID UNITED-STATES; SURVIVORS; PRODUCTIVITY; PREVALENCE; IMPACT; CHALLENGES; COSTS; CARE AB Adolescent and young adult cancer survivors-those who were ages 15-39 at their first cancer diagnosis-have important health limitations. These survivors are at risk for higher health care expenditures and lost productivity, compared to adults without a history of cancer. Using Medical Expenditure Panel Survey data, we present nationally representative estimates of the economic burden among people who were diagnosed with cancer in adolescence or young adulthood. Our findings demonstrate that surviving cancer at this age is associated with a substantial economic burden. Compared to adults without a history of cancer, adolescent and young adult cancer survivors had excess annual medical expenditures of $3,170 per person and excess annual productivity losses of $2,250 per person. Multifaceted prevention strategies, including education and sustained intervention programs to ensure access to lifelong risk-based follow-up care, may be effective ways to improve the economic outcomes associated with cancer survivorship in this population. C1 [Guy, Gery P., Jr.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Yabroff, K. Robin; Smith, Ashley Wilder] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Ekwueme, Donatus U.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Dowling, Emily C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Rechis, Ruth] LIVESTRONG Fdn, Austin, TX USA. [Nutt, Stephanie] LIVESTRONG Fdn, Res & Evaluat Team, Austin, TX USA. [Richardson, Lisa C.] CDC, Div Blood Disorders, Atlanta, GA 30333 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. EM irm2@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 17 Z9 18 U1 7 U2 14 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JUN PY 2014 VL 33 IS 6 BP 1024 EP 1031 DI 10.1377/hlthaff.2013.1425 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AK1PL UT WOS:000338187200014 PM 24889952 ER PT J AU Choi, HR Bedair, H AF Choi, Ho-Rim Bedair, Hany TI Mortality Following Revision Total Knee Arthroplasty: A Matched Cohort Study of Septic versus Aseptic Revisions SO JOURNAL OF ARTHROPLASTY LA English DT Article DE total knee arthroplasty; septic revision; aseptic revision; mortality; longer-term ID PATIENT SURVIVAL; REPLACEMENT; INFECTION AB We report the medium-term mortality after septic versus aseptic revision total knee arthroplasty (TKA) and factors that can contribute to mortality in revision TKA. Mortality rates of 88 patients undergoing septic revision (septic group) were compared with age-and year of surgery-matched 88 patients of aseptic revision (aseptic group). The overall mortality after revision TKA was 10.7% at a median of 4 years of follow-up (range, 2-7 years). However, the mortality after septic revision (18%, 16/88) was six times higher than that of aseptic revision (3%, 3/88) (P = 0.003). Infections with Staphylococcus aureus and/or methicillin resistance was not associated with higher mortality rates. Multivariate analysis indicated that increased age (P < 0.001), higher ASA class (P = 0.002), and septic revision (P < 0.001) were identified as independent predictors of increased mortality after revision TKA. (C) 2014 Elsevier Inc. All rights reserved. C1 Massachusetts Gen Hosp, Harris Orthoped Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. RP Bedair, H (reprint author), Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. NR 17 TC 4 Z9 4 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD JUN PY 2014 VL 29 IS 6 BP 1216 EP 1218 DI 10.1016/j.arth.2013.11.026 PG 3 WC Orthopedics SC Orthopedics GA AK0PC UT WOS:000338115400029 PM 24405619 ER PT J AU Altenburger, EM Tung, ES Keuthen, NJ AF Altenburger, Erin M. Tung, Esther S. Keuthen, Nancy J. TI Body esteem in adolescent hair pullers SO JOURNAL OF BEHAVIORAL ADDICTIONS LA English DT Article DE hair pulling; trichotillomania; body esteem ID SELF-ESTEEM; TRICHOTILLOMANIA; DEPRESSION; CHILDREN; SCALE AB Background and aims: Trichotillomania (TTM) often first presents in adolescence, a developmental period marked by vulnerability in body image. To date, no one has studied the relationship between this disorder and body esteem. Methods: 49 adolescents with DSM-IV TTM or chronic hair pulling (HP) and 23 control adolescents were administered diagnostic assessments and self-report measures of hair pulling and body esteem. Results: HP youth vs. controls reported lower levels of body esteem on all Body-Esteem Scale for Adolescents and Adults (BESAA) subscales (appearance, attribution and weight satisfaction). HP contributed to lowered body esteem, independent of comorbid anxiety or depression. As expected, HP youth with vs. without comorbid anxiety or depression reported lowered levels of body esteem. Further, greater HP severity and distress were significantly associated with lower levels of body esteem. HP severity alone but not distress/impairment predicted lower levels of body esteem, independent of comorbid anxiety and depression. Conclusions: Both hair pulling and comorbid anxiety and depression can independently impact body esteem in adolescent hair pullers. C1 [Altenburger, Erin M.] Ohio State Univ, Columbus, OH 43210 USA. [Tung, Esther S.; Keuthen, Nancy J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Altenburger, EM (reprint author), Ohio State Univ, Dept Psychol, 181 Psychol Bldg,1835 Neil Ave, Columbus, OH 43210 USA. EM altenburger.20@buckeyemail.osu.edu FU Greater Kansas City Foundation FX This research was financially supported by a grant from the Greater Kansas City Foundation. The funding sponsor had no role in study design, data collection, data analysis or interpretation, manuscript preparation or the decision to submit the manuscript for publication. NR 15 TC 3 Z9 3 U1 0 U2 1 PU AKADEMIAI KIADO RT PI BUDAPEST PA PRIELLE K U 19, PO BOX 245,, H-1117 BUDAPEST, HUNGARY SN 2062-5871 EI 2063-5303 J9 J BEHAV ADDICT JI J. Behav. Addict. PD JUN PY 2014 VL 3 IS 2 BP 124 EP 127 DI 10.1556/JBA.3.2014.010 PG 4 WC Psychiatry SC Psychiatry GA AK3KC UT WOS:000338321100006 PM 25215223 ER PT J AU Ho, CH Ho, MG Ho, SP Ho, HH AF Ho, Cynthia H. Ho, Michael G. Ho, Shin-Pin Ho, Helen H. TI BITTER BOTTLE GOURD (LAGENARIA SICERARIA) TOXICITY SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE Cucurbitaceae; cucurbitacin; hematemesis; food-borne illness; food poisoning ID CUCURBITACIN-B; CANCER CELLS AB Background: Bottle gourd (Lagenaria siceraria) is an edible plant in the Cucurbitaceae family. When extremely bitter, ingestion of bottle gourd can cause rapid onset diarrhea, vomiting, gastrointestinal bleeding, and hypotension due to release of a substance named cucurbitacin. Objective: Our aim was to increase physician awareness of cucurbitacin poisoning in order to facilitate accurate diagnosis and appropriate management. Case Report: Five adult patients presented with nausea, vomiting, and diarrhea within 5 to 25 min of ingesting cooked bitter bottle gourd. One patient developed severe diarrhea, hematemesis, and hypotension requiring hospitalization. All patients improved within a few days with intravenous fluids and proton pump inhibitors. To our knowledge, this is the first reported group of patients with toxicity due to ingestion of bottle gourd in the United States (US). Conclusions: Physicians should be suspicious of cucurbitacin toxicity in patients who present with symptoms within minutes of ingestion of a plant in the Cucurbitaceae family. Patients should be asked if the plant tasted unusually bitter. The most common symptoms include diarrhea and hematemesis. More than half of patients develop hypotension. There is no known antidote for bottle gourd poisoning; treatment is supportive. Proton pump inhibitors should be given to patients with gastrointestinal mucosal injury. (C) 2014 Elsevier Inc. C1 [Ho, Cynthia H.] Univ So Calif, Dept Internal Med, Los Angeles Cty Univ Southen Calif Med Ctr, Los Angeles, CA 90033 USA. [Ho, Cynthia H.] Univ So Calif, Dept Pediat, Los Angeles Cty Univ Southen Calif Med Ctr, Los Angeles, CA 90033 USA. [Ho, Michael G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Ho, Shin-Pin] Henry Mayo Newhall Mem Hosp, Newhall, CA USA. [Ho, Helen H.] White Mem Med Ctr, Dept Emergency Med, Los Angeles, CA USA. RP Ho, CH (reprint author), Univ So Calif, Dept Internal Med, 2020 Zonal Ave,IRD Room 109, Los Angeles, CA 90033 USA. OI Ho, Michael/0000-0002-4893-3016 NR 14 TC 3 Z9 3 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 EI 1090-1280 J9 J EMERG MED JI J. Emerg. Med. PD JUN PY 2014 VL 46 IS 6 BP 772 EP 775 DI 10.1016/j.jemermed.2013.08.106 PG 4 WC Emergency Medicine SC Emergency Medicine GA AK1UB UT WOS:000338201100016 PM 24360122 ER PT J AU Walling, AM Dy, SM AF Walling, Anne M. Dy, Sydney M. TI The Importance of a Comprehensive, Patient-Centered Approach to End-of-Life Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID DISCUSSIONS; PREFERENCES; OUTCOMES C1 [Walling, Anne M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Walling, Anne M.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Dy, Sydney M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Dy, Sydney M.] Johns Hopkins Kimmel Canc Ctr, Harry J Duffey Family Pain & Palliat Care Program, Baltimore, MD USA. RP Dy, SM (reprint author), Rm 609,624 N Broadway, Baltimore, MD 21205 USA. EM sdy@jhsph.edu FU NCATS NIH HHS [UL1 TR000124, KL2 TR000122, KL2TR000122] NR 14 TC 1 Z9 1 U1 3 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2014 VL 29 IS 6 BP 822 EP 823 DI 10.1007/s11606-013-2757-x PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AK1VS UT WOS:000338206600002 PM 24420868 ER PT J AU Bailey, FA Williams, BR Woodby, LL Goode, PS Redden, DT Houston, TK Granstaff, US Johnson, TM Pennypacker, LC Haddock, KS Painter, JM Spencer, JM Hartney, T Burgio, KL AF Bailey, F. Amos Williams, Beverly R. Woodby, Lesa L. Goode, Patricia S. Redden, David T. Houston, Thomas K. Granstaff, U. Shanette Johnson, Theodore M., II Pennypacker, Leslye C. Haddock, K. Sue Painter, John M. Spencer, Jessie M. Hartney, Thomas Burgio, Kathryn L. TI Intervention to Improve Care at Life's End in Inpatient Settings: The BEACON Trial SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE palliative care; end-of-life care; palliative medicine; hospice; inpatient ID ILL CANCER-PATIENTS; SMALL-SAMPLE ADJUSTMENTS; PALLIATIVE CARE; OF-LIFE; INTENSIVE-CARE; PAIN MANAGEMENT; HOSPICE CARE; LAST HOURS; DEATH; OPPORTUNITIES AB BACKGROUND: Widespread implementation of palliative care treatment plans could reduce suffering in the last days of life by adopting best practices of traditionally home-based hospice care in inpatient settings. OBJECTIVE: To evaluate the effectiveness of a multi-modal intervention strategy to improve processes of end-of-life care in inpatient settings. DESIGN: Implementation trial with an intervention staggered across hospitals using a multiple-baseline, stepped wedge design. PARTICIPANTS: Six Veterans Affairs Medical Centers (VAMCs). INTERVENTION: Staff training was targeted to all hospital providers and focused on identifying actively dying patients and implementing best practices from home-based hospice care, supported with an electronic order set and paper-based educational tools. MAIN MEASURES: Several processes of care were identified as quality endpoints for end-of-life care (last 7 days) and abstracted from electronic medical records of veterans who died before or after intervention (n=6,066). Primary endpoints were proportion with an order for opioid pain medication at time of death, do-not-resuscitate order, location of death, nasogastric tube, intravenous line infusing, and physical restraints. Secondary endpoints were administration of opioids, order/administration of antipsychotics, benzodiazepines, and scopolamine (for death rattle); sublingual administration; advance directives; palliative care consultations; and pastoral care services. Generalized estimating equations were conducted adjusting for longitudinal trends. KEY RESULTS: Significant intervention effects were observed for orders for opioid pain medication (OR: 1.39), antipsychotic medications (OR: 1.98), benzodiazepines (OR: 1.39), death rattle medications (OR: 2.77), sublingual administration (OR: 4.12), nasogastric tubes (OR: 0.71), and advance directives (OR: 1.47). Intervention effects were not significant for location of death, do-not-resuscitate orders, intravenous lines, or restraints. CONCLUSIONS: This broadly targeted intervention strategy led to modest but statistically significant changes in several processes of care, indicating its potential for widespread dissemination to improve end-of-life care for thousands of patients who die each year in inpatient settings. (C) Society of General Internal Medicine 2014 C1 [Bailey, F. Amos; Williams, Beverly R.; Woodby, Lesa L.; Goode, Patricia S.; Redden, David T.; Granstaff, U. Shanette; Burgio, Kathryn L.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Birmingham, AL USA. [Bailey, F. Amos; Williams, Beverly R.; Woodby, Lesa L.; Goode, Patricia S.; Redden, David T.; Granstaff, U. Shanette; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL USA. [Houston, Thomas K.] US Dept Vet Affairs, VA eHlth Qual Enhancement Res Initiat, Bedford, MA USA. [Houston, Thomas K.] Univ Massachusetts Med Sch, Worcester, MA USA. [Johnson, Theodore M., II] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Decatur, GA USA. [Johnson, Theodore M., II] Emory Univ, Atlanta, GA 30322 USA. [Pennypacker, Leslye C.] Malcom Randall VA Med Ctr, Gainesville, FL USA. [Haddock, K. Sue] William Jennings Bryan Dorn VA Med Ctr, Columbia, SC USA. [Painter, John M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Spencer, Jessie M.] GV Sonny Montgomery VA Med Ctr, Jackson, MS USA. [Hartney, Thomas] Charlie Norwood VA Med Ctr, Augusta, GA USA. RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, 11G,700 South 19th St, Birmingham, AL 35233 USA. EM kburgio@uabmc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service [IIR 03-126] FX This research was supported by a Merit Review grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (IIR 03-126 "Intervention to Improve Care at Life's End in VA Medical Centers;" PI: KL Burgio, Co-PI: FA Bailey). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript. NR 62 TC 14 Z9 14 U1 2 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2014 VL 29 IS 6 BP 836 EP 843 DI 10.1007/s11606-013-2724-6 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AK1VS UT WOS:000338206600008 PM 24449032 ER PT J AU Wald, HL Leykum, LK Mattison, MLP Vasilevskis, EE Meltzer, DO AF Wald, Heidi L. Leykum, Luci K. Mattison, Melissa L. P. Vasilevskis, Eduard E. Meltzer, David O. TI Road Map to a Patient-Centered Research Agenda at the Intersection of Hospital Medicine and Geriatric Medicine SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE geriatrics; hospitals; hospitalists; patient-centered care; research ID OLDER PATIENTS; CARE; ADULTS AB As the United States ages, the patient population in acute care hospitals is increasingly older and more medically complex. Despite evidence of a high burden of disease, high costs, and often poor outcomes of care, there is limited understanding of the presentation, diagnostic strategies, and management of acute illness in older adults. In this paper, we present a strategy for the development of a research agenda at the intersection of hospital and geriatric medicine. This approach is informed by the Patient-Centered Outcomes Research Institute (PCORI) framework for identification and prioritization of research areas, emphasizing input from patients and caregivers. The framework's four components are: 1) Topic generation, 2) Gap Analysis in Systematic Review, 3) Value of information (VOI) analysis, and 4) Peer Review. An inclusive process for topic generation requiring the systematic engagement of multiple stakeholders, especially patients, is emphasized. In subsequent steps, researchers and stakeholders prioritize research topics in order to identify areas that optimize patient-centeredness, population impact, impact on clinical decision making, ease of implementation, and durability. Finally, next steps for dissemination of the research agenda and evaluation of the impact of the patient-centered research prioritization process are described. (C) Society of General Internal Medicine 2014 C1 [Wald, Heidi L.] Univ Colorado Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Mattison, Melissa L. P.] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Mattison, Melissa L. P.] Harvard Univ, Sch Med, Boston, MA USA. [Vasilevskis, Eduard E.] Vanderbilt Univ, Div Gen Internal Med & Publ Hlth, Sect Hosp Med, Nashville, TN 37235 USA. [Vasilevskis, Eduard E.] Vanderbilt Univ, Ctr Qual Aging, Nashville, TN 37235 USA. [Vasilevskis, Eduard E.] GRECC, Nashville, TN USA. [Meltzer, David O.] Univ Chicago, Chicago, IL 60637 USA. RP Wald, HL (reprint author), Div Hlth Care Policy & Res, Dept Med, Campus Box F480 13199 E Moniview Blvd,Suite 400, Aurora, CO 80024 USA. EM Heidi.wald@ucdenver.edu RI Meltzer, David/C-2926-2009 OI Meltzer, David/0000-0003-2790-7393 FU American Association of Instructors of Medicine/Association of Specialty Providers; John A. Hartford Foundation; Paul Beeson Career Development Award in Aging (NIA) [5 K23 AG034544]; Rx Foundation; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [REA 05-129, CDA 07-022]; South Texas Veterans Health Care System; National Institute On Aging of the National Institutes of Health [K23AG040157]; Veterans Affairs Clinical Research Center of Excellence; Geriatric Research, Education and Clinical Center (GRECC) FX This work was supported by the American Association of Instructors of Medicine/Association of Specialty Providers, and the John A. Hartford Foundation. Dr. Wald is supported by a Paul Beeson Career Development Award in Aging (NIA 5 K23 AG034544). Dr. Mattison acknowledges the support of Rx Foundation. This work was also supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (REA 05-129, CDA 07-022). Investigator salary support (to Dr. Leykum) is provided through this funding, and through the South Texas Veterans Health Care System. Dr. Vasilevskis was supported by the National Institute On Aging of the National Institutes of Health (K23AG040157) and the Veterans Affairs Clinical Research Center of Excellence, and the Geriatric Research, Education and Clinical Center (GRECC). NR 23 TC 5 Z9 5 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2014 VL 29 IS 6 BP 926 EP 931 DI 10.1007/s11606-014-2777-1 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AK1VS UT WOS:000338206600023 PM 24557516 ER PT J AU Arbaje, AI Kansagara, DL Salanitro, AH Englander, HL Kripalani, S Jencks, SF Lindquist, LA AF Arbaje, Alicia I. Kansagara, Devan L. Salanitro, Amanda H. Englander, Honora L. Kripalani, Sunil Jencks, Stephen F. Lindquist, Lee A. TI Regardless of Age: Incorporating Principles from Geriatric Medicine to Improve Care Transitions for Patients with Complex Needs SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE care transitions; geriatrics; utilization; healthcare delivery; vulnerable populations ID CONGESTIVE-HEART-FAILURE; OLDER-ADULTS; HOSPITAL READMISSION; RANDOMIZED-TRIAL; RISK; INTERVENTION; CAREGIVERS; SETTINGS; REHOSPITALIZATIONS; DEMENTIA AB With its focus on holistic approaches to patient care, caregiver support, and delivery system redesign, geriatrics has advanced our understanding of optimal care during transitions. This article provides a framework for incorporating geriatrics principles into care transition activities by discussing the following elements: (1) identifying factors that make transitions more complex, (2) engaging care "receivers" and tailoring home care to meet patient needs, (3) building "recovery plans" into transitional care, (4) predicting and avoiding preventable readmissions, and (5) adopting a palliative approach, when appropriate, that optimizes patient and family goals of care. The article concludes with a discussion of practical aspects of designing, implementing, and evaluating care transitions programs for those with complex care needs, as well as implications for public policy. (C) Society of General Internal Medicine 2014 C1 [Arbaje, Alicia I.] Johns Hopkins Univ, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA. [Kansagara, Devan L.] Oregon Hlth & Sci Univ, Sect Gen Internal Med, Portland VA Med Ctr, Portland, OR 97201 USA. [Salanitro, Amanda H.] Vanderbilt Univ Sch Med, Nashville, TN USA. [Englander, Honora L.] Oregon Hlth & Sci Univ, Div Hosp Med, Portland, OR 97201 USA. [Kripalani, Sunil] Vanderbilt Univ Sch Med, Div Gen Internal Med & Publ Hlth, Sect Hosp Med, Nashville, TN USA. [Jencks, Stephen F.] Healthcare Safety & Qual, Baltimore, MD USA. [Lindquist, Lee A.] Northwestern Univ Feinberg Sch Med, Sect Gen Internal Med & Geriatr, Dept Med, Chicago, IL USA. RP Arbaje, AI (reprint author), Johns Hopkins Univ, Dept Med, Div Geriatr Med & Gerontol, Mason F Lord Bldg,Ctr Tower,5200 Eastern Ave,7th, Baltimore, MD 21224 USA. EM aarbaje@jhmi.edu FU Association of Specialty Professors FX The Association of Specialty Professors provided funding for the conceptualization of priority areas for publication, of which this manuscript is one. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 49 TC 2 Z9 2 U1 3 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2014 VL 29 IS 6 BP 932 EP 939 DI 10.1007/s11606-013-2729-1 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AK1VS UT WOS:000338206600024 PM 24557511 ER PT J AU Edwards, ST Mafi, JN Landon, BE AF Edwards, Samuel T. Mafi, John N. Landon, Bruce E. TI Trends and Quality of Care in Outpatient Visits to Generalist and Specialist Physicians Delivering Primary Care in the United States, 1997-2010 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE primary health care; primary care physicians; specialization; health manpower; patient-centered care ID CENTERED MEDICAL HOME; INTERNAL-MEDICINE; AMBULATORY-CARE; HEALTH; SERVICES; WORKFORCE; OUTCOMES; SYSTEM; WILL AB BACKGROUND: Although many specialists serve as primary care physicians (PCPs), the type of patients they serve, the range of services they provide, and the quality of care they deliver is uncertain. OBJECTIVE: To describe trends in patient, physician, and visit characteristics, and compare visit-based quality for visits to generalists and specialists self-identified as PCPs. DESIGN: Cross-sectional study and time trend analysis. DATA: Nationally representative sample of visits to office-based physicians from the National Ambulatory Medical Care Survey, 1997-2010. MAIN MEASURES: Proportions of primary care visits to generalist and specialists, patient characteristics, principal diagnoses, and quality. KEY RESULTS: Among 84,041 visits to self-identified PCPs representing an estimated 4.0 billion visits, 91.5 % were to generalists, 5.9 % were to medical specialists and 2.6 % were to obstetrician/gynecologists. The proportion of PCP visits to generalists increased from 88.4 % in 1997 to 92.4 % in 2010, but decreased for medical specialists from 8.0 % to 4.8 %, p=0.04). The proportion of medical specialist visits in which the physician self-identified as the patient's PCP decreased from 30.6 % in 1997 to 9.8 % in 2010 (p<0.01). Medical specialist PCPs take care of older patients (mean age 61 years), and dedicate most of their visits to chronic disease management (51.0 %), while generalist PCPs see younger patients (mean age 55.4 years) most commonly for new problems (40.5 %). Obstetrician/gynecologists self-identified as PCPs see younger patients (mean age 38.3 p<0.01), primarily for preventive care (54.0 %, p<0.01). Quality of care for cardiovascular disease was better in visits to cardiologists than in visits to generalists, but was similar or better in visits to generalists compared to visits to other medical specialists. CONCLUSIONS: Medical specialists are less frequently serving as PCPs for their patients over time. Generalist, medical specialist, and obstetrician/gynecologist PCPs serve different primary care roles for different populations. Delivery redesign efforts must account for the evolving role of generalist and specialist PCPs in the delivery of primary care. C1 [Edwards, Samuel T.] Vet Affairs VA Boston Healthcare Syst, Sect Gen Internal Med, Boston, MA USA. [Edwards, Samuel T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. [Edwards, Samuel T.; Mafi, John N.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Mafi, John N.; Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Landon, Bruce E.] Harvard Univ, Dept Hlth Care Policy, Sch Med, Boston, MA 02115 USA. RP Landon, BE (reprint author), Harvard Univ, Dept Hlth Care Policy, Sch Med, 180 Longwood Ave, Boston, MA 02115 USA. EM landon@hcp.med.harvard.edu FU Massachusetts Veteran's Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA; US Health Services and Research Administration [T32HP12706]; Ryoichi Sasakawa Fellowship Fund FX Dr. Edwards was supported by the Massachusetts Veteran's Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA. Dr. Mafi was supported by a National Research Service Award training grant T32HP12706 from the US Health Services and Research Administration and by the Ryoichi Sasakawa Fellowship Fund. NR 32 TC 12 Z9 12 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2014 VL 29 IS 6 BP 947 EP 955 DI 10.1007/s11606-014-2808-y PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AK1VS UT WOS:000338206600026 PM 24567201 ER PT J AU Chiovaro, JC Gaggar, A AF Chiovaro, Joseph C. Gaggar, Anuj TI Crystalline Bone Marrow in Systemic Oxalosis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID PRIMARY HYPEROXALURIA C1 [Chiovaro, Joseph C.] Portland VA Med Ctr, Portland, OR USA. [Chiovaro, Joseph C.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Gaggar, Anuj] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Chiovaro, JC (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA. EM jchiovaro@gmail.com NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2014 VL 29 IS 6 BP 961 EP 961 DI 10.1007/s11606-013-2618-7 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AK1VS UT WOS:000338206600028 PM 24078429 ER PT J AU Wakeman, SE AF Wakeman, Sarah E. TI One Shot SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Wakeman, Sarah E.] Massachusetts Gen Hosp, Div Gen Med, Dept Med, Boston, MA 02114 USA. [Wakeman, Sarah E.] Harvard Univ, Sch Med, Boston, MA USA. RP Wakeman, SE (reprint author), Massachusetts Gen Hosp, Div Gen Med, Dept Med, 101 Merrimac St,6th Floor, Boston, MA 02114 USA. EM swakeman@partners.org NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2014 VL 29 IS 6 BP 968 EP 969 DI 10.1007/s11606-013-2715-7 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AK1VS UT WOS:000338206600032 PM 24366396 ER PT J AU Cardo, LF Coto, E Ribacoba, R Mata, IF Moris, G Menendez, M Alvarez, V AF Cardo, Lucia F. Coto, Eliecer Ribacoba, Rene Mata, Ignacio F. Moris, German Menendez, Manuel Alvarez, Victoria TI The screening of the 3 ' UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease SO JOURNAL OF HUMAN GENETICS LA English DT Article DE DNA polymorphisms; genetic risk; LRRK2 gene; microRNAs; Parkinson's disease ID MUTATION; VARIANTS; BRAIN; SNCA; GENE AB Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common genetic determinants of familial and sporadic Parkinson's disease (PD). Most of the mutational screenings analyzed the exon-coding sequence. Our aim was to determine whether LRRK2 3' untranslated region (UTR) variants were associated with the risk of developing PD in a large cohort of patients (n = 743) and controls (n = 523) from Spain. We identified a total of 12 3'UTR variants (two new). Single-nucleotide polymorphism (SNP) rs66737902 C allele was overrepresented in patients (P = 0.005; odds ratio = 1.47). This SNP was in linkage disequilibrium with the p.R1441G mutation, but the association remained significant among mutation-negative cases. We found a significant lower level of the LRRK2 transcript in the Substantia nigra (SN) of PD postmortem donors (n = 9) who were rs66737902 C carriers (P = 0.01). This SNP was predicted to affect a binding site for miR-138-2-3p. We showed that this microRNA was expressed in all the SN samples. In conclusion, we found a significant association between SNP rs66737902 and the risk of developing PD. This effect on PD risk could be explained by differences in LRRK2 transcript levels between the two alleles. C1 [Cardo, Lucia F.; Coto, Eliecer; Alvarez, Victoria] Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo 33006, Spain. [Coto, Eliecer] Univ Oviedo, Dept Med, Oviedo, Spain. [Ribacoba, Rene; Moris, German; Menendez, Manuel] Hosp Univ Cent Asturias & Alvarez Buylla Mieres, Asturias, Spain. [Mata, Ignacio F.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Mata, Ignacio F.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. RP Alvarez, V (reprint author), Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo 33006, Spain. EM victoria.alvarez@sespa.princast.es FU 'Fundacion Parkinson Asturias'; 'Obra Social Cajastur'; Spanish 'Fondo de Investigaciones Sanitarias-Fondos FEDER' European Union [FIS 11/0093]; FICYT-Principado de Asturias FX We thank Dr Claire Troakes and the London Neurodegenerative Diseases Brain Bank for supplying all post mortem brain samples. We also thank the 'Fundacion Parkinson Asturias' and 'Obra Social Cajastur' for their support. This work was supported by grants from the Spanish 'Fondo de Investigaciones Sanitarias-Fondos FEDER' European Union (FIS 11/0093). LFC is a predoctoral fellowship from FICYT-Principado de Asturias. NR 17 TC 2 Z9 2 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1434-5161 EI 1435-232X J9 J HUM GENET JI J. Hum. Genet. PD JUN PY 2014 VL 59 IS 6 BP 346 EP 348 DI 10.1038/jhg.2014.26 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA AK1PC UT WOS:000338186000010 PM 24758914 ER PT J AU Miyamoto, N Pham, LDD Maki, T Liang, AC Arai, K AF Miyamoto, Nobukazu Pham, Loc-Duyen D. Maki, Takakuni Liang, Anna C. Arai, Ken TI A radical scavenger edaravone inhibits matrix metalloproteinase-9 upregulation and blood-brain barrier breakdown in a mouse model of prolonged cerebral hypoperfusion SO NEUROSCIENCE LETTERS LA English DT Article DE White matter injury; Prolonged cerebral hypoperfusion; Matrix metalloproteinase-9; Blood-brain barrier; Edaravone ID GENE KNOCK-OUT; MATRIX-METALLOPROTEINASE; NEUROVASCULAR UNIT; ENDOTHELIAL-CELLS; FOCAL ISCHEMIA; INJURY; MECHANISMS; STROKE; OLIGODENDROCYTE; HEALTH AB Matrix metalloproteinase-9 (MMP-9) plays key roles in the brain pathophysiology, especially in blood-brain barrier (BBB) breakdown. Therefore, inhibiting MMP-9 activity may be a promising therapy for protecting brains in cerebrovascular diseases. Here we show that in a mouse prolonged cerebral hypoperfusion model, a clinically proven radical scavenger edaravone suppressed MMP-9 and reduced BBB damage in cerebral white matter. Prolonged cerebral hypoperfusion was induced by bilateral common carotid artery stenosis in male adult C57BL/6J mice (10 weeks old). After 7 days of cerebral hypoperfusion, white matter region (e.g. corpus callosum) exhibited significant BBB leakage, assessed by IgG staining. Correspondingly, immunostaining and western blotting showed that MMP-9 was upregulated in the white matter. Edaravone treatment (3 mg/kg, i.p. at days 0 and 3) inhibited both BBB leakage and MMP-9 increase. Under the early phase of cerebral hypoperfusion conditions, oligodendrocyte precursor cells (OPCs) mainly contribute to the MMP-9 increase, but our immunostaining data showed that very little OPCs expressed MMP-9 in the edaravone-treated animals at day 7. Therefore, in vitro studies with primary rat OPCs were conducted to examine whether edaravone would directly suppressed MMP-9 expressions in OPCs. OPC cultures were exposed to sub-lethal CoCl2 for 7 days to induce prolonged chemical hypoxic stress. Prolonged chemical hypoxic stress increased MMP-9 expression in OPCs, and radical scavenging with edaravone (10 mu M for 7 days) ameliorated the increase. Taken together, our proof-of-concept study demonstrates that radical scavengers may provide a potential therapeutic approach for white matter injury by suppressing BBB damage. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Arai, K (reprint author), Neuroprotect Res Lab, MGH East 149-2401, Charlestown, MA 02129 USA. EM karai@partners.org FU National Institutes of Health, Research Abroad from the Uehara Memorial Foundation FX Supported in part by National Institutes of Health, Research Abroad from the Uehara Memorial Foundation. We thank Dr. Eng H. Lo for many helpful discussions. NR 49 TC 2 Z9 5 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 EI 1872-7972 J9 NEUROSCI LETT JI Neurosci. Lett. PD JUN PY 2014 VL 573 BP 40 EP 45 DI 10.1016/j.neulet.2014.05.005 PG 6 WC Neurosciences SC Neurosciences & Neurology GA AK4MV UT WOS:000338399700008 PM 24820542 ER PT J AU Nguyen, PL AF Nguyen, Paul L. TI The Role of Radical Prostatectomy and Lymph Node Dissection in the Treatment of Young Men With High-Grade Node-Positive Prostate Cancer: Less Is More-the Benefits of Surgery Do Not Yet Outweigh Potential Harms SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID PELVIC LYMPHADENECTOMY C1 [Nguyen, Paul L.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. [Nguyen, Paul L.] Harvard Univ, Sch Med, Boston, MA USA. RP Nguyen, PL (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD JUN PY 2014 VL 28 IS 6 BP 523 EP + PG 2 WC Oncology SC Oncology GA AK0FL UT WOS:000338088200011 PM 25134329 ER PT J AU Joseph, NT Kamarck, TW Muldoon, MF Manuck, SB AF Joseph, Nataria Tennille Kamarck, Thomas W. Muldoon, Matthew F. Manuck, Stephen B. TI Daily Marital Interaction Quality and Carotid Artery Intima-Medial Thickness in Healthy Middle-Aged Adults SO PSYCHOSOMATIC MEDICINE LA English DT Article DE marital quality; marital interaction; ecological momentary assessment; intima-media thickness; cardiovascular disease ID CORONARY-HEART-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; DAILY-LIFE; WOMEN; RISK; ASSOCIATION; STRESS; SAMPLE; PROGRESSION AB Objective: To examine the association between marital interaction quality during daily life and subclinical cardiovascular disease (CVD). Studies have shown that marital status and quality of marriage are associated with cardiovascular health. However, little is known about the role of marital interaction quality during daily life in contributing to these effects. Methods: The sample consisted of 281 healthy, employed middle-aged adults who were married or living with a partner in a marital-like relationship (mean age = 42.0 years, 88% white, 52% men). Marital interaction quality was assessed using hourly real-time ecological momentary assessments for 4 days, with participants rating their current or recent partner interactions on positive and negative characteristics (e. g., agreeableness and conflict). Carotid artery intima-medial thickness (IMT) was assessed using ultrasound imaging. Results: Adjusting for demographics, positive marital interaction was inversely associated with IMT (b = -0.02, F(1,275) = 9.18, p = .002), and negative marital interaction was positively associated with IMT (b = 0.02 F(1,275) = 10.29, p = .001). These associations were not accounted for by behavioral and biological CVD risk factors and were consistent across age, sex, race, and education. The associations were also independent of marital interaction frequency, nonmarital social interaction quality, and personality factors. Global reports of marital quality, in contrast, were not associated with IMT. Conclusions: Marital quality as measured during real-time interactions between partners was associated with subclinical CVD in healthy middle-aged adults. This study supports the use of real-time social interaction assessment for characterizing links between social relationships and cardiovascular health. C1 [Joseph, Nataria Tennille] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Kamarck, Thomas W.] Univ Pittsburgh, Dept Psychiat & Psychol, Pittsburgh, PA USA. [Muldoon, Matthew F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. RP Joseph, NT (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM nataria.joseph@va.gov FU National Institutes of Health [P01 HL040962, T32 HL007560]; VA Office of Academic Affiliations' Women's Health Fellowship Program FX This research was supported by National Institutes of Health Grants P01 HL040962 awarded to Drs. Manuck, Kamarck, and Muldoon and T32 HL007560 (fellowship) awarded to Dr. Joseph. Dr. Joseph is currently supported by the VA Office of Academic Affiliations' Women's Health Fellowship Program. The authors have no conflicts of interest to disclose. NR 49 TC 11 Z9 11 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD JUN PY 2014 VL 76 IS 5 BP 347 EP 354 DI 10.1097/PSY.0000000000000071 PG 8 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA AK0TQ UT WOS:000338128800004 PM 24915293 ER PT J AU Wallace, ZS Deshpande, V Stone, JH AF Wallace, Zachary S. Deshpande, Vikram Stone, John H. TI Ophthalmic manifestations of IgG4-related disease: Single-center experience and literature review SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE IgG4-related disease; Orbital pseudotumor; Dacryoadenitis; Myositis; Idiopathic inflammation; Rituximab ID IDIOPATHIC ORBITAL INFLAMMATION; INFRAORBITAL NERVE ENLARGEMENT; SYSTEMIC SCLEROSING DISEASE; OCULAR ADNEXA; TEMPORAL BONE; IGG4 DISEASE; FEATURES; PACHYMENINGITIS; NOMENCLATURE; PSEUDOTUMOR AB Objectives: IgG4-related disease (IgG4-RD) is an inflammatory disorder responsible for fibrosing, tumefactive lesions that can involve the lacrimal gland as well as the extraocular muscles, orbital soft tissues, sclera, and local nerves. We reviewed IgG4-related ophthalmic disease (IgG4-ROD), including the natural history, pathology, and treatment, based on our center's experience and that reported in the literature. Methods: We identified 27 patients with orbital manifestations from our IgG4-RD registry; six were excluded because no pathology was available for review. All 21 cases included had histopathologically confirmed diagnoses of IgG4-RD, 11 of which were of the orbital tissue. Other data were obtained by a retrospective medical records review. MEDLINE and PubMed literature searches in English were conducted to identify articles for a literature review on the topic. Results: Patients with IgG4-ROD were predominantly male (57%) and had an average age at symptom onset of 50 years (range: 21-79 years). The lacrimal gland was the most commonly involved structure (62%). Most patients (71%) had bilateral disease and extra-orbital involvement (71%); these patients also had elevated serum IgG4 concentrations compared to those with unilateral disease and no extra-orbital disease. Ten patients improved following rituximab treatment. Conclusions: Ophthalmic involvement is a common manifestation of IgG4-RD and can affect nearly every orbital structure. Consideration of IgG4-RD and accurate diagnosis by biopsy have important implications for prognosis and treatment following the distinction of this condition from the Sjogren syndrome (SjS), granulomatosis with polyangiitis (CPA, formerly Wegener's), sarcoidosis, lymphoma, infection, and other disorders. Rituximab holds promise as an effective steroid-sparing agent or therapy for steroid-resistant cases. (C) 2014 Published by Elsevier Inc. C1 [Wallace, Zachary S.; Stone, John H.] Massachusetts Gen Hosp, Div Allergy Immunol & Rheumatol, Boston, MA 02114 USA. [Wallace, Zachary S.; Deshpande, Vikram; Stone, John H.] Harvard Univ, Sch Med, Boston, MA USA. [Wallace, Zachary S.; Stone, John H.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Stone, JH (reprint author), Massachusetts Gen Hosp, Rheumatol Unit Yawkey 2, 55 Fruit St, Boston, MA 02114 USA. EM jhstone@partners.org FU Genentech FX Dr. Stone has received funding from Genentech for an investigator-initiated study evaluating the use of rituximab in IgG4-RD. NR 62 TC 33 Z9 36 U1 1 U2 10 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0049-0172 EI 1532-866X J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD JUN PY 2014 VL 43 IS 6 BP 806 EP 817 DI 10.1016/j.semarthrit.2013.11.008 PG 12 WC Rheumatology SC Rheumatology GA AK1KK UT WOS:000338173800015 PM 24513111 ER PT J AU Prapruttam, D Hedgire, SS Mani, SE Chandramohan, A Shyamkumar, NK Harisinghani, K AF Prapruttam, Duangkamon Hedgire, Sandeep S. Mani, Sunithi Elizabeth Chandramohan, Anuradha Shyamkumar, N. K. Harisinghani, Kukesh TI Tuberculosis-The Great Mimicker SO SEMINARS IN ULTRASOUND CT AND MRI LA English DT Article ID CONTRAST-ENHANCED CT; RADIOLOGIC-PATHOLOGICAL CORRELATION; FOCAL SPLENIC LESIONS; ABDOMINAL LYMPH-NODES; PANCREATIC TUBERCULOSIS; PULMONARY TUBERCULOSIS; GENITOURINARY TUBERCULOSIS; IMMUNOCOMPETENT PATIENT; HEPATIC TUBERCULOSIS; ADRENAL TUBERCULOSIS AB Tuberculosis is 'an immense health problem in the developing world, and it remains a health care challenge in the developed world. It can affect virtually any organ system in the body. Diagnosis of tuberculosis is often difficult. Many patients with tuberculosis present with nonspecific symptoms, negative purified protein derivative skin test result, and negative findings on culture specimens. Cross-sectional imaging with ultrasound, multidetector computed tomography, and magnetic resonance imaging plays an important role in the diagnosis of tuberculosis. Tuberculosis demonstrates a variety of radiologic features depending on the organ involved and can mimic a number of other disease entities. Cross-sectional imaging alone is insufficient in reaching a conclusive diagnosis. Tuberculosis is a great mimicker as its radiologic manifestations can simulate numerous other diseases across the body systems. However, recognition and understanding of the common and uncommon radiologic manifestations of tuberculosis should alert considering tuberculosis in the high-risk population and correct clinical setting to enable appropriate treatment. (C) 2014 Elsevier Inc. All rights reserved. C1 [Prapruttam, Duangkamon; Hedgire, Sandeep S.; Harisinghani, Kukesh] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA. [Mani, Sunithi Elizabeth; Chandramohan, Anuradha; Shyamkumar, N. K.] Christian Med Coll & Hosp, Dept Radiol, Vellore, Tamil Nadu, India. RP Hedgire, SS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent, 55 Fruit St,White 270, Boston, MA 02114 USA. EM Hedgire.Sandeep@mgh.harvard.edu NR 87 TC 6 Z9 6 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0887-2171 EI 1558-5034 J9 SEMIN ULTRASOUND CT JI Semin. Ultrasound CT MRI PD JUN PY 2014 VL 35 IS 3 BP 195 EP 214 DI 10.1053/j.sult.2014.02.002 PG 20 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AK2RX UT WOS:000338268300002 PM 24929261 ER PT J AU Diyabalanage, HVK Van de Bittner, GC Ricq, EL Hooker, JM AF Diyabalanage, Himashinie V. K. Van de Bittner, Genevieve C. Ricq, Emily L. Hooker, Jacob M. TI A Chemical Strategy for the Cell-Based Detection of HDAC Activity SO ACS CHEMICAL BIOLOGY LA English DT Article ID HISTONE DEACETYLASE INHIBITORS; ACTIVITY-BASED PROBES; FLUORESCENT-PROBES; CANCER; EPIGENETICS; DISEASE; ACETYLTRANSFERASES; ACETYLATION; VORINOSTAT; DISORDERS AB A strategy for activity-based enzyme detection using a novel enamide-based chemical strategy is described. Enzymatic cleavage of an amide bond results in the formation of an aldehyde. The interaction of this aldehyde with proteins increases retention in cells that express the enzyme. Proof of concept for this enamide-based strategy is demonstrated by detecting histone deacetylase (HDAC) activity in He La cells. The modular design of this strategy makes it amenable to in vitro and in vivo detection. C1 [Diyabalanage, Himashinie V. K.; Van de Bittner, Genevieve C.; Ricq, Emily L.; Hooker, Jacob M.] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Sch Med,Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Hooker, JM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Sch Med,Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM hooker@nmr.mgh.harvard.edu FU NIH [2T32CA009502, R01DA030321] FX This research was supported by the NIH (2T32CA009502 and R01DA030321). C. Sheridan and M. Granda are acknowledged for technical assistance in cell culture studies. The authors would like to thank members of the Hooker and Haggarty laboratories at MGH for helpful discussions. NR 38 TC 3 Z9 3 U1 4 U2 21 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD JUN PY 2014 VL 9 IS 6 BP 1257 EP 1262 DI 10.1021/cb500248r PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AJ7IN UT WOS:000337870500006 PM 25056147 ER PT J AU Gordon, M Greene, M Frumento, P Rolfson, O Garellick, G Stark, A AF Gordon, Max Greene, Meridith Frumento, Paolo Rolfson, Ola Garellick, Garan Stark, Andre TI Age- and health-related quality of life after total hip replacement Decreasing gains in patients above 70 years of age SO ACTA ORTHOPAEDICA LA English DT Article ID JOINT ARTHROPLASTY; PROGNOSTIC-FACTORS; KNEE ARTHROPLASTY; CUTPOINTS; OUTCOMES; VALUES AB Background - While age is a common confounder, its impact on health-related quality of life (HRQoL) after total hip replacement is uncertain. This could be due to improper statistical modeling of age in previous studies, such as treating age as a linear variable or by using age categories. We hypothesized that there is a non-linear association between age and HRQoL. Methods - We selected a nationwide cohort from the Swedish Hip Arthroplasty Register of patients operated with total hip replacements due to primary osteoarthritis between 2008 and 2010. For estimating HRQoL, we used the generic health outcome questionnaire EQ-5D of the EuroQol group that consits or 2 parts: the EQ-5D index and the EQ VAS estimates. Using linear regression, we modeled the EQ-5D index and the EQ VAS against age 1 year after surgery. Instead of using a straight line for age, we applied a method called restricted cubic splines that allows the line to bend in a controlled manner. Confounding was controlled by adjusting for preoperative HRQoL, sex, previous contralateral hip surgery, pain, and Charnley classification. Results - Complete data on 27,245 patients were available for analysis. Both the EQ-5D index and EQ VAS showed a non-linear relationship with age. They were fairly unaffected by age until the patients were in their late sixties, after which age had a negative effect. Interpretation - There is a non-linear relationship between age and HRQoL, with improvement decreasing in the elderly. C1 [Gordon, Max; Greene, Meridith; Rolfson, Ola; Garellick, Garan] Swedish Hip Arthroplasty Register, Gothenburg, Sweden. [Gordon, Max; Stark, Andre] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden. [Greene, Meridith] Massachusetts Gen Hosp, Orthopaed Lab, Boston, MA 02114 USA. [Frumento, Paolo] Karolinska Inst, Inst Environm Med IMM, Stockholm, Sweden. [Rolfson, Ola; Garellick, Garan] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Orthopaed, Gothenburg, Sweden. RP Gordon, M (reprint author), Swedish Hip Arthroplasty Register, Gothenburg, Sweden. EM max@gforge.se RI Gordon, Max/M-4330-2014; OI Rolfson, Ola/0000-0001-6534-1242; Gordon, Max/0000-0002-8080-5815; Stark, Andre/0000-0002-8665-2899 NR 33 TC 8 Z9 8 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1745-3674 EI 1745-3682 J9 ACTA ORTHOP JI Acta Orthop. PD JUN PY 2014 VL 85 IS 3 BP 244 EP 249 DI 10.3109/17453674.2014.916492 PG 6 WC Orthopedics SC Orthopedics GA AJ6ZI UT WOS:000337845000007 PM 24786908 ER PT J AU Goldvasser, D Hansen, VJ Noz, ME Maguire, GQ Zeleznik, MP Olivecrona, H Bragdon, CR Weidenhielm, L Malchau, H AF Goldvasser, Dov Hansen, Viktor J. Noz, Marilyn E. Maguire, Gerald Q., Jr. Zeleznik, Michael P. Olivecrona, Henrik Bragdon, Charles R. Weidenhielm, Lars Malchau, Henrik TI In vivo and ex vivo measurement of polyethylene wear in total hip arthroplasty SO ACTA ORTHOPAEDICA LA English DT Article ID CROSS-LINKED POLYETHYLENE; COMPUTED-TOMOGRAPHY; CT; TRIAL AB Background - Determination of the amount of wear in a polyethylene liner following total hip arthroplasty (THA) is important for both the clinical care of individual patients and the development of new types of liners. Patients and methods - We measured in vivo wear of the polyethylene liner using computed tomography (CT) (obtained in the course of regular clinical care) and compared it to coordinate-measuring machine (CMM) readings. Also, changes in liner thickness of the same retrieved polyethylene liner were measured using a micrometer, and were compared to CT and CMM measurements. The distance between the centers of the acetabular cup and femoral head component was measured in 3D CT, using a semi-automatic analysis method. CMM readings were performed on each acetabular liner and data were analyzed using 3D computer-aided design software. Micrometer readings compared the thickest and thinnest regions of the liner. We analyzed 10 THA CTs and retrievals that met minimal requirements for CT slice thickness and explanted cup condition. Results - For the 10 cups, the mean difference between the CT readings and the CMM readings was -0.09 (-0.38 to 0.20) mm. This difference was not statistically significant (p = 0.6). Between CT and micrometer, the mean difference was 0.11 (-0.33 to 0.55) mm. This difference was not statistically significant (p = 0.6). Interpretation - Our results show that CT imaging is ready to be used as a tool in clinical wear measurement of polyethylene liners used in THA. C1 [Goldvasser, Dov; Hansen, Viktor J.; Bragdon, Charles R.; Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. [Noz, Marilyn E.] NYU, Dept Radiol, New York, NY USA. [Maguire, Gerald Q., Jr.] KTH Royal Inst Technol, Sch Informat & Commun Technol, Kista, Sweden. [Zeleznik, Michael P.] Saya Syst Inc, Salt Lake City, UT USA. [Goldvasser, Dov; Olivecrona, Henrik; Weidenhielm, Lars] Karolinska Inst, Dept Mol Med & Surg, Sect Orthopaed & Sports Med, Stockholm, Sweden. RP Goldvasser, D (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. EM dov.goldvasser@mgh.harvard.edu RI Maguire, Gerald/G-4584-2011 OI Maguire, Gerald/0000-0002-6066-746X FU Harris Orthopaedic Laboratory, Massachusetts General Hospital, Boston MA USA FX No competing interests declared. The project was funded by the Harris Orthopaedic Laboratory, Massachusetts General Hospital, Boston MA USA NR 15 TC 3 Z9 3 U1 2 U2 11 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1745-3674 EI 1745-3682 J9 ACTA ORTHOP JI Acta Orthop. PD JUN PY 2014 VL 85 IS 3 BP 271 EP 275 DI 10.3109/17453674.2014.913225 PG 5 WC Orthopedics SC Orthopedics GA AJ6ZI UT WOS:000337845000011 PM 24758322 ER PT J AU Bera, A Das, F Ghosh-Choudhury, N Li, XN Pal, S Gorin, Y Kasinath, BS Abboud, HE Choudhury, GG AF Bera, Amit Das, Falguni Ghosh-Choudhury, Nandini Li, Xiaonan Pal, Sanjay Gorin, Yves Kasinath, Balakuntalam S. Abboud, Hanna E. Choudhury, Goutam Ghosh TI A positive feedback loop involving Erk5 and Akt turns on mesangial cell proliferation in response to PDGF SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE Akt kinase; cell proliferation; MAP kinase; receptor tyrosine kinase; renal physiology ID METANEPHRIC MESENCHYMAL CELLS; ACTIVATED PROTEIN-KINASE; INDUCED DNA-SYNTHESIS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIN D1; TRANSGENIC MICE; EXPRESSION; RECEPTOR; GLOMERULONEPHRITIS AB Platelet-derived growth factor BB and its receptor (PDGFR beta) play a pivotal role in the development of renal glomerular mesangial cells. Their roles in increased mesangial cell proliferation during mesangioproliferative glomerulonephritis have long been noted, but the operating logic of signaling mechanisms regulating these changes remains poorly understood. We examined the role of a recently identified MAPK, Erk5, in this process. PDGF increased the activating phosphorylation of Erk5 and tyrosine phosphorylation of proteins in a time-dependent manner. A pharmacologic inhibitor of Erk5, XMD8-92, abrogated PDGF-induced DNA synthesis and mesangial cell proliferation. Similarly, expression of dominant negative Erk5 or siRNAs against Erk5 blocked PDGF-stimulated DNA synthesis and proliferation. Inhibition of Erk5 attenuated expression of cyclin D1 mRNA and protein, resulting in suppression of CDK4-mediated phosphorylation of the tumor suppressor protein pRb. Expression of cyclin D1 or CDK4 prevented the dominant negative Erk5-or siErk5 mediated inhibition of DNA synthesis and mesangial cell proliferation induced by PDGF. We have previously shown that phosphatidylinositol 3-kinase (PI3-kinase) contributes to PDGF-induced proliferation of mesangial cells. Inhibition of PI3-kinase blocked PDGF-induced phosphorylation of Erk5. Since PI3-kinase acts through Akt, we determined the role of Erk5 on Akt phosphorylation. XMD8-92, dominant negative Erk5, and siErk5 inhibited phosphorylation of Akt by PDGF. Interestingly, we found inhibition of PDGF-induced Erk5 phosphorylation by a pharmacological inhibitor of Akt kinase and kinase dead Akt in mesangial cells. Thus our data unfold the presence of a positive feedback microcircuit between Erk5 and Akt downstream of PI3-kinase nodal point for PDGF-induced mesangial cell proliferation. C1 [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Adm Res Serv, San Antonio, TX USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Bera, Amit; Das, Falguni; Li, Xiaonan; Pal, Sanjay; Gorin, Yves; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU Veterans Affairs Service Merit Review [5I01BX000926]; National Institute of Diabetes and Digestive and Kidney Diseases [RO1-DK-50190]; National Institutes of Health and Veterans Affairs Research Service grants; Cancer Therapy and Research Center at San Antonio; Veterans Affairs Research Service Merit Review grant; Veterans Affairs Senior Research Career Scientist Award FX The results described in this manuscript are the work supported by Veterans Affairs Service Merit Review Grant 5I01BX000926 and National Institute of Diabetes and Digestive and Kidney Diseases Grant RO1-DK-50190 (to G. G. Choudhury). G. G. Choudhury is a recipient of Veterans Affairs Senior Research Career Scientist Award. B. S. Kasinath, Y. Gorin, and H. E. Abboud are supported by National Institutes of Health and Veterans Affairs Research Service grants (B. S. Kasinath and H. E. Abboud). N. Ghosh-Choudhury is supported by Veterans Affairs Research Service Merit Review grant and a pilot grant from Cancer Therapy and Research Center at San Antonio. NR 45 TC 7 Z9 7 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD JUN PY 2014 VL 306 IS 11 BP C1089 EP C1100 DI 10.1152/ajpcell.00387.2013 PG 12 WC Cell Biology; Physiology SC Cell Biology; Physiology GA AJ7SL UT WOS:000337897300012 PM 24740537 ER PT J AU Bateman, BT Tsen, LC AF Bateman, Brian T. Tsen, Lawrence C. TI Anesthesiologist as Epidemiologist Insights from Registry Studies of Obstetric Anesthesia-related Complications SO ANESTHESIOLOGY LA English DT Editorial Material ID DELIVERY C1 [Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Bateman, Brian T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02115 USA. [Tsen, Lawrence C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA. RP Bateman, BT (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. EM bbateman@-partners.org OI Tsen, Lawrence/0000-0002-1964-723X NR 10 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD JUN PY 2014 VL 120 IS 6 BP 1311 EP 1312 DI 10.1097/ALN.0000000000000252 PG 2 WC Anesthesiology SC Anesthesiology GA AJ5UF UT WOS:000337753900004 PM 24845916 ER PT J AU Huang, LW Lipschutz, JH AF Huang, Liwei Lipschutz, Joshua H. TI Cilia and Polycystic Kidney Disease, Kith and Kin SO BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS LA English DT Review DE polycystic kidney disease; cilia; planar cell polarity; exocyst ID PLANAR CELL POLARITY; LEFT-RIGHT AXIS; SMOOTH-MUSCLE-CELLS; INTRAFLAGELLAR TRANSPORT; EPITHELIAL-CELLS; CYSTIC KIDNEY; RENAL CILIA; INTRACELLULAR CALCIUM; PRIMARY CILIOGENESIS; MEMBRANE-PROTEIN AB In the past decade, cilia have been found to play important roles in renal cystogenesis. Many genes, such as PKD1 and PKD2 which, when mutated, cause autosomal dominant polycystic kidney disease (ADPKD), have been found to localize to primary cilia. The cilium functions as a sensor to transmit extracellular signals into the cell. Abnormal cilia structure and function are associated with the development of polyscystic kidney disease (PKD). Cilia assembly includes centriole migration to the apical surface of the cell, ciliary vesicle docking and fusion with the cell membrane at the intended site of cilium outgrowth, and microtubule growth from the basal body. This review summarizes the most recent advances in cilia and PKD research, with special emphasis on the mechanisms of cytoplasmic and intraciliary protein transport during ciliogenesis. (C) 2014 Wiley Periodicals, Inc. C1 Eastern Virginia Med Sch, Dept Med, Norfolk, VA 23501 USA. Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. RP Huang, LW (reprint author), Lewis Hall Rm 2124,740 W Olney Rd, Norfolk, VA 23501 USA. EM huangle@evms.edu FU Veterans Affairs (Merit Award); NIH [DK093625, 5P30 DK047757-18] FX Supported by a grant from the Veterans Affairs (Merit Award to J.H.L.), and NIH (DK093625 to L. H., and 5P30 DK047757-18 pilot award to J.H.L.). NR 96 TC 3 Z9 4 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-975X EI 1542-9768 J9 BIRTH DEFECTS RES C JI Birth Defects Res. Part C-Embryo Today-Rev. PD JUN PY 2014 VL 102 IS 2 BP 174 EP 185 DI 10.1002/bdrc.21066 PG 12 WC Developmental Biology; Reproductive Biology SC Developmental Biology; Reproductive Biology GA AJ8PG UT WOS:000337967700005 PM 24898006 ER PT J AU Weingart, SN Hsieh, C Lane, S Cleary, AM AF Weingart, Saul N. Hsieh, Candace Lane, Sharon Cleary, Angela M. TI Standardizing Central Venous Catheter Care by Using Observations From Patients With Cancer SO CLINICAL JOURNAL OF ONCOLOGY NURSING LA English DT Article DE central venous catheter; central line-associated bloodstream infection; practice variation; patient and family engagement; quality improvement ID BLOOD-STREAM INFECTIONS; ONCOLOGY; PREVENTION; GUIDELINES; SOCIETY AB To understand the vulnerability of patients with cancer to central line-associated bloodstream infections related to tunneled central venous catheters (CVCs), patients were asked to describe their line care at home and in clinic and to characterize their knowledge and experience managing CVCs. Forty-five adult patients with cancer were recruited to participate. Patients were interviewed about the type of line, duration of use, and observations of variations in line care. They also were asked about differences between line care at home and in the clinic, precautions taken when bathing, and their education regarding line care. Demographic information and primary cancer diagnosis were taken from the patients' medical records. Patients with hematologic and gastrointestinal malignancies were heavily represented. The majority had tunneled catheters with subcutaneous implanted ports. Participants identified variations in practice among nurses who cared for them. Although many participants expressed confidence in their knowledge of line care, some were uncertain about what to do if the dressing became loose or wet, or how to recognize an infection. Patients seemed to be astute observers of their own care and offered insights into practice variation. Their observations show that CVC care practices should be standardized, and educational interventions should be created to address patients' knowledge deficits. C1 [Weingart, Saul N.] Tufts Med Ctr, Boston, MA 02111 USA. [Hsieh, Candace] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lane, Sharon; Cleary, Angela M.] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA. RP Weingart, SN (reprint author), Tufts Med Ctr, Boston, MA 02111 USA. EM sweingart@tuftsmedicalcenter.org NR 14 TC 3 Z9 3 U1 1 U2 8 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 1092-1095 EI 1538-067X J9 CLIN J ONCOL NURS JI Clin. J. Oncol. Nurs. PD JUN PY 2014 VL 18 IS 3 BP 321 EP 326 DI 10.1188/14.CJON.321-326 PG 6 WC Oncology; Nursing SC Oncology; Nursing GA AJ0HQ UT WOS:000337331900009 PM 24867112 ER PT J AU Boucher, J Habin, K Underhill, M AF Boucher, Jean Habin, Karleen Underhill, Meghan TI Cancer Genetics and Genomics: Essentials for Oncology Nurses SO CLINICAL JOURNAL OF ONCOLOGY NURSING LA English DT Article DE genetics; genomics; biology of cancer; biotherapy; targeted therapy; staff development; staff education ID HEALTH-CARE; DISEASE PREVENTION; RISK-ASSESSMENT; SOCIETY; INTEGRATION; STATEMENT; BARRIERS AB Cancer genetics and genomics are rapidly evolving, with new discoveries emerging in genetic mutations, variants, genomic sequencing, risk-reduction methods, and targeted therapies. To educate patients and families, state-of-the-art care requires nurses to understand terminology, scientific and technological advances, and pharmacogenomics. Clinical application of cancer genetics and genomics involves working in interdisciplinary teams to properly identify patient risk through assessing family history, facilitating genetic testing and counseling services, applying risk-reduction methods, and administering and monitoring targeted therapies. C1 [Boucher, Jean] Univ Massachusetts, Sch Med, Grad Sch Nursing, Worcester, MA 01605 USA. [Habin, Karleen] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Habin, Karleen] Canc Resource Fdn Inc, Marlborough, MA USA. [Underhill, Meghan] Dana Farber Canc Inst, Phyllis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA 02115 USA. RP Boucher, J (reprint author), Univ Massachusetts, Sch Med, Grad Sch Nursing, Worcester, MA 01605 USA. EM jean.boucher@umassmed.edu FU NCI NIH HHS [U54 CA156732] NR 34 TC 0 Z9 0 U1 2 U2 6 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 1092-1095 EI 1538-067X J9 CLIN J ONCOL NURS JI Clin. J. Oncol. Nurs. PD JUN PY 2014 VL 18 IS 3 BP 355 EP 359 DI 10.1188/14.CJON.355-359 PG 5 WC Oncology; Nursing SC Oncology; Nursing GA AJ0HQ UT WOS:000337331900014 PM 24867117 ER PT J AU Clark, DG Kapur, P Geldmacher, DS Brockington, JC Harrell, L DeRamus, TP Blanton, PD Lokken, K Nicholas, AP Marson, DC AF Clark, D. G. Kapur, P. Geldmacher, D. S. Brockington, J. C. Harrell, L. DeRamus, T. P. Blanton, P. D. Lokken, K. Nicholas, A. P. Marson, D. C. TI Latent information in fluency lists predicts functional decline in persons at risk for Alzheimer disease SO CORTEX LA English DT Article DE Alzheimer's disease; Cognitive neuropsychology; Dementia; MCI (mild cognitive impairment); Machine learning; Random forests ID MILD COGNITIVE IMPAIRMENT; VERBAL FLUENCY; FINANCIAL ABILITIES; CONVERSION; DEMENTIA; DIAGNOSIS; CAPACITY; INFERIOR; ATROPHY AB Objective: We constructed random forest classifiers employing either the traditional method of scoring semantic fluency word lists or new methods. These classifiers were then compared in terms of their ability to diagnose Alzheimer disease (AD) or to prognosticate among individuals along the continuum from cognitively normal (CN) through mild cognitive impairment (MCI) to AD. Method: Semantic fluency lists from 44 cognitively normal elderly individuals, 80 MCI patients, and 41 AD patients were transcribed into electronic text files and scored by four methods: traditional raw scores, clustering and switching scores, "generalized" versions of clustering and switching, and a method based on independent components analysis (ICA). Random forest classifiers based on raw scores were compared to "augmented" classifiers that incorporated newer scoring methods. Outcome variables included AD diagnosis at baseline, MCI conversion, increase in Clinical Dementia Rating-Sum of Boxes (CDR-SOB) score, or decrease in Financial Capacity Instrument (FCI) score. Receiver operating characteristic (ROC) curves were constructed for each classifier and the area under the curve (AUC) was calculated. We compared AUC between raw and augmented classifiers using Delong's test and assessed validity and reliability of the augmented classifier. Results: Augmented classifiers outperformed classifiers based on raw scores for the outcome measures AD diagnosis (AUC .97 vs .95), MCI conversion (AUC .91 vs .77), CDR-SOB increase (AUC .90 vs .79), and FCI decrease (AUC .89 vs .72). Measures of validity and stability over time support the use of the method. Conclusion: Latent information in semantic fluency word lists is useful for predicting cognitive and functional decline among elderly individuals at increased risk for developing AD. Modem machine learning methods may incorporate latent information to enhance the diagnostic value of semantic fluency raw scores. These methods could yield information valuable for patient care and clinical trial design with a relatively small investment of time and money. Published by Elsevier Ltd. C1 [Clark, D. G.; Blanton, P. D.; Lokken, K.; Nicholas, A. P.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Clark, D. G.; Geldmacher, D. S.; Brockington, J. C.; Harrell, L.; Nicholas, A. P.; Marson, D. C.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA. [Kapur, P.] Georgia Hlth Sci Univ, Dept Biomed Sci, Augusta, GA USA. [DeRamus, T. P.] Univ Alabama Birmingham, Dept Psychol & Behav Neurosci, Birmingham, AL USA. RP Clark, DG (reprint author), 1720,7th Ave South,SC 620C, Birmingham, AL 35294 USA. EM dgclark@uab.edu FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [E6553W]; Alzheimer's Disease Research Center (Marson, PI) [2R01 AG021927, 1P50 AG16582] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (E6553W, PI David Clark, Department of Neurology). In addition, the work was supported by grants 2R01 AG021927 (Marson, PI) and 1P50 AG16582 (Alzheimer's Disease Research Center) (Marson, PI). NR 57 TC 3 Z9 3 U1 0 U2 13 PU ELSEVIER MASSON PI MILANO PA VIA PALEOCAPA 7, 20121 MILANO, ITALY SN 0010-9452 EI 1973-8102 J9 CORTEX JI Cortex PD JUN PY 2014 VL 55 SI SI BP 202 EP 218 DI 10.1016/j.cortex.2013.12.013 PG 17 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA AJ5ZY UT WOS:000337770700017 PM 24556551 ER PT J AU Everhart, RS Mitchell, DK Friedman, D Kopel, S Canino, G Fritz, G McQuaid, EL AF Everhart, Robin S. Mitchell, Daphne Koinis Friedman, Deborah Kopel, Sheryl Canino, Glorisa Fritz, Gregory McQuaid, Elizabeth L. TI Pediatric Asthma Management Within Latino and Non-Latino White Families SO FAMILIES SYSTEMS & HEALTH LA English DT Article DE pediatric asthma; management; family; balanced integration; ethnic minority ID QUALITY-OF-LIFE; MEDICATION ADHERENCE; ETHNIC-DIFFERENCES; PUERTO-RICAN; SYSTEM SCALE; CHILDREN; MORBIDITY; DISPARITIES; BELIEFS; ACCULTURATION AB Pediatric asthma disparities exist with Latino children, especially from Island Puerto Rico (PR), experiencing greater asthma prevalence and morbidity than non-Latino White (NLW) children. Families must balance attention to child asthma with other child and family needs, defined as the "balanced integration of asthma." This study examined the impact of culturally related factors on the balanced integration of asthma in NLW and Latino families in Rhode Island (RI) and PR, as well as associations between balanced integration and asthma morbidity. Participants included 601 caregivers and their children with asthma (7-16 years) from NLW and Latino backgrounds in RI and PR. Caregivers and children completed interview-administered assessments and a semistructured interview related to family asthma management. Balanced integration of asthma differed significantly by ethnic group/site (p < .001), with Island PR families having the lowest levels of balanced integration. Higher balanced integration was associated with fewer concerns about asthma medications, higher levels of Spanish proficiency in RI Latino families, lower levels of functional limitation, and no emergency department visits in the last year (all ps < .05). Findings suggest that Latino families may experience more difficulty adjusting to child asthma in the context of other child and family demands. Medication beliefs and language proficiency may begin to explain these differences. Our study suggests the importance of continuing to understand how families balance asthma with other aspects of daily life, as culturally appropriate interventions to improve family adjustment to asthma may serve to reduce child asthma morbidity. C1 [Everhart, Robin S.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA. [Mitchell, Daphne Koinis; Kopel, Sheryl; Fritz, Gregory; McQuaid, Elizabeth L.] Brown Univ, Alpert Med Sch, Bradley Hasbro Childrens Res Ctr, Providence, RI 02912 USA. [Friedman, Deborah] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA. RP Everhart, RS (reprint author), Virginia Commonwealth Univ, Dept Psychol, POB 842018, Richmond, VA 23284 USA. EM reverhart@vcu.edu FU National Heart, Lung, and Blood Institute [U01 HL072438] FX This study was funded by a grant from the National Heart, Lung, and Blood Institute (U01 HL072438) to Gregory G. Fritz and Glorisa Canino, principal investigators. NR 32 TC 2 Z9 2 U1 2 U2 3 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1091-7527 EI 1939-0602 J9 FAM SYST HEALTH JI Fam. Syst. Health PD JUN PY 2014 VL 32 IS 2 BP 167 EP 175 DI 10.1037/fsh0000005 PG 9 WC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health GA AJ8HI UT WOS:000337943600013 PM 24611719 ER PT J AU Chen, S Qin, T Seidel, J Ferrari, M van den Maagden, A Ayata, C Eikermann-Haerter, K AF Chen, S. Qin, T. Seidel, J. Ferrari, M. van den Maagden, A. Ayata, C. Eikermann-Haerter, K. TI Inhibition of the p2x7 Receptor-Pannexin1 Pore Suppresses Spreading Depression and Inflammatory Downstream Mechanisms SO HEADACHE LA English DT Meeting Abstract CT 56th Annual Scientific Meeting of the American-Headache-Society CY JUN 26-29, 2014 CL Los Angeles, CA SP Amer Headache Soc C1 [Chen, S.; Qin, T.; Seidel, J.; Ayata, C.; Eikermann-Haerter, K.] Massachusetts Gen Hosp, Neurovasc Res Lab, Charlestown, MA USA. [Ferrari, M.; van den Maagden, A.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-8748 EI 1526-4610 J9 HEADACHE JI Headache PD JUN PY 2014 VL 54 SU 1 SI SI MA OR3 BP 2 EP 2 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AJ8JX UT WOS:000337950600004 ER PT J AU Yalcin, N Yu, E Atalay, Y Ayata, C Eikermann-Haerter, K AF Yalcin, N. Yu, E. Atalay, Y. Ayata, C. Eikermann-Haerter, K. TI The Migraine Trigger Caffeine Increases Susceptibility to Spreading Depolarization SO HEADACHE LA English DT Meeting Abstract CT 56th Annual Scientific Meeting of the American-Headache-Society CY JUN 26-29, 2014 CL Los Angeles, CA SP Amer Headache Soc C1 [Yalcin, N.; Yu, E.; Atalay, Y.; Ayata, C.; Eikermann-Haerter, K.] Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-8748 EI 1526-4610 J9 HEADACHE JI Headache PD JUN PY 2014 VL 54 SU 1 SI SI MA P27 BP 25 EP 25 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AJ8JX UT WOS:000337950600048 ER PT J AU Siebert, U Arvandi, M Gothe, RM Bornschein, B Eccleston, D Walters, DL Rankin, J De Bruyne, B Fearon, WF Pijls, NH Harper, R AF Siebert, Uwe Arvandi, Marjan Gothe, Raffaella M. Bornschein, Bernhard Eccleston, David Walters, Darren L. Rankin, James De Bruyne, Bernard Fearon, William F. Pijls, Nico H. Harper, Richard TI Improving the Quality of Percutaneous Revascularisation in Patients with Multivessel Disease in Australia: Cost-Effectiveness, Public Health Implications, and Budget Impact of FFR-Guided PCI SO HEART LUNG AND CIRCULATION LA English DT Article DE Coronary artery disease; Flow reserve; Cost-benefit analysis; Percutaneous coronary intervention (PCI); Multivessel disease ID FRACTIONAL FLOW RESERVE; CORONARY INTERVENTION; ECONOMIC-EVALUATION; TASK-FORCE; ANGIOGRAPHY; FAME AB Purpose Cross Mark The international multicentre FAME Study (n=1,005) demonstrated significant health benefits for patients undergoing multivessel percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) measurement compared with angiography guidance alone (ANGIO). We determined the cost-effectiveness and the public health/budget impact for Australia. Methods We performed a prospective economic evaluation comparing FFR vs. ANGIO in patients with multivessel disease based on original patient-level FAME data. We used Australian utilities (EQ-5D) and costs to calculate quality-adjusted life years (QALYs) and incremental cost-effectiveness adopting the societal perspective. The public health and budget impact from the payer's perspective was based on Australian PCI registries. Uncertainty was explored using deterministic sensitivity analyses and the bootstrap method (n=5,000 samples). Results The cost-effectiveness analysis showed that FFR was cost-saving and reduces costs by 1,776 AUD per patient during one year. Over a two-year time horizon, the public health impact ranged from 7.8 to 73.9 QALYs gained and the budget impact from 1.8 to 14.5 million AUD total cost savings. Sensitivity analyses demonstrated that FFR was cost-saving over a wide range of assumptions. Conclusions FFR-guided PCI in patients with multivessel coronary disease substantially reduces cardiac events, improves QALYs and is cost-saving in the Australian health care system. C1 [Siebert, Uwe; Arvandi, Marjan; Gothe, Raffaella M.; Bornschein, Bernhard] UMIT Univ Hlth Sci, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria. [Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA. [Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. [Eccleston, David] Univ Melbourne, Royal Melbourne Hosp, Melbourne, Vic 3050, Australia. [Walters, Darren L.] Univ Queensland, Prince Charles Hosp, Brisbane, Qld, Australia. [Rankin, James] Royal Perth Hosp, Perth, WA 6001, Australia. [De Bruyne, Bernard] Cardiovasc Ctr Aalst, Aalst, Belgium. [Fearon, William F.] Stanford Univ, Med Ctr, Cardiovasc Inst, Stanford, CA 94305 USA. [Pijls, Nico H.] Catharina Hosp, Dept Cardiol, Eindhoven, Netherlands. [Harper, Richard] Monash Univ, Monash Med Ctr, Monash Heart, Melbourne, Vic 3004, Australia. RP Siebert, U (reprint author), UMIT, Hall In Tirol, Austria. EM uwe.siebert@umit.at FU St. Jude Medical FX This project was supported in part by an unrestricted research grant from St. Jude Medical. The authors had complete and independent control over study design, collection of data, analysis and interpretation of data, report writing, and publication, regardless of results. NR 14 TC 4 Z9 4 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1443-9506 EI 1444-2892 J9 HEART LUNG CIRC JI Heart Lung Circ. PD JUN PY 2014 VL 23 IS 6 BP 527 EP 533 DI 10.1016/j.hlc.2013.12.009 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AJ7EK UT WOS:000337859800006 PM 24560401 ER PT J AU Hodi, FS AF Hodi, F. Stephen TI Preface SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02215 USA. RP Hodi, FS (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Immunooncol, 450 Brookline Ave, Boston, MA 02215 USA. EM Stephen_Hodi@dfci.harvard.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 EI 1558-1977 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD JUN PY 2014 VL 28 IS 3 BP XIII EP XIV DI 10.1016/j.hoc.2014.04.001 PG 2 WC Oncology; Hematology SC Oncology; Hematology GA AJ8UG UT WOS:000337982700001 PM 24880951 ER PT J AU Sullivan, RJ Fisher, DE AF Sullivan, Ryan J. Fisher, David E. TI Understanding the Biology of Melanoma and Therapeutic Implications SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE BRAF; NRAS; Immunotherapy; Targeted therapy; MITF ID ACTIVATED PROTEIN-KINASE; RECOMBINANT INTERLEUKIN-2 THERAPY; UNTREATED METASTATIC MELANOMA; RANDOMIZED PHASE-II; CELL-LINES; CUTANEOUS MELANOMA; UVEAL MELANOMA; MALIGNANT-MELANOMA; MULTIKINASE INHIBITOR; IMATINIB MESYLATE AB From 1976 to 2010, only 2 medications were approved for treating metastatic melanoma. Between 2011 and 2013, 4 agents were approved and other therapies have shown great promise in clinical trials. Fundamental discoveries, such as the identification of oncogenic mutations in most melanomas, the elucidation of the molecular signaling resulting from these mutations, and the revelation that several cell surface molecules serve as regulators of immune activation, have been instrumental in this progress. This article summarizes the molecular pathogenesis of melanoma, describes the current efforts to target oncogene-driven signaling, and presents the rationale for combining immune and molecular targeting. C1 [Sullivan, Ryan J.] Harvard Univ, Massachusetts Gen Hosp, Ctr Melanoma, Canc Ctr,Med Sch, Boston, MA 02114 USA. [Fisher, David E.] Harvard Univ, Massachusetts Gen Hosp, Dept Dermatol, Canc Ctr,Med Sch, Boston, MA 02114 USA. RP Fisher, DE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Dermatol, Canc Ctr,Med Sch, Bartlett 6,55 Fruit St, Boston, MA 02114 USA. EM dfisher3@partners.org FU NCI NIH HHS [R21 CA175907, P01 CA163222, R01 CA150226]; NIAMS NIH HHS [R01 AR043369, R01 AR045662] NR 122 TC 8 Z9 8 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 EI 1558-1977 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD JUN PY 2014 VL 28 IS 3 BP 437 EP + DI 10.1016/j.hoc.2014.02.007 PG 18 WC Oncology; Hematology SC Oncology; Hematology GA AJ8UG UT WOS:000337982700003 PM 24880940 ER PT J AU Ott, PA Fritsch, EF Wu, CJ Dranoff, G AF Ott, Patrick A. Fritsch, Edward F. Wu, Catherine J. Dranoff, Glenn TI Vaccines and Melanoma SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Melanoma; Vaccine; Immunotherapy; Neoantigen ID COLONY-STIMULATING FACTOR; REFRACTORY PROSTATE-CANCER; CYTOLYTIC T-LYMPHOCYTES; EXOME ANALYSIS REVEALS; HLA-DR MOLECULES; PHASE-II TRIAL; METASTATIC MELANOMA; PEPTIDE VACCINE; CELLULAR IMMUNOTHERAPY; DENDRITIC CELLS AB The potential for therapeutic efficacy of a melanoma vaccine has been evident preclinically for many years. In melanoma patients, vaccines have resulted in the induction of immune responses, although clinical benefit has not been clearly documented. The recent achievements with immune-checkpoint blockade have shown that immunotherapy can be a powerful tool in cancer therapy. With increased understanding of tumor immunity, the limitations of previous cancer vaccination approaches have become evident. Rapid progress in technologies that enable better vaccine design raise the expectation that these limitations can be overcome, thus leading to a clinically effective melanoma vaccine in the near future. C1 [Ott, Patrick A.; Fritsch, Edward F.; Wu, Catherine J.; Dranoff, Glenn] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Ott, Patrick A.] Dana Farber Canc Inst, Melanoma Dis Ctr, Boston, MA 02215 USA. [Ott, Patrick A.] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02215 USA. [Ott, Patrick A.; Wu, Catherine J.; Dranoff, Glenn] Harvard Univ, Dept Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02215 USA. [Fritsch, Edward F.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA. [Wu, Catherine J.; Dranoff, Glenn] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02215 USA. RP Ott, PA (reprint author), Harvard Univ, Dana Farber Canc Inst, Melanoma Dis Ctr, Ctr Immunooncol,Med Sch, 450 Brookline Ave, Boston, MA 02215 USA. EM Patrick_Ott@DFCI.harvard.edu NR 42 TC 9 Z9 9 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 EI 1558-1977 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD JUN PY 2014 VL 28 IS 3 BP 559 EP + DI 10.1016/j.hoc.2014.02.008 PG 12 WC Oncology; Hematology SC Oncology; Hematology GA AJ8UG UT WOS:000337982700010 PM 24880947 ER PT J AU O'Reilly, M Federoff, HJ Fong, YM Kohn, DB Patterson, AP Ahmed, N Asokan, A Boye, SE Crystal, RG De Oliveira, S Gargiulo, L Harper, SQ Ikeda, Y Jambou, R Montgomery, M Prograis, L Rosenthal, E Sterman, DH Vandenberghe, LH Zoloth, L Abedi, M Adair, J Adusumilli, PS Goins, WF Gray, J Monahan, P Popplewell, L Sena-Esteves, M Tannous, B Weber, T Wierda, W Gopal-Srivastava, R McDonald, CL Rosenblum, D Corrigan-Curay, J AF O'Reilly, Marina Federoff, Howard J. Fong, Yuman Kohn, Donald B. Patterson, Amy P. Ahmed, Nabil Asokan, Aravind Boye, Shannon E. Crystal, Ronald G. De Oliveira, Satiro Gargiulo, Linda Harper, Scott Q. Ikeda, Yasuhiro Jambou, Robert Montgomery, Maureen Prograis, Lawrence Rosenthal, Eugene Sterman, Daniel H. Vandenberghe, Luk H. Zoloth, Laurie Abedi, Mehrdad Adair, Jennifer Adusumilli, Prasad S. Goins, William F. Gray, Jhanelle Monahan, Paul Popplewell, Leslie Sena-Esteves, Miguel Tannous, Bakhos Weber, Thomas Wierda, William Gopal-Srivastava, Rashmi McDonald, Cheryl L. Rosenblum, Daniel Corrigan-Curay, Jacqueline TI Gene Therapy: Charting a Future Course-Summary of a National Institutes of Health Workshop, April 12, 2013 SO HUMAN GENE THERAPY LA English DT Review ID LEBER CONGENITAL AMAUROSIS; CHIMERIC ANTIGEN RECEPTOR; HEMATOPOIETIC STEM/PROGENITOR CELLS; MODIFIED T-CELLS; ADENOASSOCIATED VIRUS; CANCER-IMMUNOTHERAPY; HEMOPHILIA-B; EFFICACY; SAFETY; EXPRESSION AB Recently, the gene therapy field has begun to experience clinical successes in a number of different diseases using various approaches and vectors. The workshop Gene Therapy: Charting a Future Course, sponsored by the National Institutes of Health (NIH) Office of Biotechnology Activities, brought together early and mid-career researchers to discuss the key scientific challenges and opportunities, ethical and communication issues, and NIH and foundation resources available to facilitate further clinical advances. C1 [O'Reilly, Marina; Patterson, Amy P.; Gargiulo, Linda; Jambou, Robert; Montgomery, Maureen; Rosenthal, Eugene; Corrigan-Curay, Jacqueline] Off Director, Off Sci Policy, Bethesda, MD 20892 USA. [Prograis, Lawrence] NIAID, Bethesda, MD 20892 USA. [Gopal-Srivastava, Rashmi; Rosenblum, Daniel] Natl Ctr Adv Translat Sci, Bethesda, MD 20892 USA. [McDonald, Cheryl L.] NHLBI, NIH, Bethesda, MD 20892 USA. [Federoff, Howard J.] Georgetown Univ, Med Ctr, Washington, DC 20057 USA. [Fong, Yuman; Popplewell, Leslie] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Kohn, Donald B.; De Oliveira, Satiro] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ahmed, Nabil] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Asokan, Aravind; Monahan, Paul] Univ N Carolina, Chapel Hill, NC 27599 USA. [Boye, Shannon E.] Univ Florida, Gainesville, FL 32605 USA. [Crystal, Ronald G.] Weill Cornell Med Coll, Dept Med Genet, New York, NY 10065 USA. [Harper, Scott Q.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA. [Ikeda, Yasuhiro] Mayo Clin, Rochester, MN 55905 USA. [Sterman, Daniel H.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. [Vandenberghe, Luk H.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA. [Vandenberghe, Luk H.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Zoloth, Laurie] Northwestern Univ, Evanston, IL 60208 USA. [Abedi, Mehrdad] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA. [Adair, Jennifer] Fred Hutchinson Canc Res Ctr, Seattle, WA 98102 USA. [Adusumilli, Prasad S.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. [Goins, William F.] Univ Pittsburgh, Pittsburgh, PA 15219 USA. [Gray, Jhanelle] H Lee Mofitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. [Tannous, Bakhos] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Weber, Thomas] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Wierda, William] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Corrigan-Curay, J (reprint author), NIH, Off Biotechnol Act, 6705 Rockledge Dr,Suite 750, Bethesda, MD 20892 USA. EM corrigaja@od.nih.gov RI Weber, Thomas/A-2363-2008; De Oliveira, Satiro/D-8860-2014; Kohn, Donald/N-5085-2016 OI Weber, Thomas/0000-0002-0494-0484; De Oliveira, Satiro/0000-0002-8181-7316; Kohn, Donald/0000-0003-1840-6087 FU Foundation Fighting Blindness; Massachusetts Eye and Ear Infirmary (Boston, MA); Genelux; Roche; Asklepios Biopharmaceutical; Baxter Biologics FX N.A. has patent applications in the field of T-cell and gene-modified T-cell therapy for cancer. The Center for Cell and Gene Therapy (CAGT) has research collaboration with Celgene Inc. to develop CAR-based therapeutics that is administered by Baylor College of Medicine. L. H. V. is inventor on gene therapy-related patents that are licensed to various pharmaceutical and biotechnological companies, holds equity in GenSight Biologics, consults for Novartis and GenSight Biologics, and receives funding from the Foundation Fighting Blindness and the Massachusetts Eye and Ear Infirmary (Boston, MA). He has been employed by the University of Pennsylvania and the Massachusetts Eye and Ear Infirmary. Y.F. is a paid advisor for Genelux and consultant to Roche. H.F. is a founder and advisor to MedGenesis. P.M.'s university receives or has received funding to support basic science research work in the author's laboratory from Asklepios Biopharmaceutical and Baxter Biologics. He has received remuneration for consulting work and for speaking from Asklepios Biopharmaceutical and Baxter Biologics. NR 47 TC 8 Z9 8 U1 1 U2 17 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1043-0342 EI 1557-7422 J9 HUM GENE THER JI Hum. Gene Ther. PD JUN PY 2014 VL 25 IS 6 BP 488 EP 497 DI 10.1089/hum.2014.045 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA AJ8JR UT WOS:000337949900004 PM 24773122 ER PT J AU Bakaeen, FG Reda, DJ Gelijns, AC Cornwell, L Omer, S Al Jurdi, R Kougias, P Anaya, D Berger, DH Huang, GD AF Bakaeen, Faisal G. Reda, Domenic J. Gelijns, Annetine C. Cornwell, Lorraine Omer, Shuab Al Jurdi, Rayan Kougias, Panos Anaya, Daniel Berger, David H. Huang, Grant D. TI Department of Veterans Affairs Cooperative Studies Program Network of Dedicated Enrollment Sites Implications for Surgical Trials SO JAMA SURGERY LA English DT Article ID PERCUTANEOUS CORONARY INTERVENTION; OUTCOMES RESEARCH-INSTITUTE; ARTERY-BYPASS SURGERY; RANDOMIZED-TRIAL; VALVE-REPLACEMENT; ON-PUMP; REPAIR AB IMPORTANCE Surgical clinical trials have played a critical role in shaping clinical practice, yet their launch and conduct remain challenging. Innovative approaches to carrying out such studies can not only help transform how trials produce definitive evidence but also move the field toward increased participation in trials. OBJECTIVE To review a recently launched pilot program aimed at enhancing patient enrollment and improving surgical trial operations at individual sites and nationally. SETTING AND PARTICIPANTS After a solicitation to create a national network focused on making the conduct of clinical trials more efficient, 10 Department of Veterans Affairs (VA) sites were selected. These sites, collectively called the Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES), were evaluated with regard to their previous participation in CSP multisite trials, the strength of the local clinical research environment, and presentation of innovative plans to coordinate and enhance the operations of local CSP studies and share best practices with other centers. Node accountability was also emphasized and involved metrics that tracked productivity and efficiency. RESULTS Building from available CSP experience in a range of clinical trials, including ones involving surgical interventions, NODES provides VA surgeons with resources for facilitating timely study initiation, determining patient availability, and addressing enrollment barriers. Such resources are particularly important for surgical studies, which often face challenges in patient recruitment and retention. In addition, NODES can maintain qualified and trained personnel at sites to support surgeons with limited time to fulfill the numerous administrative and regulatory responsibilities that often fall to the investigators. CONCLUSIONS AND RELEVANCE The VA's approach to enhancing trial efficiency may reinvigorate interest in surgical trials by offering a redesigned cooperative framework that builds on a core of high-yield sites and could mitigate traditional limitations of surgical trials. C1 [Bakaeen, Faisal G.; Cornwell, Lorraine; Omer, Shuab; Kougias, Panos; Anaya, Daniel; Berger, David H.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Dept Surg, Houston, TX 77030 USA. [Bakaeen, Faisal G.] Texas Heart Inst, Dept Cardiovasc Surg, Houston, TX 77025 USA. [Reda, Domenic J.; Huang, Grant D.] US Dept Vet Affairs, Cooperat Studies Program Cent Off, Washington, DC USA. [Gelijns, Annetine C.] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA. [Al Jurdi, Rayan] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Bakaeen, FG (reprint author), Michael E DeBakey VA Med Ctr, Div Cardiothorac Surg, Mail Stop OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA. EM fbakaeen@bcm.edu FU Department of Veterans Affairs Cooperative Studies Program FX This work was supported by the Department of Veterans Affairs Cooperative Studies Program. NR 25 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD JUN PY 2014 VL 149 IS 6 BP 507 EP 513 DI 10.1001/jamasurg.2013.4150 PG 7 WC Surgery SC Surgery GA AJ7WB UT WOS:000337909900005 PM 24647851 ER PT J AU Mavros, MN Economopoulos, KP Alexiou, VG Pawlik, TM AF Mavros, Michael N. Economopoulos, Konstantinos P. Alexiou, Vangelis G. Pawlik, Timothy M. TI Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma Systematic Review and Meta-analysis SO JAMA SURGERY LA English DT Article ID TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; OUTCOME FOLLOWING RESECTION; SINGLE-CENTER EXPERIENCE; LYMPH-NODE METASTASES; B-VIRUS INFECTION; MASS-FORMING TYPE; CLINICOPATHOLOGICAL FACTORS; LIVER-TRANSPLANTATION; PREDICTIVE FACTORS; SURGICAL-TREATMENT AB IMPORTANCE Data on outcomes following surgical management of intrahepatic cholangiocarcinoma (ICC) are limited. The incidence of ICC is increasing and it has a poor prognosis. No consensus has been reached regarding the optimal treatment modalities. OBJECTIVE To systematically review and synthesize the available evidence regarding treatment and prognosis in patients with ICC. DATA SOURCES The PubMed database was searched for relevant articles published between January 1, 2000, and April 1, 2013. STUDY SELECTION Only studies assessing predictors of survival or recurrence in patients undergoing curative-intent surgical treatment of ICC were included. Small series, studies reporting on mixed types of cholangiocarcinoma, or exclusively on hepatolithiasis-associated cholangiocarcinoma, and those published in a language other than English, French, German, Italian, or Greek, were excluded. Fifty-seven of 960 articles were analyzed. DATA EXTRACTION AND SYNTHESIS Data on preoperative, intraoperative, and postoperative variables were extracted by 3 independent reviewers. Multiple studies reporting on the same population were excluded. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURES We hypothesized that preoperative variables and tumor characteristics affect patient survival. The outcomes of the study were overall survival and recurrence-free survival. The hypothesis was formulated before data collection. RESULTS Fifty-seven studies (4756 patients) were included in the review. Median patient age ranged from 49 to 67 years, and 57% were male. Most patients had a solitary (69%), large (median size, 4.5-8.0 cm) tumor of the mass-forming type (86%). Approximately one-third of the patients had lymph node metastasis (34%) or vascular (38%), perineural (29%), or biliary invasion (29%). Most underwent a major hepatectomy (82%), often accompanied by lymphadenectomy (67%) and sometimes by extrahepatic bile duct resection (23%). Median and 5-year overall survival (OS) generally were approximately 28 months (range, 9-53 months) and 30% (range, 5%-56%), respectively; factors predicting shorter OS included large tumor size, multiple tumors, lymph node metastasis, and vascular invasion. Adjuvant chemotherapy or radiotherapy did not appear to be beneficial. Seven studies (2132 patients) provided data for the meta-analysis. Factors associated with shorter OS included older age (pooled hazard ratio, 1.10; 95% CI, 1.03-1.17), larger tumor size (1.09; 1.02-1.16), presence of multiple tumors (1.70; 1.43-2.02), lymph node metastasis (2.09; 1.80-2.43), vascular invasion (1.87; 1.44-2.42), and poor tumor differentiation (1.41; 1.17-1.71). CONCLUSIONS AND RELEVANCE The prognosis of ICC is dictated mainly by tumor factors. Future research could focus on the usefulness of adjuvant treatment as well as other multidisciplinary treatment modalities. C1 [Mavros, Michael N.] Medstar Washington Hosp Ctr, Dept Surg, Washington, DC USA. [Mavros, Michael N.; Alexiou, Vangelis G.] Alfa Inst Biomed Sci, Dept Surg, Athens, Greece. [Mavros, Michael N.; Economopoulos, Konstantinos P.] Soc Jr Doctors, Athens, Greece. [Economopoulos, Konstantinos P.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Economopoulos, Konstantinos P.] Harvard Univ, Sch Med, Boston, MA USA. [Pawlik, Timothy M.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Surg Oncol, Baltimore, MD USA. RP Pawlik, TM (reprint author), Johns Hopkins Univ, Sch Med, Dept Surg, Div Surg Oncol, Blalock Room 688,600 N Wolfe St, Baltimore, MD 21287 USA. EM tpawlik1@jhmi.edu OI Economopoulos, Konstantinos/0000-0003-4856-0405 NR 68 TC 43 Z9 52 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD JUN PY 2014 VL 149 IS 6 BP 565 EP 574 DI 10.1001/jamasurg.2013.5137 PG 10 WC Surgery SC Surgery GA AJ7WB UT WOS:000337909900017 PM 24718873 ER PT J AU Rosenberg, SM Partridge, AH AF Rosenberg, Shoshana M. Partridge, Ann H. TI Contralateral Prophylactic Mastectomy An Opportunity for Shared Decision Making SO JAMA SURGERY LA English DT Editorial Material ID BREAST-CANCER; WOMEN C1 [Rosenberg, Shoshana M.; Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02215 USA. RP Partridge, AH (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM ann_partridge@dfci.harvard.edu FU NCI NIH HHS [R25 CA057711, 5 R25 CA057711] NR 5 TC 4 Z9 4 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD JUN PY 2014 VL 149 IS 6 BP 589 EP 590 DI 10.1001/jamasurg.2013.5713 PG 3 WC Surgery SC Surgery GA AJ7WB UT WOS:000337909900020 PM 24848646 ER PT J AU Han, SC Castro, F Lee, LO Charney, ME Marx, BP Brailey, K Proctor, SP Vasterling, JJ AF Han, Sohyun C. Castro, Frank Lee, Lewina O. Charney, Meredith E. Marx, Brian P. Brailey, Kevin Proctor, Susan P. Vasterling, Jennifer J. TI Military unit support, postdeployment social support, and PTSD symptoms among active duty and National Guard soldiers deployed to Iraq SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Social support; Unit support; Posttraumatic stress disorder; Military personnel; Deployment; Longitudinal ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; RISK-FACTORS; LIFE EVENTS; RESILIENCE; PERSONNEL; VETERANS; EXPLANATIONS; AFGHANISTAN; EXPERIENCES AB Research suggests that military unit support and community postdeployment social support are associated with fewer PTSD symptoms following military deployment. This study extended prior research by examining the associations among predeployment unit support and PTSD symptoms before Iraq deployment as well as unit support, PTSD symptoms, and postdeployment social support after deployment among 835 U.S. Army and 173 National Guard soldiers. Multiple regression analyses indicated that predeployment unit support was not significantly associated with postdeployment PTSD severity in either group of soldiers, whereas higher unit support during deployment was significantly associated with lower postdeployment PTSD severity among active duty soldiers only. Among both groups, higher levels of postdeployment social support were associated with lower levels of postdeployment PTSD symptom severity. These findings suggest that postdeployment social support is a particularly strong buffer against postdeployment PTSD symptoms among both groups of soldiers whereas the effects of unit support may be limited. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Han, Sohyun C.; Castro, Frank; Lee, Lewina O.; Marx, Brian P.; Proctor, Susan P.; Vasterling, Jennifer J.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. [Charney, Meredith E.; Brailey, Kevin] VA Boston Healthcare Syst, Boston, MA 02130 USA. [Lee, Lewina O.; Marx, Brian P.; Brailey, Kevin; Vasterling, Jennifer J.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Proctor, Susan P.] US Army Res Inst Environm Med, Natick, MA USA. [Lee, Lewina O.; Proctor, Susan P.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA. RP Vasterling, JJ (reprint author), VA Boston Healthcare Syst 116B 4, 150 South Huntington Ave, Boston, MA 02130 USA. EM jennifer.vasterling@va.gov FU NIA NIH HHS [AG032037, AG039343] NR 31 TC 6 Z9 6 U1 3 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD JUN PY 2014 VL 28 IS 5 BP 446 EP 453 DI 10.1016/j.janxdis.2014.04.004 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AJ8WS UT WOS:000337989400003 PM 24846492 ER PT J AU Goetter, EM Herbert, JD Forman, EM Yuen, EK Thomas, JG AF Goetter, Elizabeth M. Herbert, James D. Forman, Evan M. Yuen, Erica K. Thomas, J. Graham TI An open trial of videoconference-mediated exposure and ritual prevention for obsessive-compulsive disorder SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Obsessive-compulsive disorder; Exposure and ritual prevention; Telehealth; Telemental health; Telepsychology; Videoconferencing ID THERAPY; SCALE AB The gold-standard treatment for OCD is exposure and ritual prevention (ERP), yet despite its well-established efficacy, only a small percentage of OCD patients have access to this treatment. Remote treatments (e.g., videoconferencing) are becoming increasingly popular avenues for treatment delivery and show promise in increasing patient access to evidence-based mental health care. The current pilot study utilized an open trial to examine the feasibility and preliminary efficacy of videoconference-mediated, twice weekly, ERP for adults (n = 15) with OCD. Results revealed that ERP was associated with significant improvements in OCD symptoms and large within-group effect sizes. Among the 10 individuals who completed a 3-month follow-up assessment, 30% of participants no longer met DSM-IV-TR criteria for OCD and 80% of participants were rated as very much or much improved on the CGI. This study adds to the growing body of literature suggesting that videoconference-based interventions are viable alternatives to face-to-face treatment. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Goetter, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Goetter, Elizabeth M.; Herbert, James D.; Forman, Evan M.] Drexel Univ, Philadelphia, PA 19104 USA. [Yuen, Erica K.] Univ Tampa, Tampa, FL 33606 USA. [Thomas, J. Graham] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. RP Goetter, EM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, One Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM egoetter@mgh.harvard.edu NR 19 TC 5 Z9 5 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD JUN PY 2014 VL 28 IS 5 BP 460 EP 462 DI 10.1016/j.janxdis.2014.05.004 PG 3 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AJ8WS UT WOS:000337989400005 PM 24873883 ER PT J AU Reardon, AF Hein, CL Wolf, EJ Prince, LB Ryabchenko, K Miller, MW AF Reardon, Annemarie F. Hein, Christina L. Wolf, Erika J. Prince, Lauren B. Ryabchenko, Karen Miller, Mark W. TI Intermittent explosive disorder: Associations with PTSD and other Axis I disorders in a US military veteran sample SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Posttraumatic stress disorder; Intermittent explosive disorder; Comorbidity ID POSTTRAUMATIC-STRESS-DISORDER; COMMON MENTAL-DISORDERS; DSM-IV; COMBAT VETERANS; CRIME VICTIMS; ANGER; COMORBIDITY; AGGRESSION; PREVALENCE; PERSONALITY AB This study examined the prevalence of intermittent explosive disorder (IED) and its associations with trauma exposure, posttraumatic stress disorder (PTSD), and other psychiatric diagnoses in a sample of trauma-exposed veterans (n = 232) with a high prevalence of PTSD. Structural associations between IED and latent dimensions of internalizing and externalizing psychopathology were also modeled to examine the location of IED within this influential structure. Twenty-four percent of the sample met criteria for a lifetime IED diagnosis and those with the diagnosis were more likely to meet criteria for lifetime PTSD than those without (30.3% vs. 14.3% respectively). Furthermore, regression analyses revealed lifetime PTSD severity to be a significant predictor of IED severity after controlling for combat, trauma exposure, and age. Finally, confirmatory factor analysis revealed significant cross-loadings of IED on both the externalizing and distress dimensions of psychopathology, suggesting that the association between IED and other psychiatric disorders may reflect underlying tendencies toward impulsivity and aggression and generalized distress and negative emotionality, respectively. Published by Elsevier Ltd. C1 [Reardon, Annemarie F.; Hein, Christina L.; Wolf, Erika J.; Prince, Lauren B.; Ryabchenko, Karen; Miller, Mark W.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. [Hein, Christina L.; Wolf, Erika J.; Prince, Lauren B.; Ryabchenko, Karen; Miller, Mark W.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. RP Reardon, AF (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. EM annemarie.reardon@va.gov; mark.miller5@va.gov RI Miller, Mark/G-7322-2011; OI Miller, Mark/0000-0001-6393-8563; Wolf, Erika/0000-0003-2666-2435 FU CSRD VA [I01 CX000431]; Intramural VA [CDA-2-067-10S]; NIMH NIH HHS [R01 MH079806] NR 50 TC 2 Z9 2 U1 4 U2 21 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD JUN PY 2014 VL 28 IS 5 BP 488 EP 494 DI 10.1016/j.janxdis.2014.05.001 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AJ8WS UT WOS:000337989400009 PM 24907536 ER PT J AU Mitchell, JD Mahmood, F Bose, R Hess, PE Wong, V Matyal, R AF Mitchell, John D. Mahmood, Feroze Bose, Ruma Hess, Philip E. Wong, Vanessa Matyal, Robina TI Novel, Multimodal Approach for Basic Transesophageal Echocardiographic Teaching SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE echocardiography; simulation; education; TEE ID MEDICAL-EDUCATION; SURGICAL SIMULATION; SKILLS; UTILITY; AUTOMATICITY; PROFICIENCY; PERFORMANCE; COLONOSCOPY AB Objectives: Web and simulation technology may help in creating a transesophageal echocardiography (TEE) curriculum. The authors discuss the educational principles applied to developing and implementing a multimodal TEE curriculum. Design and Setting: The authors modified a pilot course based on principles for effective simulation-based education. Key curricular elements were consistent with principles for effective simulation-based education: (1) clear goals and carefully structured objectives, (2) conveniently accessed, graduated, longitudinal instruction, (3) a protected and optimal learning environment, (4) repetition of concepts and technical skills, (5) progressive expectations for understanding and skill development, (6) introduction of abnormalities after understanding of normal anatomy and probe manipulation is achieved, (7) live learning sessions that are customizable to meet learner needs and individualized proctoring in skill sessions, (8) use of multiple approaches to teaching, (9) regular and relevant feedback, and (10) application of performance and compliance measures. Participants: Fifty-five learners participated in a curriculum with web-based modules, live teaching, and simulation practice between August 2011 and May 2013. Conclusion: It is possible to develop and implement an integrated, multimodal TEE curriculum supported by educational theory. The authors will explore the transferability of this approach to intraoperative TEE on live patients. (C) 2014 Elsevier Inc. All rights reserved. C1 [Mitchell, John D.; Mahmood, Feroze; Bose, Ruma; Hess, Philip E.; Matyal, Robina] Harvard Univ, Sch Med, Boston, MA USA. [Mitchell, John D.; Mahmood, Feroze; Bose, Ruma; Hess, Philip E.; Wong, Vanessa; Matyal, Robina] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Mitchell, JD (reprint author), Beth Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, 1 Deaconess Rd,CC-470, Boston, MA 02215 USA. EM jdmitche@bidmc.harvard.edu RI Mahmood, Feroze/B-1383-2008; Hess, Philip/A-8577-2013 OI Mahmood, Feroze/0000-0002-7071-0476; Hess, Philip/0000-0002-1206-0102 NR 41 TC 2 Z9 2 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 EI 1532-8422 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD JUN PY 2014 VL 28 IS 3 BP 800 EP 809 DI 10.1053/j.jvca.2014.01.006 PG 10 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA AK0GI UT WOS:000338090500054 PM 24746594 ER PT J AU Imel, ZE Baldwin, SA Baer, JS Hartzler, B Dunn, C Rosengren, DB Atkins, DC AF Imel, Zac E. Baldwin, Scott A. Baer, John S. Hartzler, Bryan Dunn, Chris Rosengren, David B. Atkins, David C. TI Evaluating Therapist Adherence in Motivational Interviewing by Comparing Performance With Standardized and Real Patients SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE motivational interviewing; therapist adherence; mixed models; standardized patients ID ALLIANCE-OUTCOME CORRELATION; COMPETENCE; CLINICIAN; DEPENDABILITY; VARIABILITY; ASSESSMENTS; SESSIONS; BEHAVIOR; LARGER; THINK AB Objective: The goal of measuring therapist adherence is to determine whether a therapist can perform a given treatment. Yet, the evaluation of therapist behaviors in most clinical trials is limited. Typically, randomized trials have few therapists and minimize therapist variability through training and supervision. Furthermore, therapist adherence is confounded with uncontrolled differences in patients across therapists. Consequently, the extent to which adherence measures capture differences in actual therapist adherence versus other sources of variance is unclear. Method: We estimated intra-class correlations (ICCs) for therapist adherence in sessions with real and standardized patients (RPs and SPs), using ratings from a motivational interviewing (MI) dissemination trial (Baer et al., 2009) in which 189 therapists recorded 826 sessions with both patient types. We also examined the correlations of therapist adherence between SP and RP sessions, and the reliability of therapist level adherence scores with generalizability coefficients (GCs). Results: ICCs for therapist adherence were generally large (average ICC for SPs = .44; average ICC for RPs = .40), meaning that a given therapist's adherence scores were quite similar across sessions. Both ICCs and GCs were larger for SP sessions compared to RPs on global measures of MI adherence, such as Empathy and MI Spirit. Correlations between therapist adherence with real and standardized patients were moderate to large on 3 of 5 adherence measures. Conclusion: Differences in therapist-level adherence ratings were substantial, and standardized patients have promise as tools to evaluate therapist behavior. C1 [Imel, Zac E.] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA. [Baldwin, Scott A.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA. [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Baer, John S.] VA Puget Sound Healthcare Syst, CESATE, Seattle, WA USA. [Hartzler, Bryan] Univ Washington, Alcohol Drug Abuse Inst, Seattle, WA 98195 USA. [Dunn, Chris; Atkins, David C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rosengren, David B.] Prevent Res Inst, Lexington, KY USA. RP Imel, ZE (reprint author), Univ Utah, Dept Educ Psychol, 1705 Campus Ctr Dr,Room 327, Salt Lake City, UT 84112 USA. EM zac.imel@utah.edu OI imel, zachary/0000-0001-9645-7184; Atkins, David/0000-0002-5781-9880 FU NIAAA NIH HHS [R01 AA018673, R01/AA018673]; NIDA NIH HHS [R34/DA034860, R01/DA016360, R34 DA034860, U10 DA013714] NR 28 TC 13 Z9 13 U1 0 U2 6 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD JUN PY 2014 VL 82 IS 3 BP 472 EP 481 DI 10.1037/a0036158 PG 10 WC Psychology, Clinical SC Psychology GA AJ7SF UT WOS:000337896700009 PM 24588405 ER PT J AU Naeser, MA Zafonte, R Krengel, MH Martin, PI Frazier, J Hamblin, MR Knight, JA Meehan, WP Baker, EH AF Naeser, Margaret A. Zafonte, Ross Krengel, Maxine H. Martin, Paula I. Frazier, Judith Hamblin, Michael R. Knight, Jeffrey A. Meehan, William P., III Baker, Errol H. TI Significant Improvements in Cognitive Performance Post-Transcranial, Red/Near-Infrared Light-Emitting Diode Treatments in Chronic, Mild Traumatic Brain Injury: Open-Protocol Study SO JOURNAL OF NEUROTRAUMA LA English DT Article DE executive function; mTBI; photobiomodulation; treatment for mTBI ID LEVEL LASER THERAPY; CYTOCHROME-C-OXIDASE; CEREBRAL-BLOOD-FLOW; CLOSED-HEAD-INJURY; WORKING-MEMORY; NEUROLOGICAL DEFICITS; FUNCTIONAL MRI; FOLLOW-UP; TBI; DYSFUNCTION AB This pilot, open-protocol study examined whether scalp application of red and near-infrared (NIR) light-emitting diodes (LED) could improve cognition in patients with chronic, mild traumatic brain injury (mTBI). Application of red/NIR light improves mitochondrial function (especially in hypoxic/compromised cells) promoting increased adenosine triphosphate (ATP) important for cellular metabolism. Nitric oxide is released locally, increasing regional cerebral blood flow. LED therapy is noninvasive, painless, and non-thermal (cleared by the United States Food and Drug Administration [FDA], an insignificant risk device). Eleven chronic, mTBI participants (26-62 years of age, 6 males) with nonpenetrating brain injury and persistent cognitive dysfunction were treated for 18 outpatient sessions (Monday, Wednesday, Friday, for 6 weeks), starting at 10 months to 8 years post-mTBI (motor vehicle accident [MVA] or sports-related; and one participant, improvised explosive device [IED] blast injury). Four had a history of multiple concussions. Each LED cluster head (5.35 cm diameter, 500mW, 22.2 mW/cm(2)) was applied for 10 min to each of 11 scalp placements (13 J/cm(2)). LEDs were placed on the midline from front-to-back hairline; and bilaterally on frontal, parietal, and temporal areas. Neuropsychological testing was performed pre-LED, and at 1 week, and 1 and 2 months after the 18th treatment. A significant linear trend was observed for the effect of LED treatment over time for the Stroop test for Executive Function, Trial 3 inhibition (p = 0.004); Stroop, Trial 4 inhibition switching (p = 0.003); California Verbal Learning Test (CVLT)-II, Total Trials 1-5 (p = 0.003); and CVLT-II, Long Delay Free Recall (p = 0.006). Participants reported improved sleep, and fewer post-traumatic stress disorder (PTSD) symptoms, if present. Participants and family reported better ability to perform social, interpersonal, and occupational functions. These open-protocol data suggest that placebo-controlled studies are warranted. C1 [Naeser, Margaret A.; Krengel, Maxine H.; Martin, Paula I.; Baker, Errol H.] VA Boston Healthcare Syst, Boston, MA USA. [Naeser, Margaret A.; Krengel, Maxine H.; Martin, Paula I.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Zafonte, Ross; Frazier, Judith] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA. [Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil,Brigham & Womens Hosp, Massachusetts Gen Hosp,Red Sox MGH Home Base Prog, Boston, MA USA. [Hamblin, Michael R.] Harvard Univ, Sch Med, Wellman Ctr Photomed,Massachusetts Gen Hosp, Harvard Mit Div Hlth Sci & Technol,Dept Dermatol, Cambridge, MA 02138 USA. [Knight, Jeffrey A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA. [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA. RP Naeser, MA (reprint author), VA Boston Healthcare Syst 12A, 150 So Huntington Ave, Boston, MA 02130 USA. EM mnaeser@bu.edu OI Hamblin, Michael/0000-0001-6431-4605 FU Clinical Sciences Research and Development, Department of Veterans Affairs; United States National Institutes of Health (NIH) [R01AI050875]; American Medical Society for Sports Medicine (AMSSM) Young Investigator Award; American College of Sports Medicine-American Medical Society for Sports Medicine Foundation Award FX M. Naeser was supported by the Clinical Sciences Research and Development, Department of Veterans Affairs. M. R. Hamblin was supported by United States National Institutes of Health (NIH) grant R01AI050875. W. P. Meehan was supported by an American Medical Society for Sports Medicine (AMSSM) Young Investigator Award and an American College of Sports Medicine-American Medical Society for Sports Medicine Foundation Award. The authors thank Laura Burns for assistance with participant enrollment, Iris Monge for the LED treatments, Anita Saltmarche for assistance with acquisition of the LED units and LED methodology, and Michael D. Ho for assistance with manuscript preparation. NR 72 TC 26 Z9 26 U1 9 U2 29 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN 1 PY 2014 VL 31 IS 11 BP 1008 EP 1017 DI 10.1089/neu.2013.3244 PG 10 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA AJ7RS UT WOS:000337895300003 PM 24568233 ER PT J AU Watts, LT Long, JA Chemello, J Van Koughnet, S Fernandez, A Huang, SL Shen, Q Duong, TQ AF Watts, Lora Talley Long, Justin Alexander Chemello, Jonathan Van Koughnet, Samantha Fernandez, Angelica Huang, Shiliang Shen, Qiang Duong, Timothy Q. TI Methylene Blue Is Neuroprotective against Mild Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE antioxidant; mitochondria; MRI; oxidative stress; vasogenic edema ID SPINAL-CORD-INJURY; CYCLOSPORINE-A; NEURONAL DEGENERATION; OXYGEN-CONSUMPTION; CEREBRAL-ISCHEMIA; REACTIVE GLIOSIS; FLUORO-JADE; MECHANISMS; GENERATION; PERFUSION AB Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Methylene blue (MB) has known energy-enhancing and antioxidant properties. This study tested the hypothesis that MB treatment reduces lesion volume and behavioral deficits in a rat model of mild TBI. In a randomized double-blinded design, animals received either MB (n = 5) or vehicle (n = 6) after TBI. Studies were performed on 0, 1, 2, 7, and 14 days following an impact to the primary forelimb somatosensory cortex. MRI lesion was not apparent 1 h after TBI, became apparent 3 h after TBI, and peaked at 2 days for both groups. The MB-treated animals showed significantly smaller MRI lesion volume than the vehicle-treated animals at all time points studied. The MB-treated animals exhibited significantly improved scores on forelimb placement asymmetry and foot fault tests than did the vehicle-treated animals at all time points studied. Smaller numbers of dark-stained Nissl cells and Fluoro-Jade (R) positive cells were observed in the MB-treated group than in vehicle-treated animals 14 days post-TBI. In conclusion, MB treatment minimized lesion volume, behavioral deficits, and neuronal degeneration following mild TBI. MB is already approved by the United States Food and Drug Administration (FDA) to treat a number of indications, likely expediting future clinical trials in TBI. C1 [Watts, Lora Talley; Long, Justin Alexander; Chemello, Jonathan; Van Koughnet, Samantha; Fernandez, Angelica; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wattsl@uthscsa.edu; duongt@uthscsa.edu NR 45 TC 14 Z9 15 U1 4 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN 1 PY 2014 VL 31 IS 11 BP 1063 EP 1071 DI 10.1089/neu.2013.3193 PG 9 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA AJ7RS UT WOS:000337895300009 ER PT J AU von Mehren, M Randall, RL Benjamin, RS Boles, S Bui, MM Casper, ES Conrad, EU DeLaney, TF Ganjoo, KN George, S Gonzalez, RJ Heslin, MJ Kane, JM Mayerson, J McGarry, SV Meyer, C O'Donnell, RJ Pappo, AS Paz, IB Pfeifer, JD Riedel, RF Schuetze, S Schupak, KD Schwartz, HS Van Tine, BA Wayne, JD Bergman, MA Sundar, H AF von Mehren, Margaret Randall, R. Lor Benjamin, Robert S. Boles, Sarah Bui, Marilyn M. Casper, Ephraim S. Conrad, Ernest U., III DeLaney, Thomas F. Ganjoo, Kristen N. George, Suzanne Gonzalez, Ricardo J. Heslin, Martin J. Kane, John M., III Mayerson, Joel McGarry, Sean V. Meyer, Christian O'Donnell, Richard J. Pappo, Alberto S. Paz, I. Benjamin Pfeifer, John D. Riedel, Richard F. Schuetze, Scott Schupak, Karen D. Schwartz, Herbert S. Van Tine, Brian A. Wayne, Jeffrey D. Bergman, Mary Anne Sundar, Hema TI Gastrointestinal Stromal Tumors, Version 2.2014 SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID FRENCH SARCOMA GROUP; IMATINIB MESYLATE; PHASE-III; SUCCINATE-DEHYDROGENASE; FUNCTION MUTATIONS; KINASE INHIBITOR; TYROSINE KINASE; KIT MUTATIONS; DOSE IMATINIB; SUNITINIB AB Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor a (PDGFR alpha)-activating mutations. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib. C1 [von Mehren, Margaret] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Randall, R. Lor] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Benjamin, Robert S.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Boles, Sarah] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Bui, Marilyn M.; Gonzalez, Ricardo J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Casper, Ephraim S.; Schupak, Karen D.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Conrad, Ernest U., III] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA. [DeLaney, Thomas F.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Ganjoo, Kristen N.] Stanford Canc Inst, Stanford, CA USA. [George, Suzanne] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Heslin, Martin J.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA. [Kane, John M., III] Roswell Pk Canc Inst, Buffalo, NY USA. [Mayerson, Joel] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Mayerson, Joel] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA. [McGarry, Sean V.] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. [Meyer, Christian] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [O'Donnell, Richard J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Pappo, Alberto S.] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA. [Paz, I. Benjamin] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Pfeifer, John D.; Van Tine, Brian A.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Pfeifer, John D.; Van Tine, Brian A.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Riedel, Richard F.] Duke Canc Inst, Durham, NC USA. [Schuetze, Scott] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Schwartz, Herbert S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Wayne, Jeffrey D.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. RP von Mehren, M (reprint author), Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. FU Prometheus Laboratories, Inc.; Bayer HealthCare; Onyx Pharmaceuticals, Inc.; Algeta US; Exelixis, Inc.; Genentech; Genomic Health, Inc.; NOVOCURE; Merck Sharp Dohme Corp. FX Supported by an independent educational grant from Prometheus Laboratories, Inc., and by educational grants from Bayer HealthCare, Onyx Pharmaceuticals, Inc., and Algeta US; Exelixis, Inc.; Genentech; Genomic Health, Inc.; NOVOCURE; and Merck Sharp & Dohme Corp. NR 50 TC 27 Z9 27 U1 1 U2 8 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JUN PY 2014 VL 12 IS 6 BP 853 EP 862 PG 10 WC Oncology SC Oncology GA AJ5GF UT WOS:000337710000003 PM 24925196 ER PT J AU Bichakjian, CK Olencki, T Alam, M Andersen, JS Berg, D Bowen, GM Cheney, RT Daniels, GA Glass, LF Grekin, RC Grossman, K Ho, AL Lewis, KD Lydiatt, DD Morrison, WH Nehal, KS Nelson, KC Nghiem, P Perlis, CS Shaha, AR Thorstad, WL Tuli, M Urist, MM Wang, TS Werchniak, AE Wong, SL Zic, JA McMillian, N Hoffman, K Ho, M AF Bichakjian, Christopher K. Olencki, Thomas Alam, Murad Andersen, James S. Berg, Daniel Bowen, Glen M. Cheney, Richard T. Daniels, Gregory A Glass, L. Frank Grekin, Roy C. Grossman, Kenneth Ho, Alan L. Lewis, Karl D Lydiatt, Daniel D. Morrison, William H. Nehal, Kishwer S. Nelson, Kelly C. Nghiem, Paul Perlis, Clifford S. Shaha, Ashok R Thorstad, Wade L Tuli, Malika Urist, Marshall M. Wang, Timothy S. Werchniak, Andrew E. Wong, Sandra L. Zic, John A. McMillian, Nicole Hoffman, Karin Ho, Maria TI Dermatofibrosarcoma Protuberans, Version 1.2014 SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID GROWTH-FACTOR-B; IMATINIB MESYLATE; DIFFERENTIAL-DIAGNOSIS; USEFUL MARKER; FACTOR-XIIIA; CD34; EXPRESSION; TISSUE; TUMOR AB Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue tumor characterized by a relatively high risk of local recurrence and low risk of metastasis. The NCCN Guidelines for DFSP provide multidisciplinary recommendations on the management of patients with this rare disease. These NCCN Guidelines Insights highlight the addition of the Principles of Pathology section, which provides recommendations on the pathologic assessment of DFSP. Because DFSP can mimic other lesions, immunohistochemical studies are often required to establish diagnosis. Cytogenetic testing for the characteristic translocation t(17;22)(q22;q13) can also be valuable in the differential diagnosis of DF5P with other histologically similar tumors. C1 [Bichakjian, Christopher K.; Wong, Sandra L.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Olencki, Thomas] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [Olencki, Thomas] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA. [Alam, Murad] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Andersen, James S.] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Berg, Daniel] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA. [Bowen, Glen M.; Grossman, Kenneth] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Cheney, Richard T.] Roswell Pk Canc Inst, Buffalo, NY USA. [Daniels, Gregory A] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Glass, L. Frank] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Grekin, Roy C.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Ho, Alan L.; Nehal, Kishwer S.; Shaha, Ashok R] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Lewis, Karl D] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA. [Lydiatt, Daniel D.] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. [Morrison, William H.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Nelson, Kelly C.] Duke Canc Inst, Durham, NC USA. [Perlis, Clifford S.] Fox Chase Canc Ctr, Philadelphia, PA USA. [Thorstad, Wade L] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Thorstad, Wade L] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Tuli, Malika] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA. [Urist, Marshall M.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA. [Wang, Timothy S.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Werchniak, Andrew E.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Zic, John A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. RP Bichakjian, CK (reprint author), Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. FU Prometheus Laboratories, Inc.; Bayer HealthCare; Onyx Pharmaceuticals, Inc.; Algeta US; Exelixis, Inc.; Genentech; Genomic Health, Inc.; NOVOCURE; Merck Sharp Dohme Corp. FX Supported by an independent educational grant from Prometheus Laboratories, Inc., and by educational grants from Bayer HealthCare, Onyx Pharmaceuticals, Inc., and Algeta US; Exelixis, Inc.; Genentech; Genomic Health, Inc.; NOVOCURE; and Merck Sharp & Dohme Corp. NR 24 TC 8 Z9 12 U1 0 U2 0 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JUN PY 2014 VL 12 IS 6 BP 863 EP 868 PG 6 WC Oncology SC Oncology GA AJ5GF UT WOS:000337710000004 PM 24925197 ER PT J AU Denlinger, CS Ligibel, JA Are, M Baker, KS Demark-Wahnefried, W Friedman, DL Goldman, M Friedman, DL Goldman, M Jones, L King, A Ku, GH Kvale, E Langbaum, TS Leonardi-Warren, K McCabe, MS Melisko, M Montoya, JG Mooney, K Morgan, MA Moslehi, JJ O'Connor, T Overholser, L Paskett, ED Raza, M Syrjala, KL Urba, SG Wakabayashi, MT Zee, P McMillian, N Freedman-Cass, D AF Denlinger, Crystal S. Ligibel, Jennifer A. Are, Madhuri Baker, K. Scott Demark-Wahnefried, Wendy Friedman, Debra L. Goldman, Mindy Friedman, Debra L. Goldman, Mindy Jones, Lee King, Allison Ku, Grace H. Kvale, Elizabeth Langbaum, Terry S. Leonardi-Warren, Kristin McCabe, Mary S. Melisko, Michelle Montoya, Jose G. Mooney, Kathi Morgan, Mary Ann Moslehi, Javid J. O'Connor, Tracey Overholser, Linda Paskett, Electra D. Raza, Muhammad Syrjala, Karen L. Urba, Susan G. Wakabayashi, Mark T. Zee, Phyllis McMillian, Nicole Freedman-Cass, Deborah TI Survivorship: Fatigue, Version 1.2014 SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID CANCER-RELATED FATIGUE; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIOR THERAPY; LONG-TERM SURVIVORS; BREAST-CANCER; CLINICAL-TRIAL; INSOMNIA; METAANALYSIS; EXERCISE AB Many cancer survivors report that fatigue is a disruptive symptom even after treatment ends. Persistent cancer-related fatigue affects quality of life, because individuals become too tired to fully participate in the roles and activities that make life meaningful. Identification and management of fatigue remains an unmet need for many cancer survivors. This section of the NCCN Guidelines for Survivorship provides screening, evaluation, and management recommendations for fatigue in survivors. Management includes education and counseling, physical activity, psychosocial interventions, and pharmacologic treatments. C1 [Denlinger, Crystal S.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Ligibel, Jennifer A.; Moslehi, Javid J.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Are, Madhuri] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. [Baker, K. Scott; Syrjala, Karen L.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA. [Demark-Wahnefried, Wendy; Kvale, Elizabeth] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA. [Friedman, Debra L.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Goldman, Mindy; Melisko, Michelle] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Jones, Lee; McCabe, Mary S.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [King, Allison] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [King, Allison] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Ku, Grace H.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Langbaum, Terry S.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Leonardi-Warren, Kristin; Overholser, Linda] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA. [Montoya, Jose G.] Stanford Canc Inst, Stanford, CA USA. [Mooney, Kathi] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Morgan, Mary Ann] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [O'Connor, Tracey] Roswell Pk Canc Inst, Buffalo, NY USA. [Paskett, Electra D.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [Paskett, Electra D.] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA. [Raza, Muhammad] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA. [Urba, Susan G.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Wakabayashi, Mark T.] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Zee, Phyllis] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [McMillian, Nicole; Freedman-Cass, Deborah] NCCN, Ft Washington, PA USA. RP Denlinger, CS (reprint author), Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. FU NCI NIH HHS [UM1 CA173642] NR 58 TC 9 Z9 9 U1 2 U2 8 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JUN PY 2014 VL 12 IS 6 BP 876 EP 886 PG 11 WC Oncology SC Oncology GA AJ5GF UT WOS:000337710000005 PM 24925198 ER PT J AU Zelenetz, AD Gordon, LI Wierda, WG Abramson, JS Advani, RH Andreadis, CB Bartlett, N Bellam, N Byrd, JC Czuczman, MS Fayad, LE Fisher, RI Glenn, MJ Harris, NL Hoppe, RT Horwitz, SM Kelsey, CR Kim, YH Krivacic, S LaCasce, AS Nademanee, A Porcu, P Press, O Rabinovitch, R Reddy, N Reid, E Sokol, L Swinnen, LJ Tsien, C Vose, JM Yahalom, J Zafar, N Dwyer, M Sundar, H AF Zelenetz, Andrew D. Gordon, Leo I. Wierda, William G. Abramson, Jeremy S. Advani, Ranjana H. Andreadis, C. Babis Bartlett, Nancy Bellam, Naresh Byrd, John C. Czuczman, Myron S. Fayad, Luis E. Fisher, Richard I. Glenn, Martha J. Harris, Nancy Lee Hoppe, Richard T. Horwitz, Steven M. Kelsey, Christopher R. Kim, Youn H. Krivacic, Susan LaCasce, Ann S. Nademanee, Auayporn Porcu, Pierluigi Press, Oliver Rabinovitch, Rachel Reddy, Nishitha Reid, Erin Sokol, Lubomir Swinnen, Lode J. Tsien, Christina Vose, Julie M. Yahalom, Joachim Zafar, Nadeem Dwyer, Mary Sundar, Hema TI Non-Hodgkin's Lymphomas, Version 2.2014 SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; PHASE-II TRIAL; TERM-FOLLOW-UP; STAGE FOLLICULAR LYMPHOMA; B-CELL LYMPHOMA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; ANTI-CD20 MONOCLONAL-ANTIBODY; RANDOMIZED CONTROLLED-TRIAL; HIGH-TUMOR BURDEN; TOSITUMOMAB/IODINE I-131 TOSITUMOMAB AB Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL. C1 [Zelenetz, Andrew D.; Horwitz, Steven M.; Yahalom, Joachim] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. [Gordon, Leo I.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Wierda, William G.; Fayad, Luis E.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Abramson, Jeremy S.; Harris, Nancy Lee] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Advani, Ranjana H.; Horwitz, Steven M.; Kim, Youn H.] Stanford Canc Inst, Stanford, CA USA. [Andreadis, C. Babis] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Bartlett, Nancy] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Bartlett, Nancy] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Bellam, Naresh] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA. [Byrd, John C.; Porcu, Pierluigi] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [Byrd, John C.; Porcu, Pierluigi] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY USA. [Fisher, Richard I.] Fox Chase Canc Ctr, Philadelphia, PA USA. [Glenn, Martha J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Kelsey, Christopher R.] Duke Canc Inst, Durham, NC USA. [Krivacic, Susan; LaCasce, Ann S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Nademanee, Auayporn] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Press, Oliver] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA. [Rabinovitch, Rachel] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA. [Reddy, Nishitha] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Reid, Erin] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Sokol, Lubomir] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Swinnen, Lode J.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Tsien, Christina] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Vose, Julie M.] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. [Zafar, Nadeem] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA. [Dwyer, Mary; Sundar, Hema] NCCN, Ft Washington, PA USA. RP Zelenetz, AD (reprint author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. FU NCI NIH HHS [P30 CA016672] NR 127 TC 19 Z9 22 U1 0 U2 7 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JUN PY 2014 VL 12 IS 6 BP 916 EP 945 PG 30 WC Oncology SC Oncology GA AJ5GF UT WOS:000337710000009 PM 24925202 ER PT J AU Scheiner, DL Keilp, J Mindt, MR Burke, AK Oquendo, MA Mann, JJ AF Scheiner, Diane L. Keilp, John Mindt, Monica Rivera Burke, Ainsley K. Oquendo, Maria A. Mann, J. John TI Verbal Learning Deficits in Posttraumatic Stress Disorder and Depression SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID PSYCHIATRIC-DISORDERS; HOLOCAUST SURVIVORS; MEMORY PERFORMANCE; SUICIDE ATTEMPTERS; MAJOR DEPRESSION; COMBAT VETERANS; PTSD; ATTENTION; COMORBIDITY; DYSFUNCTION AB Verbal learning and memory deficits are frequently reported in posttraumatic stress disorder (PTSD), but may be a product of its psychiatric comorbidities, especially major depressive disorder (MDD). To evaluate this hypothesis, 25 medication-free patients with PTSD and comorbid MDD were compared to 148 medication-free patients with equally severe MDD alone and to 96 nonpatients on a measure of verbal learning and memory. Additional measures of attention, working memory, and executive function were administered to evaluate their contribution to verbal memory impairment. Patients with comorbid PTSD and MDD demonstrated the greatest deficit in verbal learning compared to both MDD patients and nonpatients (omnibus effect sizes ranged d = 0.41 to 0.50), one that was not accounted for by other cognitive deficits. Findings suggest that a current diagnosis of PTSD makes a contribution to verbal learning deficits beyond the effect of depression alone. C1 [Scheiner, Diane L.; Mindt, Monica Rivera] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA. [Keilp, John; Burke, Ainsley K.; Oquendo, Maria A.; Mann, J. John] Columbia Univ, Dept Psychiat, New York, NY USA. [Keilp, John; Burke, Ainsley K.; Oquendo, Maria A.; Mann, J. John] New York State Psychiat Inst & Hosp, Div Mol Imaging & Neuropathol, New York, NY 10032 USA. RP Scheiner, DL (reprint author), West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Psychol Dept 116B, Bldg 256,Room 204,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM dscheiner@fordham.edu FU NIMH NIH HHS [MH-62155, 5P50 MH-62185] NR 55 TC 2 Z9 2 U1 3 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD JUN PY 2014 VL 27 IS 3 BP 291 EP 298 DI 10.1002/jts.21921 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AJ8JM UT WOS:000337949300006 PM 24850268 ER PT J AU Vogt, D Fox, AB Di Leone, BAL AF Vogt, Dawne Fox, Annie B. Di Leone, Brooke A. L. TI Mental Health Beliefs and Their Relationship With Treatment Seeking Among U.S. OEF/OIF Veterans SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID MILITARY PERSONNEL; PRIMARY-CARE; STIGMA; IRAQ; BARRIERS; SOLDIERS; AFGHANISTAN; INVENTORY; ATTITUDES; REDUCE AB Many veterans who would benefit from mental health care do not seek treatment. The current study provided an in-depth examination of mental health-related beliefs and their relationship with mental health and substance abuse service use in a national sample of 640 U.S. Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans. Both concerns about mental health stigma from others and personal beliefs about mental illness and mental health treatment were examined. Data were weighted to adjust for oversampling of women and nonresponse bias. Results revealed substantial variation in the nature of OEF/OIF veterans' mental health beliefs, with greater anticipated stigma in the workplace (M = 23.74) than from loved ones (M = 19.30), and stronger endorsement of negative beliefs related to mental health treatment-seeking (M = 21.78) than either mental illness (M = 18.56) or mental health treatment (M = 20.34). As expected, individuals with probable mental health problems reported more negative mental health-related beliefs than those without these conditions. Scales addressing negative personal beliefs were related to lower likelihood of seeking care (ORs = 0.80-0.93), whereas scales addressing anticipated stigma were not associated with service use. Findings can be applied to address factors that impede treatment seeking. C1 [Vogt, Dawne; Fox, Annie B.; Di Leone, Brooke A. L.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA. [Vogt, Dawne] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. RP Vogt, D (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 3, 150 South Huntington Ave, Boston, MA 02130 USA. EM Dawne.Vogt@va.gov NR 30 TC 6 Z9 6 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD JUN PY 2014 VL 27 IS 3 BP 307 EP 313 DI 10.1002/jts.21919 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AJ8JM UT WOS:000337949300008 PM 24839077 ER PT J AU Price, M Davidson, TM Ruggiero, KJ Acierno, R Resnick, HS AF Price, Matthew Davidson, Tatiana M. Ruggiero, Kenneth J. Acierno, Ron Resnick, Heidi S. TI Predictors of Using Mental Health Services After Sexual Assault SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; RAPE MEDICAL-CARE; SUBSTANCE USE; EARLY INTERVENTION; TREATMENT-SEEKING; TRAUMATIC INJURY; RECENT VICTIMS; UNITED-STATES; HELP-SEEKING AB Sexual assault increases the risk for psychopathology. Despite the availability of effective interventions, relatively few victims who need treatment receive care in the months following an assault. Prior work identified several factors associated with utilizing care, including ethnicity, insurance, and posttraumatic stress disorder (PTSD) symptoms. Few studies, however, have examined predictors of treatment utilization prospectively from the time of assault. The present study hypothesized that White racial status, younger age, being partnered, having health insurance, having previously received mental health treatment, and having more PTSD and depression symptoms would predict utilization of care in the 6 months postassault. This was examined in a sample of 266 female sexual assault victims with an average age of 26.2 years, of whom 62.0% were White and 38.0% were African American assessed at 1.5 and 6 months postassault. Available information on utilizing care varied across assessments (1.5 months, n = 214; 3 months, n = 126; 6 months, n = 204). Significant predictors included having previously received mental health treatment (OR = 4.09), 1 day depressive symptoms (OR = 1.06), and having private insurance (OR = 2.24) or Medicaid (OR = 2.19). Alcohol abuse and prior mental health care were associated with a substantial increase in treatment utilization (OR = 4.07). The findings highlight the need to help victims at risk obtain treatment after sexual assault. C1 [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Davidson, Tatiana M.; Ruggiero, Kenneth J.; Acierno, Ron; Resnick, Heidi S.] Med Univ S Carolina, Natl Crime Victims Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Resnick, HS (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, Natl Crime Victims Res & Treatment Ctr, 67 President St, Charleston, SC 29425 USA. EM resnickh@musc.edu FU NIDA NIH HHS [R01DA11158, R01 DA011158, R01 DA023099, R01DA023099]; NIMH NIH HHS [T32MH018869, T32 MH018869] NR 54 TC 10 Z9 10 U1 5 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD JUN PY 2014 VL 27 IS 3 BP 331 EP 337 DI 10.1002/jts.21915 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AJ8JM UT WOS:000337949300011 PM 24852357 ER PT J AU Gradus, JL Bozi, I Antonsen, S Svensson, E Lash, TL Resick, PA Hansen, JG AF Gradus, Jaimie L. Bozi, Imre Antonsen, Sussie Svensson, Elisabeth Lash, Timothy L. Resick, Patricia A. Hansen, Jens Georg TI Severe Stress and Adjustment Disorder Diagnoses in the Population of Denmark SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID NATIONAL COMORBIDITY SURVEY; DSM-IV DISORDERS; LIFETIME PREVALENCE; SURVEY REPLICATION; COMPLETED SUICIDE; SEX-DIFFERENCES; ONSET AB We created a registry of Danish-born citizens of Denmark with incident International Classification of Diseases (10th ed.; ICD-10) severe stress and adjustment disorder diagnoses between 1995 and 2011. A unique personal identifier was used to retrieve and merge data on demographic characteristics and diagnoses (ICD-10 codes F43.x). Here we report on the incidence of these disorders and the demographic characteristics of the subset of the Danish population who have received 1 of these diagnoses: 111,844 adults and children received a first diagnosis between 1995 and 2011. More women than men (60.1% vs. 39.9%) received a diagnosis. Diagnoses increased during the late teens through early 30s. Adjustment disorder was the most common diagnosis (65.7% of adults and 64% of children). Reaction to severe stress unspecified was the second most common (19.8% of adults and 23.8% of children), and there was a large increase in both, as well as acute stress reaction diagnoses, in 2007 (3,717-5,141, 1,248-2,520, and 348-1,024 in 2006 to 2007, respectively). Findings regarding gender and age of onset are similar to other westernized countries. This registry can be used for future research programs, contributing to the study of stress and trauma. C1 [Gradus, Jaimie L.; Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Gradus, Jaimie L.; Resick, Patricia A.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA. [Bozi, Imre; Antonsen, Sussie; Svensson, Elisabeth; Lash, Timothy L.; Hansen, Jens Georg] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark. [Lash, Timothy L.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA. [Resick, Patricia A.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. RP Gradus, JL (reprint author), 150 S Huntington Ave,116B-3, Boston, MA 02130 USA. EM Jaimie.gradus@va.gov OI Gradus, Jaimie/0000-0003-1459-5327; Svensson, Elisabeth/0000-0001-6706-6336 FU NIMH NIH HHS [1R21MH094551-01A1] NR 15 TC 7 Z9 7 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD JUN PY 2014 VL 27 IS 3 BP 370 EP 374 DI 10.1002/jts.21926 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AJ8JM UT WOS:000337949300017 PM 24948539 ER PT J AU Tang, Y Gellad, WF Men, A Donohue, JM AF Tang, Yan Gellad, Walid F. Men, Aiju Donohue, Julie M. TI Impact of Medicare Part D Plan Features on Use of Generic Drugs SO MEDICAL CARE LA English DT Article DE Medicare Part D; cost-sharing; prior authorization; step therapy; generic drugs ID D BENEFICIARIES; HEART-FAILURE; ADHERENCE; COST; COPAYMENT; PHYSICIAN; PERCEPTIONS; PROGRAM; CHOICE AB Background:Little is known about how Medicare Part D plan features influence choice of generic versus brand drugs.Objectives:To examine the association between Part D plan features and generic medication use.Methods:Data from a 2009 random sample of 1.6 million fee-for-service, Part D enrollees aged 65 years and above, who were not dually eligible or receiving low-income subsidies, were used to examine the association between plan features (generic cost-sharing, difference in brand and generic copay, prior authorization, step therapy) and choice of generic antidepressants, antidiabetics, and statins. Logistic regression models accounting for plan-level clustering were adjusted for sociodemographic and health status.Results:Generic cost-sharing ranged from $0 to $9 for antidepressants and statins, and from $0 to $8 for antidiabetics (across 5th-95th percentiles). Brand-generic cost-sharing differences were smallest for statins (5th-95th percentiles: $16-$37) and largest for antidepressants ($16-$64) across plans. Beneficiaries with higher generic cost-sharing had lower generic use [adjusted odds ratio (OR)=0.97, 95% confidence interval (CI), 0.95-0.98 for antidepressants; OR=0.97, 95% CI, 0.96-0.98 for antidiabetics; OR=0.94, 95% CI, 0.92-0.95 for statins]. Larger brand-generic cost-sharing differences and prior authorization were significantly associated with greater generic use in all categories. Plans could increase generic use by 5-12 percentage points by reducing generic cost-sharing from the 75th ($7) to 25th percentiles ($4-$5), increasing brand-generic cost-sharing differences from the 25th ($25-$26) to 75th ($32-$33) percentiles, and using prior authorization and step therapy.Conclusions:Cost-sharing features and utilization management tools were significantly associated with generic use in 3 commonly used medication categories. C1 [Tang, Yan; Men, Aiju; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] RAND Hlth, Pittsburgh, PA USA. RP Tang, Y (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A663, Pittsburgh, PA 15261 USA. EM yat11@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU RAND-University of Pittsburgh Health Initiative (RUPHI); Clinical and Translational Science Institute at the University of Pittsburgh; National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program [UL1RR024153, UL1TR000005]; VA HSR&D Career Development Award [CDA09-207] FX Supported by a pilot grant funded by both RAND-University of Pittsburgh Health Initiative (RUPHI) and the Clinical and Translational Science Institute at the University of Pittsburgh, which is supported by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program (grants UL1RR024153 and UL1TR000005). W. F. G. is additionally supported by a VA HSR&D Career Development Award (CDA09-207). NR 46 TC 1 Z9 1 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JUN PY 2014 VL 52 IS 6 BP 541 EP 548 DI 10.1097/MLR.0000000000000142 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AJ5LK UT WOS:000337723900012 PM 24824538 ER PT J AU Schrey, D Malietzis, G Chi, S Dufour, C Lafay-Cousin, L Marshall, L Carceller, F Moreno, L Zacharoulis, S AF Schrey, Dominik Malietzis, George Chi, Susan Dufour, Christelle Lafay-Cousin, Lucie Marshall, Lynley Carceller, Fernando Moreno, Lucas Zacharoulis, Stergios TI IMPACT OF HIGH DOSE CHEMOTHERAPY ON SURVIVAL OF NEWLY DIAGNOSED PATIENTS WITH ATYPICAL TERATOID RHABDOID TUMOUR (ATRT) - A SYSTEMATIC REVIEW AND RE-ANALYSIS OF MULTIMODAL THERAPY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Schrey, Dominik; Marshall, Lynley; Carceller, Fernando; Moreno, Lucas; Zacharoulis, Stergios] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England. [Malietzis, George] St Marks Hosp, Harrow, Middx, England. [Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dufour, Christelle] Inst Cancerol Gustave Roussy, Paris, France. [Lafay-Cousin, Lucie] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA AT-014 BP 4 EP 4 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200015 ER PT J AU Kieran, M Fontebasso, A Papillon-Cavanagh, S Schwartzentruber, J Nikbakht, H Gerges, N Fiset, PO Bechet, D Faury, D De Jay, N Ramkissoon, L Corcoran, A Jones, D Sturm, D Johann, P Tomita, T Goldman, S Nagib, M Bendel, A Goumnerova, L Bowers, DC Leonard, JR Rubin, JB Alden, T DiPatri, A Browd, S Leary, S Jallo, G Cohen, K Prados, MD Banerjee, A Carret, AS Ellezam, B Crevier, L Klekner, A Bognar, L Hauser, P Garami, M Myseros, J Dong, ZF Siegel, PM Gump, W Ayyanar, K Ragheb, J Khatib, Z Krieger, M Kiehna, E Robison, N Harter, D Gardner, S Handler, M Foreman, N Brahma, B MacDonald, T Malkin, H Chi, S Manley, P Bandopadhayay, P Greenspan, L Ligon, A Albrecht, S Pfister, SM Ligon, KL Majewski, J Gupta, N Jabado, N AF Kieran, Mark Fontebasso, Adam Papillon-Cavanagh, Simon Schwartzentruber, Jeremy Nikbakht, Hamid Gerges, Noha Fiset, Pierre-Oliver Bechet, Denise Faury, Damien De Jay, Nicolas Ramkissoon, Lori Corcoran, Aoife Jones, David Sturm, Dominik Johann, Pascal Tomita, Tadanori Goldman, Stewart Nagib, Mahmoud Bendel, Anne Goumnerova, Liliana Bowers, Daniel C. Leonard, Jeffrey R. Rubin, Joshua B. Alden, Tord DiPatri, Arthur Browd, Samuel Leary, Sarah Jallo, George Cohen, Kenneth Prados, Michael D. Banerjee, Anuradha Carret, Anne-Sophie Ellezam, Benjamin Crevier, Louis Klekner, Almos Bognar, Laszlo Hauser, Peter Garami, Miklos Myseros, John Dong, Zhifeng Siegel, Peter M. Gump, William Ayyanar, Kanyalakshmi Ragheb, John Khatib, Ziad Krieger, Mark Kiehna, Erin Robison, Nathan Harter, David Gardner, Sharon Handler, Michael Foreman, Nicholas Brahma, Barunashish MacDonald, Tobey Malkin, Hayley Chi, Susan Manley, Peter Bandopadhayay, Pratiti Greenspan, Lianne Ligon, Azra Albrecht, Steffen Pfister, Stefan M. Ligon, Keith L. Majewski, Jacek Gupta, Nalin Jabado, Nada TI THE BATS DIPG STUDY: A NATIONAL CLINICAL TRIAL OF UPFRONT BIOPSY AND TREATMENT STRATIFICATION FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DFCI # 10-321) SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Kieran, Mark; Ramkissoon, Lori; Corcoran, Aoife; Malkin, Hayley; Chi, Susan; Manley, Peter; Bandopadhayay, Pratiti; Greenspan, Lianne; Ligon, Azra; Ligon, Keith L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goumnerova, Liliana] Boston Childrens Hosp, Boston, MA USA. [Fontebasso, Adam; Papillon-Cavanagh, Simon; Schwartzentruber, Jeremy; Nikbakht, Hamid; Gerges, Noha; Fiset, Pierre-Oliver; Bechet, Denise; Faury, Damien; De Jay, Nicolas; Albrecht, Steffen; Majewski, Jacek; Jabado, Nada] Montreal Childrens Hosp, Montreal, PQ, Canada. [Jones, David; Sturm, Dominik; Johann, Pascal; Pfister, Stefan M.] German Canc Res Ctr, Heidelberg, Germany. [Tomita, Tadanori; Goldman, Stewart; Alden, Tord; DiPatri, Arthur] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA. [Nagib, Mahmoud; Bendel, Anne] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA. [Bowers, Daniel C.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Leonard, Jeffrey R.; Rubin, Joshua B.] Washington Univ, Sch Med, St Louis, MO USA. [Browd, Samuel; Leary, Sarah] Seattle Childrens Hosp, Seattle, WA USA. [Jallo, George; Cohen, Kenneth] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Prados, Michael D.; Banerjee, Anuradha; Gupta, Nalin] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Carret, Anne-Sophie; Ellezam, Benjamin; Crevier, Louis] CHU Ste Justine, Montreal, PQ, Canada. [Klekner, Almos; Bognar, Laszlo] Med & Hlth Sci Ctr, Debrecen, Hungary. [Hauser, Peter; Garami, Miklos] Semmelweis Univ, H-1085 Budapest, Hungary. [Myseros, John] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Dong, Zhifeng; Siegel, Peter M.] Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ, Canada. [Gump, William; Ayyanar, Kanyalakshmi] Univ Louisville, Louisville, KY 40292 USA. [Ragheb, John; Khatib, Ziad] Miami Childrens Hosp, Miami, FL USA. [Krieger, Mark; Kiehna, Erin; Robison, Nathan] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Harter, David; Gardner, Sharon] NYU, Med Ctr, New York, NY 10016 USA. [Handler, Michael; Foreman, Nicholas] Childrens Hosp Colorado, Aurora, CO USA. [Brahma, Barunashish; MacDonald, Tobey] Childrens Healthcare Atlanta, Atlanta, GA USA. RI Pfister, Stefan/F-6860-2013 OI Pfister, Stefan/0000-0002-5447-5322 NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA HG-066 BP 56 EP 57 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200213 ER PT J AU Bergthold, G Bandopadhayay, P Rich, B Chan, J Santagata, S Hoshida, Y Ramkissoon, S Ramkissoon, L Golub, T Tabak, B Ferrer-Luna, R Weng, PY Stiles, C Grill, J Kieran, MW Ligon, KL Beroukhim, R AF Bergthold, Guillaume Bandopadhayay, Pratiti Rich, Benjamin Chan, Jennifer Santagata, Sandro Hoshida, Yujin Ramkissoon, Shakti Ramkissoon, Lori Golub, Todd Tabak, Barbara Ferrer-Luna, Ruben Weng, Patrick Y. Stiles, Charles Grill, Jacques Kieran, Mark W. Ligon, Keith L. Beroukhim, Rameen TI GENE EXPRESSION ANALYSIS OF 151 PEDIATRIC LOW-GRADE GLIOMAS REVEALS UNDERLYING MOLECULAR HETEROGENEITY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Bergthold, Guillaume; Bandopadhayay, Pratiti; Ferrer-Luna, Ruben; Stiles, Charles; Kieran, Mark W.; Beroukhim, Rameen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rich, Benjamin; Chan, Jennifer; Santagata, Sandro; Ramkissoon, Shakti; Ramkissoon, Lori; Weng, Patrick Y.; Ligon, Keith L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hoshida, Yujin; Golub, Todd; Tabak, Barbara] Broad Inst MIT & Harvard, Cambridge, MA USA. [Grill, Jacques] Inst Gustave Roussy, Villejuif, France. [Grill, Jacques] Univ Paris 11, Villejuif, France. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA LG-011 BP 62 EP 62 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200235 ER PT J AU Hwang, E Mun, A Kilburn, L Chi, S Knipstein, J Oren, M Dvir, R Hardy, K Rood, B Packer, R AF Hwang, Eugene Mun, Alissa Kilburn, Lindsay Chi, Susan Knipstein, Jeffrey Oren, Michal Dvir, Rina Hardy, Kristina Rood, Brian Packer, Roger TI A MULTI-INSTITUTIONAL PHASE II STUDY OF VINORELBINE IN CHILDREN WITH RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Hwang, Eugene; Mun, Alissa; Kilburn, Lindsay; Hardy, Kristina; Rood, Brian; Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Knipstein, Jeffrey] INOVA Fairfax, Fairfax, VA USA. [Oren, Michal] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. [Dvir, Rina] Tel Aviv Med Ctr & Sch Med, Dana Childrens Hosp, IL-64239 Tel Aviv, Israel. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA LG-009 BP 62 EP 62 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200233 ER PT J AU Sun, Y Buhrlage, S Pilarz, C Alberta, J Stiles, C Gray, N AF Sun, Yu Buhrlage, Sara Pilarz, Catherine Alberta, John Stiles, Charles Gray, Nathanael TI TARGETING BRAF MUTANTS FOR PEDIATRIC LOW-GRADE ASTROCYTOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Sun, Yu; Buhrlage, Sara; Pilarz, Catherine; Alberta, John; Stiles, Charles; Gray, Nathanael] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA LG-024 BP 65 EP 65 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200248 ER PT J AU Bandopadhayay, P Bergthold, G Sauer, N Green, A Malkin, H Dabscheck, G Marcus, K Ullrich, N Goumnerova, L Chi, S Beroukhim, R Kieran, M Manley, P AF Bandopadhayay, Pratiti Bergthold, Guillaume Sauer, Nadine Green, Adam Malkin, Hayley Dabscheck, Gabriel Marcus, Karen Ullrich, Nicole Goumnerova, Liliana Chi, Susan Beroukhim, Rameen Kieran, Mark Manley, Peter TI PEDIATRIC PATIENTS WITH DIFFUSE ASTROCYTOMAS HAVE A DISTINCT CLINICAL COURSE TO THOSE DIAGNOSED AS ADULTS, WITH EXCELLENT VERY LONG TERM SURVIVAL SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA LG-032 BP 67 EP 67 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200256 ER PT J AU Sauer, N Dodgshun, A Malkin, H Bergthold, G Manley, P Chi, S Ramkissoon, S MacGregor, D Beroukhim, R Kieran, M Sullivan, M Ligon, K Bandopadhayay, P Hansford, J AF Sauer, Nadine Dodgshun, Andrew Malkin, Hayley Bergthold, Guillaume Manley, Peter Chi, Susan Ramkissoon, Shakti MacGregor, Duncan Beroukhim, Rameen Kieran, Mark Sullivan, Michael Ligon, Keith Bandopadhayay, Pratiti Hansford, Jordan TI BRAF MUTATIONS IDENTIFIED IN DISSEMINATED OLIGODENDROGLIAL-LIKE LEPTOMENINGEAL TUMOR OF CHILDHOOD SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Sauer, Nadine; Malkin, Hayley; Bergthold, Guillaume; Manley, Peter; Chi, Susan; Ramkissoon, Shakti; Beroukhim, Rameen; Kieran, Mark; Ligon, Keith; Bandopadhayay, Pratiti] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dodgshun, Andrew; MacGregor, Duncan; Sullivan, Michael; Hansford, Jordan] Royal Chlidrens Hosp, Melbourne, Vic, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA LG-037 BP 68 EP 69 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200261 ER PT J AU Lafay-Cousin, L Chi, S Madden, J Smith, A Wells, E Owens, E Strother, D Foreman, N Packer, R Bouffet, E AF Lafay-Cousin, Lucie Chi, Susan Madden, Jennifer Smith, Amy Wells, Elisabeth Owens, Emily Strother, Douglas Foreman, Nicholas Packer, Roger Bouffet, Eric TI LONG TERM FOLLOW UP OF INFANTS WITH MEDULLOBLASTOMA TREATED WITH SEQUENTIAL HIGH DOSE CHEMOTHERAPY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Lafay-Cousin, Lucie; Strother, Douglas] Alberta Children Hosp, Calgary, AB, Canada. [Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Madden, Jennifer; Foreman, Nicholas] Childrens Hosp Colorado, Denver, CO USA. [Smith, Amy; Owens, Emily] Arnold Palmer Hosp Children, Orlando, CA USA. [Wells, Elisabeth; Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Bouffet, Eric] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA MB-007 BP 72 EP 72 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200273 ER PT J AU Fay-McClymont, T Walsh, K Mabbott, D Smith, A Wells, E Madden, J Chi, S Owens, E Strother, D Packer, R Foreman, N Bouffet, E Lafay-Cousin, L AF Fay-McClymont, Taryn Walsh, Karin Mabbott, Donald Smith, Amy Wells, Elizabeth Madden, Jennifer Chi, Susan Owens, Emily Strother, Douglas Packer, Roger Foreman, Nicholas Bouffet, Eric Lafay-Cousin, Lucie TI LONG TERM NEUROPSYCHOLOGICAL FOLLOW-UP OF YOUNG CHILDREN WITH MEDULLOBLASTOMA TREATED ACCORDING TO THE CCG 99703 REGIMEN SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Fay-McClymont, Taryn; Strother, Douglas; Lafay-Cousin, Lucie] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada. [Mabbott, Donald; Bouffet, Eric] Hosp Sick Children, Toronto, ON, Canada. [Walsh, Karin; Wells, Elizabeth; Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Smith, Amy; Owens, Emily] Arnold Palmer Hosp Children, Orlando, FL USA. [Madden, Jennifer; Foreman, Nicholas] Childrens Hosp Colorado, Denver, CO USA. [Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA MB-019 BP 75 EP 75 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200285 ER PT J AU Ecker, J Oehme, I Mazitschek, R Korshunov, A Kool, M Lodrini, M Deubzer, HE von Deimling, A Kulozik, AE Pfister, SM Witt, O Milde, T AF Ecker, Jonas Oehme, Ina Mazitschek, Ralph Korshunov, Andrey Kool, Marcel Lodrini, Marco Deubzer, Hedwig E. von Deimling, Andreas Kulozik, Andreas E. Pfister, Stefan M. Witt, Olaf Milde, Till TI TARGETING CLASS I HISTONE DEACETYLASES IN HIGH RISK MEDULLOBLASTOMA - ANALYSIS OF MOLECULAR MECHANISMS AND TRANSLATIONAL IMPLICATIONS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Ecker, Jonas; Oehme, Ina; Lodrini, Marco; Deubzer, Hedwig E.; Witt, Olaf; Milde, Till] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol G340, Heidelberg, Germany. [Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Korshunov, Andrey; von Deimling, Andreas] Univ Heidelberg Hosp, Dept Neuropathol, Heidelberg, Germany. [Kool, Marcel; Pfister, Stefan M.] German Canc Res Ctr, Div Pediat Neurooncol B062, Heidelberg, Germany. [Kulozik, Andreas E.] Univ Heidelberg Hosp, Sect Pediat Brain Tumors, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany. RI Kool, Marcel/H-2541-2013; Pfister, Stefan/F-6860-2013 OI Pfister, Stefan/0000-0002-5447-5322 NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA MB-037 BP 80 EP 80 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200303 ER PT J AU Bandopadhayay, P Bergthold, G Nguyen, B Schubert, S Gholamin, S Tang, YJ Bolin, S Schumacher, S Zeid, R Masoud, S Yu, FR Vue, N Gibson, W Paolella, B Mitra, S Cheshier, S Qi, J Liu, KW Wechsler-Reya, R Weiss, W Swartling, FJ Kieran, MW Bradner, JE Beroukhim, R Cho, YJ AF Bandopadhayay, Pratiti Bergthold, Guillaume Nguyen, Brian Schubert, Simone Gholamin, Sharareh Tang, Yujie Bolin, Sara Schumacher, Steven Zeid, Rhamy Masoud, Sabran Yu, Furong Vue, Nujsaubnusi Gibson, William Paolella, Brenton Mitra, Siddhartha Cheshier, Samuel Qi, Jun Liu, Kun-Wei Wechsler-Reya, Robert Weiss, William Swartling, Fredrik J. Kieran, Mark W. Bradner, James E. Beroukhim, Rameen Cho, Yoon-Jae TI MEDULLOBLASTOMA MODELS WHICH HARBOR AMPLIFICATIONS OF MYC FAMILY MEMBERS ARE SENSITIVE TO BET-BROMODOMAIN INHIBITION SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Bandopadhayay, Pratiti; Bergthold, Guillaume; Kieran, Mark W.] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA. [Bandopadhayay, Pratiti; Bergthold, Guillaume; Kieran, Mark W.] Harvard Univ, Sch Med, Boston, MA USA. [Nguyen, Brian; Schubert, Simone; Gholamin, Sharareh; Tang, Yujie; Masoud, Sabran; Yu, Furong; Vue, Nujsaubnusi; Mitra, Siddhartha; Cheshier, Samuel; Cho, Yoon-Jae] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. [Bolin, Sara; Swartling, Fredrik J.] Uppsala Univ, Uppsala, Sweden. [Schumacher, Steven; Zeid, Rhamy; Gibson, William; Paolella, Brenton; Qi, Jun; Bradner, James E.; Beroukhim, Rameen] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Schumacher, Steven; Zeid, Rhamy; Gibson, William; Paolella, Brenton; Qi, Jun; Bradner, James E.; Beroukhim, Rameen] Broad Inst MIT & Harvard, Boston, MA USA. [Liu, Kun-Wei; Wechsler-Reya, Robert] Sanford Burnham Med Res Inst, La Jolla, CA USA. [Weiss, William] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Weiss, William] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Weiss, William] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA MB-075 BP 90 EP 90 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200341 ER PT J AU Wells, EM Ullrich, NJ Seidel, K Leisenring, W Sklar, C Armstrong, GT Diller, L King, A Krull, K Neglia, JP Stovall, M Whelan, K Robison, LL Packer, RJ AF Wells, Elizabeth M. Ullrich, Nicole J. Seidel, Kristy Leisenring, Wendy Sklar, Charles Armstrong, Gregory T. Diller, Lisa King, Allison Krull, Kevin Neglia, Joseph P. Stovall, Marilyn Whelan, Kimberly Robison, Leslie L. Packer, Roger J. TI NEUROLOGIC SEQUELAE IN BRAIN TUMOR SURVIVORS IN THE CHILDHOOD CANCER SURVIVOR STUDY (CCSS) SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Wells, Elizabeth M.; Packer, Roger J.] Childrens Natl, Washington, DC USA. [Ullrich, Nicole J.] Harvard Univ, Boston Childrens, Boston, MA 02115 USA. [Seidel, Kristy; Leisenring, Wendy] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Sklar, Charles] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Armstrong, Gregory T.; Krull, Kevin; Stovall, Marilyn] St Jude Canc Res Ctr, Memphis, TN USA. [Diller, Lisa] Dana Farber Canc Inst, Boston, MA 02115 USA. [King, Allison] Washington Univ, St Louis, MO USA. [Neglia, Joseph P.] Univ Minnesota, Minneapolis, MN USA. [Whelan, Kimberly] MD Anderson, Houston, TX USA. [Robison, Leslie L.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA QL-006 BP 112 EP 112 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200430 ER PT J AU Chi, SN Bandopadhayay, P Janeway, K Pinches, N Malkin, H Kieran, MW Manley, PE Green, A Goumnerova, L Ramkissoon, S Harris, MH Ligon, KL AF Chi, Susan N. Bandopadhayay, Pratiti Janeway, Katherine Pinches, Nathan Malkin, Hayley Kieran, Mark W. Manley, Peter E. Green, Adam Goumnerova, Liliana Ramkissoon, Shakti Harris, Marian H. Ligon, Keith L. TI PROFILE: FEASIBILITY OF AN INSTITUTE-WIDE PROJECT IN PERSONALIZED MEDICINE FOR CHILDREN WITH BRAIN TUMORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO) CY JUN 28-JUL 02, 2014 CL Singapore, SINGAPORE C1 [Chi, Susan N.; Bandopadhayay, Pratiti; Janeway, Katherine; Pinches, Nathan; Malkin, Hayley; Kieran, Mark W.; Manley, Peter E.; Green, Adam] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ramkissoon, Shakti; Ligon, Keith L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Goumnerova, Liliana; Harris, Marian H.] Boston Childrens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2014 VL 16 SU 1 MA TB-029 BP 143 EP 143 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA AJ8AK UT WOS:000337924200554 ER PT J AU Hoyos-Bachiloglu, R Morales, PS Cerda, J Talesnik, E Gonzalez, G Camargo, CA Borzutzky, A AF Hoyos-Bachiloglu, Rodrigo Morales, Pamela S. Cerda, Jaime Talesnik, Eduardo Gonzalez, Gilberto Camargo, Carlos A., Jr. Borzutzky, Arturo TI Higher latitude and lower solar radiation influence on anaphylaxis in Chilean children SO PEDIATRIC ALLERGY AND IMMUNOLOGY LA English DT Article DE allergy; anaphylaxis; food allergy; latitude; solar radiation; vitamin D ID EMERGENCY-DEPARTMENT VISITS; VITAMIN-D; FOOD ALLERGY; REGIONAL-VARIATION; PRESCRIPTIONS; AUSTRALIA; PREVALENCE AB Background: Recent studies suggest an association between higher latitude, a proxy of vitamin D (VD) status, and allergic diseases. Chile provides an ideal setting to study this association due to its latitude span and high rates of VD deficiency in southern regions. The aim of this study is to explore the associations of latitude and solar radiation with anaphylaxis admission rates. Methods: We reviewed anaphylaxis admissions in Chile's hospital discharge database between 2001 and 2010 and investigated associations with latitude and solar radiation. Results: 2316 anaphylaxis admissions were registered. Median age of patients was 41 yr; 53% were female. National anaphylaxis admission rate was 1.41 per 100,000 persons per year. We observed a strong north-south increasing gradient of anaphylaxis admissions (beta 0.04, p = 0.01), with increasing rates south of latitude 34 degrees S. A significant association was also observed between solar radiation and anaphylaxis admissions (beta -0.11, p = 0.009). Latitude was associated with food-induced (beta 0.05, p = 0.02), but not drug-induced (beta -0.002, p = 0.27), anaphylaxis. The association between latitude and food-induced anaphylaxis was significant in children (beta 0.01, p = 0.006), but not adults (beta 0.003, p = 0.16). Anaphylaxis admissions were not associated with regional sociodemographic factors like poverty, rurality, educational level, ethnicity, or physician density. Conclusions: Anaphylaxis admission rates in Chile are highest at higher latitudes and lower solar radiation, used as proxies of VD status. The associations appear driven by food-induced anaphylaxis. Our data support a possible role of VD deficiency as an etiological factor in the high anaphylaxis admission rates found in southern Chile. C1 [Hoyos-Bachiloglu, Rodrigo; Morales, Pamela S.; Talesnik, Eduardo; Borzutzky, Arturo] Pontificia Univ Catolica Chile, Div Pediat, Sch Med, Immunol Allergy & Rheumatol Unit, Santiago 8330074, Chile. [Hoyos-Bachiloglu, Rodrigo; Borzutzky, Arturo] Pontificia Univ Catolica Chile, Sch Med, Millennium Inst Immunol & Immunotherapy, Santiago 8330074, Chile. [Cerda, Jaime] Pontificia Univ Catolica Chile, Sch Med, Dept Publ Hlth, Santiago 8330074, Chile. [Gonzalez, Gilberto] Pontificia Univ Catolica Chile, Sch Med, Dept Endocrinol, Santiago 8330074, Chile. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA. RP Borzutzky, A (reprint author), Pontificia Univ Catolica Chile, Div Pediat, Lira 85, Santiago 8330074, Chile. EM arturobor@med.puc.cl RI Osborne, Nicholas/N-4915-2015; OI Osborne, Nicholas/0000-0002-6700-2284; Borzutzky, Arturo/0000-0002-7904-262X FU FONDECYT [1130615]; NIH [U01 AI-87881] FX Dr Borzutzky was supported by FONDECYT grant 1130615. Dr Camargo was supported by NIH U01 AI-87881. NR 29 TC 14 Z9 14 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0905-6157 EI 1399-3038 J9 PEDIAT ALLERG IMM-UK JI Pediatr. Allergy Immunol. PD JUN PY 2014 VL 25 IS 4 BP 338 EP 343 DI 10.1111/pai.12211 PG 6 WC Allergy; Immunology; Pediatrics SC Allergy; Immunology; Pediatrics GA AJ9NB UT WOS:000338037100006 PM 24628618 ER PT J AU Jordan, AH Litz, BT AF Jordan, Alexander H. Litz, Brett T. TI Prolonged Grief Disorder: Diagnostic, Assessment, and Treatment Considerations SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE prolonged grief; complicated grief; pathological grief; traumatic grief; psychotherapy ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; INTERNET-BASED INTERVENTION; TREATING COMPLICATED GRIEF; POSTTRAUMATIC-STRESS; LATER LIFE; BEREAVEMENT; PSYCHOTHERAPY; DEPRESSION; ANXIETY AB Normative bereavement reactions are contrasted with prolonged grief disorder (PGD). Diagnostic criteria for PGD are reviewed. PGD is distinguished from other problems occurring after loss, namely depression and PTSD. Assessment approaches are described. Recent clinical trials are reviewed, and recommendations for the psychotherapeutic treatment of PGD are developed. Consideration of medication referral is also recommended, especially in the case of co-occurring depression. C1 [Jordan, Alexander H.] VA Boston Healthcare Syst, Boston, MA USA. [Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Mental Hlth Core, Boston, MA USA. [Jordan, Alexander H.; Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02215 USA. RP Jordan, AH (reprint author), VA Boston Healthcare Syst 116B 4, 150 South Huntington Ave, Boston, MA 02130 USA. EM jordan.alexander.h@gmail.com NR 55 TC 5 Z9 5 U1 5 U2 35 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 EI 1939-1323 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD JUN PY 2014 VL 45 IS 3 BP 180 EP 187 DI 10.1037/a0036836 PG 8 WC Psychology, Multidisciplinary SC Psychology GA AJ7TN UT WOS:000337900300004 ER PT J AU Kaufmann, VG O'Farrell, TJ Murphy, CM Murphy, MM Muchowski, P AF Kaufmann, Vyga G. O'Farrell, Timothy J. Murphy, Christopher M. Murphy, Marie M. Muchowski, Patrice TI Alcohol Consumption and Partner Violence Among Women Entering Substance Use Disorder Treatment SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE partner violence; alcohol consumption; female alcoholic patients ID ABUSE TREATMENT; AGGRESSION; MEN; DRINKING; CONFLICT; SCALES AB To test the hypothesized role of alcohol consumption as a proximal risk factor for partner violence, a within-subjects analysis compared levels of alcohol consumption in violent versus nonviolent conflict events among substance-abusing women and their male partners. Participants were married or cohabiting women (N = 145) who had recently begun a substance abuse treatment program and reported both a violent and a nonviolent relationship conflict event with their male partner in the prior 6 months. The average age was 38, and 83% were White. Male partners did not participate in the study. The female participant provided information about the male partner. Women were interviewed regarding a violent conflict event in which physical violence occurred and a nonviolent conflict event in which psychological aggression occurred without physical violence. The interview assessed quantity of alcohol consumed and use of other drugs prior to each conflict. Alcohol consumption was significantly greater prior to violent versus nonviolent conflict events for all measures of women's alcohol consumption examined: any drinking, heavy drinking, number of drinks in the 12 hr preceding the conflict event, and estimated blood alcohol concentration at time of the event. Male partners' alcohol consumption showed similar results. Use of other drugs in women, but not men, was significantly more likely prior to physical conflicts. These within-subject comparisons help to rule out individual difference explanations for the alcohol-violence association and indicate that the quantity of alcohol consumption is an important proximal risk factor for partner violence in substance-abusing women and their male partners. C1 [Kaufmann, Vyga G.; O'Farrell, Timothy J.; Murphy, Marie M.] VA Boston Healthcare Syst, Dept Psychiat, Families & Addict Program, Brockton, MA USA. [Kaufmann, Vyga G.; O'Farrell, Timothy J.; Murphy, Marie M.] Harvard Univ, Sch Med, Brockton, MA 02301 USA. [Murphy, Christopher M.] Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA. [Muchowski, Patrice] AdCare Hosp Worcester Inc, Worcester, MA USA. RP O'Farrell, TJ (reprint author), Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, VAMC 116B1,940 Belmont St, Brockton, MA 02301 USA. EM timothy_ofarrell@hms.harvard.edu FU NIAAA NIH HHS [R01AA12834] NR 33 TC 2 Z9 2 U1 1 U2 9 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X EI 1939-1501 J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD JUN PY 2014 VL 28 IS 2 BP 313 EP 321 DI 10.1037/a0034971 PG 9 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA AJ7XW UT WOS:000337915800001 PM 24955661 ER PT J AU Byrne, T Fargo, JD Montgomery, AE Munley, E Culhane, DP AF Byrne, Thomas Fargo, Jamison D. Montgomery, Ann Elizabeth Munley, Ellen Culhane, Dennis P. TI The Relationship between Community Investment in Permanent Supportive Housing and Chronic Homelessness SO SOCIAL SERVICE REVIEW LA English DT Article ID NEW-YORK-CITY; MENTAL-ILLNESS; RENT CONTROL; COST-EFFECTIVENESS; HEALTH-CARE; SERVICE USE; PHILADELPHIA; PROGRAM; ADULTS; INDIVIDUALS AB In recent years, permanent supportive housing (PSH) has emerged as the preferred intervention for addressing chronic homelessness in the United States. However, almost all prior studies examining the effectiveness of PSH have been conducted at the individual level, with only minimal attempts to empirically test the relationship between PSH and chronic homelessness at the community level. This study uses longitudinal data collected by the US Department of Housing and Urban Development (HUD) and several other sources to model the relationship between measures of community investment in PSH and rates of chronic homelessness. The results show modest negative associations between increased investment in PSH and rates of chronic homelessness over time. We discuss the implications of these findings for ongoing efforts to address chronic homelessness and future research. C1 [Byrne, Thomas; Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Byrne, Thomas; Fargo, Jamison D.; Montgomery, Ann Elizabeth; Munley, Ellen; Culhane, Dennis P.] US Dept Vet Affairs, Washington, DC USA. [Fargo, Jamison D.] Utah State Univ, Logan, UT 84322 USA. RP Byrne, T (reprint author), Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. NR 54 TC 6 Z9 6 U1 5 U2 29 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0037-7961 EI 1537-5404 J9 SOC SERV REV JI Soc. Serv. Rev. PD JUN PY 2014 VL 88 IS 2 BP 234 EP 263 DI 10.1086/676142 PG 30 WC Social Work SC Social Work GA AJ5QV UT WOS:000337741600002 ER PT J AU Brahmbhatt, R Carter, SA Hicks, SC Berger, DH Liang, MK AF Brahmbhatt, Reshma Carter, Stacey A. Hicks, Stephanie C. Berger, David H. Liang, Mike K. TI Identifying Risk Factors for Surgical Site Complications after Laparoscopic Ventral Hernia Repair: Evaluation of the Ventral Hernia Working Group Grading System SO SURGICAL INFECTIONS LA English DT Article ID INCISIONAL HERNIA; WOUND-INFECTION; MESH; HERNIORRHAPHY; METAANALYSIS; RECURRENCE; OUTCOMES AB Background: In 2010, the Ventral Hernia Working Group (VHWG) published a grading system to assess the risk of surgical site complications in patients undergoing ventral hernia repair. This study evaluated the predictive value of the VHWG classification for the surgical outcomes of laparoscopic ventral hernia repair (LVHR) and identified independent factors associated with surgical site infection (SSI) and surgical site occurrence (SSO). Methods: A retrospective review was performed of all patients who underwent LVHR over a 10-year period at two institutions. The U.S. Centers for Disease Control and Prevention definition of SSI and the VHWG definition of SSO were used. Univariable analysis was performed using the Student t-test, analysis of variance, chi-square test, or Fisher exact test, as appropriate. Multivariable analysis was used to identify independent factors associated with SSI and SSO. Results: Differences in American Society of Anesthesiologists class, body mass index, diabetes mellitus, chronic obstructive pulmonary disease, tobacco use, hernia type, prior abdominal surgery, prior ventral hernia repair, hernia size, and total infections were identified by grade. There was no difference in SSI or SSO by grade. Multivariable analysis revealed institution and number of prior abdominal operations to be associated with SSI. Institution, prostate disease, and prior ventral hernia repair were associated with SSO. Conclusions: The VHWG classification was unable to predict SSI and SSO and may not be applicable in LVHR. This study identified independent factors associated with SSI and SSO in LVHR. Although further study is warranted to validate these results, the factors presented may be a useful tool to stratify patient risk of SSI and SSO with LVHR. C1 [Brahmbhatt, Reshma; Carter, Stacey A.; Berger, David H.; Liang, Mike K.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Hicks, Stephanie C.] Rice Univ, Dept Stat, Houston, TX 77251 USA. RP Liang, MK (reprint author), Michael E DeBakey VAMC, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM ml3@bcm.edu RI Liang, Mike/L-8493-2015; OI Liang, Mike/0000-0001-7063-7291; Hicks, Stephanie/0000-0002-7858-0231 FU Lifecell; KCI; Acell FX R.B., S.A.C., S.C.H., and D.H.B. declare no competing financial interests. M. K. L. has held research grants from Lifecell and unrestricted education grants from Lifecell, KCI, and Acell. NR 40 TC 7 Z9 7 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 EI 1557-8674 J9 SURG INFECT JI Surg. Infect. PD JUN PY 2014 VL 15 IS 3 BP 187 EP 193 DI 10.1089/sur.2012.179 PG 7 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA AJ9EI UT WOS:000338009600006 PM 24773169 ER PT J AU deLemos, AS Chung, RT AF deLemos, Andrew S. Chung, Raymond T. TI Hepatitis C treatment: an incipient therapeutic revolution SO TRENDS IN MOLECULAR MEDICINE LA English DT Review DE hepatitis C; pegylated interferon; NS3-4A serine protease inhibitors; direct-acting antivirals (DAAs); sofosbuvir; simeprevir ID HCV GENOTYPE 1; TREATMENT-NAIVE PATIENTS; PHASE-III TRIAL; SOFOSBUVIR PLUS RIBAVIRIN; TREATMENT-EXPERIENCED PATIENTS; PEGYLATED INTERFERON ALPHA-2A; GENOME-WIDE ASSOCIATION; VIRUS-INFECTION; SIMEPREVIR TMC435; GENETIC-VARIATION AB An exciting paradigm shift is occurring in the treatment of hepatitis C virus (HCV). We now have the capacity to specifically target therapy to HCV proteins, and thereby directly interrupt the viral life cycle. The first direct-acting antivirals (DAAs), the NS3-4A serine protease inhibitors boceprevir and telaprevir, improved the rate of sustained virologic response (SVR), but their toxicities combined with PEG-IFN and RBV limited their overall efficacy. Sofosbuvir, a nucleotide HCV polymerase inhibitor, is now available and offers better tolerability and efficacy across all HCV genotypes. The next phase of therapy will be combining several classes of DAAs without IFN in order to make sustained clearance of hepatitis C deliverable to a much larger number of infected individuals. C1 [deLemos, Andrew S.] Carolinas Med Ctr, Ctr Liver Dis & Transplantat, Dept Med, Charlotte, NC 28203 USA. [Chung, Raymond T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Liver Ctr, Boston, MA 02114 USA. [Chung, Raymond T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Div, Boston, MA 02114 USA. RP deLemos, AS (reprint author), Carolinas Med Ctr, Ctr Liver Dis & Transplantat, Dept Med, Charlotte, NC 28203 USA. EM andrew.delemos@carolinas.org; rtchung@partners.org FU Gilead; Mass Biologics; Vertex FX R.T.C. has received grant support from Gilead (clinical trial), Mass Biologics (clinical trial), and Vertex (clinical trial), and has consulted for Abbvie. NR 45 TC 25 Z9 25 U1 0 U2 16 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4914 EI 1471-499X J9 TRENDS MOL MED JI Trends Mol. Med PD JUN PY 2014 VL 20 IS 6 BP 315 EP 321 DI 10.1016/j.molmed.2014.02.002 PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA AJ7LG UT WOS:000337877600003 PM 24636306 ER PT J AU Orton, LP Cohan, RH Davenport, MS Parker, RA Parameswaran, A Caoili, EM Kaza, RK Francis, IR Ellis, JH Wolf, JS Hafez, K AF Orton, Lorenzo P. Cohan, Richard H. Davenport, Matthew S. Parker, Robert A. Parameswaran, Aishwarya Caoili, Elaine M. Kaza, Ravi K. Francis, Isaac R. Ellis, James H. Wolf, J. Stuart Hafez, Khaled TI Variability in computed tomography diameter measurements of solid renal masses SO ABDOMINAL IMAGING LA English DT Article DE Renal mass measurements; Computed tomography; Solid renal mass ID NATURAL-HISTORY; INTEROBSERVER VARIABILITY; RISING INCIDENCE; HELICAL CT; INTRAOBSERVER; MANAGEMENT; TUMORS; SIZE AB To determine whether the frequency of intra-observer measurement discrepancies a parts per thousand yen5 mm for solid renal masses varies by renal mass characteristics and CT contrast phase. This HIPAA-compliant retrospective study was approved by our IRB. We selected single CT images performed during the nephrographic phase (NP) of renal enhancement in 97 patients, each with a single solid renal mass. Mass location, margin, heterogeneity, and growth pattern were assessed. Six readers measured each mass on two occasions > 3 weeks apart. Readers also measured the masses on images in 50 patients who had corticomedullary phase (CMP) images obtained during the same study. Results were assessed using Chi-square/Fisher's exact and Wilcoxon Signed Rank tests, and logistic regression analyses. For NP to NP comparisons, intra-reader measurement differences a parts per thousand yen5 mm were seen for 3.7% (17/463) of masses < 4 cm, but increased to 16.8% (20/119) for masses > 4 cm (p < 0.0001). Masses with poorly defined margins (15.9% [22/138] vs. 3.4% [15/444] for well-defined margins, p < 0.0001) and heterogeneity (15.3% [22/144], vs. 5.0% [14/282] for minimally heterogeneous, vs. 0.6% [1/156] for homogeneous, p < 0.0001), were more frequently associated with measurement differences a parts per thousand yen5 mm. Differences a parts per thousand yen5 mm were more frequent when only CMP images were utilized (14% [42/299]), or when CMP images were compared with NP images (26% [77/299]). A a parts per thousand yen5 mm intra-reader variation in measured size of solid renal masses < 4 cm is uncommon for NP to NP comparisons. Variation increases when masses are a parts per thousand yen4 cm, poorly defined, or heterogeneous; or when CMP images are utilized. C1 [Orton, Lorenzo P.; Cohan, Richard H.; Davenport, Matthew S.; Parameswaran, Aishwarya; Caoili, Elaine M.; Kaza, Ravi K.; Francis, Isaac R.; Ellis, James H.] Univ Michigan Hosp, Dept Radiol, Ann Arbor, MI 48109 USA. [Parker, Robert A.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Directory Biometry, Boston, MA 02114 USA. [Wolf, J. Stuart; Hafez, Khaled] Univ Michigan Hosp, Dept Urol, Ann Arbor, MI 48109 USA. RP Cohan, RH (reprint author), Univ Michigan Hosp, Dept Radiol, 1500 East Med Ctr Dr,Room B1D502G, Ann Arbor, MI 48109 USA. EM rcohan@umich.edu NR 26 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0942-8925 EI 1432-0509 J9 ABDOM IMAGING JI Abdom. Imaging PD JUN PY 2014 VL 39 IS 3 BP 533 EP 542 DI 10.1007/s00261-014-0088-y PG 10 WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging GA AJ5RA UT WOS:000337742200012 PM 24535480 ER PT J AU Sainani, NI Schlett, CL Hahn, PF Gervais, DA Mueller, PR Arellano, RS AF Sainani, Nisha I. Schlett, Christopher L. Hahn, Peter F. Gervais, Debra A. Mueller, Peter R. Arellano, Ronald S. TI Computed tomography-guided percutaneous biopsy of isoattenuating focal liver lesions SO ABDOMINAL IMAGING LA English DT Article DE Liver; Focal; Biopsy; Computed tomography ID FINE-NEEDLE BIOPSY; HEPATIC-LESIONS; HEPATOCELLULAR-CARCINOMA; CIRRHOSIS; CT; DIAGNOSIS; ULTRASOUND AB The purpose of this study was to evaluate the efficacy of CT-guided percutaneous biopsy of isoattenuating liver lesions using anatomic landmarks (ALs) to guide needle placement and added value of intravenous (IV) contrast. An interventional radiology database was reviewed to identify patients with CT-guided percutaneous biopsy of isoattenuating focal liver lesions using ALs to guide needle placement. The cohort was further divided into two groups: lesions biopsied using ALs only and lesions biopsied using ALs and intravenous contrast (AL+IV). Pathology results or follow-up imaging served as reference standard. Sensitivity and accuracy were calculated, Student's t test and Fisher's exact test were used for statistical comparison between the two groups. Between January 2000 and December 2011, CT-guided percutaneous biopsy of 133 isoattenuating focal liver lesions was performed in 133 patients. The AL group included 54 patients (M:F = 29:25) with 54 lesions (size range 7-90 mm, mean 32.1 +/- A 18.1) and AL+IV group included 79 patients (M:F = 44:35) with 79 lesions (size range 7-100 mm, mean 25.6 +/- A 15.0). AL group included 23 (43%) benign and 31 (57%) malignant lesions; AL+IV group included 31 (39%) benign and 48 (61%) malignant lesions. Sensitivity and accuracy for CT-guided biopsy of focal isoattenuating liver lesions were, overall 94% and 96%, AL group 97% and 98% and AL+IV group 92% and 94%, with no statistical significant difference between the AL and AL+IV groups (P = 0.88-1.00). Accurate planning and utilizing of internal reference ALs is successful in yielding a diagnostic sample for CT-guided percutaneous biopsy of isoattenuating focal liver lesion. The confidence of accurate targeting can be enhanced by administering IV contrast, however, since the visualization provided by IV contrast can be short-lived; use of IV contrast does not obviate the need for precise planning based on ALs. C1 [Sainani, Nisha I.] Harvard Univ, Brigham & Womens Hosp, Div Abdominal Imaging & Intervent, Sch Med,Dept Radiol, Boston, MA 02115 USA. [Hahn, Peter F.; Gervais, Debra A.; Mueller, Peter R.; Arellano, Ronald S.] Harvard Univ, Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent, Sch Med,Dept Radiol, Boston, MA 02115 USA. [Schlett, Christopher L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program,Dept Radiol, Boston, MA 02115 USA. [Schlett, Christopher L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. [Schlett, Christopher L.] Univ Heidelberg Hosp, Dept Diagnost & Intervent Radiol, Heidelberg, Germany. RP Sainani, NI (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Abdominal Imaging & Intervent, Sch Med,Dept Radiol, 75 Francis St, Boston, MA 02115 USA. EM nsainani@partners.org NR 29 TC 2 Z9 2 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0942-8925 EI 1432-0509 J9 ABDOM IMAGING JI Abdom. Imaging PD JUN PY 2014 VL 39 IS 3 BP 633 EP 644 DI 10.1007/s00261-014-0089-x PG 12 WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging GA AJ5RA UT WOS:000337742200021 PM 24531352 ER PT J AU Kil, KE Zhu, AJ Zhang, ZD Choi, JK Kura, S Gong, CY Brownell, AL AF Kil, Kun-Eek Zhu, Aijun Zhang, Zhaoda Choi, Ji-Kyung Kura, Sreekanth Gong, Chunyu Brownell, Anna-Liisa TI Development of [I-123]IPEB and [I-123]IMPEB as SPECT Radioligands for Metabotropic Glutamate Receptor Subtype 5 SO ACS MEDICINAL CHEMISTRY LETTERS LA English DT Article DE metabotropic glutamate receptor subtype S (mGlu(5)); negative allosteric modulator (NAM); single photon emission computed tomography (SPECT); in vivo imaging; [I-123]IPEB; [I-123]IMPEB ID POSITRON-EMISSION-TOMOGRAPHY; SIGNAL-TRANSDUCTION; RADIATION-DOSIMETRY; PET; MGLUR5; BRAIN; PHARMACOLOGY; ANTAGONISTS; METABOTROPIC-GLUTAMATE-RECEPTOR-SUBTYPE-5; RADIOTRACERS AB mGlus play an important role in physiology and pathology to various central nervous system (CNS) diseases. Several positron emission tomography (PET) radiotracers have been developed to explore the role of mGlus in brain disorders. However, there are no single photon emission computed tomography (SPECT) radioligands for mGlus. Here we report development of [I-123]IPEB ([I-123]1) and [I-123]IMPEB ([I-123]2) as mGlu(5) radioligands for SPECT. [I-123]1 and [I-123]2 were produced by copper(I) mediated aromatic halide displacement reactions. The SPECT imaging using mouse models demonstrated that [I-123]1 readily entered the brain and accumulated specifically in mGlus-rich regions of the brain such as striatum and hippocampus. However, in comparison to the corresponding PET tracer [F-18]FPEB, [I-123]1 showed faster washout from the brain. The binding ratios of the striatum and the hippocampus compared to the cerebellum for [I-123]1 and [F-18]FPEB were similar despite unfavorable pharmacokinetics of [I-123]1. Further structural optimization of 1 may lead to more viable SPECT radiotracers for the imaging of mGlus. C1 [Kil, Kun-Eek; Zhu, Aijun; Zhang, Zhaoda; Choi, Ji-Kyung; Kura, Sreekanth; Gong, Chunyu; Brownell, Anna-Liisa] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Brownell, AL (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM abrownell@mgh.harvard.edu FU [NIBIB-R01EB012864]; [NIMH-R01MH91684]; [1S10RR029495-01]; [1S10RR026666-01]; [1S10RR023452-01] FX Funding was provided by NIBIB-R01EB012864 and NIMH-R01MH91684 to A.-L.B. Authors would like to acknowledge supporting grants for the instrumentation 1S10RR029495-01, 1S10RR026666-01, and 1S10RR023452-01. NR 35 TC 5 Z9 5 U1 0 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-5875 J9 ACS MED CHEM LETT JI ACS Med. Chem. Lett. PD JUN PY 2014 VL 5 IS 6 BP 652 EP 656 DI 10.1021/ml500007z PG 5 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA AJ2OM UT WOS:000337497200010 PM 24944738 ER PT J AU Rotstein, BH Hooker, JM Woo, J Collier, TL Brady, TJ Liang, SH Vasdev, N AF Rotstein, Benjamin H. Hooker, Jacob M. Woo, Jiyeon Collier, Thomas Lee Brady, Thomas J. Liang, Steven H. Vasdev, Neil TI Synthesis of [C-11]Bexarotene by Cu-Mediated [C-11]Carbon Dioxide Fixation and Preliminary PET Imaging SO ACS MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Bexarotene; targretin; positron emission tomography; carbon-11; carbon dioxide fixation; retinoid X receptor; Alzheimer's disease ID AD MOUSE MODELS; REVERSE DEFICITS; ALZHEIMERS-DISEASE; BETA; RECEPTORS; RAT; C-11 AB Bexarotene (Targretin) is a retinoid X receptor (RXR) agonist that has applications for treatment of T cell lymphoma and proposed mechanisms of action in Alzheimer's disease that have been the subject of recent controversy. Carbon-11 labeled bexarotene ([11C_ carbony1]4-[1-(3,5,5,8,8-pentamethylietralin-2-yOethenyllbenzoic acid) was synthesized using a Cu-mediated cross-coupling reaction employing an arylboronate precursor 1 and [C-11]carbon dioxide under atmospheric pressure in 15 +/- 2% uncorrected radiochemical yield (n = 3), based on [C-11]CO2. Judicious choice of solvents, catalysts, and additives, as well as precursor concentration and purity of [11C]CO2, enabled the preparation of this C-11-labeled carboxylic acid. Formulated [11C]bexarotene was isolated (>37 mCi) with >99% radiochemical purity in 32 mm. Preliminary positron emission tomography magnetic resonance imaging revealed rapid brain uptake in nonhuman primate in the first 75 s following intravenous administration of the radiotracer (specific activity >0.3 Ci/mu mol at time of injection), followed by slow clearance (Delta = 43%) over 60 min. Modest uptake (SUV = 0.8) was observed in whole brain and regions with high RXR expression. C1 [Rotstein, Benjamin H.; Woo, Jiyeon; Collier, Thomas Lee; Brady, Thomas J.; Liang, Steven H.; Vasdev, Neil] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Rotstein, Benjamin H.; Woo, Jiyeon; Collier, Thomas Lee; Brady, Thomas J.; Liang, Steven H.; Vasdev, Neil] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA. [Rotstein, Benjamin H.; Hooker, Jacob M.; Collier, Thomas Lee; Brady, Thomas J.; Liang, Steven H.; Vasdev, Neil] Harvard Univ, Dept Radiol, Sch Med, Boston, MA 02114 USA. [Hooker, Jacob M.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Collier, Thomas Lee] Advion Inc, Ithaca, NY 14850 USA. RP Liang, SH (reprint author), Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. EM liang.steven@mgh.harvard.edu; vasdev.neil@mgh.harvard.edu OI Hooker, Jacob/0000-0002-9394-7708; Rotstein, Benjamin/0000-0001-9707-9357 FU Natural Sciences and Engineering Research Council of Canada (NSERC) FX B.H.R. is a Natural Sciences and Engineering Research Council of Canada (NSERC) Postdoctoral Fellow. NR 25 TC 9 Z9 9 U1 0 U2 11 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-5875 J9 ACS MED CHEM LETT JI ACS Med. Chem. Lett. PD JUN PY 2014 VL 5 IS 6 BP 668 EP 672 DI 10.1021/ml500065q PG 5 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA AJ2OM UT WOS:000337497200013 PM 24944741 ER PT J AU Miller, RA Harrison, DE Astle, CM Fernandez, E Flurkey, K Han, M Javors, MA Li, XN Nadon, NL Nelson, JF Pletcher, S Salmon, AB Sharp, ZD Van Roekel, S Winkleman, L Strong, R AF Miller, Richard A. Harrison, David E. Astle, Clinton M. Fernandez, Elizabeth Flurkey, Kevin Han, Melissa Javors, Martin A. Li, Xinna Nadon, Nancy L. Nelson, James F. Pletcher, Scott Salmon, Adam B. Sharp, Zelton Dave Van Roekel, Sabrina Winkleman, Lynn Strong, Randy TI Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction SO AGING CELL LA English DT Article DE aging; caloric restriction; glucose; IGF-1; insulin; longevity; mouse; mTOR; rapamycin; xenobiotic metabolism ID GENETICALLY HETEROGENEOUS MICE; INTERVENTIONS TESTING PROGRAM; AMES DWARF MICE; INSULIN SENSITIVITY; EXTENSION; LONGEVITY; TOR; RESISTANCE; PATHWAY; GENES AB Rapamycin, an inhibitor of mTOR kinase, increased median lifespan of genetically heterogeneous mice by 23% (males) to 26% (females) when tested at a dose threefold higher than that used in our previous studies; maximal longevity was also increased in both sexes. Rapamycin increased lifespan more in females than in males at each dose evaluated, perhaps reflecting sexual dimorphism in blood levels of this drug. Some of the endocrine and metabolic changes seen in diet-restricted mice are not seen in mice exposed to rapamycin, and the pattern of expression of hepatic genes involved in xenobiotic metabolism is also quite distinct in rapamycin-treated and diet-restricted mice, suggesting that these two interventions for extending mouse lifespan differ in many respects. C1 [Miller, Richard A.; Han, Melissa; Li, Xinna; Van Roekel, Sabrina; Winkleman, Lynn] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Miller, Richard A.; Han, Melissa; Li, Xinna; Pletcher, Scott; Van Roekel, Sabrina; Winkleman, Lynn] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA. [Harrison, David E.; Astle, Clinton M.; Flurkey, Kevin] Jackson Lab, Bar Harbor, ME 04609 USA. [Fernandez, Elizabeth; Strong, Randy] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Fernandez, Elizabeth; Strong, Randy] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA. [Javors, Martin A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Nadon, Nancy L.] NIA, Div Aging Biol, Bethesda, MD 20892 USA. [Nelson, James F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Nelson, James F.; Salmon, Adam B.; Sharp, Zelton Dave; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Pletcher, Scott] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA. [Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA. RP Miller, RA (reprint author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. EM millerr@umich.edu FU NIH [AG022303, AG031736, AG022307, AG013319, AG022308, CA034196]; Department of Veterans Affairs FX This work was supported by NIH grants AG022303, AG031736 (RAM), AG022307, AG013319 (RS), and AG022308 (DEH), with important facilities supported by CA034196 (DEH) and the Department of Veterans Affairs (RS), We thank Lili Deng and Andrzej Galecki for statistical assistance, Jeff Halter for comments on an early draft of the paper, and Lisa Burmeister, Vivian Diaz, Nelson Durgin, Vicki Ingalls, Amanda Keedle, and Pam J Krason for technical assistance. NR 46 TC 103 Z9 105 U1 4 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD JUN PY 2014 VL 13 IS 3 BP 468 EP 477 DI 10.1111/acel.12194 PG 10 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA AJ2VV UT WOS:000337523400009 PM 24341993 ER PT J AU Buck, KJ Iancu, OD Walter, NAR AF Buck, K. J. Iancu, O. D. Walter, N. A. R. TI QUANTITIATIVE TRAIT LOCUS (QTL), GENE EXPRESSION AND COEXPRESSION NETWORK ANALYSES IDENTIFY A ROLE FOR OXIDATIVE PHOSPHORYLATION IN ETHANOL WITHDRAWAL SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Portland VA Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA. Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0011 BP 3A EP 3A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700012 ER PT J AU Dou, X Chen, X Chen, SY Charness, ME AF Dou, X. Chen, X. Chen, S-Y Charness, M. E. TI SRC FAMILY KINASE PHOSPHORYLATION OF Y1176 IN THE L1 CYTOPLASMIC DOMAIN IS REQUIRED FOR ETHANOL INHIBITION OF L1 ADHESION SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Dou, X.; Charness, M. E.] Harvard Univ, Sch Med, Dept Neurol, VA Boston Healthcare Syst, West Roxbury, MA 02132 USA. [Chen, X.; Chen, S-Y] Univ Illinois, Coll Med Peoria, Peoria, IL 61605 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0109 BP 28A EP 28A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700110 ER PT J AU Bergman, BG Nelson, L Slaymaker, V Kelly, JF AF Bergman, B. G. Nelson, L. Slaymaker, V. Kelly, J. F. TI A LONGITUDINAL INVESTIGATION OF CONTINUING CARE FOLLOWING RESIDENTIAL TREATMENT IN EMERGING ADULTS: ISMUTUAL-HELP "WITHOUT PARALLEL"? SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Bergman, B. G.; Nelson, L.; Slaymaker, V.; Kelly, J. F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Addict Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0208 BP 52A EP 52A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700209 ER PT J AU Labbe, AK Slaymaker, V Kelly, JF AF Labbe, A. K. Slaymaker, V. Kelly, J. F. TI TOWARD ENHANCING TWELVE-STEP FACILITATION AMONG OUNG PEOPLE: A SYSTEMATIC QUALITATIVE INVESTIGATION OF YOUNG ADULTS' 12-STEP EXPERIENCES SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Labbe, A. K.; Slaymaker, V.; Kelly, J. F.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0210 BP 53A EP 53A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700211 ER PT J AU Williams, EC Lapham, GT Lee, AK Richards, JE Berger, DB Ludman, E Bradley, KA AF Williams, E. C. Lapham, G. T. Lee, A. K. Richards, J. E. Berger, D. B. Ludman, E. Bradley, K. A. TI READINESS TO CHANGE AND SEVERITY OF UNHEALTHY ALCOHOL USE AMONG PRIMARY CARE PATIENTS RECRUITED TO A TRIAL OF COLLABORATIVE CARE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Williams, E. C.] VA Puget Sound HSR&D COIN, Seattle, WA USA. [Williams, E. C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Lapham, G. T.; Lee, A. K.; Richards, J. E.; Ludman, E.; Bradley, K. A.] Grp Hlth Res Inst, Seattle, WA USA. [Berger, D. B.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0226 BP 57A EP 57A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700227 ER PT J AU Hawkins, EJ Lapham, GT Lee, AK Kivlahan, DR Berger, BD Hebert, PL Saxon, AJ Bradley, KA AF Hawkins, E. J. Lapham, G. T. Lee, A. K. Kivlahan, D. R. Berger, B. D. Hebert, P. L. Saxon, A. J. Bradley, K. A. TI PREVALENCE AND COMORBIDITY OF PTSD AMONG HEAVY DRINKERS ENROLLED IN A COLLABORATIVE CARE TRIAL FOR ALCOHOL USE DISORDERS IN VA PRIMARY CARE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Grp Hlth Res Inst, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98118 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0252 BP 63A EP 63A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700253 ER PT J AU Pietrzykowski, AZ Mead, EA Wang, Y Thekkumthala, A Ren, J Liu, C Liu, PK AF Pietrzykowski, A. Z. Mead, E. A. Wang, Y. Thekkumthala, A. Ren, J. Liu, C. Liu, P. K. TI ALCOHOL REGULATION OF MIR-9 IN THE LIVE BRAIN SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Rutgers State Univ, New Brunswick, NJ 08901 USA. Massachusetts Gen Hosp, Charlestown, MA 02129 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0305 BP 77A EP 77A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700306 ER PT J AU Sawyer, KS Ruiz, SMM Galvez, DA Makris, N Harris, GJ Valera, EM Oscar-Berman, M AF Sawyer, K. S. Ruiz, S. M. M. Galvez, D. A. Makris, N. Harris, G. J. Valera, E. M. Oscar-Berman, M. TI CEREBELLAR MORPHOMETRIC ABNORMALITIES IN ALCOHOLICS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Boston Univ, Sch Med, Boston, MA 02118 USA. VA Healthcare Syst, Boston, MA 02130 USA. Massachusetts Gen Hosp, Martinos Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Morphometr Anal, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0475 BP 119A EP 119A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700476 ER PT J AU Bradley, KA Lapham, GT Richards, J Merrill, JO Williams, EC Lee, AK Holden, E Chavez, LJ Kivlahan, DR AF Bradley, K. A. Lapham, G. T. Richards, J. Merrill, J. O. Williams, E. C. Lee, A. K. Holden, E. Chavez, L. J. Kivlahan, D. R. TI THE PREVALENCE OF DSM-IV VERSUS DSM-5 ALCOHOL USE DISORDERS (AUD) IN PRIMARY CARE PATIENTS AT HIGH RISK FOR AUD IN THE CHOICE TRIAL SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Med, Seattle, WA 98195 USA. Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Hlth Serv, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0493 BP 124A EP 124A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700494 ER PT J AU Bergman, BG Greene, MC Slaymaker, V Hoeppner, BB Kelly, JF AF Bergman, B. G. Greene, M. C. Slaymaker, V. Hoeppner, B. B. Kelly, J. F. TI THE ROLE OF CO-OCCURRING PSYCHIATRIC DISORDERS IN EMERGING ADULTS' RESIDENTIAL SUD TREATMENT RESPONSE AND OUTCOMES SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Bergman, B. G.; Greene, M. C.; Slaymaker, V.; Hoeppner, B. B.; Kelly, J. F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Addict Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0532 BP 133A EP 133A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700533 ER PT J AU Pennington, DL Lasher, BA Herbst, E Schrodek, E Hong, E Waldrop, A Heinz, A Williams, C Abrams, G Neylan, TC Seal, K Carney, C Besterman, A Batki, SL AF Pennington, D. L. Lasher, B. A. Herbst, E. Schrodek, E. Hong, E. Waldrop, A. Heinz, A. Williams, C. Abrams, G. Neylan, T. C. Seal, K. Carney, C. Besterman, A. Batki, S. L. TI COGNITION AND SELF-REGULATION IN VETERANS WITH ALCOHOL USE DISORDER, PTSD AND TBI: BASELINE SUBJECT CHARACTERISTICS IN TOPIRAMATE TREATMENT TRIALS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Pennington, D. L.; Lasher, B. A.; Herbst, E.; Schrodek, E.; Hong, E.; Waldrop, A.; Heinz, A.; Williams, C.; Abrams, G.; Neylan, T. C.; Seal, K.; Carney, C.; Besterman, A.; Batki, S. L.] UCSF Dept Psychiat, Addict Res Program, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0547 BP 137A EP 137A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700548 ER PT J AU Gubner, NR Phillips, TJ AF Gubner, N. R. Phillips, T. J. TI EFFECTS OF VARENICLINE ON THE EXPRESSION OF ETHANOL-INDUCED LOCOMOTOR SENSITIZATION, A MOUSE MODEL OF NEUROADAPTATION SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Gubner, N. R.; Phillips, T. J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0622 BP 156A EP 156A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700623 ER PT J AU Pedrelli, P Fisher, L Farabaugh, A Nyer, M Borsari, B Parkin, S Jaeger, A MacPherson, L AF Pedrelli, P. Fisher, L. Farabaugh, A. Nyer, M. Borsari, B. Parkin, S. Jaeger, A. MacPherson, L. TI DISTRESS TOLERANCE AND HEAVY EPISODIC DRINKING IN COLLEGE STUDENTS: DOES IT MAKE A DIFFERENCE HOW IT IS MEASURED? SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Pedrelli, P.; Fisher, L.; Farabaugh, A.; Nyer, M.; Borsari, B.; Parkin, S.; Jaeger, A.; MacPherson, L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0733 BP 184A EP 184A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523700734 ER PT J AU Krenek, M Simpson, TL AF Krenek, M. Simpson, T. L. TI DEGREE OF CORRESPONDENCE BETWEEN DAILY MONITORING AND RETROSPECTIVE RECALL OF ALCOHOL USE AMONG INDIVIDUALS WITH COMORBID AUD AND PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Krenek, M.; Simpson, T. L.] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0823 BP 206A EP 206A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701023 ER PT J AU Collins, SE Duncan, MH Smart, BF Saxon, AJ Malone, DK Jackson, TR Ries, RK AF Collins, S. E. Duncan, M. H. Smart, B. F. Saxon, A. J. Malone, D. K. Jackson, T. R. Ries, R. K. TI A PILOT STUDY OF EXTENDED-RELEASE NALTREXONE AND HARM REDUCTION COUNSELING FOR CHRONICALLY HOMELESS PEOPLE WITH ALCOHOL DEPENDENCE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Collins, S. E.; Duncan, M. H.; Smart, B. F.; Ries, R. K.] Univ Washington, Seattle, WA 98195 USA. [Saxon, A. J.] VA Puget Sound, Seattle, WA 98108 USA. [Malone, D. K.] DESC, Seattle, WA 98104 USA. [Jackson, T. R.] Evergreen Treatment Serv, Seattle, WA 98134 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0850 BP 213A EP 213A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701050 ER PT J AU Batki, SL Pennington, DL Lasher, BA Herbst, E Schrodek, E Hong, E Waldrop, A Heinz, A Williams, C Abrams, G Neylan, TC Seal, K Carney, C Besterman, A AF Batki, S. L. Pennington, D. L. Lasher, B. A. Herbst, E. Schrodek, E. Hong, E. Waldrop, A. Heinz, A. Williams, C. Abrams, G. Neylan, T. C. Seal, K. Carney, C. Besterman, A. TI ALCOHOL USE DISORDER AND PTSD SEVERITY IN VETERANS WITH AND WITHOUT COMORBID TBI: BASELINE SUBJECT CHARACTERISTICS IN TOPIRAMATE TREATMENT TRIALS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Batki, S. L.; Pennington, D. L.; Lasher, B. A.; Herbst, E.; Schrodek, E.; Hong, E.; Waldrop, A.; Heinz, A.; Williams, C.; Abrams, G.; Neylan, T. C.; Seal, K.; Carney, C.; Besterman, A.] Univ Calif San Francisco, Dept Psychiat, Addict Res Program, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0855 BP 214A EP 214A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701055 ER PT J AU Barkley-Levenson, AM Crabbe, JC AF Barkley-Levenson, A. M. Crabbe, J. C. TI NEUROPEPTIDE Y AND BINGE-LIKE DRINKING IN HIGH DRINKING IN THE DARK SELECTED MICE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0896 BP 224A EP 224A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701096 ER PT J AU Wilhelm, CJ Beard, DR Hashimoto, JG Roberts, ML Loftis, JM Wiren, KM AF Wilhelm, C. J. Beard, D. R. Hashimoto, J. G. Roberts, M. L. Loftis, J. M. Wiren, K. M. TI DISTINCT GLUCOCORTICOID SIGNALING ASSOCIATED WITH ETHANOL-INDUCED INFLAMMOTOXICITY SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 0991 BP 248A EP 248A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701191 ER PT J AU McGinnis, K Tate, J Bryant, K Fiellin, D Justice, A AF McGinnis, K. Tate, J. Bryant, K. Fiellin, D. Justice, A. TI SENSITIVITY TO ALCOHOL INTOXICATION EFFECTS BY HIV STATUS AND TREATMENT SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. CT VA Healthcare Syst, Vet Aging Cohort Study, West Haven, CT USA. Yale Univ, New Haven, CT USA. NIAAA, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 1131 BP 283A EP 283A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701330 ER PT J AU Gilman, JM Calderon, V Curran, MT Evins, AE AF Gilman, J. M. Calderon, V. Curran, M. T. Evins, A. E. TI THE EFFECT OF SOCIAL INFLUENCE ON DECISION-MAKING IN YOUNG ADULTS USING ALCOHOL AND MARIJUANA: A COMPARISON SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Gilman, J. M.; Calderon, V.; Curran, M. T.; Evins, A. E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Addict Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 049 BP 305A EP 305A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701416 ER PT J AU Kelly, JF Stout, RL Greene, MC Slaymaker, V AF Kelly, J. F. Stout, R. L. Greene, M. C. Slaymaker, V. TI YOUNG ADULTS, SOCIAL NETWORKS, AND ADDICTION RECOVERY SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Kelly, J. F.; Greene, M. C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. [Stout, R. L.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Slaymaker, V.] Hazelden Fdn, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 123 BP 323A EP 323A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701490 ER PT J AU Barkley-Levenson, AM Crabbe, JC AF Barkley-Levenson, A. M. Crabbe, J. C. TI BEHAVIORAL AND MOLECULAR CHARACTERISTICS OF MICE 'AT-RISK' FOR BINGE-LIKE DRINKING SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 247 BP 354A EP 354A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701614 ER PT J AU Dou, X Chen, X Chen, SY Charness, ME AF Dou, X. Chen, X. Chen, S-Y Charness, M. E. TI IDENTIFICATION OF CANDIDATE FASD SUSCEPTIBILITY GENES IN L1 TRANSFECTED FIBROBLASTS AND MOUSE EMBRYOS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA) CY JUN 21-25, 2014 CL Bellevue, WA SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism C1 [Dou, X.; Charness, M. E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, West Roxbury, MA 02132 USA. [Dou, X.; Charness, M. E.] Harvard Univ, Sch Med, Dept Neurol, West Roxbury, MA 02132 USA. [Chen, X.; Chen, S-Y] Univ Illinois, Coll Med Peoria, Peoria, IL 61605 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 SU 1 SI SI MA 259 BP 357A EP 357A PG 1 WC Substance Abuse SC Substance Abuse GA AJ2VX UT WOS:000337523701626 ER PT J AU Rasmussen, DD Beckwith, LE Kincaid, CL Froehlich, JC AF Rasmussen, Dennis D. Beckwith, Lauren E. Kincaid, Carrie L. Froehlich, Janice C. TI Combining the 1-Adrenergic Receptor Antagonist, Prazosin, with the -Adrenergic Receptor Antagonist, Propranolol, Reduces Alcohol Drinking More Effectively Than Either Drug Alone SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Propranolol; Prazosin; Alcoholism Treatment; Noradrenergic ID PREFERRING P RATS; DEPENDENCE; ETHANOL; WITHDRAWAL; PREFERENCE AB Background Evidence suggests that activation of the noradrenergic system may contribute to alcohol drinking in animals and humans. Our previous studies demonstrated that blocking 1-adrenergic receptors with the antagonist, prazosin, decreased alcohol drinking in rats under various conditions. As noradrenergic activation is also regulated by -adrenergic receptors, we now examine the effects of the -adrenergic receptor antagonist, propranolol, alone or in combination with prazosin, on alcohol drinking in rats selectively bred for high voluntary alcohol intake and alcohol preference (P line). Methods Two studies were conducted with male P rats. In study 1, rats were allowed to become alcohol-dependent during 14weeks of ad libitum access to food, water, and 20% alcohol, and the effect of propranolol (5 to 15mg/kg, intraperitoneally [IP]) and prazosin (1 to 2mg/kg, IP) on alcohol intake during withdrawal was assessed. In study 2, the effect of propranolol (5mg/kg, IP) and prazosin (2mg/kg, IP) on alcohol intake following prolonged imposed abstinence was assessed. Results Alcohol drinking following propranolol treatment was variable, but the combination of propranolol+prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone. Conclusions Treatment with prazosin+propranolol, or a combination of other centrally active 1- and -adrenergic receptor antagonists, may assist in preventing alcohol relapse in some individuals. C1 [Rasmussen, Dennis D.] VISN 20 Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Rasmussen, Dennis D.; Beckwith, Lauren E.; Kincaid, Carrie L.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Rasmussen, Dennis D.; Beckwith, Lauren E.; Kincaid, Carrie L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Froehlich, Janice C.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. RP Rasmussen, DD (reprint author), VA Puget Sound Hlth Care Syst, Med Ctr, MIRECC 116, 1660 S Columbian Way, Seattle, WA 98108 USA. EM drasmuss@u.washington.edu FU NIH [R01 AA018604, P20 AA017839, AA018604, P60 AA007611, R24 AA15512] FX This material is based on work supported in part by resources from the VA Puget Sound Health Care System, the VA VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), and by NIH grants R01 AA018604, P20 AA017839 (DDR) and AA018604, P60 AA007611 (JCF). P rats were provided by the Alcohol Research Resource Center supported by NIH grant R24 AA15512. NR 28 TC 8 Z9 8 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 IS 6 BP 1532 EP 1539 DI 10.1111/acer.12441 PG 8 WC Substance Abuse SC Substance Abuse GA AJ2SI UT WOS:000337511400006 PM 24891220 ER PT J AU Medici, V Schroeder, DI Woods, R LaSalle, JM Geng, YZ Shibata, NM Peerson, J Hodzic, E Dayal, S Tsukamoto, H Kharbanda, KK Tillman, B French, SW Halsted, CH AF Medici, Valentina Schroeder, Diane I. Woods, Rima LaSalle, Janine M. Geng, Yongzhi Shibata, Noreene M. Peerson, Janet Hodzic, Emir Dayal, Sanjana Tsukamoto, Hidekazu Kharbanda, Kusum K. Tillman, Brittany French, Samuel W. Halsted, Charles H. TI Methylation and Gene Expression Responses to Ethanol Feeding and Betaine Supplementation in the Cystathionine Beta Synthase-Deficient Mouse SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol; S-Adenosylmethionine; S-Adenosylhomocysteine; Cystathionine Beta Synthase; DNA Methylation ID ALCOHOLIC LIVER-DISEASE; ENDOPLASMIC-RETICULUM STRESS; NITRIC-OXIDE SYNTHASE; GLOBAL DNA METHYLATION; MICROPIGS FED ETHANOL; ALPHA PPAR-ALPHA; METHIONINE METABOLISM; EPIGENETIC REGULATION; MICE; INJURY AB Background Alcoholic steatohepatitis (ASH) is caused in part by the effects of ethanol (EtOH) on hepatic methionine metabolism. Methods To investigate the phenotypic and epigenetic consequences of altered methionine metabolism in this disease, we studied the effects of 4-week intragastric EtOH feeding with and without the methyl donor betaine in cystathionine beta synthase (CS) heterozygous C57BL/6J mice. Results The histopathology of early ASH was induced by EtOH feeding and prevented by betaine supplementation, while EtOH feeding reduced and betaine supplementation maintained the hepatic methylation ratio of the universal methyl donor S-adenosylmethionine (SAM) to the methyltransferase inhibitor S-adenosylhomocysteine (SAH). MethylC-seq genomic sequencing of heterozygous liver samples from each diet group found 2 to 4% reduced methylation in gene bodies, but not promoter regions of all autosomes of EtOH-fed mice, each of which were normalized in samples from mice fed the betaine-supplemented diet. The transcript levels of nitric oxide synthase (Nos2) and DNA methyltransferase 1 (Dnmt1) were increased, while those of peroxisome proliferator receptor- (Ppar) were reduced in EtOH-fed mice, and each was normalized in mice fed the betaine-supplemented diet. DNA pyrosequencing of CS heterozygous samples found reduced methylation in a gene body of Nos2 by EtOH feeding that was restored by betaine supplementation and was correlated inversely with its expression and positively with SAM/SAH ratios. Conclusions The present study has demonstrated relationships among EtOH induction of ASH with aberrant methionine metabolism that was associated with gene body DNA hypomethylation in all autosomes and was prevented by betaine supplementation. The data imply that EtOH-induced changes in selected gene transcript levels and hypomethylation in gene bodies during the induction of ASH are a result of altered methionine metabolism that can be reversed through dietary supplementation of methyl donors. C1 [Medici, Valentina; Geng, Yongzhi; Shibata, Noreene M.; Halsted, Charles H.] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA. [Schroeder, Diane I.; Woods, Rima; LaSalle, Janine M.] Univ Calif Davis, Dept Med Microbiol & Immunol, Genome Ctr, Sacramento, CA 95817 USA. Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA. [Peerson, Janet] Univ Calif Davis, Dept Nutr, Sacramento, CA 95817 USA. [Hodzic, Emir] Univ Calif Davis, Sch Vet Med, Real Time PCR & Res Diagnost Facil, Sacramento, CA 95817 USA. [Dayal, Sanjana] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. [Tsukamoto, Hidekazu] Univ So Calif, Keck Sch Med, Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA 90033 USA. [Tsukamoto, Hidekazu] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Kharbanda, Kusum K.] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Res Serv, Omaha, NE USA. [Tillman, Brittany; French, Samuel W.] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA. RP Medici, V (reprint author), Univ Calif Davis, Div Gastroenterol & Hepatol, Dept Internal Med, 4150 5 St,Suite 3500, Sacramento, CA 95817 USA. EM valentina.medici@ucdmc.ucdavis.edu RI Schroeder, Diane/I-2200-2015; OI Schroeder, Diane/0000-0003-2282-9912; LaSalle, Janine/0000-0002-3480-2031 FU National Institutes of Health [K08DK084111, R03AA020577-01, P50AA11991]; Southern California Research Center for ALPD and Cirrhosis; Morphology Core [P50AA11991]; Department of Veterans Affairs, Office of Research and Development [BX001155]; Liver Center [P30 DK026743]; Division of Gastroenterology and Hepatology at UC Davis; [R01ES021707] FX This research was supported by National Institutes of Health grant numbers K08DK084111 (to VM), R03AA020577-01 (to CHH), P50AA11991 Southern California Research Center for ALPD and Cirrhosis (to HT), P50AA11991 Morphology Core (to SWF), R01ES021707 (to JML and DIS), and by a Biomedical Laboratory Research and Development National Merit Review grant BX001155 from the Department of Veterans Affairs, Office of Research and Development (to KKK). VM is a member of the University of California San Francisco Liver Center (Liver Center grant number P30 DK026743) and received funds from the Division of Gastroenterology and Hepatology at UC Davis. The content is the sole responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 49 TC 7 Z9 7 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 IS 6 BP 1540 EP 1549 DI 10.1111/acer.12405 PG 10 WC Substance Abuse SC Substance Abuse GA AJ2SI UT WOS:000337511400007 PM 24730561 ER PT J AU Glass, JE Williams, EC Bucholz, KK AF Glass, Joseph E. Williams, Emily C. Bucholz, Kathleen K. TI Psychiatric Comorbidity and Perceived Alcohol Stigma in a Nationally Representative Sample of Individuals with DSM-5 Alcohol Use Disorder SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Perceived Stigma; Alcoholism Stigma; Alcohol; Psychiatric Disorders; Latent Class Analysis ID SUBSTANCE USE DISORDERS; LABELING THEORY APPROACH; LATENT CLASS ANALYSIS; DRUG-USE DISORDERS; UNITED-STATES; EPIDEMIOLOGIC SURVEY; MENTAL-DISORDERS; SEXUAL MINORITY; HEALTH; CONSEQUENCES AB Background Alcohol use disorder (AUD) is among the most stigmatized health conditions and is frequently comorbid with mood, anxiety, and drug use disorders. Theoretical frameworks have conceptualized stigma-related stress as a predictor of psychiatric disorders. We described profiles of psychiatric comorbidity among people with AUD and compared levels of perceived alcohol stigma across profiles. Methods Cross-sectional data were analyzed from a general population sample of U.S. adults with past-year DSM-5 AUD (n=3,368) from the National Epidemiologic Survey on Alcohol and Related Conditions, which was collected from 2001 to 2005. Empirically derived psychiatric comorbidity profiles were established with latent class analysis, and mean levels of perceived alcohol stigma were compared across the latent classes while adjusting for sociodemographic characteristics and AUD severity. Results Four classes of psychiatric comorbidity emerged within this AUD sample, including those with: (i) high comorbidity, reflecting internalizing (i.e., mood and anxiety disorders) and externalizing (i.e., antisocial personality and drug use disorders) disorders; (ii) externalizing comorbidity; (iii) internalizing comorbidity; and (iv) no comorbidity. Perceived alcohol stigma was significantly higher in those with internalizing comorbidity (but not those with high comorbidity) as compared to those with no comorbidity or externalizing comorbidity. Conclusions Perceived stigma, as manifested by anticipations of social rejection and discrimination, may increase risk of internalizing psychiatric comorbidity. Alternatively, internalizing psychiatric comorbidity could sensitize affected individuals to perceive more negative attitudes toward them. Future research is needed to understand causal and bidirectional associations between alcohol stigma and psychiatric comorbidity. C1 [Glass, Joseph E.] Univ Wisconsin, Sch Social Work, Madison, WI 53706 USA. [Williams, Emily C.] VA Puget Sound Hlth Care Syst, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Hlth Serv Res & Dev, Seattle, WA USA. [Williams, Emily C.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Bucholz, Kathleen K.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Bucholz, Kathleen K.] Washington Univ, Sch Med, Midwest Alcoholism Res Ctr, St Louis, MO USA. RP Glass, JE (reprint author), Univ Wisconsin, Sch Social Work, 1350 Univ Ave, Madison, WI 53706 USA. EM jglass2@wisc.edu FU National Institutes of Health under Ruth L. Kirschstein National Research Service [5T32 DA015035, 1F31AA021034]; VA Health Services Research Development [CDA 12-276]; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI); National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse of the National Institute of Health [R01AA012460, P60AA011998, U01AA008401, R01AA017915, R01AA01 7444, R21AA020018, R01DA014363] FX We are grateful to Sean D. Kristjannson for consultations on the statistical analysis and the feedback that he provided on this work. Dr. Glass received support to conduct this project from the National Institutes of Health under Ruth L. Kirschstein National Research Service Awards 5T32 DA015035 and 1F31AA021034. Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276) and is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). For the research reported in this publication, KKB was supported by the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse of the National Institute of Health under award numbers R01AA012460, P60AA011998, U01AA008401, R01AA017915, R01AA01 7444, R21AA020018, and R01DA014363. NR 50 TC 5 Z9 5 U1 4 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 IS 6 BP 1697 EP 1705 DI 10.1111/acer.12422 PG 9 WC Substance Abuse SC Substance Abuse GA AJ2SI UT WOS:000337511400025 PM 24848495 ER PT J AU Schmidt, TP Pennington, DL Durazzo, TC Meyerhoff, DJ AF Schmidt, Thomas P. Pennington, David L. Durazzo, Timothy C. Meyerhoff, Dieter J. TI Postural Stability in Cigarette Smokers and During Abstinence from Alcohol SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Ataxia; Balance; Postural Stability; Alcohol Dependence; Cigarette Smoking; Abstinence ID CROSS-SECTIONAL ANALYSIS; GRAY-MATTER VOLUMES; SHORT-TERM RECOVERY; ATAXIA TEST BATTERY; NEUROCOGNITIVE RECOVERY; NICOTINE DEPENDENCE; MAGNETIC-RESONANCE; GAIT DISTURBANCES; MAJOR DEPRESSION; BRAIN STRUCTURE AB Background Static postural instability is common in alcohol-dependent individuals (ALC). Chronic alcohol consumption has deleterious effects on the neural and perceptual systems subserving postural stability. However, little is known about the effects of chronic cigarette smoking on postural stability and its changes during abstinence from alcohol. Methods A modified Fregly ataxia battery was administered to a total of 115 smoking (sALC) and nonsmoking ALC (nsALC) and to 71 smoking (sCON) and nonsmoking light/nondrinking controls (nsCON). Subgroups of abstinent ALC were assessed at 3 time points (TPs; approximately 1, 5, 34weeks of abstinence from alcohol); a subset of nsCON was retested at 40weeks. We tested whether cigarette smoking affects postural stability in CON and in ALC during extended abstinence from alcohol, and we used linear mixed effects modeling to measure change across TPs within ALC. Results Chronic smoking was associated with reduced performance on the Sharpened Romberg eyes-closed task in abstinent ALC at all 3 TPs and in CON. The test performance of nsALC increased significantly between 1 and 32weeks of abstinence, whereas the corresponding increases for sALC between 1 and 35weeks were nonsignificant. With long-term abstinence from alcohol, nsALC recovered into the range of nsCON and sALC recovered into the range of sCON. Static postural stability decreased with age and correlated with smoking variables but not with drinking measures. Conclusions Chronic smoking was associated with reduced static postural stability with eyes closed and with lower increases of postural stability during abstinence from alcohol. Smoking cessation in alcohol dependence treatment may facilitate recovery from static postural instability during abstinence. C1 [Schmidt, Thomas P.; Pennington, David L.; Durazzo, Timothy C.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. [Schmidt, Thomas P.; Pennington, David L.; Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Schmidt, TP (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM thomas.schmidt@ucsf.edu FU National Institutes of Health [AA10788, DA24136] FX This work was supported by grants from the National Institutes of Health [AA10788 to DJM.; DA24136 to TCD] administered by the Northern California Institute for Research and Education, and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. We thank Mary Rebecca Young, Kathleen Altieri, Ricky Chen, and Drs. Peter Banys, Steven Batki, and Ellen Herbst of the Veterans Administration Substance Abuse Day Hospital, and Dr. David Pating, Karen Moise, and their colleagues at the Kaiser Permanente Chemical Dependency Recovery Program in San Francisco for their valuable assistance in recruiting participants. We also wish to extend our gratitude to the study participants, who made this research possible. NR 54 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2014 VL 38 IS 6 BP 1753 EP 1760 DI 10.1111/acer.12409 PG 8 WC Substance Abuse SC Substance Abuse GA AJ2SI UT WOS:000337511400032 PM 24721012 ER PT J AU Samuels, J Shugart, YY Wang, Y Grados, MA Bienvenu, OJ Pinto, A Rauch, SL Greenberg, BD Knowles, JA Fyer, AJ Piacentini, J Pauls, DL Cullen, B Rasmussen, SA Stewart, SE Geller, DA Maher, BS Goes, FS Murphy, DL McCracken, JT Riddle, MA Nestadt, G AF Samuels, Jack Shugart, Yin Yao Wang, Ying Grados, Marco A. Bienvenu, O. Joseph Pinto, Anthony Rauch, Scott L. Greenberg, Benjamin D. Knowles, James A. Fyer, Abby J. Piacentini, John Pauls, David L. Cullen, Bernadette Rasmussen, Steven A. Stewart, S. Evelyn Geller, Dan A. Maher, Brion S. Goes, Fernando S. Murphy, Dennis L. McCracken, James T. Riddle, Mark A. Nestadt, Gerald TI Clinical Correlates and Genetic Linkage of Social and Communication Difficulties in Families with Obsessive-Compulsive Disorder: Results From the OCD Collaborative Genetics Study SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE obsessive-compulsive disorder; OCD; pragmatics; genetic linkage ID BROAD AUTISM PHENOTYPE; PSYCHIATRIC-DISORDERS; ASPERGER-SYNDROME; CHILDREN; PARENTS; INDIVIDUALS; PERSONALITY; BEHAVIORS; TRAITS; SCAN AB Some individuals with obsessive-compulsive disorder (OCD) have autistic-like traits, including deficits in social and communication behaviors (pragmatics). The objective of this study was to determine if pragmatic impairment aggregates in OCD families and discriminates a clinically and genetically distinct subtype of OCD. We conducted clinical examinations on, and collected DNA samples from, 706 individuals with OCD in 221 multiply affected OCD families. Using the Pragmatic Rating Scale (PRS), we compared the prevalence of pragmatic impairment in OCD-affected relatives of probands with and without pragmatic impairment. We also compared clinical features of OCD-affected individuals in families having at least one, versus no, individual with pragmatic impairment, and assessed for linkage to OCD in the two groups of families. The odds of pragmatic impairment were substantially greater in OCD-affected relatives of probands with pragmatic impairment. Individuals in high-PRS families had greater odds of separation anxiety disorder and social phobia, and a greater number of schizotypal personality traits. In high-PRS families, there was suggestive linkage to OCD on chromosome 12 at marker D12S1064 and on chromosome X at marker DXS7132 whereas, in low-PRS families, there was suggestive linkage to chromosome 3 at marker D3S2398. Pragmatic impairment aggregates in OCD families. Separation anxiety disorder, social phobia, and schizotypal personality traits are part of a clinical spectrum associated with pragmatic impairment in these families. Specific regions of chromosomes 12 and X are linked to OCD in high-PRS families. Thus, pragmatic impairment may distinguish a clinically and genetically homogeneous subtype of OCD. (C) 2014 Wiley Periodicals, Inc. C1 [Samuels, Jack; Wang, Ying; Grados, Marco A.; Bienvenu, O. Joseph; Cullen, Bernadette; Goes, Fernando S.; Riddle, Mark A.; Nestadt, Gerald] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Shugart, Yin Yao] NIMH, Genom Res Branch, Div Neurosci & Basic Behav Sci, NIH, Bethesda, MD 20892 USA. [Pinto, Anthony; Fyer, Abby J.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA. [Pinto, Anthony; Fyer, Abby J.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Rauch, Scott L.; Geller, Dan A.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Greenberg, Benjamin D.; Rasmussen, Steven A.] Butler Hosp, Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI 02906 USA. [Knowles, James A.] Univ So Calif, Dept Psychiat, Sch Med, Los Angeles, CA USA. [Piacentini, John; McCracken, James T.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Pauls, David L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Pauls, David L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Pauls, David L.] Harvard Univ, Sch Med, Boston, MA USA. [Stewart, S. Evelyn] Univ British Columbia, Fac Med, Dept Psychiat, Vancouver Fac Med, Vancouver, BC, Canada. [Maher, Brion S.] Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Murphy, Dennis L.] NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA. RP Samuels, J (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 550 N Broadway 901, Baltimore, MD 21205 USA. EM jacks@jhmi.edu RI Pinto, Anthony/D-2718-2017; OI Pinto, Anthony/0000-0002-6078-7242; Samuels, Jack/0000-0002-6715-7905; Stewart, S. Evelyn/0000-0002-0994-6383 FU National Institutes of Health [R01-MH-50214, R01MH071507, K23-MH-64543, NIH/NCRR/OPD-GCRC RR00052]; James E. Marshall OCD Foundation FX Grant sponsor: National Institutes of Health; Grant numbers: R01-MH-50214, R01MH071507, K23-MH-64543, NIH/NCRR/OPD-GCRC RR00052; Grant sponsor: James E. Marshall OCD Foundation. NR 57 TC 3 Z9 3 U1 3 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JUN PY 2014 VL 165 IS 4 BP 326 EP 336 DI 10.1002/ajmg.b.32235 PG 11 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA AJ4UX UT WOS:000337674600006 PM 24798771 ER PT J AU Harvey, PD Siever, LJ Huang, GD Muralidhar, S Zhao, HY Miller, P Aslan, M Mane, S McNamara, M Gleason, T Brophy, M Przygodszki, R O'Leary, TJ Gaziano, M Concato, J AF Harvey, Philip D. Siever, Larry J. Huang, Grant D. Muralidhar, Sumitra Zhao, Hongyu Miller, Perry Aslan, Mihaela Mane, Shrikant McNamara, Margaret Gleason, Theresa Brophy, Mary Przygodszki, Ronald O'Leary, Timothy J. Gaziano, Michael Concato, John TI The Genetics of Functional Disability in Schizophrenia and Bipolar Illness: Methods and Initial Results for VA Cooperative Study #572 SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE schizophrenia; bipolar; genetics; neurocognition; disability ID CONSENSUS COGNITIVE BATTERY; MENTAL-ILLNESS; UNITED-STATES; I DISORDER; CONSORTIUM; ENDOPHENOTYPES; IMPAIRMENT; PREDICTION; STABILITY; CANDIDATE AB Given the prominence of cognitive impairments and disability associated with schizophrenia and bipolar disorder, substantial interest has arisen in identifying determinants of the diseases and their features. Genetic variation has been linked to skills that underlie disability ("functional capacity" or FC), highlighting need for understanding of these relationships. We describe the design and methods of a large, multisite, observational study focusing on the genetics of functional disability in schizophrenia and bipolar disorder, presenting initial data on recruitment, and characterization of the sample. Known as Veterans Affairs (VA) Cooperative Studies Program (CSP)#572, this study is recruiting, diagnosing, and assessing U.S. Veterans with either schizophrenia or bipolar I disorder. Assessments include neuropsychological (NP) testing, FC, suicidality, and co-morbid conditions such as posttraumatic stress disorder (PTSD). A sample of "psychiatrically healthy" Veterans from another project serves as a comparison group. An interim total of 8,140 participants (42.1% schizophrenia) have been recruited and assessed as of September 30, 2013, with 9 months of enrollment remaining and with a target sample size of 9,500. Veterans with schizophrenia were more likely to never have married, whereas lifetime PTSD and suicidality were more common in the bipolar veterans. Performance on the FC measures and NP tests was consistent with previous results, with mean t-scores of 35 (-1.5 SD) for schizophrenia and 41 (-0.9 SD) for the bipolar Veterans. This large population is representative of previous studies in terms of patient performance and co-morbidities. Subsequent genomic analyses will examine the genomic correlates of performance-based measures. Published 2014. This article is a U.S. Government work and is in the public domain in the USA. C1 [Harvey, Philip D.] Bruce W Carter Miami Vet Affairs VA Med Ctr, Miami, FL USA. [Harvey, Philip D.] Univ Miami, Sch Med, Miami, FL 33136 USA. [Siever, Larry J.; McNamara, Margaret] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Siever, Larry J.; McNamara, Margaret] Mt Sinai Sch Med, New York, NY USA. [Huang, Grant D.; Muralidhar, Sumitra; Gleason, Theresa; Przygodszki, Ronald; O'Leary, Timothy J.] Vet Hlth Adm, Off Res & Dev, Washington, DC USA. [Zhao, Hongyu; Miller, Perry; Aslan, Mihaela; Concato, John] VA Connecticut Healthcare Syst, CERC, West Haven, CT USA. [Zhao, Hongyu; Miller, Perry; Aslan, Mihaela; Mane, Shrikant; Concato, John] Yale Univ, Sch Med, New Haven, CT USA. [Brophy, Mary; Gaziano, Michael] MAVERIC, Jamaica Plain, MA USA. [Brophy, Mary] Boston Univ, Sch Med, Boston, MA 02118 USA. [Gaziano, Michael] Harvard Univ, Boston, MA 02115 USA. RP Harvey, PD (reprint author), Univ Miami, Miller Sch Med, 1120 NW 14th St,Suite 1450, Miami, FL 33136 USA. EM pharvey@med.miami.edu OI Przygodzki, Ronald/0000-0002-1238-262X FU Department of Veterans Affairs Cooperative Studies Program FX Grant sponsor: Department of Veterans Affairs Cooperative Studies Program. NR 36 TC 9 Z9 9 U1 8 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JUN PY 2014 VL 165 IS 4 BP 381 EP 389 DI 10.1002/ajmg.b.32242 PG 9 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA AJ4UX UT WOS:000337674600012 PM 24798943 ER PT J AU Hirsch, JA Donovan, WD Barr, RM Nicola, GN Rosman, DA Schaefer, PW Manchikanti, L AF Hirsch, J. A. Donovan, W. D. Barr, R. M. Nicola, G. N. Rosman, D. A. Schaefer, P. W. Manchikanti, L. TI The Independent Payment Advisory Board SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Editorial Material ID INTERVENTIONAL PAIN MANAGEMENT; AFFORDABLE CARE ACT; OUTCOMES RESEARCH-INSTITUTE; PATIENT PROTECTION; NEUROINTERVENTIONALISTS; PROGNOSIS; EVOLUTION; IMPACT C1 [Hirsch, J. A.; Rosman, D. A.; Schaefer, P. W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Donovan, W. D.] Norwich Diagnost Imaging Associates, Norwich, CT USA. [Barr, R. M.] Mecklenburg Radiol Associates, Charlotte, NC USA. [Nicola, G. N.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Manchikanti, L.] Pain Management Ctr Paducah, Paducah, KY USA. [Manchikanti, L.] Univ Louisville, Louisville, KY 40292 USA. RP Hirsch, JA (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Gray Bldg,2nd Floor, Boston, MA 02114 USA. EM Hirsch@snisonline.org NR 17 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD JUN PY 2014 VL 35 IS 6 BP 1066 EP 1069 DI 10.3174/ajnr.A3736 PG 4 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA AJ4NK UT WOS:000337652900006 PM 24136648 ER PT J AU Lee, SE Kang, SY Cho, J Lee, B Chang, DK Woo, H Kim, JW Park, HY Do, IG Kim, YE Kushima, R Lauwers, GY Park, CK Kim, KM AF Lee, Seung Eun Kang, So Young Cho, Junhun Lee, Boram Chang, Dong Kyung Woo, Hyein Kim, Jong Won Park, Ha Young Do, In Gu Kim, Young Eun Kushima, Ryoji Lauwers, Gregory Y. Park, Cheol Keun Kim, Kyoung M. TI Pyloric Gland Adenoma in Lynch Syndrome SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE gastric; pyloric gland adenoma; carcinoma; precursor; Lynch syndrome ID NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; GASTRIC-CANCER; POLYPS; IMMUNOHISTOCHEMISTRY; NETHERLANDS; EXPRESSION; GUIDELINES; MANAGEMENT; MUTATIONS AB The prevalence of gastric cancer associated with Lynch syndrome (LS) is highly variable, and the underlying histologic pathway or molecular mechanisms remain unclear. From 1995 to 2012, 15 patients had been treated for both gastric and colonic adenocarcinomas and diagnosed as LS. In all cases, pathologic review, immunohistochemical analysis for mismatch-repair proteins, and microsatellite instability (MSI) tests were performed. To confirm LS, germline mutation tests and multiplex ligation-dependent probe amplification were performed. All gastric and colonic carcinomas were MSI-high and lost expressions of MLH1/PMS2 in 11 (73%) cases and MSH2/MSH6 in 4 (27%) cases. Remarkably, in a patient with LS and germline mutation of MLH1 gene, pyloric gland adenoma (PGA) transformed to adenocarcinoma during follow-up. In 2 additional cases, PGA was found adjacent to advanced gastric cancers. All PGAs in LS patients were MSI-high and lost expression of mismatch-repair proteins (MLH1/PMS2 in 2 cases and MSH2/MSH6 in 1 case), whereas none of the 14 sporadic PGAs was MSI-high or had lost expression of mismatch-repair proteins. On the basis of these observations, although very rare, we suggest the possibility that PGA may be a precursor lesion to gastric adenocarcinoma in LS and that the mismatch-repair deficient pathway of carcinogenesis is involved early in the gastric carcinogenesis pathway. C1 [Lee, Seung Eun; Kang, So Young; Cho, Junhun; Lee, Boram; Park, Ha Young; Do, In Gu; Kim, Young Eun; Park, Cheol Keun; Kim, Kyoung M.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea. [Chang, Dong Kyung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Gastroenterol, Seoul 135710, South Korea. [Woo, Hyein; Kim, Jong Won] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med, Seoul 135710, South Korea. [Kushima, Ryoji] Natl Canc Ctr, Clin Lab Div, Tokyo, Japan. [Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Kim, KM (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, 50 Irwon Dong, Seoul 135710, South Korea. EM kkmkys@skku.edu FU Korea Healthcare Technology R&D project, Ministry of Health & Welfare, Republic of Korea [A101130] FX Funded by a grant from the Korea Healthcare Technology R&D project, Ministry of Health & Welfare, Republic of Korea (A101130). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. NR 32 TC 11 Z9 11 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD JUN PY 2014 VL 38 IS 6 BP 784 EP 792 DI 10.1097/PAS.0000000000000185 PG 9 WC Pathology; Surgery SC Pathology; Surgery GA AJ0CD UT WOS:000337315800006 PM 24518125 ER PT J AU Bruinsma, BG Yeh, H Ozer, S Martins, PN Farmer, A Wu, W Saeidi, N Op den Dries, S Berendsen, TA Smith, RN Markmann, JF Porte, RJ Yarmush, ML Uygun, K Izamis, ML AF Bruinsma, B. G. Yeh, H. Oezer, S. Martins, P. N. Farmer, A. Wu, W. Saeidi, N. Op den Dries, S. Berendsen, T. A. Smith, R. N. Markmann, J. F. Porte, R. J. Yarmush, M. L. Uygun, K. Izamis, M. -L. TI Subnormothermic Machine Perfusion for Ex Vivo Preservation and Recovery of the Human Liver for Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Donation after circulatory death; liver transplantation; organ preservation; subnormothermic machine perfusion ID HEART-BEATING DONOR; RAT-LIVER; COLD-STORAGE; NORMOTHERMIC PRESERVATION; ORGAN VIABILITY; PORCINE LIVERS; HOPE PROTECTS; CARDIAC DEATH; SINGLE-CENTER; BILE-DUCTS AB To reduce widespread shortages, attempts are made to use more marginal livers for transplantation. Many of these grafts are discarded for fear of inferior survival rates or biliary complications. Recent advances in organ preservation have shown that ex vivo subnormothermic machine perfusion has the potential to improve preservation and recover marginal livers pretransplantation. To determine the feasibility in human livers, we assessed the effect of 3 h of oxygenated subnormothermic machine perfusion (21 degrees C) on seven livers discarded for transplantation. Biochemical and microscopic assessment revealed minimal injury sustained during perfusion. Improved oxygen uptake (1.30 [1.11-1.94] to 6.74 [4.15-8.16] mL O-2/min kg liver), lactate levels (4.04 [3.70-5.99] to 2.29 [1.20-3.43] mmol/L) and adenosine triphosphate content (45.0 [70.6-87.5] pmol/mg preperfusion to 167.5 [151.5-237.2] pmol/mg after perfusion) were observed. Liver function, reflected by urea, albumin and bile production, was seen during perfusion. Bile production increased and the composition of bile (bile salts/phospholipid ratio, pH and bicarbonate concentration) became more favorable. In conclusion, ex vivo subnormothermic machine perfusion effectively maintains liver function with minimal injury and sustains or improves various hepatobiliary parameters postischemia. C1 [Bruinsma, B. G.; Oezer, S.; Farmer, A.; Wu, W.; Saeidi, N.; Berendsen, T. A.; Yarmush, M. L.; Uygun, K.; Izamis, M. -L.] Harvard Univ, Sch Med, Dept Surg, Ctr Engn Med,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Bruinsma, B. G.] Univ Amsterdam, Acad Med Ctr, Dept Surg, Surg Lab, NL-1105 AZ Amsterdam, Netherlands. [Yeh, H.; Markmann, J. F.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. [Martins, P. N.] UMass Mem Med Ctr, Boston, MA USA. [Op den Dries, S.; Porte, R. J.] Univ Groningen, Univ Med Ctr Groningen, Sect Hepatobiliary Surg & Liver Transplantat, Dept Surg, Groningen, Netherlands. [Smith, R. N.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Yarmush, M. L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA. RP Uygun, K (reprint author), Harvard Univ, Sch Med, Dept Surg, Ctr Engn Med,Massachusetts Gen Hosp, Boston, MA 02115 USA. EM uygun.korkut@mgh.harvard.edu; mizamis@partners.org FU National Institutes of Health [R00DK080942, R01DK096075, R01EB008678]; Shriners Hospitals for Children FX We would like to gratefully acknowledge the NEOB and the surgical procurement teams for supporting this work through the supply of discarded livers and commendable coordination. We are also grateful to the perfusionists at MGH for their support. Funding from the National Institutes of Health (R00DK080942, R01DK096075, R01EB008678) and the Shriners Hospitals for Children are gratefully acknowledged. NR 51 TC 34 Z9 40 U1 2 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 IS 6 BP 1400 EP 1409 DI 10.1111/ajt.12727 PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ2UP UT WOS:000337519500022 PM 24758155 ER PT J AU Chandraker, A Arscott, R Murphy, GF Lian, CG Bueno, EM Marty, FM Rennke, HG Milford, E Tullius, SG Pomahac, B AF Chandraker, A. Arscott, R. Murphy, G. F. Lian, C. G. Bueno, E. M. Marty, F. M. Rennke, H. G. Milford, E. Tullius, S. G. Pomahac, B. TI The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Antibody-mediated rejection; C4d; cross-match; donor-specific antibodies; face allotransplantation; vascularized composite tissue allotransplantation ID COMPOSITE TISSUE ALLOTRANSPLANTATION; FACIAL TRANSPLANTATION; HAND ALLOGRAFT; C4D DEPOSITION; BRIGHAM AB We report on the management of the first full-face transplantation in a sensitized recipient with a positive preoperative crossmatch and subsequent antibodymediated rejection (AMR). The recipient is a 45-year-old female who sustained extensive chemical burns, with residual poor function and high levels of circulating anti-HLA antibodies. With a clear immunosuppression plan and salvage options in place, a full-face allotransplant was performed using a crossmatch positive donor. Despite plasmapheresis alongside a standard induction regimen, clinical signs of rejection were noted on postoperative day 5 (POD5). Donor-specific antibody (DSA) titers rose with evidence of C4d deposits on biopsy. By POD19, biopsies showed Banff Grade III rejection. Combination therapy consisting of plasmapheresis, eculizumab, bortezomib and alemtuzumab decreased DSA levels, improved clinical exam, and by 6 months postop she had no histological signs of rejection. This case is the first to demonstrate evidence and management of AMR in face allotransplantation. Our findings lend support to the call for an update to the Banff classification of rejection in vascularized composite tissue allotransplantation (VCA) to includeAMR, and for further studies to better classify the histology and mechanism of action of AMR in VCA. C1 [Chandraker, A.] Brigham & Womens Hosp, Div Renal, Schuster Family Transplantat Res Ctr, Boston, MA 02115 USA. [Chandraker, A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Arscott, R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA. [Murphy, G. F.; Lian, C. G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Dermatopathol,Dept Pathol, Boston, MA 02115 USA. [Bueno, E. M.; Pomahac, B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Plast Surg,Dept Surg, Boston, MA 02115 USA. [Marty, F. M.] Dana Farber Canc Inst, Div Infect Dis, Boston, MA 02115 USA. [Marty, F. M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rennke, H. G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Milford, E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Nephrol, Boston, MA 02115 USA. [Tullius, S. G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Transplant Surg,Dept Surg, Boston, MA 02115 USA. RP Chandraker, A (reprint author), Brigham & Womens Hosp, Div Renal, Schuster Family Transplantat Res Ctr, Boston, MA 02115 USA. EM achandraker@partners.org OI Lian, Christine/0000-0003-4626-1612 NR 15 TC 28 Z9 28 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2014 VL 14 IS 6 BP 1446 EP 1452 DI 10.1111/ajt.12715 PG 7 WC Surgery; Transplantation SC Surgery; Transplantation GA AJ2UP UT WOS:000337519500028 PM 24797454 ER PT J AU Kamdar, BB Kamdar, BB Needham, DM AF Kamdar, B. B. Kamdar, B. B. Needham, D. M. TI Bundling sleep promotion with delirium prevention: ready for prime time? SO ANAESTHESIA LA English DT Editorial Material ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; ICU PATIENTS; EYE MASKS; QUALITY; PERCEPTION; SEDATION; NOISE; INTERVENTION; DEPRIVATION C1 [Kamdar, B. B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Kamdar, B. B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anaesthesiol Crit Care & Pain Med, Boston, MA USA. [Needham, D. M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Outcomes Crit Illness & Surg OACIS Grp, Baltimore, MD USA. [Needham, D. M.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA. RP Kamdar, BB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. EM bkamdar@mednet.ucla.edu OI Kamdar, Biren/0000-0002-9245-6229 NR 33 TC 2 Z9 2 U1 4 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0003-2409 EI 1365-2044 J9 ANAESTHESIA JI Anaesthesia PD JUN PY 2014 VL 69 IS 6 BP 527 EP 531 DI 10.1111/anae.12686 PG 5 WC Anesthesiology SC Anesthesiology GA AJ3LV UT WOS:000337568900003 PM 24813131 ER PT J AU Edwards, FH Shahian, DM Grau-Sepulveda, MV Grover, FL Mayer, JE O'Brien, SM DeLong, E Peterson, ED McKay, C Shaw, RE Garratt, KN Dangas, GD Messenger, J Klein, LW Popma, JJ Weintraub, WS AF Edwards, Fred H. Shahian, David M. Grau-Sepulveda, Maria V. Grover, Frederick L. Mayer, John E. O'Brien, Sean M. DeLong, Elizabeth Peterson, Eric D. McKay, Charles Shaw, Richard E. Garratt, Kirk N. Dangas, George D. Messenger, John Klein, Lloyd W. Popma, Jeffrey J. Weintraub, William S. TI Composite Outcomes in Coronary Bypass Surgery Versus Percutaneous Intervention SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 49th Annual Meeting of the Society-of-Thoracic-Surgeons CY JAN 26-30, 2013 CL Los Angeles, CA SP Soc Thorac Surg ID DRUG-ELUTING STENTS; LONG-TERM SURVIVAL; 5-YEAR FOLLOW-UP; ARTERY-DISEASE; SYNTAX TRIAL; REVASCULARIZATION STRATEGIES; 3-VESSEL DISEASE; GRAFT-SURGERY; MULTIVESSEL; PROPENSITY AB Background. Recent observational studies show that patients with multivessel coronary disease have a long-term survival advantage with coronary artery bypass grafting (CABG) compared with percutaneous coronary intervention (PCI). Important nonfatal outcomes may also affect optimal treatment recommendation. Methods. CABG was compared with percutaneous catheter intervention by using a composite of death, myocardial infarction (MI), or stroke. Medicare patients undergoing revascularization for stable multivessel coronary disease from 2004 through 2008 were identified in national registries. Short-term clinical information from the registries was linked to Medicare data to obtain long-term follow-up out to 4 years from the time of the procedure. Propensity scoring with inverse probability weighting was used to adjust for baseline risk factors. Results. There were 86,244 CABG and 103,549 PCI patients. The mean age was 74 years, with a median 2.67 years of follow-up. At 4 years, the propensity-adjusted adjusted cumulative incidence of MI was 3.2% in CABG compared with 6.6% in PCI (risk ratio, 0.49; 95% confidence interval, 0.45 to 0.53). At 4 years, the cumulative incidence of stroke was 4.5% in CABG compared with 3.1% in PCI patients (risk ratio, 1.43; 95% confidence interval, 1.31 to 1.54). This difference was primarily due to the higher 30-day stroke rate for CABG (1.55% vs 0.37%). For the composite of death, MI, or stroke, the 4-year adjusted cumulative incidence was 21.6% for CABG and 26.7% for PCI (risk ratio, 0.81; 95% confidence interval, 0.78 to 0.83). Conclusions. The 4-year composite event rate of death, MI, and stroke favored CABG, whereas the risk of stroke alone favored PCI. (C) 2014 by The Society of Thoracic Surgeons C1 Soc Thorac Surg, Chicago, IL USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Duke Clin Res Inst, Durham, NC USA. Univ Colorado, Sch Med, Aurora, CO USA. Childrens Hosp Boston, Boston, MA USA. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. Calif Pacific Med Ctr, San Francisco, CA USA. Lenox Hill Heart & Vasc Inst New York, New York, NY USA. Mt Sinai Med Ctr, New York, NY 10029 USA. Advocate Illinois Masonic Med Ctr, Chicago, IL USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Christiana Care Ctr Outcome Res, Newark, DE USA. RP Edwards, FH (reprint author), STS Res Ctr, 633 N St Clair St, Chicago, IL 60611 USA. EM fred.edwards@jax.ufl.edu FU NHLBI NIH HHS [RC2HL101489, RC2 HL101489] NR 32 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUN PY 2014 VL 97 IS 6 BP 1983 EP 1990 DI 10.1016/j.athoracsur.2014.01.087 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AI9KT UT WOS:000337252200019 PM 24775805 ER PT J AU Molnar, AO Parikh, CR Coca, SG Thiessen-Philbrook, H Koyner, JL Shlipak, MG Myers, ML Garg, AX AF Molnar, Amber O. Parikh, Chirag R. Coca, Steven G. Thiessen-Philbrook, Heather Koyner, Jay L. Shlipak, Michael G. Myers, Mary Lee Garg, Amit X. CA TRIBE-AKI Consortium TI Association Between Preoperative Statin Use and Acute Kidney Injury Biomarkers in Cardiac Surgical Procedures SO ANNALS OF THORACIC SURGERY LA English DT Article ID ACUTE-RENAL-FAILURE; ISCHEMIA-REPERFUSION INJURY; URINARY BIOMARKERS; SURGERY; THERAPY; RISK; OUTCOMES; BYPASS; PRAVASTATIN; DEFINITION AB Background. Acute kidney injury (AKI) is a serious complication of cardiac operations for which there remains no specific therapy. Animal data and several observational studies suggest that statins prevent AKI, but the results are not conclusive, and many studies are retrospective in nature. Methods. We conducted a multicenter prospective cohort study of 625 adult patients undergoing elective cardiac operations. All patients were taking statins and were grouped according to whether statins were continued or held in the 24 hours before operation. The primary outcome was AKI as defined by a doubling of serum creatinine or dialysis. The secondary outcome was the peak level of several kidney injury biomarkers. The results were adjusted for demographic and clinical factors. Results. Continuing(vs holding) a statin before operation was not associated with a lower risk of AKI, as defined by a doubling of serum creatinine or dialysis (adjusted relative risk [RR] 1.09; 95% confidence interval [CI] 0.44, 2.70). However, continuing a statin was associated with a lower risk of elevation of the following AKI biomarkers: urine interleukin-18, urine neutrophil gelatinase-associated lipocalin, urine kidney injury molecule-1, and plasma neutrophil gelatinase-associated lipocalin (adjusted RR 0.34; 95% CI 0.18, 0.62), (adjusted RR 0.41; 95% CI 0.22, 0.76), (adjusted RR 0.37; 95% CI 0.20, 0.76), (adjusted RR 0.62; 95% CI 0.39, 0.98), respectively. Conclusions. Statins may prevent kidney injury after cardiac operations, as evidenced by lower levels of kidney injury biomarkers. (c) 2014 by The Society of Thoracic Surgeons C1 Univ Ottawa, Dept Med, Div Nephrol, Ottawa, ON, Canada. Yale Univ, Sch Med, Nephrol Sect, Vet Affairs CT Healthcare Syst, New Haven, CT USA. Yale Univ, Program Appl Translat Res, New Haven, CT USA. Vet Affairs Med Ctr, Dept Med, West Haven, CT USA. Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada. Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA. Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA. Univ Western Ontario, Div Cardiac Surg, London, ON, Canada. McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada. Inst Clin Evaluat Sci, Toronto, ON, Canada. RP Parikh, CR (reprint author), Yale Univ, Nephrol Sect, 950 Campbell Ave,Mail Code 151B,Bldg 35 A,Rm 219, West Haven, CT 06516 USA. EM chirag.parikh@yale.edu FU NIH [RO1HL085757, K24DK090203]; TRIBE-AKI Consortium; National Institutes of Health [K23DK080132, R01DK096549, R01HL085757]; Acute Kidney Injury (ASSESS-AKI) Consortium [U01DK082185] FX This study was supported by the NIH grant RO1HL085757 (CRP) to fund the TRIBE-AKI Consortium to study novel biomarkers of acute kidney injury in cardiac surgery. S.G.C. is supported by National Institutes of Health Grants K23DK080132, R01DK096549, and R01HL085757. C.R.P. is also supported by NIH grant K24DK090203. S.G.C., A.X.G., and C.R.P. are also members of the NIH-sponsored ASsess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Consortium (U01DK082185). The urine biomarker assays were donated by Abbott Diagnostics (IL-18 and NGAL) and Sekisui Diagnostics, LLC (KIM-1 and L-FABP). The granting agencies, Abbott Diagnostics and Sekisui Diagnostics, Inc, did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 40 TC 17 Z9 17 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JUN PY 2014 VL 97 IS 6 BP 2081 EP 2088 DI 10.1016/j.athoracsur.2014.02.033 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA AI9KT UT WOS:000337252200032 PM 24725831 ER PT J AU Domsic, RT Nihtyanova, SI Wisniewski, SR Fine, MJ Lucas, M Kwoh, CK Denton, CP Medsger, TA AF Domsic, Robyn T. Nihtyanova, Svetlana I. Wisniewski, Stephen R. Fine, Michael J. Lucas, Mary Kwoh, C. Kent Denton, Christopher P. Medsger, Thomas A., Jr. TI Derivation and Validation of a Prediction Rule for Two-Year Mortality in Early Diffuse Cutaneous Systemic Sclerosis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID CLINICAL-PREDICTION; SCLERODERMA; SURVIVAL; FEATURES; DEATH; EMPHASIS; DISEASE; COHORT; MODEL AB Objective. Systemic sclerosis (SSc) is associated with a reduction in life expectancy, but there are no validated prognostic models for determining short-term mortality. The objective of this study was to derive and validate a prediction rule for 2-year mortality in patients with early diffuse cutaneous SSc (dcSSc). Methods. We studied a prospectively enrolled cohort of 387 US Caucasian patients with early dcSSc (<2 years from the appearance of the first symptom), randomly divided into a derivation cohort (n = 260) and a validation cohort (n = 127). Predefined baseline predictor variables were analyzed in a stepwise multi-variable logistic regression model in order to identify factors independently associated with 2-year all-cause mortality using a cutoff of P < 0.05. We rounded the beta values to the nearest integer and summed the points assigned to each variable in order to stratify patients into low-risk, moderate-risk, and high-risk groups. We then applied this rule to an external validation cohort of 110 Caucasian patients with early dcSSc from a single UK center and compared stratum-specific mortality using chi-square statistics. Results. Four independent predictor variables (with assigned integer values) comprised the model: age at first visit (points allotted: -1, 0, or 1), skin thickness progression rate (points allotted: 0 or 1), gastrointestinal tract severity (points allotted: 0, 1, or 2), and anemia (points allotted: 0 or 2). The prediction model performed well, with no significant differences between the derivation cohort and the US or UK validation cohorts in the low-risk and moderate-risk groups. Conclusion. We derived a 4-variable prediction rule that can be used to stratify patients with early dcSSc into groups by risk of 2-year mortality, and we validated that prediction rule in US and UK cohorts. C1 [Domsic, Robyn T.; Wisniewski, Stephen R.; Fine, Michael J.; Lucas, Mary; Kwoh, C. Kent; Medsger, Thomas A., Jr.] Univ Pittsburgh, Pittsburgh, PA 15261 USA. [Nihtyanova, Svetlana I.; Denton, Christopher P.] UCL, Sch Med, Royal Free Hosp, London W1N 8AA, England. [Fine, Michael J.; Kwoh, C. Kent] Vet Affairs Pittsburgh Healthcare, Vet Affairs Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Domsic, RT (reprint author), Univ Pittsburgh, S724 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA. EM rtd4@pitt.edu OI Wisniewski, Stephen/0000-0002-3877-9860 FU NIH (from the National Institute of Arthritis and Musculoskeletal and Skin Diseases) [K23-AR-057845] FX Dr. Domsic's work was supported by the NIH (grant K23-AR-057845 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). NR 34 TC 9 Z9 9 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD JUN PY 2014 VL 66 IS 6 BP 1616 EP 1624 DI 10.1002/art.38381 PG 9 WC Rheumatology SC Rheumatology GA AJ0SL UT WOS:000337366200024 PM 24470430 ER PT J AU Loggia, ML Edwards, RR Harris, RE Napadow, V AF Loggia, Marco L. Edwards, Robert R. Harris, Richard E. Napadow, Vitaly TI What is the proper control group for a fibromyalgia study? Comment on the article by Loggia et al Reply SO ARTHRITIS & RHEUMATOLOGY LA English DT Letter C1 [Loggia, Marco L.; Napadow, Vitaly] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Loggia, Marco L.; Edwards, Robert R.; Napadow, Vitaly] Harvard Univ, Sch Med, Boston, MA USA. [Edwards, Robert R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Harris, Richard E.] Univ Michigan, Ann Arbor, MI 48109 USA. RP Loggia, ML (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. FU NCCIH NIH HHS [P01 AT006663, P01-AT006663, R01 AT004714, R01 AT005280, R01-AT004714, R01-AT005280]; NIA NIH HHS [R01 AG034982, R01-AG034982]; NIAMS NIH HHS [R21-AR057920, R21 AR057920] NR 3 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD JUN PY 2014 VL 66 IS 6 BP 1684 EP 1685 DI 10.1002/art.38396 PG 4 WC Rheumatology SC Rheumatology GA AJ0SL UT WOS:000337366200041 PM 24515749 ER PT J AU Sher, L Braquehais, MD AF Sher, Leo Dolores Braquehais, Maria TI Suicidal behavior in military veterans and health care professionals SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter ID MORTALITY C1 [Sher, Leo] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Sher, Leo] James J Peters Vet Adm, Med Ctr, New York, NY USA. [Dolores Braquehais, Maria] Galatea Fdn, Coll Metges Barcelona, Galatea Clin, Integral Care Program Sick Doctors, Barcelona, Spain. [Dolores Braquehais, Maria] Univ Autonoma Barcelona, Vail dHebron Univ Hosp, Dept Psychiat & Legal Med, CIBERSAM, E-08193 Barcelona, Spain. RP Sher, L (reprint author), Icahn Sch Med Mt Sinai, James J Peters Vet Adm, Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM DrLeoSher@gmail.com NR 3 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 EI 1440-1614 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD JUN PY 2014 VL 48 IS 6 BP 589 EP 589 DI 10.1177/0004867413517761 PG 1 WC Psychiatry SC Psychiatry GA AJ4RE UT WOS:000337662700020 PM 24366856 ER PT J AU Courtis, AM Santos, SA Guan, YH Hendricks, JA Ghosh, B Szantai-Kis, DM Reis, SA Shah, JV Mazitschek, R AF Courtis, Alexandra M. Santos, Sofia A. Guan, Yinghua Hendricks, J. Adam Ghosh, Balaram Szantai-Kis, D. Miklos Reis, Surya A. Shah, Jagesh V. Mazitschek, Ralph TI Monoalkoxy BODIPYs-A Fluorophore Class for Bioimaging SO BIOCONJUGATE CHEMISTRY LA English DT Article ID FLUORESCENT-PROBES; DIFLUORIDE BODIPY; LIVE CELLS; DYES; BIOLOGY; DERIVATIVES; CYCLOADDITIONS; MICROSCOPY; CHEMISTRY; SYSTEMS AB Small molecule fluorophores are indispensable tools for modern biomedical imaging techniques. In this report, we present the development of a new class of BODIPY dyes based on an alkoxy-fluoro-boron-dipyrromethene core. These novel fluorescent dyes, which we term MayaFluors, are characterized by good aqueous solubility and favorable in vitro physicochemical properties. MayaFluors are readily accessible in good yields in a one-pot, two-step approach starting from well-established BODIPY dyes, and allow for facile modification with functional groups of relevance to bioconjugate chemistry and bioorthogonal labeling. Biological profiling in living cells demonstrates excellent membrane permeability, low nonspecific binding, and lack of cytotoxicity. C1 [Courtis, Alexandra M.; Santos, Sofia A.; Hendricks, J. Adam; Ghosh, Balaram; Szantai-Kis, D. Miklos; Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Santos, Sofia A.; Ghosh, Balaram; Reis, Surya A.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Santos, Sofia A.] Univ Lisbon, Fac Farm, Inst Invest Med iMed ULisboa, P-1640003 Lisbon, Portugal. [Guan, Yinghua; Shah, Jagesh V.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. [Guan, Yinghua; Shah, Jagesh V.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Mazitschek, Ralph] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA. RP Mazitschek, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St, Boston, MA 02114 USA. EM rmazitschek@mgh.harvard.edu RI iMed.ULisboa, iMed.ULisboa/C-6292-2014; iMed.ULisboa, MedChem /B-4834-2014; OI Szantai-Kis, D. Miklos/0000-0001-5958-5478 FU NCI [P50CA086355, T32-CA079443]; Fundacao para a Ciencia e a Tecnologia [SFRH/BD/80162/2011] FX Financial support from the NCI (P50CA086355, T32-CA079443) and Fundacao para a Ciencia e a Tecnologia (SFRH/BD/80162/2011) is gratefully acknowledged. We thank Drs. R. Weissleder and S. Haggarty for support and J. Carlson for helpful discussions. NR 35 TC 16 Z9 16 U1 5 U2 36 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD JUN PY 2014 VL 25 IS 6 BP 1043 EP 1051 DI 10.1021/bc400575w PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA AJ5KB UT WOS:000337720000004 PM 24797834 ER PT J AU Sprachman, MM Laughney, AM Kohler, RH Weissleder, R AF Sprachman, Melissa M. Laughney, Ashley M. Kohler, Rainer H. Weissleder, Ralph TI In Vivo Imaging of Multidrug Resistance Using a Third Generation MDR1 Inhibitor SO BIOCONJUGATE CHEMISTRY LA English DT Article ID P-GLYCOPROTEIN; CLINICAL-RELEVANCE; ANTICANCER DRUGS; CANCER; MODULATORS; ABCB1; MECHANISMS; TARIQUIDAR; SUBSTRATE; TRANSPORT AB Cellular up-regulation of multidrug resistance protein 1 (MDR1) is a common cause for resistance to chemotherapy; development of third generation MDR1 inhibitors several of which contain a common 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline substructure-is underway. Efficacy of these agents has been difficult to ascertain, partly due to a lack of pharmacokinetic reporters for quantifying inhibitor localization and transport dynamics. Some of the recent third generation inhibitors have a pendant heterocycle, for example, a chromone moiety, which we hypothesized could be converted to a fluorophore. Following synthesis and teasing of a small set of analogues, we identified one lead compound that can be used as a cellular imaging agent that exhibits structural similarity and behavior akin to the latest generation of MDR1 inhibitors. C1 [Sprachman, Melissa M.; Laughney, Ashley M.; Kohler, Rainer H.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA. EM rweissleder@mgh.harvard.edu FU NIH [T32-CA079443] FX M.M.S. and A.M.L. were supported by a NIH grant T32-CA079443. We are grateful to Dr. Sarit Agasti for helpful discussions and the kind gift of 6-chloro-7-hydroxycoumarin-3-carboxylic acid; Dr. Ralph Mazitschek for computational modeling of the tariquidar and HM30181 structure overlays; and Dr. Jonathan Carlson, Dr. Labros Meimitis, and Dr. Eunha Kim for many helpful discussions. NR 33 TC 5 Z9 5 U1 1 U2 26 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD JUN PY 2014 VL 25 IS 6 BP 1137 EP 1142 DI 10.1021/bc500154c PG 6 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA AJ5KB UT WOS:000337720000013 PM 24806886 ER PT J AU Hurdle, V Ouellet, JF Dixon, E Howard, TJ Lillemoe, KD Vollmer, CM Sutherland, FR Ball, CG AF Hurdle, Valerie Ouellet, Jean-Francois Dixon, Elijah Howard, Thomas J. Lillemoe, Keith D. Vollmer, Charles M. Sutherland, Francis R. Ball, Chad G. TI Does regional variation impact decision-making in the management and palliation of pancreatic head adenocarcinoma? Results from an international survey SO CANADIAN JOURNAL OF SURGERY LA English DT Article ID OF-LIFE DECISIONS; INTENSIVE-CARE UNITS; SUSTAINING TREATMENTS; CRITICALLY-ILL; FAMILY-MEMBERS; END; PHYSICIANS; STATES; MORTALITY; ATTITUDES AB Background: Management and palliation of pancreatic head adenocarcinoma is challenging. End-of-life decision-making is a variable process involving multiple factors. Methods: We conducted a qualitative, physician-based, 40-question international survey characterizing the impact of medical, religious, social, training and system factors on care. Results: A total of 258 international clinicians completed the survey. Respondents were typically fellowship-trained (78%), with a mean of 16 years' experience in a university-affiliated (93%) hepato-pancreato-biliary group (96%) practice. Most (91%) believed resection is potentially curative. Most patients were discussed preoperatively by multi-disciplinary teams (94%) and medical assessment clinics (68%), but rarely critical care (21%). Intraoperative surgical palliation included double bypass or no intervention for locally advanced nonresectable tumours (41% and 49% v. 14% and 85%, respectively, for patients with hepatic metastases). Postoperative admission to the intensive care unit was frequent (58%). Severe postoperative complications were often treated with aggressive cardiopulmonary resuscitation, intubation and critical care (96%), with no defined time points for futility (74%). Admitting surgeons guided most end-of-life decisions (97%). Formal medical futility laws were rarely available (26%). Insurance status did not alter treatment (97%) or palliation (95%) in non-universal care regions. Clinician ex perience, regional culture and training background impacted treatment (all p < 0.05). Conclusion: Despite remarkable overall agreement, geographic and training differences are evident in the treatment and palliation of pancreatic head adenocarcinoma. C1 [Hurdle, Valerie; Dixon, Elijah; Sutherland, Francis R.; Ball, Chad G.] Univ Calgary, Dept Surg, Calgary, AB, Canada. [Ouellet, Jean-Francois] Univ Laval, Dept Surg, Quebec City, PQ, Canada. [Howard, Thomas J.] Community Hlth Network, Dept Surg, Indianapolis, IN USA. [Lillemoe, Keith D.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA. [Vollmer, Charles M.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA. RP Ball, CG (reprint author), Foothills Med Ctr, Dept Surg, 1403-29 St NW, Calgary, AB T2N 2T9, Canada. EM ball.chad@gmail.com NR 45 TC 0 Z9 0 U1 3 U2 5 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 0008-428X EI 1488-2310 J9 CAN J SURG JI Can. J. Surg. PD JUN PY 2014 VL 57 IS 3 BP E69 EP E74 DI 10.1503/cjs.011213 PG 6 WC Surgery SC Surgery GA AJ5SU UT WOS:000337748900003 PM 24869619 ER PT J AU Pitman, MB Layfield, LJ AF Pitman, Martha B. Layfield, Lester J. TI Guidelines for Pancreaticobiliary Cytology from the Papanicolaou Society of Cytopathology: A Review SO CANCER CYTOPATHOLOGY LA English DT Review DE pancreas; guidelines; Papanicolaou Society of Cytopathology; review ID FINE-NEEDLE-ASPIRATION; BILE-DUCT STRICTURES; PAPILLARY MUCINOUS NEOPLASMS; IN-SITU HYBRIDIZATION; PRIMARY SCLEROSING CHOLANGITIS; ACINAR CELL-CARCINOMA; ENDOSCOPIC ULTRASOUND; OF-CYTOPATHOLOGY; DIAGNOSTIC-ACCURACY; BILIARY STRICTURES AB The newest installment on state-of-the-art standards of practice in cytopathology from the Papanicolaou Society of Cytopathology (PSC) focuses on the pancreaticobiliary system. Similar to the National Cancer Institute recommendations for aspiration cytology of the thyroid, the PSC guidelines for pancreaticobiliary cytology addresses indications, techniques, terminology and nomenclature, ancillary studies, and postprocedure management. Each committee was composed of a multidisciplinary group of experts in diagnosing, managing, and treating patients with pancreaticobiliary disease. Draft documents were posted on an interactive Web-based forum hosted by the PSC Web site (www.papsociety.org) and the topics of terminology, ancillary testing, and management were presented at national and international meetings over an 18-month period for discussion and feedback from practicing pathologists around the world. This review provides a synopsis of these guidelines. (C) 2014 American Cancer Society. C1 [Pitman, Martha B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 01907 USA. [Layfield, Lester J.] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO USA. RP Pitman, MB (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 01907 USA. EM mpitman@partners.org NR 105 TC 14 Z9 16 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1934-662X EI 1934-6638 J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD JUN PY 2014 VL 122 IS 6 BP 399 EP 411 DI 10.1002/cncy.21427 PG 13 WC Oncology; Pathology SC Oncology; Pathology GA AJ4CR UT WOS:000337618400003 PM 24777782 ER PT J AU Wu, RI Yoon, WJ Brugge, WR Mino-Kenudson, M Pitman, MB AF Wu, Roseann I. Yoon, Won Jae Brugge, William R. Mino-Kenudson, Mari Pitman, Martha B. TI Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Contributes to a Triple-Negative Test in Preoperative Screening of Pancreatic Cysts SO CANCER CYTOPATHOLOGY LA English DT Article DE endoscopic ultrasound-guided fine-needle aspiration; pancreatic cyst; pancreatic neoplasms; cytopathology; carcinoembryonic antigen ID PAPILLARY MUCINOUS NEOPLASMS; INTERNATIONAL CONSENSUS GUIDELINES; LESS-THAN-OR-EQUAL-TO-3 CM; RISK-ASSESSMENT; FLUID ANALYSIS; ADDS VALUE; CYTOLOGY; MALIGNANCY; DIAGNOSIS; TUMORS AB BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of pancreatic cysts obtains cyst fluid for cytologic and biochemical analysis, which may determine whether the cyst is mucinous and malignant, contributing to patient management. Despite this added value, EUS-FNA remains controversial in the preoperative assessment of pancreatic cysts. The objective of this study was to assess the utility of EUS-FNA in a cohort of small pancreatic cysts that were benign on imaging studies. METHODS: All pancreatic cysts that underwent initial EUS-FNA in 2006 and 2007 were retrospectively analyzed. Ninety-two patients with pancreatic cysts met the inclusion criteria. Patients who had high-risk or worrisome features on imaging studies were excluded. Cytology, histology, and cyst fluid analysis data were collected. The main outcome measurements were radiologic and clinical follow-up as well as cytopathologic and histologic results. RESULTS: EUS-FNA supported a diagnosis of a mucinous cyst in 38 of 92 patients (41%) by carcinoembryonic antigen (CEA) measurement and/or cytology. Cytology demonstrated an absence of high-grade atypia (HGA) in 89 of 92 patients (97%). The mean follow-up was 4.4 years (range, 0-7.7 years), during which 6 cysts were surgically resected and 16 cysts were resampled by at least 1 subsequent EUS-FNA. The overall negative predictive value of cytologic examination for HGA was 99%. CONCLUSIONS: EUS-FNA is a screening test that contributes to a triple-negative test for pancreatic cysts-no high-risk stigmata, no worrisome features, and no HGA on cytology-providing a negative predictive value of 99% for conservative management. (C) 2013 American Cancer Society. C1 [Wu, Roseann I.; Mino-Kenudson, Mari; Pitman, Martha B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Yoon, Won Jae; Brugge, William R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Yoon, Won Jae] Inje Univ, Coll Med, Seoul Paik Hosp, Dept Internal Med, Seoul, South Korea. RP Pitman, MB (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 105,55 Fruit St, Boston, MA 02114 USA. EM mpitman@partners.org FU RedPath; Asuragen FX William R. Brugge is currently receiving research grants from RedPath and Asuragen. NR 38 TC 6 Z9 7 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1934-662X EI 1934-6638 J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD JUN PY 2014 VL 122 IS 6 BP 412 EP 419 DI 10.1002/cncy.21385 PG 8 WC Oncology; Pathology SC Oncology; Pathology GA AJ4CR UT WOS:000337618400004 PM 24327575 ER PT J AU Morales-Oyarvide, V Yoon, WJ Ingkakul, T Forcione, DG Casey, BW Brugge, WR Fernandez-del Castillo, C Pitman, MB AF Morales-Oyarvide, Vicente Yoon, Won Jae Ingkakul, Thun Forcione, David G. Casey, Brenna W. Brugge, William R. Fernandez-del Castillo, Carlos Pitman, Martha B. TI Cystic Pancreatic Neuroendocrine Tumors SO CANCER CYTOPATHOLOGY LA English DT Article DE pancreatic cyst; pancreatic endocrine tumor; endoscopic ultrasound-guided fine-needle aspiration; cytology ID FINE-NEEDLE-ASPIRATION; PAPILLARY MUCINOUS NEOPLASMS; ENDOSCOPIC ULTRASOUND; PREOPERATIVE DIAGNOSIS; ENDOCRINE TUMORS; MULTIMODAL APPROACH; MOLECULAR ANALYSIS; EPITHELIAL ATYPIA; FLUID ANALYSIS; FEATURES AB BACKGROUND: Cystic pancreatic neuroendocrine tumors (cPanNETs) account for 13% to 17% of PanNETs. Although the value of endoscopic ultrasound (EUS) imaging and cyst fluid analysis (CFA) in their preoperative diagnosis has been well described, limited information is available about the diagnostic role of cytology samples obtained from fine-needle aspiration (FNA). METHODS: Cytopathology records between 1992 and 2013 were searched for all reports of cysts interpreted as PanNET. Patient demographics, clinical and radiologic information, CFA, histopathology, and cytopathology findings were recorded. Performance characteristics of cytology and EUS for the accurate diagnosis of cPanNET were calculated. RESULTS: In total, 35 FNAs from 33 patients with cPanNETs were identified, and 34 EUS were performed. Cytology made a specific diagnosis of a cPanNET in 71% of the biopsies compared with a specific diagnosis by EUS in 38% of cases. An interpretation of suspicious for cPanNET was given in 77% of cases by cytology and in 47% by EUS. Cytology identified 86% of the lesions as high-risk pancreatic cysts compared with 56% by EUS. Diagnostic morphology was present on both cytology and cell block preparations in 60% of aspirates, on cytology only in 20%, and on cell block only in 20%. CFA was performed on 51% cyst fluids. All cysts but 1 revealed low carcinoembryonic antigen levels (range, 0.2 to >500 ng/mL; mean, 29.5 ng/mL), and amylase levels were <500 U/L in all but 2 cases (range, 16-1493 U/L; mean, 205 U/L). CONCLUSIONS: Cytology is the most accurate test for preoperative diagnosis of cPanNETs. EUS is insufficiently accurate for independent diagnosis, and carcinoembryonic antigen and amylase analyses are noncontributory. (C) 2014 American Cancer Society. C1 [Morales-Oyarvide, Vicente; Ingkakul, Thun; Fernandez-del Castillo, Carlos] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Yoon, Won Jae] Inje Univ, Coll Med, Seoul Paik Hosp, Dept Internal Med, Seoul, South Korea. [Forcione, David G.; Casey, Brenna W.; Brugge, William R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Gastroenterol Unit, Boston, MA 02114 USA. [Pitman, Martha B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Pitman, MB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 55 Fruit St,Warren 105, Boston, MA 02114 USA. EM mpitman@partners.org NR 39 TC 13 Z9 13 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1934-662X EI 1934-6638 J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD JUN PY 2014 VL 122 IS 6 BP 435 EP 444 DI 10.1002/cncy.21403 PG 10 WC Oncology; Pathology SC Oncology; Pathology GA AJ4CR UT WOS:000337618400007 PM 24591417 ER PT J AU Miller, MA Askevold, B Yang, KS Kohler, RH Weissleder, R AF Miller, Miles A. Askevold, Bjorn Yang, Katherine S. Kohler, Rainer H. Weissleder, Ralph TI Platinum Compounds for High-Resolution In Vivo Cancer Imaging SO CHEMMEDCHEM LA English DT Article DE DNA damage; fluorescent probes; intravital imaging agents; pharmacokinetics; pharmacology ID SINGLE-CELL; FLUORESCENCE MICROSCOPY; ANTICANCER DRUGS; LABELED PLATINUM; CISPLATIN; COMPLEXES; PHARMACOKINETICS; CHEMOTHERAPY; CARBOPLATIN; RESISTANCE AB Platinum(II) compounds, principally cisplatin and carboplatin, are commonly used front-line cancer therapeutics. Despite their widespread use and continued interest in the development of new derivatives, including nanoformulations with improved properties, it has been difficult to visualize platinum compounds in live subjects, in real time, and with subcellular resolution. Here, we present four novel cisplatin- and carboplatin-derived fluorescent imaging compounds for quantitative intravital cancer imaging. We conjugated 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-daiza-s-indacene (BODIPY) to PtII complexes to generate derivatives with robust in vivo fluorescence and retained DNA-damaging and cytotoxic properties. We successfully applied these compounds to image pharmacokinetics and tumor uptake in a xenograft cancer mouse model. By using a genetic reporter of single-cell DNA damage for in vivo imaging, Pt drug accumulation and resultant DNA damage could be monitored in individual tumor cells, at subcellular resolution, and in real time in a live animal model of cancer. These derivatives represent promising imaging tools that will be useful in understanding further the distribution and interactions of platinum within tumors. C1 [Miller, Miles A.; Askevold, Bjorn; Yang, Katherine S.; Kohler, Rainer H.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. RP Miller, MA (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St, Boston, MA 02114 USA. EM rweissleder@mgh.harvard.edu FU US National Institutes of Health (NIH) [U54-CA151884]; German National Academy of Sciences Leopoldina FX Part of this work was supported by the US National Institutes of Health (NIH) (U54-CA151884) and a fellowship to B.A. from the German National Academy of Sciences Leopoldina. The authors thank Alex Zaltsman, Matthew Sebas, and Olivier Kister for technical assistance, and Drs. Lippard, Farokhzad, and Langer for helpful discussions. NR 37 TC 15 Z9 15 U1 4 U2 37 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY SN 1860-7179 EI 1860-7187 J9 CHEMMEDCHEM JI ChemMedChem PD JUN PY 2014 VL 9 IS 6 SI SI BP 1131 EP 1135 DI 10.1002/cmdc.201300502 PG 5 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AJ2WN UT WOS:000337525300004 PM 24504646 ER PT J AU Wiener, RS Ouellette, DR Diamond, E Fan, VS Maurer, JR Mularski, RA Peters, JI Halpern, SD AF Wiener, Renda Soylemez Ouellette, Daniel R. Diamond, Edward Fan, Vincent S. Maurer, Janet R. Mularski, Richard A. Peters, Jay I. Halpern, Scott D. TI An Official American Thoracic Society/American College of Chest Physicians Policy Statement SO CHEST LA English DT Article ID PULMONARY ARTERIAL-HYPERTENSION; CLINICAL-PRACTICE GUIDELINES; SYSTOLIC HEART-FAILURE; LUNG-CANCER DIAGNOSIS; COMPUTED-TOMOGRAPHY; PATIENT COMMUNICATION; EMERGENCY-DEPARTMENT; EXERCISE CAPACITY; DECISION-ANALYSIS; CONTROLLED-TRIAL AB The American Board of Internal Medicine Foundation's Choosing Wisely campaign aims to curb health-care costs and improve patient care by soliciting lists from medical societies of the top five tests or treatments in their specialty that are used too frequently and inappropriately. The American Thoracic Society (ATS) and American College of Chest Physicians created a joint task force, which produced a top five list for adult pulmonary medicine. Our top five recommendations, which were approved by the executive committees of the ATS and American College of Chest Physicians and published by Choosing Wisely in October 2013, are as follows: (1) Do not perform CT scan surveillance for evaluation of indeterminate pulmonary nodules at more frequent intervals or for a longer period of time than recommended by established guidelines; (2) do not routinely offer pharmacologic treatment with advanced vasoactive agents approved only for the management of pulmonary arterial hypertension to patients with pulmonary hypertension resulting from left heart disease or hypoxemic lung diseases (groups II or III pulmonary hypertension); (3) for patients recently discharged on supplemental home oxygen following hospitalization for an acute illness, do not renew the prescription without assessing the patient for ongoing hypoxemia; (4) do not perform chest CT angiography to evaluate for possible pulmonary embolism in patients with a low clinical probability and negative results of a highly sensitive D-dimer assay; (5) do not perform CT scan screening for lung cancer among patients at low risk for lung cancer. We hope pulmonologists will use these recommendations to stimulate frank discussions with patients about when these tests and treatments are indicated-and when they are not. C1 [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Wiener, Renda Soylemez] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA. [Ouellette, Daniel R.] Henry Ford Hlth Syst, Detroit, MI USA. [Diamond, Edward] Suburban Lung Associates, Elk Grove Village, IL USA. [Fan, Vincent S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fan, Vincent S.] Univ Washington, Dept Med, Seattle, WA USA. [Maurer, Janet R.] Univ Arizona, Coll Med, Dept Med, Phoenix, AZ USA. [Maurer, Janet R.] Magellan Hlth Serv Inc, Natl Imaging Associates, Qual Improvement & Compliance, Phoenix, AZ USA. [Mularski, Richard A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Mularski, Richard A.] Northwest Permanente PC, Dept Pulm Crit Care Med, Portland, OR USA. [Mularski, Richard A.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Peters, Jay I.] UT Hlth Sci Ctr, San Antonio, TX USA. [Peters, Jay I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Halpern, Scott D.] Univ Penn, Dept Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Halpern, Scott D.] Univ Penn, Dept Biostat & Epidemiol, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Halpern, Scott D.] Univ Penn, Dept Med Eth & Hlth Policy, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Halpern, Scott D.] Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. RP Wiener, RS (reprint author), Ctr Pulm, 72 E Concord St,R-304, Boston, MA 02118 USA. EM rwiener@bu.edu OI Wiener, Renda/0000-0001-7712-2135 FU NCI NIH HHS [K07 CA138772] NR 79 TC 13 Z9 14 U1 0 U2 6 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD JUN PY 2014 VL 145 IS 6 BP 1383 EP 1391 DI 10.1378/chest.14-0670 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AJ0OV UT WOS:000337355600032 PM 24889436 ER PT J AU Siev, M Wilson, D Kainth, S Kasprowicz, VO Feintuch, CM Jenny-Avital, ER Achkar, JM AF Siev, Michael Wilson, Douglas Kainth, Supreet Kasprowicz, Victoria O. Feintuch, Catherine M. Jenny-Avital, Elizabeth R. Achkar, Jacqueline M. TI Antibodies against Mycobacterial Proteins as Biomarkers for HIV-Associated Smear-Negative Tuberculosis SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; SUBCLINICAL TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; IMMUNE-RESPONSES; SOUTH-AFRICA; BOVIS BCG; DIAGNOSIS; INCIPIENT; ANTIGENS AB Serology data are limited for patients with sputum smear-negative HIV-associated active tuberculosis (TB). We evaluated the serum antibody responses against the mycobacterial proteins MPT51, MS, and echA1 and the 38-kDa protein via enzyme-linked immunosorbent assay (ELISA) in South African (S.A.) HIV-positive (HIV+) smear-negative TB patients (n = 56), U. S. HIV+ controls with a positive tuberculin skin test (TST+; n = 21), and S. A. HIV-negative (HIV-) (n = 18) and HIV+ (n = 24) controls. TB patients had positive antibody reactivity against MPT51 (73%), echA1 (59%), MS (36%), and the 38-kDa protein (11%). Little reactivity against MPT51 and echA1 was observed in control groups at low risk for TB, i.e., S.A. HIV- (0% and 6%, respectively), and at moderate risk for TB development, i.e., U.S. HIV+ TST+ controls (14% and 10%, respectively). By contrast, more reactivity was detected in the S.A. HIV+ control group at higher risk for TB (25% and 45%, respectively). Our data hold promise that antibody detection against MPT51 and echA1 might have adjunctive value in the detection of HIV+ smear-negative TB and might reflect increasing Mycobacterium tuberculosis infection activity in asymptomatic HIV+ individuals. C1 [Siev, Michael; Kainth, Supreet; Feintuch, Catherine M.; Jenny-Avital, Elizabeth R.; Achkar, Jacqueline M.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Wilson, Douglas] Edendale Hosp, Dept Med, Pietermaritzburg, South Africa. [Kasprowicz, Victoria O.] Massachusetts Gen Hosp, MIT & Harvard, Ragon Inst, Cambridge, MA USA. [Kasprowicz, Victoria O.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Inst TB & HIV, Durban, South Africa. [Kasprowicz, Victoria O.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, Durban, South Africa. RP Achkar, JM (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. EM jacqueline.achkar@einstein.yu.edu FU National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI067665, AI105684]; Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine [AI51519]; Howard Hughes Medical Institute (HHMI) [55006535]; KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) FX This work was supported in part by funds from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID; grants AI067665 and AI105684 to J.M.A.), the Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine (grant AI51519 to J.M.A.), the Howard Hughes Medical Institute (HHMI; seed grant 55006535 to J.M.A.), and the KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) (steering grant to D.W.). NR 57 TC 4 Z9 4 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD JUN PY 2014 VL 21 IS 6 BP 791 EP 798 DI 10.1128/CVI.00805-13 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA AJ0NW UT WOS:000337352500002 PM 24671553 ER PT J AU Zenati, MA Gaziano, JM Collins, JF Biswas, K Gabany, JM Quin, JA Bitondo, JM Bakaeen, FG Kelly, RF Shroyer, AL Bhatt, DL AF Zenati, Marco A. Gaziano, J. Michael Collins, Joseph F. Biswas, Kousick Gabany, Jennifer M. Quin, Jacquelyn A. Bitondo, Jerene M. Bakaeen, Faisal G. Kelly, Rosemary F. Shroyer, A. Laurie Bhatt, Deepak L. TI Choice of Vein-Harvest Technique for Coronary Artery Bypass Grafting: Rationale and Design of the REGROUP Trial SO CLINICAL CARDIOLOGY LA English DT Article ID PROSPECTIVE RANDOMIZED-TRIAL; WOUND COMPLICATIONS; SURGERY; METAANALYSIS; PATENCY; ASSOCIATION; PUMP; REVASCULARIZATION; OUTCOMES; FAILURE AB The Randomized Endo-vein Graft Prospective (REGROUP) trial (ClinicalTrials.gov NCT01850082) is a randomized, intent-to-treat, 2-arm, parallel-design, multicenter study funded by the Cooperative Studies Program (CSP No. 588) of the US Department of Veterans Affairs. Cardiac surgeons at 16 Veterans Affairs (VA) medical centers with technical expertise in performing both endoscopic vein harvesting (EVH) and open vein harvesting (OVH) were recruited as the REGROUP surgeon participants. Subjects requiring elective or urgent coronary artery bypass grafting using cardiopulmonary bypass with use of >= 1 saphenous vein graft will be screened for enrollment using pre-established inclusion/exclusion criteria. Enrolled subjects (planned N=1150) will be randomized to 1 of the 2 arms (EVH or OVH) after an experienced vein harvester has been assigned. The primary outcomes measure is the rate of major adverse cardiac events (MACE), including death, myocardial infarction, or revascularization. Subject assessments will be performed at multiple times, including at baseline, intraoperatively, postoperatively, and at discharge (or 30 days after surgery, if still hospitalized). Assessment of leg-wound complications will be completed at 6 weeks after surgery. Telephone follow-ups will occur at 3-month intervals after surgery until the participating sites are decommissioned after the trial's completion (approximately 4.5 years after the full study startup). To assess long-term outcomes, centralized follow-up of MACE for 2 additional years will be centrally performed using VA and non-VA clinical and administrative databases. The primary MACE outcome will be compared between the 2 arms, EVH and OVH, at the end of the trial duration. C1 [Zenati, Marco A.; Gabany, Jennifer M.; Quin, Jacquelyn A.] Vet Affairs Boston Healthcare Syst, Div Cardiothorac Surg, Boston, MA USA. [Zenati, Marco A.; Gabany, Jennifer M.; Quin, Jacquelyn A.] Vet Affairs Boston Healthcare Syst, Surg Serv, Boston, MA USA. [Zenati, Marco A.; Gabany, Jennifer M.; Quin, Jacquelyn A.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Gaziano, J. Michael] MAVERIC, Boston, MA USA. [Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Boston, MA USA. [Gaziano, J. Michael] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Collins, Joseph F.; Biswas, Kousick] Vet Affairs Cooperat Studies Program Coordinating, Perry Point, MD USA. [Bitondo, Jerene M.] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA. [Bakaeen, Faisal G.] Michael E DeBakey VA Med Ctr, Div Cardiac Surg, Houston, TX USA. [Bakaeen, Faisal G.] Baylor Coll Med, Houston, TX 77030 USA. [Kelly, Rosemary F.] Minneapolis Vet Affairs Med Ctr, Div Cardiac Surg, Minneapolis, MN USA. [Kelly, Rosemary F.] Univ Minnesota, Minneapolis, MN USA. [Shroyer, A. Laurie] Northport Vet Affairs Med Ctr, Northport, NY USA. [Shroyer, A. Laurie] SUNY Stony Brook, Sch Med, Dept Surg, Stony Brook, NY 11794 USA. [Bhatt, Deepak L.] Vet Affairs Boston Healthcare Syst, Div Cardiol, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Heart & Vasc Ctr, Boston, MA 02115 USA. RP Zenati, MA (reprint author), Vet Affairs Boston Healthcare Syst, Dept Cardiothorac Surg, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM marco_zenati@hms.harvard.edu RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 FU Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Medtronic; Sanofi-Aventis; Medicines Company FX Dr. Deepak L. Bhatt has served on advisory boards for Elsevier PracticeUpdate Cardiology, Medscape Cardiology, and Regado Biosciences; has served on the board of directors for the Boston VA Research Institute and Society of Cardiovascular Patient Care; has chaired the American Heart Association Get With The Guidelines Steering Committee; has received honoraria from the American College of Cardiology (editor, Clinical Trials, CardioSource), Belvoir Publications (editor-in-chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Population Health Research Institute (clinical trial steering committee), Slack Publications (chief medical editor, Cardiology Today's Intervention), and WebMD (CME steering committees); served as senior associate editor and is now editor-in-chief for the Journal of Invasive Cardiology; has served on data-monitoring committees for Duke Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; has received research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi-Aventis, and The Medicines Company; and has conducted unfunded research for FlowCo, PLx Pharma, and Takeda. NR 35 TC 4 Z9 4 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-9289 EI 1932-8737 J9 CLIN CARDIOL JI Clin. Cardiol. PD JUN PY 2014 VL 37 IS 6 BP 325 EP 330 DI 10.1002/clc.22267 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AJ3WF UT WOS:000337597900001 PM 24633760 ER PT J AU Rhee, JW Wiviott, SD Scirica, BM Gibson, CM Murphy, SA Bonaca, MP Morrow, DA Mega, JL AF Rhee, June-Wha Wiviott, Stephen D. Scirica, Benjamin M. Gibson, C. Michael Murphy, Sabina A. Bonaca, Marc P. Morrow, David A. Mega, Jessica L. TI Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non-ST-Elevation Acute Coronary Syndrome SO CLINICAL CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CHRONIC RENAL-INSUFFICIENCY; UNITED-STATES; CREATININE CLEARANCE; ARTERY-DISEASE; TERM OUTCOMES; RISK-FACTORS; DATA-SYSTEM; DYSFUNCTION; DIALYSIS AB Background: Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular events following acute coronary syndrome (ACS). The underlying pathobiology and optimal treatments for this population continue to be evaluated. Hypothesis: Patients with CKD will receive fewer evidence-based therapies and experience high rates of adverse cardiovascular events in both the short-and long term. Methods: The MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36) trial randomized non-ST-elevation ACS patients to ranolazine or placebo, with no exclusion for renal dysfunction (except dialysis). We conducted a prespecified analysis among 6543 patients based on the degree of CKD. Results: Patients with worse renal function were older with more comorbidities (P < 0.0001 for each). They were less likely to receive evidence-based cardiovascular medicines (P < 0.04 for each). Rates of an early invasive management strategy varied based on renal function; however, among patients with the highest TIMI risk scores, the rates of an early invasive management strategy were similar regardless of glomerular filtration rate (GFR) (P-interaction = 0.005). Lower GFR was associated with increased rates of cardiovascular disease or myocardial infarction in the short and long term, even after adjustment (GFR < 30 vs >= 90 mL/min/1.73 m(2); hazard ratio [HR]: 3.24 [95% confidence interval [CI]: 1.26-8.38] through 7 days and HR: 2.12 [95% CI: 1.33-3.39]through 1 year). The effect of ranolazine vs placebo on clinical outcomes was similar among those with and without CKD (P-interaction = not significant). Conclusions: Following ACS, patients with renal dysfunction had more cardiovascular risk factors but were less likely to receive evidence-based medical therapies. A strong graded, independent relationship between the degree of CKD and poor clinical outcomes was observed over time. Continued efforts to optimize ACS treatment strategies in patients with CKD are warranted. C1 [Rhee, June-Wha] Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA. [Wiviott, Stephen D.; Scirica, Benjamin M.; Gibson, C. Michael; Murphy, Sabina A.; Bonaca, Marc P.; Morrow, David A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, Boston, MA 02115 USA. [Gibson, C. Michael] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02215 USA. RP Mega, JL (reprint author), Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA. EM jmega@partners.org FU Gilead; Abbott; Amgen; AstraZeneca; Athera; Beckman Coulter; BG Medicine; Bristol-Myers Squibb; Buhlmann Laboratories; Daiichi Sankyo; Eli Lilly Co.; Eisai; Glaxo Smith Kline; Johnson Johnson; Merck; Nanosphere; Novartis Pharmaceuticals; Ortho-Clinical Diagnostics; Pfizer; Randox; Roche Diagnostics; sanofi-aventis; Singulex; Merck/Schering-Plough; Arena Pharmaceuticals; Bayer Healthcare; Novartis; GlaxoSmithKline; Lexicon; Arena; St. Jude Medical; Boston Clinical Research Institute; Decision Resources; University of Calgary; Elsevier Practice Update Cardiology; Angel Medical Corp.; Atrium Medical System; Bayer Corp.; Ikaria, Inc.; Janssen Pharmaceuticals; Lantheus Medical Imaging; Portola Pharmaceuticals; Volcano Corp.; Walk Vascular; Atrium Medical Systems; Baxter Healthcare; Bristol Myers; Cardiovascular Research Foundation; Consensus Medical Communications; CSL Behring; Cytori Therapeutics; Daiichi Sankyo, Inc.; Eli Lily Co.; Exeter Group; Genentech, Inc.; Medicines Company; Critical Diagnostics; Genentech; Instrumentation Laboratory; Konica/Minolta; Servier; Bristol-Myers Squibb/sanofi-aventis; Boehringer Ingelheim FX The MERLIN-TIMI 36 trial was funded by Gilead. The TIMI Study Group has received significant research grant support from Abbott, Amgen, AstraZeneca, Athera, Beckman Coulter, BG Medicine, Bristol-Myers Squibb, Buhlmann Laboratories, Daiichi Sankyo, Eli Lilly & Co., Eisai, Glaxo Smith Kline, Johnson & Johnson, Merck, Nanosphere, Novartis Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Randox, Roche Diagnostics, sanofi-aventis, and Singulex.; Dr. Rhee reports no disclosures. Dr. Wiviott reports research grant support from Johnson & Johnson, Eli Lilly & Co., Daiichi Sankyo, and Merck/Schering-Plough. Dr. Wiviott has received consulting fees from Arena Pharmaceuticals, Bayer Healthcare, Bristol-Myers Squibb, and AstraZeneca. Dr. Wiviott has received continuing medical education speaking fees from Eli Lilly & Co., Daiichi Sankyo, AstraZeneca, Novartis, and Merck/Schering-Plough. Dr. Scirica reports research grant support from AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Johnson & Johnson, Bayer Healthcare, Gilead, Eisai, and Merck. Dr. Scirica has received consulting fees from Gilead, Lexicon, Arena, Eisai, St. Jude Medical, Boston Clinical Research Institute, Decision Resources, University of Calgary, and Elsevier Practice Update Cardiology. Dr. Gibson reports research grant support from Angel Medical Corp., Atrium Medical System, Bayer Corp., Ikaria, Inc., Janssen Pharmaceuticals, Johnson & Johnson, Lantheus Medical Imaging, Merck, Portola Pharmaceuticals, Roche Diagnostics, sanofi-aventis, St. Jude Medical, Volcano Corp., and Walk Vascular. Dr. Gibson has received consulting fees from AstraZeneca, Atrium Medical Systems, Baxter Healthcare, Bristol Myers, Cardiovascular Research Foundation, Consensus Medical Communications, CSL Behring, Cytori Therapeutics, Daiichi Sankyo, Inc., Eli Lily & Co., Exeter Group, Genentech, Inc., GlaxoSmithKline, St. Jude Medical, and The Medicines Company. Ms. Murphy does not report any additional disclosures apart from the TIMI Study Group. Dr. Bonaca has received consulting fees from Roche diagnostics. Dr. Morrow has received consulting fees from BG Medicine, Critical Diagnostics, Eli Lilly & Co., Genentech, Gilead, Instrumentation Laboratory, Johnson & Johnson, Konica/Minolta, Merck, Novartis, Roche Diagnostics, and Servier. Dr. Mega reports research grant support from Johnson & Johnson, Bayer Healthcare, Bristol-Myers Squibb/sanofi-aventis, Daiichi Sankyo, Inc., AstraZeneca, and Eli Lilly & Co. Dr. Mega has received consulting fees from Boehringer Ingelheim and Janssen Pharmaceuticals. NR 30 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-9289 EI 1932-8737 J9 CLIN CARDIOL JI Clin. Cardiol. PD JUN PY 2014 VL 37 IS 6 BP 350 EP 356 DI 10.1002/clc.22253 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AJ3WF UT WOS:000337597900005 PM 24481910 ER PT J AU Fan, VS Meek, PM AF Fan, Vincent S. Meek, Paula M. TI Anxiety, Depression, and Cognitive Impairment in Patients with Chronic Respiratory Disease SO CLINICS IN CHEST MEDICINE LA English DT Article DE Anxiety; Depression; Cognitive impairment; Chronic respiratory disease ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; STATE WORRY QUESTIONNAIRE; WORKING-MEMORY; COPD PATIENTS; PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; REHABILITATION PROGRAM; ARTERIAL-HYPERTENSION AB In this article, the prevalence of depression, anxiety, and cognitive impairment in persons with chronic obstructive pulmonary disease, and the impact of these psychological and cognitive factors on clinical outcomes in COPD is reviewed. Methods for screening and identification of these conditions in COPD are described. The extent to which depression, anxiety or cognitive impairment limit or modify the effectiveness of pulmonary rehabilitation, and whether pulmonary rehabilitation may ameliorate these psychological and cognitive impairments are discussed. C1 [Fan, Vincent S.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA. [Meek, Paula M.] Univ Colorado, Coll Nursing, Boulder, CO 80309 USA. RP Fan, VS (reprint author), Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA. EM Vincent.fan@va.gov NR 85 TC 5 Z9 5 U1 2 U2 23 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-5231 EI 1557-8216 J9 CLIN CHEST MED JI Clin. Chest Med. PD JUN PY 2014 VL 35 IS 2 BP 399 EP + DI 10.1016/j.ccm.2014.02.012 PG 12 WC Respiratory System SC Respiratory System GA AJ5ZL UT WOS:000337769400013 PM 24874134 ER PT J AU Bangash, HK Ibrahimi, OA Green, LJ Alam, M Eisen, DB Armstrong, AW AF Bangash, Haider K. Ibrahimi, Omar A. Green, Lawrence J. Alam, Murad Eisen, Daniel B. Armstrong, April W. TI Who Do You Prefer? A Study of Public Preferences for Health Care Provider Type in Performing Cutaneous Surgery and Cosmetic Procedures in the United States SO DERMATOLOGIC SURGERY LA English DT Article ID DERMATOLOGICAL SURGERY; LIPOSUCTION; PHOTOTHERMOLYSIS; SPECIALTIES; PERSPECTIVE; PERCEPTION AB BACKGROUND The public preference for provider type in performing cutaneous surgery and cosmetic procedures is unknown in the United States. METHODS An internet-based survey was administered to the lay public. Respondents were asked to select the health care provider (dermatologist, plastic surgeon, primary care physician, general surgeon, and nurse practitioner/physician's assistant) they mostly prefer to perform different cutaneous cosmetic and surgical procedures. RESULTS Three hundred fifty-four respondents undertook the survey. Dermatologists were identified as the most preferable health care provider to evaluate and biopsy worrisome lesions on the face (69.8%), perform skin cancer surgery on the back (73.4%), perform skin cancer surgery on the face (62.7%), and perform laser procedures (56.3%) by most of the respondents. For filler injections, the responders similarly identified plastic surgeons and dermatologists (47.3% vs 44.6%, respectively) as the most preferred health care provider. For botulinum toxin injections, there was a slight preference for plastic surgeons followed by dermatologists (50.6% vs 38.4%). Plastic surgeons were the preferred health care provider for procedures such as liposuction (74.4%) and face-lift surgery (96.1%) by most of the respondents. CONCLUSION Dermatologists are recognized as the preferred health care providers over plastic surgeons, primary care physicians, general surgeons, and nurse practitioners/physician's assistants to perform a variety of cutaneous cosmetic and surgical procedures including skin cancer surgery, on the face and body, and laser procedures. The general public expressed similar preferences for dermatologists and plastic surgeons regarding filler injections. C1 [Bangash, Haider K.] Univ Connecticut, Ctr Hlth, Dept Internal Med, Farmington, CT USA. [Ibrahimi, Omar A.] Connecticut Skin Inst, Stamford, CT 06032 USA. [Ibrahimi, Omar A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. [Green, Lawrence J.] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA. [Alam, Murad] Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA. [Eisen, Daniel B.; Armstrong, April W.] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA. RP Ibrahimi, OA (reprint author), Connecticut Skin Inst, 999 Summer St,Suite 205, Stamford, CT 06032 USA. EM omar.ibrahimi@gmail.com OI Eisen, Daniel/0000-0001-6741-3182 NR 27 TC 10 Z9 10 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1076-0512 EI 1524-4725 J9 DERMATOL SURG JI Dermatol. Surg. PD JUN PY 2014 VL 40 IS 6 BP 671 EP 678 DI 10.1111/dsu.0000000000000016 PG 8 WC Dermatology; Surgery SC Dermatology; Surgery GA AJ5FP UT WOS:000337708400010 PM 24852472 ER PT J AU Tripathy, D Clement, SC Schwenke, DC Banerji, M Bray, GA Buchanan, TA Gastaldelli, A Henry, RR Kitabchi, AE Mudaliar, S Ratner, RE Stentz, FB Musi, N Reaven, PD DeFronzo, RA AF Tripathy, Devjit Clement, Stephen C. Schwenke, Dawn C. Banerji, MaryAnn Bray, George A. Buchanan, Thomas A. Gastaldelli, Amalia Henry, Robert R. Kitabchi, Abbas E. Mudaliar, Sunder Ratner, Robert E. Stentz, Frankie B. Musi, Nicolas Reaven, Peter D. DeFronzo, Ralph A. TI Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW SO DIABETES CARE LA English DT Article ID TYPE-2 DIABETES-MELLITUS; ACTIVATED PROTEIN-KINASE; PPAR-GAMMA AGONISTS; INSULIN SENSITIVITY; GLUCOSE; RESISTANCE; EXPRESSION; PREVENTION; OXIDATION; INDEX AB OBJECTIVE Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states. We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (Si) and glucose tolerance status. RESEARCH DESIGN AND METHODS A total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years. RESULTS Pioglitazone reduced IGT conversion to diabetes by 72% in association with improved n-cell function by 64% (insulin secretion/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin concentration increased threefold from 13 +/- 0.5 to 38 +/- 2.5 mu g/mL (P < 0.001) and was strongly correlated with the improvement in SI (r = 0.436, P < 0.001) and modestly correlated with glucose area under the curve during oral glucose tolerance test (r = 0.238, P < 0.005) and insulin secretion/insulin resistance index (r = 0.306, P < 0.005). The increase in adiponectin was a strong predictor of reversion to normal glucose tolerance and prevention of T2DM. In the placebo group, plasma adiponectin did not change and was not correlated with changes in glucose levels. There was an inverse association between baseline plasma adiponectin concentration and progression to diabetes in the placebo group but not in the pioglitazone group. CONCLUSIONS Baseline adiponectin does not predict the response to pioglitazone. The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin. C1 [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] Texas Diabet Inst, San Antonio, TX 78207 USA. [Tripathy, Devjit; Gastaldelli, Amalia; Musi, Nicolas; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] South Texas VA Hlth Care Syst, Audie L Murphy Hosp, San Antonio, TX USA. [Clement, Stephen C.] Georgetown Univ, Div Endocrinol & Metab, Washington, DC USA. [Schwenke, Dawn C.; Reaven, Peter D.] Phoenix VA Hlth Care Syst, Phoenix, AZ USA. [Schwenke, Dawn C.] Arizona State Univ, Coll Nursing & Hlth Innovat, Phoenix, AZ USA. [Banerji, MaryAnn] SUNY Hlth Sci Ctr, Brooklyn, NY USA. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA. [Buchanan, Thomas A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Gastaldelli, Amalia] CNR, Inst Clin Physiol, Cardiometab Risk Unit, I-56100 Pisa, Italy. [Henry, Robert R.; Mudaliar, Sunder] VA San Diego Healthcare Syst, San Diego, CA USA. [Henry, Robert R.; Mudaliar, Sunder] Univ Calif San Diego, San Diego, CA 92103 USA. [Kitabchi, Abbas E.; Stentz, Frankie B.] Univ Tennessee, Div Endocrinol Diabet & Metab, Memphis, TN USA. [Ratner, Robert E.] Medstar Res Inst, Hyattsville, MD USA. RP DeFronzo, RA (reprint author), Texas Diabet Inst, San Antonio, TX 78207 USA. EM albarado@uthscsa.edu RI Gastaldelli, Amalia/H-3319-2014 OI Gastaldelli, Amalia/0000-0003-2594-1651 FU General Clinical Research Center at the University of Tennessee Health Science Center, Clinical and Translational Science Award [M01-RR-00221, UL1-TR-000130]; South Texas Veterans Health Care System-Audie Murphy Division; Veterans Administration Health Care System FX This study was supported in part by General Clinical Research Center grant M01-RR-00221 at the University of Tennessee Health Science Center, Clinical and Translational Science Award grant UL1-TR-000130 to the University of Southern California, and the South Texas Veterans Health Care System-Audie Murphy Division. Part (five-eighths) of R.A.D.'s salary is supported by the Veterans Administration Health Care System. Takeda Pharmaceuticals North America provided the study drug. NR 22 TC 2 Z9 2 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2014 VL 37 IS 6 BP 1706 EP 1711 DI 10.2337/dc13-1745 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AJ5RX UT WOS:000337746100048 PM 24705615 ER PT J AU Halban, PA Polonsky, KS Bowden, DW Hawkins, MA Ling, C Mather, KJ Powers, AC Rhodes, CJ Sussel, L Weir, GC AF Halban, Philippe A. Polonsky, Kenneth S. Bowden, Donald W. Hawkins, Meredith A. Ling, Charlotte Mather, Kieren J. Powers, Alvin C. Rhodes, Christopher J. Sussel, Lori Weir, Gordon C. TI beta-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment SO DIABETES CARE LA English DT Article ID STIMULATED INSULIN-SECRETION; HUMAN PANCREATIC-ISLETS; GASTRIC-BYPASS-SURGERY; DNA METHYLATION; EPIGENETIC REGULATION; HISTONE MODIFICATIONS; ACTIVATING MUTATIONS; SUSCEPTIBILITY LOCI; GLYCEMIC CONTROL; CONTROLLED-TRIAL AB OBJECTIVE This article examines the foundation of beta-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of beta-cell failure, natural history of beta-cell failure, and impact of therapeutic interventions. CONCLUSIONS beta-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased beta-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of beta-cell failure; 2) identify and characterize genetic loci for T2D; 3) target beta-cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of beta-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to beta-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and beta-cells. C1 [Halban, Philippe A.] Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland. [Polonsky, Kenneth S.] Univ Chicago, Dept Med, Endocrinol Sect, Chicago, IL 60637 USA. [Bowden, Donald W.] Wake Forest Univ, Ctr Genom & Personalized Med Res, Winston Salem, NC 27109 USA. [Bowden, Donald W.] Wake Forest Univ, Ctr Diabet Res, Winston Salem, NC 27109 USA. [Hawkins, Meredith A.] Albert Einstein Coll Med, Dept Med Endocrinol, Bronx, NY 10467 USA. [Hawkins, Meredith A.] Albert Einstein Coll Med, Global Diabet Inst, Bronx, NY 10467 USA. [Ling, Charlotte] Lund Univ, Dept Clin Sci, Lund, Sweden. [Mather, Kieren J.] Indiana Univ, Dept Endocrinol, Indianapolis, IN 46204 USA. [Powers, Alvin C.] Vanderbilt Univ, Sch Med, Div Diabet Endocrinol & Metab, Nashville, TN 37212 USA. [Rhodes, Christopher J.] Univ Chicago, Dept Med, Kovler Diabet Ctr, Chicago, IL 60637 USA. [Sussel, Lori] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY USA. [Weir, Gordon C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Halban, PA (reprint author), Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland. EM philippe.halban@unige.ch; polonsky@bsd.uchicago.edu RI Ling, Charlotte/Q-2432-2015 OI Ling, Charlotte/0000-0003-0587-7154 FU Endocrine Society; American Diabetes Association; Novo Nordisk; Sanofi; Lilly USA FX This article is based on a conference jointly sponsored by the Endocrine Society and the American Diabetes Association and supported by an educational grant from Novo Nordisk, Sanofi, and Lilly USA. NR 86 TC 59 Z9 61 U1 3 U2 19 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2014 VL 37 IS 6 BP 1751 EP 1758 DI 10.2337/dc14-0396 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AJ5RX UT WOS:000337746100055 PM 24812433 ER PT J AU Lee, S Kim, SM Dotimas, J Li, L Feener, EP Baldus, S Myers, RB Chutkow, WA Patwari, P Yoshioka, J Lee, RT AF Lee, Samuel Kim, Soo Min Dotimas, James Li, Letitia Feener, Edward P. Baldus, Stephan Myers, Ronald B. Chutkow, William A. Patwari, Parth Yoshioka, Jun Lee, Richard T. TI Thioredoxin-interacting protein regulates protein disulfide isomerases and endoplasmic reticulum stress SO EMBO MOLECULAR MEDICINE LA English DT Article DE endoplasmic reticulum stress; protein disulfide isomerases; thioredoxin-interacting protein; unfolded protein response ID ER STRESS; GLUCOSE-HOMEOSTASIS; MOUSE MODEL; CELL-DEATH; ARRESTIN; TXNIP; LINKS; INFLAMMASOME; ADIPOGENESIS; EXPRESSION AB The endoplasmic reticulum (ER) is responsible for protein folding, modification, and trafficking. Accumulation of unfolded or misfolded proteins represents the condition of ER stress and triggers the unfolded protein response (UPR), a key mechanism linking supply of excess nutrients to insulin resistance and type 2 diabetes in obesity. The ER harbors proteins that participate in protein folding including protein disulfide isomerases (PDIs). Changes in PDI activity are associated with protein misfolding and ER stress. Here, we show that thioredoxin-interacting protein (Txnip), a member of the arrestin protein superfamily and one of the most strongly induced proteins in diabetic patients, regulates PDI activity and UPR signaling. We found that Txnip binds to PDIs and increases their enzymatic activity. Genetic deletion of Txnip in cells and mice led to increased protein ubiquitination and splicing of the UPR regulated transcription factor X-box-binding protein 1 (Xbp1s) at baseline as well as under ER stress. Our results reveal Txnip as a novel direct regulator of PDI activity and a feedback mechanism of UPR signaling to decrease ER stress. C1 [Lee, Samuel; Kim, Soo Min; Dotimas, James; Li, Letitia; Myers, Ronald B.; Lee, Richard T.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Harvard Dept Stem Cell & Regenerat Biol,Harvard S, Cambridge, MA 02138 USA. [Lee, Samuel; Kim, Soo Min; Dotimas, James; Li, Letitia; Myers, Ronald B.; Chutkow, William A.; Patwari, Parth; Yoshioka, Jun; Lee, Richard T.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Cardiovasc Div,Dept Med, Cambridge, MA 02138 USA. [Lee, Samuel; Baldus, Stephan] Univ Hosp Cologne, Dept Internal Med 3, Cologne, Germany. [Feener, Edward P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Lee, RT (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Harvard Dept Stem Cell & Regenerat Biol,Harvard S, Cambridge, MA 02138 USA. EM RLee@partners.org FU Koln Fortune Program, Faculty of Medicine, University of Cologne, Germany; German Research Foundation [LE 2728/1-1]; American Diabetes Association [7-12-MN-46]; American Heart Association [13GRNT1687007]; National Institutes of Health [HL048743, HL103582] FX We thank Roland Strong for generously providing PDI reagents. We thank the CECAD Imaging Facility, University of Cologne, Germany, for providing excellent technical assistance. This work was supported by the Koln Fortune Program, Faculty of Medicine, University of Cologne, Germany (to SL), the German Research Foundation (LE 2728/1-1 to SL), the American Diabetes Association (7-12-MN-46 to RTL and SL), the American Heart Association (13GRNT1687007 to JY), and the National Institutes of Health (HL048743, HL103582). NR 49 TC 12 Z9 13 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1757-4676 EI 1757-4684 J9 EMBO MOL MED JI EMBO Mol. Med. PD JUN PY 2014 VL 6 IS 6 BP 732 EP 743 DI 10.15252/emmm.201302561 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AJ3DT UT WOS:000337546600004 PM 24843047 ER PT J AU Mentz, RJ Cotter, G Cleland, JGF Stevens, SR Chiswell, K Davison, BA Teerlink, JR Metra, M Voors, AA Grinfeld, L Ruda, M Mareev, V Lotan, C Bloomfield, DM Fiuzat, M Givertz, MM Ponikowski, P Massie, BM O'Connor, CM AF Mentz, Robert J. Cotter, Gad Cleland, John G. F. Stevens, Susanna R. Chiswell, Karen Davison, Beth A. Teerlink, John R. Metra, Marco Voors, Adriaan A. Grinfeld, Liliana Ruda, Mikhail Mareev, Viacheslav Lotan, Chaim Bloomfield, Daniel M. Fiuzat, Mona Givertz, Michael M. Ponikowski, Piotr Massie, Barry M. O'Connor, Christopher M. TI International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Acute heart failure; Length of stay; Trial; Regional differences; Global variation; Outcomes ID ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; VASOPRESSIN ANTAGONISM; HOSPITAL READMISSION; EVEREST EFFICACY; SURVEY PROGRAM; RATES; SURVIVAL; TRENDS; HF AB AimsThe implications of geographical variation are unknown following adjustment for hospital length of stay (LOS) in heart failure (HF) trials that included patients whether or not they had systolic dysfunction. We investigated regional differences in an international acute HF trial. Methods and resultsThe PROTECT trial investigated 2033 patients with acute HF and renal dysfunction hospitalized at 173 sites in 17 countries with randomization to rolofylline or placebo. We grouped enrolling countries into six regions. Baseline characteristics, in-hospital management, and outcomes were explored by region. The primary study outcome was 60-day mortality or cardiovascular/renal hospitalization. Secondary outcomes included 180-day mortality. Of 2033 patients, 33% were from Eastern Europe, 19% from Western Europe, 16% from Israel, 15% from North America, 14% from Russia, and 3% from Argentina. Marked differences in baseline characteristics, HF phenotype, in-hospital diuretic and vasodilator strategies, and LOS were observed by region. LOS was shortest in North America and Israel (median 5 days) and longest in Russia (median 15 days). Regional event rates varied significantly. Following multivariable adjustment, region was an independent predictor of the risk of mortality/hospitalization at 60 days, with the lowest risk in Russia (hazard ratio 0.39, 95% confidence interval 0.23-0.64 vs. Western Europe) due to lower rehospitalization; mortality differences were attenuated by 180 days. ConclusionsIn an international HF trial, there were differences in baseline characteristics, treatments, LOS, and rehospitalization amongst regions, but little difference in longer term mortality. Rehospitalization differences exist independent of LOS. This analysis may help inform future trial design and should be externally validated. C1 [Mentz, Robert J.; Fiuzat, Mona; O'Connor, Christopher M.] Duke Univ, Durham, NC 27710 USA. [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA. [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England. [Stevens, Susanna R.; Chiswell, Karen] Duke Clin Res Inst, Durham, NC USA. [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Voors, Adriaan A.] Univ Groningen, Groningen, Netherlands. [Grinfeld, Liliana] Univ Buenos Aires, Buenos Aires, DF, Argentina. [Ruda, Mikhail] Cardiol Res Ctr, Moscow 121552, Russia. [Mareev, Viacheslav] Russian Acad Med Sci, Cardiol Sci Ctr, Inst Clin Cardiol, Moscow, Russia. [Lotan, Chaim] Hadassah Med Org Ein Karem, Jerusalem, Israel. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. RP Mentz, RJ (reprint author), Duke Univ, Med Ctr, 2301 Erwin Rd, Durham, NC 27710 USA. EM robert.mentz@duke.edu RI Ponikowski, Piotr/O-6454-2015; OI Ponikowski, Piotr/0000-0002-3391-7064; Mareev, Vyacheslav Yurievich/0000-0002-7285-2048; Metra, Marco/0000-0001-6691-8568; Davison, Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016 FU NIGMS NIH HHS [T32 GM086330] NR 26 TC 26 Z9 26 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD JUN PY 2014 VL 16 IS 6 BP 614 EP 624 DI 10.1002/ejhf.92 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AJ2FG UT WOS:000337470400006 PM 24771609 ER PT J AU Jhund, PS Claggett, B Packer, M Zile, MR Voors, AA Pieske, B Lefkowitz, M Shi, V Bransford, T McMurray, JJV Solomon, SD AF Jhund, Pardeep S. Claggett, Brian Packer, Milton Zile, Michael R. Voors, Adriaan A. Pieske, Burkert Lefkowitz, Martin Shi, Victor Bransford, Toni McMurray, John J. V. Solomon, Scott D. TI Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Blood pressure; Heart failure; Neprilysin inhibitor; NT-proBNP; Preserved ejection fraction ID RANDOMIZED CONTROLLED-TRIAL; ATRIAL-NATRIURETIC-PEPTIDE; DIASTOLIC FUNCTION; CONVERTING ENZYME; RAT; OMAPATRILAT; MORTALITY; DIAGNOSIS AB AimsThe first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), reduce left atrial size and improve New York Heart Association (NYHA) class in patients with heart failure with preserved ejection fraction (HFpEF). We examined whether the effects of LCZ696 were independent of systolic blood pressure (SBP) lowering. Methods and resultsIn the Prospective comparison of ARNi (angiotensin receptor neprilysin inhibitor) with ARB (angiotensin receptor blocker) on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial 301 patients were randomly assigned to LCZ696 or valsartan. We examined the relationship between SBP lowering and LCZ696 on NT-proBNP level, left atrial size, NYHA class and estimated glomerular filtration rate (eGFR). By 12weeks blood pressure was reduced by 9mmHg (SD 15)/5mmHg (SD 11) in patients receiving LCZ696 in comparison with 3mmHg (SD 17)/2mmHg (SD 12) in those receiving valsartan. The change in NT-proBNP was poorly correlated with change in SBP (LCZ696, r=0.17, P=0.06; valsartan, r=0.05, P=0.58) After adjustment for change in SBP, the ratio of change in NT-proBNP at 12weeks for LCZ696 vs. valsartan was 0.76 (95% CI 0.63-0.93, P=0.008), and similar to the ratio not adjusting for SBP (0.76, 95% CI 0.63-0.92, P=0.006); P for interaction was 0.38). Similarly, reduction in left atrial volume index at 36weeks, improvement in NYHA class and eGFR were all independent of the change in SBP. ConclusionIn patients with HFpEF, the effect of the angiotensin receptor neprilysin inhibitor LCZ696 on NT-proBNP, left atrial volume, functional class, and eGFR was independent of reduction in SBP. C1 [Jhund, Pardeep S.; Claggett, Brian; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Jhund, Pardeep S.; McMurray, John J. V.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland. [Packer, Milton] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Pieske, Burkert] Med Univ Graz, Dept Cardiol, Graz, Austria. [Lefkowitz, Martin; Shi, Victor; Bransford, Toni] Novartis Pharmaceut, E Hanover, NJ USA. RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM ssolomon@rics.bwh.harvard.edu OI mcmurray, john/0000-0002-6317-3975; Jhund, Pardeep/0000-0003-4306-5317 NR 22 TC 27 Z9 30 U1 0 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD JUN PY 2014 VL 16 IS 6 BP 671 EP 677 DI 10.1002/ejhf.76 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AJ2FG UT WOS:000337470400013 PM 24692284 ER PT J AU Goldman, RH Batsis, M Petrozza, JC Souter, I AF Goldman, Randi H. Batsis, Maria Petrozza, John C. Souter, Irene TI Patient-specific predictions of outcome after gonadotropin ovulation induction/intrauterine insemination SO FERTILITY AND STERILITY LA English DT Article DE Ovulation induction; intrauterine insemination; clinical pregnancy rate; multiple pregnancy; predictive models ID CONTROLLED OVARIAN HYPERSTIMULATION; INTRAUTERINE INSEMINATION; PREOVULATORY FOLLICLES; MULTIPLE PREGNANCY; CYCLES; STIMULATION; NUMBER; SUBFERTILITY; SUCCESS; SPERM AB Objective: To use patient-specific and cycle-specific characteristics to predict clinical pregnancy, multiple pregnancy, and spontaneous abortion rates after gonadotropin ovulation induction (OI)/IUI. Design: Retrospective chart review. Setting: Academic fertility center. Patient(s): A total of 1,438 women who underwent 3,375 gonadotropin OI/IUI cycles. Intervention(s): Individual and cycle-specific characteristics were evaluated to determine predictors of the rates of clinical pregnancy, multiple pregnancy, and spontaneous abortion. Logistic regression using individual parameters was used to create predictive models. Main Outcome Measure(s): Clinical pregnancy (CPR), multiple pregnancy (MPR), and spontaneous abortion rates (SABR). Result(s): Multiple predictors were identified for CPR, MPR, and SABR. The presence of at least two follicles >= 13 mm at ovulation trigger significantly increased CPR (odds ratio [ OR], 95% confidence interval [ CI] = 1.45, 1.18-1.78) and MPR (OR, 95% CI = 5.17, 2.16-12.41). An E-2 level > 400 pg/mL significantly increased MPR (OR, 95% CI = 9.54, 2.31-39.42). Logistic regression models were developed for individualized predictions of outcome. Conclusion(s): Regression analysis reveals the patient and cycle-specific characteristics that are significant predictors of CPR, MPR, and SABR after OI/IUI. Logistic models using significant or nearly significant predictors for CPR, MPR, and SABR offer improved predictive power relative to simpler models, and allow for the development of a risk calculator for personalized patient counseling. (C) 2014 by American Society for Reproductive Medicine. C1 [Goldman, Randi H.; Petrozza, John C.; Souter, Irene] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Dept Obstet & Gynecol,Fertil Ctr, Boston, MA USA. [Batsis, Maria; Petrozza, John C.; Souter, Irene] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrinol & Infertil Div,Fertil Ctr, Boston, MA USA. RP Goldman, RH (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 4E, Boston, MA 02114 USA. EM rhgoldman@partners.org FU Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health) [8UL1TR000170-05] FX The authors thank Michele Hacker, Sc. D., M.S.P.H. for statistical consultation; and the Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award 8UL1TR000170-05 and financial contributions from Harvard University and its affiliated academic health care centers) for support. NR 21 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD JUN PY 2014 VL 101 IS 6 BP 1649 EP U504 DI 10.1016/j.fertnstert.2014.02.028 PG 9 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AJ0RU UT WOS:000337364300034 PM 24690238 ER PT J AU Ghassemi, M Van Stan, JH Mehta, DD Zanartu, M Cheyne, HA Hillman, RE Guttag, JV AF Ghassemi, Marzyeh Van Stan, Jarrad H. Mehta, Daryush D. Zanartu, Matias Cheyne, Harold A., II Hillman, Robert E. Guttag, John V. TI Learning to Detect Vocal Hyperfunction From Ambulatory Neck-Surface Acceleration Features: Initial Results for Vocal Fold Nodules SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE Ambulatory voice monitoring; clinical detection; machine learning; vocal cord; vocal fold nodules ID VOICE DISORDERS; V-RQOL; TEACHERS AB Voice disorders are medical conditions that often result from vocal abuse/misuse which is referred to generically as vocal hyperfunction. Standard voice assessment approaches cannot accurately determine the actual nature, prevalence, and pathological impact of hyperfunctional vocal behaviors because such behaviors can vary greatly across the course of an individual's typical day and may not be clearly demonstrated during a brief clinical encounter. Thus, it would be clinically valuable to develop noninvasive ambulatory measures that can reliably differentiate vocal hyperfunction from normal patterns of vocal behavior. As an initial step toward this goal we used an accelerometer taped to the neck surface to provide a continuous, noninvasive acceleration signal designed to capture some aspects of vocal behavior related to vocal cord nodules, a common manifestation of vocal hyperfunction. We gathered data from 12 female adult patients diagnosed with vocal fold nodules and 12 control speakers matched for age and occupation. We derived features from weeklong neck-surface acceleration recordings by using distributions of sound pressure level and fundamental frequency over 5-min windows of the acceleration signal and normalized these features so that intersubject comparisons were meaningful. We then used supervised machine learning to show that the two groups exhibit distinct vocal behaviors that can be detected using the acceleration signal. We were able to correctly classify 22 of the 24 subjects, suggesting that in the future measures of the acceleration signal could be used to detect patients with the types of aberrant vocal behaviors that are associated with hyperfunctional voice disorders. C1 [Ghassemi, Marzyeh; Guttag, John V.] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Van Stan, Jarrad H.; Mehta, Daryush D.; Hillman, Robert E.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA. [Van Stan, Jarrad H.; Hillman, Robert E.] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA. [Mehta, Daryush D.; Hillman, Robert E.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Zanartu, Matias] Univ Tecn Federico Santa Maria, Dept Elect Engn, Valparaiso 2390123, Chile. [Cheyne, Harold A., II] Cornell Univ, Bioacoust Res Program, Lab Ornithol, Ithaca, NY 14850 USA. RP Ghassemi, M (reprint author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM mghassem@mit.edu; JVanStan@mghihp.edu; daryush.mehta@alum.mit.edu; matias.zanartu@usm.cl; hac68@cornell.edu; hillman.robert@mgh.harvard.edu; guttag@csail.mit.edu RI Zanartu, Matias/I-3133-2012; researchers, ac3e/N-2008-2016 OI Zanartu, Matias/0000-0001-5581-4392; FU National Library of Medicine's university-based Biomedical Informatics Research Training Program; Intel Science and Technology Center; National Institutes of Health National Institute on Deafness and Other Communication Disorders [R33DC011588]; Chilean CONICYT [FONDECYT 11110147]; MIT International Science and Technology Initiatives MIT-Chile Seed Fund [2745333] FX This work was supported in part by the National Library of Medicine's university-based Biomedical Informatics Research Training Program, in part by the Intel Science and Technology Center, and in part by the National Institutes of Health National Institute on Deafness and Other Communication Disorders under Grant R33DC011588, the Chilean CONICYT under Grant FONDECYT 11110147, and the MIT International Science and Technology Initiatives MIT-Chile Seed Fund under Grant 2745333. Asterisk indicates Corresponding author. NR 26 TC 11 Z9 11 U1 6 U2 10 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0018-9294 EI 1558-2531 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD JUN PY 2014 VL 61 IS 6 BP 1668 EP 1675 DI 10.1109/TBME.2013.2297372 PG 8 WC Engineering, Biomedical SC Engineering GA AJ5PB UT WOS:000337736000009 PM 24845276 ER PT J AU Rodriguez-Diaz, E Atkinson, C Jepeal, LI Berg, A Huang, CS Cerda, SR O'Brien, MJ Bigio, IJ Farraye, FA Singh, SK AF Rodriguez-Diaz, Eladio Atkinson, Christopher Jepeal, Lisa I. Berg, Adam Huang, Christopher S. Cerda, Sandra R. O'Brien, Michael J. Bigio, Irving J. Farraye, Francis A. Singh, Satish K. TI Elastic Scattering Spectroscopy as an Optical Marker of Inflammatory Bowel Disease Activity and Subtypes SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE spectrum analysis; spectroscopy; endoscopy; inflammatory bowel disease; Crohn's disease; ulcerative colitis; biomarker ID SOURCE-DETECTOR SEPARATIONS; LIGHT-SCATTERING; CROHNS-DISEASE; MICROVASCULAR BLOOD; ULCERATIVE-COLITIS; BARRETTS-ESOPHAGUS; COLONIC NEOPLASIA; UNITED-STATES; NORMAL MUCOSA; IN-VIVO AB Background: In 10% to 15% of individuals, inflammatory bowel disease (IBD) is difficult to classify as ulcerative colitis (UC) or Crohn's disease (CD). Previous work has demonstrated that probe-based elastic scattering spectroscopy (ESS) can produce spectra, informed by parameters like tissue ultrastructure and hemoglobin content, capable of differentiating pathologies. This study investigates whether ESS is an in vivo optical biomarker for the presence, activity, and type of IBD in the colon. Methods: Pilot study, a retrospective data analysis. ESS spectra of endoscopically normal and inflamed colon were obtained from 48 patients with IBD and 46 non-IBD controls. Measurements from patients with IBD were categorized as CD or UC based on clinical diagnosis. Spectra were analyzed using high-dimensional methods. Leave-one-patient-out cross-validation was used to obtain diagnostic performance estimates. Results: Patients with IBD were distinguishable from non-IBD controls with a sensitivity of 0.93 and specificity of 0.91 based on readings from endoscopically normal mucosa, and 0.94 and 0.93 from inflamed mucosa. In patients with IBD, histologically normal and inflamed colon were distinguishable with per-class accuracies of 0.83 and 0.89, respectively; histologically normal from inactive inflammation with accuracies of 0.73 and 0.89, respectively; and inactive from active colitis with accuracies of 0.87 and 0.84, respectively. The diagnosis of CD versus UC was made with per-class accuracies of 0.92 and 0.87 in normal and 0.87 and 0.85 in inflamed mucosa, respectively. Conclusions: ESS, a simple, low-cost clinically friendly optical biopsy modality, has the potential to enhance the endoscopic assessment of IBD and its activity in real time and may help to distinguish CD from UC. C1 [Rodriguez-Diaz, Eladio; Jepeal, Lisa I.; Berg, Adam; Huang, Christopher S.; Bigio, Irving J.; Farraye, Francis A.; Singh, Satish K.] Boston Univ, Sch Med, Dept Med, Gastroenterol Sect, Boston, MA 02118 USA. [Atkinson, Christopher] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Cerda, Sandra R.; O'Brien, Michael J.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA. [Bigio, Irving J.; Singh, Satish K.] Boston Univ, Coll Engn, Dept Biomed Engn, Boston, MA 02118 USA. [Singh, Satish K.] VA Boston Healthcare Syst, Med Serv, Gastroenterol Unit, Boston, MA USA. RP Singh, SK (reprint author), Boston Univ, Sch Med, Dept Med, Gastroenterol Sect, Suite 504,650 Albany St, Boston, MA 02118 USA. EM singhsk@bu.edu FU VA CSRD Merit Award [1I01CX000347]; NIH/NCI [U54 CA10467]; Wallace H. Coulter Foundation; Center for the Integration of Medicine and Innovative Technology FX Supported by VA CSR&D Merit Award (1I01CX000347), NIH/NCI (U54 CA10467), Wallace H. Coulter Foundation, and Center for the Integration of Medicine and Innovative Technology. NR 52 TC 3 Z9 3 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JUN PY 2014 VL 20 IS 6 BP 1029 EP 1036 DI 10.1097/MIB.0000000000000058 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AJ5SY UT WOS:000337749500010 PM 24798637 ER PT J AU Bleier, BS Nocera, AL Iqbal, H Hoang, JD Alvarez, U Feldman, RE Han, X AF Bleier, Benjamin S. Nocera, Angela L. Iqbal, Hufsa Hoang, John D. Alvarez, Ulises Feldman, Rachel E. Han, Xue TI P-glycoprotein promotes epithelial T helper 2-associated cytokine secretion in chronic sinusitis with nasal polyps SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic sinusitis with nasal polyps; immunomodulator; nasal epithelium; P-glycoprotein; Th2 inflammation ID CELLS IN-VITRO; CHRONIC RHINOSINUSITIS; MULTIDRUG-RESISTANCE; EXPRESSION; IMMUNOMODULATOR; INFLAMMATION; EOTAXIN-3; REVERSAL; IL-6 AB Background Sinonasal epithelial cells are recognized as drivers of inflammation in chronic sinusitis with nasal polyps (CRSwNP) through secretion of T helper 2 (Th2)-promoting cytokines. P-glycoprotein (P-gp) is overexpressed in nasal polyps and modulates epithelial cytokine secretion in healthy mucosa. The objective of this study is to determine whether P-gp overactivity promotes Th2-associated cytokine secretion in CRSwNP. Methods Polyp explants (n = 4) and primary epithelial cell cultures (n = 5) were cultivated from patients with CRSwNP. Explant P-gp activity was determined using a calcein assay. In culture, P-gp was quantified by enzyme-linked immunosorbent assay (ELISA) and sensitivity to PSC-833 inhibition was determined using a calcein assay. Lipopolysaccharide (LPS)-stimulated cytokine secretion of interleukin 6 (IL-6), IL-8, IL-25, and granulocyte macrophage colony stimulating factor (GM-CSF) were quantified by ELISA and compared to secretion following P-gp inhibition. Differences in P-gp expression and cytokine secretion were compared using a Mann-Whitney U test. Secretion was correlated with P-gp expression using a Pearson correlation coefficient. Results Calcein retention is increased in P-gp inhibited vs uninhibited polyp explants (mean +/- standard deviation [SD]; 5.17 +/- 1.76 vs 2.55 +/- 0.62; p < 0.05) but not in controls, indicating increased nasal polyp P-gp activity. P-gp is sensitive to dose-dependent P-gp inhibition with PSC-833 in vitro. LPS-stimulated secretion of normalized GM-CSF (45.21 +/- 41.39) and IL-6 (63.16 +/- 36.37) were significantly reduced following P-gp inhibition (8.47 +/- 3.28; p < 0.01, and 39.94 +/- 31.07; p < 0.05; respectively) and secretion was highly correlated with P-gp expression(r = 0.824, p < 0.05, and r = 0.833, p < 0.05; respectively). Conclusion P-gp overactivity promotes Th2-associated epithelial cytokine secretion in nasal polyps, suggesting a novel mechanism for maintaining chronic inflammation in CRSwNP. C1 [Bleier, Benjamin S.; Feldman, Rachel E.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Nocera, Angela L.; Iqbal, Hufsa; Hoang, John D.; Alvarez, Ulises; Han, Xue] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. RP Bleier, BS (reprint author), 243 Charles St, Boston, MA 02114 USA. EM benjamin_bleier@meei.harvard.edu FU American Rhinologic Society FX American Rhinologic Society New Investigator Grant. NR 28 TC 9 Z9 9 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD JUN PY 2014 VL 4 IS 6 BP 488 EP 494 DI 10.1002/alr.21316 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA AJ3DA UT WOS:000337544500010 PM 24599606 ER PT J AU Guddati, AK Kumar, G Ahmed, S Ali, M Kumar, N Hari, P Venu, N AF Guddati, Achuta Kumar Kumar, Gagan Ahmed, Shahryar Ali, Muhammad Kumar, Nilay Hari, Parameswaran Venu, Nanda TI Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients SO INTERNATIONAL JOURNAL OF HEMATOLOGY LA English DT Article DE Hematopoietic stem cell transplant; Graft versus host disease; Clostridium difficile-associated disease; Mortality ID MARROW-TRANSPLANTATION; DIARRHEA; INFECTION; EPIDEMIOLOGY; PREVALENCE AB Hematopoietic stem cell transplant (HSCT) recipients are at a high risk of Clostridium difficile-associated disease (CDAD) given frequent hospitalizations, prolonged antibiotic usage and altered integrity of intestinal mucosa. The prevalence and trends of CDAD in HSCT patients have not been extensively studied. In this study, the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to identify CDAD in HSCT patients using a nationwide inpatient sample in the United States from 2000 to 2009. The prevalence of CDAD and in-hospital mortality in HSCT were investigated and compared to those without any transplants. Multivariate analysis was performed to identify if BMT and graft versus host disease (GVHD) were independently associated with mortality in CDAD patients. Of the 344,507 HSCT discharges, 4.7 % had CDAD. This was about 5 times higher when compared to non-transplant discharges. During engraftment admission, rates of CDAD were higher in allogenic group (8.4 vs. 5.7 %, p < 0.001). In subsequent admissions, those with GVHD had higher rates of CDAD (5.7 vs. 3.2 %, p < 0.001). On adjusted analysis in patients with CDAD, during engraftment admission, allogenic group had significantly higher mortality when compared with non-transplants (OR 3.7). Notably, there was no significant difference in mortality between patients with and without CDAD during the engraftment period for the allogeneic group. In subsequent admissions, there was higher mortality in those with GVHD (OR 4.8). Though the prevalence of CDAD in non-transplant population doubled (from 0.44 % in 2000 to 0.99 % in 2008), it has remained stable in HSCT patients (from 4.8 % in 2000 to 5.6 % in 2008). HSCT and GVHD are independently associated with CDAD though its presence does not affect mortality. C1 [Guddati, Achuta Kumar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Internal Med, Boston, MA 02163 USA. [Kumar, Gagan] Med Coll Wisconsin, Div Pulm & Crit Care, Milwaukee, WI 53226 USA. [Ahmed, Shahryar; Ali, Muhammad] Med Coll Wisconsin, Dept Internal Med, Milwaukee, WI 53226 USA. [Kumar, Nilay; Venu, Nanda] Med Coll Wisconsin, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA. [Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA. RP Guddati, AK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Internal Med, 50 Fruit St, Boston, MA 02163 USA. EM aguddati@partners.org OI Hari, Parameswaran/0000-0002-8800-297X NR 30 TC 7 Z9 8 U1 0 U2 3 PU SPRINGER JAPAN KK PI TOKYO PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN SN 0925-5710 EI 1865-3774 J9 INT J HEMATOL JI Int. J. Hematol. PD JUN PY 2014 VL 99 IS 6 BP 758 EP 765 DI 10.1007/s12185-014-1577-z PG 8 WC Hematology SC Hematology GA AJ3YG UT WOS:000337603400013 PM 24715522 ER PT J AU Tawakol, A Lo, J Zanni, MV Marmarelis, E Ihenachor, EJ MacNabb, M Wai, B Hoffmann, U Abbara, S Grinspoon, S AF Tawakol, Ahmed Lo, Janet Zanni, Markella V. Marmarelis, Eleni Ihenachor, Ezinne J. MacNabb, Megan Wai, Bryan Hoffmann, Udo Abbara, Suhny Grinspoon, Steven TI Increased Arterial Inflammation Relates to High-Risk Coronary Plaque Morphology in HIV-Infected Patients SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; arterial inflammation; coronary atherosclerotic plaque; cardiovascular disease ID ACUTE MYOCARDIAL-INFARCTION; TOMOGRAPHY; LESIONS AB Background:Mechanisms predisposing HIV-infected patients to increased cardiovascular disease (CVD) risk remain unclear.Objective:To determine the interrelationship between arterial inflammation and high-risk coronary plaque morphology in HIV-infected patients with subclinical coronary atherosclerosis.Methods:Forty-one HIV-infected patients on stable antiretroviral therapy without known CVD but with atherosclerotic plaque on coronary CT angiography were evaluated with F-18-FDG-PET. Patients were stratified into 2 groups based on relative degree of arterial inflammation [aortic target-to-background ratio (TBR)]. High-risk coronary atherosclerotic plaque morphology features were compared between groups.Results:HIV-infected patients with higher and lower TBRs were similar with respect to traditional CVD risk parameters. Among HIV-infected patients with higher TBR, an increased percentage of patients demonstrated at least 1 low-attenuation coronary atherosclerotic plaque (40% vs. 10%, P = 0.02) and at least 1 coronary atherosclerotic plaque with both low attenuation and positive remodeling (35% vs. 10%, P = 0.04). Moreover, in the higher TBR group, both the number of low-attenuation plaques per patient (P = 0.02) and the number of vulnerability features in the most vulnerable plaque (P = 0.02) were increased. TBR grouping remained significantly related to the number of low-attenuation plaques/subject ( = 0.35, P = 0.004), controlling for age, gender, low-density lipoprotein, duration of HIV, and CD4.Conclusions:These data demonstrate a relationship between arterial inflammation on F-18-FDG-PET and high-risk coronary atherosclerotic plaque features among HIV-infected patients with subclinical coronary atherosclerosis. Further studies are needed to determine whether arterial inflammation and related high-risk coronary morphology increase the risk of clinical CVD events in the HIV population. C1 [Tawakol, Ahmed; MacNabb, Megan] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Tawakol, Ahmed; Lo, Janet; Zanni, Markella V.; Marmarelis, Eleni; Ihenachor, Ezinne J.; MacNabb, Megan; Wai, Bryan; Hoffmann, Udo; Abbara, Suhny; Grinspoon, Steven] Harvard Univ, Sch Med, Boston, MA USA. [Lo, Janet; Zanni, Markella V.; Marmarelis, Eleni; Ihenachor, Ezinne J.; Grinspoon, Steven] Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA. [Wai, Bryan; Hoffmann, Udo; Abbara, Suhny] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Grinspoon, S (reprint author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,5 Longfellow Plaza,Suite 207, Boston, MA 02114 USA. EM sgrinspoon@partners.org FU NIH [R01 HL095123, K23 HL092792] FX Supported by the grants NIH R01 HL095123 to S. G. and NIH K23 HL092792 to J.L. NR 14 TC 14 Z9 14 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUN 1 PY 2014 VL 66 IS 2 BP 164 EP 171 DI 10.1097/QAI.0000000000000138 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AJ4YJ UT WOS:000337685800018 PM 24828267 ER PT J AU Allred, EN Capone, A Fraioli, A Dammann, O Droste, P Duker, J Gise, R Kuban, K Leviton, A O'Shea, TM Paneth, N Petersen, R Trese, M Stoessel, K Vanderveen, D Wallace, DK Weaver, G AF Allred, Elizabeth N. Capone, Antonio, Jr. Fraioli, Anthony Dammann, Olaf Droste, Patrick Duker, Jay Gise, Robert Kuban, Karl Leviton, Alan O'Shea, T. Michael Paneth, Nigel Petersen, Robert Trese, Michael Stoessel, Kathleen Vanderveen, Deborah Wallace, David K. Weaver, Grey TI Retinopathy of prematurity and brain damage in the very preterm newborn SO JOURNAL OF AAPOS LA English DT Article ID PREGNANCY DISORDERS; CEREBRAL-PALSY; CHILDREN BORN; WHITE-MATTER; BIRTH-WEIGHT; INFLAMMATION; RISK; INFANTS; AGE; HYPOTHYROXINEMIA AB PURPOSE To explain why very preterm newborns who develop retinopathy of prematurity (ROP) appear to be at increased risk of abnormalities of both brain structure and function. METHODS A total of 1,085 children born at <28 weeks' gestation had clinically indicated retinal ex-. aminations and had a developmental assessment at 2 years corrected age. Relationships between ROP categories and brain abnormalities were explored using logistic regression models with adjustment for potential confounders. RESULTS The 173 children who had severe ROP, defined as prethreshold ROP (n = 146) or worse (n = 27) were somewhat more likely than their peers without ROP to have brain ultrasound lesions or cerebral palsy. They were approximately twice as likely to have very low Bayley Scales scores. After adjusting for risk factors common to both ROP and brain disorders, infants who developed severe ROP were at increased risk of low Bayley Scales only. Among children with prethreshold ROP, exposure to anesthesia was not associated with low Bayley Scales. CONCLUSIONS Some but not all of the association of ROP with brain disorders can be explained by common risk factors. Most of the increased risks of very low Bayley Scales associated with ROP are probably not a consequence of exposure to anesthetic agents. C1 [Allred, Elizabeth N.; Leviton, Alan; Petersen, Robert; Vanderveen, Deborah] Boston Childrens Hosp, Boston, MA 02115 USA. [Allred, Elizabeth N.; Fraioli, Anthony; Leviton, Alan; Petersen, Robert; Vanderveen, Deborah] Harvard Univ, Sch Med, Boston, MA USA. [Capone, Antonio, Jr.; Trese, Michael] William Beaumont Hosp, Royal Oak, MI 48072 USA. [Fraioli, Anthony] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dammann, Olaf; Duker, Jay] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Dammann, Olaf; Duker, Jay] Tufts Med Ctr, Floating Hosp Children, Boston, MA USA. [Dammann, Olaf] Hannover Med Sch, Hannover, Germany. [Droste, Patrick] Helen DeVos Childrens Hosp, Grand Rapids, MI USA. [Gise, Robert] UMass Mem Med Ctr, Worcester, MA USA. [Gise, Robert] Univ Massachusetts, Sch Med, Worcester, MA USA. [Kuban, Karl] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA. [O'Shea, T. Michael; Weaver, Grey] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Paneth, Nigel] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA. [Stoessel, Kathleen] Yale Univ, Sch Med, New Haven, CT USA. [Wallace, David K.] Duke Eye Ctr, Durham, NC USA. RP Leviton, A (reprint author), Boston Childrens Hosp, Au-414,300 Longwood Ave, Boston, MA 02115 USA. EM alan.leviton@childrens.harvard.edu OI Droste, Patrick/0000-0002-6584-9721 FU NEI NIH HHS [R01 EY021820]; NINDS NIH HHS [U01 NS040069] NR 47 TC 4 Z9 4 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1091-8531 EI 1528-3933 J9 J AAPOS JI J. AAPOS PD JUN PY 2014 VL 18 IS 3 BP 241 EP 247 DI 10.1016/j.jaapos.2014.01.014 PG 7 WC Ophthalmology; Pediatrics SC Ophthalmology; Pediatrics GA AJ5IM UT WOS:000337715900007 PM 24924276 ER PT J AU Kradin, R AF Kradin, Richard TI Converting a Freudian analysis into a Jungian one: obsession, addiction, and an answer from Job SO JOURNAL OF ANALYTICAL PSYCHOLOGY LA English DT Article DE addiction; Freud; Job; Jungian analysis; obsessive-compulsive; Oedipal conflict; psychoanalysis; resistance; super-ego; therapeutic alliance; transference AB In his analyses of obsessional patients, Sigmund Freud suggested that they suffered from intrusive cognitions and compulsive activities. Early psychoanalysts delineated the phenomenology of obsessionality, but did not differentiate what is currently termed obsessive-compulsive disorder from obsessional personality. However, it was widely recognized that the success of psychoanalysis with obsessional patients was limited due to rigid characterological defences and transference resistances. The present paper examines the case of a middle-aged obsessional academic who had been treated for nearly twenty years in a 'classical' Freudian psychoanalysis prior to entering Jungian analysis. It examines how persistent focus on Oedipal conflicts undesirably reinforced the transference resistance in this obsessional man, and suggests that focusing instead on diminishing the harshness of the super-ego via the therapeutic alliance, and fostering faith in the salutary aspects of unconscious processing has led to salutary results in this case. The biblical book of Job is adopted as ancient instruction in how to address the scrupulosity and addictive mental structuring of obsessionality in analysis. C1 [Kradin, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kradin, Richard] CG Jung Inst, Boston, MA USA. [Kradin, Richard] Mind Body Med Inst, Boston, MA USA. [Kradin, Richard] Harvard Univ, Med Sch, Cambridge, MA 02138 USA. RP Kradin, R (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM RKRADIN@mgh.harvard.edu NR 29 TC 0 Z9 0 U1 4 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-8774 EI 1468-5922 J9 J ANAL PSYCHOL JI J. Anal. Psychol. PD JUN PY 2014 VL 59 IS 3 BP 346 EP 365 DI 10.1111/1468-5922.12082 PG 20 WC Psychology, Psychoanalysis SC Psychology GA AJ4CB UT WOS:000337616600005 PM 24919628 ER PT J AU Goto, H Takasugi, N Kuwahara, T Verrier, RL AF Goto, Hiroko Takasugi, Nobuhiro Kuwahara, Takashi Verrier, Richard L. TI QRST-Wave Alternans in a Child with Type 3 Long-QT Syndrome: An Ominous ECG Pattern Appearing During Transition from T-Wave Alternans to Polymorphic VT SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article C1 [Goto, Hiroko; Kuwahara, Takashi] Gifu Prefectural Gen Med Ctr, Dept Pediat, Gifu, Japan. [Takasugi, Nobuhiro] Gifu Univ Hosp, Div Cardiovasc Med, Gifu 5011194, Japan. [Verrier, Richard L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Sch Med, Boston, MA 02215 USA. RP Takasugi, N (reprint author), Gifu Univ Hosp, Div Cardiovasc Med, 1-1 Yanagido, Gifu 5011194, Japan. EM konezumi@ccn3.aitai.ne.jp NR 1 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 EI 1540-8167 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD JUN PY 2014 VL 25 IS 6 BP 657 EP 658 DI 10.1111/jce.12354 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AJ2UB UT WOS:000337518000014 PM 24383991 ER PT J AU Schmittdiel, JA Dyer, W Uratsu, C Magid, DJ O'Connor, PJ Beck, A Butler, M Ho, MP Vazquez-Benitez, G Adams, AS AF Schmittdiel, Julie A. Dyer, Wendy Uratsu, Connie Magid, David J. O'Connor, Patrick J. Beck, Arne Butler, Melissa Ho, Michael P. Vazquez-Benitez, Gabriela Adams, Alyce S. TI Initial Persistence With Antihypertensive Therapies Is Associated With Depression Treatment Persistence, But Not Depression SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; MEDICATION ADHERENCE; UNITED-STATES; HYPERTENSIVE PATIENTS; SYSTEM FACTORS; HEART-DISEASE; BLACK-MEN; PREVALENCE; SYMPTOMS; TRENDS AB The purpose of this study was to examine the relationship between the presence of clinical depression and persistence to drug therapy treatment for depression with early nonpersistence to antihypertensive therapies in a large, diverse cohort of newly treated hypertension patients. Using a hypertension registry at Kaiser Permanente Northern California, the authors conducted a retrospective cohort study of 44,167 adults (18years and older) with hypertension who were new users of antihypertensive therapy in 2008. We used multivariate logistic regression analysis to model the relationships between the presence of clinical depression and early nonpersistence (defined as failing to refill the first prescription within 90days after the end of the first fill days' supply) to antihypertensive therapies, controlling for sociodemographic and clinical risk factors. Within the group of 1484 patients who had evidence of clinical depression in the 12months prior to the initiation of antihypertensive therapy, the authors examined the relationship between drug therapy treatment for depression and 6-month persistence with antidepressant therapy with early nonpersistence with antihypertensive therapies. No association was found between the presence of clinical depression and early nonpersistence to antihypertensive therapies after adjustment for individual demographic and clinical characteristics and neighborhood-level socioeconomic status. However, among the subset of 1484 patients with documented evidence of clinical depression in the 12months prior to the initiation of antihypertensive therapy, being prescribed and persistence with antidepressant therapy was strongly associated with lower odds of early nonpersistence to antihypertensive medications (odds ratio, 0.64; confidence interval, 0.42-0.96). In an integrated delivery system, the authors found that treatment for depression was associated with higher levels of antihypertensive persistence. Improving quality of depression care in patients with comorbid hypertension may be an important strategy in decreasing cardiovascular disease risk in these patients. C1 [Schmittdiel, Julie A.; Dyer, Wendy; Uratsu, Connie; Adams, Alyce S.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Magid, David J.; Beck, Arne; Ho, Michael P.] Kaiser Permanente, Inst Res, Denver, CO USA. [Magid, David J.; Ho, Michael P.] Univ Colorado, Denver, CO 80202 USA. [O'Connor, Patrick J.; Vazquez-Benitez, Gabriela] HealthPartners Res Fdn, Minneapolis, MN USA. [Butler, Melissa] Kaiser Permanente, Ctr Hlth Res Southeast, Atlanta, GA USA. [Ho, Michael P.] Denver VA Med Ctr, Denver, CO USA. RP Schmittdiel, JA (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM Julie.A.Schmittdiel@kp.org FU National Heart, Lung, and Blood Institute [3U19HL091179-04S1]; National Institute for Mental Health; Health Delivery Systems Center for Diabetes Translational Research - National Institute for Diabetes, Digestive and Kidney Diseases [P30DK092924] FX This study was funded by [3U19HL091179-04S1] the National Heart, Lung, and Blood Institute and the National Institute for Mental Health as a supplement to the HMO Research Network Cardiovascular Disease Network. Additional support for Drs Adams, Schmittdiel, and OConnor was also provided by the Health Delivery Systems Center for Diabetes Translational Research [P30DK092924], funded by the National Institute for Diabetes, Digestive and Kidney Diseases. The funders had no role in the design or conduct of the study, data collection, management, analysis or interpretation, or in the preparation, review, or approval of this manuscript. The authors report no conflicts of interest. Dr Schmittdiel had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 31 TC 2 Z9 2 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JUN PY 2014 VL 16 IS 6 BP 412 EP 417 DI 10.1111/jch.12300 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AJ3XE UT WOS:000337600400007 PM 24716533 ER PT J AU Shah, RV Abbasi, SA Yamal, JM Davis, BR Barzilay, J Einhorn, PT Goldfine, A AF Shah, Ravi V. Abbasi, Siddique A. Yamal, Jose-Miguel Davis, Barry R. Barzilay, Joshua Einhorn, Paula T. Goldfine, Allison CA ALLHAT Collaborative Res Grp TI Impaired Fasting Glucose and Body Mass Index as Determinants of Mortality in ALLHAT: Is the Obesity Paradox Real? SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID CORONARY-HEART-DISEASE; FAT DISTRIBUTION; RISK; ASSOCIATION; ADULTS; HYPERTENSION; METAANALYSIS; OVERWEIGHT; WEIGHT; STROKE AB Emerging literature suggests that obesity may be protective against mortality and cardiovascular outcomes, while dysglycemia may worsen outcomes regardless of obesity. The authors measured the association of weight, smoking, and glycemia with mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Among 5423 ALLHAT participants without established diabetes or cardiovascular disease, 3980 (73%) had normal fasting glucose and 1443 (27%) had impaired fasting glucose (IFG) levels at study entry. After a median of 4.9years follow-up, 554 (10%) had died (37% cardiovascular). IFG was associated with higher all-cause mortality (adjusted hazard ratio [HR], 1.23; 95% confidence interval [CI], 1.02-1.50), while obesity was associated with lower all-cause mortality (adjusted HR, 0.76; 95% CI, 0.60-0.96). However, after excluding underweight individuals (body mass index [BMI] <22kg/m2) and smokers, neither obesity nor IFG was associated with all-cause mortality, but IFG identifies individuals at greater risk in the nonobese population. Although obesity appeared protective against mortality, this association was not significant in never-smokers or after exclusion of BMI <22kg/m2. The obesity paradox may result from confounding by a sicker, underweight referent population and smoking. C1 [Shah, Ravi V.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Abbasi, Siddique A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yamal, Jose-Miguel; Davis, Barry R.] Univ Texas Houston, Sch Publ Hlth, Div Biostat, Houston, TX 77030 USA. [Barzilay, Joshua] Kaiser Permanente Georgia, Gwinnett Comprehens Med Ctr, Duluth, GA USA. [Einhorn, Paula T.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Goldfine, Allison] Joslin Diabet Ctr, Boston, MA 02215 USA. RP Yamal, JM (reprint author), Univ Texas Houston, Sch Publ Hlth, Coordinating Ctr Clin Trials, 1200 Pressler St, Houston, TX 77030 USA. EM jose-miguel.yamal@uth.tmc.edu OI Abbasi, Siddique/0000-0002-9601-7565 FU National Heart, Lung, and Blood Institute [NO1-HC-35130, HHSN268201100036C]; American Heart Association Post-Doctoral Research Award; Pfizer, Inc. FX This study was supported by contracts NO1-HC-35130 and HHSN268201100036C with the National Heart, Lung, and Blood Institute and an American Heart Association Post-Doctoral Research Award to Dr Shah. The ALLHAT investigators acknowledge study medications contributed by Pfizer, Inc (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support provided by Pfizer, Inc. NR 32 TC 8 Z9 8 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JUN PY 2014 VL 16 IS 6 BP 451 EP 458 DI 10.1111/jch.12325 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AJ3XE UT WOS:000337600400013 PM 24779706 ER PT J AU Friedmann, DP Avram, MM Cohen, SR Duncan, DI Goldman, MP Weiss, ET Young, VL AF Friedmann, Daniel P. Avram, Mathew M. Cohen, Steven R. Duncan, Diane I. Goldman, Mitchel P. Weiss, Elliot T. Young, V. Leroy TI An evaluation of the patient population for aesthetic treatments targeting abdominal subcutaneous adipose tissue SO JOURNAL OF COSMETIC DERMATOLOGY LA English DT Article DE subcutaneous adipose tissue; central abdominal adiposity; obesity; body mass index; cryolipolysis; high-intensity focused ultrasound ID INTENSITY FOCUSED ULTRASOUND; LEVEL LASER THERAPY; NONINVASIVE FAT REMOVAL; BODY-IMAGE; ADRENERGIC-STIMULATION; ADRENOCEPTOR FUNCTION; LAYER REDUCTION; CELL LIPOLYSIS; OBESE MEN; LIPOSUCTION AB A large and growing population of patients currently seeks minimally invasive therapeutic options for the aesthetic treatment of localized, central abdominal subcutaneous adipose tissue (SAT). We sought to evaluate the ideal population for aesthetic treatment of central abdominal SAT, highlight the existing disparities between SAT in obese (body mass index [BMI]30; BMI) and nonobese (BMI<30) patients, and review the available FDA-cleared, minimally invasive treatment options for central abdominal adiposity. The cosmetic issue of localized, central (periumbilical) abdominal adiposity in nonobese individuals is quite distinct from abdominal bulging secondary to obesity. Given the recognized clinical and physiologic differences between obese and nonobese counterparts, the exclusion of obese patients from clinical study by currently available FDA-cleared devices targeting abdominal fat, and the status of obesity as a chronic, systemic disease requiring medical, surgical, and/or lifestyle-altering therapies, minimally invasive therapeutic options for aesthetic reductions in central abdominal SAT must be limited to the nonobese population. C1 [Friedmann, Daniel P.] Westlake Dermatol & Cosmet Surg, Westlake Dermatol Clin Res Ctr, Austin, TX USA. [Avram, Mathew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatol Laser & Cosmet Ctr, Boston, MA USA. [Avram, Mathew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. [Cohen, Steven R.] Univ Calif San Diego, Div Plast Surg, San Diego, CA 92103 USA. [Cohen, Steven R.] FACES Plast Surg Skin & Laser Ctr, San Diego, CA USA. [Duncan, Diane I.] Plast Surg Associates Ft Collins PC, Ft Collins, CO USA. [Goldman, Mitchel P.] Univ Calif San Diego, Dept Dermatol, San Diego, CA 92103 USA. [Friedmann, Daniel P.; Goldman, Mitchel P.] Goldman Butterwick Fitzpatrick Groff & Fabi Cosme, San Diego, CA 92121 USA. [Weiss, Elliot T.] Weill Cornell Med Coll, Dept Dermatol, New York, NY USA. [Weiss, Elliot T.] Laser & Skin Surg Ctr New York, New York, NY USA. [Young, V. Leroy] Body Aesthet Plast Surg & Skincare Ctr, St Louis, MO USA. RP Friedmann, DP (reprint author), Goldman Butterwick Fitzpatrick Groff & Fabi Cosme, 9339 Genesee Ave,Ste 300, San Diego, CA 92121 USA. EM danf2300@gmail.com NR 52 TC 2 Z9 2 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1473-2130 EI 1473-2165 J9 J COSMET DERMATOL-US JI J. Cosmet. Dermatol. PD JUN PY 2014 VL 13 IS 2 BP 119 EP 124 DI 10.1111/jocd.12088 PG 6 WC Dermatology SC Dermatology GA AJ3SE UT WOS:000337586800007 PM 24910275 ER PT J AU Garshick, MK Chang, ALS Kimball, AB AF Garshick, Marisa Kardos Chang, Anne Lynn S. Kimball, Alexandra Boer TI Only Skin Deep: Optimism and Public Self-Consciousness Did Not Associate With the Placebo Response in a Dermatology Clinical Trial SO JOURNAL OF DRUGS IN DERMATOLOGY LA English DT Article ID PHASE-III; DOUBLE-BLIND; PSORIASIS; EXPECTATIONS AB Objective: Although not well-understood, dermatologic diseases studied in clinical trials often demonstrate substantial response to placebo. The study objective is to determine if optimism, public self-consciousness and other personality traits predict response to placebo or active treatment in a dermatology clinical trial. Methods: A questionnaire was mailed to subjects previously enrolled in a two-center rosacea study who had been randomized to either a treatment or placebo gel. The questionnaire included the Revised Life Orientation Test (LOT-R), the Public Self-Consciousness Scale, and questions to assess personality traits. Results: Forty-seven subjects out of 83 (57%) returned the questionnaire, There was no statistically significant difference in the LOT-R score in those who responded to placebo versus those who did not (18.08 vs 1792, P=0.92) nor in those who responded to active treatment versus those who did not (16.27 vs 15.86, P=0.79). There was no statistically significant difference in public-self consciousness among placebo or active treatment responders versus non-responders (11.75 vs 10.67, P=0.66; 13.55 vs 14.45, P=0.68). The placebo responders were more likely to report that they were not unusually sensitive to most drugs/medications (X-2=8.33, P=0.004). Conclusion: Although this pilot study is small, there was no meaningful difference in levels of optimism or public self-consciousness among those who responded to placebo. Placebo responders were more likely to report that they were not sensitive to most drugs/medications, raising the possibility that they are actually less likely to detect when they are on medications. C1 [Garshick, Marisa Kardos; Kimball, Alexandra Boer] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Chang, Anne Lynn S.] Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA. RP Kimball, AB (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA. EM harvardskinstudies@partners.org NR 15 TC 1 Z9 1 U1 0 U2 6 PU JOURNAL OF DRUGS IN DERMATOLOGY PI NEW YORK PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA SN 1545-9616 J9 J DRUGS DERMATOL JI J. Drugs Dermatol. PD JUN PY 2014 VL 13 IS 6 BP 719 EP 722 PG 4 WC Dermatology SC Dermatology GA AJ3FS UT WOS:000337552500013 PM 24918563 ER PT J AU Tang, VL Halm, EA Fine, MJ Johnson, CS Anzueto, A Mortensen, EM AF Tang, Victoria L. Halm, Ethan A. Fine, Michael J. Johnson, Christopher S. Anzueto, Antonio Mortensen, Eric M. TI Predictors of rehospitalization after admission for pneumonia in the veterans affairs healthcare system SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; ELDERLY-PATIENTS; DISCHARGE; OUTCOMES; RISK; READMISSION; INSTABILITY; MORTALITY AB INTRODUCTION Although some factors associated with rehospitalization after community-acquired pneumonia have been identified, other factors such as medical care utilization and medication usage have not been previously studied. We investigated novel predictors of rehospitalization in patients admitted with pneumonia. METHODS Using Department of Veteran Affairs (VA) administrative data from October 2001 to September 2007, we examined a cohort of patients 65 years old and older, who were hospitalized with pneumonia, in 150 VA acute care hospitals. The cohort was randomly split into derivation and validation samples, and then logistic regression models were used to identify and validate predictors of all-cause rehospitalization within 30 days. RESULTS Of the 45,134 subjects, 13% were rehospitalized within 30 days. No significant differences were noted between the derivation and validation cohorts. Factors associated with readmission included age, marital status, chronic renal disease, prior malignancy, nursing home residence, congestive heart failure, use of oral corticosteroids, number of emergency department visits a year prior, prior admission, number of outpatient clinic visits in a year prior, and length of hospital stay. The C statistics for the derivation and validation models were 0.615 and 0.613, respectively. CONCLUSIONS Factors associated with readmission were largely unrelated to the underlying pneumonia, but were related to demographics, comorbidities, healthcare utilization, and length of stay on index admission. Journal of Hospital Medicine 2014;9:379-383. 2014 Society of Hospital Medicine C1 [Tang, Victoria L.; Johnson, Christopher S.; Mortensen, Eric M.] VA North Texas Hlth Care Syst, Div Gen Internal Med, Dallas, TX USA. [Tang, Victoria L.; Halm, Ethan A.; Johnson, Christopher S.; Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA. [Fine, Michael J.] Univ Pittsburgh, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Mortensen, EM (reprint author), Dallas VA Med Ctr, 111E,4500 South Lancaster, Dallas, TX 75216 USA. EM eric.mortensen@UTSouthwestern.edu OI Mortensen, Eric/0000-0002-3880-5563 FU National Institute of Nursing Research [R01NR010828] FX The project described was supported by grant number R01NR010828 from the National Institute of Nursing Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research or the National Institutes of Health. This material is the result of work supported with resources and the use of facilities at the VA North Texas Health Care System. Funding agencies had no role in conducting the study, or role in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 18 TC 2 Z9 3 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JUN PY 2014 VL 9 IS 6 BP 379 EP 383 DI 10.1002/jhm.2184 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA AJ2VK UT WOS:000337522100006 PM 24648401 ER PT J AU Amri, R Stronks, K Bordeianou, LG Sylla, P Berger, DL AF Amri, Ramzi Stronks, Karien Bordeianou, Liliana G. Sylla, Patricia Berger, David L. TI Gender and ethnic disparities in colon cancer presentation and outcomes in a US universal health care setting SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE colonic neoplasms; healthcare disparities; minority health; health status disparities; neoplasm staging; disease-free survival; mortality ID COLORECTAL-CANCER; UNITED-STATES; SOCIOECONOMIC-STATUS; SURVIVAL; MORTALITY; STAGE; RACE; STATISTICS; GUIDELINES; INSURANCE AB Objective Access to care is a pillar of U.S. healthcare reform and could potentially challenge existing ethnic and gender disparities in care. We present a snapshot of these disparities in surgical colon cancer patients in the largest public hospital in Massachusetts, a state leading in providing universal healthcare, to indicate potential changes that might result from universal care access. Methods All surgical colon cancer patients at Massachusetts General Hospital (2004-2011) were included. Baseline characteristics, perioperative, and long-term outcomes were compared. Results Among 1,071 patients, the 110 (10.3%) minority patients presented with more comorbid (mean Charlson score 0.84 vs. 0.71; P=0.039), metastatic (21.8% vs. 14%; P=0.026), and node-positive disease (50% vs. 38.8%; P=0.014). Women (n=521; 48.6%) had less screening diagnoses (overall: 17.8% vs. 22.6%; P=0.049, screening age: 26.4% vs. 32.7%; P=0.036) with subsequently higher rates of metastatic disease on pathology (11.3% vs. 7.1%, P=0.02). Multivariate adjustment for baseline staging makes outcome disparities no longer statistically significant. Conclusions Significant gender and ethnic disparities subsist at baseline despite long-standing low-threshold healthcare access, although seemingly mitigated by enrollment into high-level care, empowering equal chances for underprivileged groups. The outcomes are also a reminder that universal healthcare will not be a panacea for the deeply rooted and dynamic causes of presentation inequalities. J. Surg. Oncol 2014; 109:645-651. (c) 2014 Wiley Periodicals, Inc. C1 [Amri, Ramzi; Bordeianou, Liliana G.; Sylla, Patricia; Berger, David L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen & Gastrointestinal Surg, Boston, MA USA. [Stronks, Karien] Univ Amsterdam, Acad Med Ctr, Dept Publ Hlth, NL-1105 AZ Amsterdam, Netherlands. RP Berger, DL (reprint author), Massachusetts Gen Hosp, Div Gen Surg & Gastrointestinal Surg, 15 Parkman St, Boston, MA 02114 USA. EM dberger@mgh.harvard.edu OI Amri, Ramzi/0000-0001-7416-6650 FU The Fulbright Foundation; Harvard Catalyst \ The Harvard Clinical and Translational Science Center; Dutch Cancer Society; Dutch Digestive Society; Amsterdam University Funds FX Grant sponsor: The Fulbright Foundation, Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center, the Dutch Cancer Society, the Dutch Digestive Society, and the Amsterdam University Funds. NR 36 TC 8 Z9 8 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4790 EI 1096-9098 J9 J SURG ONCOL JI J. Surg. Oncol. PD JUN PY 2014 VL 109 IS 7 BP 645 EP 651 DI 10.1002/jso.23567 PG 7 WC Oncology; Surgery SC Oncology; Surgery GA AJ2RH UT WOS:000337507000005 PM 24474677 ER PT J AU Murai, T Yamada, S Fuchs, BC Fujii, T Nakayama, G Sugimoto, H Koike, M Fujiwara, M Tanabe, KK Kodera, Y AF Murai, Toshifumi Yamada, Suguru Fuchs, Bryan C. Fujii, Tsutomu Nakayama, Goro Sugimoto, Hiroyuki Koike, Masahiko Fujiwara, Michitaka Tanabe, Kenneth K. Kodera, Yasuhiro TI Epithelial-to-mesenchymal transition predicts prognosis in clinical gastric cancer SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE gastric cancer; epithelial-to-mesenchymal transition; Zeb-1; prognosis ID E-CADHERIN EXPRESSION; TUMOR PROGRESSION; UP-REGULATION; LUNG-CANCER; TWIST; METASTASIS; CELLS; PLASTICITY; CARCINOMA; VIMENTIN AB Background Epithelial-to-mesenchymal transition (EMT) is considered to play an important role in cancer invasion and metastasis. Methods The mRNA levels of an epithelial marker (E-cadherin), mesenchymal marker (vimentin), and Zeb-1 were measured in 11 gastric cancer cell lines. Functional analysis was performed using Zeb-1 knockdown. EMT status of 116 gastric cancer patients was determined by calculating the vimentin/E-cadherin mRNA expression ratio in cancerous tissue and the correlation between EMT status, clinicopathological factors, prognosis, and Zeb-1 were analyzed. Results Cell lines were classified as epithelial or mesenchymal. Zeb-1 expression was significantly correlated with the mesenchymal phenotype. Treatment with Zeb-1 siRNA also reduced the capacity to proliferate, migrate, and invade. Patients were classified as epithelial or mesenchymal by V/E ratio (vimentin/E-cadherin ratio) and as Zeb-1 low or high expression group. The mesenchymal group was significantly associated with diffuse type cancer and stage IV. On multivariate analysis, the EMT status (mesenchymal group) was an independent prognostic factor (P=0.022). There was a significant correlation between the V/E ratio and Zeb-1 expression (r=0.73). Patients in Zeb-1 high group had significantly poorer survival than those in low group (P=0.0071). Conclusions EMT is a critical prognostic factor for gastric cancer. Zeb-1 might be a promising therapeutic target. J. Surg. Oncol 2014; 109:684-689. (c) 2014 Wiley Periodicals, Inc. C1 [Murai, Toshifumi; Yamada, Suguru; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Koike, Masahiko; Fujiwara, Michitaka; Kodera, Yasuhiro] Nagoya Univ, Dept Gastroenterol Surg Surg 2, Grad Sch Med, Nagoya, Aichi 4668550, Japan. [Fuchs, Bryan C.; Tanabe, Kenneth K.] Massachusetts Gen Hosp, Div Surg Oncol, Ctr Canc, Boston, MA 02114 USA. [Fuchs, Bryan C.; Tanabe, Kenneth K.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Yamada, S (reprint author), Nagoya Univ, Dept Gastroenterol Surg Surg 2, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan. EM suguru@med.nagoya-u.ac.jp RI Kodera, Yasuhiro/M-4912-2014; Koike, Masahiko/M-4913-2014; Fujii, Tsutomu/M-4838-2014 FU Charitable Trust Soyu Medical Fundation FX Grant sponsor: Charitable Trust Soyu Medical Fundation. NR 32 TC 14 Z9 14 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4790 EI 1096-9098 J9 J SURG ONCOL JI J. Surg. Oncol. PD JUN PY 2014 VL 109 IS 7 BP 684 EP 689 DI 10.1002/jso.23564 PG 6 WC Oncology; Surgery SC Oncology; Surgery GA AJ2RH UT WOS:000337507000010 PM 24453058 ER PT J AU Shaqdan, K Aran, S Besheli, LD Abujudeh, H AF Shaqdan, Khalid Aran, Shima Besheli, Laleh Daftari Abujudeh, Hani TI Root-Cause Analysis and Health Failure Mode and Effect Analysis: Two Leading Techniques in Health Care Quality Assessment SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Quality; errors; root-cause analysis; RCA; health failure mode effect analysis; HFMEA ID RADIOLOGY AB In this review article, the authors provide a detailed series of guidelines for effectively performing root-cause analysis (RCA) and health failure mode and effect analysis (HFMEA). RCA is a retrospective approach used to ascertain the "root cause" of a problem that has already occurred, whereas HFMEA is a prospective risk assessment tool whose aim is to recognize risks to patient safety. RCA and HFMEA are used for the prevention of errors or recurring errors to create a safer workplace, maintain high standards in health care quality, and incorporate time-saving and cost-saving modifications to favorably affect the patient care environment. The principles and techniques provided here should allow reviewers to better understand the features of RCA and HFMEA and how to apply these processes appropriately. These principles include how to organize a team, identify root causes, seed out proximate causes, graphically describe the process, conduct a hazard analysis, and develop and implement potential action plans. C1 [Shaqdan, Khalid; Aran, Shima; Besheli, Laleh Daftari; Abujudeh, Hani] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Abujudeh, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,Founders 202, Boston, MA 02114 USA. EM habujudeh@partners.org NR 24 TC 6 Z9 7 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUN PY 2014 VL 11 IS 6 BP 572 EP 579 DI 10.1016/j.jacr.2013.10.024 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AJ0HJ UT WOS:000337331000010 PM 24507549 ER PT J AU Lackey, AE Pandey, T Moshiri, M Lalwani, N Lall, C Bhargava, P AF Lackey, Amanda E. Pandey, Tarun Moshiri, Mariam Lalwani, Neeraj Lall, Chandana Bhargava, Puneet TI Productivity, Part 2: Cloud Storage, Remote Meeting Tools, Screencasting, Speech Recognition Software, Password Managers, and Online Data Backup SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Productivity; cloud applications; collaboration ID RADIOLOGY EDUCATION 2.0-ON; CUSP AB It is an opportune time for radiologists to focus on personal productivity. The ever increasing reliance on computers and the Internet has significantly changed the way we work. Myriad software applications are available to help us improve our personal efficiency. In this article, the authors discuss some tools that help improve collaboration and personal productivity, maximize e-learning, and protect valuable digital data. C1 [Lackey, Amanda E.; Pandey, Tarun] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA. [Moshiri, Mariam; Lalwani, Neeraj] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Lall, Chandana] Univ Calif Irvine, Orange, CA 92668 USA. [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Bhargava, P (reprint author), Univ Washington, Mail Box 358280,S-114 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu RI Lalwani, Neeraj/A-3490-2011; OI Lalwani, Neeraj/0000-0001-5514-2805; Bhargava, Puneet/0000-0002-3849-9666 NR 27 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUN PY 2014 VL 11 IS 6 BP 580 EP 588 DI 10.1016/j.jacr.2013.11.021 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AJ0HJ UT WOS:000337331000011 PM 24674716 ER PT J AU Knshnaraj, A Dutta, S Reisner, AT Landman, AB Choy, G Biddinger, P Lin, A Joshi, N AF Knshnaraj, Arun Dutta, Sayon Reisner, Andrew T. Landman, Adam B. Choy, Garry Biddinger, Paul Lin, Abraham Joshi, Neeraj TI Optimizing Emergency Department Imaging Utilization Through Advanced Health Record Technology SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material ID INFORMATION-TECHNOLOGY; DECISION-SUPPORT; RADIOLOGY; EFFICIENCY C1 [Knshnaraj, Arun] Univ Virginia, Charlottesville, VA 22902 USA. [Dutta, Sayon; Reisner, Andrew T.; Biddinger, Paul] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Choy, Garry; Lin, Abraham; Joshi, Neeraj] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Landman, Adam B.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Knshnaraj, A (reprint author), Univ Virginia, Dept Radiol & Med Imaging, 1215 Lee St,POB 800170, Charlottesville, VA 22902 USA. EM ak8jj@virginia.edu OI Landman, Adam/0000-0002-2166-0521 NR 18 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUN PY 2014 VL 11 IS 6 BP 625 EP 628 DI 10.1016/j.jacr.2013.07.011 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AJ0HJ UT WOS:000337331000019 ER PT J AU Germino, JC Rapp, EJ Hippe, DS Shah, AC McFall, ME Bhargava, P AF Germino, Jessica C. Rapp, Elliot J. Hippe, Daniel S. Shah, Anura C. McFall, Miles E. Bhargava, Puneet TI Assessing and Optimizing Imaging of Patients with Posttraumatic Stress Disorder SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material ID CLAUSTROPHOBIA; ANXIETY; EXPERIENCES C1 [Germino, Jessica C.; Rapp, Elliot J.; Hippe, Daniel S.] Univ Washington, Dept Radiol, Seattle, WA 98108 USA. [Shah, Anura C.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Dept Prevent & Management Disrupt Behav, Seattle, WA USA. [McFall, Miles E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [McFall, Miles E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. [Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98108 USA. [Bhargava, Puneet] VA Puget Hlth Care Syst, Seattle, WA 98108 USA. RP Bhargava, P (reprint author), Univ Washington, S-114 RAD,1660 S Columbian Way,Mail Box 358280, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 14 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUN PY 2014 VL 11 IS 6 BP 629 EP 631 DI 10.1016/j.jacr.2013.10.020 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AJ0HJ UT WOS:000337331000020 PM 24613448 ER PT J AU Makam, AN Boscardin, WJ Mao, YH Steinman, MA AF Makam, Anil N. Boscardin, W. John Mao, Yinghui Steinman, Michael A. TI Risk of Thiazide-Induced Metabolic Adverse Events in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE aged; adverse effects; sodium chloride symporter inhibitors; hypertension; outcome assessment (health care) ID INDUCED HYPONATREMIA; BLOOD-PRESSURE; SYSTOLIC HYPERTENSION; CARDIOVASCULAR EVENTS; ELDERLY PROGRAM; CLINICAL-TRIALS; DRUG-REACTIONS; DIURETICS; OUTCOMES; METAANALYSIS AB Objectives To evaluate the risk and predictors of thiazide-induced adverse events (AEs) in multimorbid older adults in real-world clinical settings. Design Observational cohort study. Setting National Veterans Affairs data from 2007 to 2008. Participants Veterans aged 65 and older newly prescribed a thiazide (N=1,060) compared with propensity-matched nonusers of antihypertensive medications (N=1,060). Measurements The primary outcome was a composite of metabolic AEs defined as sodium less than 135mEq/L, potassium less than 3.5mEq/L, or a decrease in the estimated glomerular filtration rate (eGFR) of more than 25% from the baseline rate. Secondary outcomes included sev-ere AEs (sodium <130mEq/L, potassium <3.0mEq/L, or a decrease in eGFR of more than 50%). Results Over 9months of follow-up, 14.3% of new thiazide users developed an AE, compared with 6.0% of nonusers (number needed to harm (NNH) 12, 95% confidence interval (CI)=9-17, P<.001); 1.8% of new users developed a severe AE, compared with 0.6% of nonusers (NNH=82, P=.008), and 3.8% of new users had an emergency department visit or hospitalization with an AE, compared with 2.0% of nonusers (NNH=56, P=.02). Risk of AEs did not vary according to age, but having five or more comorbidities was associated with 3.0 times the odds (95% CI=1.4-6.2) of developing an AE as having one comorbidity (hypertension). Low-normal and unmeasured baseline sodium and potassium values were among the strongest predictors of hyponatremia and hypokalemia, respectively. Only 42% of thiazide users had laboratory monitoring within 90days after initiation. Conclusion Thiazide-induced AEs are common in older adults. Greater attention should be paid to potential complications in prescribing thiazides to older adults, including closer laboratory monitoring before and after initiation of thiazides. C1 [Makam, Anil N.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA. [Boscardin, W. John; Mao, Yinghui; Steinman, Michael A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Makam, AN (reprint author), 5323 Harry Hines Blvd,Mail Code 9169, Dallas, TX 75390 USA. EM anil.makam@utsouthwestern.edu OI Makam, Anil/0000-0001-7072-9946 FU National Institute on Aging (NIA) [K23-AG030999, RC1-AG036377]; federal training grant from the National Research Service Award [T32HP19025-07-00] FX Conflict of Interest: This study was supported by Grants K23-AG030999 and RC1-AG036377 from the National Institute on Aging (NIA). Dr. Makam's work on this project was completed while he was a primary care research fellow at the University of California at San Francisco, funded by a federal training grant from the National Research Service Award (T32HP19025-07-00). NR 36 TC 7 Z9 7 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2014 VL 62 IS 6 BP 1039 EP 1045 DI 10.1111/jgs.12839 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AJ4EJ UT WOS:000337624300005 PM 24823661 ER PT J AU Weiner, DK Morone, NE Spallek, H Karp, JF Schneider, M Washburn, C Dziabiak, MP Hennon, JG Elnicki, DM AF Weiner, Debra K. Morone, Natalia E. Spallek, Heiko Karp, Jordan F. Schneider, Michael Washburn, Carol Dziabiak, Michael P. Hennon, John G. Elnicki, D. Michael CA Univ Pittsburgh Ctr Excellence Pai TI E-Learning Module on Chronic Low Back Pain in Older Adults: Evidence of Effect on Medical Student Objective Structured Clinical Examination Performance SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE medical student education; older adults; low back pain; objective structured clinical examination ID EDUCATION; CARE; COMPETENCE; OUTCOMES AB The Institute of Medicine has highlighted the urgent need to close undergraduate and graduate educational gaps in treating pain. Chronic low back pain (CLBP) is one of the most common pain conditions, and older adults are particularly vulnerable to potential morbidities associated with misinformed treatment. An e-learning case-based interactive module was developed at the University of Pittsburgh Center of Excellence in Pain Education, one of 12 National Institutes of Health-designated centers, to teach students important principles for evaluating and managing CLBP in older adults. A team of six experts in education, information technology, pain management, and geriatrics developed the module. Teaching focused on common errors, interactivity, and expert modeling and feedback. The module mimicked a patient encounter using a standardized patient (the older adult with CLBP) and a pain expert (the patient provider). Twenty-eight medical students were not exposed to the module (Group 1) and 27 were exposed (Group 2). Their clinical skills in evaluating CLBP were assessed using an objective structured clinical examination (OSCE). Mean scores were 62.0 +/- 8.6 for Group 1 and 79.5 +/- 10.4 for Group 2 (P<.001). Using an OSCE pass-fail cutoff score of 60%, 17 of 28 Group 1 students (60.7%) and 26 of 27 Group 2 students (96.3%) passed. The CLBP OSCE was one of 10 OSCE stations in which students were tested at the end of a Combined Ambulatory Medicine and Pediatrics Clerkship. There were no between-group differences in performance on eight of the other nine OSCE stations. This module significantly improved medical student clinical skills in evaluating CLBP. Additional research is needed to ascertain the effect of e-learning modules on more-advanced learners and on improving the care of older adults with CLBP. C1 [Weiner, Debra K.; Morone, Natalia E.; Hennon, John G.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.; Morone, Natalia E.; Karp, Jordan F.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Morone, Natalia E.; Dziabiak, Michael P.; Elnicki, D. Michael] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Spallek, Heiko] Univ Pittsburgh, Sch Dent Med, Dept Dent Publ Hlth, Pittsburgh, PA USA. [Schneider, Michael] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Pittsburgh, PA USA. [Washburn, Carol] Univ Pittsburgh, Ctr Instruct Dev & Distance Educ, Pittsburgh, PA USA. [Hennon, John G.] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA USA. RP Weiner, DK (reprint author), Suite 500,3471 Fifth Ave, Pittsburgh, PA 15213 USA. EM dweiner@pitt.edu OI Spallek, Heiko/0000-0001-6865-4818; Schneider, MIchael/0000-0001-7190-3379 FU Altarum Institute; NIH Pain Consortium [HHSN271201100111U] FX Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any-other kind of personal conflicts with this paper. This work was supported by funding awarded to Centers of Excellence in Pain Education by the Altarum Institute, which received funding from the NIH Pain Consortium (HHSN271201100111U). Dr. Karp has received medication supplies from Pfizer and Reckitt Benckiser for investigator-initiated trials. The contents of this report do not necessarily represent the views of the Department of Veterans Affairs OF the U.S. government. NR 29 TC 1 Z9 1 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2014 VL 62 IS 6 BP 1161 EP 1167 DI 10.1111/jgs.12871 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AJ4EJ UT WOS:000337624300023 PM 24833496 ER PT J AU Moody, SY Newsom, EM Covinsky, KE AF Moody, Sandra Y. Newsom, Edwina M. Covinsky, Kenneth E. TI Determinants of Perceived Emotional Recovery and Perceived Change in Health After a Disaster SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID HURRICANE KATRINA; STORM C1 [Moody, Sandra Y.; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94117 USA. [Moody, Sandra Y.; Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Moody, Sandra Y.] Kameda Med Ctr, Kamogawa, Japan. [Newsom, Edwina M.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA. RP Moody, SY (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94117 USA. FU NCATS NIH HHS [UL1 TR000004]; NCRR NIH HHS [UL1 RR024131]; NIA NIH HHS [5R01AG28621, R01 AG028621] NR 10 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2014 VL 62 IS 6 BP 1189 EP 1191 DI 10.1111/jgs.12852 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AJ4EJ UT WOS:000337624300031 PM 24925556 ER PT J AU Abtahian, F Weinberg, I Hawkins, BM Cefalo, P Nasser, NJ MacKay, C Jaff, MR AF Abtahian, F. Weinberg, I Hawkins, B. M. Cefalo, P. Nasser, N. J. MacKay, C. Jaff, M. R. TI Inferior vena cava filter usage, complications, and retrieval rate in cancer patients SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Abtahian, F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Weinberg, I; MacKay, C.; Jaff, M. R.] Massachusetts Gen Hosp, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA. [Hawkins, B. M.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA. [Cefalo, P.] Massachusetts Gen Hosp, Dept Med & Phys Med & Rehabil, Boston, MA 02114 USA. [Nasser, N. J.] Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2014 VL 12 SU 1 SI SI MA HM07 BP 52 EP 52 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA AJ5BR UT WOS:000337696100138 ER PT J AU Savchenko, AS Martinod, K Seidman, MA Wong, SL Borissoff, JI Piazza, G Libby, P Goldhaber, SZ Mitchell, RN Wagner, DD AF Savchenko, A. S. Martinod, K. Seidman, M. A. Wong, S. L. Borissoff, J. I. Piazza, G. Libby, P. Goldhaber, S. Z. Mitchell, R. N. Wagner, D. D. TI Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Article DE blood platelets; clinical pathology; histones; neutrophils; venous thromboembolism ID DEEP-VEIN THROMBOSIS; VON-WILLEBRAND-FACTOR; INNATE IMMUNITY; CHROMATIN DECONDENSATION; MICE; HISTONES; DNA; COAGULATION; ACTIVATION; GENERATION AB Background A growing health problem, venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), requires refined diagnostic and therapeutic approaches. Neutrophils contribute to thrombus initiation and development in experimental DVT. Recent animal studies recognized neutrophil extracellular traps (NETs) as an important scaffold supporting thrombus stability. However, the hypothesis that human venous thrombi involve NETs has not undergone rigorous testing. Objective To explore the cellular composition and the presence of NETs within human venous thrombi at different stages of development. Patients and Methods We examined 16 thrombi obtained from 11 patients during surgery or at autopsy using histomorphological, immunohistochemical and immunofluorescence analyses. Results We classified thrombus regions as unorganized, organizing and organized according to their morphological characteristics. We then evaluated them, focusing on neutrophil and platelet deposition as well as micro-vascularization of the thrombus body. We observed evidence of NET accumulation, including the presence of citrullinated histone H3 (H3Cit)-positive cells. NETs, defined as extracellular diffuse H3Cit areas associated with myeloperoxidase and DNA, localized predominantly during the phase of organization in human venous thrombi. Conclusions NETs are present in organizing thrombi in patients with VTE. They are associated with thrombus maturation in humans. Dissolution of NETs might thus facilitate thrombolysis. This finding provides new insights into the clinical development and pathology of thrombosis and provides new perspectives for therapeutic advances. C1 [Savchenko, A. S.; Martinod, K.; Wong, S. L.; Borissoff, J. I.; Wagner, D. D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Savchenko, A. S.; Wong, S. L.; Borissoff, J. I.; Wagner, D. D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Martinod, K.] Harvard Univ, Sch Med, Div Med Sci, Grad Program Immunol, Boston, MA USA. [Seidman, M. A.; Mitchell, R. N.] Harvard Univ, Brigham & Womens Hosp, Med Sch, Dept Pathol & Lab Med, Boston, MA 02115 USA. [Piazza, G.; Libby, P.; Goldhaber, S. Z.] Harvard Univ, Brigham & Womens Hosp, Med Sch, Cardiovasc Med Div, Boston, MA 02115 USA. [Wagner, D. D.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. RP Wagner, DD (reprint author), Boston Childrens Hosp, 3 Blackfan Circle,3rd Floor, Boston, MA 02115 USA. EM Denisa.Wagner@childrens.harvard.edu OI Martinod, Kimberly/0000-0002-1026-6107; Seidman, Michael/0000-0002-9594-827X FU National Heart, Lung, and Blood Institute of the National Institutes of Health [R01HL102101]; Netherlands Organization for Scientific Research [825.11.019] FX The authors thank L. Cowan for help with the preparation of the manuscript. This research was supported by National Heart, Lung, and Blood Institute of the National Institutes of Health grant R01HL102101 (DDW). JIB is a recipient of a Rubicon fellowship (825.11.019) from the Netherlands Organization for Scientific Research. NR 38 TC 46 Z9 48 U1 3 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2014 VL 12 IS 6 BP 860 EP 870 DI 10.1111/jth.12571 PG 11 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA AJ5AB UT WOS:000337691200009 PM 24674135 ER PT J AU Stankovic, I Krismer, F Jesic, A Antonini, A Benke, T Brown, RG Burn, DJ Holton, JL Kaufmann, H Kostic, VS Ling, H Meissner, WG Poewe, W Semnic, M Seppi, K Takeda, A Weintraub, D Wenning, GK AF Stankovic, Iva Krismer, Florian Jesic, Aleksandar Antonini, Angelo Benke, Thomas Brown, Richard G. Burn, David J. Holton, Janice L. Kaufmann, Horacio Kostic, Vladimir S. Ling, Helen Meissner, Wassilios G. Poewe, Werner Semnic, Marija Seppi, Klaus Takeda, Atsushi Weintraub, Daniel Wenning, Gregor K. CA Movement Disorders Soc MSA MODIMSA TI Cognitive Impairment in Multiple System Atrophy: A Position Statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) Study Group SO MOVEMENT DISORDERS LA English DT Article DE cognition; multiple system atrophy; neuropsychology ID PROGRESSIVE SUPRANUCLEAR PALSY; VOXEL-BASED MORPHOMETRY; IDIOPATHIC PARKINSONS-DISEASE; BRAIN GLUCOSE-METABOLISM; CEREBELLAR TYPE; STRIATONIGRAL DEGENERATION; FRONTAL-LOBE; OLIVOPONTOCEREBELLAR ATROPHY; DEPRESSIVE SYMPTOMS; CLINICAL-PARAMETERS AB Consensus diagnostic criteria for multiple system atrophy consider dementia as a nonsupporting feature, despite emerging evidence demonstrating that cognitive impairments are an integral part of the disease. Cognitive disturbances in multiple system atrophy occur across a wide spectrum from mild single domain deficits to impairments in multiple domains and even to frank dementia in some cases. Frontal-executive dysfunction is the most common presentation, while memory and visuospatial functions also may be impaired. Imaging and neuropathological findings support the concept that cognitive impairments in MSA originate from striatofrontal deafferentation, with additional contributions from intrinsic cortical degeneration and cerebellar pathology. Based on a comprehensive evidencebased review, the authors propose future avenues of research that ultimately may lead to diagnostic criteria for cognitive impairment and dementia associated with multiple system atrophy. (C) 2014 International Parkinson and Movement Disorder Society C1 [Stankovic, Iva; Kostic, Vladimir S.] Univ Belgrade, Sch Med, Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia. [Krismer, Florian; Benke, Thomas; Poewe, Werner; Seppi, Klaus; Wenning, Gregor K.] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria. [Jesic, Aleksandar; Semnic, Marija] Univ Novi Sad, Neurol Clin, Clin Ctr Vojvodina, Sch Med Novi Sad, Novi Sad 21000, Serbia. [Antonini, Angelo] IRCCS, Fdn Osped San Camillo, Dept Parkinsons Dis, Venice, Italy. [Brown, Richard G.] Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England. [Burn, David J.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Holton, Janice L.; Ling, Helen] UCL, Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England. [Kaufmann, Horacio] NYU, Langone Med Ctr, Dysautonomia Ctr, New York, NY USA. [Meissner, Wassilios G.] Univ Bordeaux, Inst Malad Neurodegenerat, Bordeaux, France. [Takeda, Atsushi] Sendai Nishitaga Hosp, Natl Hosp Org, Dept Neurol, Sendai, Miyagi, Japan. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. RP Wenning, GK (reprint author), Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria. EM gregor.wenning@i-med.ac.at RI Ling, Helen/J-3751-2013; Brown, Richard/A-9599-2010; Meissner, Wassilios/C-7817-2015; OI Brown, Richard/0000-0001-9021-0172; Meissner, Wassilios/0000-0003-2172-7527; Kaufmann, Horacio/0000-0002-1851-9981 FU Austrian Science Fund (FWF) [F04404-B19]; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre; Dementia Biomedical Research Unit at South London, and Maudsley NHS Foundation Trust and King's College London; Reta Lila Weston Institute for Neurological Studies; Multiple System Atrophy Trust; National Institute for Health Research University College London Hospitals Biomedical Research Centre FX This study was supported by funds of the Austrian Science Fund (FWF): F04404-B19. Dr. Brown acknowledges support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Biomedical Research Unit at South London, and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. Dr. Holton is supported by the Reta Lila Weston Institute for Neurological Studies and the Multiple System Atrophy Trust. Part of the study was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. NR 80 TC 29 Z9 29 U1 2 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2014 VL 29 IS 7 BP 857 EP 867 DI 10.1002/mds.25880 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA AJ4TZ UT WOS:000337670600007 PM 24753321 ER PT J AU Achey, M Aldred, JL Aljehani, N Bloem, BR Biglan, KM Chan, P Cubo, E Dorsey, ER Goetz, CG Guttman, M Hassan, A Khandhar, SM Mari, Z Spindler, M Tanner, CM van den Haak, P Walker, R Wilkinson, JR AF Achey, Meredith Aldred, Jason L. Aljehani, Noha Bloem, Bastiaan R. Biglan, Kevin M. Chan, Piu Cubo, Esther Dorsey, E. Ray Goetz, Christopher G. Guttman, Mark Hassan, Anhar Khandhar, Suketu M. Mari, Zoltan Spindler, Meredith Tanner, Caroline M. van den Haak, Pieter Walker, Richard Wilkinson, Jayne R. CA Int Parkinson Movement Disorder TI The Past, Present, and Future of Telemedicine for Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE telemedicine; Parkinson's disease ID NURSING-HOME RESIDENTS; RANDOMIZED CONTROLLED-TRIAL; SEDENTARY PATIENTS; PHYSICAL-ACTIVITY; CLINICAL-TRIALS; UNITED-STATES; HEALTH-CARE; PREVALENCE; HISTORY; PEOPLE AB Travel distance, growing disability, and uneven distribution of doctors limit access to care for most Parkinson's disease (PD) patients worldwide. Telemedicine, the use of telecommunications technology to deliver care at a distance, can help overcome these barriers. In this report, we describe the past, present, and likely future applications of telemedicine to PD. Historically, telemedicine has relied on expensive equipment to connect single patients to a specialist in pilot programs in wealthy nations. As the cost of video conferencing has plummeted, these efforts have expanded in scale and scope, now reaching larger parts of the world and extending the focus from care to training of remote providers. Policy, especially limited reimbursement, currently hinders the growth and adoption of these new care models. As these policies change and technology advances and spreads, the following will likely develop: integrated care networks that connect patients to a wide range of providers; education programs that support patients and health care providers; and new research applications that include remote monitoring and remote visits. Together, these developments will enable more individuals with PD to connect to care, increase access to expertise for patients and providers, and allow more-extensive, less-expensive participation in research. (C) 2014 International Parkinson and Movement Disorder Society C1 [Achey, Meredith; Dorsey, E. Ray] Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA. [Aldred, Jason L.] Northwest Neurol PLLC, Spokane, WA USA. [Aljehani, Noha; Mari, Zoltan] Johns Hopkins Med, Dept Neurol, Baltimore, MD USA. [Bloem, Bastiaan R.; van den Haak, Pieter] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, Nijmegen, Netherlands. [Biglan, Kevin M.; Dorsey, E. Ray] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA. [Chan, Piu] Capital Med Univ, Dept Neurol & Neurobiol, Xuanwu Hosp,Beijing Inst Brain Disorders, Beijing Key Lab Parkinsons Dis,Parkinsons Dis Ctr, Beijing, Peoples R China. [Cubo, Esther] Univ Hosp, Dept Neurol, Burgos, Spain. [Goetz, Christopher G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Guttman, Mark] Univ Toronto, Div Neurol, Ctr Movement Disorders, Markham, ON, Canada. [Hassan, Anhar] Mayo Clin, Dept Neurol, Rochester, MN USA. [Khandhar, Suketu M.] Kaiser Permanente, Movement Disorders Program, Raleigh, NC USA. [Spindler, Meredith; Wilkinson, Jayne R.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Tanner, Caroline M.] Univ Calif San Francisco, Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Walker, Richard] North Tyneside Gen Hosp, Dept Med, North Shields, Tyne & Wear, England. [Wilkinson, Jayne R.] Dept Vet Affairs, Dept Neurol, Philadelphia, PA USA. RP Dorsey, ER (reprint author), Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, 265 Crittenden Blvd,CU 420694, Rochester, NY 14642 USA. EM ray.dorsey@chet.rochester.edu RI Bloem, B.R./H-8013-2014 FU Davis Phinney Foundation; Great Lakes NeuroTechnologies; Michael J. Fox Foundation; Patient-Centered Outcomes Research Institute FX Dr. Biglan has telemedicine research-related grants with the Davis Phinney Foundation, Great Lakes NeuroTechnologies, Michael J. Fox Foundation, and the Patient-Centered Outcomes Research Institute and has filed a patent related to telemedicine and neurology. Dr. Dorsey has telemedicine research-related grants with the Davis Phinney Foundation, Great Lakes NeuroTechnologies, Michael J. Fox Foundation, and the Patient-Centered Outcomes Research Institute, is a member of the medical advisory board for, and has stock options in, Grand Rounds (an online second opinion service), is an unpaid advisor to SBR Health and Vidyo, and has filed a patent related to telemedicine and neurology. Dr. Goetz is an officer of the International Parkinson and Movement Disorder Society (MDS) that supports this program. Dr. Tanner is a coinvestigator on telemedicine research-related grants with the Davis Phinney Foundation, the Patient-Centered Outcomes Research Institute, and the MDS. NR 89 TC 22 Z9 22 U1 4 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2014 VL 29 IS 7 BP 871 EP 883 DI 10.1002/mds.25903 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA AJ4TZ UT WOS:000337670600011 PM 24838316 ER PT J AU Gardner, CD Whitsel, LP Thorndike, AN Marrow, MW Otten, JJ Foster, GD Carson, JAS Johnson, RK AF Gardner, Christopher D. Whitsel, Laurie P. Thorndike, Anne N. Marrow, Mary W. Otten, Jennifer J. Foster, Gary D. Carson, Jo Ann S. Johnson, Rachel K. TI Food-and-beverage environment and procurement policies for healthier work environments SO NUTRITION REVIEWS LA English DT Review DE food and beverage environments; nutrition policy; procurement standards; public health; work environments ID AMERICAN-HEART-ASSOCIATION; POINT-OF-PURCHASE; NEW-YORK-CITY; FINANCIAL INCENTIVES; SCIENTIFIC STATEMENT; CALORIE INFORMATION; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; LABELING REGULATION; CONSUMER AWARENESS AB The importance of creating healthier work environments by providing healthy foods and beverages in worksite cafeterias, in on-site vending machines, and at meetings and conferences is drawing increasing attention. Large employers, federal and state governments, and hospital systems are significant purchasers and providers of food and beverages. The American Heart Association, federal government, and other organizations have created procurement standards to guide healthy purchasing by these entities. There is a need to review how procurement standards are currently implemented, to identify important minimum criteria for evaluating health and purchasing outcomes, and to recognize significant barriers and challenges to implementation, along with success stories. The purpose of this policy paper is to describe the role of food-and-beverage environment and procurement policy standards in creating healthier worksite environments; to review recently created national model standards; to identify elements across the standards that are important to consider for incorporation into policies; and to delineate issues to address as standards are implemented across the country. C1 [Gardner, Christopher D.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Whitsel, Laurie P.] Amer Heart Assoc, Washington, DC USA. [Thorndike, Anne N.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Marrow, Mary W.] William Mitchell Coll Law, Publ Hlth Law Ctr, St Paul, MN USA. [Otten, Jennifer J.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Foster, Gary D.] Temple Univ, Dept Med, Philadelphia, PA 19122 USA. [Foster, Gary D.] Temple Univ, Dept Publ Hlth, Philadelphia, PA 19122 USA. [Foster, Gary D.] Temple Univ, Dept Psychiat, Philadelphia, PA 19122 USA. [Carson, Jo Ann S.] Univ Texas SW Med Ctr Dallas, Dept Clin Nutr, Dallas, TX 75390 USA. [Johnson, Rachel K.] Univ Vermont, Dept Nutr & Food Sci, Burlington, VT USA. RP Gardner, CD (reprint author), 1265 Welch Rd,SPRC 310, Stanford, CA 94305 USA. EM cgardner@stanford.edu FU NIH/National Heart Lung and Blood Institute [K23 HL93221] FX Funding. Dr Thorndike is supported by the NIH/National Heart Lung and Blood Institute, grant K23 HL93221. None of the other authors have any funding sources to report. NR 84 TC 7 Z9 7 U1 5 U2 35 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0029-6643 EI 1753-4887 J9 NUTR REV JI Nutr. Rev. PD JUN PY 2014 VL 72 IS 6 BP 390 EP 410 DI 10.1111/nure.12116 PG 21 WC Nutrition & Dietetics SC Nutrition & Dietetics GA AJ3VU UT WOS:000337596800004 PM 24801009 ER PT J AU Huerta, CI Sarkar, PR Duong, TQ Laird, AR Fox, PT AF Huerta, Claudia I. Sarkar, Pooja R. Duong, Timothy Q. Laird, Angela R. Fox, Peter T. TI Neural Bases of Food Perception: Coordinate-Based Meta-Analyses of Neuroimaging Studies in Multiple Modalities SO OBESITY LA English DT Article ID ALE METAANALYSIS; FUNCTIONAL MRI; BRAIN; ACTIVATION; ADDICTION; CALORIE; OBESITY; INSULA; CUES AB Objective: The purpose of this study was to compare the results of the three food-cue paradigms most commonly used for functional neuroimaging studies to determine: i) commonalities and differences in the neural response patterns by paradigm and ii) the relative robustness and reliability of responses to each paradigm. Methods: Functional magnetic resonance imaging studies using standardized stereotactic coordinates to report brain responses to food cues were identified using online databases. Studies were grouped by food-cue modality as: i) tastes (8 studies); ii) odors (8 studies); and, iii) images (11 studies). Activation likelihood estimation was used to identify statistically reliable regional responses within each stimulation paradigm. Results: Brain response distributions were distinctly different for the three stimulation modalities, corresponding to known differences in location of the respective primary and associative cortices. Visual stimulation induced the most robust and extensive responses. The left anterior insula was the only brain region reliably responding to all three stimulus categories. Conclusions: These findings suggest visual food-cue paradigm as promising candidate for imaging studies addressing the neural substrate of therapeutic interventions. C1 [Huerta, Claudia I.; Sarkar, Pooja R.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Huerta, Claudia I.; Sarkar, Pooja R.; Duong, Timothy Q.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Duong, Timothy Q.; Laird, Angela R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Huerta, CI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. EM fox@uthscsa.edu RI Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU [R01 MH074457] FX This study was funded by R01 MH074457 (PTF and ARL, PIs). NR 40 TC 10 Z9 10 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD JUN PY 2014 VL 22 IS 6 BP 1439 EP 1446 DI 10.1002/oby.20659 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA AJ3AM UT WOS:000337537000009 PM 24174404 ER PT J AU Ciaranello, A Lu, ZG Ayaya, S Losina, E Musick, B Vreeman, R Freedberg, KA Abrams, EJ Dillabaugh, L Doherty, K Ssali, J Yiannoutsos, CT Wools-Kaloustian, K AF Ciaranello, Andrea Lu, Zhigang Ayaya, Samuel Losina, Elena Musick, Beverly Vreeman, Rachel Freedberg, Kenneth A. Abrams, Elaine J. Dillabaugh, Lisa Doherty, Katie Ssali, John Yiannoutsos, Constantin T. Wools-Kaloustian, Kara TI Incidence of World Health Organization Stage 3 and 4 Events, Tuberculosis and Mortality in Untreated, HIV-infected Children Enrolling in Care Before 1 Year of Age An IeDEA (International Epidemiologic Databases To Evaluate AIDS) East Africa Regional Analysis SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE pediatric HIV; opportunistic infection; morbidity; mortality ID RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED CHILDREN; DISEASE PROGRESSION; SOUTH-AFRICA; INFANTS BORN; ZAMBIAN CHILDREN; UGANDAN CHILDREN; LYMPHOCYTE COUNT; POOLED ANALYSIS AB Background: Few studies have reported CD4%- and age-stratified rates of World Health Organization Stage 3 (WHO3) events, World Health Organization Stage 4 (WHO4) events, tuberculosis (TB) and mortality in HIV-infected infants before initiation of antiretroviral therapy. Methods: HIV-infected children enrolled before 1 year of age in the International Epidemiologic Databases to Evaluate AIDS East Africa region (October 1, 2002, to November, 2008) were included. We estimated incidence rates of earliest clinical event (WHO3, WHO4 and TB), before antiretroviral therapy initiation per local guidelines, stratified by current age (< or >= 6 months) and current CD4% (<15%, 15-24%, >= 25%). CD4%-stratified mortality rates were estimated separately for children who did not experience a clinical event ("background" mortality) and for children who experienced an event, including "acute" mortality (<= 30 days post event) and "later" mortality (>30 days post event). Results: Among 847 children (median enrollment age: 4.8 months; median pre-antiretroviral therapy follow up: 10.8 months; 603 (71%) with >= 1 CD4% recorded), event rates were comparable for those aged <6 and >= 6 months. Current CD4% was associated with risk of WHO4 events for children <6 months of age and with all evaluated events for children >= 6 months old (P < 0.05). "Background" mortality was 3.7-8.4/100 person-years (PY). "Acute" mortality (<= 30 days post event) was 33.8/100 PY (after TB) and 41.1/100 PY (after WHO3 or WHO4). "Later" mortality (>30 days post event) ranged by CD4% from 4.7 to 29.1/100 PY. Conclusions: In treatment-naive, HIV-infected infants, WHO3, WHO4 and TB events were common before and after 6 months of age and led to substantial increases in mortality. Early infant HIV diagnosis and treatment are critically important, regardless of CD4%. C1 [Ciaranello, Andrea; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Ciaranello, Andrea; Lu, Zhigang; Losina, Elena; Freedberg, Kenneth A.; Doherty, Katie] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. [Lu, Zhigang; Losina, Elena; Freedberg, Kenneth A.; Doherty, Katie] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Ayaya, Samuel] Moi Univ, Sch Med, Dept Child Hlth & Paediat, Eldoret, Kenya. [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. [Musick, Beverly; Yiannoutsos, Constantin T.] Indiana Univ, Dept Biostat, Indianapolis, IN 46204 USA. [Vreeman, Rachel] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA. [Abrams, Elaine J.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10027 USA. [Abrams, Elaine J.] Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA. [Dillabaugh, Lisa] Family AIDS Care & Educ Serv FACES Program, Kisumu, Kenya. [Dillabaugh, Lisa] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Ssali, John] AHF Uganda Cares Masaka, Masaka Reg Referral Hosp, Masaka, Uganda. [Wools-Kaloustian, Kara] Indiana Univ Sch Med, Div Infect Dis, Indianapolis, IN 46202 USA. RP Ciaranello, A (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,Room 920, Boston, MA 02114 USA. EM aciaranello@partners.org FU National Institutes of Health through the International Epidemiologic Databases to Evaluate AIDS (IeDEA); International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT); National Institute of Allergy and Infectious Disease (NIAID) [K01 AI078754, R01 AI058736]; President's Emergency Fund for AIDS Relief (PEPfAR); Elizabeth Glaser Pediatric AIDS Foundation; NIAID; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Cancer Institute [U01 AI069911]; NIAID [U01 AI068632]; Eunice Kennedy Shriver NICHD; National Institute of Mental Health (NIMH) [AI068632]; Statistical and Data Analysis Center at Harvard School of Public Health, under the NIAID [5 U01 AI41110]; Pediatric AIDS Clinical Trials Group (PACTG) [1 U01 AI068616]; IMPAACT Group; NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network - NICHD [N01-DK-9-001/HHSN267200800001C] FX Funding for this work was provided by the National Institutes of Health through the International Epidemiologic Databases to Evaluate AIDS (IeDEA: S. A., B. M., R. V., J.S., C.T.Y., K. W. K.), the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT; A. L. C., Z.L., K. A. F., K. D.), and the National Institute of Allergy and Infectious Disease (NIAID) (K01 AI078754 [ALC], R01 AI058736 [Z.L., E. L., K. A. F., K. D.]), as well as the President's Emergency Fund for AIDS Relief (PEPfAR; S. A., B. M., R. V., C.T.Y., K. W. K.), and the Elizabeth Glaser Pediatric AIDS Foundation (A. L. C., K. A. F.). The funders had no role in study design, interpretation of results, or decision to publish. The authors have no other funding or conflicts of interest to disclose.; Overall support for IeDEA was provided by the NIAID, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Cancer Institute, through U01 AI069911.; Overall support for IMPAACT was provided by the NIAID (U01 AI068632), the Eunice Kennedy Shriver NICHD, and the National Institute of Mental Health (NIMH) (AI068632). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported by the Statistical and Data Analysis Center at Harvard School of Public Health, under the NIAID cooperative agreement #5 U01 AI41110 with the Pediatric AIDS Clinical Trials Group (PACTG) and #1 U01 AI068616 with the IMPAACT Group. Support of the sites was provided by the NIAID and the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network funded by NICHD (contract number N01-DK-9-001/HHSN267200800001C). NR 35 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JUN PY 2014 VL 33 IS 6 BP 623 EP 629 DI 10.1097/INF.0000000000000223 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA AJ0OL UT WOS:000337354400018 PM 24378935 ER PT J AU Kaafarani, HMA Velmahos, GC AF Kaafarani, H. M. A. Velmahos, G. C. TI DAMAGE CONTROL RESUSCITATION IN TRAUMA SO SCANDINAVIAN JOURNAL OF SURGERY LA English DT Review DE Resuscitation; hemorrhage; consumption coagulopathy; blood component transfusion; wounds and injury; acidosis ID FRESH-FROZEN PLASMA; RED-BLOOD-CELL; MASSIVE TRANSFUSION PROTOCOL; RANDOMIZED CONTROLLED-TRIAL; HYPERTONIC SALINE RESUSCITATION; LIFE-THREATENING COAGULOPATHY; ADVERSELY AFFECTS OUTCOMES; GLUE GRANT DATABASE; FLUID RESUSCITATION; HEMORRHAGIC-SHOCK AB Introduction: Most preventable trauma deaths are due to uncontrolled hemorrhage. Methods: In this article, we briefly describe the pathophysiology of the classical triad of death in trauma, namely, acidosis, hypothermia, and coagulopathy, and then suggest damage control resuscitation strategies to prevent and/or mitigate the effects of each in the bleeding patient. Results: Damage control resuscitation strategies include body rewarming, restrictive fluid administration, permissive hypotension, balanced blood product administration, and the implementation of massive transfusion protocols. Conclusion: Resuscitating and correcting the coagulopathy of the exsanguinating trauma patient is essential to improve chances of survival. C1 [Kaafarani, H. M. A.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Kaafarani, H. M. A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Kaafarani, HMA (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM hkaafarani@partners.org NR 79 TC 13 Z9 14 U1 1 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1457-4969 EI 1799-7267 J9 SCAND J SURG JI Scand. J. Surg. PD JUN PY 2014 VL 103 IS 2 BP 81 EP 88 PG 8 WC Surgery SC Surgery GA AJ3NL UT WOS:000337573400002 PM 24777616 ER PT J AU Ellis, LE Beckman, JA AF Ellis, Lauren E. Beckman, Joshua A. TI Baby blue SO VASCULAR MEDICINE LA English DT Editorial Material ID DERMATOSES C1 [Ellis, Lauren E.] Massachusetts Gen Hosp, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA. [Beckman, Joshua A.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. RP Beckman, JA (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM jbeckman@partners.org OI Beckman, Joshua/0000-0001-8332-8439 NR 2 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1358-863X EI 1477-0377 J9 VASC MED JI Vasc. Med. PD JUN PY 2014 VL 19 IS 3 BP 215 EP 215 DI 10.1177/1358863X14526949 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AJ3PS UT WOS:000337579800008 PM 24608693 ER PT J AU Moore, EK Gu, XK Olin, JW Froehlich, JB Bacharach, JM Jaff, MR Katzen, BT Kline-Rogers, E Mace, PD Matsumoto, AH McBane, RD White, CJ Kim, ESH Gornik, HL Gray, BH AF Moore, Erin K. Gu, Xiaokui Olin, Jeffrey W. Froehlich, James B. Bacharach, J. Michael Jaff, Michael R. Katzen, Barry T. Kline-Rogers, Eva Mace, Pamela D. Matsumoto, Alan H. McBane, Robert D. White, Christopher J. Kim, Esther S. H. Gornik, Heather L. Gray, Bruce H. TI Registry findings of fibromuscular dysplasia of the mesenteric arteries SO VASCULAR MEDICINE LA English DT Meeting Abstract C1 [Moore, Erin K.; Gray, Bruce H.] Greenville Hlth Syst, Greenville, SC USA. [Gu, Xiaokui; Froehlich, James B.; Kline-Rogers, Eva] Univ Michigan, Ann Arbor, MI 48109 USA. [Olin, Jeffrey W.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Bacharach, J. Michael] North Cent Heart, Sioux Falls, SD USA. [Jaff, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Katzen, Barry T.] Miami Baptist Cardiac Vasc Inst, Miami, FL USA. [Mace, Pamela D.] Fibromuscular Dysplasia Soc Amer, Rocky River, OH USA. [Matsumoto, Alan H.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [McBane, Robert D.] Mayo Clin, Rochester, MN USA. [White, Christopher J.] Ochsner Clin & Alton Ochsner Med Fdn, New Orleans, LA USA. [Kim, Esther S. H.; Gornik, Heather L.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1358-863X EI 1477-0377 J9 VASC MED JI Vasc. Med. PD JUN PY 2014 VL 19 IS 3 MA YIA 4 BP 224 EP 225 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AJ3PS UT WOS:000337579800015 ER PT J AU Yen, PJ Mefford, ME Hoxie, JA Williams, KC Desrosiers, RC Gabuzda, D AF Yen, Po-Jen Mefford, Megan E. Hoxie, James A. Williams, Kenneth C. Desrosiers, Ronald C. Gabuzda, Dana TI Identification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques SO VIROLOGY LA English DT Article DE Human immunodeficiency virus (HIV); Simian immunodeficiency virus (SIV); Envelope glycoprotein (Env); Macrophage tropism; Brain ID SIMIAN-IMMUNODEFICIENCY-VIRUS; N-LINKED GLYCOSYLATION; CENTRAL-NERVOUS-SYSTEM; HIV-1 VACCINE EFFICACY; NEUTRALIZATION SENSITIVITY; RHESUS MACAQUES; MOLECULAR CLONES; IN-VIVO; BIOLOGICAL CHARACTERIZATION; PERIVASCULAR MACROPHAGES AB Macrophages play an important role in HIV/SIV pathogenesis by serving as a reservoir for viral persistence in brain and other tissues. Infected macrophages have been detected in brain early after infection, but macrophage-tropic viruses are rarely isolated until late-stage infection. Little is known about early variants that establish persistent infection in brain. Here, we characterize a unique macrophage-tropic SW envelope glycoprotein (Env) variant from two weeks post-infection in blood of an SIVmac251-infected macaque that is closely related to sequences in brain from animals with neurological disease. SIVmac251 clones expressing this Env are highly fusogenic, and replicate efficiently in T cells and macrophages. N173 and N481 were identified as novel determinants of macrophage tropism and neutralization sensitivity. These results imply that macrophage-tropic SW capable of establishing viral reservoirs in brain can be present in blood during early infection. Furthermore, these SIVmac251 clones will be useful for studies on pathogenesis, eradication, and vaccines. (C) 2014 The Authors. Published by Elsevier Inc. C1 [Yen, Po-Jen; Mefford, Megan E.; Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA. [Yen, Po-Jen; Mefford, Megan E.] Harvard Univ, Sch Med, Div Med Sci, Program Virol, Boston, MA USA. [Hoxie, James A.] Univ Penn, Dept Med, Hematol Oncol Div, Philadelphia, PA 19104 USA. [Williams, Kenneth C.] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA. [Desrosiers, Ronald C.] Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Immunobiol, Southborough, MA 01772 USA. [Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. RP Gabuzda, D (reprint author), Dana Farber Canc Inst, CLS-1010,450 Brookline Ave, Boston, MA 02215 USA. EM Dana_Gabuzda@dfci.harvard.edu FU NIH [MH83588, MH97659]; NIH fellowship [F31NS060611] FX This work was supported by NIH grants MH83588 and MH97659 to D.G. M.E.M. was supported in part by NIH fellowship F31NS060611. Core facilities were supported by Harvard Medical School Center for AIDS Research (CFAR) and DFCI/Harvard Cancer Center grants. NR 89 TC 5 Z9 5 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD JUN PY 2014 VL 458 BP 53 EP 68 DI 10.1016/j.virol.2014.03.024 PG 16 WC Virology SC Virology GA AJ4RZ UT WOS:000337664800007 PM 24928039 ER PT J AU Geffrey, AL Shinnick, JE Staley, BA Boronat, S Thiele, EA AF Geffrey, Alexandra L. Shinnick, Julianna E. Staley, Brigid A. Boronat, Susana Thiele, Elizabeth A. TI Lymphedema in tuberous sclerosis complex SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE edema; lymphatic abnormalities; lymphedema; tuberous sclerosis complex ID CONGENITAL LYMPHEDEMA; DISEASE; LYMPHANGIOLEIOMYOMATOSIS; PROGNOSIS; TSC2 AB Congenital lymphedema has been described as a possible rare association of tuberous sclerosis complex (TSC), with only six previous cases reported in the literature. TSC is an autosomal dominant, multisystem disorder connected to aberrant regulation of the mammalian target of rapamycin (mTOR) pathway. The aim of this study is to review cases of lymphedema in a large cohort of TSC patients. The medical records of 268 patients seen at The Herscot Center for Children and Adults with Tuberous Sclerosis Complex at the Massachusetts General Hospital from 2002 to 2012 were retrospectively reviewed for reports of lymphedema or edema of unknown etiology. Genotypic and phenotypic data were collected in accordance with institutional review board (IRB) approval. This cohort presents two new cases of congenital lymphedema in TSC patients and acquired lymphedema was found in eight additional cases. Thus, we report 10 new cases of lymphedema in TSC (4%). The two patients with congenital lymphedema were female, as were the previous six reported cases. The frequency of lymphedema reported here (4%) is higher than the estimated prevalence in the general population (0.133-0.144%), suggesting a higher frequency of lymphedema in TSC. This study shows that patients with TSC and lymphedema are more likely to be females with renal AMLs and suggests that congenital lymphedema is a gender-specific (female) manifestation of TSC. Exploration of the potential role of mTOR antagonists may be important in treatment of lymphedema in TSC patients. (c) 2014 Wiley Periodicals, Inc. C1 [Geffrey, Alexandra L.; Shinnick, Julianna E.; Staley, Brigid A.; Boronat, Susana; Thiele, Elizabeth A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Boronat, Susana] Univ Autonoma Barcelona, Vall dHebron Hosp, Dept Pediat Neurol, E-08193 Barcelona, Spain. RP Thiele, EA (reprint author), Herscot Ctr Tuberous Sclerosis Complex, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM ethiele@partners.org FU Herscot Center for Tuberous Sclerosis Complex; NIH/NINDS [P01 NS024279] FX Grant sponsor: Herscot Center for Tuberous Sclerosis Complex; Grant sponsor: NIH/NINDS; Grant number: P01 NS024279. NR 28 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD JUN PY 2014 VL 164 IS 6 BP 1438 EP 1442 DI 10.1002/ajmg.a.36469 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA AH2BV UT WOS:000335926600011 PM 24668795 ER PT J AU Huddle, TS Kertesz, SG Nash, RR AF Huddle, Thomas S. Kertesz, Stefan G. Nash, Ryan R. TI Health Care Institutions Should Not Exclude Smokers From Employment SO ACADEMIC MEDICINE LA English DT Article ID SMOKING; WORKPLACE AB Some health care institutions, including academic health centers, have adopted policies excluding smokers from employment. Claims advanced on behalf of these policies include financial savings from reduced health costs and absenteeism as well as advantages consonant with their message of healthy living. The authors suggest that the institutional savings from these policies are speculative and unproven. Also, in settings where large medical schools operate, it is likely to be the poor, including members of minority groups, who, under an employee smoker ban, will lose the opportunity to work for an employer that offers health insurance and other benefits. In response to the incentives created by such bans, some will quit smoking, but most will not. Thus, at the community level, employee smoker bans are more likely to be harmful than beneficial. Although private businesses may rightly choose not to hire smokers in the 19 states where such policies are legal, health care institutions, including academic health centers, should consider hiring choices in light of the values they profess. The traditional values of medicine include service to all persons in need, even when illness results from addiction or unsafe behavior. Secular academic communities require a shared dedication to discovery without requiring strict conformity of private behavior or belief. The authors conclude that for health care institutions, policies of hiring smokers and helping them to quit are both prudent and expressive of the norms of medical care, such as inclusion, compassion, and fellowship, that academic health professionals seek to honor. C1 [Huddle, Thomas S.; Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Huddle, Thomas S.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA. [Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Nash, Ryan R.] Ohio State Univ, Ctr Bioeth, Columbus, OH 43210 USA. RP Huddle, TS (reprint author), FOT 720,1530 3rd Ave S, Birmingham, AL 35294 USA. EM thuddle@uab.edu OI Kertesz, Stefan/0000-0001-6101-8421 NR 24 TC 3 Z9 3 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD JUN PY 2014 VL 89 IS 6 BP 843 EP 847 DI 10.1097/ACM.0000000000000247 PG 5 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA AI8NU UT WOS:000337176300012 PM 24871233 ER PT J AU Beresin, EV Balon, R Coverdale, J AF Beresin, Eugene V. Balon, Richard Coverdale, John TI The Psychiatry Milestones: New Developments and Challenges SO ACADEMIC PSYCHIATRY LA English DT Editorial Material ID MEDICAL-ETHICS C1 [Beresin, Eugene V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Balon, Richard] Wayne State Univ, Detroit, MI USA. [Coverdale, John] Baylor Coll Med, Houston, TX 77030 USA. RP Beresin, EV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. EM eberesin@partners.org NR 16 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1042-9670 EI 1545-7230 J9 ACAD PSYCHIATR JI Acad. Psych. PD JUN PY 2014 VL 38 IS 3 BP 249 EP 252 DI 10.1007/s40596-014-0119-6 PG 4 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA AI8FH UT WOS:000337143800001 PM 24764014 ER PT J AU Benjamin, S Widge, A Shaw, K AF Benjamin, Sheldon Widge, Alik Shaw, Kailie TI Neuropsychiatry and Neuroscience Milestones for General Psychiatry Trainees SO ACADEMIC PSYCHIATRY LA English DT Article ID CLINICAL NEUROSCIENCE; NEUROLOGY; RESIDENTS; EDUCATION; FUTURE C1 [Benjamin, Sheldon] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. [Widge, Alik] Massachusetts Gen Hosp, Charlestown, MA USA. [Shaw, Kailie] Univ S Florida, Morsani Coll Med, Tampa, FL USA. RP Benjamin, S (reprint author), Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. EM sheldon.benjamin@umassmed.edu OI Benjamin, Sheldon/0000-0001-6279-1934 NR 41 TC 3 Z9 3 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1042-9670 EI 1545-7230 J9 ACAD PSYCHIATR JI Acad. Psych. PD JUN PY 2014 VL 38 IS 3 BP 275 EP 282 DI 10.1007/s40596-014-0112-0 PG 8 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA AI8FH UT WOS:000337143800006 PM 24715675 ER PT J AU Widge, AS Hunt, J Servis, M AF Widge, Alik S. Hunt, Jeffrey Servis, Mark TI Systems-Based Practice and Practice-Based Learning for the General Psychiatrist: Old Competencies, New Emphasis SO ACADEMIC PSYCHIATRY LA English DT Article ID HEALTH-CARE; MENTAL-HEALTH; QUALITY IMPROVEMENT; COLLABORATIVE CARE; OPPORTUNITIES; RESIDENCY; EDUCATION; SETTINGS; RECOVERY; CENTERS C1 [Hunt, Jeffrey] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Servis, Mark] Univ Calif Davis, Sacramento, CA 95817 USA. RP Widge, AS (reprint author), Massachusetts Gen Hosp, Charlestown, MA 02129 USA. EM awidge@partners.org NR 41 TC 5 Z9 5 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1042-9670 EI 1545-7230 J9 ACAD PSYCHIATR JI Acad. Psych. PD JUN PY 2014 VL 38 IS 3 BP 288 EP 293 DI 10.1007/s40596-014-0104-0 PG 6 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA AI8FH UT WOS:000337143800008 PM 24711094 ER PT J AU Widge, AS Schultz, HE AF Widge, Alik S. Schultz, Heather E. TI Opportunities and Challenges: Residents' Perspectives on the Next Accreditation System in Psychiatry SO ACADEMIC PSYCHIATRY LA English DT Editorial Material DE Accreditation; Graduate medical education; Internship and residency ID ACGME; COUNCIL C1 [Widge, Alik S.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Schultz, Heather E.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. RP Widge, AS (reprint author), Massachusetts Gen Hosp, Charlestown, MA 02129 USA. EM awidge@partners.org NR 7 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1042-9670 EI 1545-7230 J9 ACAD PSYCHIATR JI Acad. Psych. PD JUN PY 2014 VL 38 IS 3 BP 303 EP 304 DI 10.1007/s40596-014-0094-y PG 2 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA AI8FH UT WOS:000337143800010 PM 24664610 ER PT J AU Dickey, C Dismukes, R Topor, D AF Dickey, Chandlee Dismukes, Rodney Topor, David TI Creating Opportunities for Organizational Leadership (COOL): Creating a Culture and Curriculum that Fosters Psychiatric Leadership Development and Quality Improvement SO ACADEMIC PSYCHIATRY LA English DT Article DE Psychiatry residents; Leadership; Curriculum development ID MANAGEMENT; PROGRAM AB The authors describe the Harvard South Shore Psychiatry Residency Training Program curriculum "Creating Opportunities for Organizational Leadership," an innovative, multitiered, resident-driven, outcome-focused set of experiences designed to develop residents' leadership skills in personal leadership, organizational leadership, negotiation, strategic thinking, and systems redesign. C1 [Dickey, Chandlee; Dismukes, Rodney; Topor, David] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA. RP Dickey, C (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA. EM Chandlee.Dickey@va.gov NR 20 TC 1 Z9 1 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1042-9670 EI 1545-7230 J9 ACAD PSYCHIATR JI Acad. Psych. PD JUN PY 2014 VL 38 IS 3 BP 383 EP 387 DI 10.1007/s40596-014-0082-2 PG 5 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA AI8FH UT WOS:000337143800027 PM 24664604 ER PT J AU Momplaisir, F Yehia, BR Harhay, MO Fetzer, B Brady, KA Long, JA AF Momplaisir, Florence Yehia, Baligh R. Harhay, Michael O. Fetzer, Bradley Brady, Kathleen A. Long, Judith A. TI HIV Testing Trends: Southeastern Pennsylvania, 2002-2010 SO AIDS PATIENT CARE AND STDS LA English DT Article ID FOR-DISEASE-CONTROL; EMERGENCY-DEPARTMENT; ANTIRETROVIRAL THERAPY; UNITED-STATES; CLINICAL GUIDELINES; PREVALENCE AREA; SEXUAL HISTORY; CARE; PREVENTION; PROGRAM AB There are limited data on HIV testing trends after 2006 when the Centers for Disease Control and Prevention (CDC) introduced opt-out HIV testing with the aims of identifying HIV-infected persons early and linking them to care. We used data from the Southeastern Pennsylvania Household Health Survey between 2002 and 2010 to evaluate HIV testing over time. 50,698 adult (>= 18 years) survey respondents were included. HIV testing increased after the CDC recommendations: 42.1% of survey respondents received testing at least once in 2002 versus 51.4% in 2010, p < 0.001. Testing trends increased among all demographic groups, but existing differences in testing before 2006 persisted after that year as follows: younger patients, racial/ethnic minorities, patients on Medicaid were all more likely to get tested than their counterparts. Blacks and patients seeking care in community health centers had the fastest rise in HIV testing. The probability of HIV testing in Blacks was 0.56 (95% CI 0.54-0.60) in 2002 and increased to 0.73 (0.70-0.76) by 2010. Patients seeking care in community health centers had a probability of HIV testing of 0.57 (0.47-0.66) in 2002, which increased to 0.69 (0.60-0.77) by 2010. In comparison, patients in private clinics had an HIV testing probability of 0.40 (0.360.43) in 2002 compared to 0.47 (0.40-0.54) in 2010. HIV testing is increasing, particularly among ethnic minorities and in community health centers. However, testing remains to be improved in that setting and across all clinic types. C1 [Momplaisir, Florence] Temple Univ Hosp & Med Sch, Infect Dis Sect, Philadelphia, PA 19140 USA. [Yehia, Baligh R.] Univ Penn, Div Infect Dis, Perelman Sch Med, Philadelphia, PA 19104 USA. [Harhay, Michael O.; Fetzer, Bradley; Long, Judith A.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Brady, Kathleen A.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Momplaisir, F (reprint author), Temple Univ Hosp & Med Sch, Suite 501,3401 North Broad St, Philadelphia, PA 19140 USA. EM Florence.Momplaisir@tuhs.temple.edu OI Harhay, Michael/0000-0002-0553-674X FU NIMH NIH HHS [K23 MH097647] NR 48 TC 4 Z9 4 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD JUN PY 2014 VL 28 IS 6 BP 303 EP 310 DI 10.1089/apc.2014.0044 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AI9CG UT WOS:000337224700005 PM 24742326 ER PT J AU Buckheit, RW Sexauer, SB Sedaghat, AR Wilke, CO Laeyendecker, O Basseth, CR Blankson, JN AF Buckheit, Robert W., III Sexauer, Stephen B. Sedaghat, Ahmad R. Wilke, Claus O. Laeyendecker, Oliver Basseth, Christie R. Blankson, Joel N. TI Long-Term Control of Viral Replication in a Group O, Human Immunodeficiency Virus Type 1-Infected Individual SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Letter ID HIV-1; INFECTION; EVOLUTION; CAMEROON C1 [Buckheit, Robert W., III; Sexauer, Stephen B.; Laeyendecker, Oliver; Basseth, Christie R.; Blankson, Joel N.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Sedaghat, Ahmad R.] Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Wilke, Claus O.] Ctr Computat Biol & Bioinformat, Sect Integrat Biol, Austin, TX USA. [Wilke, Claus O.] Univ Texas Austin, Inst Cell & Mol Biol, Austin, TX 78712 USA. [Laeyendecker, Oliver] NIAID, Div Intramural Res, NIH, Baltimore, MD USA. RP Blankson, JN (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, 733 North Broadway,BRB 880, Baltimore, MD 21205 USA. EM jblanks@jhmi.edu OI Laeyendecker, Oliver/0000-0002-6429-4760; Wilke, Claus/0000-0002-7470-9261 FU NIGMS NIH HHS [T32 GM008752] NR 13 TC 2 Z9 2 U1 0 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JUN PY 2014 VL 30 IS 6 BP 511 EP 513 DI 10.1089/aid.2014.0054 PG 3 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AI9CE UT WOS:000337224400001 PM 24798496 ER PT J AU Pena, J Jones, NG Bousheri, S Bangsberg, DR Cao, HY AF Pena, Jose Jones, Norman G. Bousheri, Stephanie Bangsberg, David R. Cao, Huyen TI Lymphocyte Activation Gene-3 Expression Defines a Discrete Subset of HIV-Specific CD8(+) T Cells That Is Associated with Lower Viral Load SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID MHC CLASS-II; NEGATIVE REGULATORY FUNCTION; ANTIRETROVIRAL THERAPY; DISEASE PROGRESSION; PD-1 EXPRESSION; FLOW-CYTOMETRY; UP-REGULATION; LAG-3; INFECTION; CD223 AB Mechanisms leading to the observed immune dysregulation in chronic HIV infection are not well understood. The MHC-II class ligand, lymphocyte activation gene-3 (LAG-3, CD223), has been implicated in the complex regulation mechanism of immune functions. In this study, we describe a new population of HIV-specific CD8(+) T cells expressing LAG-3. These LAG-3(+)CD8(+) T cells do not display immunophenotypic patterns traditionally attributed to regulatory T cells. The LAG3(+)CD8(+) T cells are CCR7(+), CD127(-), and display heterogeneous surface expressions of CD45RA and CD25. Interestingly, HIV-specific LAG-3(+)CD8(+) T cells do not substantially express CTLA-4 and LAG-3 expression does not correlate with interleukin (IL)-10 or tumor growth factor (TGF)-beta production. In addition, HIV-specific LAG3(+)CD8(+) T cells do not produce interferon (IFN-gamma) or express CD107a. The frequency of HIV-specific LAG3(+)CD8(+) T cells negative correlated with plasma viral load. Our study introduces a new population of HIV-specific CD8(+) T cells and proposes additional mechanisms of immune regulation in chronic HIV infection. C1 [Pena, Jose; Jones, Norman G.; Bousheri, Stephanie; Cao, Huyen] Calif Dept Publ Hlth, Richmond, CA USA. [Bangsberg, David R.] Harvard Univ, Ragon Inst MGH MIT & Harvard, Massachusetts Gen Hosp Ctr Global Hlth, Mbarara Univ Sci & Technol,Med Sch, Boston, MA USA. RP Pena, J (reprint author), Care Of Huyen Cao, Calif Dept Publ Hlth, VRDL, 850 Marina Bay Pkwy, Richmond, CA 94804 USA. EM huyen.cao@cdph.dhs.ca.gov FU NIH [AI43885, MH54907, AI71772, K24 MH87227] FX This work was supported by NIH grants AI43885, MH54907, AI71772, and K24 MH87227. NR 43 TC 4 Z9 6 U1 1 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JUN PY 2014 VL 30 IS 6 BP 535 EP 541 DI 10.1089/aid.2012.0195 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AI9CE UT WOS:000337224400005 PM 24180338 ER PT J AU Kang, SK Huang, WC Pandharipande, PV Chandarana, H AF Kang, Stella K. Huang, William C. Pandharipande, Pari V. Chandarana, Hersh TI Solid Renal Masses: What the Numbers Tell Us SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE angiomyolipoma; diffusion-weighted imaging; oncocytoma; renal cell carcinoma; renal mass ID SEGMENTAL ENHANCEMENT INVERSION; CELL CARCINOMA SUBTYPES; FINE-NEEDLE-ASPIRATION; DIFFUSION-WEIGHTED MRI; T2 SIGNAL INTENSITY; CHEMICAL-SHIFT MRI; MINIMAL FAT; HELICAL CT; TUMOR SIZE; PATHOLOGICAL FEATURES AB OBJECTIVE. Solid renal masses are most often incidentally detected at imaging as small (<= 4 cm) localized lesions. These lesions comprise a wide spectrum of benign and malignant histologic subtypes, but are largely treated with surgical resection given the limited ability of imaging to differentiate among them with consistency and high accuracy. Numerous studies have thus examined the ability of CT and MRI techniques to separate benign lesions from malignancies and to predict renal cancer histologic grade and subtype. This article synthesizes the evidence regarding renal mass characterization at CT and MRI, provides diagnostic algorithms for evidence-based practice, and highlights areas of further research needed to drive imaging-based management of renal masses. CONCLUSION. Despite extensive study of morphologic and quantitative criteria at conventional imaging, no CT or MRI techniques can reliably distinguish solid benign tumors, such as oncocytoma and lipid-poor angiomyolipoma, from malignant renal tumors. Larger studies are required to validate recently developed techniques, such as diffusion-weighted imaging. Evidence-based practice includes MRI to assess renal lesions in situations where CT is limited and to help guide management in patients who are considered borderline surgical candidates. C1 [Kang, Stella K.; Chandarana, Hersh] NYU, Langone Med Ctr, New York, NY 10016 USA. [Huang, William C.] NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA. [Pandharipande, Pari V.] Massachusetts Gen Hosp, Inst Technol Assessment, Dept Radiol, Boston, MA 02114 USA. RP Kang, SK (reprint author), NYU, Langone Med Ctr, 550 First Ave, New York, NY 10016 USA. EM stella.kang@nyumc.org RI Kang, Stella/O-7003-2015; OI Chandarana, Hersh/0000-0002-6807-4589; Kang, Stella/0000-0003-2402-3787; Huang, William/0000-0001-5261-0650 FU Association of University Radiologists GE Radiology Research Academic Fellowship; National Cancer Institute [K07CA133097] FX S. K. Kang is funded in part by the Association of University Radiologists GE Radiology Research Academic Fellowship. P. V. Pandharipande has received support from the National Cancer Institute (award number K07CA133097). The research content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. NR 97 TC 12 Z9 12 U1 0 U2 5 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2014 VL 202 IS 6 BP 1196 EP 1206 DI 10.2214/AJR.14.12502 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AI6DB UT WOS:000336959000026 PM 24848816 ER PT J AU Lillemoe, KD AF Lillemoe, Keith D. TI Surgical Perspectives: An Introduction SO ANNALS OF SURGERY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Lillemoe, KD (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,WHT 506, Boston, MA 02114 USA. EM klillemoe@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD JUN PY 2014 VL 259 IS 6 BP 1037 EP 1037 DI 10.1097/SLA.0000000000000720 PG 1 WC Surgery SC Surgery GA AI9WW UT WOS:000337296700009 PM 24814501 ER PT J AU Tsai, TC Orav, EJ Joynt, KE AF Tsai, Thomas C. Orav, E. John Joynt, Karen E. TI Disparities in Surgical 30-Day Readmission Rates for Medicare Beneficiaries by Race and Site of Care SO ANNALS OF SURGERY LA English DT Article DE disparity; quality improvement; race; readmission; surgery ID HIGH-VOLUME HOSPITALS; RACIAL DISPARITIES; QUALITY-IMPROVEMENT; CONTROLLED-TRIAL; BLACK PATIENTS; HEART-FAILURE; COLON-CANCER; SURGERY; MORTALITY; REVASCULARIZATION AB Objective: To determine whether black patients have higher odds of readmission than white patients after major surgery, and to ascertain whether these disparities are related to where black patients receive care. Background: Racial disparities are known to exist for many aspects of surgical care. However, it is unknown if disparities exist in readmissions after a surgical procedure, an area which is becoming a prime focus for clinical leaders and policymakers. Methods: Using national Medicare data from 2007 to 2010, we examined 30-day readmissions for patients undergoing coronary artery bypass grafting, pulmonary lobectomy, endovascular abdominal aortic aneurysm repair, open abdominal aortic aneurysm repair, colectomy, and hip replacement. The main outcome measure was risk-adjusted odds of all-cause 30-day readmission. We used multivariate logistic regression to determine if black patients had higher readmission rates than white patients, and if so, whether this effect was mediated by the hospitals at which patients received care, or by poverty. Results: Black patients had higher readmission rates than white patients (14.8% vs 12.8%, odds ratio [OR] 1.19; 95% confidence interval [CI], 1.16-1.22; P < 0.001). Patients undergoing major surgery at minority-serving hospitals also had higher readmission rates (14.3% vs 12.8%, OR 1.14, 95% CI 1.09-1.19; P < 0.001). In multivariate analyses, black patients at minority-serving hospitals had the highest overall odds of readmissions (OR 1.34). White patients at minority-serving hospitals (OR 1.15) and black patients at non-minority-serving hospitals (OR 1.20) also had higher odds of readmission than the reference group of white patients at non-minority-serving hospitals. Racial disparities were mediated in part by poverty. Conclusions: Among Medicare beneficiaries, black patients were more likely to be readmitted after hospitalization for surgical procedures. Since racial disparities in readmission rates are mediated both by patients' race and the hospital at which care is delivered, efforts at reducing disparities should focus not only on race-based measures but also on improving outcomes of care at minority-serving hospitals. C1 [Tsai, Thomas C.; Joynt, Karen E.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Orav, E. John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Tsai, Thomas C.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Joynt, Karen E.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. [Orav, E. John] Brigham & Womens Hosp, Boston, MA 02115 USA. [Joynt, Karen E.] VA Boston Healthcare Syst, Boston, MA USA. RP Tsai, TC (reprint author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA. EM ttsai@hsph.harvard.edu FU National Cancer Institute [R25CA92203]; National Heart, Lung, and Blood Institute [1K23HL109177-01]; Lerner Research Award from Brigham and Women's Hospital, Cardiovascular Division FX T.C.T. was supported by grant R25CA92203 from the National Cancer Institute. K.E.J. was supported by grant 1K23HL109177-01 from the National Heart, Lung, and Blood Institute and the Lerner Research Award from Brigham and Women's Hospital, Cardiovascular Division. No conflicts of interests are declared. NR 33 TC 38 Z9 38 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD JUN PY 2014 VL 259 IS 6 BP 1086 EP 1090 DI 10.1097/SLA.0000000000000326 PG 5 WC Surgery SC Surgery GA AI9WW UT WOS:000337296700018 PM 24441810 ER PT J AU Ndiaye, MA Nihal, M Wood, GS Ahmad, N AF Ndiaye, Mary A. Nihal, Minakshi Wood, Gary S. Ahmad, Nihal TI Skin, Reactive Oxygen Species, and Circadian Clocks SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review ID SLEEP-WAKE CYCLES; OXIDATIVE STRESS; VITAMIN-A; DNA-DAMAGE; SIGNAL-TRANSDUCTION; RETINOIC ACID; EPIDERMAL-KERATINOCYTES; MELATONINERGIC SYSTEMS; EPITHELIAL-CELLS; BARRIER FUNCTION AB Significance: Skin, a complex organ and the body's first line of defense against environmental insults, plays a critical role in maintaining homeostasis in an organism. This balance is maintained through a complex network of cellular machinery and signaling events, including those regulating oxidative stress and circadian rhythms. These regulatory mechanisms have developed integral systems to protect skin cells and to signal to the rest of the body in the event of internal and environmental stresses. Recent Advances: Interestingly, several signaling pathways and many bioactive molecules have been found to be involved and even important in the regulation of oxidative stress and circadian rhythms, especially in the skin. It is becoming increasingly evident that these two regulatory systems may, in fact, be interconnected in the regulation of homeostasis. Important examples of molecules that connect the two systems include serotonin, melatonin, vitamin D, and vitamin A. Critical Issues: Excessive reactive oxygen species and/or dysregulation of antioxidant system and circadian rhythms can cause critical errors in maintaining proper barrier function and skin health, as well as overall homeostasis. Unfortunately, the modern lifestyle seems to contribute to increasing alterations in redox balance and circadian rhythms, thereby posing a critical problem for normal functioning of the living system. Future Directions: Since the oxidative stress and circadian rhythm systems seem to have areas of overlap, future research needs to be focused on defining the interactions between these two important systems. This may be especially important in the skin where both systems play critical roles in protecting the whole body. C1 [Ndiaye, Mary A.; Nihal, Minakshi; Wood, Gary S.; Ahmad, Nihal] Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA. [Wood, Gary S.; Ahmad, Nihal] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Ahmad, N (reprint author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Room 423 1300 Univ Ave, Madison, WI 53706 USA. EM nahmad@wisc.edu FU NIH [R01AR059130, R01CA176748]; VA Merit Review Award [1I01BX001008] FX This work was partly supported by funding to N.A. from the NIH (R01AR059130 and R01CA176748) and VA Merit Review Award (1I01BX001008). NR 123 TC 5 Z9 6 U1 4 U2 22 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JUN PY 2014 VL 20 IS 18 BP 2982 EP 2996 DI 10.1089/ars.2013.5645 PG 15 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA AI8LN UT WOS:000337167100008 PM 24111846 ER PT J AU Zhu, YN Shah, K AF Zhu, Yanni Shah, Khalid TI Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384 SO CANCER BIOLOGY & THERAPY LA English DT Article DE EGFR; PI3K; mTOR; glioblastoma (GBM); PF-00299804; dacomitinib; PF-05212384 ID BECLIN 1 PHOSPHORYLATION; LUNG-CANCER; STEM-CELLS; EGFR; RESISTANCE; AUTOPHAGY; GENES; CONTRIBUTES; CONCOMITANT; GEFITINIB AB A novel pan ERBB inhibitor PF-00299804 (dacomitinib) is currently in phase II clinical trials in glioblastoma multiforme (GBM) patients; however its pre-clinical efficacy in GBMs has not been tested. In this study, we evaluated the efficacy of dacomitinib alone or in combination with PI3K/mTOR dual inhibitor PF-05212384 in GBM and assessed the mechanisms of resistance and the molecular determinants of response. A panel of established and patient derived primary GBM lines that present different molecular profiles and also the GBM lines engineered to express EGFRvIII mutant or PTEN were treated with either dacomitinib, PF-05212384, or combination and assessed for their viability and changes in EGFR/PI3K/mTOR signaling. We show that dacomitinib significantly reduced phosphorylated EGFR in all the GBM lines but did not show a dose-dependent response on cell viability in a majority of the lines tested. Multiple lesions in the receptor tyrosine kinases (RTKs) pathway including PTEN mutation, co-activation of RTKs, and EGFRvIII mutation resulted in unaltered active status of PI3K/mTOR in the GBM lines even in the presence of EGFR inhibition. Blocking PI3K/mTOR dramatically inhibited cell proliferation in most GBM lines and enhanced dacomitinib induction of apoptosis in a GBM line that has both EGFR amplification and EGFR-independent PI3K activation. These data suggest molecular profiling of EGFR/PI3K/PTEN status to select GBM patients for EGFR or/and PI3K/mTOR targeted therapies. C1 [Zhu, Yanni; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02163 USA. [Zhu, Yanni; Shah, Khalid] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Shah, Khalid] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Shah, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02163 USA. EM kshah@mgh.harvard.edu FU Pfizer Inc.; [NIH-R01CA138922] FX This work was supported by Pfizer Inc. (K. S.) and NIH-R01CA138922 (K.S.). NR 25 TC 8 Z9 8 U1 0 U2 4 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4047 EI 1555-8576 J9 CANCER BIOL THER JI Cancer Biol. Ther. PD JUN PY 2014 VL 15 IS 6 BP 815 EP 822 DI 10.4161/cbt.28585 PG 8 WC Oncology SC Oncology GA AI8MC UT WOS:000337169500019 PM 24658109 ER PT J AU Hata, AN Yeo, A Faber, AC Lifshits, E Chen, Z Cheng, KA Walton, Z Sarosiek, KA Letai, A Heist, RS Mino-Kenudson, M Wong, KK Engelman, JA AF Hata, Aaron N. Yeo, Alan Faber, Anthony C. Lifshits, Eugene Chen, Zhao Cheng, Katherine A. Walton, Zandra Sarosiek, Kristopher A. Letai, Anthony Heist, Rebecca S. Mino-Kenudson, Mari Wong, Kwok-Kin Engelman, Jeffrey A. TI Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers SO CANCER RESEARCH LA English DT Article ID KINASE INHIBITORS; ACTIVATION; RESISTANCE; GEFITINIB; PROMOTES; PATHWAY; TUMORS; CELLS; EGFR AB Although several groups have demonstrated that concomitant use of MEK and phosphoinositide 3-kinase (PI3K) inhibitors (MEKi/PI3Ki) can induce dramatic tumor regressions in mouse models of KRAS-mutant non-small cell lung cancer (NSCLC), ongoing clinical trials investigating this strategy have been underwhelming to date. While efficacy may be hampered by a narrow therapeutic index, the contribution of biologic heterogeneity in the response of KRAS-mutant NSCLCs to MEKi/PI3Ki has been largely unexplored. In this study, we find that most human KRAS-mutant NSCLC cell lines fail to undergo marked apoptosis in response to MEKi/PI3Ki, which is key for tumor responsiveness in vivo. This heterogeneity of apoptotic response occurs despite relatively uniform induction of growth arrest. Using a targeted short hairpin RNA screen of BCL-2 family members, we identify BIM, PUMA, and BCL-XL as key regulators of the apoptotic response induced by MEKi/PI3Ki, with decreased expression of BIM and PUMA relative to BCL-XL in cell lines with intrinsic resistance. In addition, by modeling adaptive resistance to MEKi/PI3Ki both in vitro and in vivo, we find that, upon the development of resistance, tumors have a diminished apoptotic response due to downregulation of BIM and PUMA. These results suggest that the inability to induce apoptosis may limit the effectiveness of MEKi/PI3Ki for KRAS-mutant NSCLCs by contributing to intrinsic and adaptive resistance to this therapy. C1 [Hata, Aaron N.; Yeo, Alan; Faber, Anthony C.; Lifshits, Eugene; Heist, Rebecca S.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. [Hata, Aaron N.; Chen, Zhao; Heist, Rebecca S.; Wong, Kwok-Kin; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Chen, Zhao; Cheng, Katherine A.; Walton, Zandra; Sarosiek, Kristopher A.; Letai, Anthony; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Engelman, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, 149 13th St, Charlestown, MA 02129 USA. EM jengelman@partners.org FU NIH [R01CA137008-01, R01CA140594, 1U01CA141457-01, R01CA122794, R01CA137181, 1RC2CA147940]; NCI Lung [SPORE P50CA090578]; V Foundation Translational Research Grant; American Cancer Society [RSG-06-102-01-CCE]; Ellison Foundation Scholar Award; American Lung Cancer Association Lung Cancer Discover Award; Uniting Against Lung Cancer Foundation; Susan Spooner Research Fund FX The study was supported by the following grants: NIH R01CA137008-01 (J.A. Engelman), R01CA140594 (J.A. Engelman/K.-K. Wong), 1U01CA141457-01 (J.A. Engelman), R01CA122794 (K.-K. Wong), R01CA137181 (K.-K. Wong), 1RC2CA147940 (K.-K. Wong), NCI Lung SPORE P50CA090578 (J.A. Engelman/K.-K. Wong), V Foundation Translational Research Grant (J.A. Engelman), American Cancer Society RSG-06-102-01-CCE (J.A. Engelman), Ellison Foundation Scholar Award (J.A. Engelman), American Lung Cancer Association Lung Cancer Discover Award (J.A. Engelman), Uniting Against Lung Cancer Foundation (K.-K. Wong), and the Susan Spooner Research Fund (K.-K. Wong). NR 39 TC 26 Z9 26 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD JUN 1 PY 2014 VL 74 IS 11 BP 3146 EP 3156 DI 10.1158/0008-5472.CAN-13-3728 PG 11 WC Oncology SC Oncology GA AI8ML UT WOS:000337170600024 PM 24675361 ER PT J AU Sumer, H Kim, K Liu, J Ng, K Daley, GQ Verma, PJ AF Sumer, Huseyin Kim, Kitai Liu, Jun Ng, Kitwa Daley, George Q. Verma, Paul J. TI Functional Evaluation of ES-Somatic Cell Hybrids In Vitro and In Vivo SO CELLULAR REPROGRAMMING LA English DT Article ID EMBRYONIC STEM-CELLS; NUCLEAR TRANSFER; MOUSE; FUSION; PLURIPOTENCY; GENE; EXPRESSION; GENERATION; MICE AB Embryonic stem cells (ESCs) have previously been reported to reprogram somatic cells following fusion. The resulting ES-somatic cell hybrids have been shown to adopt the transcriptional profile of ESCs, suggesting that the pluripotent program is dominant. ES-somatic cell hybrids have most characteristics of pluripotent cells in vitro; however, it remains unclear whether the somatic genome is an active partner in the hybrid cells or simply retained predominately as silent cargo. Furthermore, the functional properties of ES-somatic cell hybrids in vivo have been limited to studies on their contribution to teratomas and developing embryos/chimeras. The extent of their pluripotency remains largely unclear. Here we determined that the somatic genome is actively transcribed by generating ES-somatic cell hybrids using Rag2-deficient ESCs fused to autologous wild-type somatic cells. Rag2 expression was detected during in vitro differentiation, suggesting that the somatic genome follows the correct temporal cues during differentiation. Furthermore, ES-somatic cell hybrids maintain their tetraploid state following 4 weeks of differentiation in vivo and are immune tolerated when transferred into matched individuals. The ES-somatic cell hybrids can efficiently differentiate into hematopoietic precursors in both myeloid and lymphoid lineages in vitro, suggesting that the somatic genome is actively transcribed following cell fusion based reprogramming. However, the ES-somatic cell hybrids showed an altered hematopoietic potential following in vitro differentiation and were unable to show hematopoietic engraftment in a mouse model. C1 [Sumer, Huseyin; Liu, Jun; Verma, Paul J.] Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia. [Sumer, Huseyin] Swinburne Univ Technol, Dept Chem & Biotechnol, Fac Sci Engn & Technol, Hawthorn, Vic 3122, Australia. [Kim, Kitai; Ng, Kitwa; Daley, George Q.] Childrens Hosp Boston, Stem Cell Transplantat Program, Div Pediat Hematol Oncol, Manton Ctr Orphan Dis Res,Howard Hughes Med Inst, Boston, MA 02115 USA. [Kim, Kitai; Ng, Kitwa; Daley, George Q.] Dana Farber Canc Inst, Boston, MA USA. [Kim, Kitai; Ng, Kitwa; Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA USA. [Kim, Kitai; Ng, Kitwa; Daley, George Q.] Harvard Univ, Dept Biol Chem & Mol Pharmacol, Sch Med, Boston, MA USA. [Kim, Kitai; Ng, Kitwa; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA. [Kim, Kitai] Sloan Kettering Inst, Canc Biol & Genet Program, Ctr Cell Engn, Ctr Stem Cell Biol, New York, NY USA. [Kim, Kitai] Cornell Univ, Weill Med Coll, New York, NY USA. [Verma, Paul J.] Turretfield Res Ctr, South Australian Res Inst SARDI, Rosedale, SA 5350, Australia. RP Sumer, H (reprint author), Swinburne Univ Technol, Dept Chem & Biotechnol, Fac Sci Engn & Technol, John St, Melbourne, Vic 3122, Australia. EM hsumer@swin.edu.au OI Liu, Jun/0000-0003-4561-1190 FU Australian Stem Cell Centre; NH & MRC Biomedical Training Fellowship; Dairy Australia; Dairy Futures CRC; MIMR; Victorian Government's Operational Infrastructure Support Program; National Institutes of Health (NIH) [K99HL093212-01]; Leukemia & Lymphoma Society (LLS) [3567-07]; Cooley's Anemia Foundation FX This project was supported by funding from the Australian Stem Cell Centre. We would like to thank R. Jaenisch for the kind gift of the Rag2 ntES cells and the pSicoR-Hygro-Tk vector. H.S. was supported by an NH & MRC Biomedical Training Fellowship and an Establishment Gift from the Clive and Vera Ramaciotti Foundation. H.S. and P.J.V. acknowledge funding support from Dairy Australia, funding from the Dairy Futures CRC, and MIMR infrastructure funding supported by the Victorian Government's Operational Infrastructure Support Program. K. K. was supported by the National Institutes of Health (NIH; grant no. K99HL093212-01), Leukemia & Lymphoma Society (LLS; grant no. 3567-07), and Cooley's Anemia Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 0 Z9 0 U1 2 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2152-4971 EI 2152-4998 J9 CELL REPROGRAM JI Cell. Reprogramm. PD JUN PY 2014 VL 16 IS 3 BP 167 EP 174 DI 10.1089/cell.2013.0079 PG 8 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Genetics & Heredity SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA AI9JO UT WOS:000337249100001 PM 24787484 ER PT J AU Wakimoto, H Tanaka, S Curry, WT Loebel, F Zhao, D Tateishi, K Chen, JX Klofas, LK Lelic, N Kim, JC Dias-Santagata, D Ellisen, LW Borger, DR Fendt, SM Vander Heiden, MG Batchelor, TT Iafrate, AJ Cahill, DP Chi, AS AF Wakimoto, Hiroaki Tanaka, Shota Curry, William T. Loebel, Franziska Zhao, Dan Tateishi, Kensuke Chen, Juxiang Klofas, Lindsay K. Lelic, Nina Kim, James C. Dias-Santagata, Dora Ellisen, Leif W. Borger, Darrell R. Fendt, Sarah-Maria Vander Heiden, Matthew G. Batchelor, Tracy T. Iafrate, A. John Cahill, Daniel P. Chi, Andrew S. TI Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas SO CLINICAL CANCER RESEARCH LA English DT Article ID REDUCTIVE GLUTAMINE-METABOLISM; HIGH-GRADE ASTROCYTOMAS; CANCER STEM-CELLS; BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; OLIGODENDROGLIOMA; EVOLUTION; CLASSIFICATION; CHEMOTHERAPY; INHIBITION AB Purpose: Isocitrate dehydrogenase (IDH) gene mutations occur in low-grade and high-grade gliomas. We sought to identify the genetic basis of malignant phenotype heterogeneity in IDH-mutant gliomas. Methods: We prospectively implanted tumor specimens from 20 consecutive IDH1-mutant glioma resections into mouse brains and genotyped all resection specimens using a CLIA-certified molecular panel. Gliomas with cancer driver mutations were tested for sensitivity to targeted inhibitors in vitro. Associations between genomic alterations and outcomes were analyzed in patients. Results: By 10 months, 8 of 20 IDH1-mutant gliomas developed intracerebral xenografts. All xenografts maintained mutant IDH1 and high levels of 2-hydroxyglutarate on serial transplantation. All xenograft-producing gliomas harbored "lineage-defining" mutations in CIC (oligodendroglioma) or TP53 (astrocytoma), and 6 of 8 additionally had activating mutations in PIK3CA or amplification of PDGFRA, MET, or N-MYC. Only IDH1 and CIC/TP53 mutations were detected in non-xenograft-forming gliomas (P = 0.0007). Targeted inhibition of the additional alterations decreased proliferation in vitro. Moreover, we detected alterations in known cancer driver genes in 13.4% of IDH-mutant glioma patients, including PIK3CA, KRAS, AKT, or PTEN mutation or PDGFRA, MET, or N-MYC amplification. IDH/CIC mutant tumors were associated with PIK3CA/KRAS mutations whereas IDH/TP53 tumors correlated with PDGFRA/MET amplification. Presence of driver alterations at progression was associated with shorter subsequent progression-free survival (median 9.0 vs. 36.1 months; P = 0.0011). Conclusion: A subset of IDH-mutant gliomas with mutations in driver oncogenes has a more malignant phenotype in patients. Identification of these alterations may provide an opportunity for use of targeted therapies in these patients. (C) 2014 AACR. C1 [Wakimoto, Hiroaki; Curry, William T.; Loebel, Franziska; Tateishi, Kensuke; Lelic, Nina; Cahill, Daniel P.] MIT, Stephen E & Catherine Pappas Ctr Neurooncol, Dept Neurosurg, Cambridge, MA 02139 USA. [Tanaka, Shota; Zhao, Dan; Klofas, Lindsay K.; Batchelor, Tracy T.; Chi, Andrew S.] MIT, Stephen E & Catherine Pappas Ctr Neurooncol, Dept Neurol, Div Hematol Oncol, Cambridge, MA 02139 USA. [Chen, Juxiang; Dias-Santagata, Dora; Ellisen, Leif W.; Borger, Darrell R.; Iafrate, A. John] MIT, Translat Res Lab, Cambridge, MA 02139 USA. [Kim, James C.; Iafrate, A. John] MIT, Dept Pathol, Cambridge, MA 02139 USA. [Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Wakimoto, Hiroaki; Tanaka, Shota; Loebel, Franziska; Zhao, Dan; Tateishi, Kensuke; Chen, Juxiang; Klofas, Lindsay K.; Lelic, Nina; Batchelor, Tracy T.; Cahill, Daniel P.; Chi, Andrew S.] Harvard Univ, Sch Med, Translat Neurooncol Lab, Boston, MA 02114 USA. [Wakimoto, Hiroaki; Tanaka, Shota; Curry, William T.; Loebel, Franziska; Zhao, Dan; Tateishi, Kensuke; Chen, Juxiang; Klofas, Lindsay K.; Lelic, Nina; Kim, James C.; Dias-Santagata, Dora; Ellisen, Leif W.; Borger, Darrell R.; Batchelor, Tracy T.; Iafrate, A. John; Cahill, Daniel P.; Chi, Andrew S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Fendt, Sarah-Maria] VIB, Vesalius Res Ctr, Leuven, Belgium. [Fendt, Sarah-Maria] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium. RP Chi, AS (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM cahill@mgh.harvard.edu; chi.andrew@mgh.harvard.edu OI Cahill, Daniel/0000-0003-2552-6546; Fendt, Sarah-Maria/0000-0001-6018-9296 FU American Cancer Society Institutional Research Grant; Richard B. Simches Scholars Award; Burroughs-Wellcome Career Award; Koch Institute Dana Farber/Harvard Cancer Center Bridge Project FX This work was supported by the American Cancer Society Institutional Research Grant and Richard B. Simches Scholars Award (A.S. Chi), Burroughs-Wellcome Career Award (D.P. Cahill), and The Koch Institute Dana Farber/Harvard Cancer Center Bridge Project (H. Wakimoto, A.S. Chi, D.P. Cahill and M. G. Vander Heiden). NR 50 TC 31 Z9 31 U1 1 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2014 VL 20 IS 11 BP 2898 EP 2909 DI 10.1158/1078-0432.CCR-13-3052 PG 12 WC Oncology SC Oncology GA AI8IS UT WOS:000337157000010 PM 24714777 ER PT J AU Psyrri, A Lee, JW Pectasides, E Vassilakopoulou, M Kosmidis, EK Burtness, BA Rimm, DL Wanebo, HJ Forastiere, AA AF Psyrri, Amanda Lee, Ju-Whei Pectasides, Eirini Vassilakopoulou, Maria Kosmidis, Efstratios K. Burtness, Barbara A. Rimm, David L. Wanebo, Harold J. Forastiere, Arlene A. TI Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303 SO CLINICAL CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; NECK-CANCER; SUBCELLULAR-LOCALIZATION; SIGNAL TRANSDUCER; PLUS CETUXIMAB; KINASE PATHWAY; ADVANCED HEAD; RESISTANCE; EGFR AB Purpose: We sought to evaluate the correlation between tissue biomarker expression (using standardized, quantitative immunofluorescence) and clinical outcome in the E2303 trial. Experimental Design: Sixty-three eligible patients with operable stage III/IV head and neck squamous cell cancer (HNSCC) participated in the Eastern Cooperative Oncology Group (ECOG) 2303 phase II trial of induction chemotherapy with weekly cetuximab, paclitaxel, and carboplatin followed by chemoradiation with the same regimen. A tissue microarray (TMA) was constructed and EGF receptor (EGFR), ERK1/2, Met, Akt, STAT3, beta-catenin, E-cadherin, EGFR Variant III, insulin-like growth factor-1 receptor, NF-kappa B, p53, PI3Kp85, PI3Kp110a, PTEN, NRAS, and pRb protein expression levels were assessed using automated quantitative protein analysis (AQUA). For each dichotomized biomarker, overall survival (OS), progression- free survival (PFS), and event-free survival (EFS) were estimated by the Kaplan-Meier method and compared using log-rank tests. Multivariable Cox proportional hazards models were used to estimate HRs and test for significance. Results: Forty-two of 63 patients with TMAdata on at least one biomarker were included in the biomarker analysis. Tumor extracellular signal-regulated kinase (ERK) 1/2 levels were significantly associated with PFS [HR (low/high), 3.29; P = 0.026] and OS[HR (low/high), 4.34; P = 0.008]. On multivariable Cox regression analysis, ERK1/2 remained significantly associated with OS (P = 0.024) and PFS (P = 0.022) after controlling for primary site (oropharynx vs. non-oropharynx) and disease stage (III vs. IV), respectively. Clustering analysis revealed that clusters indicative of activated RAS/MAPK/ERK and/or PI3K/Akt pathways were associated with inferior OS and/or PFS and maintained significance in multivariable analysis. Conclusions: These results implicate PI3K/Akt and RAS/MAPK/ERK pathways in resistance to cetuximab-containing chemoradiation in HNSCC. Large prospective studies are required to validate these results. (C) 2014 AACR. C1 [Psyrri, Amanda; Pectasides, Eirini; Vassilakopoulou, Maria; Rimm, David L.] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Lee, Ju-Whei] Dana Farber Canc Inst, Boston, MA 02115 USA. [Burtness, Barbara A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Wanebo, Harold J.] Landmark Med Ctr, Woonsocket, RI USA. [Forastiere, Arlene A.] Johns Hopkins Univ, Baltimore, MD USA. [Kosmidis, Efstratios K.] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece. RP Psyrri, A (reprint author), Yale Univ, Sch Med, New Haven, CT 06520 USA. FU Public Health Service [CA23318, CA66636, CA21115, CA27525, CA16116]; National Cancer Institute; NIH; Department of Health and Human Services FX This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M. D., Chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA27525, and CA16116 and from the National Cancer Institute, NIH, and the Department of Health and Human Services. NR 36 TC 10 Z9 10 U1 1 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2014 VL 20 IS 11 BP 3023 EP 3032 DI 10.1158/1078-0432.CCR-14-0113 PG 10 WC Oncology SC Oncology GA AI8IS UT WOS:000337157000021 PM 24700741 ER PT J AU Cilio, MR Thiele, EA Devinsky, O AF Cilio, Maria Roberta Thiele, Elizabeth A. Devinsky, Orrin TI The case for assessing cannabidiol in epilepsy SO EPILEPSIA LA English DT Article DE Epilepsy; Childhood; Cannabidiol ID PHARMACORESISTANT EPILEPSY; DELTA(9)-TETRAHYDROCANNABINOL; CANNABINOIDS; PHARMACOLOGY; PSYCHOSIS; SEIZURES; CHILDREN; DRUG; AGE AB Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the major nonpsychotropic compound of Cannabis sativa. Basic research studies have provided strong evidence for safety and anticonvulsant properties of CBD. However, the lack of pure, pharmacologically active compounds and legal restrictions have prevented clinical research and confined data on efficacy and safety to anecdotal reports. Pure CBD appears to be an ideal candidate among phytocannabinoids as a therapy for treatment-resistant epilepsy. A first step in this direction is to systematically investigate the safety, pharmacokinetics, and interactions of CBD with other antiepileptic drugs and obtain an initial signal regarding efficacy at different dosages. These data can then be used to plan double-blinded placebo-controlled efficacy trials. C1 [Cilio, Maria Roberta] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Cilio, Maria Roberta] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Thiele, Elizabeth A.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Thiele, Elizabeth A.] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Devinsky, Orrin] NYU Langone Sch Med, Dept Neurol, New York, NY USA. RP Cilio, MR (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. EM maria.cilio@ucsf.edu OI Devinsky, Orrin/0000-0003-0044-4632 FU Epilepsy Therapy Project/Epilepsy Foundation Seal Award FX The authors received an Epilepsy Therapy Project/Epilepsy Foundation Seal Award to support a cannabidiol study. NR 28 TC 23 Z9 23 U1 1 U2 38 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD JUN PY 2014 VL 55 IS 6 BP 787 EP 790 DI 10.1111/epi.12635 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA AJ4DE UT WOS:000337620200006 PM 24854434 ER PT J AU Devinsky, O Cilio, MR Cross, H Fernandez-Ruiz, J French, J Hill, C Katz, R Di Marzo, V Jutras-Aswad, D Notcutt, WG Martinez-Orgado, J Robson, PJ Rohrback, BG Thiele, E Whalley, B Friedman, D AF Devinsky, Orrin Cilio, Maria Roberta Cross, Helen Fernandez-Ruiz, Javier French, Jacqueline Hill, Charlotte Katz, Russell Di Marzo, Vincenzo Jutras-Aswad, Didier Notcutt, William George Martinez-Orgado, Jose Robson, Philip J. Rohrback, Brian G. Thiele, Elizabeth Whalley, Benjamin Friedman, Daniel TI Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders SO EPILEPSIA LA English DT Review DE Cannabidiol; Cannabis; Tetrahydroacannabinol; Dravet syndrome; GPR55; Medical marijuana ID IN-VITRO; ANTICONVULSANT ACTION; HYPOXIA-ISCHEMIA; BRAIN-DAMAGE; NEWBORN PIGS; RATS; CANNABINOIDS; SEIZURES; SYMPTOMS; MODEL AB To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data from studies with animal models and human subjects. Cannabis has been used to treat disease since ancient times. 9-Tetrahydrocannabinol (9-THC) is the major psychoactive ingredient and CBD is the major nonpsychoactive ingredient in cannabis. Cannabis and 9-THC are anticonvulsant in most animal models but can be proconvulsant in some healthy animals. The psychotropic effects of 9-THC limit tolerability. CBD is anticonvulsant in many acute animal models, but there are limited data in chronic models. The antiepileptic mechanisms of CBD are not known, but may include effects on the equilibrative nucleoside transporter; the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the 3 and 1 glycine receptors. CBD has neuroprotective and antiinflammatory effects, and it appears to be well tolerated in humans, but small and methodologically limited studies of CBD in human epilepsy have been inconclusive. More recent anecdotal reports of high-ratio CBD:9-THC medical marijuana have claimed efficacy, but studies were not controlled. CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic-ischemic encephalopathy. However, we lack data from well-powered double-blind randomized, controlled studies on the efficacy of pure CBD for any disorder. Initial dose-tolerability and double-blind randomized, controlled studies focusing on target intractable epilepsy populations such as patients with Dravet and Lennox-Gastaut syndromes are being planned. Trials in other treatment-resistant epilepsies may also be warranted. C1 [Devinsky, Orrin; Friedman, Daniel] NYU, Sch Med, Comprehens Epilepsy Ctr, Dept Neurol, New York, NY 10016 USA. [Cilio, Maria Roberta] Univ Calif San Francisco, Dept Neurol, Pediat Epilepsy Ctr, San Francisco, CA USA. [Cross, Helen] Children NHS Fdn Trust, Great Ormond St Hosp, London, England. [Fernandez-Ruiz, Javier] Univ Complutense Madrid, Fac Med, Dept Biochem & Mol Biol, Ctr Networked Biomed Res Neurodegenerat Dis, Madrid, Spain. [Fernandez-Ruiz, Javier] Ramon & Cajal Inst Hlth Res, Madrid, Spain. [Hill, Charlotte; Whalley, Benjamin] Univ Reading, Reading Sch Pharm, Reading, Berks, England. [Di Marzo, Vincenzo] Natl Res Council Italy, ERG, Inst Biomol Chem, Naples, Italy. [Jutras-Aswad, Didier] Univ Montreal, Ctr Hlth, Res Ctr, Montreal, PQ, Canada. [Jutras-Aswad, Didier] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada. [Notcutt, William George] James Paget Univ Hosp, Great Yarmouth, Norfolk, England. [Notcutt, William George] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England. [Martinez-Orgado, Jose] Univ Hosp Puerta de Hierro, Dept Pediat, Madrid, Spain. [Robson, Philip J.] GW Res Ltd, Salisbury, Wilts, England. [Rohrback, Brian G.] Infometrix Inc, Bothell, WA USA. [Thiele, Elizabeth] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Devinsky, O (reprint author), NYU, Sch Med, Comprehens Epilepsy Ctr, 223 East 34th St, New York, NY 10016 USA. EM od4@nyu.edu OI Devinsky, Orrin/0000-0003-0044-4632; French, Jacqueline/0000-0003-2242-8027; Di Marzo, Vincenzo/0000-0002-1490-3070 FU GW Pharmaceuticals; Epilepsy Therapy Project for human trials of CBD; UCB; Eisai; Action Medical Research; Epilepsy Research UK; Great Ormond Street Hospital Children's Charity; Bristol-Myers Squibb; Mylan; Pfizer; Reckitt Benckiser Pharmaceuticals; Merck; CHUM Department of Psychiatry; Universite de Montreal Department of Psychiatry; CHUM Research Center; National Institutes of Health (National Center for the Advancement of Translational Science) [UL1 TR000038] FX The content of this review was adapted from a conference entitled "Cannabidiols: Potential use in epilepsy and other neurological disorders" held at the NYU Langone School of Medicine on October 4, 2013. This conference, whose content was reviewed by an independent advisory board for potential conflicts of interest as per the policies of the NYU Postgraduate Medical School, was sponsored by an unrestricted medical education grant from GW Pharmaceuticals. The selection of speakers and contributors was made by the conference chair (O.D.). GW Pharmaceuticals has a commercial interest in developing cannabidiols for the treatment of epilepsy and other conditions, some of which are detailed in this article. In addition:; O.D. has received an unrestricted medical education grant from GW Pharmaceuticals and funding from the Epilepsy Therapy Project for human trials of CBD. Dr Devinsky is involved in assessing the safety and tolerability, and is involved in planning randomized controlled trials of CBD supplied by GW Pharmaceuticals in patients with epilepsy.; M.R.C. has received funding from Epilepsy Therapy Project for human trials of CBD.; J.H.C. J. Helen Cross holds an endowed Chair through University College, London. She has sat on Advisory Panels for Eisai and Viropharma for which remuneration has been paid to her department. She has received money to the Department as an educational grant from UCB and Eisai for a Clinical Training Fellowship in Epilepsy. She currently holds grants for research as from Action Medical Research, Epilepsy Research UK, and the Great Ormond Street Hospital Children's Charity. She worked as Clinical Advisor to the update of the National Institute of Health and Care Excellence guidelines on the diagnosis and management of epilepsy (20092012) and is currently Clinical Advisor to the Children's Epilepsy Surgery Service (England & Wales) for which remuneration is made to her department. J. F-R. receives funds for research from GW Pharmaceuticals. J. F. has no relevant disclosures. C. H. has no relevant disclosures. R. K. has no relevant disclosures. V. D. is a consultant for GW Pharmaceuticals and receives research funds from GW Pharmaceuticals. D.J-A. has received research/education grant support from Bristol-Myers Squibb, Mylan, Pfizer, and Reckitt Benckiser Pharmaceuticals; presentation honoraria from Janssen-Ortho; consultation fees from Merck; as well as grant support from the CHUM Department of Psychiatry, Universite de Montreal Department of Psychiatry, and the CHUM Research Center. W.G.N. Research supported by grants from GW Pharmaceuticals as well as fees from consultancies to GW Pharmaceuticals. J.M-O. receives research support from GW Pharmaceuticals. P. J. R. is a part-time employee with GW Research Ltd as Medical Director of its Cannabinoid Research Institute, and holds stock in the company. B. G. R. serves as the president of Infometrix, a company under contract by GW Pharmaceuticals to produce a quality assurance system in the manufacture of Sativex/Nabiximols. E. T. agreement with GW Pharmaceuticals to supply CBD to patients in an investigator initiated study. B. J. W. received research support from GW Pharmaceuticals. He is named as an inventor on patents that have arisen from this research, although he has waived any rights to financial or other material benefits that may come from these patents in the future. He has also acted as a consultant for GW Pharmaceuticals, but has received no financial payment for this activity and hold no shares in the company. D. F. receives grant funding from the National Institutes of Health (UL1 TR000038 from the National Center for the Advancement of Translational Science). We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. NR 75 TC 110 Z9 111 U1 23 U2 170 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD JUN PY 2014 VL 55 IS 6 BP 791 EP 802 DI 10.1111/epi.12631 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA AJ4DE UT WOS:000337620200007 PM 24854329 ER PT J AU Puskarjov, M Kahle, KT Ruusuvuori, E Kaila, K AF Puskarjov, Martin Kahle, Kristopher T. Ruusuvuori, Eva Kaila, Kai TI Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures SO EPILEPSIA LA English DT Review DE KCC2; NKCC1; Cation-chloride cotransporters; Neonate; Bumetanide ID K-CL COTRANSPORTER; CORTICOTROPIN-RELEASING HORMONE; CRITICALLY ILL INFANTS; PITUITARY-ADRENAL AXIS; NA+-K+-2CL(-) COTRANSPORTER; HYPOXIA-ISCHEMIA; PROTEIN-BINDING; NA-K-2CL COTRANSPORTER; GABAERGIC EXCITATION; GABA(A) RECEPTORS AB Seizures are a common manifestation of acute neurologic insults in neonates and are often resistant to the standard antiepileptic drugs that are efficacious in children and adults. The paucity of evidence-based treatment guidelines, coupled with a rudimentary understanding of disease pathogenesis, has made the current treatment of neonatal seizures empiric and often ineffective, highlighting the need for novel therapies. Key developmental differences in -aminobutyric acid (GABA)ergic neurotransmission between the immature and mature brain, and trauma-induced alterations in the function of the cation-chloride cotransporters (CCCs) NKCC1 and KCC2, probably contribute to the poor efficacy of standard antiepileptic drugs used in the treatment of neonatal seizures. Although CCCs are attractive drug targets, bumetanide and other existing CCC inhibitors are suboptimal because of pharmacokinetic constraints and lack of target specificity. Newer approaches including isoform-specific NKCC1 inhibitors with increased central nervous system penetration, and direct and indirect strategies to enhance KCC2-mediated neuronal chloride extrusion, might allow therapeutic modulation of the GABAergic system for neonatal seizure treatment. C1 [Puskarjov, Martin; Ruusuvuori, Eva; Kaila, Kai] Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland. [Puskarjov, Martin; Ruusuvuori, Eva; Kaila, Kai] Univ Helsinki, Neurosci Ctr, FIN-00014 Helsinki, Finland. [Kahle, Kristopher T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA. RP Kaila, K (reprint author), Univ Helsinki, Dept Biosci, POB 65 Viikinkaari 1, FIN-00014 Helsinki, Finland. EM kai.kaila@helsinki.fi RI Kaila, Kai/R-8528-2016 OI Kaila, Kai/0000-0003-0668-5955 FU Letten Foundation; Academy of Finland; Sigrid Juselius Foundation; Jane and Aatos Erkko Foundation; National Institutes of Health; Manton Center for Orphan Disease Research FX We thank Prof. Wolfgang Loscher, Drs. Tarek Z. Deeb, Jamie Maguire, and Patricia Seja for comments on an early version of the manuscript. The authors' original research work was supported by grants from the Letten Foundation, the Academy of Finland, the Sigrid Juselius Foundation, the Jane and Aatos Erkko Foundation (K. Kaila), the National Institutes of Health, and the Manton Center for Orphan Disease Research (K. Kahle). NR 114 TC 29 Z9 29 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD JUN PY 2014 VL 55 IS 6 BP 806 EP 818 DI 10.1111/epi.12620 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA AJ4DE UT WOS:000337620200009 PM 24802699 ER PT J AU Barron, DS Tandon, N Lancaster, JL Fox, PT AF Barron, Daniel S. Tandon, Nitin Lancaster, Jack L. Fox, Peter T. TI Thalamic structural connectivity in medial temporal lobe epilepsy SO EPILEPSIA LA English DT Article DE Hippocampal sclerosis; Magnetic resonance imaging; Diffusion-weighted imaging; Thalamic connectivity ID DEEP BRAIN-STIMULATION; SEGMENTATION; PULVINAR; SEIZURES; NUCLEUS AB The thalamus has been implicated in various stages of medial temporal lobe epilepsy (MTLE) seizure evolution. The relative density and functional significance (in epileptogenesis) of thalamic projections to MTL subregions, however, remains to be determined. This study used structural and diffusion magnetic resonance imaging (MRI) to evaluate thalamic connection density with distinct MTL subregions in terms of location and volume. Nineteen MTLE patients with unilateral hippocampal sclerosis (HS; 12 right; 10 female) were compared to 19 age-matched controls. Five regions of interest (ROIs) per hemisphere were created in native space: thalamus, amygdala, entorhinal cortex, hippocampus, and parahippocampus. Separate probabilistic tractography analyses were performed between the thalamus and each ipsilateral MTL subregion (four per hemisphere). Individual connectivity profiles and regional volumes were assessed. The medial pulvinar consistently showed the highest connection density with the hippocampus in healthy controls and in MTLE patients. Decreased thalamic connected volume was observed for thalamohippocampal pathways in patients with MTLE, and indicates pathway-specific deafferentation. Regional hippocampal and thalamic atrophy was also observed, indicating gray and white matter loss in the thalamohippocampal pathway. Consistent localization of dense medial pulvinar (PuM) connectivity with the hippocampus suggests chronic PuM stimulation could modulate the MTLE seizure network. Decreased thalamic connected volume is a promising biomarker for epileptogenesis that merits longitudinal validation. C1 [Barron, Daniel S.; Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Barron, Daniel S.] Yale Univ, Sch Med, New Haven, CT 06510 USA. [Tandon, Nitin] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA. [Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr Houston, Dept Radiol, Houston, TX 77030 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Peoples R China. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. RP Barron, DS (reprint author), Yale Univ, Sch Med, 367 Cedar St, New Haven, CT 06510 USA. EM daniel.s.barron@yale.edu RI Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU [1F31 NS083160-01]; [RO1 MH074457] FX The authors thank Jose E. Cavazos (UTHSC-SA, edits), Kristin S. Budde (UTHSC-SA, edits), Vatche G. Baboyan (UTHSC-H, data transfer), and the patients who participated in this study. The authors also thank the anonymous reviewers for their time and helpful directives. This study was funded by 1F31 NS083160-01 (D.S.B.) and RO1 MH074457 (P.T.F.). NR 16 TC 14 Z9 15 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD JUN PY 2014 VL 55 IS 6 BP e50 EP e55 DI 10.1111/epi.12637 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA AJ4DE UT WOS:000337620200001 PM 24802969 ER PT J AU Lee, KM Stott, RT Zhao, GP SooHoo, J Xiong, W Lian, MM Fitzgerald, L Shi, S Akrawi, E Lei, J Deng, SP Yeh, H Markmann, JF Kim, JI AF Lee, Kang Mi Stott, Ryan T. Zhao, Gaoping SooHoo, Julie Xiong, Wei Lian, Moh Moh Fitzgerald, Lindsey Shi, Shuai Akrawi, Elsie Lei, Ji Deng, Shaoping Yeh, Heidi Markmann, James F. Kim, James I. TI TGF-beta-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE Breg cells; TGF-beta; Transplant; Treg cells; Tolerance ID GROWTH-FACTOR-BETA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ALLERGIC AIRWAY DISEASE; IMMUNE-RESPONSES; MURINE MODEL; MICE; IL-10; LIPOPOLYSACCHARIDE; LYMPHOCYTES; EXPRESSION AB Regulatory B (Breg) cells have been shown to play a critical role in immune homeostasis and in autoimmunity models. We have recently demonstrated that combined anti-T cell immunoglobulin domain and mucin domain-1 and anti-CD45RB antibody treatment results in tolerance to full MHC-mismatched islet allografts in mice by generating Breg cells that are necessary for tolerance. Breg cells are antigen-specific and are capable of transferring tolerance to untreated, transplanted animals. Here, we demonstrate that adoptively transferred Breg cells require the presence of regulatory T (Treg) cells to establish tolerance, and that adoptive transfer of Breg cells increases the number of Treg cells. Interaction with Breg cells in vivo induces significantly more Foxp3 expression in CD4+CD25- T cells than with naive B cells. We also show that Breg cells express the TGF beta- associated latency-associated peptide and that Breg-cell mediated graft prolongation post-adoptive transfer is abrogated by neutralization of TGF-beta activity. Breg cells, like Treg cells, demonstrate preferential expression of both C-C chemokine receptor 6 and CXCR3. Collectively, these findings suggest that in this model of antibody-induced transplantation tolerance, Breg cells promote graft survival by promoting Treg-cell development, possibly via TGF-beta production. C1 [Lee, Kang Mi; Stott, Ryan T.; Zhao, Gaoping; SooHoo, Julie; Xiong, Wei; Lian, Moh Moh; Fitzgerald, Lindsey; Shi, Shuai; Akrawi, Elsie; Lei, Ji; Deng, Shaoping; Yeh, Heidi; Markmann, James F.; Kim, James I.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Transplantat Unit,Sch Med, Boston, MA 02114 USA. [Zhao, Gaoping; Xiong, Wei; Deng, Shaoping] Sichuan Prov Peoples Hosp, Dept Surg, Chengdu, Sichuan Provinc, Peoples R China. [Zhao, Gaoping; Xiong, Wei; Deng, Shaoping] Sichuan Acad Med Sci, Chengdu, Sichuan Provinc, Peoples R China. RP Markmann, JF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Transplantat Unit,Sch Med, 55 Fruit St 5 White, Boston, MA 02114 USA. EM jmarkmann@partners.org FU NIH [RO1AI057851-05, K08-DK094965, 5T32AI7529] FX This work was supported in part by NIH grant RO1AI057851-05 (JFM), K08-DK094965 (HY), and 5T32AI7529 (KML). We thank Alicia Johnson, PhD, for statistical analysis. We thank the MGH Flow Cytometry Core for cell sorting. NR 36 TC 42 Z9 48 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD JUN PY 2014 VL 44 IS 6 BP 1728 EP 1736 DI 10.1002/eji.201344062 PG 9 WC Immunology SC Immunology GA AJ2YL UT WOS:000337531200017 PM 24700192 ER PT J AU Wang, T Peng, YB Shen, NC Yu, Y Yao, M Zhu, JY AF Wang, Ti Peng, Yinbo Shen, Nianci Yu, Yan Yao, Min Zhu, Jingyin TI Photochemical activation increases the porcine corneal stiffness and resistance to collagenase digestion SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE photochemical activation; corneal cross-linking; Rose Bengal; tensile strength; collagenase ID HYPOOSMOLAR RIBOFLAVIN SOLUTION; TREATMENT IN-VITRO; CROSS-LINKING; ULTRAVIOLET-A; BIOMECHANICAL CHANGES; ROSE-BENGAL; KERATOCONUS; LIGHT; SKIN; INCISIONS AB In this study, we explore the effect of photochemical activation induced corneal cross-linking, utilizing Rose Bengal (RB) and 532 nm green light irradiation (RB-PCL), on porcine corneal biomechanical rigidity and the biochemical resistance against collagenase digestion. A protocol with a wavelength of 532 nm and illumination intensity of 0.4W/cm(2) for 250 s to deliver a dose of 100 J/cm(2) was chosen. Using confocal microscopy, we demonstrated that the diffusion depth of RB into porcine cornea was approximately 150 gm and mostly localized in anterior stroma 25 min followed by RB application. After photochemical cross-linking, an increase in tensile strength (by average 200%) and Young's modulus (by average 200%) in porcine corneas was observed. The corneal buttons treated by RB-PCL showed doubling of collagenase digestion time from 10.8 +/- 3.1 days in the blank group to 19.7 +/- 6.2 days in the RB-PCL group, indicating increased resistance to enzymatic digestion. In conclusion, Collagen cross-linking by RB-PCL increased both the biomechanical stiffness and the biochemical resistance against collagenase digestion in porcine corneas, therefore to allow stabilizing and solidifier the cornea. The advantages and disadvantages of RB-PCL versus UVA/riboflavin cross-linking technique (UV-CXL) are fully explored. Due to the nature of minimal penetration of RB into corneal stroma, the RB-PCL method could potentially be used in patients with corneal thickness less than 400 gm where UV-CXL is limited. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Wang, Ti] 85th Hosp PLA, Dept Ophthalmol, Shanghai 200052, Peoples R China. [Peng, Yinbo; Yao, Min] Shanghai Jiao Tong Univ, Peoples Hosp 3, Dept Burns & Plast Surg, Shanghai 201900, Peoples R China. [Peng, Yinbo; Yao, Min] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201900, Peoples R China. [Shen, Nianci; Zhu, Jingyin] Fudan Univ, Huadong Hosp, Dept Ophthalmol, Shanghai 200040, Peoples R China. [Yu, Yan] RA Consulting, Chalfont, PA 18914 USA. [Yao, Min] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Zhu, JY (reprint author), Fudan Univ, Huadong Hosp, Dept Ophthalmol, 221 West Yan An Rd,Bldg 7-410, Shanghai 20040, Peoples R China. EM jingyinz@gmail.com FU Shanghai Municipal Health Bureau Foundation [2010253]; Young Scholars Foundation from Fudan University School of Medicine; Shanghai Key Laboratory of Clinical Geriatric Medicine [13dz2260700]; Medical Foundation from Nanjing Region of PLA; Huadong Hospital Foundation FX This work was supported by Shanghai Municipal Health Bureau Foundation (#2010253), Young Scholars Foundation from Fudan University School of Medicine (2010), Shanghai Key Laboratory of Clinical Geriatric Medicine (13dz2260700), Medical Foundation from Nanjing Region of PLA (2012), and Huadong Hospital Foundation (2010). We are grateful for the technical assistance of Prof. Hongjiu Hu, Xiaolong Zhang, MS and Chen Lu, MD. NR 43 TC 5 Z9 5 U1 1 U2 13 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 EI 1096-0007 J9 EXP EYE RES JI Exp. Eye Res. PD JUN PY 2014 VL 123 SI SI BP 97 EP 104 DI 10.1016/j.exer.2014.04.008 PG 8 WC Ophthalmology SC Ophthalmology GA AJ0HY UT WOS:000337332800010 PM 24768762 ER PT J AU Campos, SM Brady, WE Moxley, KM O'Cearbhaill, RE Lee, PS DiSilvestro, PA Rotmensch, J Rose, PG Thaker, PH O'Malley, DM Hanjani, P Zuna, RE Hensley, ML AF Campos, Susana M. Brady, William E. Moxley, Katherine M. O'Cearbhaill, Roisin E. Lee, Paula S. DiSilvestro, Paul A. Rotmensch, Jacob Rose, Peter G. Thaker, Premal H. O'Malley, David M. Hanjani, Parviz Zuna, Rosemary E. Hensley, Martee L. TI A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study SO GYNECOLOGIC ONCOLOGY LA English DT Article DE Carcinosarcoma; Uterus; VEGFR inhibitors; Angiogenesis ID MIXED MULLERIAN TUMORS; ENDOTHELIAL GROWTH-FACTOR; ENDOMETRIAL CANCER; PROGNOSTIC-SIGNIFICANCE; UTERINE CARCINOSARCOMA; MESODERMAL TUMOR; OPEN-LABEL; TRIAL; ANGIOGENESIS; PACLITAXEL AB Objective. Carcinosarcomas of the female genital tract, also called malignant mixed mullerian tumors, are aggressive biphasic tumors. Second-line treatment options in the recurrent/persistent setting have yielded marginal responses. Given the potential role of angiogenesis in the gynecological carcinomas, pazopanib, a VEGFR inhibitor, was investigated in the management of patients with recurrent carcinosarcoma of the uterus. Methods. Eligible patients had histologically confirmed carcinosarcoma of the uterus, a maximum of two prior lines of therapy, adequate renal, hepatic and hematologic function and a performance status of 0-2. Pazopanib was administered orally at 800 mg. Two dose reductions were allowed. The primary objective was to ascertain the activity of pazopanib as measured by the proportion of patients who survive progression-free for at least six months and the proportion of patients that have objective tumor responses. Secondary objectives included the frequency and severity of adverse events as assessed by CTCAE v4.0. Results. Of the 22 enrolled patients, 19 were eligible and evaluable for toxicity and survival. No patients had a partial or complete response (90% confidence interval [CI]: 0%, 14.6%). Three patients (15.8%) had PFS >= 6 months (90% CI: 4.4%, 35.9%). The median PFS was 2.0 months (first and third quartiles were 1.6 and 4.0 months, respectively). The median overall survival was 8.7 months (first and third quartiles were 2.6 and 14.0 months, respectively). Conclusion. Pazopanib demonstrated minimal activity as a second or third line treatment for advanced uterine carcinosarcoma. Potential clinical trial participation should be discussed with the patients. (C) 2014 Elsevier Inc. All rights reserved. C1 [Campos, Susana M.] Dana Farber Canc Inst, Dana Farber Partners Canc Care, Boston, MA 02115 USA. [Brady, William E.] Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data Ctr, Buffalo, NY 14263 USA. [Moxley, Katherine M.; Zuna, Rosemary E.] Univ Oklahoma, Ctr Sci, Oklahoma City, OK 73104 USA. [O'Cearbhaill, Roisin E.; Hensley, Martee L.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA. [Lee, Paula S.] Duke Univ, Med Ctr, Durham, NC 27710 USA. [DiSilvestro, Paul A.] Brown Univ, Women & Infants Hosp, Providence, RI 02905 USA. [Rotmensch, Jacob] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA. [Rose, Peter G.] Cleveland Clin, Cleveland, OH 44195 USA. [Thaker, Premal H.] Washington Univ, Sch Med, St Louis, MO 63110 USA. [O'Malley, David M.] Ohio State Univ, Columbus Canc Council, Hilliard, OH 43026 USA. [Hanjani, Parviz] Abington Mem Hosp, Abington, PA 19001 USA. RP Campos, SM (reprint author), Dana Farber Canc Inst, Dana Farber Partners Canc Care, 44 Binney St, Boston, MA 02115 USA. EM Susana_Campos@dfci.harvard.edu RI OMalley, David/E-3789-2011 FU National Cancer Institute [CA 27469]; Gynecological Oncology Study Group Statistical Office [CA 37517] FX This study was supported by the National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469) and the Gynecological Oncology Study Group Statistical Office (CA 37517). The following Gynecologic Oncology institutions participated in this study: Abington Memorial Hospital, Columbus Cancer Council/Ohio State, Walter Reed Army Medical Center, Memorial Sloan Kettering Cancer Center, Women and Infants' Hospital, University of Oklahoma, Washington University Medical Center, The Cleveland Clinic Foundation, Rush University Medical Center, University of North Carolina School of Medicine and Duke University Medical Center. NR 42 TC 8 Z9 9 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 EI 1095-6859 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD JUN PY 2014 VL 133 IS 3 BP 537 EP 541 DI 10.1016/j.ygyno.2014.02.036 PG 5 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA AI8ZH UT WOS:000337215000024 PM 24594074 ER PT J AU Konstantinopoulos, PA Wilson, AJ Saskowski, J Wass, E Khabele, D AF Konstantinopoulos, Panagiotis A. Wilson, Andrew J. Saskowski, Jeanette Wass, Erica Khabele, Dineo TI Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer SO GYNECOLOGIC ONCOLOGY LA English DT Article DE Vorinostat (SAHA); Olaparib (Ola); Histone deacetylase inhibitors (HDACi); Poly(ADP-ribose) polymerase inhibitors (PARPi); Phosphorylated gamma histone H2AX (pH2AX); Ovarian cancer ID T-CELL LYMPHOMA; POLY(ADP-RIBOSE) POLYMERASE; HISTONE DEACETYLASES; IONIZING-RADIATION; REPLICATION FORKS; BREAST-CANCER; STRAND BREAKS; VORINOSTAT; INHIBITORS; CARCINOMA AB Objectives. Approximately 50% of serous epithelial ovarian cancers (EOC) contain molecular defects in homologous recombination (HR) DNA repair pathways. Poly(ADP-ribose) polymerase inhibitors (PARPi) have efficacy in HR-deficient, but not in HR-proficient, EOC tumors as a single agent. Our goal was to determine whether the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize HR-proficient ovarian cancer cells to the PARPi AZD-2281 (olaparib). Methods. Ovarian cancer cell lines (SKOV-3, OVCAR-8, NCI/ADR-Res, UWB1.289 BRCA1 null and UWB1.289 + BRCA1 wild-type) were treated with saline vehicle, olaparib, SAHA or olaparib/SAHA. Sulforhodamine B (SRB) assessed cytotoxicity and immunofluorescence and Western blot assays assessed markers of apoptosis (cleaved PARP) and DNA damage (pH2AX and RAD51). Drug effects were also tested in SKOV-3 xenografts in Nude mice. Affymetrix microarray experiments were performed in vehicle and SAHA-treated SKOV-3 cells. Results. In a microarray analysis, SAHA induced coordinated down-regulation of HR pathway genes, including RAD51 and BRCA1. Nuclear co-expression of RAD51 and pH2AX, a marker of efficient HR repair, was reduced approximately 40% by SAHA treatment alone and combined with olaparib. SAHA combined with olaparib induced apoptosis and pH2AX expression to a greater extent than either drug alone. Olaparib reduced cell viability at increasing concentrations and SAHA enhanced these effects in 4 of 5 cell lines, including BRCA1 null and wild-type cells, in vitro and in SKOV-3 xenografts in vivo. Conclusions. These results provide preclinical rationale for targeting DNA damage response pathways by combining small molecule PARPi with HDACi as a mechanism for reducing HR efficiency in ovarian cancer. (C) 2014 Published by Elsevier Inc. C1 [Konstantinopoulos, Panagiotis A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Med Gynecol Oncol Program, Boston, MA 02115 USA. [Wilson, Andrew J.; Saskowski, Jeanette; Wass, Erica; Khabele, Dineo] Vanderbilt Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Med Ctr, Nashville, TN 37232 USA. [Khabele, Dineo] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. RP Khabele, D (reprint author), Vanderbilt Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, 21st Ave South,B-1100 Med Ctr North, Nashville, TN 37232 USA. EM dineo.khabele@vanderbilt.edu FU Department of Defense Ovarian Cancer Academy Award [DOD W81XWH-10-1-0585/OC093426]; [1K08CA148887-01] FX 1K08CA148887-01 (DK) and the Department of Defense Ovarian Cancer Academy Award DOD W81XWH-10-1-0585/OC093426 (PAK). NR 39 TC 30 Z9 30 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 EI 1095-6859 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD JUN PY 2014 VL 133 IS 3 BP 599 EP 606 DI 10.1016/j.ygyno.2014.03.007 PG 8 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA AI8ZH UT WOS:000337215000034 PM 24631446 ER PT J AU Groeneweg, JW Hall, TR Zhang, L Kim, M Byron, VF Tambouret, R Sathayanrayanan, S Foster, R Rueda, BR Growdon, WB AF Groeneweg, Jolijn W. Hall, Tracilyn R. Zhang, Ling Kim, Minji Byron, Virginia F. Tambouret, Rosemary Sathayanrayanan, Sriram Foster, Rosemary Rueda, Bo R. Growdon, Whitfield B. TI Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model SO GYNECOLOGIC ONCOLOGY LA English DT Article DE Uterine serous carcinoma; Notch; Gamma secretase inhibitor; Patient derived xenograft model ID NOTCH SIGNALING MOLECULES; IN-SITU HYBRIDIZATION; CANCER STEM-CELLS; OVARIAN-CANCER; ENDOMETRIAL CANCER; TARGETING NOTCH; HER-2/NEU OVEREXPRESSION; PAPILLARY CARCINOMA; GENE AMPLIFICATION; PATHWAY AB Objective. Uterine serous carcinoma (USC) represents an aggressive subtype of endometrial cancer. We sought to understand Notch pathway activity in USC and determine if pathway inhibition has anti-tumor activity. Methods. Patient USC tissue blocks were obtained and used to correlate clinical outcomes with Notchl expression. Three established USC cell lines were treated with gamma-secretase inhibitor (GSI) in vitro. Mice harboring cell line derived or patient derived USC xenografts (PDXs) were treated with vehicle, GSI, paclitaxel and carboplatin (P/C), or combination GSI and P/C. Levels of cleaved Notchl protein and Hes1 mRNA were determined in GSI treated samples. Statistical analysis was performed using the Wilcoxon rank sum and Kaplan-Meier methods. Results. High nuclear Notch1 protein expression was observed in 58% of USC samples with no correlation with overall sUrvival. GSI induced dose-dependent reductions in Cell number and decreased levels of cleaved Notchl protein and Hes1 mRNA in vitro. Treatment of mice with GSI led to decreased Hes1 mRNA expression in USC xenografts. In addition, GSI impeded tumor growth of cell line xenografts as well as UT1 USC PDXs. When GSI and P/C were combined, synergistic anti-tumor activity was observed in UT1 xenografts. Conclusions. Notch1 is expressed in a large subset of USC. GSI-mediated Notch pathway inhibition led to both reduced cell numbers in vitro and decreased tumor growth of USC some xenograft models. When combined with conventional chemotherapy, GSI augmented anti-tumor activity in one USC PDX line suggesting that targeting of the Notch signaling pathway is a potential therapeutic strategy for future investigation. (C) 2014 Elsevier Inc. All rights reserved. C1 [Groeneweg, Jolijn W.; Hall, Tracilyn R.; Zhang, Ling; Kim, Minji; Byron, Virginia F.; Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Groeneweg, Jolijn W.; Hall, Tracilyn R.; Tambouret, Rosemary; Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Harvard Univ, Sch Med, Boston, MA USA. [Hall, Tracilyn R.; Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02114 USA. [Sathayanrayanan, Sriram] Merck Oncol, Boston, MA USA. [Tambouret, Rosemary] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Growdon, WB (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Vincent Dept Obstet & Gynecol, THR 901,55 Fruit St, Boston, MA 02114 USA. EM wgrowdon@partners.org FU Advanced Medical Research Foundation (BRR); Vincent Memorial Research Funds; Federal Proton Share Program Career Development Grant (WBG); Merck Oncology FX This research was funded in part by the Advanced Medical Research Foundation (BRR), Vincent Memorial Research Funds, Federal Proton Share Program Career Development Grant (WBG) and Merck Oncology. We acknowledge Dr. Santin, Yale University, for generously providing the ARK1 and ARK2 cell lines as well as Dr. Fidler, MD Anderson for generously providing the SPEC2 cell line. NR 40 TC 7 Z9 7 U1 0 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 EI 1095-6859 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD JUN PY 2014 VL 133 IS 3 BP 607 EP 615 DI 10.1016/j.ygyno.2014.03.560 PG 9 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA AI8ZH UT WOS:000337215000035 PM 24667249 ER PT J AU Eckhard, A Lowenheim, H AF Eckhard, A. Loewenheim, H. TI Water regulation in the cochlea. Do molecular water channels facilitate potassium-dependent sound transduction? SO HNO LA German DT Article DE Aquaporin 4; Perilymph; Endolymph; Cochlea; Hearing loss, sensorineural ID CENTRAL-NERVOUS-SYSTEM; GUINEA-PIG COCHLEA; INNER-EAR; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; ION-TRANSPORT; CELLS; AQUAPORIN-4; HEARING; MEMBRANE AB Sound transduction in the cochlea critically depends on the circulation of potassium ions (K+) along so-called "K+ recycling routes" between the endolymph and perilymph. These K+ currents generate high ionic and osmotic gradients, which potentially impair the excitability of sensory hair cells and threaten cell survival in the entire cochlear duct. Molecular water channels-aquaporins (AQP)-are expressed in all cochlear supporting cells along the K+ recycling routes; however, their significance for osmotic equilibration in cochlear duct cells is unknown. The diffusive and osmotic water permeabilies of Reissner's membrane, the organ of Corti and the entire cochlear duct epithelium were determined. Expression of the potassium channel Kir4.1 and the water channel AQP4 in the cochlear duct was investigated by immunohistochemistry. The calculated water permeability values indicate the extent of AQP-facilitated water flux across the cochlear duct epithelium. Immunohistochemically, Kir4.1 and AQP4 were found to colocalize in distinct membrane domains of supporting cells along the K+-recycling routes. These observations suggest the presence of a rapid AQP-mediated water exchange between the endolymph, the cells of the cochlear duct and the perilymph. The subcellular colocalization of Kir4.1 and AQP4 in epithelial supporting cells indicates functional coupling of potassium and water flow in the cochlea. Finally, this offers an explanation for the hearing impairment observed in individuals with mutations in the AQP4 gene. C1 [Eckhard, A.; Loewenheim, H.] Univ Klinikum Tubingen, Klin Hals Nasen Ohren Heilkunde, D-72076 Tubingen, Germany. [Eckhard, A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Eaton Peabody Labs, Boston, MA USA. RP Eckhard, A (reprint author), Univ Klinikum Tubingen, Klin Hals Nasen Ohren Heilkunde, Elfriede Aulhorn Str 5, D-72076 Tubingen, Germany. EM andreas.eckhard@klinikum.uni-tuebingen.de NR 38 TC 0 Z9 0 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0017-6192 EI 1433-0458 J9 HNO JI HNO PD JUN PY 2014 VL 62 IS 6 BP 423 EP 431 DI 10.1007/s00106-014-2872-y PG 9 WC Otorhinolaryngology SC Otorhinolaryngology GA AJ2PG UT WOS:000337499600004 PM 24916350 ER PT J AU Worley, MJ Joseph, NT Berkowitz, RS Goldstein, DP AF Worley, Michael J., Jr. Joseph, Naima T. Berkowitz, Ross S. Goldstein, Donald P. TI Women With a Partial Mole During Their First Pregnancy and Diagnosed Earlier in Gestation Are at Increased Risk of Developing Gestational Trophoblastic Neoplasia SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Article DE Partial mole; Gestational trophoblastic disease; Gestational trophoblastic neoplasia ID PARTIAL HYDATIDIFORM MOLE; CURRENT MANAGEMENT; PRIMARY THERAPY; FOLINIC ACID; DISEASE; EXPERIENCE; METHOTREXATE; PREDICTORS; TUMORS AB Objective: The aim of this study is to identify factors associated with gestational trophoblastic neoplasia (GTN) after partial molar pregnancy. Methods: We retrospectively evaluated clinical data from 111 patients with a partial molar pregnancy between 1995 and 2010. Results: A total of 111 patients with a partial molar pregnancy were available for analysis. There was no significant difference between patients who did and did not develop GTN with respect to patient age, parity, history of prior molar pregnancy, presenting signs/symptoms, uterine size greater than gestational age, clinical diagnosis, preevacuation sonogram findings, or the preevacuation human chorionic gonadotropin value. Patients who developed GTN had fewer prior pregnancies (median, 2 vs 3; P = 0.02) and were more likely to have had a partial molar pregnancy as their first gestational event (37.1% vs 17.1%; P = 0.03). Among the 35 patients who developed GTN, the median time to diagnosis of GTN was 47 days (range, 25-119 days), and the median human chorionic gonadotropin value at the time of GTN diagnosis was 475 mIU/mL (range, 20-52,630 mIU/mL). All women (100%) who developed GTN had stage I disease, and all patients (100%) had low-risk GTN. All 35 women (100%) were able to achieve remission, and most (85.7%) of these patients received methotrexate as first-line chemotherapy. Conclusions: Women with a partial molar pregnancy as their first gestational event and diagnosed earlier in gestation are more likely to develop postmolar GTN. C1 [Worley, Michael J., Jr.; Berkowitz, Ross S.; Goldstein, Donald P.] Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA 02115 USA. [Worley, Michael J., Jr.; Berkowitz, Ross S.; Goldstein, Donald P.] New England Trophoblast Dis Ctr, Trophoblast Tumor Registry, Boston, MA USA. [Worley, Michael J., Jr.; Berkowitz, Ross S.; Goldstein, Donald P.] Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. [Worley, Michael J., Jr.; Berkowitz, Ross S.; Goldstein, Donald P.] Harvard Univ, Sch Med, Boston, MA USA. [Joseph, Naima T.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Integrated Residency Program Obstet & Gynecol, Boston, MA 02114 USA. RP Berkowitz, RS (reprint author), Brigham & Womens Hosp, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA. EM rberkowitz@partners.org NR 22 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD JUN PY 2014 VL 24 IS 5 BP 941 EP 945 DI 10.1097/IGC.0000000000000130 PG 5 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA AI9IS UT WOS:000337246900020 PM 24819660 ER PT J AU Gaffney, DK Jhingran, A Portelance, L Viswanathan, A Schefter, T Weidhaas, J Small, W AF Gaffney, David K. Jhingran, Anuja Portelance, Lorraine Viswanathan, Akila Schefter, Tracey Weidhaas, Joanne Small, William, Jr. TI Radiation Therapy Oncology Group Gynecologic Oncology Working Group Comprehensive Results SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Review DE RTOG; Cervix; Uterus; Radiation ID ADVANCED CERVICAL-CANCER; MODULATED PELVIC RADIOTHERAPY; EXTENDED-FIELD IRRADIATION; TWICE-DAILY FRACTIONATION; CLINICAL TARGET VOLUME; PARAAORTIC LYMPH-NODES; PHASE-II; ENDOMETRIAL CANCER; CONCURRENT CHEMOTHERAPY; EXTERNAL IRRADIATION AB The purpose of this report was to comprehensively describe the activities of the Gynecologic Oncology Working Group within the Radiation Therapy Oncology Group (RTOG). Clinical trials will be reviewed as well as translational science and ancillary activities. During the past 40 years, a myriad of clinical trials have been performed within the RTOG with the aim of improving overall survival (OS) and decreasing morbidity in women with cervical or endometrial cancer. Major study questions have included hyperbaric oxygen, neutron radiotherapy, altered fractionation, hypoxic cell sensitization, chemosensitization, and volume-directed radiotherapy. RTOG 7920 demonstrated improvement in OS in patients with stages IB through IIB cervical carcinoma receiving prophylactic para-aortic irradiation compared to pelvic radiation alone. RTOG 9001 demonstrated that cisplatin and 5-FU chemoradiotherapy to the pelvis for advanced cervix cancer markedly improved OS compared to extended field radiotherapy alone. More recent trials have used radioprotectors, molecular-targeted therapy, and intensity-modulated radiation therapy. Ancillary studies have developed clinical target volume atlases for research protocols and routine clinical use. Worldwide practice patterns have been investigated in cervix, endometrial, and vulvar cancer through the Gynecologic Cancer Intergroup. Translational studies have focused on immunohistochemical markers, changes in gene expression, and miRNA patterns impacting prognosis. The RTOG gynecologic working group has performed clinical trials that have defined the standard of care, improved survival, and added to our understanding of the biology of cervical and endometrial cancers. C1 [Gaffney, David K.] Univ Utah, Dept Radiat Oncol, Huntsman Canc Hosp, Salt Lake City, UT 84112 USA. [Jhingran, Anuja] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Portelance, Lorraine] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA. [Viswanathan, Akila] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Schefter, Tracey] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Weidhaas, Joanne] Yale Univ, Dept Radiat Oncol, New Haven, CT USA. [Small, William, Jr.] Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, Chicago, IL 60611 USA. RP Gaffney, DK (reprint author), Univ Utah, Dept Radiat Oncol, Huntsman Canc Hosp, 1950 Circle Hope Rd, Salt Lake City, UT 84112 USA. EM david.gaffney@hci.utah.edu OI Weidhaas, Joanne/0000-0002-5096-3281 FU NCI NIH HHS [U10 CA180818] NR 38 TC 1 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD JUN PY 2014 VL 24 IS 5 BP 956 EP 962 DI 10.1097/IGC.0000000000000135 PG 7 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA AI9IS UT WOS:000337246900023 PM 24819663 ER PT J AU Patel, H Higgins, JM AF Patel, Harsh Higgins, John M. TI MATHEMATICAL MODEL-BASED ESTIMATION OF RED BLOOD CELL CLEARANCE PREDICTS FUTURE ANEMIA IN PATIENTS WITH NORMAL COMPLETE BLOOD COUNTS SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY LA English DT Meeting Abstract C1 [Patel, Harsh; Higgins, John M.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Higgins, John M.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-5521 EI 1751-553X J9 INT J LAB HEMATOL JI Int. J. Lab. Hematol. PD JUN PY 2014 VL 36 SU 1 SI SI BP 72 EP 72 PG 1 WC Hematology SC Hematology GA AI9HS UT WOS:000337244300166 ER PT J AU Ghamande, S Lin, CC Cho, DC Shapiro, GI Kwak, EL Silverman, MH Tseng, YL Kuo, MW Mach, WB Hsu, SC Coleman, T Yang, JCH Cheng, AL Ghalib, MH Chuadhary, I Goel, S AF Ghamande, Sharad Lin, Chia-Chi Cho, Daniel C. Shapiro, Geoffrey I. Kwak, Eunice L. Silverman, Michael H. Tseng, Yunlong Kuo, Min-Wen Mach, Wendy B. Hsu, Shu-Chi Coleman, Teresa Yang, James Chih-Hsin Cheng, Ann-Lii Ghalib, Mohammad H. Chuadhary, Imran Goel, Sanjay TI A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors SO INVESTIGATIONAL NEW DRUGS LA English DT Article DE Camptothecin; Topotecan; Phase 1 trial; Hypoxia-inducible factor; Topoisomerase ID TOPOISOMERASE-I INHIBITOR; TOPOTECAN; CANCER; TRIAL AB Purpose The first-in-human phase 1 trial examined the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetic profile, and antitumor activity of TLC388, a novel camptothecin with a unique lactone ring modification, in patients with advanced solid tumors. Experimental design TLC388 was administered intravenously to patients with metastatic chemotherapy refractory solid tumors on days 1, 8, and 15 of a 28-day cycle. Patients underwent tumor assessments every other cycle. Pharmacokinetic samples were drawn on days 1, 8, and 15 of cycles 1 and 2. Results Fifty-four patients were enrolled at doses ranging from 1.5 to 60.0 mg/m(2) over 12 cohorts. Treatment was generally well-tolerated and no cumulative toxicity observed. Two of six patients treated at 60.0 mg/m(2) developed DLTs of grade 3 neutropenia causing dose delay and grade 3 febrile neutropenia. The next lower dose, 50.0 mg/m(2), was declared as MTD. Treatment-related grade 3-4 hematologic toxicities included neutropenia (19 %), leukopenia (15 %), anemia (9 %), and thrombocytopenia (7 %). Grade 3-4 nonhematologic toxicities included diarrhea (2 %) and hyponatremia (4 %). Pharmacokinetics of both diastereomers (S,R and S,S) of TLC388, a mixture of two diastereomers, was dose independent; mean (SD) values for the volume of distribution at steady-state and clearance were 857 (1122) L/m(2) for S,R and 996 (1333) L/m(2) for S,S, and 2174 (2526) L/h-m(2) for S,R and 2670 (2988) L/h-m(2) for S,S, respectively. The half-life values averaged 0.67 (1.15) hours for S,R and 0.64 (1.11) hours for S,S. The best overall response was stable disease in 21 (39 %) patients. Prolonged (a parts per thousand yen 6 months) stable disease was noted in eight patients. Conclusions TLC388 at 50 mg/m(2) on the current treatment schedule is generally safe and well tolerated. C1 [Ghamande, Sharad; Coleman, Teresa] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA. [Lin, Chia-Chi; Yang, James Chih-Hsin; Cheng, Ann-Lii] Natl Taiwan Univ Hosp, Taipei, Taiwan. [Cho, Daniel C.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Shapiro, Geoffrey I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kwak, Eunice L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Silverman, Michael H.] BioStrateg Consulting Ltd, Marblehead, MA USA. [Tseng, Yunlong; Kuo, Min-Wen; Mach, Wendy B.; Hsu, Shu-Chi] Taiwan Liposome Co Ltd, Taipei, Taiwan. [Ghalib, Mohammad H.; Chuadhary, Imran; Goel, Sanjay] Montefiore Med Ctr, Bronx, NY 10461 USA. [Goel, Sanjay] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10461 USA. RP Goel, S (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, 1825 Eastchester Rd,Room 2S-52, Bronx, NY 10461 USA. EM sgoel@montefiore.org OI Cheng, Ann-Lii/0000-0002-9152-6512; Yang, James Chih-Hsin/0000-0002-5586-5138 FU Taiwan Liposome Company, Inc. FX Yunlong Tseng, Min-Wen Kuo, Wendy B. Mach, and Shu-Chi Hsu are the employees of the study sponsor (Taiwan Liposome Company, Inc.). The remaining authors declare that they have no conflict of interest. NR 9 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0167-6997 EI 1573-0646 J9 INVEST NEW DRUG JI Invest. New Drugs PD JUN PY 2014 VL 32 IS 3 BP 445 EP 451 DI 10.1007/s10637-013-0044-7 PG 7 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA AI7OU UT WOS:000337084000006 PM 24271274 ER PT J AU Greenspon, AJ Le, KY Prutkin, JM Sohail, MR Vikram, HR Baddour, LM Danik, SB Peacock, J Falces, C Miro, JM Naber, C Carrillo, RG Tseng, CH Uslan, DZ AF Greenspon, Arnold J. Le, Katherine Y. Prutkin, Jordan M. Sohail, M. Rizwan Vikram, Holenarasipur R. Baddour, Larry M. Danik, Stephan B. Peacock, James Falces, Carlos Miro, Jose M. Naber, Christoph Carrillo, Roger G. Tseng, Chi-Hong Uslan, Daniel Z. TI Influence of Vegetation Size on the Clinical Presentation and Outcome of Lead-Associated Endocarditis Results From the MEDIC Registry SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE endocarditis; implantable cardioverter-defibrillator; permanent pacemaker ID ELECTRONIC DEVICE INFECTIONS; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; STAPHYLOCOCCUS-AUREUS BACTEREMIA; CARDIAC DEVICES; PACEMAKERS; MANAGEMENT; DIAGNOSIS; TRENDS; ECHOCARDIOGRAPHY; EXTRACTION AB OBJECTIVES The purpose of this study was to determine whether the clinical presentation of lead-associated endocarditis (LAE) is related to the size of lead vegetations and how size is related to bacteriology and clinical outcomes. BACKGROUND Cardiac implantable electronic device (CIED) infection may present as either local pocket infection or bloodstream infection with or without LAE. LAE is associated with significant morbidity and mortality. METHODS The clinical presentation and course of LAE were evaluated by the MEDIC (Multicenter Electrophysiologic Device Cohort) registry, an international registry enrolling patients with CIED infection. Consecutive LAE patients enrolled in the MEDIC registry between January 1, 2009 and December 31, 2012 were analyzed. The clinical features and outcomes of 2 groups of patients were compared based on the size of the lead vegetation detected by echocardiography (> or <1 cm in diameter). RESULTS There were 129 patients with LAE enrolled into the MEDIC registry. Of these, 61 patients had a vegetation <1 cm in diameter (Group I) whereas 68 patients had a vegetation >= 1 cm in diameter (Group II). Patients in Group I more often presented with signs of local pocket infection, whereas Group II patients presented with clinical evidence of systemic infection. Staphylococcus aureus was the organism most often responsible for LAE, whereas infection with coagulase-negative staphylococci was associated with larger vegetations. Outcomes were improved among those who underwent complete device removal. However, major complications were associated with an open surgical approach for device removal. CONCLUSIONS The clinical presentation of LAE is influenced by the size of the lead vegetation. Prompt recognition and management of LAE depends on obtaining blood cultures and echocardiography, including transesophageal echocardiography, in CIED patients who present with either signs of local pocket or systemic infection. (C) 2014 by the American College of Cardiology Foundation C1 [Greenspon, Arnold J.] Thomas Jefferson Univ Hosp, Dept Med, Cardiac Electrophysiol Lab, Div Cardiol, Philadelphia, PA 19107 USA. [Le, Katherine Y.; Sohail, M. Rizwan; Baddour, Larry M.] Mayo Clin, Coll Med, Dept Med, Div Infect Dis, Rochester, MN USA. [Prutkin, Jordan M.] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA. [Vikram, Holenarasipur R.] Mayo Clin, Dept Med, Div Infect Dis, Phoenix, AZ USA. [Danik, Stephan B.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Peacock, James] Wake Forest Univ, Dept Med, Div Infect Dis, Winston Salem, NC 27109 USA. [Falces, Carlos; Miro, Jose M.] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Dept Med,Div Infect Dis, Barcelona, Spain. [Naber, Christoph] Elisabeth Hosp, Dept Med, Div Cardiol, Essen, Germany. [Carrillo, Roger G.] Univ Miami, Dept Surg, Div Cardiothorac Surg, Miami, FL USA. [Tseng, Chi-Hong] Univ Calif Los Angeles, Dept Gen Intemal Med & Hlth Serv, Los Angeles, CA USA. [Uslan, Daniel Z.] Univ Calif Los Angeles, Dept Med, Div Infect Dis, Los Angeles, CA 90024 USA. RP Greenspon, AJ (reprint author), Thomas Jefferson Univ Hosp, Jefferson Heart Inst, Cardiac Electrophysiol Lab, 925 Chestnut St, Philadelphia, PA 19107 USA. EM arnold.greenspon@jefferson.edu RI Carrillo, Roger/C-2231-2015; Sohail, Muhammad/K-1803-2016; OI Carrillo, Roger/0000-0002-0443-8689; Sohail, Muhammad/0000-0001-6355-0526; Falces, Carlos/0000-0002-3483-3786 FU American Heart Association; Medtronic; Boston Scientific; Spectranetics; Biotronik; St. Jude Medical; Tyco FX This study was funded, in part, by a grant from the American Heart Association (to Dr. Uslan). Dr. Greenspon has received honoraria from Medtronic, Boston Scientific, and St. Jude Medical; and research grants from Medtronic and Boston Scientific. Dr. Sohail has received consulting fees from Spectranetics. Dr. Carrillo has received consulting fees from Spectranetics, Medtronic, Biotronik, St. Jude Medical, and Tyco; and a research grant from St. Jude Medical. Dr. Uslan has received a research grant from Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 31 TC 8 Z9 8 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD JUN PY 2014 VL 7 IS 6 BP 541 EP 549 DI 10.1016/j.jcmg.2014.01.015 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AJ0HP UT WOS:000337331800001 PM 24813965 ER PT J AU Shaw, LJ Berman, DS Picard, MH Friedrich, MG Kwong, RY Stone, GW Senior, R Min, JK Hachamovitch, R Scherrer-Crosbie, M Mieres, JH Marwick, TH Phillips, LM Chaudhry, FA Pellikka, PA Slomka, P Arai, AE Iskandrian, AE Bateman, TM Heller, GV Miller, TD Nagel, E Goyal, A Borges-Neto, S Boden, WE Reynolds, HR Hochman, JS Maron, DJ Douglas, PS AF Shaw, Leslee J. Berman, Daniel S. Picard, Michael H. Friedrich, Matthias G. Kwong, Raymond Y. Stone, Gregg W. Senior, Roxy Min, James K. Hachamovitch, Rory Scherrer-Crosbie, Marielle Mieres, Jennifer H. Marwick, Thomas H. Phillips, Lawrence M. Chaudhry, Farooq A. Pellikka, Patricia A. Slomka, Piotr Arai, Andrew E. Iskandrian, Ami E. Bateman, Timothy M. Heller, Gary V. Miller, Todd D. Nagel, Eike Goyal, Abhinav Borges-Neto, Salvador Boden, William E. Reynolds, Harmony R. Hochman, Judith S. Maron, David J. Douglas, Pamela S. CA ISCHEMIA Trial Investigators TI Comparative Definitions for Moderate-Severe Ischemia in Stress Nuclear, Echocardiography, and Magnetic Resonance Imaging SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE cardiac imaging; ischemia; prognosis ID CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; VENTRICULAR EJECTION FRACTION; INCREMENTAL PROGNOSTIC VALUE; OPTIMAL MEDICAL THERAPY; MYOCARDIAL-PERFUSION SCINTIGRAPHY; AMERICAN-HEART-ASSOCIATION; EXERCISE ECHOCARDIOGRAPHY; RISK STRATIFICATION; REVASCULARIZATION PROCEDURES AB The lack of standardized reporting of the magnitude of ischemia on noninvasive imaging contributes to variability in translating the severity of ischemia across stress imaging modalities. We identified the risk of coronary artery disease (CAD) death or myocardial infarction (MI) associated with >= 10% ischemic myocardium on stress nuclear imaging as the risk threshold for stress echocardiography and cardiac magnetic resonance. A narrative review revealed that >= 10% ischemic myocardium on stress nuclear imaging was associated with a median rate of CAD death or MI of 4.9%/year (interquartile range: 3.75% to 5.3%). For stress echocardiography, >= 3 newly dysfunctional segments portend a median rate of CAD death or MI of 4.5%/year (interquartile range: 3.8% to 5.9%). Although imprecisely delineated, moderate-severe ischemia on cardiac magnetic resonance may be indicated by >= 4 of 32 stress perfusion defects or >= 3 dobutamine-induced dysfunctional segments. Risk-based thresholds can define equivalent amounts of ischemia across the stress imaging modalities, which will help to translate a common understanding of patient risk on which to guide subsequent management decisions. (C) 2014 by the American College of Cardiology Foundation C1 [Shaw, Leslee J.; Goyal, Abhinav] Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30324 USA. [Berman, Daniel S.] Cedars Sinai Med Ctr, Dept Med, Div Cardiac Imaging Nucl Cardiol, Los Angeles, CA 90048 USA. [Picard, Michael H.; Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Friedrich, Matthias G.] Montreal Heart Inst, Dept Med, Div Cardiol, Montreal, PQ H1T 1C8, Canada. [Kwong, Raymond Y.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. [Stone, Gregg W.] Columbia Univ, New York Presbyterian Hosp, Med Ctr, Dept Med,Div Cardiol, New York, NY USA. [Senior, Roxy] Univ London Imperial Coll Sci Technol & Med, Dept Cardiovasc Med, Div Cardiol, London, England. [Min, James K.] Weill Cornell Med Coll, Dept Cardiovasc Med, Div Radiol, New York, NY USA. [Hachamovitch, Rory] Cleveland Clin Fdn, Dept Cardiovasc Med, Div Cardiol, Cleveland, OH 44195 USA. [Mieres, Jennifer H.] North Shore Long Isl Jewish Hosp, Dept Med, Div Cardiol, Manhasset, NY USA. [Marwick, Thomas H.] Menzies Res Inst Tasmania, Dept Med, Div Cardiol, Hobart, Tas, Australia. [Phillips, Lawrence M.; Reynolds, Harmony R.; Hochman, Judith S.] NYU, Med Ctr, Dept Med, Div Cardiol, New York, NY 10016 USA. [Chaudhry, Farooq A.] Icahn Sch Med Mt Sinai, Dept Med, Div Cardiol, New York, NY USA. [Pellikka, Patricia A.; Miller, Todd D.] Mayo Clin, Dept Med, Div Cardiovasc Med, Rochester, MN USA. [Slomka, Piotr] Cedars Sinai Med Ctr, Dept Med, Div Imaging, Los Angeles, CA 90048 USA. [Arai, Andrew E.] NHLBI, Dept Med, Div Cardiovasc Med, NIH, Bethesda, MD 20892 USA. [Iskandrian, Ami E.] Univ Alabama Birmingham, Dept Radiol, Div Cardiovasc Dis, Birmingham, AL USA. [Bateman, Timothy M.] St Lukes Mid Amer Heart Inst, Dept Med, Div Cardiol, Kansas City, MO USA. [Heller, Gary V.] Hartford Hosp, Hartford, CT 06115 USA. [Nagel, Eike] Kings Coll London, Dept Med, Div Cardiovasc Med, London, England. [Borges-Neto, Salvador] Duke Clin Res Inst, Dept Nucl Med, Div Radiol, Durham, NC USA. [Boden, William E.] Samuel S Stratton VA Med Ctr, Dept Med, Div Cardiol, Albany, NY USA. [Maron, David J.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA. [Douglas, Pamela S.] Duke Clin Res Inst, Dept Med, Div Cardiol, Durham, NC USA. RP Shaw, LJ (reprint author), Emory Univ, Sch Med, Emory Clin Cardiovasc Res Inst, 1462 Clifton Rd NE,Room 529, Atlanta, GA 30324 USA. EM lshaw3@emory.edu RI Nagel, Eike/C-6903-2008; OI Nagel, Eike/0000-0002-6044-950X; Reynolds, Harmony/0000-0003-0284-0655; Picard, Michael/0000-0002-9264-3243; Hochman, Judith/0000-0002-5889-5981 FU Astellas; Bracco Diagnostics Inc.; GE Healthcare; Philips Healthcare; Siemens; Lantheus Medical Imaging; Spectrum Dynamics; Bayer HealthCare; GlaxoSmithKline FX Dr. Shaw has received research support from Astellas and Bracco Diagnostics Inc. Dr. Friedrich is a board member, advisor, and shareholder for Circle Cardiovascular Imaging. Dr. Senior is a member of the speaker's bureau for and has received honoraria from Bracco Diagnostics Inc. and Philips Healthcare. Dr. Min is a member of the medical advisory board and speaker's bureau for and has received research support from GE Healthcare; is a member of the medical advisory board for Arineta Ltd.; has received research support from Philips Healthcare; and holds equity interest in TC3 and MDDX. Dr. Arai has received research support from Siemens. Dr. Iskandrian is a member of the advisory committee for Rapidscan Pharma. Dr. Bateman is a member of the advisory committee for and receives research support from Astellas, Lantheus Medical Imaging, GE Healthcare, and Spectrum Dynamics. Dr. Miller is a consultant for Astellas. Dr. Nagel has received research support from Philips Healthcare and Bayer HealthCare. Dr. Borges-Neto is a member of the speaker's bureau and advisory board for and has received grant support from Astellas and is a member of the advisory board for and has received grant support from GE Healthcare. Dr. Hochman has received a consulting fee and modest honoraria from GlaxoSmithKline. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 65 TC 34 Z9 34 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD JUN PY 2014 VL 7 IS 6 BP 593 EP 604 DI 10.1016/j.jcmg.2013.10.021 PG 12 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AJ0HP UT WOS:000337331800008 PM 24925328 ER PT J AU Cone, EB Eisner, BH Ursiny, M Pareek, G AF Cone, Eugene B. Eisner, Brian H. Ursiny, Michal Pareek, Gyan TI Cost-Effectiveness Comparison of Renal Calculi Treated with Ureteroscopic Laser Lithotripsy Versus Shockwave Lithotripsy SO JOURNAL OF ENDOUROLOGY LA English DT Article ID WAVE LITHOTRIPSY; URETERAL CALCULI; STONES AB Purpose: To evaluate the cost-effectiveness of shockwave lithotripsy (SWL) vs ureteroscopic lithotripsy (URS) for patients with renal stones < 1.5 cm in diameter. Methods: Patient age, stone diameter, stone location, and stone-free status were recorded for patients treated with SWL or URS for renal stones < 1.5 cm in maximal diameter over a 1-year period. Institutional charges were obtained from in-house billing. A decision analysis model was constructed to compare the cost-effectiveness of SWL and URS and using our results and success rates for modeling. Three separate models were created to reflect practice patterns for SWL. Results: One hundred fifty-eight patients were included in the study-78 underwent SWL and 80 underwent URS as primary treatment. Single procedure stone-free rates (SFR) for SWL and URS were 55% and 95%, respectively (P < 0.0001). Decision analysis modeling demonstrated cost-effectiveness of SWL when SWL single procedure SFR were 65% to 67% or when URS single procedure SFR was 72% to 84%. Conclusions: This retrospective study revealed superior SFR results for renal stones < 1.5 cm for URS compared with SWL. Our decision analysis model demonstrates that for SWL SFR less than 65% to 67% or for URS SFR greater than 72% to 84%, SWL is not a cost-effective treatment option. Based on these findings, careful stratification and selection of stone patients may enable surgeons to increase the cost-effectiveness of SWL. C1 [Cone, Eugene B.] Duke Univ, Sch Med, Div Urol, Med Ctr, Durham, NC 27708 USA. [Eisner, Brian H.; Ursiny, Michal] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA USA. [Pareek, Gyan] Brown Univ, Div Urol, Warren Alpert Med Sch, Providence, RI 02912 USA. RP Cone, EB (reprint author), Duke Univ, Sch Med, Div Urol, Med Ctr, 200 Trent Dr, Durham, NC 27708 USA. EM eugene.cone@duke.edu OI Cone, Eugene/0000-0002-0292-7534 NR 12 TC 9 Z9 10 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0892-7790 EI 1557-900X J9 J ENDOUROL JI J. Endourol. PD JUN PY 2014 VL 28 IS 6 BP 639 EP 643 DI 10.1089/end.2013.0669 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA AI9BN UT WOS:000337221600004 PM 24444144 ER PT J AU Porto, I Ducci, KJ Angioli, P Grotti, S Falsini, G Vergallo, R Liistro, F Bolognese, L AF Porto, Italo Ducci, Kenneth J. Angioli, Paolo Grotti, Simone Falsini, Giovanni Vergallo, Rocco Liistro, Francesco Bolognese, Leonardo TI Optical Frequency-Domain Imaging to Guide Implantation of a Paclitaxel-Eluting Stent in the Femoral Artery SO JOURNAL OF ENDOVASCULAR THERAPY LA English DT Editorial Material ID COHERENCE TOMOGRAPHY C1 [Porto, Italo; Ducci, Kenneth J.; Angioli, Paolo; Grotti, Simone; Falsini, Giovanni; Liistro, Francesco; Bolognese, Leonardo] San Donato Hosp, Intervent Cardiol Unit, Arezzo, Italy. [Vergallo, Rocco] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. RP Porto, I (reprint author), San Donato Hosp, Intervent Cardiol Unit, Arezzo, Italy. EM italo.porto@gmail.com OI Grotti, Simone/0000-0002-7165-7355 NR 5 TC 0 Z9 0 U1 0 U2 0 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1526-6028 EI 1545-1550 J9 J ENDOVASC THER JI J. Endovascular Ther. PD JUN PY 2014 VL 21 IS 3 BP 456 EP 459 DI 10.1583/13-4634.1 PG 4 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AJ0IK UT WOS:000337334000016 PM 24915597 ER PT J AU Thomas, MP Whangbo, J McCrossan, G Deutsch, AJ Martinod, K Walch, M Lieberman, J AF Thomas, Marshall P. Whangbo, Jennifer McCrossan, Geoffrey Deutsch, Aaron J. Martinod, Kimberly Walch, Michael Lieberman, Judy TI Leukocyte Protease Binding to Nucleic Acids Promotes Nuclear Localization and Cleavage of Nucleic Acid Binding Proteins SO JOURNAL OF IMMUNOLOGY LA English DT Article ID NEUTROPHIL EXTRACELLULAR TRAPS; PROGRAMMED CELL-DEATH; HUMAN GRANZYME; PANCREATIC ELASTASE; CRYSTAL-STRUCTURE; SPECIFICITY; RNA; DNA; SERGLYCIN; AFFINITY AB Killer lymphocyte granzyme (Gzm) serine proteases induce apoptosis of pathogen-infected cells and tumor cells. Many known Gzm substrates are nucleic acid binding proteins, and the Gzms accumulate in the target cell nucleus by an unknown mechanism. In this study, we show that human Gzms bind to DNA and RNA with nanomolar affinity. Gzms cleave their substrates most efficiently when both are bound to nucleic acids. RNase treatment of cell lysates reduces Gzm cleavage of RNA binding protein targets, whereas adding RNA to recombinant RNA binding protein substrates increases in vitro cleavage. Binding to nucleic acids also influences Gzm trafficking within target cells. Preincubation with competitor DNA and DNase treatment both reduce Gzm nuclear localization. The Gzms are closely related to neutrophil proteases, including neutrophil elastase (NE) and cathepsin G. During neutrophil activation, NE translocates to the nucleus to initiate DNA extrusion into neutrophil extracellular traps, which bind NE and cathepsin G. These myeloid cell proteases, but not digestive serine proteases, also bind DNA strongly and localize to nuclei and neutrophil extracellular traps in a DNA-dependent manner. Thus, high-affinity nucleic acid binding is a conserved and functionally important property specific to leukocyte serine proteases. Furthermore, nucleic acid binding provides an elegant and simple mechanism to confer specificity of these proteases for cleavage of nucleic acid binding protein substrates that play essential roles in cellular gene expression and cell proliferation. C1 Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Lieberman, J (reprint author), Harvard Univ, Sch Med, WAB 255,200 Longwood Ave, Boston, MA 02115 USA. EM jennifer.whangbo@childrens.harvard.edu; lieberman@childrens.harvard.edu RI Lieberman, Judy/A-2717-2015; OI Deutsch, Aaron/0000-0001-6750-5335; Martinod, Kimberly/0000-0002-1026-6107 FU National Science Foundation graduate research fellowship; National Institutes of Health K08 [HL094460]; Boston Children's Hospital Career Development Fellowship; National Institutes of Health [AI45587] FX This work was supported by a National Science Foundation graduate research fellowship (to M.P.T.), National Institutes of Health K08 Grant HL094460 (to J.W.), a Boston Children's Hospital Career Development Fellowship (to J.W.), and National Institutes of Health Grant AI45587 (to J.L.). NR 39 TC 7 Z9 7 U1 1 U2 4 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD JUN 1 PY 2014 VL 192 IS 11 BP 5390 EP 5397 DI 10.4049/jimmunol.1303296 PG 8 WC Immunology SC Immunology GA AI8MT UT WOS:000337171800050 PM 24771851 ER PT J AU Gupta, M Leskov, I Kruger, JM Cestari, DM AF Gupta, Meenakashi Leskov, Ilya Kruger, Joshua M. Cestari, Dean M. TI Intermittent Horner Syndrome in a Pediatric Patient SO JOURNAL OF NEURO-OPHTHALMOLOGY LA English DT Editorial Material ID HEADACHE SINE HEADACHE; CERVICAL SPINAL-CORD; CLUSTER HEADACHE AB Intermittent Horner syndrome is uncommon in both the adult and pediatric population. We describe a case of a pediatric patient with an intermittent Horner syndrome. Infrared photography and videography were used to help establish the diagnosis. (C) 2013 by North American Neuro-Ophthalmology Society C1 [Gupta, Meenakashi; Leskov, Ilya; Cestari, Dean M.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Cestari, Dean M.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Neuroophthalmol Serv, Boston, MA 02114 USA. [Gupta, Meenakashi; Leskov, Ilya; Cestari, Dean M.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Cestari, DM (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Neuroophthalmol Serv, 243 Charles St, Boston, MA 02114 USA. FU NIGMS NIH HHS [T32GM007753] NR 12 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-8022 EI 1536-5166 J9 J NEURO-OPHTHALMOL JI J. Neuro-Ophthal. PD JUN PY 2014 VL 34 IS 2 BP 149 EP 150 DI 10.1097/WNO.0000000000000062 PG 2 WC Clinical Neurology; Ophthalmology SC Neurosciences & Neurology; Ophthalmology GA AI9IL UT WOS:000337246200008 PM 24135969 ER PT J AU Deyo, RA Dworkin, SF Amtmann, D Andersson, G Borenstein, D Carragee, E Carrino, J Chou, R Cook, K DeLitto, A Goertz, C Khalsa, P Loeser, J Mackey, S Panagis, J Rainville, J Tosteson, T Turk, D Von Korff, M Weinertt, DK AF Deyo, Richard A. Dworkin, Samuel F. Amtmann, Dagmar Andersson, Gunnar Borenstein, David Carragee, Eugene Carrino, John Chou, Roger Cook, Karon DeLitto, Anthony Goertz, Christine Khalsa, Partap Loeser, John Mackey, Sean Panagis, James Rainville, James Tosteson, Tor Turk, Dennis Von Korff, Michael Weinertt, Debra K. TI Report of the NIH Task Force on Research Standards for Chronic Low Back Pain SO JOURNAL OF PAIN LA English DT Article DE Low back pain; chronic low back pain; research standards; minimum dataset; NIH Task Force ID CLINICAL-PRACTICE GUIDELINE; DEFINING CHRONIC PAIN; INFORMATION-SYSTEM PROMIS; FUNCTION ITEM BANK; QUALITY-OF-LIFE; PRIMARY-CARE; PROGNOSTIC APPROACH; SCREENING TOOL; START BACK; OUTCOME MEASURES AB Despite rapidly increasing intervention, functional disability due to chronic low back pain (cLBP) has increased in recent decades. We often cannot identify mechanisms to explain the major negative impact cLBP has on patients' lives. Such cLBP is often termed non-specific and may be due to multiple biologic and behavioral etiologies. Researchers use varied inclusion criteria, definitions, baseline assessments, and outcome measures, which impede comparisons and consensus. Therefore, NIH Pain Consortium charged a Research Task Force (RTF) to draft standards for research on cLBP. The resulting multidisciplinary panel recommended using 2 questions to define cLBP; cLBP by its impact (defined by pain intensity, pain interference, and physical function); use of a minimum dataset to describe research participants (drawing heavily on the PROMIS methodology); reporting "responder analyses" in addition to mean outcome scores; and suggestions for future research and dissemination. The Pain Consortium has approved the recommendations, which investigators should incorporate into NIH grant proposals. The RTF believes that these recommendations will advance the field, help to resolve controversies, and facilitate future research addressing the genomic, neurologic, and other mechanistic substrates of chronic low back pain. We expect that the RTF recommendations will become a dynamic document and undergo continual improvement. Perspective: A task force was convened by the NIH Pain Consortium with the goal of developing research standards for chronic low back pain. The results included recommendations for definitions, a minimum dataset, reporting outcomes, and future research. Greater consistency in reporting should facilitate comparisons among studies and the development of phenotypes. (C) 2014 by the American Pain Society. Published by Elsevier Inc. All rights reserved C1 [Deyo, Richard A.; Chou, Roger] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Dworkin, Samuel F.; Amtmann, Dagmar; Loeser, John; Turk, Dennis] Univ Washington, Seattle, WA 98195 USA. [Andersson, Gunnar] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Borenstein, David] George Washington Univ, Washington, DC USA. [Carragee, Eugene; Mackey, Sean] Stanford Univ, Stanford, CA 94305 USA. [Carrino, John] Johns Hopkins Univ, Baltimore, MD USA. [Cook, Karon] Northwestern Univ, Evanston, IL USA. [DeLitto, Anthony; Weinertt, Debra K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [DeLitto, Anthony; Weinertt, Debra K.] Univ Pittsburgh, Pittsburgh, PA USA. [Goertz, Christine] Palmer Coll Chiropract, Davenport, IA USA. [Khalsa, Partap] Natl Ctr Complementary & Alternat Med, Bethesda, MD USA. [Panagis, James] NIAMSD, Bethesda, MD 20892 USA. [Rainville, James] New England Baptist Hosp, Roxbury Crossing, MA USA. [Tosteson, Tor] Dartmouth Coll, Hanover, NH USA. [Von Korff, Michael] Grp Hlth Res Inst, Seattle, WA USA. RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM deyor@ohsu.edu FU National Center for Complementary and Alternative Medicine; National Institute for Arthritis, Musculoskeletal, and Skin Diseases FX This study was supported by the National Center for Complementary and Alternative Medicine and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases. NR 127 TC 29 Z9 29 U1 9 U2 19 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD JUN PY 2014 VL 15 IS 6 BP 569 EP 585 DI 10.1016/j.jpain.2014.03.005 PG 17 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AJ0HM UT WOS:000337331400001 PM 24787228 ER PT J AU Kwolek, CJ Rordorf, G Patel, VI Rosenfield, K Hirsch, J Jaff, M AF Kwolek, Christopher J. Rordorf, Guy Patel, Virendra I. Rosenfield, Kenneth Hirsch, Joshua Jaff, Michael TI Prospective Independent Neurologic Evaluation of Patients Undergoing Carotid Revascularization: Can We Match the CREST results SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Kwolek, Christopher J.; Rordorf, Guy; Patel, Virendra I.; Rosenfield, Kenneth; Hirsch, Joshua; Jaff, Michael] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 6S EP 7S PG 2 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400009 ER PT J AU Robinson, WP Huang, W Rosen, A Schanzer, A Fang, H Anderson, F Messina, L AF Robinson, William P. Huang, Wei Rosen, Amy Schanzer, Andres Fang, Hua Anderson, Frederick Messina, Louis TI Agency for Healthcare Research and Quality (AHRQ) Inpatient Quality Indicator #11 Fails to Provide Accurate Assessment of Mortality After Abdominal Aortic Aneurysm Repair SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Robinson, William P.; Schanzer, Andres; Messina, Louis] Univ Massachusetts, Sch Med, Div Vasc & Endovasc Surg, Worcester, MA USA. [Huang, Wei; Anderson, Frederick] Univ Massachusetts, Sch Med, Ctr Outcomes Res, Worcester, MA USA. [Fang, Hua] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Rosen, Amy] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 12S EP 12S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400023 ER PT J AU Sobel, JD Vartanian, SM Gasper, WJ Grenon, M Rapp, JH Hiramoto, JS Chuter, TA Reilly, LM AF Sobel, Julia D. Vartanian, Shant M. Gasper, Warren J. Grenon, Marlene Rapp, Joseph H. Hiramoto, Jade S. Chuter, Timothy A. Reilly, Linda M. TI Factors Associated With Spinal Cord Ischemia After Multibranched Endovascular Thoracoabdominal Aneurysm Repair SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Sobel, Julia D.; Vartanian, Shant M.; Gasper, Warren J.; Hiramoto, Jade S.; Chuter, Timothy A.; Reilly, Linda M.] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA. [Grenon, Marlene; Rapp, Joseph H.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 22S EP 23S PG 2 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400046 ER PT J AU Durham, CA Wang, L Ergul, EA Aranson, NJ Patel, VI Cambria, R Conrad, MF AF Durham, Christopher A. Wang, Linda Ergul, Emel A. Aranson, Nathan J. Patel, Virendra I. Cambria, Richard Conrad, Mark F. TI Natural History of Medically-Managed Acute Type B Aortic Dissections SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Durham, Christopher A.; Wang, Linda; Ergul, Emel A.; Aranson, Nathan J.; Patel, Virendra I.; Cambria, Richard; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 24S EP 24S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400049 ER PT J AU Ozaki, CK Hamdan, AD Barshes, NR Wyers, MC Hevelone, ND Belkin, M Nguyen, LL AF Ozaki, C. K. Hamdan, Allen D. Barshes, Neal R. Wyers, Mark C. Hevelone, Nathanael D. Belkin, Michael Nguyen, Louis L. TI Prospective, Randomized, Multi-Institutional Clinical Trial of a Silver Alginate Dressing to Reduce Lower Extremity Vascular Surgery Wound Complications SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Ozaki, C. K.; Hevelone, Nathanael D.; Belkin, Michael; Nguyen, Louis L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Hamdan, Allen D.; Wyers, Mark C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Medidcal Sch, Boston, MA 02215 USA. [Barshes, Neal R.] Baylor Coll Med, Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 31S EP 31S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400063 ER PT J AU Azarbal, AF Harris, S Mitchell, E Liem, TK Landry, GJ Edwards, J McLafferty, R Moneta, GL AF Azarbal, Amir F. Harris, Sheena Mitchell, Erica Liem, Timothy K. Landry, Gregory J. Edwards, James McLafferty, Robert Moneta, Gregory L. TI Nasal Methacillin-Resistant Staphylococcus aureus Colonization Is Associated With a Higher Postoperative Infection Rate After Major Lower Extremity Amputation SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Azarbal, Amir F.; Edwards, James; McLafferty, Robert] Portland VA Med Ctr, Portland, OR USA. [Harris, Sheena; Mitchell, Erica; Liem, Timothy K.; Landry, Gregory J.; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 72S EP 72S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400150 ER PT J AU Saraidaridis, J Patel, VI Lancaster, RT Mukhopadhyay, S Cambria, R Conrad, MF AF Saraidaridis, Julia Patel, Virendra I. Lancaster, Robert T. Mukhopadhyay, Shankha Cambria, Richard Conrad, Mark F. TI Applicability of the Society for Vascular Surgery's Objective Performance Goals for Critical Limb Ischemia to Current Practice of Lower Extremity Bypass SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Saraidaridis, Julia; Patel, Virendra I.; Lancaster, Robert T.; Mukhopadhyay, Shankha; Cambria, Richard; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 72S EP 72S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400151 ER PT J AU Fallon, JM Goodney, PP Stone, DH Patel, VI Nolan, BW Kalish, JA Zhao, YY Hamdan, AD AF Fallon, John M. Goodney, Philip P. Stone, David H. Patel, Virendra I. Nolan, Brian W. Kalish, Jeffrey A. Zhao, Yuanyuan Hamdan, Allen D. TI Dissecting the Results of Lower Extremity Revascularization in Dialysis-Dependent Patients SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Fallon, John M.; Goodney, Philip P.; Stone, David H.; Nolan, Brian W.; Zhao, Yuanyuan] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Patel, Virendra I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kalish, Jeffrey A.] Boston Med Ctr, Boston, MA USA. [Hamdan, Allen D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 74S EP 74S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400013 ER PT J AU Kwolek, CJ Moore, R AF Kwolek, Christopher J. Moore, Randy CA Terumo Anaconda Investigators TI One-Year Results of the Terumo Anaconda One-Lok Trial for Endovascular Aneurysm Repair SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Kwolek, Christopher J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Moore, Randy] Peter Lougheed Ctr, Calgary, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 98S EP 98S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400205 ER PT J AU Landry, GJ Yarmosh, A Shukla, B Azarbal, AF Liem, TK Mitchell, E McLafferty, R Moneta, GL AF Landry, Gregory J. Yarmosh, Alla Shukla, Bhavesh Azarbal, Amir F. Liem, Timothy K. Mitchell, Erica McLafferty, Robert Moneta, Gregory L. TI Current Status of Symptomatic Nonatherosclerotic Mesenteric Vascular Disease SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 05-07, 2014 CL Boston, MA SP Soc Vasc Surg C1 [Landry, Gregory J.; Yarmosh, Alla; Shukla, Bhavesh; Liem, Timothy K.; Mitchell, Erica; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Azarbal, Amir F.; McLafferty, Robert] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2014 VL 59 IS 6 SU S BP 105S EP 105S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA AI9ND UT WOS:000337258400219 ER PT J AU Kaatz, A Carnes, M AF Kaatz, Anna Carnes, Molly TI Stuck in the Out-Group: Jennifer Can't Grow Up, Jane's Invisible, and Janet's Over the Hill SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID WOMEN; STEREOTYPES; SPECIALTY; MEDICINE; CULTURE; FEMALE; SCHOOL; SEX AB Fifty years after Title IX, women remain sparsely represented in high ranks and leadership in academic medicine. Although men and women enter the career pipeline at similar rates, academic medicine does not equivalently advance them. Currently, women account for 32% of associate professors, 20% of full professors, 14% of department chairs, and 11% of deans at U. S. medical schools-far from the near sex parity seen in medical students since the 1990s. Over 30 years of research confirms that gender stereotypes can operate to disadvantage women in review processes and consequently bar their advancement in domains like science and medicine. The authors present three vignettes to illustrate how gender stereotypes can also operate to disadvantage women in social interactions by positioning them in the "out-group" for many career-advancing opportunities. The authors argue that policies alone will not achieve gender equity in the academic medicine workforce. Addressing stereotype-based gender bias is critical for the future of academic medicine. Interventions that treat gender bias as a remediable habit show promise in promoting gender equity and transforming institutional culture to achieve the full participation of women at all career stages. A critical step is to recognize when gender stereotyped assumptions are influencing judgments and decision making in ourselves and others, challenge them as unjust, and deliberately practice replacing them with accurate and objective data. C1 [Kaatz, Anna; Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Med, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53715 USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM mlcarnes@wisc.edu FU NIGMS NIH HHS [R25 GM083252, R01 GM111002] NR 27 TC 11 Z9 11 U1 3 U2 15 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JUN PY 2014 VL 23 IS 6 BP 481 EP 484 DI 10.1089/jwh.2014.4766 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AI9BT UT WOS:000337222700001 PM 24844292 ER PT J AU Vogt, D AF Vogt, Dawne TI Research on Gender Differences in Deployment Stress and Postdeployment Mental Health: Addressing Conceptual and Methodological Challenges and Expanding Our Research Agenda SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID COMBAT C1 [Vogt, Dawne] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA. [Vogt, Dawne] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Vogt, D (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B3, Womens Hlth Sci Div, 150 South Huntington Ave, Boston, MA 02130 USA. EM Dawne.Vogt@va.gov NR 6 TC 1 Z9 1 U1 2 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JUN PY 2014 VL 23 IS 6 BP 485 EP 487 DI 10.1089/jwh.2014.4880 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AI9BT UT WOS:000337222700002 PM 24905670 ER PT J AU Clark, CR Soukup, J Riden, H Tovar, D Orton, P Burdick, E Capistran, ME Morisset, J Browne, EE Fitzmaurice, G Johnson, PA AF Clark, Cheryl R. Soukup, Jane Riden, Heather Tovar, Dora Orton, Piper Burdick, Elisabeth Capistran, Mary Ellen Morisset, Jennifer Browne, Elizabeth E. Fitzmaurice, Garrett Johnson, Paula A. TI Preventive Care for Low-Income Women in Massachusetts Post-Health Reform SO JOURNAL OF WOMENS HEALTH LA English DT Article ID MAMMOGRAPHY; INSURANCE; SERVICES AB Background: Before enacting health insurance reform in 2006, Massachusetts provided free breast, cervical cancer, and cardiovascular risk screening for low-income uninsured women through a federally subsidized program called the Women's Health Network (WHN). This article examines whether, as women transitioned to insurance to pay for screening tests after health reform legislation was passed, cancer and cardiovascular disease screening changed among WHN participants between 2004 and 2010. Methods: We examined claims data from the Massachusetts health insurance exchange and chart review data to measure utilization of mammography, Pap smear, and blood pressure screening among WHN participants in five community health centers in greater Boston. We conducted a longitudinal analysis, by insurance type, using generalized estimating equations to examine the likelihood of screening at recommended intervals in the postreform period compared to the prereform period. Results: Pre- and postreform, we found a high prevalence of recommended mammography (86% vs. 88%), Pap smear (88% vs. 89%), and blood pressure screening (87% vs. 91%) that was similar or improved for most women postreform. Screening use differed by insurance type. Recommended mammography screening was statistically significantly increased among women with state-subsidized private insurance (odds ratio [OR] 1.58, p < 0.05). Women with unsubsidized private insurance or Medicare had decreased Pap smear use postreform. Although screening prevalence was high, 31% of women required state safety-net funds to pay for screening tests. Conclusion: Our results suggest a continued need for safety-net programs to support preventive screening among low-income women after implementation of healthcare reform. C1 [Clark, Cheryl R.; Soukup, Jane; Burdick, Elisabeth; Fitzmaurice, Garrett] Harvard Univ, Sch Med, Div Gen Med & Primary Care, Boston, MA USA. [Clark, Cheryl R.] Ctr Community Hlth & Hlth Equ, Boston, MA USA. [Clark, Cheryl R.] Brigham & Womens Faulkner Hospitalist Program, Boston, MA USA. [Clark, Cheryl R.; Riden, Heather; Tovar, Dora; Johnson, Paula A.] Brigham & Womens Hosp, Div Womens Hlth, Boston, MA 02120 USA. [Riden, Heather; Tovar, Dora; Orton, Piper; Johnson, Paula A.] Brigham & Womens Hosp, Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02120 USA. [Capistran, Mary Ellen] Massachusetts Gen Hosp, Chelsea HealthCare Ctr, Chelsea, MA USA. [Morisset, Jennifer] Mattapan Community Hlth Ctr, Boston, MA USA. [Browne, Elizabeth E.] Joseph M Smith Community Hlth Ctr, Allston, MA USA. RP Clark, CR (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St,OBC 2, Boston, MA 02120 USA. EM crclark@partners.org FU CDC [U58DP000821]; Advancing System Improvements to Support Targets for Healthy People (ASIST) grant from the Office on Women's Health in the US Department of Health and Human Services [ASTWH070011] FX This article was supported by CDC Cooperative Agreement Number U58DP000821. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. All authors' work related to this article was supported by Advancing System Improvements to Support Targets for Healthy People (ASIST) 2010 grant (No. ASTWH070011) from the Office on Women's Health in the US Department of Health and Human Services. We acknowledge the ongoing assistance from the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital for making this work possible. NR 16 TC 6 Z9 6 U1 1 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JUN PY 2014 VL 23 IS 6 BP 493 EP 498 DI 10.1089/jwh.2013.4612 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AI9BT UT WOS:000337222700004 PM 24798240 ER PT J AU Greenberg, SM Salman, RAS Biessels, GJ van Buchem, M Cordonnier, C Lee, JM Montaner, J Schneider, JA Smith, EE Vernooij, M Werring, DJ AF Greenberg, Steven M. Salman, Rustam Al-Shahi Biessels, Geert Jan van Buchem, Mark Cordonnier, Charlotte Lee, Jin-Moo Montaner, Joan Schneider, Julie A. Smith, Eric E. Vernooij, Meike Werring, David J. TI Developing biomarkers for cerebral amyloid angiopathy trials: do potential disease phenotypes hold promise? Reply SO LANCET NEUROLOGY LA English DT Letter ID CLINICAL SPECTRUM C1 [Greenberg, Steven M.] Massachusetts Gen Hosp, MGH Stroke Res Ctr, Boston, MA 02114 USA. [Salman, Rustam Al-Shahi] Univ Edinburgh, Ctr Clin Brain Sci, Div Clin Neurosci, Edinburgh, Midlothian, Scotland. [Biessels, Geert Jan] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands. [van Buchem, Mark] Leiden Univ, Dept Radiol, Med Ctr, Leiden, Netherlands. [Cordonnier, Charlotte] Univ Lille Nord France, Lille Univ Hosp, Dept Neurol, Lille, France. [Lee, Jin-Moo] Washington Univ, Sch Med, Dept Neurol, Dept Radiol, St Louis, MO 63110 USA. [Lee, Jin-Moo] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO USA. [Montaner, Joan] Vail dHebron Univ Hosp & Res Inst, Dept Neurol, Barcelona, Spain. [Montaner, Joan] Autonomous Univ Barcelona, Res Inst, Barcelona, Spain. [Schneider, Julie A.] Rush Univ, Dept Pathol, Med Ctr, Chicago, IL 60612 USA. [Schneider, Julie A.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. [Vernooij, Meike] Erasmus Univ, Dept Radiol & Epidemiol, Med Ctr, Rotterdam, Netherlands. [Werring, David J.] UCL Inst Neurol, London, England. RP Greenberg, SM (reprint author), Massachusetts Gen Hosp, MGH Stroke Res Ctr, Boston, MA 02114 USA. EM sgreenberg@mgh.harvard.edu RI Smith, Eric/C-5443-2012; Montaner, Joan/D-3063-2015; IBIS, NEUROVASCULAR/O-1855-2015 OI Smith, Eric/0000-0003-3956-1668; FU Medical Research Council [G1002605] NR 6 TC 0 Z9 0 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD JUN PY 2014 VL 13 IS 6 BP 540 EP 540 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AI8YK UT WOS:000337212700013 PM 24849857 ER PT J AU Whitman, SP Kohlschmidt, J Maharry, K Volinia, S Mrozek, K Nicolet, D Schwind, S Becker, H Metzeler, KH Mendler, JH Eisfeld, AK Carroll, AJ Powell, BL Carter, TH Baer, MR Kolitz, JE Park, IK Stone, RM Caligiuri, MA Marcucci, G Bloomfield, CD AF Whitman, S. P. Kohlschmidt, J. Maharry, K. Volinia, S. Mrozek, K. Nicolet, D. Schwind, S. Becker, H. Metzeler, K. H. Mendler, J. H. Eisfeld, A-K Carroll, A. J. Powell, B. L. Carter, T. H. Baer, M. R. Kolitz, J. E. Park, I-K Stone, R. M. Caligiuri, M. A. Marcucci, G. Bloomfield, C. D. TI GAS6 expression identifies high-risk adult AML patients: potential implications for therapy SO LEUKEMIA LA English DT Article DE GAS6; acute myeloid leukemia; prognosis ID ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATIONS; RECEPTOR TYROSINE KINASES; AGE 60 YEARS; GROUP-B; OLDER PATIENTS; GROWTH ARREST; DISTINCT GENE; PROGNOSTIC-SIGNIFICANCE; PREDICTS ADVERSE AB Emerging data demonstrate important roles for the TYRO3/AXL/MERTK receptor tyrosine kinase (TAM RTK) family in diverse cancers. We investigated the prognostic relevance of GAS6 expression, encoding the common TAM RTK ligand, in 270 adults (n=71 aged <60 years; n=199 aged >= 60 years) with de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients expressing GAS6 (GAS6+), especially those aged >= 60 years, more often failed to achieve a complete remission (CR). In all patients, GAS6+ patients had shorter disease-free (DFS) and overall (OS) survival than patients without GAS6 expression (GAS6-). After adjusting for other prognostic markers, GAS6+ predicted CR failure (P=0.02), shorter DFS (P=0.004) and OS (P=0.04). To gain further biological insights, we derived a GAS6-associated gene-expression signature (P<0.001) that in GAS6+ patients included overexpressed BAALC and MN1, known to confer adverse prognosis in CN-AML, and overexpressed CXCL12, encoding stromal cell-derived factor, and its receptor genes, chemokine (C-X-C motif) receptor 4 (CXCR4) and CXCR7. This study reports for the first time that GAS6 expression is an adverse prognostic marker in CN-AML. Although GAS6 decoy receptors are not yet available in the clinic for GAS6+ CN-AML therapy, potential alternative therapies targeting GAS6+-associated pathways, for example, CXCR4 antagonists, may be considered for GAS6+ patients to sensitize them to chemotherapy. C1 [Whitman, S. P.; Kohlschmidt, J.; Maharry, K.; Mrozek, K.; Nicolet, D.; Schwind, S.; Becker, H.; Metzeler, K. H.; Mendler, J. H.; Eisfeld, A-K; Park, I-K; Caligiuri, M. A.; Marcucci, G.; Bloomfield, C. D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Kohlschmidt, J.; Maharry, K.; Nicolet, D.] Mayo Clin, Alliance Clin Trials Oncol Stat, Rochester, MN USA. [Kohlschmidt, J.; Maharry, K.; Nicolet, D.] Mayo Clin, Ctr Data, Rochester, MN USA. [Volinia, S.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. [Carroll, A. J.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA. [Powell, B. L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Carter, T. H.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. [Baer, M. R.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Kolitz, J. E.] N Shore Univ Hosp, Manhasset, NY USA. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Caligiuri, MA (reprint author), Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Suite 519,300W,10th Ave, Columbus, OH 43210 USA. EM michael.caligiuri@osumc.edu; guido.marcucci@osumc.edu; clara.bloomfield@osumc.edu RI Mrozek, Krzysztof/A-3142-2008; Metzeler, Klaus/C-2118-2009; OI Metzeler, Klaus/0000-0003-3920-7490; Carter, Thomas/0000-0001-7796-2986; Mendler, Jason/0000-0001-5605-5324; Volinia, Stefano/0000-0003-0910-3893 FU National Cancer Institute [CA101140, CA114725, CA140158, CA31946, CA33601, CA16058, CA77658, CA129657]; Coleman Leukemia Research Foundation; Deutsche Krebshilfe-Dr Mildred Scheel Cancer Foundation; Pelotonia Fellowship Program; Conquer Cancer Foundation FX We thank Donna Bucci and the Alliance Leukemia Tissue Bank for sample processing and storage services, Lisa J Sterling and Christine Finks for data management and the OSU NCI-designated Comprehensive Cancer Center Microarray and Nucleic Acid shared resources for sample analyses. We also thank Dan Sargent for critical review of the manuscript. We also thank the physicians, nurses, clinical support staff and, most of all, patients for their invaluable contributions to these studies. This work was supported in part by the National Cancer Institute (Grants CA101140, CA114725, CA140158, CA31946, CA33601, CA16058, CA77658 and CA129657), the Coleman Leukemia Research Foundation, the Deutsche Krebshilfe-Dr Mildred Scheel Cancer Foundation (to HB), the Pelotonia Fellowship Program (to A-KE), and the Conquer Cancer Foundation (to JHM). NR 62 TC 17 Z9 17 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD JUN PY 2014 VL 28 IS 6 BP 1252 EP 1258 DI 10.1038/leu.2013.371 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA AI9DV UT WOS:000337230300009 PM 24326683 ER PT J AU Maroz, A Stachorski, L Emmrich, S Reinhardt, K Xu, J Shao, Z Kabler, S Dertmann, T Hitzler, J Roberts, I Vyas, P Juban, G Hennig, C Hansen, G Li, Z Orkin, S Reinhardt, D Klusmann, JH AF Maroz, A. Stachorski, L. Emmrich, S. Reinhardt, K. Xu, J. Shao, Z. Kaebler, S. Dertmann, T. Hitzler, J. Roberts, I. Vyas, P. Juban, G. Hennig, C. Hansen, G. Li, Z. Orkin, S. Reinhardt, D. Klusmann, J-H TI GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia SO LEUKEMIA LA English DT Article DE Down syndrome; eosinophilia; GATA1s; MYC; E2F ID ACUTE MEGAKARYOBLASTIC LEUKEMIA; CELL-CYCLE PROGRESSION; IN-VIVO BIOTINYLATION; EMBRYONIC STEM-CELLS; MAJOR BASIC-PROTEIN; MYELOID-LEUKEMIA; TRANSCRIPTION FACTORS; CHROMATIN OCCUPANCY; BLAST CELLS; MAST-CELLS AB Transient leukemia (TL) is evident in 5-10% of all neonates with Down syndrome (DS) and associated with N-terminal truncating GATA1 mutations (GATA1s). Here we report that TL-cell clones generate abundant eosinophils in a substantial fraction of patients. Sorted eosinophils from patients with TL and eosinophilia carried the same GATA1s mutations as sorted TL blasts, consistent with their clonal origin. TL blasts exhibited a genetic program characteristic of eosinophils and differentiated along the eosinophil lineage in vitro. Similarly, ectopic expression of Gata1s, but not Gata1, in wild-type CD34(+)-hematopoietic stem and progenitor cells induced hyperproliferation of eosinophil promyelocytes in vitro. Although GATA1s retained the function of GATA1 to induce eosinophil genes by occupying their promoter regions, GATA1s was impaired in its ability to repress oncogenic MYC and the pro-proliferative E2F transcription network. Chromatin Immunoprecipitation Sequencing (ChIP-seq) indicated reduced GATA1s occupancy at the MYC promoter. Knockdown of MYC, or the obligate E2F-cooperation partner DP1, rescued the GATA1s-induced hyperproliferative phenotype. In agreement, terminal eosinophil maturation was blocked in Gata1(Delta e2) knockin mice, exclusively expressing Gata1s, leading to accumulation of eosinophil precursors in blood and bone marrow. These data suggest a direct relationship between the N-terminal truncating mutations of GATA1 and clonal eosinophilia in DS patients. C1 [Maroz, A.; Stachorski, L.; Emmrich, S.; Reinhardt, K.; Kaebler, S.; Dertmann, T.; Reinhardt, D.; Klusmann, J-H] Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany. [Xu, J.; Shao, Z.; Orkin, S.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Xu, J.; Shao, Z.; Orkin, S.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. [Xu, J.; Shao, Z.; Orkin, S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Hitzler, J.] Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada. [Roberts, I.] Univ Oxford, Dept Paediat, Childrens Hosp, Oxford, England. [Roberts, I.] John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Haematol Unit, Oxford, England. [Vyas, P.; Juban, G.] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England. [Vyas, P.; Juban, G.] NHS Trust, Oxford Univ Hosp, Dept Haematol, Oxford, England. [Hennig, C.; Hansen, G.] Hannover Med Sch, Dept Pediat Pneumol, Hannover, Germany. [Li, Z.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA. RP Klusmann, JH (reprint author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany. EM Klusmann.jan-henning@mh-hannover.de RI Klusmann, Jan-Henning/M-9655-2015; OI Klusmann, Jan-Henning/0000-0002-1070-0727; Vyas, Paresh/0000-0003-3931-0914 FU Hannover Biomedical Research School; German Research Foundation [KL-2374/2-1, KL-2374/1-1] FX The authors thank J Strouboulis and E Karkoulia for providing BioGata1/Gata1s ESCs. J Schoening for general lab support; Drs K Weber and B Fehse for providing plasmids; Dr A Mirenska for chip cytometry data analysis; Dr R Geffers for microarray analysis. AM, LS, SE and TD were supported by the Hannover Biomedical Research School. JHK is a fellow of the Emmy Noether-Programme from the German Research Foundation (KL-2374/2-1). This work was supported by a grant to JHK from the German Research Foundation (KL-2374/1-1). NR 58 TC 6 Z9 6 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD JUN PY 2014 VL 28 IS 6 BP 1259 EP 1270 DI 10.1038/leu.2013.373 PG 12 WC Oncology; Hematology SC Oncology; Hematology GA AI9DV UT WOS:000337230300010 PM 24336126 ER PT J AU Guo, FJ Moellering, DR Garvey, WT AF Guo, Fangjian Moellering, Douglas R. Garvey, W. Timothy TI Use of HbA1c for Diagnoses of Diabetes and Prediabetes: Comparison with Diagnoses Based on Fasting and 2-Hr Glucose Values and Effects of Gender, Race, and Age SO METABOLIC SYNDROME AND RELATED DISORDERS LA English DT Article ID LIFE-STYLE; PREVENTION PROGRAM; HEMOGLOBIN A(1C); TOLERANCE; ADULTS; A1C; PREVALENCE; TRIAL; CLASSIFICATION; MANAGEMENT AB Background: Glycated hemoglobin (HbA1c) has been advocated for the diagnosis of diabetes and prediabetes. Its performance has been commonly assessed in corroboration with elevated fasting plasma glucose (FPG), but not the combination of FPG and 2-hr glucose values. This study assesses receiver operating characteristics (ROC) curves of HbA1c pertaining to the diagnoses of prediabetes and diabetes by FPG and/or 2-hr glucose, and the effects of age, gender, and race. Methods: We assessed the utility of HbA1c for diagnosing diabetes and prediabetes among 5395 adults without known diabetes from the National Health and Nutrition Examination Survey (NHANES) 2005-2010. Results: Current cutoffs of HbA1c for diabetes (6.5%) or prediabetes (5.7%) exhibited low sensitivity (0.249 and 0.354, respectively) and high specificity in identifying patients diagnosed using both FPG and 2-hr glucose, resulting in large false-negative rates (75.1% and 64.9%). Misdiagnosis rates increased with age and in non-Hispanic whites and Mexican Americans. When HbA1c was combined with FPG for diagnoses, the false-negative rate remained high for diabetes (45.7%), but was reduced for prediabetes (9.2%). Conclusions: When assessed against diagnoses using both FPG and 2-hr glucose, HbA1c had low sensitivity and high specificity for identifying diabetes and prediabetes, which varied as a function of age and race. Regarding recently released American Diabetes Association (ADA) and joint European guidelines, it is important to consider that HbA1c values below 6.5% and 5.7% do not reliably exclude the presence of diabetes and prediabetes, respectively. Overall, the data argue for greater use of oral glucose tolerance tests (OGTTs) and both FPG and 2-hr glucose values for diagnosis of diabetes and prediabetes. C1 [Guo, Fangjian; Moellering, Douglas R.; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35233 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Guo, FJ (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 241,1675 Univ Blvd, Birmingham, AL 35233 USA. EM ilovedd@uab.edu; garveyt@uab.edu RI Guo, Fangjian/B-7705-2015 OI Guo, Fangjian/0000-0003-3729-2724 FU Merit Review program of the Department of Veterans Affairs, National Institutes of Health [DK-038765, DK-083562]; UAB Diabetes Research Center [P30-DK079626] FX We gratefully acknowledge our funding resources, including the Merit Review program of the Department of Veterans Affairs, National Institutes of Health (DK-038765 and DK-083562), and the UAB Diabetes Research Center (P30-DK079626). All data used in this study were collected by the National Center for Health Statistics Centers for Disease Control and Prevention. NR 35 TC 16 Z9 18 U1 4 U2 18 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-4196 EI 1557-8518 J9 METAB SYNDR RELAT D JI Metab. Syndr. Relat. Disord. PD JUN PY 2014 VL 12 IS 5 BP 258 EP 268 DI 10.1089/met.2013.0128 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AI9JV UT WOS:000337249800003 PM 24512556 ER PT J AU Tsai, SQ Wyvekens, N Khayter, C Foden, JA Thapar, V Reyon, D Goodwin, MJ Aryee, MJ Joung, JK AF Tsai, Shengdar Q. Wyvekens, Nicolas Khayter, Cyd Foden, Jennifer A. Thapar, Vishal Reyon, Deepak Goodwin, Mathew J. Aryee, Martin J. Joung, J. Keith TI Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing SO NATURE BIOTECHNOLOGY LA English DT Article ID ZINC-FINGER NUCLEASES; TARGET DNA; CAS9; ENDONUCLEASE; ACTIVATION; NICKASES; TALENS; SYSTEM; GENES AB Monomeric CRISPR-Cas9 nucleases are widely used for targeted genome editing but can induce unwanted off-target mutations with high frequencies. Here we describe dimeric RNA-guided FokI nucleases (RFNs) that can recognize extended sequences and edit endogenous genes with high efficiencies in human cells. RFN cleavage activity depends strictly on the binding of two guide RNAs (gRNAs) to DNA with a defined spacing and orientation substantially reducing the likelihood that a suitable target site will occur more than once in the genome and therefore improving specificities relative to wild-type Cas9 monomers. RFNs guided by a single gRNA generally induce lower levels of unwanted mutations than matched monomeric Cas9 nickases. In addition, we describe a simple method for expressing multiple gRNAs bearing any 5' end nucleotide, which gives dimeric RFNs a broad targeting range. RFNs combine the ease of RNA-based targeting with the specificity enhancement inherent to dimerization and are likely to be useful in applications that require highly precise genome editing. C1 [Tsai, Shengdar Q.; Wyvekens, Nicolas; Khayter, Cyd; Foden, Jennifer A.; Thapar, Vishal; Reyon, Deepak; Goodwin, Mathew J.; Aryee, Martin J.; Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. [Tsai, Shengdar Q.; Wyvekens, Nicolas; Khayter, Cyd; Foden, Jennifer A.; Thapar, Vishal; Reyon, Deepak; Goodwin, Mathew J.; Aryee, Martin J.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA. [Tsai, Shengdar Q.; Wyvekens, Nicolas; Khayter, Cyd; Foden, Jennifer A.; Reyon, Deepak; Goodwin, Mathew J.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA USA. [Tsai, Shengdar Q.; Reyon, Deepak; Aryee, Martin J.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Joung, JK (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. EM jjoung@mgh.harvard.edu FU National Institutes of Health (NIH) Director's Pioneer Award [DP1 GM105378, NIH R01 GM088040, NIH P50 HG005550, NIH R01 AR063070]; Jim and Ann Orr Massachusetts General Hospital (MGH) Research Scholar Award; NIH [F32 GM105189]; US Army Research Laboratory and the US Army Research Office [W911NF-11-2-0056] FX We thank Y. Fu and M. Maeder for helpful discussions and Y. Fu, J. Angstman and B. Kleinstiver for comments on the manuscript. This work was funded by a National Institutes of Health (NIH) Director's Pioneer Award (DP1 GM105378), NIH R01 GM088040, NIH P50 HG005550, NIH R01 AR063070, and the Jim and Ann Orr Massachusetts General Hospital (MGH) Research Scholar Award. S.Q.T. was supported by NIH F32 GM105189. This material is based upon work supported by, or in part by, the US Army Research Laboratory and the US Army Research Office under grant number W911NF-11-2-0056. Plasmids described in this work will be deposited with and made available through the nonprofit plasmid distribution service Addgene (http://www. addgene. org/crispr-cas). NR 31 TC 278 Z9 306 U1 22 U2 114 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 EI 1546-1696 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD JUN PY 2014 VL 32 IS 6 BP 569 EP + DI 10.1038/nbt.2908 PG 9 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA AI9EV UT WOS:000337233800020 PM 24770325 ER PT J AU Chen, JY Feeney, ER Chung, RT AF Chen, Jennifer Y. Feeney, Eoin R. Chung, Raymond T. TI HCV and HIV co-infection: mechanisms and management SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY LA English DT Review ID HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INTERFERON PLUS RIBAVIRIN; SUSTAINED VIROLOGICAL RESPONSE; ACTIVE ANTIRETROVIRAL THERAPY; LIVER-RELATED COMPLICATIONS; TO-CHILD TRANSMISSION; INJECTION-DRUG USERS; ALL-CAUSE MORTALITY; INFECTED PATIENTS AB HCV and HIV co-infection is associated with accelerated hepatic fibrosis progression and higher rates of liver decompensation and death compared to HCV monoinfection, and liver disease is a leading cause of non-AIDS-related mortality among HIV-infected patients. New insights have revealed multiple mechanisms by which HCV and HIV lead to accelerated disease progression, specifically that HIV infection increases HCV replication, augments HCV-induced hepatic inflammation, increases hepatocyte apoptosis, increases microbial translocation from the gut and leads to an impairment of HCV-specific immune responses. Treatment of HIV with antiretroviral therapy and treatment of HCV have independently been shown to delay the progression of fibrosis and reduce complications from end-stage liver disease among co-infected patients. However, rates of sustained virologic response with PEG-IFN and ribavirin have been significantly inferior among co-infected patients compared with HCV-monoinfected patients, and treatment uptake has remained low given the limited efficacy and tolerability of current HCV regimens. With multiple direct-acting antiviral agents in development to treat HCV, a unique opportunity exists to redefine the treatment paradigm for co-infected patients, which incorporates data on fibrosis stage as well as potential drug interactions with antiretroviral therapy. C1 [Chen, Jennifer Y.; Chung, Raymond T.] Massachusetts Gen Hosp, Ctr Liver, Boston, MA 02114 USA. [Chen, Jennifer Y.; Chung, Raymond T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Feeney, Eoin R.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Chung, RT (reprint author), Massachusetts Gen Hosp, Ctr Liver, 55 Fruit St, Boston, MA 02114 USA. EM rtchung@partners.org OI Feeney, Eoin/0000-0003-4118-4945 FU HHS/NIH [T32DK007191, DK098079, DA033541]; Harvard University Center for AIDS Research (HU CFAR NIH/NIAID fund) [5P30AI060354-09] FX The work of the authors is supported by HHS/NIH grants T32DK007191 (J.Y.C.), DK098079 and DA033541 (R.T.C.) and by the Harvard University Center for AIDS Research (HU CFAR NIH/NIAID fund 5P30AI060354-09 to E.R.F.). NR 133 TC 48 Z9 50 U1 2 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5045 EI 1759-5053 J9 NAT REV GASTRO HEPAT JI Nat. Rev. Gastroenterol. Hepatol. PD JUN PY 2014 VL 11 IS 6 DI 10.1038/nrgastro.2014.17 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AI9DX UT WOS:000337230500007 PM 24535328 ER PT J AU Genta, RM Sonnenberg, A AF Genta, Robert M. Sonnenberg, Amnon TI Big data in gastroenterology research SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; PEPTIC-ULCER DISEASE; HELICOBACTER-PYLORI; HOSPITAL ADMISSION; BARRETTS-ESOPHAGUS; SURVEILLANCE; RISK; PREVALENCE; ENDOSCOPY; MORTALITY AB In epidemiological research, large datasets are essential to reliably capture small variations among comparative groups or detect new unsuspected associations. Although large databases of web-search information, social media, airline traffic and telephone records are already widely used to capture social trends, large databases in medical research are just emerging. With the universal use of electronic medical records underway, vast amounts of health-related information will become available for biomedical research. Accepting such new research tools-based on the analysis of large pre-existing datasets rather than hypothesis-driven, in-depth prospective study-will require a new mindset in clinical research, as data might be `messy' and only associations, but not causality, can be detected. In spite of such limitations, the utilization of these new resources for medical research harbours great potential for advancing knowledge about digestive diseases. C1 [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Med Ctr, Dallas, TX 75390 USA. [Genta, Robert M.] Mirace Life Sci, Miraca Life Sci Res Inst, Irving, TX 75039 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. RP Genta, RM (reprint author), Univ Texas SW Med Ctr Dallas, Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM robert.genta@utsouthwestern.edu NR 39 TC 8 Z9 8 U1 1 U2 24 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5045 EI 1759-5053 J9 NAT REV GASTRO HEPAT JI Nat. Rev. Gastroenterol. Hepatol. PD JUN PY 2014 VL 11 IS 6 DI 10.1038/nrgastro.2014.18 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AI9DX UT WOS:000337230500009 PM 24594912 ER PT J AU Musolino, PL Lund, TC Pan, J Escolar, ML Paker, AM Duncan, CN Eichler, FS AF Musolino, Patricia L. Lund, Troy C. Pan, Jessica Escolar, Maria L. Paker, Asif M. Duncan, Christine N. Eichler, Florian S. TI Hematopoietic Stem Cell Transplantation in the Leukodystrophies: A Systematic Review of the Literature SO NEUROPEDIATRICS LA English DT Review DE leukodystrophy; bone marrow transplantation; white matter diseases ID X-LINKED ADRENOLEUKODYSTROPHY; UMBILICAL-CORD BLOOD; BONE-MARROW-TRANSPLANTATION; NEUROCOGNITIVE FUNCTION; PEDIATRIC-PATIENTS; KRABBE-DISEASE; OUTCOMES; PROGRESSION AB Objective The objective of this study is to systematically review the literature on worldwide numbers of leukodystrophy patients undergoing hematopoietic stem cell transplantation (HSCT) as well as the safety and efficacy of the procedure in this patient population. Materials and Methods A PubMed and EMBASE search up to June 2012 was conducted with a manual search of references from relevant articles. Selected studies were evaluated using internationally accepted criteria. The effect estimates of HSCT upon survival in early-stage disease versus late-stage disease were compared. Results One hundred and fifty-two studies qualified for inclusion and reported on a total of 689 patients. Study quality ranged from poor to good; no study was rated excellent. Small sample sizes limited most studies. Meta-analysis in a subset of larger studies indicates that transplantation in earlier stages of disease fairs better than in the late stages. Beyond survival, little longitudinal data on functional outcome is reported and neurological outcome is sparse. Conclusion Further studies are needed to determine the neurological outcome following HSCT in the leukodystrophies. HSCT in the early stages of cerebral disease is still recommended for select leukodystrophies. C1 [Musolino, Patricia L.; Pan, Jessica; Paker, Asif M.; Eichler, Florian S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Lund, Troy C.] Univ Minnesota, Div Pediat Blood & Marrow Transplantat, Minneapolis, MN USA. [Escolar, Maria L.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA. [Duncan, Christine N.] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA. RP Eichler, FS (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St,ACC 708, Boston, MA 02114 USA. EM feichler@partners.org RI Escolar, Maria/J-3721-2016 FU Bluebird Bio FX Florian Eichler and Asif Paker have served as consultants to Bluebird Bio (Cambridge, Massachusetts, United States). Florian Eichler and Christine Duncan are both coinvestigators of a clinical trial of gene therapy for X-linked ALD sponsored by Bluebird Bio. NR 16 TC 9 Z9 9 U1 0 U2 7 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0174-304X EI 1439-1899 J9 NEUROPEDIATRICS JI Neuropediatrics PD JUN PY 2014 VL 45 IS 3 BP 169 EP 174 DI 10.1055/s-0033-1364179 PG 6 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA AI8NG UT WOS:000337173900004 PM 24459069 ER PT J AU Connery, HS Albright, BB Rodolico, JM AF Connery, Hilary Smith Albright, Brittany B. Rodolico, John M. TI Adolescent Substance Use and Unplanned Pregnancy Strategies for Risk Reduction SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Adolescents; Substance use; Unintended pregnancy; Contraception; Motivational interviewing ID ACTING REVERSIBLE CONTRACEPTION; ALCOHOL-EXPOSED PREGNANCIES; UNINTENDED PREGNANCY; UNITED-STATES; MENTAL-HEALTH; MOTIVATIONAL INTERVENTION; SEXUAL RISK; YOUNG-WOMEN; DRUG-USE; ABUSE AB Substance use among adolescents increases the risk of unplanned pregnancies, which then increases the risk of fetal exposure to addictive, teratogenic substances. Specific interventions are necessary to target pregnancy planning and contraception among reproductive-age substance users. Screening for substance use using the CRAFFT is recommended in all health care settings treating adolescent patients. Screening for tobacco and nicotine use is also recommended along with the provision of smoking cessation interventions. Using motivational interviewing style and strategies is recommended to engage adolescents in discussions related to reducing substance use, risky sexual behavior, and probability of unplanned pregnancy or late-detection pregnancy. C1 [Connery, Hilary Smith] McLean Hosp, Div Alcohol & Drug Abuse, Belmont, MA 02478 USA. [Connery, Hilary Smith] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Albright, Brittany B.] Massachusetts Gen Hosp, McLean Hosp, Adult Psychiat Residency Program, Boston, MA 02114 USA. [Rodolico, John M.] McLean Hosp, Div Child & Adolescent Psychiat, Belmont, MA 02478 USA. [Rodolico, John M.] Harvard Univ, Sch Med, Boston, MA USA. RP Connery, HS (reprint author), McLean Hosp, Div Alcohol & Drug Abuse, 115 Mill St,Mailstop 222, Belmont, MA 02478 USA. EM hconnery@mclean.harvard.edu FU NIH [U10DA15831]; NIHMS [567747] FX Funding: NIH, U10DA15831; NIHMS-ID, 567747. NR 61 TC 4 Z9 4 U1 3 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8545 EI 1558-0474 J9 OBSTET GYN CLIN N AM JI Obstet. Gynecol. Clin. N. Am. PD JUN PY 2014 VL 41 IS 2 BP 191 EP + DI 10.1016/j.ogc.2014.02.011 PG 14 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AJ0HD UT WOS:000337330200004 PM 24845484 ER PT J AU Chang, G AF Chang, Grace TI Screening for Alcohol and Drug Use During Pregnancy SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Biomarkers; Questionnaires; Sensitivity; Specificity ID NEONATAL ABSTINENCE; UNITED-STATES; WOMEN; ABUSE AB The use of alcohol and other substances is not infrequent during pregnancy and may be associated with adverse effects on pregnancy outcome. Many pregnant women may continue these practices throughout pregnancy and even after delivery, unless they are recognized and assessed. Screening may be one way to achieve consistent and early identification. Prenatal health care providers may wish to screen all pregnant patients for their use of alcohol and other drugs using an approach that works best in their setting. A positive screen is an opportunity for the clinician and patient to discuss health practices and behaviors. C1 [Chang, Grace] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Chang, Grace] VA Boston Healthcare Syst, Dept Psychiat, Brockton, MA 02301 USA. RP Chang, G (reprint author), VA Boston Healthcare Syst, Dept Psychiat, 940 Belmont St, Brockton, MA 02301 USA. EM Grace.Chang2@va.gov NR 23 TC 2 Z9 2 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8545 EI 1558-0474 J9 OBSTET GYN CLIN N AM JI Obstet. Gynecol. Clin. N. Am. PD JUN PY 2014 VL 41 IS 2 BP 205 EP + DI 10.1016/j.ogc.2014.02.002 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AJ0HD UT WOS:000337330200005 PM 24845485 ER PT J AU Neophytou, AM Picciotto, S Hart, JE Garshick, E Eisen, EA Laden, F AF Neophytou, Andreas M. Picciotto, Sally Hart, Jaime E. Garshick, Eric Eisen, Ellen A. Laden, Francine TI A structural approach to address the healthy-worker survivor effect in occupational cohorts: an application in the trucking industry cohort SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID FAILURE-TIME MODELS; ARSENIC EXPOSURE; AIR-POLLUTION; HEART-DISEASE; LUNG-CANCER; US CITIES; MALE BUS; MORTALITY; DRIVERS; RISK AB Background Occupational cohort studies are often challenged by the Healthy Worker Survivor Effect, which may bias standard methods of analysis. G-estimation of structural failure time models is an approach for reducing this type of bias. Accelerated failure time models have recently been applied in an occupational cohort but cumulative failure time models have not. Methods We used g-estimation of a cumulative failure time model to assess the effect of working as a long-haul driver on ischaemic heart disease mortality in a cohort of 30 448 men employed in the unionised US trucking industry in 1985. Exposure was defined by job title and based on work records. We also applied g-estimation of an accelerated failure time model as a sensitivity analysis and approximated HRs from both models to compare them. Results The risk ratio (RR) obtained from the cumulative failure time model, comparing the observed risk under no intervention to the risk had nobody ever been exposed as a long-haul driver, was 1.09 (95% CI 1.02 to 1.16). The RR comparing the risk had everyone been exposed as long-haul driver for 8 years to the risk had nobody ever been exposed was 1.20 (95% CI 1.04 to 1.46). After HR approximations, accelerated failure time model results were similar. Conclusions The cumulative failure time model can effectively control time-varying confounding by Healthy Worker Survivor Effect, and provides an easily interpretable effect estimate. RRs estimated from the cumulative failure time model indicate an elevated ischaemic heart disease mortality risk for long-haul drivers in the US trucking industry. C1 [Neophytou, Andreas M.; Hart, Jaime E.; Garshick, Eric; Laden, Francine] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Neophytou, Andreas M.; Picciotto, Sally; Eisen, Ellen A.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. [Hart, Jaime E.; Laden, Francine] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [Hart, Jaime E.; Laden, Francine] Harvard Univ, Sch Med, Boston, MA USA. [Garshick, Eric] VA Boston Healthcare Syst, Primary & Crit Care Med Sect, Boston, MA USA. RP Neophytou, AM (reprint author), UC Berkeley Sch Publ Hlth, Div Environm Hlth Sci, 772 Univ Hall, Berkeley, CA 94720 USA. EM aneophytou@berkeley.edu FU National Institute of Health, National Cancer Institute [R01 CA90792]; National Institute of Environmental Health Sciences [R01 ES016284]; AG Leventis foundation FX The study was supported by grants from the National Institute of Health, National Cancer Institute (R01 CA90792), National Institute of Environmental Health Sciences (R01 ES016284) and the AG Leventis foundation. NR 40 TC 7 Z9 8 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD JUN PY 2014 VL 71 IS 6 BP 442 EP 447 DI 10.1136/oemed-2013-102017 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AI9MV UT WOS:000337257600010 PM 24727736 ER PT J AU Mays, D Gilman, SE Rende, R Luta, G Tercyak, KP Niaura, RS AF Mays, Darren Gilman, Stephen E. Rende, Richard Luta, George Tercyak, Kenneth P. Niaura, Raymond S. TI Parental Smoking Exposure and Adolescent Smoking Trajectories SO PEDIATRICS LA English DT Article DE cigarette smoking; nicotine dependence; parental smoking; intergenerational smoking ID MIDWESTERN COMMUNITY SAMPLE; NICOTINE DEPENDENCE; CIGARETTE-SMOKING; INTERGENERATIONAL TRANSMISSION; DEVELOPMENTAL TRAJECTORIES; MULTIPLE TRAJECTORIES; TOBACCO CONTROL; EARLY ADULTHOOD; RISK-FACTORS; CESSATION AB OBJECTIVE: In a multigenerational study of smoking risk, the objective was to investigate the intergenerational transmission of smoking by examining if exposure to parental smoking and nicotine dependence predicts prospective smoking trajectories among adolescent offspring. METHODS: Adolescents (n = 406) ages 12 to 17 and a parent completed baseline interviews (2001-2004), and adolescents completed up to 2 follow-up interviews 1 and 5 years later. Baseline interviews gathered detailed information on parental smoking history, including timing and duration, current smoking, and nicotine dependence. Adolescent smoking and nicotine dependence were assessed at each time point. Latent Class Growth Analysis identified prospective smoking trajectory classes from adolescence into young adulthood. Logistic regression was used to examine relationships between parental smoking and adolescent smoking trajectories. RESULTS: Four adolescent smoking trajectory classes were identified: early regular smokers (6%), early experimenters (23%), late experimenters (41%), and nonsmokers (30%). Adolescents with parents who were nicotine-dependent smokers at baseline were more likely to be early regular smokers (odds ratio 1.18, 95% confidence interval 1.05-1.33) and early experimenters (odds ratio 1.04, 95% confidence interval 1.04-1.25) with each additional year of previous exposure to parental smoking. Parents' current non-nicotine-dependent and former smoking were not associated with adolescent smoking trajectories. CONCLUSIONS: Exposure to parental nicotine dependence is a critical factor influencing intergenerational transmission of smoking. Adolescents with nicotine-dependent parents are susceptible to more intense smoking patterns and this risk increases with longer duration of exposure. Research is needed to optimize interventions to help nicotine-dependent parents quit smoking early in their children's lifetime to reduce these risks. C1 [Mays, Darren; Luta, George; Tercyak, Kenneth P.; Niaura, Raymond S.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Gilman, Stephen E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rende, Richard] Brown Univ, Sch Med, Providence, RI 02912 USA. [Niaura, Raymond S.] Amer Legacy Fdn, Schroeder Inst Tobacco Res & Policy Studies, Washington, DC USA. [Niaura, Raymond S.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Mays, D (reprint author), Georgetown Univ, Med Ctr, Canc Prevent & Control Program, Lombardi Comprehens Canc Ctr, 3300 Whitehaven St NW,Suite 4100, Washington, DC 20007 USA. EM dmm239@georgetown.edu RI Gilman, Stephen/E-7632-2010; OI Gilman, Stephen/0000-0002-8331-6419; Luta, George/0000-0001-9013-2207; Luta, George/0000-0002-4035-7632 FU National Institutes of Health Transdisciplinary Tobacco Research Center award [CA084719]; Biostatistics and Bioinformatics Shared Resource of Georgetown Lombardi Comprehensive Cancer Center through Comprehensive Cancer Center support grant [P30CA051008]; National Institutes of Health (NIH) FX Supported by National Institutes of Health Transdisciplinary Tobacco Research Center award CA084719 and by the Biostatistics and Bioinformatics Shared Resource of Georgetown Lombardi Comprehensive Cancer Center through Comprehensive Cancer Center support grant P30CA051008. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Funded by the National Institutes of Health (NIH). NR 49 TC 18 Z9 18 U1 4 U2 22 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2014 VL 133 IS 6 BP 983 EP 991 DI 10.1542/peds.2013-3003 PG 9 WC Pediatrics SC Pediatrics GA AI8MY UT WOS:000337172600047 PM 24819567 ER PT J AU Taveras, EM Gillman, MW Pena, MM Redline, S Rifas-Shiman, SL AF Taveras, Elsie M. Gillman, Matthew W. Pena, Michelle-Marie Redline, Susan Rifas-Shiman, Sheryl L. TI Chronic Sleep Curtailment and Adiposity SO PEDIATRICS LA English DT Article DE sleep curtailment; adiposity; fat mass index; BMI; obesity; early childhood ID BODY-MASS INDEX; CIRCADIAN CLOCK GENE; RISK-FACTORS; CHILDHOOD OVERWEIGHT; BLOOD-PRESSURE; LIFE-STYLE; CHILDREN; OBESITY; ADOLESCENTS; DURATION AB OBJECTIVES: To examine the extent to which chronic sleep curtailment from infancy to mid-childhood is associated with total and central adiposity. METHODS: We studied 1046 children participating in a prospective cohort study. At age 6 months and yearly from age 1 to 7 years, mothers reported their children's sleep duration in a usual 24-hour period. The main exposure was a sleep curtailment score from age 6 months to 7 years. The range of the total score was 0 to 13, where 0 indicated the maximal sleep curtailment and 13 indicated never having curtailed sleep. Outcomes in mid-childhood were BMI z score, dual X-ray absorptiometry total and trunk fat mass index (kg/m(2)), and waist and hip circumferences (cm). RESULTS: The mean (SD) sleep score was 10.2 (2.7); 4.4% scored a 0 to 4, indicating multiple exposures to sleep curtailment between age 6 months to 7 years, 12.3% scored 5 to 7, 14.1% scored 8 to 9, 28.8% scored 10 to 11, and 40.3% scored 12 to 13. In multivariable models, children who had a sleep score of 0 to 4 had a BMI z score that was 0.48 U (95% confidence interval, 0.13 to 0.83) higher than those who had a sleep score of 12 to 13. We observed similar associations of higher total and trunk fat mass index and waist and hip circumferences, and higher odds of obesity (odds ratio, 2.62; 95% confidence interval, 0.99 to 6.97) among children who had a score of 0 to 4 vs 12 to 13. CONCLUSIONS: Chronic sleep curtailment from infancy to school age was associated with higher overall and central adiposity in midchildhood. C1 [Taveras, Elsie M.; Pena, Michelle-Marie] Massachusetts Gen Hosp Children, Dept Pediat, Div Gen Acad Pediat, Boston, MA USA. [Gillman, Matthew W.; Rifas-Shiman, Sheryl L.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA USA. [Gillman, Matthew W.; Rifas-Shiman, Sheryl L.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Taveras, Elsie M.; Gillman, Matthew W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Redline, Susan] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA. RP Taveras, EM (reprint author), Massachusetts Gen Hosp, Dept Pediat, Div Gen Acad Pediat, 100 Cambridge St,15th Floor, Boston, MA 02114 USA. EM etaveras@partners.org FU National Cancer Institute's Centers for Transdisciplinary Research on Energetics and Cancer (TREC) [U54CA116847]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [R37HD034568]; National Institutes of Health (NIH) FX This work was supported by the National Cancer Institute's Centers for Transdisciplinary Research on Energetics and Cancer (TREC) (U54CA116847) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R37HD034568). The opinions or assertions contained herein are the private ones of the authors and are not considered as official or reflecting the views of the National Institutes of Health. Funded by the National Institutes of Health (NIH). NR 58 TC 25 Z9 25 U1 3 U2 16 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2014 VL 133 IS 6 BP 1013 EP 1022 DI 10.1542/peds.2013-3065 PG 10 WC Pediatrics SC Pediatrics GA AI8MY UT WOS:000337172600051 PM 24843068 ER PT J AU Boudreau, AA Goodman, E Kurowski, D Perrin, JM Cooley, WC Kuhlthau, K AF Boudreau, Alexy Arauz Goodman, Elizabeth Kurowski, Daniel Perrin, James M. Cooley, W. Carl Kuhlthau, Karen TI Care Coordination and Unmet Specialty Care Among Children With Special Health Care Needs SO PEDIATRICS LA English DT Article DE medical home; health care delivery/access; quality of care; children ID MEDICAL HOME; NATIONAL-SURVEY; SERVICES; ACCESS; YOUTH; DISPARITIES; SYSTEMS; IMPACT AB OBJECTIVES: Care coordination and the medical home may ensure access to specialty care. Children with special health care needs (CSHCN) have higher rates of specialty care use and unmet need compared with the general pediatric population. We hypothesized that care coordination, regardless of whether it was provided in a medical home, would decrease unmet specialty care needs among CSHCN and that the effect of care coordination would be greater among low-income families. METHODS: Secondary data analysis of participants in the 2009-2010 National Survey of CSHCN who reported unmet specialty care needs and for whom care coordination and medical home status could be determined (n = 18 905). Logistic regression models explored the association of unmet need with care coordination and medical home status adjusting for household income. RESULTS: Approximately 9% of CSHCN reported having unmet specialty care needs. Care coordination was associated with reduced odds of unmet specialty care need (without a medical home, odds ratio: 0.63, 95% confidence interval: 0.47-0.86; within a medical home, odds ratio: 0.22, 95% confidence interval: 0.16-0.29) with a greater reduction among those receiving care coordination within a medical home versus those receiving care coordination without a medical home. We did not find differences in the impact of care coordination by percentage of the federal poverty level. CONCLUSIONS: Care coordination is associated with family report of decreased unmet specialty care needs among CSHCN independent of household income. The effect of care coordination is greater when care is received in a medical home. C1 [Boudreau, Alexy Arauz; Goodman, Elizabeth; Perrin, James M.; Kuhlthau, Karen] MassGen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, Div Gen Acad Pediat, Boston, MA 02114 USA. [Boudreau, Alexy Arauz; Goodman, Elizabeth; Perrin, James M.; Kuhlthau, Karen] Harvard Univ, Sch Med, Boston, MA USA. [Kurowski, Daniel] New York Ctr Homecare Policy & Res, Visiting Nurse Serv, New York, NY USA. [Cooley, W. Carl] Crotched Mt Fdn & Rehabil Ctr, Greenfield, NH USA. [Cooley, W. Carl] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA. RP Boudreau, AA (reprint author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, 15th Floor C100,100 Cambridge St, Boston, MA 02114 USA. EM aarauz@partners.org FU Massachusetts General Hospital Multicultural Affairs Career Development Award FX Supported by the Massachusetts General Hospital Multicultural Affairs Career Development Award. NR 45 TC 15 Z9 16 U1 0 U2 9 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2014 VL 133 IS 6 BP 1046 EP 1053 DI 10.1542/peds.2013-2174 PG 8 WC Pediatrics SC Pediatrics GA AI8MY UT WOS:000337172600055 PM 24864172 ER PT J AU Green, AL Srivatsa, A Rodriguez-Galindo, C AF Green, Adam L. Srivatsa, Abhinash Rodriguez-Galindo, Carlos TI Delayed Diagnosis and False Relapse Due to Paternal Testosterone Use in Adrenocortical Carcinoma SO PEDIATRICS LA English DT Article DE adrenocortical carcinoma; children; delay; diagnosis; exogenous; paternal; recurrence; testosterone; topical; virilization ID CHILDREN; TUMORS; VIRILIZATION AB The prognosis of pediatric adrenocortical carcinoma often depends on prompt diagnosis to begin treatment before metastatic progression. We discuss a girl who presented at 8 months of age with virilization, which was thought to be due to exposure to a topical testosterone preparation being used by her father. Her testosterone level did not decrease promptly after her father discontinued the medication, however, and when she followed up with signs of Cushing syndrome 5 months later, metastatic adrenocortical carcinoma was diagnosed. The patient was successfully treated with surgery and multiagent chemotherapy. Nine months after the end of treatment, her testosterone level was again found to be elevated. Testosterone precursors were now absent, however, and there were no imaging signs of recurrence. Further history showed that her father had restarted topical testosterone, and this time, exogenous exposure was correctly diagnosed. As use of topical testosterone becomes more prevalent, exogenous exposure must be considered in the differential diagnosis of childhood virilization. Any persistent testosterone elevation after exposure ceases or signs of hypercortisolism, however, are inconsistent with this diagnosis. We believe that the risk-benefit ratio favors abdominal ultra-sound to rule out malignancy in all children presenting with virilization. C1 [Green, Adam L.; Rodriguez-Galindo, Carlos] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Green, Adam L.; Rodriguez-Galindo, Carlos] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Srivatsa, Abhinash] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA. RP Green, AL (reprint author), Dana Farber Canc Inst, Dana 3,450 Brookline Ave, Boston, MA 02215 USA. EM adam.green@childrens.harvard.edu NR 11 TC 1 Z9 1 U1 1 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2014 VL 133 IS 6 BP E1772 EP E1776 DI 10.1542/peds.2013-1454 PG 5 WC Pediatrics SC Pediatrics GA AI8MY UT WOS:000337172600037 PM 24799542 ER PT J AU Powers, BW Chaguturu, SK AF Powers, Brian W. Chaguturu, Sreekanth K. TI Employer Health Incentives: Balancing Consumerism and Coordination SO POPULATION HEALTH MANAGEMENT LA English DT Editorial Material C1 [Powers, Brian W.; Chaguturu, Sreekanth K.] Harvard Univ, Sch Med, Boston, MA USA. [Powers, Brian W.; Chaguturu, Sreekanth K.] Partners HealthCare, Boston, MA 02199 USA. [Chaguturu, Sreekanth K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Chaguturu, SK (reprint author), Partners HealthCare, 800 Boylston St, Boston, MA 02199 USA. EM schaguturu@partners.org NR 5 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 EI 1942-7905 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD JUN PY 2014 VL 17 IS 3 BP 137 EP 138 DI 10.1089/pop.2014.0009 PG 2 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AI9BZ UT WOS:000337223600001 PM 24865283 ER PT J AU Tomko, RL Solhan, MB Carpenter, RW Brown, WC Jahng, S Wood, PK Trull, TJ AF Tomko, Rachel L. Solhan, Marika B. Carpenter, Ryan W. Brown, Whitney C. Jahng, Seungmin Wood, Phillip K. Trull, Timothy J. TI Measuring Impulsivity in Daily Life: The Momentary Impulsivity Scale SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE ambulatory assessment; ecological momentary assessment; impulsivity; borderline personality disorder; scale development ID BORDERLINE PERSONALITY-DISORDER; DUAL SYSTEMS-MODEL; AFFECTIVE INSTABILITY; SELF-REPORT; BEHAVIORAL MEASURES; SENSATION SEEKING; COMMUNITY SAMPLE; ALCOHOL-USE; DEPRESSION; EXPERIENCE AB Impulsivity is a core feature of many psychiatric disorders. Traditionally, impulsivity has been assessed using retrospective questionnaires or laboratory tasks. Both approaches neglect intraindividual variability in impulsivity and do not capture impulsivity as it occurs in real-world settings. The goal of the current study was to provide a method for assessing impulsivity in daily life that provides both between-individual and within-individual information. Participants with borderline personality disorder (BPD; n = 67) or a depressive disorder (DD; n = 38) carried an electronic diary for 28 days and responded to 9 impulsivity items up to 6 times per day. Item distributions and iterative exploratory factor analysis (EFA) results were examined to select the items that best captured momentary impulsivity. A brief 4-item scale was created that can be used for the assessment of momentary impulsivity. Model fit was good for both within-and between-individual EFA. As expected, the BPD group showed significantly higher scores on our Momentary Impulsivity Scale than the DD group, and the resulting scale was moderately correlated with common trait impulsivity scales. C1 [Tomko, Rachel L.; Carpenter, Ryan W.; Brown, Whitney C.; Wood, Phillip K.; Trull, Timothy J.] Univ Missouri, Dept Psychol Sci, Columbia, MO 65211 USA. [Tomko, Rachel L.; Carpenter, Ryan W.; Brown, Whitney C.; Wood, Phillip K.; Trull, Timothy J.] Midwest Alcoholism Res Ctr, St Louis, MO USA. [Solhan, Marika B.; Jahng, Seungmin] Univ Missouri Columbia, Dept Psychol Sci, Midwest Alcoholism Res Ctr, St Louis, MO USA. [Solhan, Marika B.] VA Boston Healthcare Syst, Boston, MA USA. [Jahng, Seungmin] Hallym Univ, Dept Psychol, Chunchon, South Korea. RP Trull, TJ (reprint author), Univ Missouri, Dept Psychol Sci, 210 McAlester Hall, Columbia, MO 65211 USA. EM TrullT@missouri.edu FU NIAAA NIH HHS [F31 AA022031, K05 AA017242, T32 AA013526]; NIMH NIH HHS [R21 MH069472] NR 62 TC 17 Z9 17 U1 3 U2 25 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 EI 1939-134X J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD JUN PY 2014 VL 26 IS 2 BP 339 EP 349 DI 10.1037/a0035083 PG 11 WC Psychology, Clinical SC Psychology GA AJ5EU UT WOS:000337706000001 PM 24274047 ER PT J AU Lewin, AB Piacentini, J De Nadai, AS Jones, AM Peris, TS Geffken, GR Geller, DA Nadeau, JM Murphy, TK Storch, EA AF Lewin, Adam B. Piacentini, John De Nadai, Alessandro S. Jones, Anna M. Peris, Tara S. Geffken, Gary R. Geller, Daniel A. Nadeau, Joshua M. Murphy, Tanya K. Storch, Eric A. TI Defining Clinical Severity in Pediatric Obsessive-Compulsive Disorder SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE OCD; CYBOCS; normative; child; Children's Yale Brown Obsessive Compulsive Scale ID CHILDREN; ADOLESCENTS; RELIABILITY; VALIDITY; FEATURES; THERAPY; SCALE; OCD AB Despite extensive use of the Children's Yale Brown Obsessive Compulsive Scale (CYBOCS; Scahill et al., 1997), the lack of normative data impedes interpretation of individual CYBOCS scores. Consequently, psychometrics on CYBOCS severity scores from 815 treatment-seeking youth with obsessive-compulsive disorder (OCD) are presented, across age and sex, so that normative comparisons of obsessive, compulsive, and combined obsessive-compulsive severity could be calculated. Our findings suggest no evidence for marked age or sex differences. Further, obsessive-compulsive symptom severity scores (measured via the CYBOCS) appear consistent with global OCD syndrome severity (measured via the Clinician Global Impression-Severity scale [CGI-S; Guy, 1976]; r = .58). This study contributes the 1st empirically based guidelines for interpreting obsessive-compulsive symptom severity scores. After a diagnosis of OCD is determined, the CYBOCS can be used to determine severity of illness (however, categories of severity proposed by this article should not be used in the screening of OCD symptoms). Findings can facilitate clinicians' and investigators' ability to draw comparisons across obsessive-compulsive severity scores. C1 [Lewin, Adam B.; Jones, Anna M.; Nadeau, Joshua M.; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, Dept Pediat, St Petersburg, FL 33701 USA. [Lewin, Adam B.; De Nadai, Alessandro S.; Storch, Eric A.] Univ S Florida, Dept Psychol, St Petersburg, FL 33701 USA. [Lewin, Adam B.; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, Dept Psychiat, St Petersburg, FL 33701 USA. [Piacentini, John; Peris, Tara S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Geffken, Gary R.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA. [Geffken, Gary R.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA. [Geller, Daniel A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. RP Lewin, AB (reprint author), Univ S Florida, Coll Med, Rothman Ctr Neuropsychiat, 880 6th St South,Suite 460 Box 7523, St Petersburg, FL 33701 USA. EM alewin@health.usf.edu RI Nadeau, Joshua/F-1462-2015; Murphy, Tanya/J-7079-2013 OI Nadeau, Joshua/0000-0002-9886-4709; NR 19 TC 10 Z9 10 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 EI 1939-134X J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD JUN PY 2014 VL 26 IS 2 BP 679 EP 684 DI 10.1037/a0035174 PG 6 WC Psychology, Clinical SC Psychology GA AJ5EU UT WOS:000337706000030 PM 24320764 ER PT J AU Viswanathan, A AF Viswanathan, Anand TI Shades of White Separating Degrees of Injury in the Aging Brain SO STROKE LA English DT Editorial Material DE aging; cognition; leukoencephalopathies ID MATTER HYPERINTENSITIES; ELDERLY-PEOPLE; MRI; DISEASE; LESIONS; PREVALENCE; SEVERITY; AGE C1 [Viswanathan, Anand] Massachusetts Gen Hosp, Kistler Stroke Res Ctr, Dept Neurol, Boston, MA 02114 USA. RP Viswanathan, A (reprint author), Massachusetts Gen Hosp, Kistler Stroke Res Ctr, 175 Cambridge St,Suite 300, Boston, MA 02114 USA. EM aviswanathan1@partners.org FU NIA NIH HHS [P50-AG00513430]; PHS HHS [K23-] NR 21 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD JUN PY 2014 VL 45 IS 6 BP 1606 EP 1607 DI 10.1161/STROKEAHA.114.005165 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AI7QR UT WOS:000337090700011 PM 24781085 ER PT J AU Wong, KSL Hu, DY Oomman, A Tan, RS Patel, MR Singer, DE Breithardt, G Mahaffey, KW Becker, RC Califf, R Fox, KAA Berkowitz, SD Hacke, W Hankey, GJ AF Wong, Ka Sing Lawrence Hu, Dai Yi Oomman, Abraham Tan, Ru-San Patel, Manesh R. Singer, Daniel E. Breithardt, Guenter Mahaffey, Kenneth W. Becker, Richard C. Califf, Robert Fox, Keith A. A. Berkowitz, Scott D. Hacke, Werner Hankey, Graeme J. CA Executive Steering Comm ROCKET AF Study Investigators TI Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial SO STROKE LA English DT Article DE atrial fibrillation; Far East; rivaroxaban; stroke ID ATRIAL-FIBRILLATION; JAPANESE PATIENTS; WARFARIN; ANTICOAGULATION; THERAPY; CHINA; PHARMACODYNAMICS; PHARMACOKINETICS; INTENSITY; SUBTYPES AB Background and Purpose-In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban was noninferior to dose-adjusted warfarin in preventing stroke or systemic embolism among patients with nonvalvular atrial fibrillation at moderate to high stroke risk. Because of differences in patient demographics, epidemiology, and stroke risk management in East Asia, outcomes and relative effects of rivaroxaban versus warfarin were assessed to determine consistency among East Asians versus other ROCKET AF participants. Methods-Baseline demographics and interaction of treatment effects of rivaroxaban and warfarin among patients within East Asia and outside were assessed. Results-A total of 932 (6.5%) ROCKET AF participants resided in East Asia. At baseline, East Asians had lower weight, creatinine clearance, and prior vitamin K antagonist use; higher prevalence of prior stroke; and less congestive heart failure and prior myocardial infarction than other participants. Despite higher absolute event rates for efficacy and safety outcomes in East Asians, the relative efficacy of rivaroxaban (20 mg once daily; 15 mg once daily for creatinine clearance of 30-49 mL/min) versus warfarin with respect to the primary efficacy end point (stroke/systemic embolism) was consistent among East Asians and non-East Asians (interaction P=0.666). Relative event rates for the major or nonmajor clinically relevant bleeding in patients treated with rivaroxaban and warfarin were consistent among East Asians and non-East Asians (interaction P=0.867). Conclusions-Observed relative efficacy and safety of rivaroxaban versus warfarin were similar among patients within and outside East Asia. Rivaroxaban, 20 mg once daily, is an alternative to warfarin for stroke prevention in East Asians with nonvalvular atrial fibrillation. C1 [Wong, Ka Sing Lawrence] Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China. [Hu, Dai Yi] Peking Univ, Peoples Hosp, Ctr Heart, Beijing 100871, Peoples R China. [Oomman, Abraham] Apollo Hosp, Dept Cardiol, Madras, Tamil Nadu, India. [Tan, Ru-San] Natl Heart Ctr, Singapore, Singapore. [Patel, Manesh R.; Mahaffey, Kenneth W.; Becker, Richard C.] Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Clin Res Inst, Durham, NC 27710 USA. [Califf, Robert] Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Translat Med Inst, Durham, NC 27710 USA. [Singer, Daniel E.] Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA. [Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA. [Breithardt, Guenter] Univ Hosp Munster, Dept Cardiovasc Med, Munster, Germany. [Fox, Keith A. A.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland. [Fox, Keith A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland. [Berkowitz, Scott D.] Bayer HealthCare Pharmaceut, Montville, NJ USA. [Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany. [Hankey, Graeme J.] Univ Western Australia, Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6009, Australia. RP Wong, KSL (reprint author), Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China. EM ks-wong@cuhk.edu.hk RI Hankey, Graeme /H-4968-2014; Wong, Ka Sing Lawrence/N-3434-2015 OI Hankey, Graeme /0000-0002-6044-7328; Wong, Ka Sing Lawrence/0000-0002-2031-9866 FU Janssen Research and Development, LLC; Bayer HealthCare Pharmaceuticals FX The ROCKET study was funded by Janssen Research and Development, LLC, and Bayer HealthCare Pharmaceuticals. NR 29 TC 37 Z9 37 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD JUN PY 2014 VL 45 IS 6 BP 1739 EP + DI 10.1161/STROKEAHA.113.002968 PG 20 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AI7QR UT WOS:000337090700034 PM 24763930 ER PT J AU Radmanesh, F Falcone, GJ Anderson, CD Battey, TWK Ayres, AM Vashkevich, A McNamara, KA Schwab, K Romero, JM Viswanathan, A Greenberg, SM Goldstein, JN Rosand, J Brouwers, HB AF Radmanesh, Farid Falcone, Guido J. Anderson, Christopher D. Battey, Thomas W. K. Ayres, Alison M. Vashkevich, Anastasia McNamara, Kristen A. Schwab, Kristin Romero, Javier M. Viswanathan, Anand Greenberg, Steven M. Goldstein, Joshua N. Rosand, Jonathan Brouwers, H. Bart TI Risk Factors for Computed Tomography Angiography Spot Sign in Deep and Lobar Intracerebral Hemorrhage Are Shared SO STROKE LA English DT Article DE cerebral amyloid angiopathy; cerebral small vessel disease; computed tomography angiography; hypertension; intracerebral hemorrhage; spot sign ID HEMATOMA EXPANSION AB Background and Purpose-Patients with intracerebral hemorrhage (ICH) who present with a spot sign on computed tomography angiography are at increased risk of hematoma expansion and poor outcome. Because primary ICH is the acute manifestation of chronic cerebral small vessel disease, we investigated whether different clinical or imaging characteristics predict spot sign presence, using ICH location as a surrogate for arteriolosclerosis-and cerebral amyloid angiopathy-related ICH. Methods-Patients with primary ICH and available computed tomography angiography at presentation were included. Predictors of spot sign were assessed using uni-and multivariable regression, stratified by ICH location. Results-Seven hundred forty-one patients were eligible, 335 (45%) deep and 406 (55%) lobar ICH. At least one spot sign was present in 76 (23%) deep and 102 (25%) lobar ICH patients. In multivariable regression, warfarin (odds ratio [OR], 2.42; 95% confidence interval [CI], 1.01-5.71; P=0.04), baseline ICH volume (OR, 1.20; 95% CI, 1.09-1.33, per 10 mL increase; P<0.001), and time from symptom onset to computed tomography angiography (OR, 0.89; 95% CI, 0.80-0.96, per hour; P=0.009) were associated with the spot sign in deep ICH. Predictors of spot sign in lobar ICH were warfarin (OR, 3.95; 95% CI, 1.87-8.51; P<0.001) and baseline ICH volume (OR, 1.20; 95% CI, 1.10-1.31, per 10 mL increase; P<0.001). Conclusions-The most potent associations with spot sign are shared between deep and lobar ICH, suggesting that the acute bleeding process that arises in the setting of different chronic small vessel diseases shares commonalities. C1 [Radmanesh, Farid; Falcone, Guido J.; Anderson, Christopher D.; Battey, Thomas W. K.; Rosand, Jonathan; Brouwers, H. Bart] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Radmanesh, Farid; Falcone, Guido J.; Anderson, Christopher D.; Battey, Thomas W. K.; Rosand, Jonathan; Brouwers, H. Bart] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Boston, MA 02114 USA. [Radmanesh, Farid; Falcone, Guido J.; Anderson, Christopher D.; Battey, Thomas W. K.; Ayres, Alison M.; Vashkevich, Anastasia; McNamara, Kristen A.; Schwab, Kristin; Viswanathan, Anand; Greenberg, Steven M.; Rosand, Jonathan; Brouwers, H. Bart] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA. [Romero, Javier M.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Goldstein, Joshua N.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Brouwers, H. Bart] Univ Utrecht, Dept Neurosurg, Univ Med Ctr Utrecht, Utrecht, Netherlands. RP Brouwers, HB (reprint author), Univ Med Ctr Utrecht, Dept Neurosurg, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands. EM brouwers@chgr.mgh.harvard.edu RI Goldstein, Joshua/H-8953-2016; Falcone, Guido/L-2287-2016; OI Falcone, Guido/0000-0002-6407-0302; Anderson, Christopher/0000-0002-0053-2002 FU National Institutes of Health (NIH)-National Institute of Neurological Disorders and Stroke (NINDS) [R01NS073344, R01NS059727, 5K23NS059774]; American Heart Association [0755984T] FX This study was supported by grants R01NS073344, R01NS059727, and 5K23NS059774 from the National Institutes of Health (NIH)-National Institute of Neurological Disorders and Stroke (NINDS) and 0755984T from American Heart Association. NR 9 TC 9 Z9 9 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD JUN PY 2014 VL 45 IS 6 BP 1833 EP + DI 10.1161/STROKEAHA.114.005276 PG 11 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA AI7QR UT WOS:000337090700047 PM 24876264 ER PT J AU Parangi, S Suh, H AF Parangi, Sareh Suh, Hyunsuk TI The Role of Genetic Markers in the Evaluation and Management of Thyroid Nodules SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article DE Thyroid nodules; Indeterminate cytology; Molecular markers; Genetic testing ID NEEDLE-ASPIRATION BIOPSIES; TERT PROMOTER MUTATIONS; BRAF MUTATION; EXPRESSION CLASSIFIER; BETHESDA SYSTEM; INDETERMINATE; CANCER; CARCINOMA; CYTOLOGY; IMPACT AB Thyroid nodules are common, with increasing incidence, but only 5% to 15% of nodules are malignant. Genetic markers should only be used as an ancillary diagnostic tool for indeterminate thyroid nodules. Veracyte Afirma may improve the diagnostic accuracy for a subset of indeterminate cytologic diagnosis. Overall clinical, imaging, and cytopathologic evaluation in addition to patient preference should guide the management of indeterminate nodules. Further multicentered and independent validation studies are needed in order to prove the efficacy of commercially available genetic markers. C1 [Parangi, Sareh] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Unit Endocrine Surg, Boston, MA 02115 USA. [Suh, Hyunsuk] Massachusetts Gen Hosp, Dept Gen Surg, Boston, MA 02115 USA. RP Parangi, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Unit Endocrine Surg, Wang ACC 460,15 Parkman St, Boston, MA 02115 USA. EM sparangi@partners.org NR 36 TC 4 Z9 4 U1 1 U2 19 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0039-6109 EI 1558-3171 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD JUN PY 2014 VL 94 IS 3 BP 515 EP + DI 10.1016/j.suc.2014.03.001 PG 15 WC Surgery SC Surgery GA AJ0HB UT WOS:000337330000005 PM 24857574 ER PT J AU Lubitz, CC Economopoulos, KP Pawlak, AC Lynch, K Dias-Santagata, D Faquin, WC Sadow, PM AF Lubitz, Carrie C. Economopoulos, Konstantinos P. Pawlak, Amanda C. Lynch, Kerry Dias-Santagata, Dora Faquin, William C. Sadow, Peter M. TI Hobnail Variant of Papillary Thyroid Carcinoma: An Institutional Case Series and Molecular Profile SO THYROID LA English DT Article ID BRAF V600E MUTATION; PROGNOSTIC-SIGNIFICANCE; MICROPAPILLARY PATTERN; HISTOLOGICAL VARIANT; FOLLICULAR VARIANT; COMMON TYPE; RISK GROUP; FOLLOW-UP; CANCER; FEATURES AB Background: Papillary thyroid carcinoma (PTC) is increasing in incidence while mortality is unchanged. Identifying patients with higher risk of recurrence and death is essential. Case series identify the hobnail variant of PTC (HVPTC), which is characterized by micropapillary architecture, apocrine features, and loss of cellular polarity. Herein, we describe the clinical course, pathologic features, and mutational profile of patients at our institution with HVPTC. Methods: A query into the surgical pathologic database (2009-2012) was performed, and clinicopathologic data were collected on all patients carrying the diagnosis of HVPTC. BRAF(V600E) testing was performed on paraffin-embedded blocks using SNaPshot mutational analysis. Results: Twelve patients with HVPTC were identified, with an average age of 54.1 +/- 18.8 years. Seven patients (63.6%) were AJCC Stage III or IV at presentation. Tumors were large (3.7 +/- 2.0 cm), some were multifocal (33.3%), and frequently with extrathyroidal extension (58.3%), lymphovascular invasion (41.7%), and lymph node metastasis (75%). Forty percent of the patients had concomitant tall cell features (TCF), and two had small foci of undifferentiated (anaplastic) thyroid carcinoma (ATC). Eighty percent of tumors undergoing mutational analysis had the BRAF(V600E) mutation, and the remaining 20% harbored a RET/PTC1 gene rearrangement. No other known thyroid cancer mutations were identified on SNaPshot analysis. At median follow-up of 26 months, four patients had recurrent or persistent disease, one of whom died from the disease one year after surgery. Conclusions: The hobnail variant of PTC has an aggressive behavior, with a high incidence of infiltrative tumors and metastatic disease. Strikingly, all tumors in our series harbored a PTC-associated genetic abnormality, either a BRAF(V600E) mutation (80%) or a RET/PTC1 rearrangement (20%). This histologic variant warrants further study, and patients with this diagnosis should be observed closely for recurrence. C1 [Lubitz, Carrie C.; Economopoulos, Konstantinos P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Surg Unit,Dept Surg, Boston, MA 02114 USA. [Pawlak, Amanda C.; Lynch, Kerry; Dias-Santagata, Dora; Faquin, William C.; Sadow, Peter M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. RP Lubitz, CC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Surg Oncol, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA. EM clubitz@partners.org OI Economopoulos, Konstantinos/0000-0003-4856-0405 FU Program in Cancer Outcomes Research Training Grant [NCI R25CA092203]; Massachusetts General Hospital Department of Surgery; Massachusetts General Hospital American Cancer Society Institutional Research Grant FX Funded, in part, by the Program in Cancer Outcomes Research Training Grant (NCI R25CA092203), Massachusetts General Hospital Department of Surgery, and Massachusetts General Hospital American Cancer Society Institutional Research Grant. NR 37 TC 10 Z9 11 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PD JUN PY 2014 VL 24 IS 6 BP 958 EP 965 DI 10.1089/thy.2013.0573 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AI9CB UT WOS:000337224000005 PM 24417340 ER PT J AU Bigdeli, TB Neale, BM Neale, MC AF Bigdeli, T. Bernard Neale, Benjamin M. Neale, Michael C. TI Statistical Properties of Single-Marker Tests for Rare Variants SO TWIN RESEARCH AND HUMAN GENETICS LA English DT Article DE genome-wide association; next-generation sequencing; significance testing; rare variation ID GENOME-WIDE ASSOCIATION; COMMON DISEASES; SAMPLE-SIZE; RISK; SUSCEPTIBILITY; PROPORTIONS; HYPOTHESES; GENOTYPES; GENES AB With the dramatic technological developments of genome-wide association single-nucleotide polymorphism (SNP) chips and next generation sequencing, human geneticists now have the ability to assay genetic variation at ever-rarer allele frequencies. To fully understand the impact of these rare variants on common, complex diseases, we must be able to accurately assess their statistical significance. However, it is well established that classical association tests are not appropriate for the analysis of low-frequency variation, giving spurious findings when observed counts are too few. To further our understanding of the asymptotic properties of traditional association tests, we conducted a range of simulations of a typical rare variant (similar to 1%) under the null hypothesis and tested the allelic chi(2), Cochran-Armitage trend, Wald, and Fisher's exact tests. We demonstrate that rare variation shows marked deviation from the expected distributional behavior for each test, with fewer minor alleles corresponding to a greater degree of test statistics deflation. The effect becomes more pronounced at progressively smaller a levels. We also show that the Wald test is particularly deflated at a levels consistent with genome-wide association significance, much more so than the other association tests considered. In general, these classical association tests are inappropriate for the analysis of variants for which the minor allele is observed fewer than 80 times, largely irrespective of sample size. C1 [Bigdeli, T. Bernard; Neale, Michael C.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA. [Bigdeli, T. Bernard; Neale, Michael C.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA USA. [Neale, Benjamin M.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Neale, Benjamin M.] Harvard Univ, Sch Med, Boston, MA USA. [Neale, Benjamin M.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA. [Neale, Michael C.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA. [Neale, Michael C.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA. RP Neale, BM (reprint author), Broad Inst Harvard & MIT, 7 Cambridge Ctr, Cambridge, MA 02142 USA. EM bneale@broadinstitute.org FU Netherlands Scientific Organization [NWO 480-05-003]; suppler-nett from the Dutch Brain Foundation; VU University Amsterdam FX We thank Mark Daly for useful feedback and comments on the manuscript. Statistical analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003), along with a suppler-nett from the Dutch Brain Foundation and the VU University Amsterdam. NR 25 TC 2 Z9 2 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1832-4274 EI 1839-2628 J9 TWIN RES HUM GENET JI Twin Res. Hum. Genet. PD JUN PY 2014 VL 17 IS 3 BP 143 EP 150 DI 10.1017/thg.2014.17 PG 8 WC Genetics & Heredity; Obstetrics & Gynecology SC Genetics & Heredity; Obstetrics & Gynecology GA AI9NL UT WOS:000337259200001 PM 24739319 ER PT J AU Sher, DJ Parikh, RB Mays-Jackson, S Punglia, RS AF Sher, David J. Parikh, Ravi B. Mays-Jackson, Shawnda Punglia, Rinaa S. TI Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate Cancer SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS LA English DT Article DE cost-effectiveness analysis; prostate cancer; radiotherapy; IMRT; stereotactic body radiotherapy ID STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; PRIMARY MANAGEMENT; STATES AB Objectives: Intensity-modulated radiation therapy (IMRT) has been established as the standard external-beam modality in treating low-risk prostate cancer. Stereotactic body radiotherapy (SBRT) is a novel approach involving high-dose radiotherapy in 5 fractions. This analysis compared their cost-effectiveness. Methods: A Markov model was constructed to delineate the health states after treatment with IMRT and SBRT. Disease, treatment, and toxicity data were extracted from the literature. Costs included both robotic (R-SBRT) and nonrobotic (NR-SBRT) reimbursement. Deterministic and probabilistic sensitivity analyses (PSA) were performed over a wide range of potential parameters. Results: The quality-adjusted life expectancy after IMRT was slightly higher than after SBRT, because we assumed worse toxicity after SBRT. However, the incremental cost-effectiveness ratios (ICER) for IMRT over R-SBRT and NR-SBRT were $285,000 and $591,100/quality-adjusted life year (QALY), respectively. On sensitivity analysis, SBRT was almost always the cost-effective therapy, in which the ICER for IMRT was generally over $100,000/QALY. Reimbursement for R-SBRT versus NR-SBRT significantly influenced its ICER. Treatment efficacy, rectal toxicity and impotence, and the potential for unforeseen SBRT late effects were the most critical parameters in the model; when including these uncertain parameters in a PSA, SBRT was still most likely to be cost-effective at a willingness to pay of $ 100,000/QALY. Conclusions: SBRT clearly contained more value than IMRT for external-beam treatment. Given the increasing prevalence of the disease and its superb convenience, intensive research should be performed on this novel modality, including the marginal benefit and cost of robotic treatment. C1 [Sher, David J.; Mays-Jackson, Shawnda] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA. [Parikh, Ravi B.; Punglia, Rinaa S.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Parikh, Ravi B.; Punglia, Rinaa S.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Sher, DJ (reprint author), Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA. EM david_j_sher@rush.edu NR 20 TC 11 Z9 11 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0277-3732 EI 1537-453X J9 AM J CLIN ONCOL-CANC JI Am. J. Clin. Oncol.-Cancer Clin. Trials PD JUN PY 2014 VL 37 IS 3 BP 215 EP 221 DI 10.1097/COC.0b013e31827a7d2a PG 7 WC Oncology SC Oncology GA AI6CU UT WOS:000336958200001 PM 23275277 ER PT J AU Nguyen, PL Aizer, A Assimos, DG D'Amico, AV Frank, SJ Gottschalk, AR Gustafson, GS Hsu, ICJ McLaughlin, PW Merrick, G Rosenthal, SA Showalter, TN Taira, AV Vapiwala, N Yamada, Y Davis, BJ AF Nguyen, Paul L. Aizer, Ayal Assimos, Dean G. D'Amico, Anthony V. Frank, Steven J. Gottschalk, Alexander R. Gustafson, Gary S. Hsu, I-Chow Joe McLaughlin, Patrick W. Merrick, Gregory Rosenthal, Seth A. Showalter, Timothy N. Taira, Al V. Vapiwala, Neha Yamada, Yoshiya Davis, Brian J. CA Expert Panel Radiation Oncology-Pr TI ACR Appropriateness Criteria (R) Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS LA English DT Review DE appropriateness criteria; prostate cancer; external-beam radiation; radiation therapy ID CONFORMAL RADIATION-THERAPY; PHASE-III TRIAL; INTENSITY-MODULATED RADIOTHERAPY; DOSE-ESCALATION TRIAL; STEREOTACTIC BODY RADIOTHERAPY; ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; TREATMENT RELATED MORBIDITY; RELAPSE-FREE SURVIVAL; QUALITY-OF-LIFE AB Purpose: To present the most updated American College of Radiology consensus guidelines formed from an expert panel on the appropriate use of external-beam radiation to manage stage T1 and T2 prostate cancer. Methods: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Results: The panel summarized the most recent and relevant literature on the topic and voted on 3 clinical variants illustrating the appropriate dose, techniques, and use of adjuvant hormone therapy with external-beam radiation for low-risk, intermediate-risk, and high-risk prostate cancer. Numerical rating and commentary reflecting the panel consensus was given for each treatment approach in each variant. Conclusions: External-beam radiation is a key component of the curative management of T1 and T2 prostate cancer. By combining the most recent medical literature and expert opinion, this guideline can aid clinicians in the appropriate use of external-beam radiation for prostate cancer. C1 [Nguyen, Paul L.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Aizer, Ayal] Harvard Radiat Oncol Program, Boston, MA USA. [Assimos, Dean G.] Univ Alabama Birmingham, Sch Med, Dept Urol, Birmingham, AL USA. [Assimos, Dean G.] Amer Urol Assoc, Linthicum, MD USA. [D'Amico, Anthony V.] Joint Ctr Radiat Therapy, Boston, MA 02115 USA. [D'Amico, Anthony V.] Amer Soc Clin Oncol, Alexandria, VA USA. [Frank, Steven J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Gottschalk, Alexander R.; Hsu, I-Chow Joe] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA. [Rosenthal, Seth A.] Radiol Associates Sacramento, Sacramento, CA USA. [Rosenthal, Seth A.] Sutter Canc Ctr, Sacramento, CA USA. [Taira, Al V.] Mt View Oncol, Western Radiat Oncol, Mountain View, CA USA. [Gustafson, Gary S.] William Beaumont Hosp, Troy, NY USA. [McLaughlin, Patrick W.] Univ Michigan, Dept Radiat Oncol, Novi, MI USA. [Merrick, Gregory] Schiffler Canc Ctr, Wheeling, WV USA. [Merrick, Gregory] Wheeling Jesuit Univ, Wheeling, WV USA. [Showalter, Timothy N.] Univ Virginia, Dept Radiat Oncol, Charlottesville, VA USA. [Vapiwala, Neha] Univ Penn, Dept Radiat Oncol, Philadelphia, PA USA. [Yamada, Yoshiya] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Davis, Brian J.] Mayo Clin, Rochester, MN USA. RP Nguyen, PL (reprint author), Amer Coll Radiol, 1891 Preston White Dr, Reston, VA 20191 USA. EM pnguyen@lroc.harvard.edu FU NCI NIH HHS [P30 CA016672] NR 105 TC 5 Z9 5 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0277-3732 EI 1537-453X J9 AM J CLIN ONCOL-CANC JI Am. J. Clin. Oncol.-Cancer Clin. Trials PD JUN PY 2014 VL 37 IS 3 BP 278 EP 288 DI 10.1097/COC.0000000000000049 PG 11 WC Oncology SC Oncology GA AI6CU UT WOS:000336958200011 PM 25180754 ER PT J AU Welles, CC Whooley, MA Karumanchi, SA Hod, T Thadhani, R Berg, AH Ix, JH Mukamal, KJ AF Welles, Christine C. Whooley, Mary A. Karumanchi, S. Ananth Hod, Tammy Thadhani, Ravi Berg, Anders H. Ix, Joachim H. Mukamal, Kenneth J. TI Vitamin D Deficiency and Cardiovascular Events in Patients With Coronary Heart Disease: Data From the Heart and Soul Study SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE cardiovascular events; coronary heart disease; nutrition; vitamin D; vitamin D deficiency ID PERIPHERAL ARTERIAL-DISEASE; 25-HYDROXYVITAMIN D LEVELS; CHRONIC KIDNEY-DISEASE; PARATHYROID-HORMONE; SERUM 25-HYDROXYVITAMIN-D; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; INCIDENT HYPERTENSION; DEPRESSIVE SYMPTOMS; D SUPPLEMENTATION AB A growing body of evidence supports an association between vitamin D and cardiovascular disease. However, the mechanisms underlying this association are unknown. From 2000 to 2002, we identified 946 participants with stable cardiovascular disease in San Francisco, California, and followed them prospectively for cardiovascular events (heart failure, myocardial infarction, stroke, or cardiovascular death). We then examined the extent to which the association was attenuated by adjustment for poor health behaviors, comorbid health conditions, and potential biological mediators. During a median follow-up period of 8.0 years (through August 24, 2012), 323 subjects (34.1%) experienced a cardiovascular event. Following adjustment for sociodemographic factors, season of blood measurement, health behaviors, and comorbid conditions, 25-hydroxyvitamin D levels under 20 ng/mL remained independently associated with cardiovascular events (hazard ratio = 1.30, 95% confidence interval: 1.01, 1.67). However, after further adjustment for potential biological mediators, the independent association was no longer present (hazard ratio = 1.11, 95% confidence interval: 0.85, 1.44). Parathyroid hormone, a potentially modifiable biological factor downstream from 25-hydroxyvitamin D, was responsible for the majority of this attenuation. These findings highlight the need for randomized controlled trials to determine whether vitamin D supplementation in persons with deficiency could be beneficial for the primary or secondary prevention of cardiovascular events. C1 [Welles, Christine C.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, Sch Med, San Francisco, CA USA. [Ix, Joachim H.] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Sch Med, Dept Med, Div Nephrol Hypertens, San Diego, CA 92103 USA. [Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Karumanchi, S. Ananth; Hod, Tammy] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA. [Berg, Anders H.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. RP Welles, CC (reprint author), San Francisco VA Med Ctr, Dept Med, Gen Internal Med Sect, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM christywelles@gmail.com FU Veterans Affairs National Quality Scholars Program; Department of Veterans Affairs; National Heart, Lung, and Blood Institute; American Federation for Aging Research; Robert Wood Johnson Foundation; Ischemia Research and Education Foundation; National Institutes of Health [DK094486, DK094872] FX Dr. Christine C. Welles was supported by the Veterans Affairs National Quality Scholars Program. The Heart and Soul Study was supported by the Department of Veterans Affairs, the National Heart, Lung, and Blood Institute, the American Federation for Aging Research, the Robert Wood Johnson Foundation, and the Ischemia Research and Education Foundation. Dr. S. Ananth Karumanchi is an investigator of the Howard Hughes Medical Institute. Dr. Ravi Thadhani was supported by National Institutes of Health grants DK094486 and DK094872. NR 46 TC 22 Z9 22 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2014 VL 179 IS 11 BP 1279 EP 1287 DI 10.1093/aje/kwu059 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AI6ZI UT WOS:000337027400001 PM 24699783 ER PT J AU Welles, CC Whooley, MA Karumanchi, SA Hod, T Thadhani, R Berg, AH Ix, JH Mukamal, KJ AF Welles, Christine C. Whooley, Mary A. Karumanchi, S. Ananth Hod, Tammy Thadhani, Ravi Berg, Anders H. Ix, Joachim H. Mukamal, Kenneth J. TI Welles et al. Respond to "Low Vitamin D and Cardiovascular Disease" SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material C1 [Welles, Christine C.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, Sch Med, San Francisco, CA USA. [Ix, Joachim H.] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Sch Med, Div Nephrol Hypertens, San Diego, CA 92103 USA. [Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Karumanchi, S. Ananth; Hod, Tammy] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA. [Berg, Anders H.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. RP Welles, CC (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, Dept Med, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM christywelles@gmail.com FU NIDDK NIH HHS [K24 DK094872, R01 DK094486] NR 4 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2014 VL 179 IS 11 BP 1291 EP 1292 DI 10.1093/aje/kwu058 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AI6ZI UT WOS:000337027400003 PM 24699785 ER PT J AU He, LZ Marioutina, M Dunaief, JL Marneros, AG AF He, Lizhi Marioutina, Mariya Dunaief, Joshua L. Marneros, Alexander G. TI Age- and Gene-Dosage-Dependent Cre-Induced Abnormalities in the Retinal Pigment Epithelium SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID MAMMALIAN-CELLS; RECOMBINASE; TOXICITY; EXPRESSION; SITES; MOUSE AB To conditionally inactivate genes in the retinal pigment epithelium (RPE) transgenic mouse strains have been developed, in which Cre recombinase (Cre) expression is driven by an RPE-specific gene promoter. The RPE is a quiescent epithelium, and continuous expression of Cre could affect its function. Here, we tested the hypothesis that continuous postnatal Cre expression in the RPE may lead to cellular abnormalities, which may depend on both age and Cre gene dosage. We therefore examined the eyes of homozygous and heterozygous VMD2-Cre mice at various ages. In VMD2-Cre heterozygous mice variable progressive age-dependent RPE abnormalities were noticed, including attenuation of phalloidin and cytoplasmic active beta-catenin staining, reduced cell size, and loss of the typical honeycomb pattern of RPE morphology in those RPE cells that stained for Cre. These morphological RPE abnormalities were not noticed in Cre-negative RPE cells in VMD2-Cre or age-matched control mice. In addition, an abnormal number and morphology of cell nuclei were noticed in a subset of Cre-expressing RPE cells in aged heterozygous VMD2-Cre mice, whereas more severe nuclear abnormalities were observed already in young homozygous VMD2-Cre mice. Thus, continuous postnatal expression of Cre causes abnormalities in the RPE in an age- and Cre gene dosage-dependent manner, which needs to be considered in the interpretation of gene targeting studies in the RPE. C1 [He, Lizhi; Marioutina, Mariya; Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. [He, Lizhi; Marioutina, Mariya; Marneros, Alexander G.] Harvard Univ, Sch Med, Dept Dermatol, Charlestown, MA USA. [Dunaief, Joshua L.] Univ Penn, Dept Ophthalmol, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA. RP Marneros, AG (reprint author), MGH E, CBRC, CNY 149,Rm 3-216,13th St, Charlestown, MA 02129 USA. EM amarneros@mgh.harvard.edu FU NIH National Eye Institute [R01-EY019297] FX This work was supported by NIH National Eye Institute grant R01-EY019297 (A.G.M.). NR 19 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD JUN PY 2014 VL 184 IS 6 BP 1660 EP 1667 DI 10.1016/j.ajpath.2014.02.007 PG 8 WC Pathology SC Pathology GA AI5ZE UT WOS:000336948700004 PM 24854863 ER PT J AU Axon, RN Penney, FT Kyle, TR Zapka, J Marsden, J Zhao, YM Mauldin, PD Moran, WP AF Axon, Robert N. Penney, Fletcher T. Kyle, Thomas R. Zapka, Jane Marsden, Justin Zhao, Yumin Mauldin, Patrick D. Moran, William P. TI A Hospital Discharge Summary Quality Improvement Program Featuring Individual and Team-based Feedback and Academic Detailing SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Care transitions; Hospital discharge; Discharge summary; Quality improvement ID PRIMARY-CARE PHYSICIANS; INTERNAL-MEDICINE; VULNERABLE ELDERS; AFTER-DISCHARGE; RE-AIM; COMMUNICATION; PERFORMANCE AB Background: Discharge summaries are an important component of hospital care transitions typically completed by interns in teaching hospitals. However, these documents are often not completed in a timely fashion or do not include pertinent details of hospitalization. This report outlines the development and impact of a curriculum intervention to improve the quality of discharge summaries by interns and residents in Internal Medicine. A previous study demonstrated that a discharge summary curriculum featuring individualized feedback was associated with improved summary quality, but few subsequent studies have described implementation of similar curricula. No information exists on the utility of other strategies such as team-based feedback or academic detailing. Methods: Study participants were 96 Internal Medicine intern and resident physicians at an academic medical center-based training program. A comprehensive evidence-based discharge summary quality improvement program was developed and implemented that featured a discharge summary template to facilitate summary preparation, individual feedback, team-based feedback, academic detailing and an objective discharge summary evaluation instrument. Results: The discharge summary evaluation instrument had moderate interrater reliability (kappa = 0.72). Discharge summary scores improved from mean score of 70% to 82% (P = 0.05). Interns and residents participating in this program also reported increased confidence in producing and critiquing summaries. Conclusions: A comprehensive discharge summary curriculum can be feasibly implemented within the context of a residency program. Team-based feedback and academic detailing may serve to reinforce individual feedback and extend program reach. C1 [Axon, Robert N.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC 29425 USA. [Axon, Robert N.; Penney, Fletcher T.; Kyle, Thomas R.; Marsden, Justin; Zhao, Yumin; Mauldin, Patrick D.; Moran, William P.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Zapka, Jane] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Mauldin, Patrick D.] South Carolina Coll Pharm, Charleston, SC USA. RP Axon, RN (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, 135 Rutledge Ave,MSC 591, Charleston, SC 29425 USA. EM axon@musc.edu FU Donald W. Reynolds Foundation; Medical University of South Carolina (MUSC) FX This study was supported by a grant from the Donald W. Reynolds Foundation entitled "Aging Q3: Quality Education, Quality Care, and Quality of Life" and matching funds provided by the Medical University of South Carolina (MUSC). NR 22 TC 7 Z9 7 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD JUN PY 2014 VL 347 IS 6 BP 472 EP 477 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA AI5IG UT WOS:000336898500009 PM 24845304 ER EF